<SEC-DOCUMENT>0001628280-21-022902.txt : 20211112
<SEC-HEADER>0001628280-21-022902.hdr.sgml : 20211112
<ACCEPTANCE-DATETIME>20211110175556
ACCESSION NUMBER:		0001628280-21-022902
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211112
DATE AS OF CHANGE:		20211110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Regulus Therapeutics Inc.
		CENTRAL INDEX KEY:			0001505512
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				264738379
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35670
		FILM NUMBER:		211398119

	BUSINESS ADDRESS:	
		STREET 1:		4224 CAMPUS POINT COURT
		STREET 2:		SUITE 210
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-202-6300

	MAIL ADDRESS:	
		STREET 1:		4224 CAMPUS POINT COURT
		STREET 2:		SUITE 210
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rgls-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:b020128b-c098-4c8f-bf82-e0af5aef1570,g:5e73ec3e-18f1-4a85-a5f0-f7e7f348b77f,d:1bd3a25286f94961af32b70947dcc597--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:rgls="http://www.regulusrx.com/20210930" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rgls-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl8xLTEtMS0xLTYxMDM_d31c86ce-273a-4803-8aca-5c23a9ecd0f0">false</ix:nonNumeric><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl8yLTEtMS0xLTYxMDM_8940b273-28a2-4dac-92a7-e5aff592b199">2021</ix:nonNumeric><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl8zLTEtMS0xLTYxMDM_80f620cf-c933-4d94-94a3-a2394d258026">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl80LTEtMS0xLTYxMDM_30e5274d-11be-497d-b18f-deabbd48dd2b">REGULUS THERAPEUTICS INC.</ix:nonNumeric><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl81LTEtMS0xLTYxMDM_56355a57-4d0b-44f1-9d12-8aa4eed7df00">0001505512</ix:nonNumeric><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl82LTEtMS0xLTYxMDM_136ddd96-3995-4f25-a8b2-047ef2573111">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_565d7559-28ba-4345-9a0b-75933eaa77e7">http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember</ix:nonNumeric><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_59cfb3be-2728-482e-ae52-18bdd71ebc3f">http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember</ix:nonNumeric><ix:nonNumeric contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_7ca68d24-3d91-478b-b761-58d0319ff7a8">http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember</ix:nonNumeric><ix:nonNumeric contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_90ce62b6-7870-4d8c-9f4c-aed84ce70c1e">http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rgls-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8111d7345b08453e894915175538e2d9_I20211105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c50d853f72c4c36960bcf1c2165224d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iec5a7ece68f34af9a1c0b10216bcff29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA1ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA1ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e7272b1621e4746803c762bf1a81ca5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8b178ce8274601b70fd58c2f287d14_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0c73a09494482383aa980fa7b3693f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic60d06be298b4e55a466408378417d03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i868ed48256c846129326496101c3afa4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01168e5978e14e958219e06962200018_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c3f16817aff4123aca2966839b53fda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddc56a36fc5e488986a42a9c474e76c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72366e3fa5d44f0e9f12dbd590832293_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id753b733b8084902acfdb79365d408e4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70db96b959cb44848f3b413e51827d92_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i051ea96b453f429caa68e3801ce5bc29_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if883ca285d9e4b31bc6d7edfdd22e3b6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6ee41175879423c93045b232c54bfe7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea678063a4e5490b8f065fd950d4952d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i266c364e78cb46aeab7659ca36e88cbf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a3a053cc647497aacd5d5b56004d10f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfad87cc9de4cc090746542475df981_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb4b3672299546139d7e04d964128b42_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5525c2dcee4a4d748f8cfbc31dfc8db3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9d36a105ae449beb839ab6a815bcf59_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020405b1a3e24f1281f97a16daf92291_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32e9077c24de4469bfd47b1d8acb39a3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fdcfbfd5e98440c85fbaf81e72f285d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4935d8a23a6f420385a4f517fac836e2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ca9e82037e4fc2adef24baea0d6e30_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c825f130c2462d822bff3231997bf0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c707f52c3ad423d9929a3b102a980e8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3d073fce4e748a79a7a58c6ebd79572_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c592b3c93f247f4bdddc3f28cf0bcc4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1329e87d85994ed5aec3fc36abc2f3f6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eb8b8d131534c03ad4f1dc07b5cd25c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3092be79f8214d54a1f70f92a5d08c86_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b19f57325c448582fbbc67739c326b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb8e219bee614949b739b6c590453b4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3320ae2f75043c2bb5c26a7ec8241e0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46dcde68ee6949fabac04d61528c3adb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88172ee03d6b45da9f2508fc8c899e50_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0839129300ae490a88abf37136846111_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e728fa3cb540d5917b1e146d5c075e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec31e70363d949bc869ebd9d662e556f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fdfa6760cde47c78598ec14f20df863_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41608b92ab1e405c9505107aa8fd4a10_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica4813bf265846af86e7cc13ba14b04c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6f736255edb4fd394dcac61f435857f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i937a88a09ffe475e93aa3271b6d32b6e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106931b626c24de2b02765bb0b3ff2e3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if57f750264234676ba54c29635f86b6e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0273fa1e721f4669bb524150f471d493_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd72b68db08a4f389c46d913ec8ff603_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i797de9f7b8c94355addeba1011495bd6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if302f494d5d1498abe569565dbdf97a7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1408d312334eb79d917b31476e9f45_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddcc9b19c42a47b09baa002a71fba35e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d830f02b3e14451ad9e64b964c38013_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90d7713a719f4a73b660cf6b5827d495_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6725b24da6f44eb8a2bdef563ccfd0e1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6943c5db1485450bb348ad14827a1cd3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865538f5e6944ffbab25f061268e630e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ccc29ee690e4861959d540c320ce357_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d268293b00748cb90f4f7273393b95f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f6d4248d2b4dc986c29c6a7ad68bf0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac0a725c51e4495a0c3d3346febea7b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5d5b6ce568c40dc86b3246c0c3574fc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2751e06f46463a94612500556b66a8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e558bd57cca45c5b203fdaf82f601e8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3dd88f2ee24d50940e2d23ae23e499_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6bf61ba9c4435e80870c56d0a0f96b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a47324fa24547688554544bf8a88ebb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e7c32d4abb4857a652dbaf35a42b0b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b42f9a435294e1c9a483222e912c132_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09deb282dd9b4bf58f7a624fb80f547f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fdd8f019e3c491b8732a68d899250a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce7ee44d1194a78aa295bd978dc3ae7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b176df93ed4f47b0455d5746bf050e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6383c5f184bf4004ba7ac38c997e14c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i523ebcbfef6d4b6aa814dd3ff356bd8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7695f94fcc4a2b92b921a5c6aa94bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ecd930760914ed780a9b7337dc50c31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f4532b2830348528c01118566cacbce_D20160622-20160622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-22</xbrli:startDate><xbrli:endDate>2016-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ica365f62a18542a3bd628586ba2316d7_I20160617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56addd06803544669ea6adfb1f85223b_D20160617-20160617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-17</xbrli:startDate><xbrli:endDate>2016-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>rgls:payment</xbrli:measure></xbrli:unit><xbrli:unit id="amendment"><xbrli:measure>rgls:amendment</xbrli:measure></xbrli:unit><xbrli:context id="i03875b50705141378eeb6a7f3db6d93c_D20171001-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic806cb07df3044b1b53e64130fffba72_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i892f5ef11b7f487eb34d5314ea17e4fd_D20200825-20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TenthAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-25</xbrli:startDate><xbrli:endDate>2020-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd75439e0974679b47a6cff8366c288_I20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TenthAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i380cfb226da64264aa858aa432603785_D20200930-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-30</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b747865a07948508c75f1aa6b053b63_D20201008-20201008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-08</xbrli:startDate><xbrli:endDate>2020-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16ee745789f48d18517ec4b1a9769cf_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8cb641775b42569a9458112a507826_D20200930-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-30</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46549a65d985413b8403edb46967d1b0_D20201008-20201008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-08</xbrli:startDate><xbrli:endDate>2020-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic64856709b654f068e893bde533341f9_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d6534d80e9479592a4aa31ef10377f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2905a20cdd80471abc18cd4877622e4b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="prepayment"><xbrli:measure>rgls:prepayment</xbrli:measure></xbrli:unit><xbrli:context id="i923277ec32bd4699a80593ceda7d7e81_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de3b934180e4445a01ae3a427e91b3f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd548549c7b7438bb6836f7b080e3d0f_I20200423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>rgls:vote</xbrli:measure></xbrli:unit><xbrli:context id="ie53dd4b291ee4100afcd9f063f293242_D20200122-20200122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-22</xbrli:startDate><xbrli:endDate>2020-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie740123647534dc7b2a846af038991a4_D20200122-20200122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-22</xbrli:startDate><xbrli:endDate>2020-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1f2d1ed7234256bace1246be18d4ee_I20200122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie68f8c41edfb46ee9870928b23961edc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="closing"><xbrli:measure>rgls:closing</xbrli:measure></xbrli:unit><xbrli:context id="i3322efb25d9a4f5f9fb3224308d86541_I20190503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674455781c874bdbbef4fcb1f436968d_D20190507-20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-07</xbrli:startDate><xbrli:endDate>2019-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2c4232052049e3a363d782b40cb6bc_I20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50625ecf1d0a45eeb2ecec6aac3745e9_I20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b3e274349048899a6baf2136cbce5c_D20190507-20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-07</xbrli:startDate><xbrli:endDate>2019-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd6803fc0e58407c98e7e6efe7b48823_I20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21a6fc5988124fb9a3c0daca71b52647_D20190507-20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-07</xbrli:startDate><xbrli:endDate>2019-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead2605b5d6e40c59a34f098e26f325d_D20191224-20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2019-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i360a9fad1f764e37b7a0392838193495_I20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e3c72e4f312454cb6e94e3624438bd4_D20191224-20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2019-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9d49856529484a9241d0f6562c00ce_D20191224-20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2019-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief922b305f3046a1a28f76ddcd1e5862_D20191224-20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2019-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7662e8163acd4dc8adc61570e5adde5d_I20191224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if073e6ccc7cc48ab99b972e5ac765b10_D20201204-20201204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-04</xbrli:startDate><xbrli:endDate>2020-12-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie514dfd04114480cb2e11b8bf5bb0435_I20201204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i919f61d52aec4ec9804c967d05a0ac34_I20201204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a2c7b41e9fc4304b5170c4d5ee66271_I20201204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77c7496e13cb499b9175da4b6316b202_D20201204-20201204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-04</xbrli:startDate><xbrli:endDate>2020-12-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba02a52203c4223911077232c49cee7_I20201204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic598bb91fd7e4fed8d09bafbe5180ce0_D20201204-20201204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-04</xbrli:startDate><xbrli:endDate>2020-12-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a0858e919543a98b9c64121d1e1830_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbea8938a1694e83b04dda860ed7dd2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79e9b8c233642bbb9cebdf5dfb40760_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45d5562fcca646dd99b09cd41afa34ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752592ed38104bc78a16c74ec4d542fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia03dfcdae3b1407bb022fb54e0a8156b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i383282b176b840d4a8c19a6ac7b18315_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6af434f9895c4a8abcdc67b6e14c6efe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0bbfe3a36da493c9161915cc9d72948_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36e6a371c8a44609f70ce29521cf931_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd6bbd169a646cdac5d2d64ecd91d4a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62444203267d47c385eec5d087d4d8da_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39b26e0a123149da8e318c905c14d733_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c861e934bbb434fb65de130aef4d7f0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26455c9e63ec418298d96a228a52ea5c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74040130c2df49589afc08ad9a809499_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i254490f02c4c4c589f3f3c5081713988_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95228771e65f4d69be9591692885d592_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2c3a10cf064f479a81fd8b17777c0f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f4afbe5d8c34f8998934e3231e70d99_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc0c2d79507405e933216b019d4edde_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if247eeb7c16c4eb39296da50e9a88a87_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0325f8a593a4d04848243185ea3662f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7022c7df72d41e099622cfcf6c5ac69_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie294014d4c6e4e89b676a5f599db291f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e29c7e6e8d7461aa5503106164f57ee_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id175542746b14dbe92632e7c763d73a4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4e4836ff49d45a0813f0bf3e816e560_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc483577ed845e8bf93c991053ea7c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f8532096be04b6d9015d6367f7d8fdc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55ea03d6757422cb1b7c98ef85d4d29_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i436d75c6db184475b193def39aa233c2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d7ff325bb64f3ba97014fba8f446f6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1f198ef1d3d40c590316253a4a859b3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib871a39aa1ac437eaa31e7324e95ec4f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e829145a1ef44a3801129514bd80961_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i968ebf92b9924a3f927dd3367b7ee9b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica7c16fbdde44fcab2f8edcb368cb2ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6455474e083246cbbfdf27a81a04fd9c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23dd736c354b4baca7d8a7e5ad03a16f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b9351df4284c69984f500e694a6369_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3352e5aab04142a5979bb162e53c6330_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2451dacc95664a628df7a419490f93d5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74a57decb14440bf86a20216c8b58def_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i688d71ec835347f28d95349cfa461c90_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86de16f9b2f842129ce65f588a7a7aa9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230bbacb14564b7287002929b04072b6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1162c4370f4f1495d1b38cb8c36886_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dc114989d2e49059136125c88e9d784_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida746cb1127f4a02913c9868d13207b9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17a1ebeb40054eee85bbb7562a88622b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc530cdf0a042f3b6cfcb98f0abe16d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec999a5bafc747db893bef4a0ad2b58a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf571b5851d240cc8cda05c8c168c970_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b2924209bd04bb7a40a2a56f99caa9f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2af4520400a4c80a524537bc2037d39_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b1959cfd8084de1ad61cf35bcfd27a2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c97aedbf36c4a329ed8b131afa706da_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6923a101d07842c3b5768ebb561bc42e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6b75c985414d3a94e6080ae2260895_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa784103a1544b79cc572714fbd6000_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070064518ba64c48988cb9ebab49b967_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7db41969a844eb099ad7cacafdc6a43_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb123cc427924d9d83494db5ea171543_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3593e979f61242e4974999e7d07215d2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i786a3068e05841b28df2e45b562e51ee_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99418e2e85d14e5491bd379d2557e64f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i952837312fd74bb6ad3761bd0f543858_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c184c7909e14f73a331173806592ad9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5de04397b02498d82ebeda41dd65f11_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e2ff0b853b425197ddbce613a8c517_I20181212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89cc80809f64492f8d626470ab85255a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b63a4e5d7f548ab874621e4d0e59f70_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f0579c541c24aefa982bf42729d197c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c72dba56f1642e4bb4ba0d460f36bff_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c836c16b926435386de34b3cc16d880_I20210810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6122f172c1574c4da14a5e4fd4d6e9da_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e0fa5dcfa6f41d78143b478d0a01b56_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rgls:ClassA1ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0c87ad7a8d436fa4ccaa34c29d3a34_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b79769fd334fd287d6b5137a7b5c74_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rgls:ClassA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8041ada6a3e4d52bcb9c494a7798bca_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rgls:InitialClosingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3341a1d23c5c4c2cace6220943a0f34f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rgls:MilestoneClosingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd5d41a28e04fa0b27f308560cc92c1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rgls:A2020PIPEWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c2342f58c454d05b39c846426605b48_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdae785f59024129a26a080f3e9b9224_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:TwentyTwelvePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f4406481484bada9b1cf86ce076050_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i951d796d9ed84f84b26dc055c3e072b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644ae87d631747999899d8f3a2d4e933_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11f92ae4880433b90d114da1ab87247_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70017d07079c4189905253f72a203dfa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic504631e11784f66848db26f50687d26_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6794a82e447847f0b259ae873682904e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5e74c99c434af4873f28aa394abae8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4dc078f58b49e3b773f4556b8a3b41_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b8f3c6cf464d83b2c2ae2abd93eef6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65465aaa0a2b4eff99ceadebe06d4c4b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f2e97743f414d1694ca8d0fce5260f4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id179c53c4d4246068ac3e3d9d3e878bf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c9397744df49d28775440c5244e2ab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i817be33db9a14559bd6acb439e8aab8f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id91c48b0026b42dc91f4d51602dab771_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i207c6ee7766e4b7b8321acdabc61f642_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib574d1151949442b9717daf3b9f1afcd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91edac16aa02482ab13c5c6191291f75_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>rgls:target</xbrli:measure></xbrli:unit><xbrli:context id="i00c63c04aad146a4a4b300df5bf7b017_D20120701-20120731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-07-01</xbrli:startDate><xbrli:endDate>2012-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bcfd2d3e6b4477b9224c2ddab8e9c58_D20140201-20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-02-01</xbrli:startDate><xbrli:endDate>2014-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4e945ac07d4765bd2b5ffc2566e5ae_D20130601-20130630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-06-01</xbrli:startDate><xbrli:endDate>2013-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a9a1a9f277465e8d50fdad1c657692_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ProofofConceptTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1929ac258c9c450cae6fef04bef7a0e8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba95955f98f043a68a1e97b6a00b2b51_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i153b7153a94d40aebf670759f33de31f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:RegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a4f0ed7dc74ea5888ebe893d2216a7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfab0a14bbcd45099cc675f73f91da2d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26e5dcd2596c41159528a70c01a1e7c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fabccc96bc64e1d9de7b84c7b313a57_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f3e037391ac473094c869e8548228db_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa94d177b51946f9b13662dc829b3dc7_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if665882f71ff45d8bb6f588594d45f74_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe78a5b02aa8476385726b454cc854b6_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:EnrollmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i353569e61e144d2db9c5ffc37b740344_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b7fba7009e439bbd4b1263221e7cf2_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7415adf3f848789ba227aa56299001_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1806af5ab5b1428dbecc44603e625189_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:MaterialsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d5dfcdeeecf40d4bbfce822eba097da_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:AchievementOfEnrollmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i539bb433e4534e329bc2c02884235317_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5bd7d664de45838a638a9e07b56636_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38edd55d27744d19aae8f3e58923a1d8_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8ceffe851924b93b694c2c233f516a4_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a88aa30ce5f40f6915bd8be98ea9592_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i03c5d4dd537e4ff08c58974c361af177_I20190619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:PriorPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25175afe9d9d4c0f895fef5eab8d5af5_I20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:PriorPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i158c1d7853cc43d08c48916341fcc559_I20210211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:CampusPointLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i695ef34b99df4efc8fc1b1d5d72d82f2_D20210211-20210211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:CampusPointLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>rgls:contract</xbrli:measure></xbrli:unit><xbrli:context id="i9f5be9f84b7d49a28e6d8c05f8aaaa70_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505512</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:CampusPointLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1bd3a25286f94961af32b70947dcc597_1"></div><div style="min-height:31.5pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6ZmNhMDg5ODYwMTllNDU2MGFkNThmNDlmNTUwNjFkYjYvdGFibGVyYW5nZTpmY2EwODk4NjAxOWU0NTYwYWQ1OGY0OWY1NTA2MWRiNl8wLTItMS0xLTYxMDM_a0ee81bd-bfdb-403a-aad8-b65092e09918">10-Q</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NmJkMjU5ZmQ2ZmI1NDFjNTk4OTAzMTc4MjczNGIzYmUvdGFibGVyYW5nZTo2YmQyNTlmZDZmYjU0MWM1OTg5MDMxNzgyNzM0YjNiZV8wLTAtMS0xLTYxMDM_336bf064-d9c3-4d10-817a-7cb662f52689">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xMjU_5a30e98d-a5a3-4ff6-82c4-29d192864013">SEPTEMBER 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6ZTNiYmRlYWQyNTdkNGUzMmE0OGNkY2FjMDljZTYwYTAvdGFibGVyYW5nZTplM2JiZGVhZDI1N2Q0ZTMyYTQ4Y2RjYWMwOWNlNjBhMF8wLTAtMS0xLTYxMDM_080defea-8a50-4057-87b3-6cb2739d9e2a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TO </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc0_303baa3f-d620-4a7c-b882-6d080919f23c">001-35670</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%">Regulus Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl8wLTAtMS0xLTYxMDM_1031ccba-af0a-4b0b-836d-9314b31dd743">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl8wLTItMS0xLTYxMDM_ef8340f3-665c-43b8-95a9-4b7424e05c55">26-4738379</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl8zLTAtMS0xLTYxMDM_2f8a134a-2a05-4b09-8577-aea272dd6587">4224 Campus Point Court, Suite 210</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl8zLTItMS0xLTYxMDM_b850c983-9a80-41a8-b8f3-233c1df663c7">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl80LTAtMS0xLTYxMDM_5fbade03-a80a-4484-8c7b-c95f4e5d2dda">San Diego</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl81LTAtMS0xLTYxMDM_bdd676b3-b4b2-4f9d-9f25-4f7b0c6afd3d">CA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc1_50f44ecb-d0f8-4cc8-8e4a-73534e13b356">858</ix:nonNumeric>-<ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc2_cd8c4110-fbe4-4660-8fee-cd4bec3c115c">202-6300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.674%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NTBkN2M4ZDg1YmY1NDM2YWE3MTcxNTYxMmQyNmVhNjgvdGFibGVyYW5nZTo1MGQ3YzhkODViZjU0MzZhYTcxNzE1NjEyZDI2ZWE2OF8xLTAtMS0xLTYxMDM_90df24c1-df4a-4f93-8af6-a3b5acbf88b4">Common Stock, par value $0.001 per share</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NTBkN2M4ZDg1YmY1NDM2YWE3MTcxNTYxMmQyNmVhNjgvdGFibGVyYW5nZTo1MGQ3YzhkODViZjU0MzZhYTcxNzE1NjEyZDI2ZWE2OF8xLTItMS0xLTYxMDM_3f4a11ab-cd51-4aee-9e74-f80e3fc5a49d">RGLS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NTBkN2M4ZDg1YmY1NDM2YWE3MTcxNTYxMmQyNmVhNjgvdGFibGVyYW5nZTo1MGQ3YzhkODViZjU0MzZhYTcxNzE1NjEyZDI2ZWE2OF8xLTQtMS0xLTYxMDM_5c2b25d3-a78f-4be5-8fd9-9b7b28236b51">The Nasdaq Stock Market LLC</ix:nonNumeric><br/></span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc3_9ec55fb2-7546-443c-b584-f7dcacb32ced">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc4_705aadb4-59b4-4382-9440-551860a56ad1">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6M2Q2ZjhiZWUxZTIwNDRhOWFkNDhmZjVlOGYxYTVjZjIvdGFibGVyYW5nZTozZDZmOGJlZTFlMjA0NGE5YWQ0OGZmNWU4ZjFhNWNmMl8xLTAtMS0xLTYxMDM_2fde46eb-57df-4075-904e-5ad190b3e375">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6M2Q2ZjhiZWUxZTIwNDRhOWFkNDhmZjVlOGYxYTVjZjIvdGFibGVyYW5nZTozZDZmOGJlZTFlMjA0NGE5YWQ0OGZmNWU4ZjFhNWNmMl8xLTYtMS0xLTYxMDM_0c23cc09-9235-4a4a-a92e-33549451c259">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6M2Q2ZjhiZWUxZTIwNDRhOWFkNDhmZjVlOGYxYTVjZjIvdGFibGVyYW5nZTozZDZmOGJlZTFlMjA0NGE5YWQ0OGZmNWU4ZjFhNWNmMl8yLTYtMS0xLTYxMDM_7349673c-485d-495d-8d7d-b909d572639d">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xODgy_8250a955-7464-4081-99b7-1bb46ce7798b">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">f November&#160;5, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i8111d7345b08453e894915175538e2d9_I20211105" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTE0_a316034f-a30b-4dfb-acc8-3f86a532f8a5">87,047,832</ix:nonFraction> sha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">res of Common Stock ($0.001 par value) outstanding.  </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1bd3a25286f94961af32b70947dcc597_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGULUS THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I. FINANCIAL INFORMATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_16">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_19">Condensed Balance Sheets as of September 30, 2021 (Unaudited) and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_22">Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2021 and 2020 (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_25">Condensed Statements of Changes in Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2021 and 2020 (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_28">Condensed Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_31">Notes to Condensed Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_61">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_61">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_85">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_85">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_88">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_88">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II. OTHER INFORMATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_94">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_94">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_97">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_97">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_100">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_100">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_103">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_103">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_106">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_106">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_109">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_109">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_112">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bd3a25286f94961af32b70947dcc597_112">59</a></span></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:12pt"><span><br/></span></div><div id="i1bd3a25286f94961af32b70947dcc597_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RISK FACTOR SUMMARY</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Below is a summary of the material factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; under Part II, Item 1A of this Quarterly Report and should be carefully considered, together with other information in this Quarterly Report before making investment decisions regarding our common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The approach we are taking to discover and develop drugs is novel and may never lead to marketable products.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We may not be successful in our efforts to identify or discover potential product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Preclinical and clinical studies of our product candidates may not be successful. If we are unable to generate successful results from our preclinical and clinical studies of our product candidates, or experience significant delays in doing so, our business may be materially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Payments under the instruments governing our indebtedness may reduce our working capital. In addition, a default under our loan and security agreement could cause a material adverse effect on our financial position.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We have never generated any revenue from product sales and may never be profitable.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We will depend upon collaborations for the development and eventual commercialization of certain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RNA product candidates. If these collaborations are unsuccessful or are terminated, we may be unable to commercialize certain product candidates and we may be unable to generate revenues from our development programs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We rely on limited sources of supply for the drug substance of product candidates and any disruption in the chain of supply may cause a delay in developing and commercializing these product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If we are unable to obtain or protect intellectual property rights related to our future products and product candidates, we may not be able to compete effectively in our markets.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our business could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations globally, including at our headquarters in San Diego, and at our clinical trial sites, as well as the business or operations of our collaborators, manufacturers, contract research organizations ("CROs") or other third parties with whom we conduct business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The market price of our common stock may be highly volatile.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We may be unable to comply with the applicable continued listing requirements of The Nasdaq Capital Market.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1bd3a25286f94961af32b70947dcc597_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="padding-left:27pt;padding-right:27pt;text-align:center;text-indent:-54pt"><span><br/></span></div><div id="i1bd3a25286f94961af32b70947dcc597_16"></div><div style="padding-left:103.5pt;text-indent:-103.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. &#160;&#160;&#160;&#160;FINANCIAL STATEMENTS </span></div><div id="i1bd3a25286f94961af32b70947dcc597_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulus Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNC0xLTEtMS02MTAz_844fd44b-abf6-4651-86b5-b5f3f7b8a66a">35,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNC0zLTEtMS02MTAz_f0369073-affe-41e9-8267-4019e2d24313">31,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNi0xLTEtMS02MTAz_ec9fd2b2-ae90-4f7d-903f-7924f0460043">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNi0zLTEtMS02MTAz_52900be6-3553-4700-89e2-1406947e1eef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNy0xLTEtMS02MTAz_1db43bc1-aa1d-4ea3-9368-0dc5ec797627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNy0zLTEtMS02MTAz_6fd1c589-7380-4177-a5be-268a231888ba">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid materials, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfOC0xLTEtMS02MTAz_51169c70-d893-4fd8-8df4-88ae22fd168a">3,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfOC0zLTEtMS02MTAz_9c0eeb07-1034-4ab8-be6e-3d2a1dca7787">3,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfOS0xLTEtMS02MTAz_2fc8c1b7-954c-4816-adc5-942c1df34d48">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfOS0zLTEtMS02MTAz_3ba58bad-f878-4a35-94a3-ba2cc148e692">1,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTAtMS0xLTEtNjEwMw_b9cd008f-d28b-4190-8a23-bac0a6011f43">39,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTAtMy0xLTEtNjEwMw_2732b7da-9e9d-4222-8de7-bbfc3112c302">36,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTEtMS0xLTEtNjEwMw_3bf55de3-0915-4e86-8088-52e0e1076846">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTEtMy0xLTEtNjEwMw_95b4c357-7505-4e59-ad84-84f027ce073d">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTItMS0xLTEtNjEwMw_05aeaf9f-8366-44f3-ac53-0712a0be9b12">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTItMy0xLTEtNjEwMw_e8f618e8-5a27-4dfb-91ae-7823c4fc608e">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTMtMS0xLTEtNjEwMw_b58440a4-8782-499e-8c48-e4fbeaf0898e">2,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTMtMy0xLTEtNjEwMw_43ea867b-98e9-490e-82e4-2d284924f730">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTQtMS0xLTEtNjEwMw_75fd47fe-489e-4119-8361-87c40033dd23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTQtMy0xLTEtNjEwMw_72bd9e3d-5894-41ca-b359-ba8062993c7c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTUtMS0xLTEtNjEwMw_a429bdec-4b57-4e1c-87b5-9c681b7a584e">43,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTUtMy0xLTEtNjEwMw_84c2cd50-4097-413a-8300-34a7bd15a6e4">37,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTgtMS0xLTEtNjEwMw_a885b34e-2755-488d-95e2-d259e65f3361">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTgtMy0xLTEtNjEwMw_9b8870ed-6fbf-4c16-935e-9e5bd9037212">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTktMS0xLTEtNjEwMw_acc190b5-da60-4790-9bfe-169c13e1d72d">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTktMy0xLTEtNjEwMw_71b90a55-b137-4d53-b9b9-17e26ce450de">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="rgls:AccruedResearchAndDevelopmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjAtMS0xLTEtNjEwMw_0c4a3c6e-9251-4e87-953c-3da5b3187843">2,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="rgls:AccruedResearchAndDevelopmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjAtMy0xLTEtNjEwMw_70c1b0b0-27fb-4ce9-8537-dc1799dfb138">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjEtMS0xLTEtNjEwMw_16e7d35c-d2d8-4686-8272-948d2f583339">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjEtMy0xLTEtNjEwMw_e863ec26-0174-44ba-b192-52411cb47c3f">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of term loan, less debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjItMS0xLTEtNjEwMw_7bc5e95e-bb1d-4946-8c74-1f0156d19410">4,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjItMy0xLTEtNjEwMw_81e20453-b41f-4149-b59b-c258e445af9e">4,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjUtMS0xLTEtNjEwMw_78341102-c52e-4ddc-aaa9-68ce3ebfcb5d">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjUtMy0xLTEtNjEwMw_f5b24770-6c38-48c7-92fb-d3e4ee521fb8">2,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjYtMS0xLTEtNjEwMw_e706ea8d-3b83-4063-8395-be2d04575607">11,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjYtMy0xLTEtNjEwMw_844ee5c8-537e-4c95-818c-0e25a9288174">11,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzAtMS0xLTEtNjEwMw_e681f4a7-b86d-4f49-ace5-c7ff3e655a84">2,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzAtMy0xLTEtNjEwMw_6e6c554a-dc30-446e-a564-964fddd9aeb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzItMS0xLTEtNjEwMw_226c549d-befd-4225-aec8-cf66afe139d2">14,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzItMy0xLTEtNjEwMw_edb16882-239a-4bf1-ac49-2abcc228da06">11,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzMtMS0xLTEtNjEwMw_4923c1bb-7057-4a6f-a90a-de3ef50ee081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzMtMy0xLTEtNjEwMw_0ba4382c-0e4e-4e9e-87a0-a04196a23753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-1 convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzQz_13ebbc0b-2f20-41ce-8907-b85fc874b0cd"><ix:nonFraction unitRef="usdPerShare" contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzQz_4b6ff5cd-194c-4be6-a93e-d8947bafaf12">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_046d87c0-be1b-49f4-a7dc-93929e917244"><ix:nonFraction unitRef="shares" contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_53b663ad-94a5-4278-8e9a-4b8a4a02ddeb"><ix:nonFraction unitRef="shares" contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_75a74915-ecdf-475d-b9f2-6c870404f813"><ix:nonFraction unitRef="shares" contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_a32d9995-f714-4c51-9c28-db0bc474268c"><ix:nonFraction unitRef="shares" contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_c027a46b-951e-415f-ba0d-089765503e6f"><ix:nonFraction unitRef="shares" contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_f8e6116e-b629-4ec7-8fe7-93d63cd221b6">256,700</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued, and outstanding at September 30, 2021 (unaudited) and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMS0xLTEtNjEwMw_33955a6a-9643-4308-a0ab-a23a3daf2434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMy0xLTEtNjEwMw_433a9699-0a38-4f50-9b63-36028e5e1c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-2 convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzQz_8eadd80f-cab9-424b-bfb5-c8dc6dbc52a3"><ix:nonFraction unitRef="usdPerShare" contextRef="iec8b178ce8274601b70fd58c2f287d14_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzQz_eba3f7d3-a2e2-48f5-b8a4-8c21c7192fb4">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzU3_928f4314-12a6-4c49-8958-346b112234cf"><ix:nonFraction unitRef="shares" contextRef="iec8b178ce8274601b70fd58c2f287d14_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzU3_dfe47a93-b316-4896-a37d-fad235acc366"><ix:nonFraction unitRef="shares" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzU3_f5063e13-e5b1-49e3-99d0-9ccca111cc53">1,330,832</ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzY0_1d3c41bb-ccc2-4bdc-a60f-68da7d87921e"><ix:nonFraction unitRef="shares" contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzY0_3a8e8aa2-ccb7-4ecd-92e3-6a3a44ee2c19"><ix:nonFraction unitRef="shares" contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzY0_795f0864-baf3-40c3-86d7-39635282aa8a">1,416,453</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued, and outstanding at September 30, 2021 (unaudited) and December 31, 2020, respectively </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec8b178ce8274601b70fd58c2f287d14_I20210930" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMS0xLTEtNjEwMw_09aaef99-89ca-40cd-bdb1-5f44ad68cfb0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMy0xLTEtNjEwMw_56682c0b-2c63-4116-8615-aec2a3e5257f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-3 convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzQz_41bbe767-94f8-432b-a41a-642f557e2b22"><ix:nonFraction unitRef="usdPerShare" contextRef="ic60d06be298b4e55a466408378417d03_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzQz_e981ec38-ab73-4465-8fd3-73e169d3de80">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_5b9631a6-6d77-4296-802f-c157f039c622"><ix:nonFraction unitRef="shares" contextRef="ic60d06be298b4e55a466408378417d03_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_89b4a14a-ab23-4b1f-8c2e-4cc915634c3b"><ix:nonFraction unitRef="shares" contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_bdf48984-e605-4385-8661-8dd2af2ece17"><ix:nonFraction unitRef="shares" contextRef="ic60d06be298b4e55a466408378417d03_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_c8156336-82f3-4b77-989b-21a1f5157d59"><ix:nonFraction unitRef="shares" contextRef="ic60d06be298b4e55a466408378417d03_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_f4292218-a880-4a0c-b0f4-adec6a13d7ca"><ix:nonFraction unitRef="shares" contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_f85bd27c-7fc8-4bc5-b1d7-0ed581855f77">258,707</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued, and outstanding at September 30, 2021 (unaudited) and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMS0xLTEtNjEwMw_ded0372e-3f64-4a4a-8da6-3c2f2e1a76f4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic60d06be298b4e55a466408378417d03_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMy0xLTEtNjEwMw_9d4fcf3b-eb32-47ee-b408-40058ee6403c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzE4_0998ab02-d030-48de-b753-5be3fe939c08"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzE4_5b3256dc-7860-46c7-b210-35203c65d09d">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzMy_b951a404-f150-46ee-b193-24d368b54beb">400,000,000</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzQ2_97d30e61-6000-4953-959b-977c5bfefd6c">200,000,000</ix:nonFraction> authorized at September 30, 2021 and December 31, 2020, respectively; <ix:nonFraction unitRef="shares" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzExNA_0d0d2474-71f0-47e2-b292-f9218b9df631"><ix:nonFraction unitRef="shares" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzExNA_c2fb4856-4018-40e9-89f8-673aafa1eae3">87,047,832</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzEyMQ_db4fd1fb-5e8b-4959-b2e7-0cb307ede5ec"><ix:nonFraction unitRef="shares" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzEyMQ_eb7d3271-98e7-4eb7-b3da-28eb4d342905">67,432,712</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2021 (unaudited) and December&#160;31, 2020, respectively </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMS0xLTEtNjEwMw_62b3eeee-f5b1-4baf-b022-7aaed1b0eb8e">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMy0xLTEtNjEwMw_a76acad1-7667-409b-bbf7-a3baa9358659">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzktMS0xLTEtNjEwMw_e376153c-9794-4151-b737-d9cd41dd77df">476,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzktMy0xLTEtNjEwMw_7ebe81ce-8afc-4898-9036-488b1a6076a4">453,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDEtMS0xLTEtNjEwMw_8d105ebc-2a84-454e-91ce-16aad7b5e768">447,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDEtMy0xLTEtNjEwMw_de75f1d4-1ed4-4691-92e8-75a1f29c856b">427,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDItMS0xLTEtNjEwMw_88dd299c-011c-4ecd-8f38-3237f12dbc68">29,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDItMy0xLTEtNjEwMw_9f27063c-50f3-4c51-9fa6-266d5cc82f17">26,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDMtMS0xLTEtNjEwMw_df304bb7-cd32-46b9-94f6-276022f96685">43,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDMtMy0xLTEtNjEwMw_50c959dc-6861-4df2-9f6d-699e5abe257e">37,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these condensed financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1bd3a25286f94961af32b70947dcc597_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulus Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_565d7559-28ba-4345-9a0b-75933eaa77e7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_59cfb3be-2728-482e-ae52-18bdd71ebc3f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_7ca68d24-3d91-478b-b761-58d0319ff7a8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_90ce62b6-7870-4d8c-9f4c-aed84ce70c1e">Revenue under collaborations</span></span></span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0xLTEtMS02MTAz_5e0981da-e334-4094-8210-59edb1e5763b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0zLTEtMS02MTAz_4fb5e8c3-84e0-4f27-9fd5-dc00f4364020">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC01LTEtMS02MTAz_2822f4cb-f798-433e-9f01-cdd135c064cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC03LTEtMS02MTAz_1888301c-e9c2-4867-b09c-af1b0b22d673">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNS0xLTEtMS02MTAz_67478895-7752-487c-8f7f-aad796fbf8e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNS0zLTEtMS02MTAz_3d8ac9c0-44aa-4767-8ca6-937aab505904">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNS01LTEtMS02MTAz_1868ab70-775b-4272-845e-f8e2716751ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNS03LTEtMS02MTAz_d0a7c41d-0214-4efa-a247-689bed8741f2">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNy0xLTEtMS02MTAz_6dd8d99e-3372-4a6a-8bf7-86078f3d6358">5,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNy0zLTEtMS02MTAz_066b32ed-c848-4a53-8257-11f30727e145">4,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNy01LTEtMS02MTAz_c3a1c60d-1cc9-4029-9ec3-8b453d1b5160">13,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNy03LTEtMS02MTAz_669be64a-c539-40fc-83ef-60732efbdfe5">11,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOC0xLTEtMS02MTAz_2e764590-3c0b-4d07-8a4f-a93b7fe4b874">2,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOC0zLTEtMS02MTAz_b23013a2-3b06-43e4-ad9b-eca1b246c104">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOC01LTEtMS02MTAz_47e3ce90-88b0-4abf-bd2f-bfbc9c624424">7,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOC03LTEtMS02MTAz_31deeca3-34ad-4a37-bdfb-60a12f0a2866">6,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOS0xLTEtMS02MTAz_fc73d992-3b0a-4dae-878d-8414fc49c003">8,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOS0zLTEtMS02MTAz_965ba984-3730-433b-8bdf-5cfd551985be">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOS01LTEtMS02MTAz_0d46ad32-9025-4341-9995-dbc6b97e9372">20,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOS03LTEtMS02MTAz_74b3554d-2060-45a9-a077-9a52e22d8ca7">18,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTAtMS0xLTEtNjEwMw_a4a07e65-dcae-48e4-8bb9-997e7d2f830e">8,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTAtMy0xLTEtNjEwMw_305c06f5-201a-4255-bdc2-76de2dafecea">1,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTAtNS0xLTEtNjEwMw_fcbc66dd-3042-41da-8da1-5e4ce7222009">20,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTAtNy0xLTEtNjEwMw_7620c854-a0bf-42d4-92d0-7d84425c027f">13,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTItMS0xLTEtNjEwMw_3cc2d1f8-f40b-48dc-b1a9-1a5468ed4c2a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTItMy0xLTEtNjEwMw_cf10c740-ce12-4017-bf26-e630ad71bbf1">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTItNS0xLTEtNjEwMw_b60a5e3d-841a-4aa4-abbe-4af6977fe709">823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTItNy0xLTEtNjEwMw_550410ba-abfd-4376-ac29-c5f0abcb28e4">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTMtMS0xLTEtNjEwMw_977b551b-8bea-47f7-953f-ceaffa85ea14">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTMtMy0xLTEtNjEwMw_5a16cc64-308e-4245-90ba-70fac2bb2395">466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTMtNS0xLTEtNjEwMw_8f2f82d2-aba2-4664-9612-3cdb95a65579">641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTMtNy0xLTEtNjEwMw_b9d04fd7-b658-484e-b750-54b37c4092be">1,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTUtMS0xLTEtNjEwMw_4d213056-1970-41fe-93dd-d620be08939e">8,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTUtMy0xLTEtNjEwMw_a17aab4f-f93d-4b9b-a547-5f24fbd270b2">1,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTUtNS0xLTEtNjEwMw_64894ab0-c60e-412b-af30-8182b0990ba1">20,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTUtNy0xLTEtNjEwMw_207bc442-7ff9-4fb0-9d72-968475e95865">14,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTYtMS0xLTEtNjEwMw_4322e17d-9c84-4749-9c00-5fdbe6420a23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTYtMy0xLTEtNjEwMw_56f82adb-1bb6-4e09-b51f-815119f5cb3c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTYtNS0xLTEtNjEwMw_317869bd-4bd1-4d96-987b-f30f1de163b8">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTYtNy0xLTEtNjEwMw_87a8408c-5745-437b-9a01-3a5f11f08527">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTctMS0xLTEtNjEwMw_55af8e09-2d3a-428d-84f8-8ba4ee657fa1">8,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTctMy0xLTEtNjEwMw_6be744ee-f2fb-4bca-bf7b-ebb0d1c2875d">1,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTctNS0xLTEtNjEwMw_8a92fd52-c528-409e-b7fa-b617bd612476">20,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTctNy0xLTEtNjEwMw_76880a23-a1ff-412b-aca2-01ef9885c851">14,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtMS0xLTEtNjEwMw_6b7ed4f8-bd95-415a-b62f-1ca9d995a2b9"><ix:nonFraction unitRef="usdPerShare" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtMS0xLTEtNjEwMw_f2eaed93-08f4-4b98-b1ac-6e2841437cff">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtMy0xLTEtNjEwMw_698b1cc2-74fe-4d56-9444-a7ac366c77b1"><ix:nonFraction unitRef="usdPerShare" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtMy0xLTEtNjEwMw_ec79aa01-f36b-458d-ac60-d6ea97b73d87">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtNS0xLTEtNjEwMw_0b420a0f-cb22-41a1-b07f-f189a5e80d29"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtNS0xLTEtNjEwMw_935ff82e-eaa3-4dfd-a0b5-733e1c52c56c">0.26</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtNy0xLTEtNjEwMw_0c61de94-accc-4433-9afe-69a5c7c4a454"><ix:nonFraction unitRef="usdPerShare" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtNy0xLTEtNjEwMw_638a014f-1539-48d4-8ce0-b3c65c4f430f">0.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItMS0xLTEtNjEwMw_2ce63866-2ca9-4fb8-9ac5-d3d72be1f819"><ix:nonFraction unitRef="shares" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItMS0xLTEtNjEwMw_fbb8e4a7-2734-4730-aa60-d90d0f37ecd0">87,042,437</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItMy0xLTEtNjEwMw_f2b1087e-efe3-45c4-a226-e813272d3aa8"><ix:nonFraction unitRef="shares" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItMy0xLTEtNjEwMw_fd246c27-92fe-4e7c-b1d3-80b4bc688c13">38,137,281</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItNS0xLTEtNjEwMw_d1448ed7-5e07-4d2c-b8c2-92949d64e93b"><ix:nonFraction unitRef="shares" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItNS0xLTEtNjEwMw_e429cb10-751b-490a-a9ce-1f3079dad128">78,560,760</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItNy0xLTEtNjEwMw_05a89572-7a46-47d8-a91a-b7e118e2b3e7"><ix:nonFraction unitRef="shares" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItNy0xLTEtNjEwMw_d99f9e42-4f15-44a2-9eb2-4e1f6612b42c">30,695,137</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these condensed financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i1bd3a25286f94961af32b70947dcc597_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulus Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.186%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity&#160;(deficit)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01168e5978e14e958219e06962200018_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtMS0xLTEtNjEwMw_1659305c-af51-455e-923b-3562b8b9d1f5">1,931,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01168e5978e14e958219e06962200018_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtMy0xLTEtNjEwMw_25d6fe5e-86eb-49c9-a036-43cd4c3ed176">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c3f16817aff4123aca2966839b53fda_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtNS0xLTEtNjEwMw_16286674-d184-464e-ac1f-96ccf9d37ba1">67,432,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3f16817aff4123aca2966839b53fda_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtNy0xLTEtNjEwMw_8cca0a76-1c76-4715-8fed-71a650f4873e">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc56a36fc5e488986a42a9c474e76c6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtOS0xLTEtNjEwMw_7accb952-f756-4fc3-aab9-13d57eedf4e7">453,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72366e3fa5d44f0e9f12dbd590832293_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtMTMtMS0xLTYxMDM_51a9f9df-c2b5-40d4-be5d-fb4e2082f63f">427,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtMTUtMS0xLTYxMDM_c59157a6-f50c-4301-8aef-6fde859770c1">26,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDYtNS0xLTEtNjEwMw_c3591dfa-2d62-482d-86f6-2299bf7f4ccf">16,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDctNS0xLTEtNjEwMw_56fa5659-3e31-4c13-8600-219ec2ec749a">26,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDctOS0xLTEtNjEwMw_e3a6551d-31f3-4c2d-a8b3-dc78a2638ed5">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDctMTUtMS0xLTYxMDM_c48bd710-a30d-420f-a792-a3fe1c0f08e5">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="rgls:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDgtNS0xLTEtNjEwMw_cbe093de-f40c-4d88-b4e3-0ce4d4756e0e">2,418,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331" decimals="-3" name="rgls:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDgtNy0xLTEtNjEwMw_e59ecaee-6715-41c6-a574-5cdf10e446bd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331" decimals="-3" name="rgls:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDgtOS0xLTEtNjEwMw_5479e610-c837-4e88-89d7-5e95b505d9d6">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331" decimals="-3" name="rgls:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDgtMTUtMS0xLTYxMDM_40581095-e97f-49e3-bfec-c90d4d284db0">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock through ATM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDktNS0xLTEtNjEwMw_f5fd469f-d37c-46c7-8ee6-109477397148">4,009,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDktNy0xLTEtNjEwMw_431b1789-c19e-4887-9889-9490889abffb">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDktOS0xLTEtNjEwMw_7d0d8451-0f6b-4388-82f5-12a99e871179">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDktMTUtMS0xLTYxMDM_9c211d31-b860-49c8-bbbd-71377aed5d11">5,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTAtNS0xLTEtNjEwMw_60850dcf-656b-4b95-a836-6a8a742809a3">4,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTAtOS0xLTEtNjEwMw_5de3c655-7851-4ee5-9777-e4b1522a60e6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTAtMTUtMS0xLTYxMDM_3c74956b-5abf-4e31-9b07-8c435d1a4e16">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversions of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i70db96b959cb44848f3b413e51827d92_D20210101-20210331" decimals="INF" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtMS0xLTEtNjEwMw_9f11bf20-37ca-449d-a898-57d7d8d1ebb2">78,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtNS0xLTEtNjEwMw_8dfacee3-2a55-4908-811d-1f5c33f4316e">780,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtNy0xLTEtNjEwMw_62a7d5b4-567d-4a53-bcde-32ef21f4d9fd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtOS0xLTEtNjEwMw_0e2ea32b-278e-47a3-90ad-741ddee3bee5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtMTUtMS0xLTYxMDM_a400509c-5574-4b31-a399-6a270d123439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTItOS0xLTEtNjEwMw_92db44b6-4700-462f-9fa1-b9ab90b3e6fb">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTItMTUtMS0xLTYxMDM_a40ba516-098b-4589-98af-3255901ae0b0">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i051ea96b453f429caa68e3801ce5bc29_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTgtMTMtMS0xLTYxMDM_fb939133-eb09-4687-a343-c931c43ef3ab">6,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTgtMTUtMS0xLTYxMDM_0ebbfa46-8ac3-4fd2-8e36-6e60cd0c1118">6,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if883ca285d9e4b31bc6d7edfdd22e3b6_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktMS0xLTEtNjEwMw_aac89ea6-f901-4e05-bc7d-2adb0e85e4a5">1,853,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if883ca285d9e4b31bc6d7edfdd22e3b6_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktMy0xLTEtNjEwMw_134c2998-4d3c-45b0-95ff-a25dadf9383c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6ee41175879423c93045b232c54bfe7_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktNS0xLTEtNjEwMw_8f86f476-0d1e-4f0c-b504-4f5c5e91e7ce">74,689,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ee41175879423c93045b232c54bfe7_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktNy0xLTEtNjEwMw_35e205c1-b420-45a0-b8ca-c8471e9a39f9">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea678063a4e5490b8f065fd950d4952d_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktOS0xLTEtNjEwMw_80d42f4f-9b93-4626-9c64-71c8dc0b3b32">460,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i266c364e78cb46aeab7659ca36e88cbf_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktMTMtMS0xLTYxMDM_011b9794-375f-4e0c-88ac-c839053fc290">433,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3a053cc647497aacd5d5b56004d10f_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktMTUtMS0xLTYxMDM_d975a4eb-289e-4a89-96e9-343821b12d3f">27,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjAtNS0xLTEtNjEwMw_748b71e3-c517-4e39-8460-63d4966459f9">16,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjEtNS0xLTEtNjEwMw_768e4f7a-011c-4f59-b014-6fb3be6ee95f">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjEtMTUtMS0xLTYxMDM_f32e2636-b3f5-4eec-b9b0-f857eb72f19a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="rgls:StockIssuedDuringPeriodSharesExerciseOfWarrants" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjItNS0xLTEtNjEwMw_f1585a5d-ee34-43b1-8cb8-d45220d8303d">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4b3672299546139d7e04d964128b42_D20210401-20210630" decimals="-3" name="rgls:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjItOS0xLTEtNjEwMw_a813343b-da36-4749-a130-d0a90ea47e8e">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630" decimals="-3" name="rgls:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjItMTUtMS0xLTYxMDM_a8705e91-6cbe-445e-b99a-099f887c7967">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock through ATM</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjMtNS0xLTEtNjEwMw_34da03c6-2919-4001-8c17-7f6b1810b845">12,007,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjMtNy0xLTEtNjEwMw_19bb4261-da53-441d-96a8-ebf21028cea6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4b3672299546139d7e04d964128b42_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjMtOS0xLTEtNjEwMw_47e8bc81-202b-4ebb-b3c0-31daf645b208">14,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjMtMTUtMS0xLTYxMDM_7ab7653e-ceac-4c5a-aebd-802d921aba91">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversions of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5525c2dcee4a4d748f8cfbc31dfc8db3_D20210401-20210630" decimals="INF" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjUtMS0xLTEtNjEwMw_4612f375-9bbb-49b3-b239-bbc777927efa">7,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjUtNS0xLTEtNjEwMw_d19b6369-c40f-4f70-acfb-46396ede66c8">75,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjUtMTUtMS0xLTYxMDM_0bd6c0f8-cfd9-41a3-a1c5-feb863e15f77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4b3672299546139d7e04d964128b42_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjYtOS0xLTEtNjEwMw_fc49d0f8-5c0e-4a41-8baa-1c54144af738">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjYtMTUtMS0xLTYxMDM_a468fd2c-ea94-4877-98e0-12781b904a98">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d36a105ae449beb839ab6a815bcf59_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjctMTMtMS0xLTYxMDM_a2553734-8bd1-494e-b7ad-28dc5f06bee8">6,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjctMTUtMS0xLTYxMDM_6c241c7d-978e-48b9-99f7-43c723d703f8">6,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i020405b1a3e24f1281f97a16daf92291_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtMS0xLTEtNjEwMw_cd19176a-da4b-4319-ac76-369ad7cbe2a8">1,846,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020405b1a3e24f1281f97a16daf92291_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtMy0xLTEtNjEwMw_5048faa0-937d-4de7-bef4-ecd7a9e65b8f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32e9077c24de4469bfd47b1d8acb39a3_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtNS0xLTEtNjEwMw_b181ddc2-70fd-4bb0-bc77-380f48ed031b">87,040,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e9077c24de4469bfd47b1d8acb39a3_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtNy0xLTEtNjEwMw_37aef6b3-4715-4430-8fed-b10dffd14561">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdcfbfd5e98440c85fbaf81e72f285d_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtOS0xLTEtNjEwMw_2774be93-43ac-4d60-b216-aa88ea57cea3">475,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4935d8a23a6f420385a4f517fac836e2_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtMTMtMS0xLTYxMDM_8b6d6ff2-2174-4cef-a373-bb40b4adfffb">439,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ca9e82037e4fc2adef24baea0d6e30_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtMTUtMS0xLTYxMDM_d3540efb-14dd-4b36-a99b-3b7733a9d1f3">36,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69c825f130c2462d822bff3231997bf0_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzMtNS0xLTEtNjc3Nw_859662d6-2bfc-47cb-9920-a777edd2885a">7,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c707f52c3ad423d9929a3b102a980e8_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzMtOS0xLTEtNjc3Nw_5737e134-3e86-42e9-acd6-7252d4d119b5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzMtMTUtMS0xLTY3Nzc_db9b0c94-ac2b-4f8a-ad3c-902528cc3d16">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c707f52c3ad423d9929a3b102a980e8_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtOS0xLTEtNjc3OQ_e976f7e6-a742-45f8-994f-25664a24980e">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtMTUtMS0xLTY3Nzk_07ef892c-b583-4067-b149-adadd9c18a78">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3d073fce4e748a79a7a58c6ebd79572_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMTMtMS0xLTY3Nzk_bde71601-3af0-4feb-a4d0-3f6d6b75a977">8,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMTUtMS0xLTY3Nzk_f1a1ab34-3b52-4b69-99e6-e8c46ef2a1d7">8,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c592b3c93f247f4bdddc3f28cf0bcc4_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMS0xLTEtNjc3OQ_70e828bd-7ada-4d86-96ac-9e5ba51a65ac">1,846,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c592b3c93f247f4bdddc3f28cf0bcc4_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMy0xLTEtNjc3OQ_bd212719-bc6a-4c8a-b290-ff2b9560d976">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1329e87d85994ed5aec3fc36abc2f3f6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctNS0xLTEtNjc3OQ_4ab03ddf-f5d1-4852-8783-e0abc5f0b8fe">87,047,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329e87d85994ed5aec3fc36abc2f3f6_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctNy0xLTEtNjc3OQ_0224085e-6b0c-45f0-93c1-df636a5b95c5">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb8b8d131534c03ad4f1dc07b5cd25c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctOS0xLTEtNjc3OQ_945b28d8-de71-464d-9510-e85056cf6e55">476,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3092be79f8214d54a1f70f92a5d08c86_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMTMtMS0xLTY3Nzk_82e2eac0-06dc-4c9d-93f9-8c7708aa134e">447,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMTUtMS0xLTY3Nzk_7b58f1bf-7f9a-46a9-9f47-6facfb9394e5">29,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.186%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity&#160;(deficit)</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00b19f57325c448582fbbc67739c326b_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtMS0xLTEtNjEwMw_8c1cf5b6-2985-47d5-8cc3-a91ba3ae0d78">3,704,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b19f57325c448582fbbc67739c326b_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtMy0xLTEtNjEwMw_8beea695-4a3c-4f9b-8c1d-c84eb0a56f01">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb8e219bee614949b739b6c590453b4e_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtNS0xLTEtNjEwMw_63301f51-0674-4bce-83f0-31a6e7fd0cd4">21,018,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e219bee614949b739b6c590453b4e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtNy0xLTEtNjEwMw_2d1ba0f7-0b85-4044-97b4-701790ee857c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3320ae2f75043c2bb5c26a7ec8241e0_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtOS0xLTEtNjEwMw_559ed2d9-6b51-4fa1-8a58-111cc64802ac">431,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46dcde68ee6949fabac04d61528c3adb_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtMTMtMS0xLTYxMDM_f98129c2-ada4-48ed-9405-571e03ffe31a">411,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88172ee03d6b45da9f2508fc8c899e50_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtMTUtMS0xLTYxMDM_548bb742-e4c6-41fa-88bb-897e04b85325">20,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzItNS0xLTEtNjEwMw_5fbeafd2-825e-4a87-a299-f8f17d8f12f5">21,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzQtNS0xLTEtNjEwMw_d119fef4-21f1-4711-81af-315c20ce1a81">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzQtMTUtMS0xLTYxMDM_8428b4a2-142c-4529-bcd7-aa8755bcf841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtNS0xLTEtNjEwMw_47f88a82-9ee2-4f3c-bd22-b8959c6f99f1">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e728fa3cb540d5917b1e146d5c075e_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtOS0xLTEtNjEwMw_8073806e-5382-48d2-972a-bacd0a0c18a5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtMTUtMS0xLTYxMDM_45df6831-c65a-46cd-b81e-320b1ccd81e4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversions of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iec31e70363d949bc869ebd9d662e556f_D20200101-20200331" decimals="INF" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMS0xLTEtNjEwMw_adf3d10f-5236-4674-b178-de81862828fa">656,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec31e70363d949bc869ebd9d662e556f_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMy0xLTEtNjEwMw_80186c5d-7e05-44d9-9c4d-7e59d51abd7a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtNS0xLTEtNjEwMw_36f37a70-dbbe-4080-91ba-bbee6ce5885c">6,566,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtNy0xLTEtNjEwMw_f796119a-33a6-4825-950c-8bc436582523">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57e728fa3cb540d5917b1e146d5c075e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtOS0xLTEtNjEwMw_e12546d5-ca70-4709-85bd-9e3453a9e458">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMTUtMS0xLTYxMDM_e6024b3b-70aa-4d88-8242-0e5ea12ff44b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e728fa3cb540d5917b1e146d5c075e_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctOS0xLTEtNjEwMw_49f3e77c-e41c-4556-9ad7-c79edfbe37de">823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMTUtMS0xLTYxMDM_04617552-337e-4c07-9f2b-fa54c9c38ae2">823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fdfa6760cde47c78598ec14f20df863_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzgtMTMtMS0xLTYxMDM_f429f4f7-de17-4bd6-b506-d2220310da83">5,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzgtMTUtMS0xLTYxMDM_308837c4-62d8-4754-9579-8cab6df3c0c8">5,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41608b92ab1e405c9505107aa8fd4a10_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktMS0xLTEtNjEwMw_67bb3d32-0d43-4726-9dc8-1c83bf56e572">3,047,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41608b92ab1e405c9505107aa8fd4a10_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktMy0xLTEtNjEwMw_1eea81a5-8b72-427f-aa01-afc1c1091966">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica4813bf265846af86e7cc13ba14b04c_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktNS0xLTEtNjEwMw_d79553fa-8e1d-4e40-82ef-0a6d0834a239">27,608,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica4813bf265846af86e7cc13ba14b04c_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktNy0xLTEtNjEwMw_02e20b17-a214-4587-819f-d8956e10f2df">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f736255edb4fd394dcac61f435857f_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktOS0xLTEtNjEwMw_c53c3b6b-0669-4984-b8b9-5971dd3d27e1">432,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i937a88a09ffe475e93aa3271b6d32b6e_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktMTMtMS0xLTYxMDM_e6a95ee6-b2a7-4a5e-87f1-3dee79608534">417,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106931b626c24de2b02765bb0b3ff2e3_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktMTUtMS0xLTYxMDM_fe95b13a-5633-419b-9c82-5ba58363b1c6">14,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57f750264234676ba54c29635f86b6e_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODAtOS0xLTEtNjEwMw_2d00f672-4481-4eff-9489-711bbc2e5016">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0273fa1e721f4669bb524150f471d493_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODAtMTUtMS0xLTYxMDM_053a93b9-5e2f-496f-bcb6-4518ebb24070">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd72b68db08a4f389c46d913ec8ff603_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODEtNS0xLTEtNjEwMw_216aaa05-988d-4726-b60e-770351fadb89">17,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversions of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i797de9f7b8c94355addeba1011495bd6_D20200401-20200630" decimals="INF" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItMS0xLTEtNjEwMw_39336956-f9a4-4973-99a8-7f6ca73b4faf">829,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797de9f7b8c94355addeba1011495bd6_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItMy0xLTEtNjEwMw_29427da7-d433-4a71-bb75-ee6e8d577050">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd72b68db08a4f389c46d913ec8ff603_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItNS0xLTEtNjEwMw_f7b4060c-b1b9-4331-b3af-f9963204fe1b">8,296,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd72b68db08a4f389c46d913ec8ff603_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItNy0xLTEtNjEwMw_2d0bbb4c-3fc6-4c39-9dea-48e37e138dc7">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if57f750264234676ba54c29635f86b6e_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItOS0xLTEtNjEwMw_cce0ffe1-205b-48dc-95bc-08028520e35c">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0273fa1e721f4669bb524150f471d493_D20200401-20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItMTUtMS0xLTYxMDM_36fcd041-b81f-4916-9a3c-2c627c495c1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if302f494d5d1498abe569565dbdf97a7_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODMtMTMtMS0xLTYxMDM_63f28ae6-68cb-4bd6-94da-51d30b4db8db">6,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0273fa1e721f4669bb524150f471d493_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODMtMTUtMS0xLTYxMDM_6fdd7a6f-3870-45b8-b903-c124bb57fdca">6,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d1408d312334eb79d917b31476e9f45_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtMS0xLTEtNjEwMw_e4ba5f23-56d0-421b-b6c3-ec1195ced2a1">2,217,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1408d312334eb79d917b31476e9f45_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtMy0xLTEtNjEwMw_c5b08cc5-7578-46e7-96aa-66e901e9793d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddcc9b19c42a47b09baa002a71fba35e_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtNS0xLTEtNjEwMw_7bea14dc-384b-4bd4-bdc4-d55cf70c57ad">35,922,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddcc9b19c42a47b09baa002a71fba35e_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtNy0xLTEtNjEwMw_854302d0-c535-40af-8761-856a838e6882">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d830f02b3e14451ad9e64b964c38013_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtOS0xLTEtNjEwMw_6b9d4832-36a0-4e78-ad0d-2b59b759167a">432,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90d7713a719f4a73b660cf6b5827d495_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtMTMtMS0xLTYxMDM_2eadcfbe-9416-4763-a318-60762b23bb15">424,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6725b24da6f44eb8a2bdef563ccfd0e1_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtMTUtMS0xLTYxMDM_b6305a1f-0057-4b5d-a2b9-eb5db9633252">8,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6943c5db1485450bb348ad14827a1cd3_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAxLTktMS0xLTY3ODE_67f83c0e-cb74-4b2b-b688-ba1c6854a067">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAxLTE1LTEtMS02Nzgx_be9a93e3-7b7e-48f0-88e1-8b6d440b1e57">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAyLTUtMS0xLTY3ODE_dc7d1e10-cbdd-43a8-a530-948be9c4d48b">19,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAzLTUtMS0xLTY3ODM_223090ad-474a-4ef6-bbaf-071d5f4e2653">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6943c5db1485450bb348ad14827a1cd3_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAzLTktMS0xLTY3ODM_39900ef0-b7f6-4c2a-9229-6c54a26c5a64">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAzLTE1LTEtMS02Nzgz_fead3ab9-b552-4091-871c-020874c41db8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversions of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i865538f5e6944ffbab25f061268e630e_D20200701-20200930" decimals="INF" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTEtMS0xLTY3ODU_f1e39344-dcc9-4233-8c63-35cebf841e43">321,748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865538f5e6944ffbab25f061268e630e_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTMtMS0xLTY3ODU_1549a643-35d7-47e1-9169-26f9ee355129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTUtMS0xLTY3ODU_6d8cc970-b7ed-4466-a0da-024cb7b6ca5d">3,217,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTctMS0xLTY3ODU_bb1790b0-1b2f-4b29-9793-83d63b88bc38">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6943c5db1485450bb348ad14827a1cd3_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTktMS0xLTY3ODU_056bcd16-f8c4-4d09-b857-335e80ac87fc">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTE1LTEtMS02Nzg1_ad21ffe7-46e7-47b5-9bb8-6ecaca8feecb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ccc29ee690e4861959d540c320ce357_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA1LTEzLTEtMS02Nzg3_d01c470a-0c03-4dc8-b0d2-4abfc85da25a">1,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA1LTE1LTEtMS02Nzg3_b2bf5f31-3b62-48fa-a69c-66712c9b94f5">1,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d268293b00748cb90f4f7273393b95f_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTEtMS0xLTY3ODk_3cdbd3f6-9483-4c02-a324-5747648fd7b7">1,896,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d268293b00748cb90f4f7273393b95f_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTMtMS0xLTY3ODk_52a83e8d-c3ed-45a2-b883-2353fd6c03fb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9f6d4248d2b4dc986c29c6a7ad68bf0_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTUtMS0xLTY3ODk_982f8f78-0187-4220-99ed-56c8a47d6dc5">39,163,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f6d4248d2b4dc986c29c6a7ad68bf0_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTctMS0xLTY3ODk_a5bead61-14df-4fa2-ad32-0c8bed8fde16">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac0a725c51e4495a0c3d3346febea7b_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTktMS0xLTY3ODk_170e9b73-d6fa-40ec-9f94-b0a9a652da4b">433,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d5b6ce568c40dc86b3246c0c3574fc_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTEzLTEtMS02Nzg5_2d302ab0-8fc3-4af6-951f-cd4fdcc0fca7">425,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2751e06f46463a94612500556b66a8_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTE1LTEtMS02Nzg5_af7d91b9-3b3e-4737-b1cd-002959bb6360">7,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i1bd3a25286f94961af32b70947dcc597_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulus Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNC0xLTEtMS02MTAz_ed4db5cd-a21a-4b5e-837d-db7cbfaeb247">20,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNC0zLTEtMS02MTAz_25d275e7-a39f-466c-b0e5-95cc003dae30">14,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNi0xLTEtMS02MTAz_dd337a14-7b0f-4c01-a784-0dc3342ea671">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNi0zLTEtMS02MTAz_f407b566-fffe-41c1-88b8-5899b554f6ca">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNy0xLTEtMS02MTAz_58ea0307-46e1-46ce-a025-5baecd486512">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNy0zLTEtMS02MTAz_033d400d-b70a-4c4d-830d-124fc6b04f45">2,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="rgls:GainLossOnLoanForgiveness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTAtMS0xLTEtNjEwMw_106ce340-cd10-48e1-b97a-6bc3afd6e6cd">662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="rgls:GainLossOnLoanForgiveness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTAtMy0xLTEtNjEwMw_737db966-9243-4b6b-8e69-6d718d4287b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTEtMS0xLTEtNjEwMw_58e21f8e-d64e-4e8b-b393-dbad4f021306">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTEtMy0xLTEtNjEwMw_c8825d49-e1e7-4529-a84d-224d03853f14">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTMtMS0xLTEtNjEwMw_2ec80fd1-fc8e-47ad-8393-a73dffcf14a3">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTMtMy0xLTEtNjEwMw_eff29475-b0a2-4008-8d3f-782a27c75825">2,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTQtMS0xLTEtNjEwMw_3f341ce3-3da7-44fc-bf05-f31b8c7bfe0d">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTQtMy0xLTEtNjEwMw_b0eb9d1c-3f0a-4274-8259-f243fbc209d9">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTUtMS0xLTEtNjEwMw_0114b12e-866d-46a9-80bb-662857352be2">784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTUtMy0xLTEtNjEwMw_29072e7d-bd1a-431d-8382-3fadb6a0c550">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTctMS0xLTEtNjEwMw_6cb7c5f9-744b-458e-9bd7-6f67dbaa0d8e">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTctMy0xLTEtNjEwMw_17bb56c9-bec3-4144-b9fc-ae6eccbc3406">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTgtMS0xLTEtNjEwMw_5c69d468-d311-4f8e-a057-0099c82a9588">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTgtMy0xLTEtNjEwMw_89b3054c-a7e0-4f5c-b2bd-b69b67e280f6">208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="rgls:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTktMS0xLTEtNjEwMw_6d887bf7-6031-40d5-bb38-4e765aac0ddd">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" name="rgls:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTktMy0xLTEtNjEwMw_d339e775-bfda-49b5-9dd7-d07ca1770d57">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjAtMS0xLTEtNjEwMw_f1868818-0457-4b9e-8e7b-21e75bb115c1">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjAtMy0xLTEtNjEwMw_928f2510-b0ff-4e2e-bddf-575391a79043">416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="rgls:OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjItMS0xLTEtNjEwMw_ec835309-6451-4e34-9c40-7c1380730685">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="rgls:OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjItMy0xLTEtNjEwMw_662ce760-129c-4ee6-a9b4-7d61c9a2a5cc">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjMtMS0xLTEtNjEwMw_301835bf-bee9-4351-a0f6-62b4c7937736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjMtMy0xLTEtNjEwMw_2430ee67-1235-4957-8a12-1d2125a62d32">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjUtMS0xLTEtNjEwMw_56558b62-3f11-4ef6-88b8-926b0a39f5b8">729</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjUtMy0xLTEtNjEwMw_7feed7fa-2477-49ea-a0f2-8cabba827a39">1,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjYtMS0xLTEtNjEwMw_833dc7a0-e7a3-447a-ba08-91522d7c9246">16,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjYtMy0xLTEtNjEwMw_3c3b6602-b081-43f8-bd7e-7bcbd9ec5326">15,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzAtMS0xLTEtNjEwMw_8c9a24fc-cf2b-428a-bbed-7a42da1bff74">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzAtMy0xLTEtNjEwMw_393bf966-c3f7-4f6f-a990-3b3d7b08924d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzItMS0xLTEtNjEwMw_93234ac2-c233-4db9-afc8-275be73a4478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzItMy0xLTEtNjEwMw_319be98f-20f9-4ffd-b74b-a71d12023665">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzMtMS0xLTEtNjEwMw_116da160-9dbd-4173-a2fc-8ae5cd140399">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzMtMy0xLTEtNjEwMw_1b8f784b-cb02-4687-95e6-e44cf78d9a0e">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from borrowing under Paycheck Protection Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="rgls:ProceedsFromFederalProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzYtMS0xLTEtNjEwMw_af7c21de-0a9e-4341-b9c1-4baf1664390d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" name="rgls:ProceedsFromFederalProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzYtMy0xLTEtNjEwMw_a1050fd2-0661-4b96-9299-7b3080319ba3">662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzgtMS0xLTEtNjEwMw_4a8bbb98-d09f-4827-b4bd-dbc14c91c9d4">21,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzgtMy0xLTEtNjEwMw_64981942-339b-4e6a-9e0e-4f8f78b60afe">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzktMS0xLTEtNjEwMw_9fb1c702-b632-45d2-a721-06859575d9f8">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzktMy0xLTEtNjEwMw_e0e79b90-2a39-49ef-b2ac-1cc4b46aa78f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDAtMS0xLTEtNjEwMw_07a83af1-9ba5-4ebe-a7cd-d1f80ac2b465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDAtMy0xLTEtNjEwMw_3f30e50c-050d-4d69-a4c5-348c2fe7795f">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on financing leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="rgls:PaymentsonFinanceLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDMtMS0xLTEtNjEwMw_1f75e73e-f821-4e7a-9f92-aa34f643be28">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" name="rgls:PaymentsonFinanceLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDMtMy0xLTEtNjEwMw_d87317e2-6a14-4868-9419-0ac9fb778836">207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDQtMS0xLTEtNjEwMw_b494c15c-2990-40be-a226-8e412b2229cd">21,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDQtMy0xLTEtNjEwMw_2070c2cf-6532-4e91-aaf3-ee5c7c79f7d5">542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDUtMS0xLTEtNjEwMw_8e3ce6f4-ad2e-4d4d-b3e2-05cdaf841b2a">4,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDUtMy0xLTEtNjEwMw_bdc28a46-960e-414c-a45d-18f37c9f4aec">16,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDYtMS0xLTEtNjEwMw_7324ec56-5a46-4fd3-af94-82bcfcff06e9">31,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88172ee03d6b45da9f2508fc8c899e50_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDYtMy0xLTEtNjEwMw_27f01717-03c9-4d46-b3af-ff2deaf3bf24">34,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDctMS0xLTEtNjEwMw_09224614-15ca-42f4-abd2-7258691670e1">35,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2751e06f46463a94612500556b66a8_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDctMy0xLTEtNjEwMw_b0d0825b-ed35-40c2-8bc0-f3c1c5db8b18">17,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDktMS0xLTEtNjEwMw_825717fa-5fa3-4a7e-aac5-8e319f0ae1b6">35,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2751e06f46463a94612500556b66a8_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDktMy0xLTEtNjEwMw_e6c0f428-aaec-4db8-af28-e1bc4a829ee4">17,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTAtMS0xLTEtNjEwMw_8c44756b-1699-4053-913d-f6a4b66749a1">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2751e06f46463a94612500556b66a8_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTAtMy0xLTEtNjEwMw_7e7fa16d-9a31-4328-aeb8-8972ba2a1242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTEtMS0xLTEtNjEwMw_a733c5a5-d860-4198-a2bb-0f86d3725340">35,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2751e06f46463a94612500556b66a8_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTEtMy0xLTEtNjEwMw_21b12417-0da5-4fd5-a8f5-2d478a4045dd">17,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paycheck Protection Program loan forgiveness</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="rgls:PaycheckProtectionProgramLoanForgiveness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTQtMS0xLTEtNjEwMw_408cdf83-4358-4cb8-8e60-a05c38a8a9cd">662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="rgls:PaycheckProtectionProgramLoanForgiveness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTQtMy0xLTEtNjEwMw_2af432d0-fab1-49fa-83d1-824e000bd30c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTUtMS0xLTEtNjEwMw_ba251137-a58d-4928-a8d8-417b4e7fd8e6">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTUtMy0xLTEtNjEwMw_0109369d-ede5-4cb9-80fb-f1f666d7365b">1,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTYtMS0xLTEtNjEwMw_3a7cf638-919d-4252-b92f-1299d95f4deb">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTYtMy0xLTEtNjEwMw_6c799c6e-7478-450a-b34d-1a6da28c0671">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i1bd3a25286f94961af32b70947dcc597_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulus Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i1bd3a25286f94961af32b70947dcc597_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwMzA_250ce6bb-7a50-4ca3-87d0-2fef1aac80e0" continuedAt="ib79328996372499786f6f972232901c2" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ib79328996372499786f6f972232901c2" continuedAt="i8ffa0e77977d45babdfc46d0f704b4f7"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNDc_800cee70-73cf-42b4-9ba9-72a168effe1c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, from which the balance sheet information herein was derived.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a&#160;going&#160;concern.&#160;Through the date of the issuance of these financial statements, we have principally been financed through proceeds received from the sale of our common stock and other equity securities, debt financings, up-front payments and milestones received from collaboration agreements, totaling $<ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="rgls:FinancingfromSaleProceedsDebtAgreementRevenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTcyOA_4097b252-ae73-466d-83a2-f684ad1ce0c2">505.6</ix:nonFraction> million.&#160;As of&#160;September&#160;30, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTc3NA_3b3c9bd4-4b8b-429f-bd70-1f0bd43ab622">35.8</ix:nonFraction>&#160;million of cash and cash equivalents. Based on our operating plans, we believe our cash and cash equivalents may not be sufficient to fund our operations for the period one year following the issuance of these financial statements. As a result, there is substantial doubt about our ability to continue as a going concern. All amo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unts due under the Term Loan (see note 5) have been classified as a current liability as of September 30, 2021 and December 31, 2020, due to the considerations discussed above and the assessment that the material adverse change clause under the Term Loan is not within our control. In the first quarter of 2021, we received a waiver from the Lender (as defined below) with respect to noncompliance with a covenant under the Loan Agreement (as defined below). We are in compliance with all Loan Agreement covenants.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity, or cease operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock.</span></div><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNDU_5066d37c-028e-4614-b26c-4ce92b4744f5" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Additionally, the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwMzI_bafb1f2d-4e49-4458-9e2d-fa3a3bfcbec5" continuedAt="ic46f2370d0544853bd51413b27e33aac" escape="true"><div style="margin-top:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under license and collaboration agreements. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i8ffa0e77977d45babdfc46d0f704b4f7" continuedAt="ibe543a95b7f0482f857b0f3bb4ee1061"><ix:continuation id="ic46f2370d0544853bd51413b27e33aac"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which could affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.</span></div></ix:continuation><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwMzM_2e7faf4e-49c2-41b4-93c9-43343b315c35" continuedAt="id88bb3597399408bac7ef889e3580c83" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="ibe543a95b7f0482f857b0f3bb4ee1061" continuedAt="i16dc3044e8e04cb09ad31ec19df01756"><ix:continuation id="id88bb3597399408bac7ef889e3580c83"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i)&#160;the fair value of the award is determined on the grant date, (ii)&#160;we assess the probability of the individual milestones under the award being achieved and (iii)&#160;the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.</span></div></ix:continuation><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="rgls:AccruedExpensePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNjY_58ca4c1d-956c-40b5-8e65-7683fd0653f6" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites and CROs and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="rgls:PrepaidExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNDE_2da8207a-f6d1-4643-a028-325631346eb8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Materials</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our preclinical and clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process.&#160;We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which an impairment is identified.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNTE_ea6b5713-690f-477b-bb08-86c7eb3912b4" continuedAt="ie3f1f04488e34e1cb9cb09685ccaa5e5" escape="true"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequently, in November 2018, the FASB issued&#160;ASU&#160;2018-19,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;ASU 2016-13&#160;requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d reasonable and supportable forecasts.&#160;ASU 2016-13&#160;also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December&#160;15, 2022, with early adoption permitted. We are assessing the impact this standard will have on our financial statements and disclosures.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reference Rate Reform (Topic 848), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which provides guidance around reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation in response to concerns about structural risks of interbank offered rates and the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments in the ASU provide option expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform and apply only if such contracts, hedging relationships and other transactions that reference LIBOR or another reference rate are expected to be discontinued because of reference rate reform. The guidance does not apply to contract modifications made, and hedging relationships entered into or evaluated, after December 31, 2022. We are assessing the impact this standard will have on our financial statements and disclosures. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-indent:22.5pt"><ix:continuation id="i16dc3044e8e04cb09ad31ec19df01756"><ix:continuation id="ie3f1f04488e34e1cb9cb09685ccaa5e5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. The adoption of this standard on January 1, 2021 did not impact our financial statements or disclosures.</span></ix:continuation></ix:continuation></div><div id="i1bd3a25286f94961af32b70947dcc597_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfMTE2NA_3d94d3c7-01e1-4685-b839-710ce6d2d3aa" continuedAt="i68b245e9c0704cb88a1689cae3b15878" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i68b245e9c0704cb88a1689cae3b15878" continuedAt="i6d96b1b913464db6bbc6c57c8952ebc7">Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method or if-converted method. Dilutive common stock equivalents are comprised of stock options, restricted stock units and convertible preferred stock outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</ix:continuation></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6d96b1b913464db6bbc6c57c8952ebc7">Potentially dilutive securities not included in the calculation of diluted net loss per common share, because to do so would be anti-dilutive, were (in common stock equivalent shares) <ix:nonFraction unitRef="shares" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfODc4_4545037f-d5f4-42cc-8070-e00a6f749987"><ix:nonFraction unitRef="shares" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfODc4_fd399e00-9f67-485e-a67e-924b55fbcc85">28,635,276</ix:nonFraction></ix:nonFraction> for the three months and nine months ended September 30, 2021, consisting of convertible preferred stock, stock options and restricted stock units, and <ix:nonFraction unitRef="shares" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfMTAyNw_0c775e68-4b15-406e-bf03-dd1dd6bedbf7"><ix:nonFraction unitRef="shares" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfMTAyNw_86e61d16-9bab-402a-8729-8f8c08e0ee81">25,813,032</ix:nonFraction></ix:nonFraction> for the three and nine months ended September 30, 2020, consisting of convertible preferred stock, stock options and restricted stock units.</ix:continuation> </span></div><div id="i1bd3a25286f94961af32b70947dcc597_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180MC9mcmFnOmM4ZmI1ZDYwYjQyYjQ5YTQ5OWE3NDJhZjBhMmQzY2RiL3RleHRyZWdpb246YzhmYjVkNjBiNDJiNDlhNDk5YTc0MmFmMGEyZDNjZGJfNDQ3_0e80aac6-5854-4add-b5d3-8613d1b1c1f1" continuedAt="i152ca75539f0450db260891d4e0a289d" escape="true">Investments</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i152ca75539f0450db260891d4e0a289d">Historically, we have invested our excess cash primarily in debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. We generally hold our investments to maturity and do not sell our investments before we have recovered our amortized cost basis. As of September&#160;30, 2021 and December&#160;31, 2020, our cash balance was comprised entirely of cash and cash equivalents (money market funds).</ix:continuation></span></div><div id="i1bd3a25286f94961af32b70947dcc597_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RleHRyZWdpb246NGYxMTkyY2E1Mzk4NGY4ODhjODA4MGQyMjYzODgyZmFfMjY4Mg_3044fb1d-ead2-4fa1-9677-ef494338041a" continuedAt="i4e004bc3074e440c8778f749303bbb2d" escape="true"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RleHRyZWdpb246NGYxMTkyY2E1Mzk4NGY4ODhjODA4MGQyMjYzODgyZmFfMjY4OQ_9cc30120-ca36-4d33-9fb7-385951ba372a" continuedAt="i8ab6ec4cd3d0446087252fdbd7bc562f" escape="true">Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i4e004bc3074e440c8778f749303bbb2d" continuedAt="if1a9478826034bc1af6def4ec86c89e4"><ix:continuation id="i8ab6ec4cd3d0446087252fdbd7bc562f"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i)&#160;independent, (ii)&#160;knowledgeable, (iii)&#160;able to transact, and (iv)&#160;willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management&#8217;s own assumptions.</span></div></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets Measured at Fair Value</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="if1a9478826034bc1af6def4ec86c89e4" continuedAt="i27a654e1a51e4fbfb65904724f87b3f1"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RleHRyZWdpb246NGYxMTkyY2E1Mzk4NGY4ODhjODA4MGQyMjYzODgyZmFfMjY4NQ_30e9fd45-33f8-4477-8e3b-bd8adad12d3b" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value as of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e558bd57cca45c5b203fdaf82f601e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfMy0xLTEtMS02MTAz_a24c473b-2325-48d6-b009-8f4c8ea5c82d">33,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3dd88f2ee24d50940e2d23ae23e499_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfMy0zLTEtMS02MTAz_91e465ac-5c31-46a4-a44a-243230de35fa">33,904</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6bf61ba9c4435e80870c56d0a0f96b_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfMy01LTEtMS02MTAz_f1d8832c-652d-4462-9ee0-321ec2f9bcd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47324fa24547688554544bf8a88ebb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfMy03LTEtMS02MTAz_304709f8-68d8-4589-8b66-38e4dbf28164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfOS0xLTEtMS02MTAz_600d62c2-6d3e-48e2-918b-077ae118571c">33,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e7c32d4abb4857a652dbaf35a42b0b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfOS0zLTEtMS02MTAz_4257727e-0313-44ab-bc38-6aab36894a59">33,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b42f9a435294e1c9a483222e912c132_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfOS01LTEtMS02MTAz_93f475a8-8c95-4ef0-8bad-11b39ade817b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09deb282dd9b4bf58f7a624fb80f547f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfOS03LTEtMS02MTAz_a3b5f424-79fe-43d3-980a-96437cb41e7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value as of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fdd8f019e3c491b8732a68d899250a0_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfMy0xLTEtMS02MTAz_47445caa-48f0-44cd-bb99-2711c8d5e4e2">26,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce7ee44d1194a78aa295bd978dc3ae7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfMy0zLTEtMS02MTAz_aaddfa74-a4d1-4aa3-b55b-1b144e29fad8">26,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b176df93ed4f47b0455d5746bf050e_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfMy01LTEtMS02MTAz_a0862e58-65b3-4947-aa4f-5230ac892294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6383c5f184bf4004ba7ac38c997e14c7_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfMy03LTEtMS02MTAz_c66753f5-b05f-4d01-8ebb-1e598be0c495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfOS0xLTEtMS02MTAz_dd086341-c675-4124-98ac-c05606fd4a6b">26,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i523ebcbfef6d4b6aa814dd3ff356bd8c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfOS0zLTEtMS02MTAz_84adc3f5-a85f-4529-8283-863152f9e6dc">26,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f7695f94fcc4a2b92b921a5c6aa94bc_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfOS01LTEtMS02MTAz_1dec5b7a-3190-41d1-93ee-0f71b14a5cc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecd930760914ed780a9b7337dc50c31_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfOS03LTEtMS02MTAz_30a8db9c-bf93-4103-bdce-a0b1f73546d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i27a654e1a51e4fbfb65904724f87b3f1">We obtain pricing information from quoted market prices or quotes from brokers/dealers. We have historically determined the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers.</ix:continuation> </span></div><div id="i1bd3a25286f94961af32b70947dcc597_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNjkxMQ_b2171780-6515-496f-be54-805884cf4fbe" continuedAt="ia41aaa8350954accb127a4b3b15f1faf" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="ia41aaa8350954accb127a4b3b15f1faf" continuedAt="i6fe61246eebd43a2a16a2fcc17874c11"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2016, we entered into a loan and security agreement ("Loan Agreement") with Oxford Finance, LLC, (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lender</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), pursuant to which we received $<ix:nonFraction unitRef="usd" contextRef="i8f4532b2830348528c01118566cacbce_D20160622-20160622" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMTgw_77b2b6a2-3b4b-4a38-b751-85ab8e86f7a2">20.0</ix:nonFraction> million in proceeds, net of debt issuance costs, on June 22, 2016 (the "Term Loan"). </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding Term Loan will mature on May 1, 2022 (the &#8220;Maturity Date&#8221;) and bears interest at a floating per annum rate equal to (i) <ix:nonFraction unitRef="number" contextRef="ica365f62a18542a3bd628586ba2316d7_I20160617" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzk3_f2d0661a-9ec5-4ca3-a8dc-cc3888e17198">8.51</ix:nonFraction>% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) <ix:nonFraction unitRef="number" contextRef="i56addd06803544669ea6adfb1f85223b_D20160617-20160617" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNjE1_a59cc6ab-35e7-4df2-8baa-dbf20a755292">0.44</ix:nonFraction>%. Under the original Loan Agreement, we were required to make interest-only payments through June 1, 2018, followed by <ix:nonFraction unitRef="payment" contextRef="ica365f62a18542a3bd628586ba2316d7_I20160617" decimals="INF" name="rgls:NumberofMonthlyPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNzM2_888ce3d1-cd3f-42ef-a3d9-ca9900b1ff77">24</ix:nonFraction> equal monthly payments of principal and unpaid accrued interest.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement was amended <ix:nonFraction unitRef="amendment" contextRef="i03875b50705141378eeb6a7f3db6d93c_D20171001-20190531" decimals="INF" format="ixt-sec:numwordsen" name="rgls:NumberOfAmendments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfODM2_06fe2256-3530-4c40-b289-b1053c1f1204">eight</ix:nonFraction> times between October 2017 through May 2019. On May 1, 2020 we entered into a ninth amendment to the Term Loan with the Lender (the &#8220;Ninth Amendment&#8221;). Pursuant to the terms of the Ninth Amendment, (i) the approximately $<ix:nonFraction unitRef="usd" contextRef="ic806cb07df3044b1b53e64130fffba72_I20200501" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMTA1OQ_b2adb290-a2d4-4d5a-a91c-aee2ab5927ba">0.7</ix:nonFraction>&#160;million of loan proceeds (the "PPP Loan") we received under the Paycheck Protection Program ("PPP") was included as permitted indebtedness under the terms of the Term Loan, (ii) we agreed to apply for forgiveness of the maximum amount of PPP Loan permissible in accordance with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and use best efforts to cause not less than $<ix:nonFraction unitRef="usd" contextRef="ic806cb07df3044b1b53e64130fffba72_I20200501" decimals="-5" format="ixt:num-dot-decimal" name="rgls:ForgivenessAmountThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMTQ0OQ_86e3db31-c42b-45a3-9627-b35731847656">0.5</ix:nonFraction>&#160;million of the PPP Loan to be forgiven by the PPP Loan lender on or before September 30, 2020 and (iii) we agreed not to amend any material provision in any document relating to the PPP Loan nor make any prepayment of the PPP Loan unless such prepayment is necessary or advisable due to change in the applicable law or guidance issued by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Small Business Administration (&#8220;SBA&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ugust 25, 2020 we entered into a tenth amendment to the Term Loan with the Lender (the "Tenth Amendment").  Pursuant to the terms of the Tenth Amendment, we are eligible for up to an additional <ix:nonNumeric contextRef="i892f5ef11b7f487eb34d5314ea17e4fd_D20200825-20200825" format="ixt-sec:durwordsen" name="rgls:InterestOnlyPaymentExtension" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjAyOQ_942823b2-7108-4d59-8ebb-666986c5585f">seven months</ix:nonNumeric> of interest only payments in the event we paid down $<ix:nonFraction unitRef="usd" contextRef="iefd75439e0974679b47a6cff8366c288_I20200825" decimals="INF" format="ixt:num-dot-decimal" name="rgls:PrepaymentRequirement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjA4NA_f062bc37-1f1f-4fa1-bd77-22fcbb971f73">10.0</ix:nonFraction>&#160;million in loan principal before April 30, 2021 (the "Principal Paydown Event"). In the event the Principal Paydown Event did not occur by April 30, 2021, we would make principal and accrued interest payments, in arrears, commencing May 1, 2021, in accordance with the terms of the Eighth Amendment. If the Principal Paydown Event occurred after April 30, 2021 but on or before July 31, 2021, we would recommence an extended interest only payment period through December 31, 2021. In the event we received the additional interest only period, principal and accrued interest payments would recommence on January 1, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We received $<ix:nonFraction unitRef="usd" contextRef="i380cfb226da64264aa858aa432603785_D20200930-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjcxMg_c58b5919-f0f6-48c5-b879-69a6b0e7c661">1.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i5b747865a07948508c75f1aa6b053b63_D20201008-20201008" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjcxNg_7570894e-b04f-45a0-a4d5-da7c378670c2">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id16ee745789f48d18517ec4b1a9769cf_D20201130-20201130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjcyMw_4219a6ef-b0bb-4c6e-aae8-3c4a4dc699c0">5.0</ix:nonFraction>&#160;million in proceeds from Sanofi (see Note 7) on September 30, 2020, October 8, 2020 and November 30, 2020, respectively. Under the terms of the Tenth Amendment, we prepaid $<ix:nonFraction unitRef="usd" contextRef="i8c8cb641775b42569a9458112a507826_D20200930-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjg5MA_5c832357-4787-4f21-84f5-583b483d56c8">1.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i46549a65d985413b8403edb46967d1b0_D20201008-20201008" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjg5NA_ea46e260-3b12-4daa-bc63-a3e3f82dc262">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic64856709b654f068e893bde533341f9_D20201130-20201130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjkwMQ_efe2a8e7-78f1-4554-bc1c-dd39a933974d">5.0</ix:nonFraction>&#160;million of outstanding principal to the Lender on September 30, 2020, October 8, 2020 and November 30, 2020, respectively, for a total of $<ix:nonFraction unitRef="usd" contextRef="ic7d6534d80e9479592a4aa31ef10377f_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzAzNA_7cddae61-6b6d-4a58-951a-29c35e84102f">10.0</ix:nonFraction>&#160;million. We also paid the applicable <ix:nonFraction unitRef="number" contextRef="i2905a20cdd80471abc18cd4877622e4b_I20210930" decimals="3" name="rgls:PaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzA2Ng_c2292099-4b48-469b-bdc0-2c6a3c3b7e87">5.5</ix:nonFraction>% final payment fees related to the <ix:nonFraction unitRef="prepayment" contextRef="i2905a20cdd80471abc18cd4877622e4b_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="rgls:NumberOfPrepaymentsToLender" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzEwMw_1566d8a7-bf20-4546-91a6-3b0a5020c142">three</ix:nonFraction> prepayments to the Lender. As the Principal Paydown Event occurred by April 30, 2021, we received an additional <ix:nonNumeric contextRef="ic7d6534d80e9479592a4aa31ef10377f_D20210101-20210930" format="ixt-sec:durwordsen" name="rgls:AdditionalExtensionForInterestOnlyPayments" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzIxOA_bf9209ac-a3b4-4c3e-970e-ef2466f86cb5" continuedAt="i8c4d806c32574cca930e980750f32dfc">seven </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i6fe61246eebd43a2a16a2fcc17874c11" continuedAt="i2edc37a6a86643229b8b2985ae3f6726"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i8c4d806c32574cca930e980750f32dfc">months</ix:continuation> of interest only payment extension and are not obligated to make principal payments on the Term Loan until January 1, 2022.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the proceeds from the Term Loan solely for working capital and to fund our general business requirements.  Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, other than our intellectual property, for which the Lender currently has a positive lien, and certain assets under finance lease obligations. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement. The Loan Agreement includes customary events of default, including instances of a material adverse change in our operations, that may require prepayment of the outstanding Term Loan. During the first quarter of 2021, we received a waiver from the Lender with respect to noncompliance with a covenant under the Loan Agreement. We are in compliance with all Loan Agreement covenants as of the date of the filing of this Form 10-Q.&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i923277ec32bd4699a80593ceda7d7e81_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNDM2Ng_b65bbebf-2af3-4b48-9ca4-9311bca2b3cd">4.7</ix:nonFraction> million was outstanding under the Term Loan. An additional $<ix:nonFraction unitRef="usd" contextRef="i923277ec32bd4699a80593ceda7d7e81_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNDQyMA_415c5da7-a2d2-4266-87f0-d5b97b8be36f">1.3</ix:nonFraction> million is also payable at the conclusion of the Term Loan (presented in other current liabilities on our balance sheet at September 30, 2021). We had less than $<ix:nonFraction unitRef="usd" contextRef="i923277ec32bd4699a80593ceda7d7e81_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNDU3MQ_797478db-2a38-4648-844d-67ec5faf1a8c">0.1</ix:nonFraction> million of debt issuance costs outstanding as of September 30, 2021, which are being accreted to interest expense over the life of the Term Loan using an effective interest rate of <ix:nonFraction unitRef="number" contextRef="i923277ec32bd4699a80593ceda7d7e81_I20210930" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNDc0Mg_d1a6ec82-c89a-4780-818b-4c4d6982e081">8.98</ix:nonFraction>%. The exit fees are being accrued over the life of the Term Loan through interest expense.</span></div><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNjkxMA_ce68e097-cad2-4131-a21a-f597f01cf57f" escape="true"><div style="margin-bottom:5pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de3b934180e4445a01ae3a427e91b3f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RhYmxlOjVjNDgxYmI3ZTYxNzQ3OThiZDYwZGM5Y2FhNzNjOGQ4L3RhYmxlcmFuZ2U6NWM0ODFiYjdlNjE3NDc5OGJkNjBkYzljYWE3M2M4ZDhfMS0xLTEtMS02MTAz_410bea09-b791-47c1-8043-e5f43137d75b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de3b934180e4445a01ae3a427e91b3f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RhYmxlOjVjNDgxYmI3ZTYxNzQ3OThiZDYwZGM5Y2FhNzNjOGQ4L3RhYmxlcmFuZ2U6NWM0ODFiYjdlNjE3NDc5OGJkNjBkYzljYWE3M2M4ZDhfMi0xLTEtMS02MTAz_76380507-7166-4a1e-a836-a110e88e546c">4,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de3b934180e4445a01ae3a427e91b3f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RhYmxlOjVjNDgxYmI3ZTYxNzQ3OThiZDYwZGM5Y2FhNzNjOGQ4L3RhYmxlcmFuZ2U6NWM0ODFiYjdlNjE3NDc5OGJkNjBkYzljYWE3M2M4ZDhfMy0xLTEtMS02MTAz_ba77679f-7731-43c7-9d30-e1468e625f48">4,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:4pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, we received the proceeds from the PPP Loan in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ifd548549c7b7438bb6836f7b080e3d0f_I20200423" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNTA4OQ_b0d6a8f5-c2a3-44f2-b7f7-59c2f67fc02c">0.7</ix:nonFraction>&#160;million from Silicon Valley Bank, as lender, pursuant to the PPP of the CARES Act. The PPP Loan was set to mature on April 23, 2022 and bore interest at a rate of 1.0% per annum. The PPP Loan was evidenced by a promissory note dated April 23, 2020, which contained customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The PPP Loan was prepayable by us at any time prior to maturity with no prepayment penalties.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the CARES Act and PPP Flexibility Act, loan forgiveness is available for the sum of documented payroll costs, covered mortgage interest, covered rent payments and covered utilities during the 24 week period beginning on the date of loan disbursement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> For purposes of the PPP, payroll costs exclude compensation of an individual employee in excess of $100,000, annualized, prorated for the covered period. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines during the covered period as compared to specified reference periods, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%, unless certain safe harbors are satisfied. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal and includes accrued interest.</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i2edc37a6a86643229b8b2985ae3f6726">We have used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments, and we sought forgiveness in accordance with the program. We received full forgiveness of our PPP Loan in the second quarter of 2021. We accounted for the full forgiveness of our PPP Loan by recording a gain in interest and other income for the nine months ended September 30, 2021.</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div id="i1bd3a25286f94961af32b70947dcc597_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNTQ_8856501c-99b7-4663-9f18-66b4d5e52f4f" continuedAt="ib6cbb63dd73d44b0899020b5b8bd4835" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="margin-top:3pt"><span><br/></span></div><ix:continuation id="ib6cbb63dd73d44b0899020b5b8bd4835" continuedAt="i5a5a5cfcbde94df196fa200bd4065ce5"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNzY_e70e8261-41f1-4b04-874c-f407bf8f5d25">87,047,832</ix:nonFraction> shares of common stock outstanding. Each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="rgls:CommonStockVotingRightsVotes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTU3_d7766a34-90ad-4f1c-8a76-aaab1479cff1">one</ix:nonFraction> vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by our Board of Directors. </span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Equity Incentive Plan</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i5a5a5cfcbde94df196fa200bd4065ce5" continuedAt="i308be0570396415fb526604a8c7b01ae"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2019, the Company's board of directors approved, and on August 1, 2019 the Company's stockholders approved, the Company's 2019 Equity Incentive Plan (the "2019 Plan"). The 2019 Plan is intended as the successor to and continuation of the Company's 2012 Equity Incentive Plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares authorized for issuance under the 2019 Plan may be increased by (a) the shares subject to outstanding stock awards granted under the Company&#8217;s 2009 Equity Incentive Plan (the &#8220;2009 Plan&#8221;) and the Company&#8217;s 2012 Equity Incentive Plan (together the with 2009 Plan, the &#8220;Prior Plans&#8221;) that on or after the effective date of the 2019 Plan (i) expire or terminate for any reason prior to exercise or settlement; (ii) are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise return to the Company, or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award. No further grants will be made under the Prior Plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. In addition, on January 22, 2020, an additional <ix:nonFraction unitRef="shares" contextRef="ie53dd4b291ee4100afcd9f063f293242_D20200122-20200122" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTQ5NQ_f02b0368-c0b1-426d-b424-5bc043e7cca4">4,166,860</ix:nonFraction> shares of common stock became available for issuance under the 2019 Plan pu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rsuant to the Milestone Closing (defined below) of the May 2019 SPA (defined below). Further, on January&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year, for a period of not more than <ix:nonNumeric contextRef="ie740123647534dc7b2a846af038991a4_D20200122-20200122" format="ixt-sec:durwordsen" name="rgls:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTcyNg_272d9693-f04e-4c9a-96b9-e04392b5ec38">ten years</ix:nonNumeric>, beginning on January&#160;1, 2021 and continuing through January&#160;1, 2029, the number of shares authorized for issuance under the 2019 Plan will increase by <ix:nonFraction unitRef="number" contextRef="i9a1f2d1ed7234256bace1246be18d4ee_I20200122" decimals="INF" name="rgls:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTg4MQ_e702c0ec-718b-4f48-b2d4-4255dc842255">5.0</ix:nonFraction>% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares as may be determined by our Board of Directors. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, <ix:nonFraction unitRef="shares" contextRef="ie68f8c41edfb46ee9870928b23961edc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjA5Mg_6f90976f-bd12-489e-bae5-e35f3fb2fd53">853,111</ix:nonFraction> shares of common stock were available for new equity award grants under the 2019 Plan and <ix:nonFraction unitRef="shares" contextRef="ie68f8c41edfb46ee9870928b23961edc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjE4NQ_d49032d0-86dd-4aef-9717-2732c8722d01">10,172,886</ix:nonFraction> shares of common stock are reserved for issuance pursuant to equity awards outstanding as of September 30, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Private Placements of Common Stock, Non-Voting Preferred Stock and Warrants</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2019, we entered into a securities purchase agreement (the "May 2019 SPA") with certain institutional and other accredited investors, including certain directors, executive officers and employees of the Company (the &#8220;Purchasers&#8221;), pursuant to which we agreed to sell and issue shares of our common stock, shares of our newly designated non-voting convertible preferred stock, and warrants to purchase common stock, in up to <ix:nonFraction unitRef="closing" contextRef="i3322efb25d9a4f5f9fb3224308d86541_I20190503" decimals="INF" format="ixt-sec:numwordsen" name="rgls:NumberOfClosings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjgwOA_44464227-ec10-4900-9239-b5402b2b8b4b">two</ix:nonFraction> closings, in a private placement transaction (the &#8220;Private Placement&#8221;).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At an initial closing under the May 2019 SPA that occurred on May 7, 2019 (the &#8220;Initial Closing&#8221;), we sold and issued to the Purchasers (i) <ix:nonFraction unitRef="shares" contextRef="i674455781c874bdbbef4fcb1f436968d_D20190507-20190507" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzAyNg_6c082dca-b893-49ac-b734-e552bbd2e208">9,730,534</ix:nonFraction> shares of common stock and accompanying warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzExMg_233cc08b-97f8-493d-af46-58f255242aa2">9,730,534</ix:nonFraction> shares of common stock at a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzE3MA_884b277d-44f3-44aa-a6db-d2af40a2c571">1.205</ix:nonFraction> per share, and (ii) <ix:nonFraction unitRef="shares" contextRef="i0f2c4232052049e3a363d782b40cb6bc_I20190507" decimals="INF" format="ixt:num-dot-decimal" name="rgls:NonvotingConvertiblePreferredStockIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzE5Mw_dfe5a96c-6ff1-49db-867f-d920cea71adb">415,898</ix:nonFraction> shares of non-voting Class A-1 convertible preferred stock, in lieu of shares of common stock, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f2c4232052049e3a363d782b40cb6bc_I20190507" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzMwNQ_448975f8-400c-48e8-8370-5d6df38bc5d9">10.80</ix:nonFraction> per share, and accompanying warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0f2c4232052049e3a363d782b40cb6bc_I20190507" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzM3Mw_c40ccd12-b5c3-4cbf-8f19-fc2cb1aaabfc">4,158,980</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i50625ecf1d0a45eeb2ecec6aac3745e9_I20190507" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzQxMw_5ef626a1-17b6-408a-a972-63cc1c35fac1">0.125</ix:nonFraction> for each share of common stock underlying such warrants. Total gross proceeds from the Initial Closing were approximately $<ix:nonFraction unitRef="usd" contextRef="i674455781c874bdbbef4fcb1f436968d_D20190507-20190507" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzUzOA_e3006c20-8a78-41f1-b7a1-0f36fafa9ed4">16.7</ix:nonFraction> million, which does not include any proceeds that may be received upon exercise of the warrants. Each share of non-voting Class A-1 convertible preferred stock is convertible into <ix:nonFraction unitRef="shares" contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzcxMw_8b7f3a67-1715-4ff5-8ae6-3fd6e00a2979">10</ix:nonFraction> shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of <ix:nonNumeric contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzg0OQ_292c385e-4dac-4981-8bb4-49e518e3fd47">five years</ix:nonNumeric> following the date of issuance and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzkxMw_a5d07ef9-fb0c-442b-8246-73645adc4533">1.08</ix:nonFraction> per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise "cashless" basis. An aggregate of <ix:nonFraction unitRef="shares" contextRef="i81b3e274349048899a6baf2136cbce5c_D20190507-20190507" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNDEwOA_2ae85153-cb3d-480d-9d81-9e43ce715ce9">526,083</ix:nonFraction> shares of common stock and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="icd6803fc0e58407c98e7e6efe7b48823_I20190507" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNDE2NQ_e31fd439-173f-4638-8ceb-7dd8fd22d256">526,083</ix:nonFraction> shares of common stock were purchased for $<ix:nonFraction unitRef="usd" contextRef="i21a6fc5988124fb9a3c0daca71b52647_D20190507-20190507" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNDIxMA_2c04822e-5441-4655-b226-ba4c05a4a3a5">0.6</ix:nonFraction> million by certain directors and executive officers of the Company under the Initial Closing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the May 2019 SPA, in the event our Board of Directors unanimously resolved to recommence our Phase 1 multiple ascending dose clinical trial of our RGLS4326 product candidate for the treatment of ADPKD (the &#8220;Phase 1 Trial&#8221;) based on correspondence from the U.S. Food and Drug Administration&#8217;s Division of Cardiovascular and Renal Products, and thereafter but on or before December 31, 2019, we made a public announcement of our plan to recommence the Phase 1 Trial (the &#8220;Public Announcement&#8221;), we would sell and the Purchasers would purchase, at a second closing under the May 2019 SPA (&#8220;Milestone Closing&#8221;), shares of our non-voting convertible preferred stock and accompanying warrants to purchase shares of Common Stock (collectively, "Milestone Securities"). On December&#160;15, 2019, the Company's Board of Directors unanimously resolved to recommence the Phase 1 Trial based on correspondence from the U.S. Food&#160;&amp; Drug Administration&#8217;s Division of Cardiovascular and Renal Products and on December&#160;16, 2019, we made the related Public Announcement, triggering the Milestone Closing, which occurred on December&#160;24, 2019. At the Milestone Closing, we sold and issued to the Purchasers <ix:nonFraction unitRef="shares" contextRef="iead2605b5d6e40c59a34f098e26f325d_D20191224-20191224" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTQ5Ng_61a07309-2bee-4a2c-9545-c5e6a7569a43">3,288,390</ix:nonFraction> shares of&#160;non-voting&#160;Class&#160;A-2&#160;convertible preferred stock and accompanying warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i360a9fad1f764e37b7a0392838193495_I20191224" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTYxMg_72db59e5-ccda-48cb-b5ad-9f5a0d1f794d">32,883,900</ix:nonFraction> shares of common stock for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="iead2605b5d6e40c59a34f098e26f325d_D20191224-20191224" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTY4Nw_7242cb38-9378-4c8a-ab3b-9d02554355ec">26.0</ix:nonFraction> million. Net proceeds to the Company from the Milestone Closing were approximately $<ix:nonFraction unitRef="usd" contextRef="i6e3c72e4f312454cb6e94e3624438bd4_D20191224-20191224" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTc2NQ_3b70ec6f-bb65-47ea-ba8e-7b96519b5b90">24.6</ix:nonFraction> million. Each share of&#160;non-voting&#160;Class&#160;A-2&#160;convertible preferred stock is convertible into <ix:nonFraction unitRef="number" contextRef="i9e9d49856529484a9241d0f6562c00ce_D20191224-20191224" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTg1Mg_f8f32fec-32c8-41bc-bf38-6a4042c39a00">10</ix:nonFraction> shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants will be exercisable for a period of <ix:nonNumeric contextRef="i360a9fad1f764e37b7a0392838193495_I20191224" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTk5Mg_b4809165-73a0-48c5-97aa-d757211521e6">five years</ix:nonNumeric> following the date of issuance and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i360a9fad1f764e37b7a0392838193495_I20191224" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNjA1Ng_568134f1-e36c-410c-ae80-855ab81723d4">0.666</ix:nonFraction> per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise &#8220;cashless&#8221; basis. An aggregate of <ix:nonFraction unitRef="shares" contextRef="ief922b305f3046a1a28f76ddcd1e5862_D20191224-20191224" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNjI1MQ_2aa056ac-469f-4e47-b62f-569eb593801f">121,581</ix:nonFraction> shares of Class A-2 convertible preferred stock and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i7662e8163acd4dc8adc61570e5adde5d_I20191224" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNjMzMw_dd5bf243-60e1-48ba-ae79-52e8b156295e">1,215,810</ix:nonFraction> shares of common stock were purchased for approximately $<ix:nonFraction unitRef="usd" contextRef="ief922b305f3046a1a28f76ddcd1e5862_D20191224-20191224" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNjM5Mg_ac21899f-fd60-4687-a62e-65a9e4eed08e">1.0</ix:nonFraction> million by certain directors and executive officers of the Company under the Milestone Closing.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i308be0570396415fb526604a8c7b01ae" continuedAt="i7ab56e02c05e4916a718839f4138b3ee"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated the non-voting Class A-1 convertible preferred stock and common stock warrants sold in the Initial Closing and the Class A-2 convertible preferred stock and common stock warrants sold in the Milestone Closing under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and determined permanent equity treatment was appropriate for these freestanding financial instruments. The Initial Closing and Milestone Closing did not include any embedded features that required bifurcation. The non-voting Class A-2 convertible preferred stock and warrants issuable under the Milestone Closing were not subject to accounting recognition until the Milestone Closing occurred, as the terms of the Milestone Closing did not provide a right or an obligation on either the Company nor the Purchasers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2020, we entered into a Securities Purchase Agreement (the "December 2020 SPA") with certain institutional and other accredited investors, including certain directors, executive officers and employees of the Company (the &#8220;2020 Purchasers&#8221;), pursuant to which we agreed to sell and issue shares of our common stock, shares of newly designated non-voting convertible preferred stock and warrants to purchase common stock (the &#8220;2020 PIPE&#8221;).  </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing under the December 2020 SPA that occurred on December 4, 2020 (the &#8220;2020 Closing&#8221;), we sold and issued to the 2020 Purchasers (i) <ix:nonFraction unitRef="shares" contextRef="if073e6ccc7cc48ab99b972e5ac765b10_D20201204-20201204" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNzkxNw_05418956-48b4-4c0c-91ea-3ca108c007d8">24,341,607</ix:nonFraction> shares of common stock and accompanying warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie514dfd04114480cb2e11b8bf5bb0435_I20201204" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODAwMw_4ce3f4f2-02ec-4c58-bd28-d54882ef7a28">18,256,204</ix:nonFraction> shares of common stock at a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie514dfd04114480cb2e11b8bf5bb0435_I20201204" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODA2MQ_3c4344e3-3c4e-4939-bc9f-b4d74a740331">0.7464</ix:nonFraction> per share, and (ii) <ix:nonFraction unitRef="shares" contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204" decimals="INF" format="ixt:num-dot-decimal" name="rgls:NonvotingConvertiblePreferredStockIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODA4NA_2787941e-b273-411f-a7f0-e5494dee8f92">272,970</ix:nonFraction> shares of non-voting Class A-3 convertible preferred stock, in lieu of shares of common stock, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODE5Ng_1607d588-fe4f-4657-9269-985dfba9b3f5">6.22</ix:nonFraction> per share, and accompanying warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODI2NA_3e899e68-2735-457d-9f40-4216736a9d4a">2,047,276</ix:nonFraction> shares of common stock at a price of  $<ix:nonFraction unitRef="usdPerShare" contextRef="i6a2c7b41e9fc4304b5170c4d5ee66271_I20201204" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODMwNQ_94abde67-0224-4f89-85d4-d99ed99a2272">0.125</ix:nonFraction> for each share of common stock underlying such warrants. Total gross proceeds from the 2020 Closing were approximately $<ix:nonFraction unitRef="usd" contextRef="if073e6ccc7cc48ab99b972e5ac765b10_D20201204-20201204" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODQyNw_d27358aa-0407-47c8-9d57-35e62210d6be">19.4</ix:nonFraction>&#160;million, which does not include any proceeds that may be received upon exercise of the warrants. Each share of non-voting Class A-3 convertible preferred stock is convertible into <ix:nonFraction unitRef="shares" contextRef="ie514dfd04114480cb2e11b8bf5bb0435_I20201204" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODYwMg_0a1725de-5855-4443-b11a-f24fa8f8007a">10</ix:nonFraction> shares of common stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of <ix:nonNumeric contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODczOA_f8c2360f-1c6b-4937-bac0-f08536fbd4bc">five years</ix:nonNumeric> following the date of issuance and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODgwMg_8e41323d-31b8-4416-8679-b0bb9786425f">0.7464</ix:nonFraction> per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise "cashless" basis. An aggregate of <ix:nonFraction unitRef="shares" contextRef="i77c7496e13cb499b9175da4b6316b202_D20201204-20201204" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODk5Nw_571fba30-51cd-4a01-8eff-496a3cae6310">833,208</ix:nonFraction> shares of common stock and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i1ba02a52203c4223911077232c49cee7_I20201204" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfOTA1NA_033cbc3c-cf61-4b37-8875-9dcb19c020da">624,906</ix:nonFraction> shares of common stock were purchased for $<ix:nonFraction unitRef="usd" contextRef="ic598bb91fd7e4fed8d09bafbe5180ce0_D20201204-20201204" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfOTA5OQ_20740177-a272-4226-87e6-0323388259d1">0.6</ix:nonFraction>&#160;million by certain directors and executive officers of the Company at the 2020 Closing.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated the non-voting Class A-3 convertible preferred stock and common stock warrants sold in the 2020 PIPE under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and determined permanent equity treatment was appropriate for these freestanding financial instruments and there were no embedded features that required bifurcation. </span></div><div style="text-indent:31.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="rgls:ActivityOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNjc_84826c54-1101-49c2-9dc7-4fbf870e773b" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes preferred stock conversions and warrant exercises (and the related impact on common stoc</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k) under the 2019 SPA and 2020 SPA for the three and nine months ended September 30, 2021 and 2020 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A-1 Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A-2 Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A-3 Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0a0858e919543a98b9c64121d1e1830_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS0xLTEtMS02MTAz_7c0ee33b-5bd7-40b9-8e0e-082ebd7e1f19">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbea8938a1694e83b04dda860ed7dd2d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS0zLTEtMS02MTAz_b772b120-064e-4f86-a6a8-18f1446779eb">1,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia79e9b8c233642bbb9cebdf5dfb40760_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS01LTEtMS02MTAz_51b7041b-ddd1-4a65-8153-b1c1b324720c">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45d5562fcca646dd99b09cd41afa34ee_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS03LTEtMS02MTAz_b525e801-fed5-478d-8cf5-a28cca07bc77">66,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i752592ed38104bc78a16c74ec4d542fc_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS05LTEtMS02MTAz_1161cee6-0eab-4a74-b3df-a790bdcdfbb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia03dfcdae3b1407bb022fb54e0a8156b_D20210101-20210331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS0xLTEtMS02MTAz_1387c637-3957-4035-867a-69d353a887f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i383282b176b840d4a8c19a6ac7b18315_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS0zLTEtMS02MTAz_44b8c279-d07f-4eca-8270-de43fc986008">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6af434f9895c4a8abcdc67b6e14c6efe_D20210101-20210331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS01LTEtMS02MTAz_c705b212-6dcf-4ed7-84e9-e9eeb62d86ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic0bbfe3a36da493c9161915cc9d72948_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS03LTEtMS02MTAz_eea01386-7c47-4387-bc87-70f39902b943">3,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia36e6a371c8a44609f70ce29521cf931_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS05LTEtMS02MTAz_c4a62b85-e610-4d2a-af04-dc32f0de8bdf">3,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dd6bbd169a646cdac5d2d64ecd91d4a_I20210331" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi0xLTEtMS02MTAz_2ec6a882-0c4c-44e6-830c-25570cecd5d0">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62444203267d47c385eec5d087d4d8da_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi0zLTEtMS02MTAz_9ff1c85d-237d-4c25-979e-30738fbc6576">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39b26e0a123149da8e318c905c14d733_I20210331" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi01LTEtMS02MTAz_8a137ba9-5eea-43f4-90a5-0fbf622ac8ea">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c861e934bbb434fb65de130aef4d7f0_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi03LTEtMS02MTAz_05491f08-aa92-436c-8eb6-4a17c77024d8">62,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i26455c9e63ec418298d96a228a52ea5c_I20210331" xsi:nil="true" name="us-gaap:CommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi05LTEtMS02MTAz_a296dd12-5a01-4626-9571-33f9184b5349"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74040130c2df49589afc08ad9a809499_D20210401-20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy0xLTEtMS02MTAz_65af5b89-ee58-4cca-a98a-8f7e83f1ec7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i254490f02c4c4c589f3f3c5081713988_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy0zLTEtMS02MTAz_dfff1149-4b9e-41a8-af87-d327227ecbcd">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95228771e65f4d69be9591692885d592_D20210401-20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy01LTEtMS02MTAz_d69ddea4-dd38-4d49-9ccd-c5f2ca314ca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9c2c3a10cf064f479a81fd8b17777c0f_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy03LTEtMS02MTAz_9d0f50c0-edc0-4d7b-9622-9016b751a60b">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f4afbe5d8c34f8998934e3231e70d99_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy05LTEtMS02MTAz_b145b5bd-969e-4374-a179-6155e39e3478">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dc0c2d79507405e933216b019d4edde_I20210630" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC0xLTEtMS02MTAz_5163f8db-5490-4c1e-84e4-b5864f660559">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if247eeb7c16c4eb39296da50e9a88a87_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC0zLTEtMS02MTAz_b307e0fe-dcb5-487a-a457-df5d866ed1c2">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0325f8a593a4d04848243185ea3662f_I20210630" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC01LTEtMS02MTAz_5a55169a-14e0-4e1e-b06b-4ee595e92e6e">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7022c7df72d41e099622cfcf6c5ac69_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC03LTEtMS02MTAz_c502a444-0b04-4dea-aeaf-2bdb9f5c5820">61,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="ie294014d4c6e4e89b676a5f599db291f_I20210630" xsi:nil="true" name="us-gaap:CommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC05LTEtMS02MTAz_7f770aa1-271b-42be-998c-43e6eb4d102f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e29c7e6e8d7461aa5503106164f57ee_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS0xLTEtMS03MDI4_e4dc04c7-6667-4a10-a931-f0fa21df55da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id175542746b14dbe92632e7c763d73a4_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS0zLTEtMS03MDI4_62c73e11-cbfd-4fe0-92a8-25048e774e81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4e4836ff49d45a0813f0bf3e816e560_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS01LTEtMS03MDI4_1acdff92-2ea0-403b-b838-ac13dea95a2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fc483577ed845e8bf93c991053ea7c9_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS03LTEtMS03MDI4_7caead83-89a1-4fc4-bc0d-f6e934fc4153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8532096be04b6d9015d6367f7d8fdc_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS05LTEtMS03MDI4_7bab3502-fe38-45f9-8f6c-52bd09362629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic55ea03d6757422cb1b7c98ef85d4d29_I20210930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtMS0xLTEtNzAyOA_936b6b8d-7a05-47f1-8375-ec86156e2a6f">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i436d75c6db184475b193def39aa233c2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtMy0xLTEtNzAyOA_218c2bea-fe2e-4054-8116-c21cc0696e5c">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24d7ff325bb64f3ba97014fba8f446f6_I20210930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtNS0xLTEtNzAyOA_24a5cf31-865f-4ca4-b491-0f90cd5a947b">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1f198ef1d3d40c590316253a4a859b3_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtNy0xLTEtNzAyOA_f2d97dd8-4701-4b7c-8022-e37c36147da7">61,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="ib871a39aa1ac437eaa31e7324e95ec4f_I20210930" xsi:nil="true" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtOS0xLTEtNzAyOA_0a629ba4-5dd3-406d-b8b4-e2d5cba936ea"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e829145a1ef44a3801129514bd80961_I20191231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtMS0xLTEtNjEwMw_6c320d1c-344c-4dbe-b2b7-1d2f203d7897">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i968ebf92b9924a3f927dd3367b7ee9b9_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtMy0xLTEtNjEwMw_f9d4d964-be2f-4732-add4-185d6a42144e">3,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica7c16fbdde44fcab2f8edcb368cb2ec_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtNS0xLTEtNjEwMw_7694428e-715d-4e8e-b32b-5614c8fa846a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6455474e083246cbbfdf27a81a04fd9c_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtNy0xLTEtNjEwMw_bb7db8ad-27ca-4ce8-9731-af8f942e937e">46,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23dd736c354b4baca7d8a7e5ad03a16f_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtOS0xLTEtNjEwMw_2cbf65a3-1765-4528-82c9-fb74a78fd98c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20b9351df4284c69984f500e694a6369_D20200101-20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtMS0xLTEtNjEwMw_a345c910-b246-418b-b6ef-5760592674b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3352e5aab04142a5979bb162e53c6330_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtMy0xLTEtNjEwMw_b34ea499-4868-4123-8535-a3a485630005">656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2451dacc95664a628df7a419490f93d5_D20200101-20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtNS0xLTEtNjEwMw_d7d5be39-268b-461e-ae42-84852f4cd604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74a57decb14440bf86a20216c8b58def_D20200101-20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtNy0xLTEtNjEwMw_c1ee3a4f-c93a-4da5-a5f3-7ed9d37eb75b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i688d71ec835347f28d95349cfa461c90_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtOS0xLTEtNjEwMw_957f7324-eac5-4d70-bb13-05746e348525">6,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86de16f9b2f842129ce65f588a7a7aa9_I20200331" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtMS0xLTEtNjEwMw_aac84331-bd1d-470b-a0be-7c1d5a42871f">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i230bbacb14564b7287002929b04072b6_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtMy0xLTEtNjEwMw_c5a8a11d-4fb3-47c3-9834-8ddfb18f30dc">2,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf1162c4370f4f1495d1b38cb8c36886_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtNS0xLTEtNjEwMw_3da56389-9714-4445-8c4d-bb41f2df6791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dc114989d2e49059136125c88e9d784_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtNy0xLTEtNjEwMw_c9dc4af8-bb6c-4119-8a29-e54f6b9b1e3a">46,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="ida746cb1127f4a02913c9868d13207b9_I20200331" xsi:nil="true" name="us-gaap:CommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtOS0xLTEtNjEwMw_00dcaa2c-26ad-4d93-9430-27633a119111"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i17a1ebeb40054eee85bbb7562a88622b_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtMS0xLTEtNjEwMw_03a847a1-51f5-4fe6-9422-6392b4b686c0">159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0bc530cdf0a042f3b6cfcb98f0abe16d_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtMy0xLTEtNjEwMw_41dcc9cb-51d5-466f-b313-aa9d040cb6b0">671</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec999a5bafc747db893bef4a0ad2b58a_D20200401-20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtNS0xLTEtNjEwMw_2e26fe55-c015-4642-a4a0-7432d87f9883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf571b5851d240cc8cda05c8c168c970_D20200401-20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtNy0xLTEtNjEwMw_ce09ab51-ff76-40f8-a690-01167a9c5570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b2924209bd04bb7a40a2a56f99caa9f_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtOS0xLTEtNjEwMw_127bb13d-b039-43f9-8b06-8d5568f02487">8,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2af4520400a4c80a524537bc2037d39_I20200630" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtMS0xLTEtNjEwMw_3cd31de6-9cf2-4659-a394-50bddff41694">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b1959cfd8084de1ad61cf35bcfd27a2_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtMy0xLTEtNjEwMw_56b180fa-a862-4bed-9ae5-cd44edb387e2">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c97aedbf36c4a329ed8b131afa706da_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtNS0xLTEtNjEwMw_befdbb12-d736-4d05-8332-13be0ea9ba24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6923a101d07842c3b5768ebb561bc42e_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtNy0xLTEtNjEwMw_e3390658-f1d0-4060-88a5-8b2f7d3190da">46,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="iac6b75c985414d3a94e6080ae2260895_I20200630" xsi:nil="true" name="us-gaap:CommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtOS0xLTEtNjEwMw_e15e769f-a7b5-48a2-9b89-45b95d866f7c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fa784103a1544b79cc572714fbd6000_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktMS0xLTEtNzAzMQ_8dedfc6d-7fdb-49c3-81a1-15d5cb2f53ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i070064518ba64c48988cb9ebab49b967_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktMy0xLTEtNzAzMQ_0d3985ed-8833-4056-a137-61463b681e84">322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7db41969a844eb099ad7cacafdc6a43_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktNS0xLTEtNzAzMQ_2bb28dbb-dd54-4201-bb87-5e76f7b1cd0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb123cc427924d9d83494db5ea171543_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktNy0xLTEtNzAzMQ_d52175a0-f652-469b-84bb-22a246847f7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3593e979f61242e4974999e7d07215d2_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktOS0xLTEtNzAzMQ_7eb31570-efc2-484b-b66d-0a58a803338a">3,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September&#160;30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i786a3068e05841b28df2e45b562e51ee_I20200930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtMS0xLTEtNzAzMQ_2a89bee6-4a58-43f0-97ab-95aeaecc2089">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99418e2e85d14e5491bd379d2557e64f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtMy0xLTEtNzAzMQ_da65353e-4716-475b-9e20-610bac222f57">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i952837312fd74bb6ad3761bd0f543858_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtNS0xLTEtNzAzMQ_16d99668-6b26-49d3-9794-758b0eab6912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c184c7909e14f73a331173806592ad9_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtNy0xLTEtNzAzMQ_37e25d1d-c92e-4a79-a29e-b7ed571f718f">46,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="id5de04397b02498d82ebeda41dd65f11_I20200930" xsi:nil="true" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtOS0xLTEtNzAzMQ_a10b1e35-2a4a-4479-abd6-89ef0e87a2d8"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i7ab56e02c05e4916a718839f4138b3ee" continuedAt="ie27abd87247141a49c6f666e2f9b86b9"><div style="margin-top:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ATM Offering</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 12, 2018, we entered into a Common Stock Sales Agreement (the &#8220;Stock Sales Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;), pursuant to which we may sell and issue shares of our common stock from time to time through HCW, as our sales agent (the &#8220;ATM Offering&#8221;). We have no obligation to sell any shares of common stock in the ATM Offering, and may at any time suspend offers under the Stock Sales Agreement or terminate the Stock Sales Agreement. Subject to the terms and conditions of the Stock Sales Agreement, HCW will use its commercially reasonable efforts to sell shares of our common stock from time to time based upon our instructions (including any price, time or size limits or other parameters or conditions that we may impose, subject to certain restrictions). We pay HCW a commission of <ix:nonFraction unitRef="number" contextRef="i76e2ff0b853b425197ddbce613a8c517_I20181212" decimals="INF" name="rgls:CommissionFeeRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTA2MTg_be25db5b-ac4a-4d29-9ece-115c8ce5dc90">3.0</ix:nonFraction>% of the gross sales price of any shares sold under the Stock Sales Agreement. <ix:nonFraction unitRef="shares" contextRef="i89cc80809f64492f8d626470ab85255a_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjc0ODc3OTA4MzIyMA_fe17811c-154f-4c31-bb1b-2480f66374f7">No</ix:nonFraction> shares were sold under the ATM Offering during the three months ended September 30, 2021. A total of <ix:nonFraction unitRef="shares" contextRef="i4b63a4e5d7f548ab874621e4d0e59f70_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTA4NjY_d060c737-f938-4f7d-904d-582d2a69bf98">16,017,131</ix:nonFraction> shares were sold and settled for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i4b63a4e5d7f548ab874621e4d0e59f70_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTA5MTQ_5a23e24b-21df-4919-816c-4212e5ac9d1c">20.5</ix:nonFraction>&#160;million (net of $<ix:nonFraction unitRef="usd" contextRef="i4b63a4e5d7f548ab874621e4d0e59f70_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForCommissions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTA5MjU_3220afca-f774-4a8f-b90f-24b62a553098">0.8</ix:nonFraction>&#160;million in offering costs) under the ATM Offering during the nine months ended September 30, 2021. <ix:nonFraction unitRef="shares" contextRef="i0f0579c541c24aefa982bf42729d197c_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTEwMTM_1891194e-458a-4d63-9162-83a380c77ded"><ix:nonFraction unitRef="shares" contextRef="i3c72dba56f1642e4bb4ba0d460f36bff_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTEwMTM_e0397060-b4a6-490e-b9be-d37268b2bf70">No</ix:nonFraction></ix:nonFraction> shares were sold under the ATM Offering during the three and nine months ended September 30, 2020. On August 10, 2021, we increased the amount of common stock available for sale in ATM Offerings under the Stock Sales Agreement to $<ix:nonFraction unitRef="usd" contextRef="i7c836c16b926435386de34b3cc16d880_I20210810" decimals="-5" format="ixt:num-dot-decimal" name="rgls:SaleOfStockValueOfSharesAvailable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTEzMjQ_1922ef70-112b-4b97-beff-0791b7ba73e1">50.0</ix:nonFraction>&#160;million. At September 30, 2021, approximately $<ix:nonFraction unitRef="usd" contextRef="i6122f172c1574c4da14a5e4fd4d6e9da_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="rgls:SaleOfStockValueOfSharesAvailable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjc0ODc3OTA4MzIyMg_82b436b7-8340-4630-8976-34fa9245e508">50.0</ix:nonFraction>&#160;million remained available for sale in the ATM Offering.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="rgls:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNzM_a58dd564-cc84-445c-962a-5742901214ff" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares of common stock were reserved for future issuance as of September&#160;30, 2021 (in thousands):</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-1 convertible preferred stock outstanding (as-converted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e0fa5dcfa6f41d78143b478d0a01b56_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMC0xLTEtMS02MTAz_fe8806d8-1f6e-486a-a70d-80503d008f65">2,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-2 convertible preferred stock outstanding (as-converted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a0c87ad7a8d436fa4ccaa34c29d3a34_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMS0xLTEtMS02MTAz_6f4fdee2-aefb-4a6f-a6cd-edb7b080817a">13,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-3 convertible preferred stock outstanding (as-converted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8b79769fd334fd287d6b5137a7b5c74_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMi0xLTEtMS02MTAz_3c0679fa-89ab-4160-9331-5d69ea709c13">2,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 PIPE Initial Closing warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8041ada6a3e4d52bcb9c494a7798bca_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMy0xLTEtMS02MTAz_9b6dfe54-4d24-4824-89d2-fb490a271dd0">12,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 PIPE Milestone Closing warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3341a1d23c5c4c2cace6220943a0f34f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfNC0xLTEtMS02MTAz_6a5d4ed4-fc5a-4bd6-b3af-a491895aca6e">30,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 PIPE warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dd5d41a28e04fa0b27f308560cc92c1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfNS0xLTEtMS02MTAz_37510c07-0903-4cba-a027-8738d019c150">18,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfNi0xLTEtMS02MTAz_89944826-8b13-4f71-bb0a-b987f5444724">9,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c2342f58c454d05b39c846426605b48_I20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfNy0xLTEtMS02MTAz_25bf7002-483b-47a2-b082-5ba6e824cc68">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for future grant under 2019 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdae785f59024129a26a080f3e9b9224_I20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfOC0xLTEtMS02MTAz_87e9f2bb-d182-45ea-811e-fa17c394467f">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f4406481484bada9b1cf86ce076050_I20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMTEtMS0xLTEtNjEwMw_c788c80e-b461-446b-9cf8-49137fedd654">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMTItMS0xLTEtNjEwMw_d74e71a2-2708-473c-8241-fa07cdc7278c">91,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNTc_a9c700ff-5058-4146-8e58-e6f610af11a2" escape="true"><div style="margin-top:7pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock option and RSU (together Stock Awards) activity under all equity incentive plans for the nine months ended September&#160;30, 2021 (shares in thousands):</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Awards outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i951d796d9ed84f84b26dc055c3e072b5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMS0xLTEtMS02MTAz_d97cd4de-c459-4852-aa22-72cd076567ac">6,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i951d796d9ed84f84b26dc055c3e072b5_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMS0zLTEtMS02MTAz_2191d2c3-64f0-413b-8e00-7272da434f4b">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i644ae87d631747999899d8f3a2d4e933_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMS01LTEtMS02MTAz_1e502e6b-4948-43d5-be7b-169525698bf1">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i644ae87d631747999899d8f3a2d4e933_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMS03LTEtMS02MTAz_bc0f28ee-2e67-403e-ba40-99daec94d23f">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMi0xLTEtMS02MTAz_19dd0372-2c87-4104-be7b-931340736c6c">3,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMi0zLTEtMS02MTAz_e551bd87-dc9f-49bc-bfa1-47e8e297c40f">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMi01LTEtMS02MTAz_e61b30e1-e55e-4d0f-9fd5-7e8eab143b1b">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMi03LTEtMS02MTAz_0cb8727c-4b3d-4701-9389-32be5b1e6fa8">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised (options) or Vested (RSUs)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMy0xLTEtMS02MTAz_7fd79264-7e2f-4d45-87dd-e180727225fb">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMy0zLTEtMS02MTAz_899a96bf-f898-4104-b221-42167597983d">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMy01LTEtMS02MTAz_7d229427-226c-4769-b03a-7f650ac1cf92">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMy03LTEtMS02MTAz_eae324b2-a6a8-4b82-be6a-6c28e6d1d742">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNC0xLTEtMS02MTAz_80440033-d47a-4140-822a-123970a3ab3d">201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNC0zLTEtMS02MTAz_5138296e-1e44-4f12-857c-330d769a4e1b">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNC01LTEtMS02MTAz_38cb478a-353c-43a4-8519-d8c76889580f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNC03LTEtMS02MTAz_77be09df-b523-41a8-a0da-58c1919e3e96">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Awards outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib11f92ae4880433b90d114da1ab87247_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNS0xLTEtMS02MTAz_ed60c82f-aa6a-4395-881f-d04e6a2e38fd">9,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib11f92ae4880433b90d114da1ab87247_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNS0zLTEtMS02MTAz_217a5b1f-6ece-4a16-9b92-186c083eac52">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c2342f58c454d05b39c846426605b48_I20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNS01LTEtMS02MTAz_18cd3a57-529b-4900-9e1e-4e2b30aae770">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c2342f58c454d05b39c846426605b48_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNS03LTEtMS02MTAz_2e2fd8a0-a91b-4c4f-87c8-411aa876fb3f">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNTk_7fc0c1cf-fa65-477a-88c4-02acfc0a9bf1" continuedAt="if1bf7d63765e4444893934ce15e01cd6" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan, 2015 Inducement Plan, 2019 Equity Incentive Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="ie27abd87247141a49c6f666e2f9b86b9"><div style="margin-top:5pt"><ix:continuation id="if1bf7d63765e4444893934ce15e01cd6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70017d07079c4189905253f72a203dfa_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMy0xLTEtMS02MTAz_57ee9282-d30c-4a37-a78c-bafe9aace1b3">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic504631e11784f66848db26f50687d26_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMy0zLTEtMS02MTAz_66ea33d9-1862-4395-b1d0-b2a0668cea77">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMy01LTEtMS02MTAz_3a4b8325-0c7b-4344-954c-c5406285c75f">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMy03LTEtMS02MTAz_f6353944-73d3-4c26-b042-4c31a50fe95c">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70017d07079c4189905253f72a203dfa_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNC0xLTEtMS02MTAz_50c43a11-1137-4787-9998-6b6bb1704eb1">96.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic504631e11784f66848db26f50687d26_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNC0zLTEtMS02MTAz_fe6ca959-a228-48da-b286-4aaa47fa7653">95.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNC01LTEtMS02MTAz_97657759-7ac3-4ced-8e45-04372d029a16">95.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNC03LTEtMS02MTAz_d89d2d4a-c90b-4c4b-aceb-81654f0c1941">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dividend yield </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70017d07079c4189905253f72a203dfa_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNS0xLTEtMS02MTAz_5ddbfcf4-76ee-46e7-8bdf-753efe00e5bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic504631e11784f66848db26f50687d26_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNS0zLTEtMS02MTAz_fd3699f0-89aa-45be-8666-2f85120edd6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNS01LTEtMS02MTAz_dd7b9f32-a5ab-4598-b9b3-ae1ca4fe7c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNS03LTEtMS02MTAz_5cd76485-0c16-4cc7-ae8c-c3aac5b9f3ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i70017d07079c4189905253f72a203dfa_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNi0xLTEtMS02MTAz_e3429c41-9d17-4422-adaf-01f3c2ab018d">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic504631e11784f66848db26f50687d26_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNi0zLTEtMS02MTAz_cfd0fba9-4db8-49aa-b921-30ed4246fc96">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNi01LTEtMS02MTAz_ffc32455-c009-4064-935d-961b92454d34">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNi03LTEtMS02MTAz_ae7ea73d-fc3e-4125-aeec-cf607661df6a">6.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930" decimals="3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOC0xLTEtMS02MTAz_ab19d7fb-b82c-4bf9-8036-f2183009d487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6794a82e447847f0b259ae873682904e_D20200701-20200930" decimals="3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOC0zLTEtMS02MTAz_467524dd-0979-4979-9215-0fd6d0a28e39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOC01LTEtMS02MTAz_01eb436b-2d26-403e-97c2-a779ccd01e1b">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOC03LTEtMS02MTAz_f1234f0d-0cab-4ec0-9852-6d21f6c917a2">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930" decimals="3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOS0xLTEtMS02MTAz_af7ef04b-7347-4672-a67d-2b27cb0c3b7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6794a82e447847f0b259ae873682904e_D20200701-20200930" decimals="3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOS0zLTEtMS02MTAz_dfd7a4da-b6f3-414e-8a0c-c576d4bf41a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOS01LTEtMS02MTAz_d47d05bf-1d55-4c64-a5d0-1be0d53cf0c2">95.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOS03LTEtMS02MTAz_92fc891c-9b98-4c29-96a1-56eb6a3f73e9">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTAtMS0xLTEtNjEwMw_7ade320c-57a7-4a00-82ff-7a0ea0e7d770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6794a82e447847f0b259ae873682904e_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTAtMy0xLTEtNjEwMw_bd287384-0e57-4b22-ae43-936856c18569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTAtNS0xLTEtNjEwMw_c6908f46-9252-4752-bdca-84f8179b432b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTAtNy0xLTEtNjEwMw_649c3ab0-d77a-438e-b2ba-a4bb4dbaafa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTEtMS0xLTEtNjEwMw_ce9e5049-1228-43c1-a6f5-01b0999ac5dd">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6794a82e447847f0b259ae873682904e_D20200701-20200930" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTEtMy0xLTEtNjEwMw_de001074-4064-4832-8503-631638aae37d">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTEtNS0xLTEtNjEwMw_175bd7e4-24a9-4910-b9a8-bd100b989b87">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTEtNy0xLTEtNjEwMw_833f65ee-bba6-4fbb-a513-6eca5ca9188b">6.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTMtMS0xLTEtNjEwMw_d057f558-f092-4179-ba76-d95e58132182">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTMtMy0xLTEtNjEwMw_cd44560e-4d63-4066-8476-4b1becba4d6f">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTMtNS0xLTEtNjEwMw_4cecff88-880b-471a-afa2-d7cc6558ae83">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTMtNy0xLTEtNjEwMw_7163b286-bd26-4d99-bb9b-613453ee145f">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTQtMS0xLTEtNjEwMw_7750c938-3abf-4e03-b479-700ca0c51787">103.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTQtMy0xLTEtNjEwMw_d1a44f61-bfc3-47be-91b3-6a46a9bc7624">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTQtNS0xLTEtNjEwMw_a667423d-32e1-433a-8159-3596affc4ed9">104.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTQtNy0xLTEtNjEwMw_d0fd8e89-13f1-4561-ac3a-c25fd2c73436">98.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTUtMS0xLTEtNjEwMw_c6bfe0ed-3ce0-48fa-9761-f57eded9c512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTUtMy0xLTEtNjEwMw_89f5fe1f-dbd5-48d5-adf3-adf3d99c5967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTUtNS0xLTEtNjEwMw_29adf1a6-6479-46b1-a67d-c2cbc9c85080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTUtNy0xLTEtNjEwMw_83310da3-c3c0-479e-85b4-19aa3379447a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTYtMS0xLTEtNjEwMw_821651f5-b060-4c73-b083-cdfb150adda4">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTYtMy0xLTEtNjEwMw_e61fc404-2fc8-48cc-8243-5afc29dd5b04">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTYtNS0xLTEtNjEwMw_83e41215-c870-4413-bf8a-449259ee736e">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTYtNy0xLTEtNjEwMw_48bbfd39-0422-42f3-91c9-60625c3b5fb1">0.5</ix:nonNumeric></span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNjQ_6a6df8fa-eab0-4fcd-9c75-dd50841b6d00" escape="true"><div style="margin-top:13pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd5e74c99c434af4873f28aa394abae8_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfMi0xLTEtMS02MTAz_f555b0d7-d4bf-4f02-915c-76955bf36b46">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4dc078f58b49e3b773f4556b8a3b41_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfMi0zLTEtMS02MTAz_045f3b94-5a4c-470c-88b7-d3129654fe92">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b8f3c6cf464d83b2c2ae2abd93eef6_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfMi01LTEtMS02MTAz_ffb50154-5583-4928-b66b-1c82fd58ee8e">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65465aaa0a2b4eff99ceadebe06d4c4b_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfMi03LTEtMS02MTAz_413d3a50-58f8-49df-a41a-4d4b42007211">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f2e97743f414d1694ca8d0fce5260f4_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNC0xLTEtMS02MTAz_dc1de5d9-e3d3-4cae-9588-083292e1a214">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id179c53c4d4246068ac3e3d9d3e878bf_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNC0zLTEtMS02MTAz_6c5f8ffe-5d86-4687-900e-ab1946c64670">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c9397744df49d28775440c5244e2ab_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNC01LTEtMS02MTAz_def3c9d6-6093-4ecf-800e-78885de3acb1">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817be33db9a14559bd6acb439e8aab8f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNC03LTEtMS02MTAz_2b64a11d-8ae1-4882-87e6-4a7d8449ba30">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNi0xLTEtMS02MTAz_e2ec0734-5ba9-4ceb-8f37-997f356868b1">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNi0zLTEtMS02MTAz_5cc8324a-7417-49be-a226-7a84c3693216">692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNi01LTEtMS02MTAz_72c74275-78c8-4090-80f9-6317bf8f761b">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNi03LTEtMS02MTAz_4bd87544-be58-4b11-b4bd-3486e089efbf">2,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1bd3a25286f94961af32b70947dcc597_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNzE4MQ_cc6c697e-ab25-4221-8fda-9ffd87a00c19" continuedAt="ib06d89a8b52847db921443ba6d17498d" escape="true">Collaborations</ix:nonNumeric></span></div><ix:continuation id="ib06d89a8b52847db921443ba6d17498d" continuedAt="i06f37d0768504d34981d3a487b5371a9"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from our strategic collaborations was <ix:nonFraction unitRef="usd" contextRef="id91c48b0026b42dc91f4d51602dab771_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfODA_1832be8a-01ea-4718-bb69-ea3e3c40e3de"><ix:nonFraction unitRef="usd" contextRef="i207c6ee7766e4b7b8321acdabc61f642_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfODA_cf87dce1-367c-4844-986d-d3adcb737960">zero</ix:nonFraction></ix:nonFraction> for the three and nine months ended September 30, 2021, compared to $<ix:nonFraction unitRef="usd" contextRef="ib574d1151949442b9717daf3b9f1afcd_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMTU0_1e5bca90-b038-4655-b8c2-5a60f19862dc"><ix:nonFraction unitRef="usd" contextRef="i91edac16aa02482ab13c5c6191291f75_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjc0ODc3OTA3ODY1MQ_25382cf1-df35-413d-ab52-e294ae8bc0d0">5.0</ix:nonFraction></ix:nonFraction>&#160;million for the three and nine months ended September 30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sanofi</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA alliance targets to be developed under such agreement. The following elements were delivered as part of the strategic collaboration with Sanofi: (1)&#160;a license for up to <ix:nonFraction unitRef="target" contextRef="i00c63c04aad146a4a4b300df5bf7b017_D20120701-20120731" decimals="INF" format="ixt-sec:numwordsen" name="rgls:CollaborativeAreasGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTUz_3bbea230-4ba8-4c12-bf07-f365d12f3db1">four</ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA targets; and (2)&#160;a research license under our technology collaboration.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which Sanofi was granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport syndrome. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, we and Sanofi entered into a second amended and restated collaboration and license agreement (the &#8220;2014 Sanofi Amendment&#8221;) to discover, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutics to focus on specific orphan disease and oncology targets. Under the terms of the 2014 Sanofi Amendment, Sanofi had opt-in rights to our clinical fibrosis program targeting miR-21 for the treatment of Alport syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical program targeting miR-221/222 for hepatocellular carcinoma (&#8220;HCC&#8221;). We were responsible for developing each of these programs to proof-of-concept, at which time Sanofi had an exclusive option on each program. If Sanofi chooses to exercise its option on any of these programs, Sanofi would reimburse us for a significant portion of our preclinical and clinical development costs and would also pay us an option exercise fee for any such program, provided that $<ix:nonFraction unitRef="usd" contextRef="i3bcfd2d3e6b4477b9224c2ddab8e9c58_D20140201-20140228" decimals="-4" format="ixt:num-dot-decimal" name="rgls:DeferredRevenueCreditableAgainstFutureMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjAzNw_7ab8332a-f4d8-4327-b097-693677d5fea9">1.25</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i9f4e945ac07d4765bd2b5ffc2566e5ae_D20130601-20130630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjA0Nw_2972c3ad-5f5a-4d4b-80e4-643bc11ef658">2.5</ix:nonFraction>&#160;million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i06f37d0768504d34981d3a487b5371a9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be creditable against such option exercise fee. We are eligible to receive royalties on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products relating to our preclinical program targeting miR-221/222. As indicated below, we entered into an additional amendment with Sanofi in November 2018, under which Sanofi's opt-in rights to our miR-21 programs under the 2014 Sanofi Amendment were relinquished. Sanofi's opt-in rights with regard to our miR-221/222 preclinical program under the 2014 Sanofi Amendment remained unchanged.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are eligible to receive milestone payments related to the development and commercialization of miR-221/222 for HCC of up to $<ix:nonFraction unitRef="usd" contextRef="i41a9a1a9f277465e8d50fdad1c657692_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjg1Mg_fb4c087a-d1e3-4554-9cc9-6e1cb20373f7">38.8</ix:nonFraction> million for proof-of-concept option exercise fees (net of $<ix:nonFraction unitRef="usd" contextRef="i1929ac258c9c450cae6fef04bef7a0e8_D20210101-20210930" decimals="-4" format="ixt:num-dot-decimal" name="rgls:DeferredRevenueCreditableAgainstFutureMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjkwNQ_82ecb6b8-5077-4c23-b103-75d8707a812d">1.25</ix:nonFraction> million creditable, as noted above), $<ix:nonFraction unitRef="usd" contextRef="iba95955f98f043a68a1e97b6a00b2b51_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjkzNw_1f76afae-655e-46d3-9df6-a5583b655b32">25.0</ix:nonFraction> million for clinical milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i153b7153a94d40aebf670759f33de31f_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjk3NA_def3f23a-54ea-4911-a7ed-2a4fab42c084">130.0</ix:nonFraction> million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales of any products from the miR-221/222 program which, in the case of sales in the United States, will be in the middle of the <ix:nonFraction unitRef="number" contextRef="i54a4f0ed7dc74ea5888ebe893d2216a7_D20210101-20210930" decimals="INF" name="rgls:RoyaltyPercentageBasedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMzIyOA_612b5cb3-19b1-4183-bf49-092060e4253b">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibfab0a14bbcd45099cc675f73f91da2d_D20210101-20210930" decimals="INF" name="rgls:RoyaltyPercentageBasedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMzIzNA_e3d4babb-66bb-4b5b-b69c-b0e76a193c34">20</ix:nonFraction>% range, and, in the case of sales outside of the United States, will range from the low end to the middle of the <ix:nonFraction unitRef="number" contextRef="i26e5dcd2596c41159528a70c01a1e7c8_D20210101-20210930" decimals="INF" name="rgls:RoyaltyPercentageBasedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMzM0OQ_c79fa114-61b1-4a18-af92-2a50f07b94fe">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3fabccc96bc64e1d9de7b84c7b313a57_D20210101-20210930" decimals="INF" name="rgls:RoyaltyPercentageBasedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMzM1NQ_be2a1ba2-00e0-4551-9f5a-37ef0c4a1fdf">20</ix:nonFraction>% range, depending upon the volume of sales. If we exercise our option to co-promote a miR-221/222 product, we will continue to be eligible to receive royalties on net sales of each product in the United States at the same rate, unless we elect to share a portion of Sanofi&#8217;s profits from sales of such product in the United States in lieu of royalties.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we entered into an amendment to the 2014 Sanofi Amendment with Sanofi to modify the parties&#8217; rights and obligations with respect to our miR-21 programs, including our RG-012 program (the &#8220;2018 Sanofi Amendment&#8221;). Under the terms of the 2018 Sanofi Amendment, we have granted Sanofi a worldwide, royalty-free, fee-bearing, exclusive license, with the right to grant sublicenses, under our know-how and patents to develop and commercialize miR-21 compounds and products for all indications, including Alport Syndrome. Sanofi will control and will assume all responsibilities and obligations for developing and commercializing each of our miR-21 programs, including our obligations regarding the administration and expense of clinical trials and all other costs, including in-license royalties and other in-license payments, related to our miR-21 programs. Under the terms of the 2018 Sanofi Amendment, we have assigned to Sanofi certain agreements, product-specific patents and all materials directed to miR-21 or to any miR-21 compound or product and are required to provide reasonable technical assistance to Sanofi for a period of <ix:nonNumeric contextRef="i0f3e037391ac473094c869e8548228db_D20181101-20181130" format="ixt-sec:durmonth" name="rgls:AgreementPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNDg2MA_336dfbf2-4876-429c-ab64-1f569d2471f5">24</ix:nonNumeric> months after the date of the 2018 Sanofi Amendment. Under the terms of the 2018 Sanofi Amendment, we were eligible to receive approximately $<ix:nonFraction unitRef="usd" contextRef="ifa94d177b51946f9b13662dc829b3dc7_I20181130" decimals="INF" format="ixt:num-dot-decimal" name="rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNDk5Ng_457c4699-3a2f-4a40-9620-044edb57765b">6.8</ix:nonFraction> million in upfront payments for the license and for miR-21 program-related materials (collectively, the &#8220;Upfront Amendment Payments&#8221;). We were also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="if665882f71ff45d8bb6f588594d45f74_I20181130" decimals="-5" format="ixt:num-dot-decimal" name="rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTE2NQ_caa25f3e-5535-4fab-b0d2-0d3bcdb49943">40.0</ix:nonFraction> million in development milestone payments, including a $<ix:nonFraction unitRef="usd" contextRef="ibe78a5b02aa8476385726b454cc854b6_I20181130" decimals="-5" format="ixt:num-dot-decimal" name="rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTIxNQ_c1162a4f-efba-4810-925a-f3b011503b9d">10.0</ix:nonFraction>&#160;million payment for an interim enrollment milestone (the "Enrollment Milestone"). In addition, Sanofi has agreed to reimburse us for certain out-of-pocket transition activities and assume our upstream license royalty obligations. In 2019, we completed the performance obligations under the 2018 Sanofi Amendment and recognized revenue for the $<ix:nonFraction unitRef="usd" contextRef="i353569e61e144d2db9c5ffc37b740344_D20190101-20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTU1Mw_f2b306fd-ae31-4d78-95b0-68c12f9e750d">6.8</ix:nonFraction>&#160;million in Upfront Amendment Payments. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an amendment to the 2018 Sanofi Amendment (the "2020 Sanofi Amendment"). Under the terms of the 2020 Sanofi Amendment, we agreed to transfer to Sanofi additional RG-012 development program materials (the &#8220;Materials&#8221;) in exchange for a payment from Sanofi of $<ix:nonFraction unitRef="usd" contextRef="i29b7fba7009e439bbd4b1263221e7cf2_D20200801-20200831" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTg3OA_fc1f0464-b0fa-41a6-a16a-093427181516">1.0</ix:nonFraction>&#160;million (the &#8220;Transfer Payment&#8221;). In addition, in lieu of the $<ix:nonFraction unitRef="usd" contextRef="i2e7415adf3f848789ba227aa56299001_I20200831" decimals="-5" format="ixt:num-dot-decimal" name="rgls:EnrollmentMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTkzNQ_7bc65534-7822-4067-b8ec-83c32640c9f0">10.0</ix:nonFraction>&#160;million Enrollment Milestone under the 2018 Sanofi Amendment, Sanofi agreed to pay us a $<ix:nonFraction unitRef="usd" contextRef="i1806af5ab5b1428dbecc44603e625189_I20200831" decimals="-5" format="ixt:num-dot-decimal" name="rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjAxOA_c9485a65-7a9b-4a4d-be4c-b04c1d636228">4.0</ix:nonFraction>&#160;million milestone upon the completion of the transfer and verification of the Materials, and $<ix:nonFraction unitRef="usd" contextRef="i5d5dfcdeeecf40d4bbfce822eba097da_I20200831" decimals="-5" format="ixt:num-dot-decimal" name="rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjEwNg_9cad7950-53bf-416d-9aa7-ea4de6b39cae">5.0</ix:nonFraction>&#160;million upon achievement of the Enrollment Milestone. Additionally, we are eligible to receive $<ix:nonFraction unitRef="usd" contextRef="i539bb433e4534e329bc2c02884235317_I20200831" decimals="-5" format="ixt:num-dot-decimal" name="rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjE5Ng_aa34c20f-ba44-40b5-bb72-8d5b3db673b5">25.0</ix:nonFraction>&#160;million upon achievement of an additional development milestone related to Sanofi's development of the miR-21 compounds. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we received $<ix:nonFraction unitRef="usd" contextRef="ifa5bd7d664de45838a638a9e07b56636_D20200901-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjM0Mw_299423d9-072b-47e0-92a1-f8c71d4185a9">1.0</ix:nonFraction>&#160;million in exchange for the transfer of the Materials to Sanofi, and received an additional $<ix:nonFraction unitRef="usd" contextRef="i38edd55d27744d19aae8f3e58923a1d8_D20201001-20201031" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjQzMA_15a1a590-c382-4697-bdfb-afc942c112cd">4.0</ix:nonFraction>&#160;million in October 2020 as a result of Sanofi's completion and verification of the Materials in September 2020. As the performance obligations associated with both of these payments had been satisfied under Topic 606 as of September 30, 2020, both amounts were recognized as revenue in the third quarter of 2020. In November 2020, we received $<ix:nonFraction unitRef="usd" contextRef="ia8ceffe851924b93b694c2c233f516a4_I20201130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjc2OA_9b4adb63-9040-41ce-83d6-5c956351b312">5.0</ix:nonFraction>&#160;million upon achievement of the Enrollment Milestone. As the performance obligations associated with this payment had been satisfied under Topic 606 as of December 31, 2020, this amount was recognized as revenue in the fourth quarter of 2020.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e $<ix:nonFraction unitRef="usd" contextRef="i4a88aa30ce5f40f6915bd8be98ea9592_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="rgls:DevelopmentMilestoneNotAchievable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNzAzMQ_ed81afc7-8afa-40a1-ac11-bec029cccb37">25.0</ix:nonFraction> million in development milestone payments (variable consideration) is fully constrained and therefore, does not meet the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> criteria for revenue recognition.</span></div></ix:continuation><div id="i1bd3a25286f94961af32b70947dcc597_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNjI0OQ_3e8a47a5-9a7f-490b-aa1e-e22d9067a20d" continuedAt="i6f4a462869034394bd0cd6a4b9b7e79a" escape="true">Leases</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6f4a462869034394bd0cd6a4b9b7e79a" continuedAt="i3279f622c13041cc9368e305138e6264">At the inception of a contractual arrangement, we determine whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. For operating leases with an initial term greater than 12 months, we recognize operating lease right of use assets ("ROU assets") and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease ROU assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when we are reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i3279f622c13041cc9368e305138e6264" continuedAt="ib60ca1dcccc24dff8fb35fe63b48bd12"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our operating leases, we generally cannot determine the interest rate implicit in the lease, in which case we use our incremental borrowing rate as the discount rate for the lease. We estimate our incremental borrowing rate for our operating leases based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with a lease term of 12 months or less at inception are not recorded on the unaudited condensed balance sheet. Instead, we recognize lease expense for these leases on a straight-line basis over the lease term. Our lease agreements do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Certain leases require us to pay taxes, insurance, utilities, and maintenance costs for the building, which do not represent lease components. We elected to not separate lease and non-lease components.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;19, 2019, we entered into a lease agreement (the &#8220;Prior Lease&#8221;) with&#160;ARE SD Region No.44 LLC ("Landlord") for the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="i03c5d4dd537e4ff08c58974c361af177_I20190619" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetRentableArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjA0Ng_1b4475b5-e373-434a-b874-24e71d00c615">8,727</ix:nonFraction> square feet of rentable area of the building located at 10628 Science Center Drive, Suite 225, San Diego, California 92121 (the &#8220;Prior Premises&#8221;). The commencement date of the Prior Lease was July&#160;1, 2019 (the &#8220;Prior Commencement Date&#8221;). We used the Prior Premises as our principal executive offices and as a laboratory for research and development and other related uses. The term of the Prior Lease (the &#8220;Prior Initial Term&#8221;) was <ix:nonNumeric contextRef="i03c5d4dd537e4ff08c58974c361af177_I20190619" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjQ4MQ_eecfb8f4-b1ca-48c7-8f31-82f878e70662">two years, six months</ix:nonNumeric>, ending December&#160;31, 2021. The base rent payments due for the Prior Premises were $<ix:nonFraction unitRef="usd" contextRef="i03c5d4dd537e4ff08c58974c361af177_I20190619" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjU2Ng_45efdfaa-3518-495b-a7f8-f2990f740a94">0.4</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i03c5d4dd537e4ff08c58974c361af177_I20190619" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjU4MQ_17c449ea-7b1a-4675-9c20-fb7bb735c9b0">0.4</ix:nonFraction> million in 2021, net of certain rent abatement terms. We were also responsible for the payment of additional rent to cover our share of the annual operating expenses of the building, the annual tax expenses of the building and the annual utilities cost of the building.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2019, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i25175afe9d9d4c0f895fef5eab8d5af5_I20190701" decimals="-5" format="ixt:num-dot-decimal" name="rgls:InitialDirectCostLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjg3Nw_ff36eb46-b872-4978-8575-bdb71e9e62bd">0.8</ix:nonFraction> million lease liability for the Prior Lease, which was calculated as the present value of future lease payments to be made under the Prior Lease. A $<ix:nonFraction unitRef="usd" contextRef="i25175afe9d9d4c0f895fef5eab8d5af5_I20190701" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMzAyMA_d9099204-a594-4b56-b160-123b653bd6f9">0.6</ix:nonFraction> million ROU asset was also recorded on July 1, 2019, which represents the difference between the lease liability and the remaining $<ix:nonFraction unitRef="usd" contextRef="i25175afe9d9d4c0f895fef5eab8d5af5_I20190701" decimals="-5" format="ixt:num-dot-decimal" name="rgls:DeferredCreditOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMzE0Ng_0ed24db5-adb2-4934-bf9a-84faa4601de3">0.2</ix:nonFraction> million deferred credit for the reduction of the lease liability under the operating lease agreement with Landlord dated February 25, 2019. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2021, we entered into a lease agreement (the "Campus Point Lease") with ARE-SD Region No. 61, LLC (as successor in interest to ARE-SD Region No. 58, LLC) ("Campus Point Landlord"), for the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211" decimals="0" format="ixt:num-dot-decimal" name="rgls:RentedArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMzUxMA_2d647ce2-64ab-4065-8d0b-0e937f637170">13,438</ix:nonFraction> square feet of rentable area located at 4224 Campus Point Court, Suite 210, San Diego, California, 92121 (the "Campus Point Premises"). The commencement date of the Campus Point Lease was April 15, 2021. However, for accounting purposes the lease commencement date was February 11, 2021. We are using the Campus Point Premises as our new principal executive offices and as a laboratory for research and development, manufacturing and other related uses. The term of the Campus Point Lease (&#8220;Campus Point Initial Term&#8221;) is <ix:nonNumeric contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNDAzNQ_f41796f0-3276-4e35-ac50-7cb857ae24b8">60</ix:nonNumeric> months, ending April 30, 2026. The aggregate base rent due over the initial term of the Campus Point Lease is approximately $<ix:nonFraction unitRef="usd" contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNDE1NQ_604dfea8-197e-4f0d-ad1a-5051f2852bcc">3.8</ix:nonFraction>&#160;million. We are also responsible for the payment of additional amounts to cover our share of the annual operating expenses of the building, the annual tax expenses of the building and the utilities costs for the building.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2021, concurrently with entry into the Campus Point Lease, we entered into an Assignment and Assumption of Lease (the &#8220;Assignment Agreement&#8221;) with Turning Point Therapeutics, Inc. (&#8220;Assignee&#8221;) and a Consent to Assignment (the "Consent") with Landlord. Pursuant to the Assignment Agreement, we assigned all rights, title, and interest under the Prior Lease to Assignee and delivered the Prior Premises to Assignee</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on April 22, 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. Pursuant to the Assignment Agreement, Assignee paid us $<ix:nonFraction unitRef="usd" contextRef="i695ef34b99df4efc8fc1b1d5d72d82f2_D20210211-20210211" decimals="-3" format="ixt:num-dot-decimal" name="rgls:NonrefundableLeaseCostForAssignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNDg3NQ_0eb5d136-0a6e-42f6-9055-c59b3667494f">60,000</ix:nonFraction> in non-refundable assignment consideration. Additionally, the Consent stipulates that we were not required to pay a fee pursuant to the Prior Lease in connection with the assignment.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The execution of the Campus Point Lease, Consent, and Assignment Agreement resulted in a modification which was not accounted for as a separate contract. Rather, we accounted for the <ix:nonFraction unitRef="contract" contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211" decimals="INF" format="ixt-sec:numwordsen" name="rgls:NumberOfOperatingLeaseContracts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTI0NQ_5e991dac-c9c6-4213-8519-621469666a21">three</ix:nonFraction> contracts with Campus Point Landlord in combination, as they were entered into at the same time and negotiated as a package to achieve the same commercial objective. We accounted for a $<ix:nonFraction unitRef="usd" contextRef="i9f5be9f84b7d49a28e6d8c05f8aaaa70_I20210430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsLeasingAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTQzMw_d44f5733-7581-4a0b-bf26-f3a3f0e97f64">0.2</ix:nonFraction>&#160;million reduction in the lease liability for the Prior Lease as a deferred credit that is amortized as a reduction to rent expense over the term of the Campus Point Lease. A lease liability of less than $<ix:nonFraction unitRef="usd" contextRef="i9f5be9f84b7d49a28e6d8c05f8aaaa70_I20210430" decimals="-5" format="ixt:num-dot-decimal" name="rgls:InitialDirectCostLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTYzMQ_2a31d9c1-086d-4b22-8d3a-3c1c2ef173ca">0.1</ix:nonFraction>&#160;million and ROU asset of less than $<ix:nonFraction unitRef="usd" contextRef="i9f5be9f84b7d49a28e6d8c05f8aaaa70_I20210430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTY2MQ_e3bf64f4-b2c1-417f-83ce-862af4a2ff9f">0.1</ix:nonFraction>&#160;million remained with respect to the Prior Lease and was fully amortized as of April 30, 2021. On February 11, 2021, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211" decimals="-5" format="ixt:num-dot-decimal" name="rgls:InitialDirectCostLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTc4Nw_b422f106-ae8d-45c3-8fd6-c45f3633b548">3.2</ix:nonFraction>&#160;million lease liability for the Campus Point Lease, which was calculated as the present value of future lease payments to be made under the Campus Point Lease. A $<ix:nonFraction unitRef="usd" contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTk0NA_282c745e-5d83-43db-8e3a-bd95a0720139">3.0</ix:nonFraction>&#160;million ROU asset was also recorded on February 11, 2021, which represents the difference between the lease liability and the $<ix:nonFraction unitRef="usd" contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211" decimals="-5" format="ixt:num-dot-decimal" name="rgls:DeferredCreditOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNjA2NQ_acbbba8f-a047-4a75-80e2-e90cd2b6fbfc">0.2</ix:nonFraction>&#160;million deferred credit for the reduction of the lease liability under the Prior Lease.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="ib60ca1dcccc24dff8fb35fe63b48bd12"><ix:nonNumeric contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNjI1NA_ea31f4dc-5565-4ba9-b680-8eb3f43011a9" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future lease payments under operating leases at September 30, 2021 are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMS0xLTEtMS02MTAz_7574649f-d2bb-49b7-b35e-5448200bb51b">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMi0xLTEtMS02MTAz_548686a8-a674-4fb1-aac9-fc38b48e307a">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfNy0xLTEtMS02MTAz_04a6b193-e175-4593-a94a-a32f53585a07">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfOC0xLTEtMS02MTAz_ade42d09-53a0-4cf6-94c5-dcfadafbae2b">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="rgls:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfOS0xLTEtMS02MTAz_66f7ecba-7699-4461-a863-64d7eb328586">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTAtMS0xLTEtNjEwMw_2743e306-1df0-4ed4-99b4-a07d52f776c0">3,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTEtMS0xLTEtNjEwMw_8efb1ff3-9fdf-4439-9d3f-c304f11f55b6">471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligations under leases</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTItMS0xLTEtNjEwMw_bd40e21a-a63c-4dc9-9913-b02acef4e0f1">3,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTMtMS0xLTEtNjEwMw_2ce13fb9-84db-446a-be16-1bc94c76e986">575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTQtMS0xLTEtNjEwMw_1b02ef54-7a85-4f6b-8575-21fdeb664891">2,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1bd3a25286f94961af32b70947dcc597_61"></div><div style="margin-top:18pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The interim unaudited condensed financial statements and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&#160;31, 2020 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or Annual Report, filed with the Securities and Exchange Commission on March&#160;9, 2021. Past operating results are not necessarily indicative of results that may occur in future periods.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part&#160;II, Item&#160;1A, &#8220;Risk Factors&#8221; in this quarterly report on Form 10-Q. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate&#8221; or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, cost, timing, progress and results of, and our expected ability to undertake certain activities and accomplish certain goals with respect to our research and development activities, preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain funding for our operations;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to research, develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential election of any strategic collaboration partner to pursue development and commercialization of any programs or product candidates that are subject to a collaboration with such partner;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract collaborators with relevant development, regulatory and commercialization expertise;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future activities to be undertaken by our strategic collaboration partners, collaborators and other third parties;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance of our third-party suppliers and manufacturers;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully secure and deploy capital;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy our debt obligations;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding future expenses, future revenues, capital requirements and need for additional financing; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the COVID-19 pandemic on our business; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and other forward-looking statements described under the caption &#8220;Risk Factors&#8221; under Part II, Item&#160;1A of this quarterly report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RNAs to treat diseases with significant unmet medical need. We were formed in 2007 when Alnylam Pharmaceuticals, Inc. ("Alnylam") and Ionis Pharmaceuticals, Inc. ("Ionis") contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RNAs pursuant to a license and collaboration agreement. Our lead product candidates are RG-012 and RGLS8429. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease with no approved therapy available. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi. As a result, Sanofi became responsible for all costs incurred in the development of RG-012 and any other miR-21 programs. The transition activities were completed in the second quarter of 2019. RGLS8429, an anti-miR targeting miR-17, is our next-generation compound for the treatment of autosomal dominant polycystic kidney disease ("ADPKD"), which is currently in initial new drug application (&#8220;IND&#8221;)-enabling studies. In addition to these programs, we continue to develop a pipeline of preclinical drug product candidates.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs are naturally occurring ribonucleic acid ("RNA") molecules that play a critical role in regulating key biological pathways. Scientific research has shown that an imbalance, or dysregulation, of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs is directly linked to many diseases. Furthermore, many different infectious pathogens interact and bind to host </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA to survive. To date, over 500 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs have been identified in humans, each of which can bind to multiple messenger RNAs that control key aspects of cell biology. Since many diseases are multi-factorial, involving multiple targets and pathways, the ability to modulate multiple pathways by targeting a single </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA provides a new therapeutic approach for treating complex diseases.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA plays an essential role in the process used by cells to encode and translate genetic information from deoxyribonucleic acid ("DNA") to proteins. RNA is comprised of subunits called nucleotides and is synthesized from a DNA template by a process known as transcription. Transcription generates different types of RNA, including messenger RNAs that carry the information for proteins in the sequence of their nucleotides. In contrast, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs are RNAs that do not code for proteins but rather are responsible for regulating gene expression by modulating the translation and decay of target messenger RNAs. By interacting with many messenger RNAs, a single </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA can regulate the expression of multiple genes involved in the normal function of a biological pathway. Many pathogens, including viruses, bacteria and parasites, also use host </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs to regulate the cellular environment for survival. In some instances, the host </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs are essential for the replication and/or survival of the pathogen. For example, miR-122 is a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA expressed in human hepatocytes and is a key factor for the replication of the hepatitis C virus ("HCV").  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutics have the potential to become a new and major class of drugs with broad therapeutic application for the following reasons:</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs play a critical role in regulating biological pathways by controlling the translation of many target genes;</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutics regulate disease pathways which may result in more effective treatment of complex multi-factorial diseases; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">many human pathogens, including viruses, bacteria and parasites, use </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs (host and pathogen encoded) to enable their replication and suppression of host immune responses; and</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutics may be synergistic with other therapies because of their different mechanism of action.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled significant expertise in the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA field, including expertise in&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA biology and oligonucleotide chemistry, a broad intellectual property estate, relationships with key opinion leaders and a disciplined drug discovery and development process. We are using our&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA expertise to develop chemically modified, single-stranded oligonucleotides that we call anti-miRs to modulate&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs and address underlying disease. We believe&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs may play a critical role in complex disease and that targeting them with anti-miRs may become a source of a new and major class of drugs with broad therapeutic application, much like small molecules, biologics and monoclonal antibodies. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA biomarkers may be used to select optimal patient segments in clinical trials and to monitor di</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sease progression or relapse. We believe these </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA biomarkers can be applied toward drugs that we develop and drugs developed by other companies with which we partner or collaborate.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception through September&#160;30, 2021, we have received $384.0&#160;million from the sale of our equity and convertible debt securities, $101.8&#160;million from our strategic collaborations, principally from upfront payments, research funding and preclinical and clinical milestones, and $19.8 million in net proceeds from our Term Loan. As of September&#160;30, 2021, we had cash and cash equivalents of $35.8 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lead Product Candidates</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two lead product candidates. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RG-012:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2017, we completed a Phase 1 multiple-ascending dose ("MAD") clinical trial in 24 healthy volunteers (six-week repeat dosing) to determine safety, tolerability and pharmacokinetics ("PK") of RG-012 prior to chronic dosing in patients. In Phase 1 clinical trials to date, RG-012 was well-tolerated, and there were no serious adverse events ("SAEs") reported. In the third quarter of 2017, we initiated HERA, a Phase 2 randomized (1:1), double-blinded, placebo-controlled clinical trial evaluating the safety and efficacy of RG-012 in 40 Alport syndrome patients. In parallel, a renal biopsy study was also initiated in the third quarter of 2017 to evaluate RG-012 renal tissue PK, target engagement and downstream effects on genomic disease biomarkers. Kidney tissue concentrations were achieved in biopsy patients that would be predictive of therapeutic benefit based on animal disease models. In addition, modulation of the target, miR-21, was observed. In December 2017, we concluded our global ATHENA natural history of disease study. RG-012 has received orphan designation in both the United States and Europe. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program to Sanofi. As a result, Sanofi became responsible for all costs incurred in the development of these miR-21 programs. The transition activities, including the transfer of the IND, were co</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mpleted in the second quarter of 2019. Sanofi is currently enrolling patients into a Phase 2 clinical trial, with sites in the United States, Europe, Australia and China.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RGLS8429: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RGLS8429, an anti-miR targeting miR-17, is our next-generation compound for the treatment of ADPKD. In October 2021, we announced that we would discontinue further development of our first generation compound for the treatment of ADP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KD, RGLS4326, based on discussions with the FDA and data from the second cohort of patients in the Phase 1b trial of RGLS4326. RGLS8429 has completed an extensive 14-week non-GLP toxicity study in mice at significantly higher doses than RGLS4326. Additionally, with the completion of the dosing phase of the IND-enabling GLP toxicity studies, we believe RGLS8429 has demonstrated a superior pharmacological profile. Administration of RGLS8429 has not shown any of the off-target CNS effects that were seen with RGLS4326 at the top doses tested in chronic preclinical toxicology studies, and has equal potency to RGLS4326 for its molecular target (miR-17) in both in-vitro and in-vivo efficacy studies. We expect to have a pre-IND meeting with the FDA for RGLS8429 in late 2021. We plan to submit an IND, and, subject to FDA clearance of the IND, initiate a Phase 1 clinical study for RGLS8429 in the second quarter of 2022. Our Phase 1 plans include a single dose escalation study in healthy volunteers to enable a multi-dose study in ADPKD patients around the dose levels where robust clinical biomarker effects were demonstrated with RGLS4326. We anticipate reporting top-line biomarker data in the first cohort of RGLS8429 treated patients in early 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Preclinical Pipeline</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A major focus of our preclinical research has historically targeted dysregulated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs implicated in diseases of high unmet medical need where we know we can effectively deliver to the target tissue or organ, such as the liver and kidney. We also have early discovery programs investigating additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA targets for immunology, nephrology, oncology and indications for which there is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA dysregulation or in disease settings where the host </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs are essential for the replication and/or survival of the pathogen. We have multiple programs in various stages of preclinical development. While we are not currently advancing these programs to IND, we are working to explore the potential of microRNAs in these therapeutic areas.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under collaboration agreements.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from a combination of license fees and other upfront payments, payments for research and development services, milestone payments, product sales and royalties in connection with strategic collaborations. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of our achievement of preclinical, clinical, regulatory and commercialization milestones, if at all, the timing and amount of payments relating to such milestones and the extent to which any of our products are approved and successfully commercialized by us or our strategic collaboration partners. If our current or future collaboration partners do not elect or otherwise agree to fund our development costs pursuant to our current or future strategic collaboration agreements, or we or our strategic collaboration partner fails to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues, and our results of operations and financial position would be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research activities, including our drug discovery efforts and the development of our therapeutic programs. Our research and development expenses include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, or CROs, contract manufacturing organizations, or CMOs, other clinical trial related vendors, consultants and our scientific advisors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">license fees; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, amortization of leasehold improvements and equipment, and laboratory and other supplies.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. Certain of the raw materials used in the process of manufacturing drug product are capitalized upon their acquisition and expensed upon usage, as we have determined these materials have alternative future use.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have conducted research on many differe</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs with the goal of understanding how they function and identifying those that might be targets for therapeutic modulation. At any given time we are working on multiple targets, primarily within our therapeutic areas of focus. Our organization is structured to allow the rapid deployment and shifting of resources to focus on the most promising targets based on our ongoing research. As a result, in the early phase of our development programs, our research and development costs are not tied to any specific target. However, we are currently spending the vast majority of our research and development resources on our lead development programs.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred a total of approximately $386.8 million in research and development expenses through September&#160;30, 2021.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting clinical trials and preclini</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cal studies necessary to obtain regulatory approval is costly and time consuming. We, or our strategic collaboration partners, may never succeed in achieving marketing approval for any of our product candidates. The probability of success for each product candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of future product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future product candidate and are difficult to predict. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to our ability to maintain or enter into new collaborations with respect to each program or potential product candidate, the scientific and clinical success of each future product candidate, as well as ongoing assessments as to each future product candidate&#8217;s commercial potential. We will need to raise additional capital and may seek additional collaborations in the future in order to advance our various programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses and professional fees for auditing, tax and legal services, some of which are incurred as a result of being a publicly-traded company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of interest income and expense and various income or expense items of a non-recurring nature. We earn interest income from interest-bearing accounts and money market funds for cash and cash equivalents and marketable securities, such as interest-bearing bonds, for our short-term investments. Interest expense is primarily attributable to interest charges associated with borrowings under our secured Term Loan. </span></div><div id="i1bd3a25286f94961af32b70947dcc597_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting policies since December&#160;31, 2020. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our financial statements, refer to Item&#160;7 in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and Note 1 to our financial statements contained in our Annual Report and Note 1 to our condensed financial statements contained in this quarterly report on Form 10-Q.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the three and nine months ended September&#160;30, 2021 and 2020 </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands):&#160;&#160;&#160;&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other (expenses) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue under collaborations</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our revenues are generated from ongoing collaborations, and generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services. Revenue was zero for the three and nine months ended September 30, 2021, compared to $5.0 million for the three and nine months ended September 30, 2020. Revenue during the three and nine months ended September 30, 2020 primarily consisted of $5.0 million of revenue recognized during the third quarter of 2020 upon the completion of transfer and verification of certain materials sold to Sanofi. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following tables summarize the components of our research and development expenses for the periods indicated, together with year-over-year changes (dollars in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.923%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended               September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended            September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Personnel and internal expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Third-party and outsourced expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,915&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.923%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months     ended               September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended            September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Personnel and internal expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Third-party and outsourced expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $5.9 million and $13.4 million for the three and nine months ended September&#160;30, 2021, compared to $4.0 million and $11.4 million for the three and nine months ended September&#160;30, 2020. These amounts reflect the internal and external costs associated with advancing our clinical and preclinical pipeline. The aggregate increases for the three and nine months ended September 30, 2021, as compared to the three and nine months ended September 30, 2020, were attributable to increases in external research and development expenses, which were primarily driven by an increase in spend on third-party drug manufacturing for our RG8429 product candidate.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $2.5 million and $7.5 million for the three and nine months ended September&#160;30, 2021, compared to $2.1 million and $6.7 million for the three and nine months ended September 30, 2020. These amounts reflect personnel-related and ongoing general business operating costs. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income (expenses), net</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net interest and other expenses were $0.2 million for the three months ended September 30, 2021, compared to net interest and other expenses of $0.4 million for the three months ended September 30, 2020. These amounts were primarily related to interest charges associated with our outstanding Term Loan. Net interest and other income was $0.2 million for the nine months ended September&#160;30, 2021, compared to net interest and other expenses of $1.3 million for the nine months ended September 30, 2020. Net interest and other income for the nine months ended September 30, 2021 included a $0.7 million gain on forgiveness of our PPP loan during the second quarter of 2021, partially offset by interest charges associated with our outstanding Term Loan. Net interest and other expenses for the nine months ended September 30, 2020 were primarily related to interest charges associated with our outstanding Term Loan.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_79"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception through September&#160;30, 2021, we have received $384.0&#160;million from the sale of our equity and convertible debt securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $101.8&#160;million from our collaborations, principally from upfront payments, research funding and preclinical and clinical milestones, and $19.8 million in net proceeds from our Term Loan. As of September&#160;30, 2021, we had cash and cash equivalents of $35.8 million. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as a&#160;going&#160;concern.&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that we will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of our existing stockholders. These factors raise substantial doubt about our ability to continue as a going concern. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements are difficult to forecast and will depend on many factors, including: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">whether and when we achieve any milestones under our collaboration and license agreement with Sanofi; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the terms and timing of any other strategic collaboration, licensing and other arrangements that we may establish; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the initiation, progress, timing and completion of preclinical studies and clinical trials for our development programs and product candidates, and associated costs; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the number and characteristics of product candidates that we pursue; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the outcome, timing and cost of regulatory approvals; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">delays that may be caused by changing regulatory requirements; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the cost and timing of hiring new employees to support our continued growth; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the costs and timing of procuring clinical and commercial supplies of our product candidates; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the costs and timing of establishing sales, marketing and distribution capabilities, and the pricing and reimbursement for any products for which we may receive regulatory approval;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12.25pt">the extent to which we acquire or invest in businesses, products or technologies; and</span></div><div style="margin-top:1.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">payments under our Term Loan.</span></div><div style="margin-top:4.5pt;padding-left:11.25pt;text-indent:2.25pt"><span><br/></span></div><div style="margin-top:1.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the nine months ended September&#160;30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,278)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $16.3 million for the nine months ended September&#160;30, 2021, compared to $15.7 million for the nine months ended September&#160;30, 2020. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.2 million for the nine months ended September 30, 2021, compared to less than $0.1 million for the nine months ended September 30, 2020. </span></div><div style="margin-top:15pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $21.3 million for the nine months ended September&#160;30, 2021, compared to net cash used in financing activities of $0.5 million for the nine months ended September 30, 2020. Net cash provided by financing activities for the nine months ended September 30, 2021 was primarily attributable to proceeds from the issuance of our common stock in our ATM Offering.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS AND COMMITMENTS</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, there have been no material changes, outside of the ordinary course of business, in our outstanding contractual obligations from those disclosed in Note 8 Commitments and Contingencies, Note 9 Debt, and Note 13 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases to our financial statements contained in our Annual Report, with the exception of the Campus Point Lease, Assignment Agreement and Consent with Campus Point Landlord concerning our new corporate headquarters and the assignment of our previous corporate headquarters (refer to Note 8 to our condensed financial statements contained in this quarterly report on Form 10-Q), and full forgiveness of our $0.7 million PPP Loan (refer to Note 5 to our condensed financial statements contained in this quarterly report on Form 10-Q). </span></div><div style="margin-bottom:5pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we did not have any off-balance sheet arrangements.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the securities that we invest in have market risk where a change in prevailing interest rates may cause the principal amount of short-term investments to fluctuate. Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. We invest our excess cash primarily in money market funds. The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. We have established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the short-term maturities of our cash equivalents, we do not believe that an increase in market rates would have any significant impact on the realized value of our cash equivalents. If a 10% change in interest rates were to have occurred on September&#160;30, 2021, this change would not have had a material effect on the fair value of our cash equivalents as of that date.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have interest rate exposure as a result of our outstanding Term Loan. As of September&#160;30, 2021, the outstanding principal amount of the Term Loan was $4.7 million. The Term Loan bears interest at a floating per annum rate equal to (i) 8.51% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) 0.44%. Changes in the U.S. Dollar LIBOR rate may therefore affect our interest expense associated with the Term Loan. LIBOR is currently scheduled to be phased out by the end of 2021.&#160;Before&#160;LIBOR is phased out, we may need to renegotiate the&#160;Term Loan&#160;to replace&#160;LIBOR</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Secured Overnight Financing Rate (&#8220;SOFR&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The consequences of these developments cannot be entirely predicted, but could result in higher interest rates on the principal amount of the Term Loan. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  If a 10% change in interest rates were to have occurred on September&#160;30, 2021, this change would not have had a material effect on our interest expense as of that date.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_88"></div><div style="margin-top:18pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based, in part, upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September&#160;30, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) of the Exchange Act. An evaluation was also performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i1bd3a25286f94961af32b70947dcc597_94"></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our results of operations or financial position.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_97"></div><div style="margin-top:18pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all the factors described when evaluating our business. The risk factors set forth below that are marked with an asterisk (*)&#160;contain changes to the similarly titled risk factors included in, Item&#160;1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO THE DISCOVERY AND DEVELOPMENT OF PRODUCT CANDIDATES</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The approach we are taking to discover and develop drugs is novel and may never lead to marketable products.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our therapeutic product research and development efforts on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA technology, and our future success depends on the successful development of this technology and products based on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA product platform. Neither we, nor any other company, has received regulatory approval to market therapeutics targeting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs. The scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If we do not successfully develop and commercialize product candidates based upon our technological approach, we may not become profitable and the value of our common stock may decline.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our focus solely on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA technology for developing drugs as opposed to multiple, more proven technologies for drug development increases the risks associated with the ownership of our common stock. If we are not successful in developing any product candidates using </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA technology, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover potential product candidates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutics. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research methodology or that of any collaboration partner may be unsuccessful in identifying potential product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current or future collaboration partners may change their development profiles for potential product candidates or abandon a therapeutic area.&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preclinical and clinical studies of our product candidates may not be successful. If we are unable to generate successful results from our preclinical and clinical studies of our product candidates, or experience significant delays in doing so, our business may be materially harmed. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested a significant portion of our efforts and financial resources in the identification and development of product candidates that target </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our product candidates will depend on several factors, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully designing preclinical studies which may be predictive of clinical outcomes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful results from preclinical and clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection for future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining manufacturing relationships with third parties or establishing our own manufacturing capability; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully commercializing our products, if and when approved, whether alone or in collaboration with others.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully complete the development of, or commercialize, our product candidates, which would materially harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.* </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of product candidates, we or a collaboration partner must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical trials are expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Events which may result in a delay or unsuccessful completion of clinical development include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching an agreement with the FDA or other regulatory authorities on final trial design;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a clinical hold of our clinical trial operations or trial sites by the FDA or other regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to adhere to clinical trial requirements directly or with third parties such as CROs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in obtaining required institutional review board approval at each clinical trial site;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in recruiting suitable patients to participate in a trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays caused by patients dropping out of a trial due to protocol procedures or requirements, product side effects or disease progression;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites dropping out of a trial to the detriment of enrollment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">time required to add new clinical sites; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, in July 2018, we voluntarily paused our Phase 1 MAD clinical trial for RGLS4326 due to unexpected observations in our 27-week mouse chronic toxicity study, which was designed to support the Phase 2 proof-of-concept clinical trial in ADPKD previously planned to start in mid-2019. The observations in the mouse chronic toxicity study were unexpected, given the favorable safety profile of RGLS4326 in previous non-GLP and GLP toxicity studies at the same or similar doses supporting the IND and Phase 1 clinical trial. In consultation with the FDA, we initiated a new mouse chronic toxicity study with certain changes that are believed to address the unexpected observations. In January 2019, we announced data from a planned interim analysis of this study after 13 weeks of dosing in which no adverse or other significant findings across the range of doses tested were shown. We submitted a comprehensive data package for RGLS4326 to FDA that included the results from the planned 13-week interim analysis of the ongoing repeat mouse chronic toxicity study, as well as results from additional investigations, analytical testing, additional data from the previously terminated mouse chronic toxicity study, data from the completed Phase 1 SAD study and data from the first cohort of the Phase 1 MAD study to support our plan to resume the Phase 1 MAD study. In July 2019, FDA notified us of additional nonclinical data requirements and placed the IND on a partial clinical hold, formalizing the specific requirements to initiate the MAD study and further proceed into chronic dosing. The additional data requirements have been outlined in two parts. In order to resume the MAD study, FDA requested the final reports from the chronic toxicity studies in both mice and non-human primates and satisfactory related analyses to ensure subjects can be safely dosed. In November 2019, we submitted a complete response to the partial clinical hold in order to be able to resume the MAD study and in December 2019 FDA lifted the partial clinical hold of the MAD study. We recommenced the MAD study in February 2020. Following the completion of the MAD study in healthy volunteers, we initiated a Phase 1b study in patients with ADPKD to evaluate RGLS4326 for safety, PK, and changes in levels of PC1 and PC2. We met with FDA in a Type A meeting and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, based on FDA&#8217;s likely limitations on dose and duration of therapy and data from the second cohort of patients in the Phase 1b trial of RGLS4326 in ADPKD, we believe that a strategic prioritization of our next-generation compound, RGLS8429, represents a more judicious use of our resources, rather than continuing the development of RGLS4326, our first generation compound.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In October 2021, we announced we would discontinue development of RGLS4326 and would instead pr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ioritize RGLS8429, targeting miR-17. We may be incorrect in our expectation that the development work for RGLS4326 will benefit the development of RGLS8429. Additionally, FDA may not approve of our IND filing. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In additio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n, enrollment and retention of patients in clinical trials could be disrupted by man-made or natural disasters, public health pandemics or epidemics or other business interruptions, including the ongoing COVID-19 pandemic. COVID-19 has impacted, and may continue to impact, our future clinical activities and/or the activities of our partnered programs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we or our current or future collaboration partners are required to conduct additional clinical trials or other testing of any product candidates beyond those that are currently contemplated, are unable to successfully complete clinical trials of any such product candidates or other testing, or if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we or our current or future collaboration partners may:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for our future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as originally intended or desired;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. Any inability to successfully complete preclinical and clinical development, whether independently or with a collaboration partner, could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events ("AEs") caused by our product candidates could cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. Certain oligonucleotide therapeutics have shown injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our future product candidates may induce similar AEs.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If AEs are observed in any clinical trials of our product candidates, including those that a collaboration partner may develop under an agreement with us, our or our collaboration partners&#8217; ability to obtain regulatory approval for product candidates may be negatively impacted.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if any of our future products, if and when approved for commercial sale, cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;&#160;or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us or our collaboration partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products either on our own or with a collaboration partner.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither we nor any collaboration partner can commercialize a product until the appropriate regulatory authorities, such as the FDA, have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee recommends restrictions on approval or recommends non-approval. In addition, we or a collaboration partner may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.*</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval in the United States, the FDA may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. The holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review,&#160;in addition to other potentially applicable federal and state laws.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices ("cGMP") and adherence to commitments made in the NDA. If we or a regulatory agency discovers previously unknown problems with a product such as AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue a warning letter asserting that we are in violation of the law;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve a pending NDA or supplements to an NDA submitted by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize product; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA closely regulates the marketing, labeling, advertising and promotion of pharmaceutical products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Companies may also share truthful and not misleading information that is otherwise consistent with the labeling. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in significant civil, criminal and administrative penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA made in the physician&#8217;s independent medical judgement. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our future products and generate revenues.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RNA targets, drug compounds and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently we have rights to the intellectual property, through licenses from third parties and under patents that we own, to modulate only a subset of the known </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA targets. Because our programs may involve a range of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA targets, including targets that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we may collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.* </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and human resources, our existing strategy is to pursue collaboration agreements for the development and commercialization of our programs and potential product candidates in indications with potentially large </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial markets such as ADPKD, HCC, fibrosis and HBV, while focusing our internal development resources and any internal sales and marketing organization that we may establish on research programs and product candidates for selected markets, such as orphan diseases. As a result, we may forego or delay pursuit of opportunities with other programs or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">RISKS RELATED TO OUR FINANCIAL CONDITION AND NEED FOR ADDITIONAL CAPITAL</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern.*</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q includes disclosures regarding management&#8217;s assessment of our ability to continue as a going concern as our current liquidity position and recurring losses from operations since inception and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern. As of September 30, 2021, we had approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35.8 million of cash and cash equivalents and we had $6.0 million of outstanding debt obligations (which includes $4.7 million of outstanding principal and $1.3 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of final payment and loan amendment fees) under our Term Loan. We will need to raise additional capital to fund our operations and service our debt obligations, and if we are unable to raise additional capital when needed, we will not be able to continue as a going concern.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our research and development expenses to substantially increase in connection with our ongoing activities, particularly as we advance our product candidates towards or through clinical trials. We will need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Additionally, our collaboration partners may not elect to pursue the development and commercialization of any of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA product candidates that are subject to their respective collaboration agreements with us. Any of these events may increase our development costs more than we expect. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, which will be responsible for all costs incurred in the development of our miR-21 programs. As a result, we will not receive royalties in the event our miR-21 programs are eventually commercialized and will also receive significantly reduced milestones for these programs. We may need to raise additional capital or otherwise obtain funding through additional collaborations if we choose to initiate clinical trials for new product candidates other than programs currently partnered. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, future product candidates.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the foreseeable future, we expect to rely primarily on equity and/or debt financings to fund our operations. Raising additional capital through the sale of securities could cause significant dilution to our stockholders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part, on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital when required or on acceptable terms, we may be required to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly delay, scale back or discontinue the development or commercialization of any future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek collaborations, or amend existing collaborations, for research and development programs at an earlier stage than otherwise would be desirable or for the development of programs that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue the sale of our company to a third party at a price that may result in a loss on investment for our stockholders; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">file for bankruptcy or cease operations altogether.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our business, operating results and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payments under the instruments governing our indebtedness may reduce our working capital. In addition, a default under our loan and security agreement could cause a material adverse effect on our financial position.*</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a Loan Agreement with the Lender. Under the terms of the Loan Agreement, the Lender provided us with a $20.0 million Term Loan. Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, except for the assets that were licensed, assigned and transferred to Sanofi pursuant to the 2018 Sanofi Amendment that modify the parties&#8217; rights and obligations with respect to our miR-21 programs, including our RG-012 program, provided that the Lender will continue to have liens on all proceeds received by us pursuant to the Sanofi License Agreement. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement. Our required monthly payments to the Lender are comprised of interest only through and including the payment to be made in December 2021. We are required to maintain $3.0 million in cash in a collateral account.  During the first quarter of 2021, we received a waiver from the Lender with respect to noncompliance with a covenant under the Loan Agreement.  We are in compliance with all Loan Agreement covenants as of the date of the filing of this Form 10-Q.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Term Loan mature on May 1, 2022. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Term Loan, our interest rate on borrowed amounts is dependent on LIBOR. LIBOR is the basic rate of interest used i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n lending between banks on the London interbank market and is widely used as a reference for setting the interest rate on loans globally. In July 2017, the Chief Executive of the United Kingdom Financial Conduct Authority (&#8220;FCA&#8221;), which regulates LIBOR, announced that the FCA intends to phase out the use of LIBOR by the end of 2021. In addition, the U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing LIBOR with SOFR, a new index calculated by short-term repurchase agreements, backed by Treasury securities. Although there have been certain issuances utilizing SOFR, it is unknown whether this or any other alternative reference rate will attain market acceptance as a replacement for LIBOR. The consequences of these developments cannot be entirely predicted, but could result in higher interest rates on our outstanding principal amount under the Term Loan. We cannot provide assurance that future interest rate changes will not have a material negative impact on our business, financial position, or operating results.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement requires us, and any debt arrangements we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> dispose of assets;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> complete mergers or acquisitions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> incur indebtedness;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> encumber assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> pay dividends or make other distributions to holders of our capital stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> make specified investments; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> engage in transactions with our affiliates.  </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These restrictions could inhibit our ability to pursue our business strategies. If we default under our obligations under the Loan Agreement, the lender could proceed against the collateral granted to it to secure our indebtedness or declare all obligation under the Loan Agreement to be due and payable. In certain circumstances, procedures by the lenders could result in a loss by us of all of our equipment and inventory, which are included in the collateral granted to the lenders. If any indebtedness under the Loan Agreement were to be accelerated, there can be no assurance that our assets would be sufficient to repay in full that indebtedness. In addition, upon any distribution of assets pursuant to any liquidation, insolvency, dissolution, reorganization or similar proceeding, the holders of secured indebtedness will be entitled to receive payment in full from the proceeds of the collateral securing our secured indebtedness before the holders of other indebtedness or our common stock will be entitled to receive any distribution with respect thereto.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur additional indebtedness in the future. The debt instruments governing such indebtedness may contain provisions that are as, or more, restrictive than the provisions governing our existing indebtedness under the Loan Agreement. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against the collateral or force us into bankruptcy or liquidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.*</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, our operations have been primarily limited to acquiring and in-licensing intellectual property rights, developing our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA product platform, undertaking basic research around </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA targets and conducting preclinical and clinical studies for our initial programs. We have not yet obtained regulatory approval for any product candidates. Consequently, any predictions about our future success or viability, or any evaluation of our business and prospects, may not be accurate.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses in each year since our inception in September 2007. Our net loss was&#160;$8.6 million and $20.7 million for the three and nine months ended September 30, 2021, compared to $1.5 million and $14.4 million for the three and nine months ended September 30, 2020. As of September&#160;30, 2021, we had an accumulated deficit of $447.7 million.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted most of our financial resources to research and development, including our preclinical and clinical development activities. To date, we have financed our operations primarily through the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sale of equity securities and convertible debt, through our Term Loan and from revenue received from our collaboration partners. We have a collaboration with Sanofi relating to the development of our miR-221/222 program for oncology indications. Under our collaboration and license agreement with Sanofi, Sanofi has an option to obtain exclusive worldwide licenses for the development, manufacture and commercialization of our preclinical program targeting miR-221/222 for HCC. If Sanofi exercises its option, it will assume responsibility for funding and conducting further clinical development and commercialization activities for such product candidate. However, if Sanofi does not exercise its option, we will be responsible for funding further development of the applicable product candidate and may not have the resources to do so unless we are able to enter into another collaboration for such product candidate. Pursuant to the 2018 Sanofi Amendment, we completed the transition of further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, in the second quarter of 2019. As a result, Sanofi became responsible for all costs incurred in the development of our miR-21 programs. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to obtain funding through equity or debt financings, collaborations or grants. We plan to initiate clinical development of RGLS8429 in the second quarter of 2022, subject to FDA clearance. Even if we or a collaboration partner successfully obtains regulatory approval to market a product candidate, our revenues will also depend upon the size of any markets in which our product candidates have received market approval, and our ability to achieve sufficient market acceptance and adequate market share for our products.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we: continue our research and preclinical and clinical development of our product candidates, both independently and under our collaboration agreements; seek to identify additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA targets and product candidates; acquire or in-license </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other products and technologies; continue with clinical development of our product candidates; seek marketing approvals for our product candidates that successfully complete clinical trials; ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; maintain, expand and protect our intellectual property portfolio; hire additional clinical, regulatory, research and administrative personnel; and create additional infrastructure to support our operations and our product development and planned future commercialization efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have never generated any revenue from product sales and may never be profitable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaboration partners, to successfully complete the development of, obtain the necessary regulatory approvals for and commercialize product candidates. We do not anticipate generating revenues from sales of products for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying and validating new </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs as therapeutic targets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing our research and preclinical development of product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiating and completing clinical trials for product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking and obtaining marketing approvals for product candidates that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching and commercializing product candidates for which we obtain marketing approval, with a collaboration partner or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting and expanding our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring and retaining qualified personnel.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of increased expenses and when we will be able to achieve or maintain profitability, if ever. In addition, our expenses could increase beyond expectations if we are required by the FDA or foreign regulatory agencies to perform studies and trials in addition to those that we currently anticipate.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of the product candidates that we independently develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We will depend upon collaborations for the development and eventual commercialization of certain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RNA product candidates. If these collaborations are unsuccessful or are terminated, we may be unable to commercialize certain product candidates and we may be unable to generate revenues from our development programs. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are likely to depend upon third party collaboration partners for financial and scientific resources for the clinical development and commercialization of certain of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA product candidates. These collaborations will likely provide us with limited control over the course of development of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA product candidate, especially once a candidate has reached the stage of clinical development. For example, in our strategic collaboration with Sanofi, Sanofi has the option to obtain an exclusive worldwide license to develop, manufacture and commercialize our preclinical program targeting miR-221/222 for HCC upon the achievement of relevant endpoints in clinical trials. However, Sanofi is not under any obligation to exercise this option. While Sanofi has development obligations with respect to programs that it may elect to pursue under our agreement, our ability to ultimately recognize revenue from this and future relationships will depend upon the ability and willingness of our collaboration partners to successfully meet their respective responsibilities under our agreements with them. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi. As a result, Sanofi became responsible for all costs incurred in the development of our miR-21 program, but we will not receive royalties in the event our miR-21 programs are eventually commercialized, and the milestone payments we are eligible to receive for these programs has been significantly reduced.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our ability to recognize revenues from successful collaborations may be impaired by several factors including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaboration partner may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaboration partner may cease development in therapeutic areas which are the subject of our collaborations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaboration partner may change the success criteria for a particular program or potential product candidate thereby delaying or ceasing development of such program or candidate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaboration partner could develop a product that competes, either directly or indirectly, with a collaboration product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaboration partner may exercise its rights under the agreement to terminate the collaboration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a dispute may arise between us and a collaboration partner concerning the research, development or commercialization of a program or product candidate resulting in a delay in milestones, royalty payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaboration partner may use our proprietary information or intellectual property in such a way as to invite litigation from a third party or fail to maintain or prosecute intellectual property rights such that our rights in such property are jeopardized.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to termination rights, Sanofi may terminate the entire collaboration or its current collaboration target program for any or no reason upon 30 days&#8217; written notice to us. The agreement with Sanofi may also be terminated by either party for material breach by the other party, including a failure to comply with such party&#8217;s diligence obligations that remains uncured after 120 days. Depending on the timing of any such termination, we may not be entitled to receive the option exercise fees or milestone payments, as these payments terminate with termination of the respective program or agreement. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Sanofi does not elect to pursue the development and commercialization of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA development candidates covered by our collaboration and license agreement with Sanofi or if Sanofi terminates the agreement, then, depending on the event:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">under certain circumstances, we may owe Sanofi royalties with respect to product candidates covered by our agreement with Sanofi that we elect to continue to commercialize, depending upon the stage of development at which such product commercialization rights reverted back to us, or additional payments if we license such product candidates to third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates subject to the Sanofi agreement, as applicable, may be terminated or significantly delayed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce resources to the development and commercialization of product candidates that were previously funded by Sanofi; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the Sanofi agreement, including the reimbursement of third parties; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in order to fund further development and commercialization, we may need to seek out and establish alternative collaborations with third-party partners; this may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Any of these events could have a material adverse effect on our results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on third parties to conduct some aspects of our compound formulation, research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such formulation, research or testing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to independently conduct all aspects of our drug discovery activities, compound formulation research or preclinical studies of product candidates. We currently rely and expect to continue to rely on third parties to conduct some aspects of our preclinical studies and formulation development.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols for the trial.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us or our collaboration partners to select viable product candidates for IND submissions and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on third-party manufacturers to produce our preclinical and clinical product candidates, and we intend to rely on third parties to produce future clinical supplies of product candidates that we advance into clinical trials and commercial supplies of any approved product candidates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks, including risks that we would not be subject to if we manufactured the product candidates ourselves, including:</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to meet any product specifications and quality requirements consistently;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a delay or inability to procure or expand sufficient manufacturing capacity;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and product quality issues related to scale-up of manufacturing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and validation of new equipment and facilities required for scale-up;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a failure to comply with cGMP and similar foreign standards;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to negotiate manufacturing or supply agreements with third parties under commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reliance on a limited number of sources, and in some cases, single sources for raw materials, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell future product candidates in a timely fashion, in sufficient quantities or under acceptable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of qualified backup suppliers for any raw materials that are currently purchased from a single source supplier;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">carrier disruptions or increased costs that are beyond our control;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to deliver products under specified storage conditions and in a timely manner.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to clinical study delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on limited sources of supply for the drug substance of product candidates and any disruption in the chain of supply may cause a delay in developing and commercializing these product candidates. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established manufacturing relationships with a limited number of suppliers to manufacture raw materials and the drug substance of any product candidate for which we are responsible for preclinical or clinical development. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain. As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA prior to commercialization. If supply from the approved vendor is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our collaboration partners elect to pursue the development and commercialization of certain programs, we will lose control over the manufacturing of the product candidate subject to the agreement. For example, in November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, who is responsible for all costs incurred in the development of our miR-21 programs. As a result, we will no longer be involved in the development or commercialization of our miR-21 programs. Sanofi will be free to use a manufacturer of its own choosing or manufacture the product candidates in its own manufacturing facilities. In such a case, we will have no control over Sanofi&#8217;s processes or supply chains to ensure the timely manufacture and supply of the product candidates. In addition, we will not be able to ensure that the product candidates will be manufactured under the correct conditions to permit the product candidates to be used in such clinical trials. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, delay milestone payments owed to us or cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to deliver the required commercial quantities of active pharmaceutical ingredients on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production in a timely manner at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we scale-up manufacturing of product candidates and conduct required stability testing, product, packaging, equipment and process-related issues may require refinement or resolution in order to proceed with any clinical trials and obtain regulatory approval for commercial marketing. We may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical programs and regulatory approval, increases in our operating expenses, or failure to obtain or maintain approval for product candidates or any approved products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaboration partners rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we will have agreements governing their activities, we and our collaboration partners have limited influence over their actual performance. We control only certain aspects of our CROs&#8217; activities. Nevertheless, we or our collaboration partners are responsible for ensuring that each of our clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our collaboration partners and our CROs are required to comply with the FDA&#8217;s or other regulatory agency&#8217;s good clinical practices ("GCPs") for conducting, recording and reporting the results of IND-enabling studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The FDA and non-U.S. regulatory agencies enforce these GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or applicable non-U.S. regulatory agency may require us to perform additional clinical trials before approving any marketing applications for the relevant jurisdiction. Upon inspection, the FDA or applicable non-U.S. regulatory agency may determine that our clinical trials did not comply with GCPs. In addition, our clinical trials will require a sufficiently large number of test subjects to evaluate the safety and effectiveness of a potential drug product. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay the regulatory approval process.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs will not be our employees, and we will not be able to control whether or not they devote sufficient time and resources to our clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for such products and any product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on other third parties to store and distribute drug products for any clinical trials that we may conduct. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to obtain or protect intellectual property rights related to our future products and product candidates, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our future products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in patents with claims that cover the products in the United States or in other countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found; such prior art can invalidate a patent or prevent a patent from issuing based on a pending patent application. Even if patents do successfully issue, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. A patent may be challenged through one or more of several administrative proceedings including post-grant challenges, re-examination or opposition before the U.S. PTO or foreign patent offices. Any successful challenge of patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we or our collaboration partners may develop.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, in certain situations, if we and one or more third parties have filed patent applications in the United States and claiming the same subject matter, an administrative proceeding, known as an interference, can be initiated to determine which applicant is entitled to the patent on that subject matter. Such an interference proceeding provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications, or those of our collaboration partners or licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of a patent or patent application in such a proceeding may not be successful and, even if successful, may result in substantial costs and distract our management and other employees.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available however the life of a patent, and the protection it affords, is limited. Once the patent life has expired for a product, we may be open to competition from generic medications. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although each of our employees agrees to assign their inventions to us through an employee inventions agreement, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In addition, others may independently discover our trade secrets and proprietary information. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaboration partners are pursuing development candidates. For example, we are aware that Roche Innovation Center Copenhagen has patents and patent applications in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutics space, including patents and patent applications related to targeting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs, such as miR-122, for the treatment of disease. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. For example, our exclusive license agreements with our founding companies, Alnylam and Ionis, provide us with rights to nucleotide technologies in the field of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutics based on oligonucleotides that modulate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAs. Some of these technologies, such as intellectual property relating to the chemical modification of oligonucleotides, are relevant to our product candidate development programs. If our license agreements with Alnylam or Ionis are terminated, or our business relationships with either of these companies or our other licensors are disrupted by events that may include the acquisition of either company, our access to critical intellectual property rights will be materially and adversely affected.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense in a litigation may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO COMMERCIALIZATION OF PRODUCT CANDIDATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The commercial success of our programs that are part of our collaboration agreements with Sanofi or others will depend in large part on the development and marketing efforts of our collaboration partners. If our collaboration partners are unable or unwilling to perform in accordance with the terms of our agreements, our potential to generate future revenue from these programs would be significantly reduced and our business would be materially and adversely harmed. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi. The transition activities were completed in the second quarter of 2019. As a result, we have no influence and/or control over their approaches to development and commercialization of our miR-21 programs. If Sanofi or any potential future collaboration partners do not perform in the manner that we expect or fail to fulfill their responsibilities in a timely manner, or at all, the clinical development, regulatory approval and commercialization efforts related to product candidates we have licensed to such collaboration partners could be delayed or terminated. If we terminate any of our collaborations or any program thereunder due to a material breach by Sanofi, and except in the case of RG-012, we have the right to assume the responsibility at our own expense for the development of the applicable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA product candidates. Assuming sole responsibility for further development will increase our expenditures and may mean we will need to limit the size and scope of one or more of our programs, seek additional funding and/or choose to stop work altogether on one or more of the affected product candidates. This could result in a limited potential to generate future revenue from such </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA product candidates and our business could be materially and adversely affected. Further, under certain circumstances, we may owe Sanofi royalties on any product candidate that we may successfully commercialize.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are intensely competitive. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. Our competitors may have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, drug products that are more effective or less costly than any product candidate that we may develop.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our programs are targeted toward indications for which there are approved products on the market or product candidates in clinical development. We will face competition from other drugs currently approved or that will be approved in the future for the same therapeutic indications. Our ability to compete successfully will depend largely on our ability to leverage our experience in drug discovery and development to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discover and develop therapeutics that are superior to other products in the market;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">attract qualified scientific, product development and commercial personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">obtain patent and/or other proprietary protection for our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">RNA product platform and future product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">obtain required regulatory approvals; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new therapeutics.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. We will not achieve our business plan if the acceptance of any of these products is inhibited by price competition or the reluctance of physicians to switch from existing drug products to our products, or if physicians switch to other new drug products or choose to reserve our future products for use in limited circumstances. The inability to compete with existing or subsequently introduced drug products would have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing product candidates before we do, which would have a material adverse impact on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The commercial success of our product candidates will depend upon the acceptance of these product candidates by the medical community, including physicians, patients and healthcare payors. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of market acceptance of any product candidates will depend on a number of factors, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of clinical safety and efficacy compared to other products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience, ease of administration and acceptance by physicians, patients and healthcare payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any AEs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in the FDA-approved label for such products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost-effectiveness;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any collaborators&#8217; sales and marketing strategies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain hospital formulary approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain sufficient third party coverage and adequate reimbursement; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of third party coverage.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless other formulations are developed in the future, we expect our compounds to be formulated in an injectable form. Injectable medications may be disfavored by patients or their physicians in the event drugs which are easy to administer, such as oral medications, are available. If a product is approved, but does not achieve an adequate level of acceptance by physicians, patients and healthcare payors, we may not generate sufficient revenues from such product and we may not become or remain profitable. For example, several new antivirals and antiviral combinations have been approved for the treatment of the HCV </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">since we commenced our HCV program. Such increased competition may decrease any future potential revenue for future product candidates due to increasing pressure for lower pricing and higher discounts in the commercialization of our product.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. For example, in order to exercise our co-promotion rights with Sanofi with respect to our miR-221/222 program, we would need to build our sales, marketing, managerial and other non-technical capabilities in order to effectively carry out sales or co-promotion activities with respect to any approved products that are developed through these programs. With respect to certain of our current programs as well as future programs, we may rely completely on a collaboration partner for sales and marketing. In addition, we intend to enter into collaborations with third parties to commercialize other product candidates, including in markets outside of the United States or for other large markets that are beyond our resources. Although we intend to establish a sales organization if we are able to obtain approval to market any product candidates for niche markets in the United States, we will also consider the option to enter into collaborations for future product candidates in the United States if commercialization requirements exceed our available resources. This will reduce the revenue generated from the sales of these products.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and any future collaboration partners may not dedicate sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective collaborations to enable the sale of our product candidates to healthcare professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential future collaboration partners do not successfully commercialize the product candidates, our ability to generate revenues from product sales will be adversely affected.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidates that we develop are approved for commercialization, we may also enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters, including earthquakes, typhoons, floods and fires, public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell products profitably.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of any product candidates that we develop will depend on coverage and reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third party payors, such as private health insurers, government payors and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. We cannot be sure that coverage and adequate reimbursement will be available for any future product candidates. Also, inadequate reimbursement amounts may reduce the demand for, or the price of, our future products.  Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize product candidates that we develop.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot be certain if and when we will obtain formulary approval to allow us to sell any products that we may develop and commercialize into our target markets. Obtaining formulary approval from hospitals and from payors can be an expensive and time-consuming process. Failure to obtain timely formulary approval will limit our commercial success.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell products profitably. These legislative and/or regulatory changes may negatively impact the reimbursement for drug products, following approval. The availability of numerous generic treatments may also substantially reduce the likelihood of reimbursement for our future products. The potential application of user fees to generic drug products may expedite the approval of additional generic drug treatments. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. If we fail to successfully secure and maintain reimbursement coverage for our future products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our future products and our business will be harmed.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally tend to be priced significantly lower.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR BUSINESS OPERATIONS AND INDUSTRY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in preclinical studies and clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee might impede the progress of our research, development and commercialization objectives.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations.* </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had 25 employees, all of which were full-time employees. In the future, we may need to expand our organization. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. Moreover, if our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative sanctions.</span></div><div style="margin-bottom:5pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may undertake internal restructuring activities that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we may undertake internal restructuring activities as we continue to evaluate and attempt to optimize our cost and operating structure in light of developments in our business strategy and long-term operating plans. For example, we initiated a corporate restructuring in May 2017 and in July 2018, each of which resulted in a reduction in our workforce.  Any such restructuring activities may result in write-offs or other restructuring charges. There can be no assurance that any restructuring activities that we have undertaken or undertake in the future will achieve the cost savings, operating efficiencies or other benefits that we may initially expect. Restructuring activities may also result in a loss of continuity, accumulated knowledge and inefficiency during transitional periods and thereafter. In addition, internal restructurings can require a significant amount of time and focus from management and other employees, which may divert attention from commercial operations. If any internal restructuring activities we have undertaken or undertake in the future fail to achieve some or all of the expected benefits therefrom, our business, results of operations and financial condition could be materially and adversely affected. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain current and future relationships with customers and third party payors as well as certain of our business operations may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws,  health information privacy and information security laws and other privacy and information security laws. If we are unable to comply, or have not fully complied or are perceived to have not fully complied, with such laws, we could face significant penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.*</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations may be directly, or indirectly through our relationships with customers, third party payors, healthcare providers, and others subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, because we process personal data and other sensitive and confidential information, including patient data, we may be subject to data privacy laws and regulations and other privacy requirements by the federal government and by the U.S. states and foreign jurisdictions in which we conduct our business. Data privacy and information security obligations are stringent and changing, with new data privacy and information security laws being proposed or enacted. The laws and regulations that may affect our ability to operate include, but may not be limited to:</span></div><div style="margin-top:0.2pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="padding-left:40.5pt;padding-right:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="margin-top:9pt;padding-left:40.5pt;padding-right:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including Medicare or Medicaid, that are false or fraudulent;</span></div><div style="margin-top:9pt;padding-left:40.5pt;padding-right:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Education and Clinical Health Act ("HITECH"), and their implementing regulations, which imposes certain requirements on certain types of individuals and entities relating to the privacy, security and transmission of certain individually identifiable health information; </span></div><div style="margin-top:9pt;padding-left:40.5pt;padding-right:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the&#160;European General Data Protection Regulation ("GDPR") adopted by the European Union ("EU") in May 2018, which contains provisions specifically directed at the processing of health information and, more broadly, imposes significant and complex compliance burdens on processing personal data, with high sanctions and extra-territoriality measures intended to bring non-EU companies under the regulation's scope; we anticipate that over time we may expand our business operations to include additional operations in the EU, including potentially conducting preclinical and clinical trials and, with such expansion, we would be subject to increased governmental regulation in the EU countries in which we might operate, including but not limited to the GDPR;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">California enacted the California Consumer Privacy Act ("CCPA") in 2018, which created new individual privacy rights for consumers (as that word is broadly defined in the law) and placed increased privacy and security obligations on entities handling personal data of covered consumers or households. The CCPA, which went into effect on January 1, 2020, requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allows for a new cause of action for data breaches, which is expected to increase data breach class action litigation and may result in significant legal exposure. The CCPA&#8217;s interpretation and enforcement remain uncertain, which further increases compliance costs.  Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws may impact (possibly significantly) our business activities depending on how it is interpreted. Furthermore, it is anticipated that the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), effective January 1, 2023, will expand the CCPA, and several other states have enacted or proposed data privacy laws, further exemplifying the evolving regulatory environment related to personal data and, particularly, protected health information;</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services ("CMS") information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, and further requires applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding its payment and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and</span></div><div style="margin-top:9pt;padding-left:40.5pt;padding-right:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign law equivalents of each of the above federal laws, such as: anti-kickback and false claims laws which may apply to items or services reimbursed by any third party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information related to drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information and other sensitive information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation (or perceived to be in violation) of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, litigation, significant civil, criminal and administrative penalties, damages, fines, possible exclusion from Medicare, Medicaid and other government healthcare programs, disgorgement, imprisonment, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, including interrupting or stopping clinical trials, and our results of operations.</span></div><div style="padding-right:2.25pt"><span><br/></span></div><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent and future healthcare legislation may further impact our business operations.* </span></div><div style="padding-left:4.5pt;padding-right:2.25pt;text-indent:2.25pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;) was passed and includes measures to significantly change the way healthcare is financed by both governmental and private insurers. There have been executive, judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (&#8220;Tax Act&#8221;) includes a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, except for a temporary suspension from May 1, 2020 through December 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, at the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, President Trump announced several executive orders related to prescription drug pricing that attempted to implement several of the Trump administration proposals. As a result, the FDA released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed by the Biden administration until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries. As a result of litigation challenging the Most Favored Nation model, on August 10, 2021, CMS published a proposed rule that seeks to rescind the Most Favored Nation Model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. Certain oligonucleotide therapeutics have shown injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our current and future product candidates may induce similar adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs due to related litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management&#8217;s attention from our primary business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates, if approved for commercial sale.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain product liability insurance relating to the use of our therapeutics in clinical trials. However, such insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity risks and the failure to maintain the security, confidentiality, integrity, and availability of our computer hardware, software, services, networks, communications, data, and Internet applications and related tools and functions, and those maintained on our behalf, could result in material adverse impact to our business, including without limitation a material interruption to our operations, including clinical trials, damage to our reputation and/or subject us to costs, fines or lawsuits.*</span></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business requires manipulating, analyzing and storing large amounts of data, including personal data (including health information), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties. We also maintain personally identifiable information about our employees. We rely on a global enterprise software system to operate and manage our business, and our business therefore depends on the continuous, effective, reliable, and secure operation of our computer hardware, software, services, networks, communications, Internet servers and related infrastructure. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyberattacks, malicious internet-based activity and online and offline fraud are prevalent and continue to increase.  In addition to traditional computer &#8220;hackers,&#8221; threat actors, software bugs, malicious code (such as viruses and worms), employee theft or misuse, denial-of-service attacks (such as credential stuffing), and ransomware attacks, sophisticated nation-state and nation-state supported actors now engage in attacks (including advanced persistent threat intrusions). We may also be the subject of phishing attacks, viruses, malware installation, server malfunction, software or hardware failures, loss of data or other computer assets, adware or other similar issues. Ransomware attacks are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, disruption of clinical trials, loss of data (including data related to clinical trials), loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the impact of a ransomware attack it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency. Despite security controls we have in place, such attacks are difficult to avoid.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the aforementioned threats could cause a security incident, which, in turn, could result in unauthorized access to, damage to, disablement or encryption of, use or misuse of, disclosure of, modification of, destruction of, or loss of our data or our customers&#8217; data, or disrupt our ability to provide our services or our service providers&#8217; ability to support our services. As a result, our business could suffer. The integrity and protection of our sensitive data, including employee and personal health information, is critical to our business, and employees and others have a high expectation that we will adequately protect their personal information.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may expend significant resources, fundamentally change our business activities and practices, or modify our operations, including our clinical trial activities, or information technology in an effort to protect against security incidents and to mitigate, detect, and remediate actual and potential vulnerabilities. Applicable data protection laws, privacy policies or other obligations related to data privacy (e.g. contractual obligations, obligations related to membership in industry organizations) may require us to implement specific security measures or use industry-standard or reasonable measures to protect against security measures. The regulatory environment governing information, security and privacy is increasingly demanding and continues to evolve. Maintaining compliance with applicable information security and privacy obligations may increase our operating costs. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against a security incident, there can be no assurance that our security measures or those of our partners will be effective in protecting against a security incident. We may be unable in the future to detect, anticipate, measure or prevent threats or techniques used to detect or exploit vulnerabilities in our (or our partners&#8217;) information technology, services, communications or software because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after an incident has occurred.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or a third party upon whom we rely, experience a security incident, or are perceived to have experienced a security incident, it may result in: government enforcement actions that could include investigations, fines, penalties, audits and inspections; additional reporting requirements and/or oversight; temporary or permanent bans on all or some processing of personal data (which could impact our clinical trials or training of our algorithm); or orders to destroy or not use personal data. Further, individuals or other relevant stakeholders could sue us for our actual or perceived failure to comply with our security obligations, including, without limitation, in class action litigation. We may also need to notify relevant stakeholders in the event of a security incident, as required by applicable laws, which is costly and could damage our reputation. Security incidents could also result in indemnity obligations, negative publicity and financial loss.   </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or otherwise protect us from liabilities or damages if we fail to comply with applicable data protection laws, privacy policies or data protection obligations related to information security or security incident. Additio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nally, we cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or material adverse impacts arising out of our privacy and security practices, processing or security incidents we may experience, or that such coverage will continue to be available on commercially reasonable terms or at all.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in funding for&#160;FDA, the SEC&#160;and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the&#160;FDA and the SEC, have had to furlough critical&#160;FDA, SEC and other government&#160;employees and stop critical activities. If a prolonged&#160;government&#160;shutdown&#160;occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The withdrawal of the United Kingdom from the European Union, commonly referred to as &#8220;Brexit,&#8221; may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union, result in restrictions or imposition of taxes and duties for importing our product candidates into the European Union, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the European Union.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the result of a referendum in 2016, the United Kingdom left the European Union on January 31, 2020, commonly referred to as &#8220;Brexit.&#8221; Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom was subject to a transition period that ended December 31, 2020, or the Transition Period, during which EU rules continued to apply. A trade and cooperation agreement, or the Trade and Cooperation Agreement, that outlines the future trading relationship between the United Kingdom and the European Union was agreed in December 2020.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from EU directives and regulations, Brexit has had, and may continue to have, a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the European Union. For example, Great Britain is no longer covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA and a separate marketing authorization will be required to market our product candidates in Great Britain. It is currently unclear whether the Medicines &amp; Healthcare products Regulatory Agency ("MHRA"), in the U.K. is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the Trade and Cooperation Agreement provides for the tariff-free trade of medicinal products between the UK and the EU there may be additional non-tariff costs to such trade which did not exist prior to the end of the Transition Period.  Further, should the UK diverge from the EU from a regulatory perspective in relation to medicinal products, tariffs could be put into place in the future.  We could therefore, both now and in the future, face significant additional expenses (when compared to the position prior to the end of the Transition Period) to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">particular, trade between the impacted nations and the UK It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business and operations might be disrupted or adversely affected by catastrophic events.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters are located in San Diego County. We are vulnerable to natural disasters such as earthquakes and wild fires, as well as other events that could disrupt our operations. We do not carry insurance for earthquakes or other natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations. In addition, natural disasters or other catastrophic events in various parts of the world, including interruptions in the supply of natural resources, political and governmental changes, disruption in transportation networks or delivery services, severe weather conditions, wildfires and other fires, explosions, actions of animal rights activists, terrorist attacks, earthquakes, wars and public health issues (including, for example, the COVID-19 pandemic) could disrupt our operations or those of our collaborators, contractors and vendors or contribute to unfavorable economic or other conditions that could adversely impact us. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations globally, including at our headquarters in San Diego and at our clinical trial sites, as well as the business or operations of our collaborators, manufacturers, CROs or other third parties with whom we conduct business.* </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic. The ongoing COVID-19 pandemic is impacting domestic and worldwide economic activity, including global financial markets. The COVID-19 pandemic also poses the risk that we or our clinical trial subjects, employees, contractors, collaborators and vendors may be prevented from conducting certain clinical trials or other business activities for an indefinite period of time, including due to travel restrictions, quarantines, &#8220;stay-at-home&#8221; and "shelter-in-place" orders or shutdowns that have been or may in the future be requested or mandated by governmental authorities. In addition, the COVID-19 pandemic has, and could continue to, impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which could potentially disrupt the supply chain for our product candidates in our collaborators&#8217; ongoing clinical trials. For examp</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">le, some of our CROs have previously delayed the commencement of preclinical studies due to shelter-in-place orders. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials have been, and are likely to continue to be, affected by the ongoing COVID-19 pandemic. Site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic, and some patients may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, could be delayed or disrupted, which would adversely impact our clinical trial operations. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the long-term economi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c impact and the duration of the COVID-19 pandemic may be difficult to predict, the pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could reduce our ability to access capital and could negatively affect our liquidity and the liquidity and stability of markets for our common stock and convertible notes. The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hile the potential economic impact brought by, and the duration of, the COVID-19 pandemic, may be difficult to assess or predict, there have previously been significant disruptions of global financial markets as a result of the COVID-19 pandemic and similar disruptions may be experienced in the future. Any such disruption could make it more difficult for us to access capital or to comply with the covenants contained in the Loan Agreement, which could negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic continues to evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">s, and we will continue to monitor the COVID-19 situation closely.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR COMMON STOCK</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The market price of our common stock may be highly volatile.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has historically been, and is expected to continue to be, highly volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results or delays in preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain additional funding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in filing an IND or NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that IND or NDA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing collaborations or enter into new collaborations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our collaboration partners to elect to develop and commercialize product candidates under our collaboration agreements or the termination of any programs under our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us or our licensors and collaboration partners to prosecute, maintain or enforce our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our preclinical and clinical development activities, product candidates or future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory decisions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products, services or technologies by our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial projections we may provide to the public;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed the estimates and projections of the investment community;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by man-made or natural disasters, public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our collaboration partners or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders in the future; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies trading in the stock market in general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be unable to comply with the applicable continued listing requirements of The Nasdaq Capital Market.* </span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on The Nasdaq Capital Market. In order to maintain the listing of our common stock on The Nasdaq Capital Market, we must satisfy minimum financial and other continued listing requirements and standards, including a minimum closing bid price requirement for our common stock of $1.00 per share and a minimum stockholders&#8217; equity requirement of $2.5 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have failed to comply with Nasdaq&#8217;s minimum bid price requirement and minimum stockholders&#8217; equity requirement on multiple other occasions during the last several years. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Most recently, on August 9, 2021, we received a letter from The Nasdaq Stock Market advising us that for 30 consecutive trading days preceding the date of the letter, the bid price of our common stock had closed below the $1.00 per share minimum price required for continued listing on The Nasdaq Capital Market, and therefore we could become subject to delisting if our common stock does not meet the $1.00 minimum bid price for a minimum of 10 consecutive trading days within the 180-day period following the date of the letter, or within an additional 180-day period if we meet certain conditions. We intend to monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options, including a reverse stock split, to regain compliance with the minimum closing bid price requirement. There can be no assurance that we will be able to regain and maintain compliance with the $1.00 minimum bid price requirement o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">r maintain compliance with  the minimum stockholders&#8217; equity requirement, or continuously satisfy Nasdaq's other continued listing standards in the future. If we are ultimately not able to maintain or timely regain compliance with Nasdaq&#8217;s continued listing requirements, our common stock will be subject to delisting. In the event that our common stock is delisted from Nasdaq and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for our common stock and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further. In addition, the delisting of our common stock from The Nasdaq Capital Market would constitute an event of default under our Loan Agreement with the Lender.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The requirements of being a publicly traded company may strain our resources and divert management&#8217;s attention. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a publicly traded company, we have incurred, and will continue to incur, significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The Nasdaq Capital Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the "Dodd-Frank Act") was enacted. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel have devoted and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Financial Accounting Standards Board ("FASB"), either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our financial position, results of operations or reported cash flows. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Any difficulties in adopting or implementing any new accounting standard could result in our failure to meet our financial reporting obligations, which could result in regulatory discipline and harm investors&#8217; confidence in us. Finally, if we were to change our critical accounting estimates, including those related to the recognition of collaboration revenue, our operating results could be significantly affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our stock price to fall. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our outstanding shares of common stock are available for public sale, subject in some cases to volume and other limitations. If our existing stockholders sell substantial amounts of our common stock in the public market, or the market perceives that such sales may occur, the trading price of our common stock could decline. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans are or may become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.* </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, preferred stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time, any of which may result in material dilution to investors and/or our existing stockholders. New investors could also be issued securities with rights superior to those of our existing stockholders. As of September 30, 2021, warrants to exercise an aggregate of 61.9 million shares of our common stock were outstanding at a weighted-average exercise price per share of $0.78. In addition, as of September 30, 2021, an aggregate of 18.5 million shares were issuable upon conversion of shares of our Class A-1, Class A-2 and Class A-3 preferred stock at the option of the holder, subject to beneficial ownership limitations. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our 2019 Equity Incentive Plan (the "2019 Plan"), our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. In addition, the number of shares available for future grant under the 2019 Plan will automatically increase on January 1st each year commencing on January 1, 2021 through January 1, 2029, by 5% of all shares of our capital stock outstanding as of December&#160;31st of the preceding calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Furthermore, we may grant or provide for the grant of rights to purchase shares of our common stock pursuant to our 2012 Employee Stock Purchase Plan ("ESPP"). The number of shares of our common stock reserved for issuance under the ESPP will automatically increase on January&#160;1 of each calendar year by the lessor of 1% of the total number of shares of our common stock outstanding on December&#160;31st of the preceding calendar year and 41,666 shares, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the 2019 Plan and the ESPP each year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">We may be the subject of putative securities class action litigation in the future.*</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. For example, certain putative class action complaints were filed against us, Paul C. Grint (our former Chief Executive Officer), Joseph P. Hagan (then our Chief Operating Officer and currently our President and Chief Executive Officer), Timothy M. Wright (our former Chief Research &amp; Development Officer) and Michael Huang (our former Vice President of Clinical Development) in January 2017 alleging that the defendants violated the federal securities laws by making materially false and misleading statements regarding our business and the prospects for RG-101, thereby artificially inflating the price of our securities. On December 29, 2020, the court entered a final judgment and dismissed the action with prejudice. It is possible that additional lawsuits will be filed, or allegations made by stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. While we carry liability insurance, there is no assurance that any losses we incur in connection with the current lawsuits or any future lawsuits will be covered or that coverage, if any, will be sufficient. In addition, the current lawsuits and similar future litigation could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.*</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.* </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, we had net operating loss ("NOL") carryforwards for U.S. federal and California state tax purposes </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of $342.4&#160;million and $289.2 million, respectively.&#160;A portion of the federal and California state NOL carryforwards will begin to expire, if not utilized, in 2030 and 2031, respectively. NOLs that expire unused will be unavailable to offset future income tax liabilities. Under the Tax Act, as modified by the CARES ACT, federal NOLs incurred in taxable years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020 is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Tax Act or the CARES Act. In addition, under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended (the "Code"), and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">use its pre-c</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">hange NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income and taxes may be limited. We have determined that we triggered an &#8220;ownership change&#8221; limitation at the completion of our initial public offering in October 2012 and in July 2015. The Company has not performed a Section 382 ownership-change analysis through December 31, 2020, and it is possible there may have been additional ownership changes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change NOL carryforwards to offset U.S. federal taxable income will be subject to limitations, which could harm our future operating results by effectively increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California imposed limits on the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely affect our future cash flows.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, our ability to pay cash dividends is currently prohibited by the terms of our secured debt, and any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminating the ability of stockholders to call a special meeting of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing the state of Delaware as the sole forum for certain legal actions against the Company, its officers and directors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to Section&#160;203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change in control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i1bd3a25286f94961af32b70947dcc597_100"></div><div style="margin-top:18pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i1bd3a25286f94961af32b70947dcc597_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_106"></div><div style="margin-top:18pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i1bd3a25286f94961af32b70947dcc597_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i1bd3a25286f94961af32b70947dcc597_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:54pt;text-indent:-54pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:8.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000162828016018315/ex-3120160630.htm">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-35670), filed with the SEC on August 3, 2016).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312518290991/d630756dex31.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-35670), filed with the SEC on October 2, 2018).</a></span></div><div><span><br/></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312521192088/d169767dex31.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-35670), filed with the SEC on June 16, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312519143173/d689955dex31.htm">Certificate of Designation of Preferences, Rights and Limitations of Class A-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-35670), filed with the SEC on May 9, 2019).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312519323073/d856972dex31.htm">Certificate of Designation of Preferences, Rights and Limitations of&#160;Class&#160; A-2&#160;Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K&#160;(file&#160;No.&#160; 001-35670),&#160;filed with the SEC on December&#160;26, 2019).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312520310641/d39466dex31.htm">Certificate of Designation of Preferences, Rights and Limitations of Class A-3 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrants&#8217; Current Report on Form 8-K (File No. 001-35670) filed with the SEC on December 4, 2020).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312520310641/d39466dex32.htm">Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Class A-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-35670), filed with the SEC on December 4, 2020).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312520310641/d39466dex33.htm">Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Class A-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.3 to the Registrant's Current Report on Form 8-K (File No. 001-35670), filed with the SEC on December 4, 2020).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312516616627/d203908dex31.htm">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-35670), filed with the SEC on June 8, 2016).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000162828016018315/ex-3120160630.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312518290991/d630756dex31.htm">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312521192088/d169767dex31.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312519143173/d689955dex31.htm">3.4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312519323073/d856972dex31.htm">3.5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312520310641/d39466dex31.htm">3.6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312520310641/d39466dex32.htm">3.7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312520310641/d39466dex33.htm">3.8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312516616627/d203908dex31.htm">3.9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000162828018014023/ex-42x20180930.htm">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-35670), filed with the SEC on November 9, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312519143173/d689955dex42.htm">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K (File No. 001-35670), filed with the SEC on May 9, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1505512/000119312520310641/d39466dex42.htm">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K (File No. 001-35670), filed with the SEC on December 4, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-311x20210930.htm">Certification of the Chief Executive Officer pursuant to Rule&#160;13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:22.5pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:8.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-312x20210930.htm">Certification of the Chief Financial Officer pursuant to Rule&#160;13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-321x20210930.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Registrant&#8217;s Quarterly Report on Form 10-Q has been formatted in Inline XBRL.</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section&#160;1350, and are not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div id="i1bd3a25286f94961af32b70947dcc597_115"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:45.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulus Therapeutics Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 10, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Joseph P. Hagan</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph P. Hagan</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 10, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Cris Calsada</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cris Calsada</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex-311x20210930.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7231dad030f8485492b5078e6119132a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph P. Hagan, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1. I have reviewed this quarterly report on Form 10-Q of Regulus Therapeutics Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c. evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;d. disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:57.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.437%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph P. Hagan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph P. Hagan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex-312x20210930.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib270e38f51ea45bfa3a17f46de3108f5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Cris Calsada, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1. I have reviewed this quarterly report on Form 10-Q of Regulus Therapeutics Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c. evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;d. disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:57.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.437%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Cris Calsada</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cris Calsada</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex-321x20210930.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i00d9177bf5034a89939296bc63d6c1bf_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the quarterly report of Regulus Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Joseph P. Hagan, President and Chief Executive Officer of the Company, and I, Cris Calsada, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:57.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.960%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph P. Hagan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph P. Hagan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Cris Calsada</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cris Calsada</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section&#160;1350 and is not being filed as part of the Report or as a separate disclosure document and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rgls-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b020128b-c098-4c8f-bf82-e0af5aef1570,g:5e73ec3e-18f1-4a85-a5f0-f7e7f348b77f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rgls="http://www.regulusrx.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.regulusrx.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rgls-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rgls-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rgls-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rgls-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.regulusrx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.regulusrx.com/role/NetLossPerShare">
        <link:definition>2104102 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://www.regulusrx.com/role/NetLossPerShareDetails">
        <link:definition>2405402 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.regulusrx.com/role/Investments">
        <link:definition>2106103 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.regulusrx.com/role/FairValueMeasurements">
        <link:definition>2107104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.regulusrx.com/role/FairValueMeasurementsTables">
        <link:definition>2308301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2409403 - Disclosure - Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.regulusrx.com/role/Debt">
        <link:definition>2110105 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.regulusrx.com/role/DebtTables">
        <link:definition>2311302 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.regulusrx.com/role/DebtNarrativeDetails">
        <link:definition>2412404 - Disclosure - Debt (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtFuturePrincipalPaymentsDetails" roleURI="http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails">
        <link:definition>2413405 - Disclosure - Debt (Future Principal Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.regulusrx.com/role/StockholdersEquity">
        <link:definition>2114106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.regulusrx.com/role/StockholdersEquityTables">
        <link:definition>2315303 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2416406 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityShareActivityDetails" roleURI="http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails">
        <link:definition>2417407 - Disclosure - Stockholders' Equity (Share Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityATMOfferingDetails" roleURI="http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails">
        <link:definition>2418408 - Disclosure - Stockholders' Equity (ATM Offering) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockReservedforFutureIssuanceDetails" roleURI="http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails">
        <link:definition>2419409 - Disclosure - Stockholders' Equity (Common Stock Reserved for Future Issuance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionandRSUActivityDetails" roleURI="http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails">
        <link:definition>2420410 - Disclosure - Stockholders' Equity (Stock Option and RSU Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails" roleURI="http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails">
        <link:definition>2421411 - Disclosure - Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockBasedCompensationExpenseAllocationDetails" roleURI="http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails">
        <link:definition>2422412 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborations" roleURI="http://www.regulusrx.com/role/Collaborations">
        <link:definition>2123107 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsDetails" roleURI="http://www.regulusrx.com/role/CollaborationsDetails">
        <link:definition>2424413 - Disclosure - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.regulusrx.com/role/Leases">
        <link:definition>2125108 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.regulusrx.com/role/LeasesTables">
        <link:definition>2326304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.regulusrx.com/role/LeasesNarrativeDetails">
        <link:definition>2427414 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingandFinanceMaturitiesDetails" roleURI="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails">
        <link:definition>2428415 - Disclosure - Leases (Operating and Finance Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingandFinanceMaturitiesDetails_1" roleURI="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1">
        <link:definition>2428415 - Disclosure - Leases (Operating and Finance Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rgls_EnrollmentMilestone" abstract="false" name="EnrollmentMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_RegulatoryAndCommercializationMilestonesMember" abstract="true" name="RegulatoryAndCommercializationMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_DevelopmentMilestoneNotAchievable" abstract="false" name="DevelopmentMilestoneNotAchievable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rgls_MaterialsSoldMember" abstract="true" name="MaterialsSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_ProceedsFromFederalProgram" abstract="false" name="ProceedsFromFederalProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_ActivityOfSharesRollForward" abstract="true" name="ActivityOfSharesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rgls_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_ClassA1ConvertiblePreferredStockAsConvertedMember" abstract="true" name="ClassA1ConvertiblePreferredStockAsConvertedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_AgreementPeriod" abstract="false" name="AgreementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rgls_ProofofConceptTrialMember" abstract="true" name="ProofofConceptTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_PrepaymentRequirement" abstract="false" name="PrepaymentRequirement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_ClassA3ConvertiblePreferredStockMember" abstract="true" name="ClassA3ConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_FinancingfromSaleProceedsDebtAgreementRevenues" abstract="false" name="FinancingfromSaleProceedsDebtAgreementRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_ForgivenessAmountThreshold" abstract="false" name="ForgivenessAmountThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_PaymentFee" abstract="false" name="PaymentFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rgls_CommonStockVotingRightsVotes" abstract="false" name="CommonStockVotingRightsVotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rgls_RevenueUnderCollaborationsMember" abstract="true" name="RevenueUnderCollaborationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_PriorPremisesMember" abstract="true" name="PriorPremisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_InitialClosingWarrantsMember" abstract="true" name="InitialClosingWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_CollaborativeAreasGranted" abstract="false" name="CollaborativeAreasGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" abstract="false" name="OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_DeferredRevenueCreditableAgainstFutureMilestones" abstract="false" name="DeferredRevenueCreditableAgainstFutureMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_RentedArea" abstract="false" name="RentedArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="rgls_PPPLoanMember" abstract="true" name="PPPLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rgls_AdditionalExtensionForInterestOnlyPayments" abstract="false" name="AdditionalExtensionForInterestOnlyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_CertainDirectorsandExecutiveOfficersMember" abstract="true" name="CertainDirectorsandExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_CommissionFeeRate" abstract="false" name="CommissionFeeRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rgls_A2019SPAAnd2020SPAMember" abstract="true" name="A2019SPAAnd2020SPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_ClassAOneConvertiblePreferredStockMember" abstract="true" name="ClassAOneConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_NumberOfPrepaymentsToLender" abstract="false" name="NumberOfPrepaymentsToLender" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rgls_ClassATwoConvertiblePreferredStockMember" abstract="true" name="ClassATwoConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_MilestoneClosingWarrantsMember" abstract="true" name="MilestoneClosingWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_DevelopmentCommercializationAndLicenseAgreementMember" abstract="true" name="DevelopmentCommercializationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_TenthAmendmentMember" abstract="true" name="TenthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_RoyaltyPercentageBasedOnNetSales" abstract="false" name="RoyaltyPercentageBasedOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rgls_PaycheckProtectionProgramLoanForgiveness" abstract="false" name="PaycheckProtectionProgramLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_StrategicAlliancesAxis" abstract="true" name="StrategicAlliancesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="rgls_A2020PIPEWarrantsMember" abstract="true" name="A2020PIPEWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_AchievementOfEnrollmentMilestoneMember" abstract="true" name="AchievementOfEnrollmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_MilestoneClosingMember" abstract="true" name="MilestoneClosingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" abstract="false" name="IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_AccruedResearchAndDevelopmentCurrent" abstract="false" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rgls_InitialDirectCostLiability" abstract="false" name="InitialDirectCostLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_StockIssuedDuringPeriodValueExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_AtTheMomentMember" abstract="true" name="AtTheMomentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_ActivityOfSharesTableTextBlock" abstract="false" name="ActivityOfSharesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rgls_PaymentsonFinanceLeases" abstract="false" name="PaymentsonFinanceLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_NumberOfAmendments" abstract="false" name="NumberOfAmendments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rgls_InterestOnlyPaymentExtension" abstract="false" name="InterestOnlyPaymentExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rgls_NonvotingConvertiblePreferredStockIssued" abstract="false" name="NonvotingConvertiblePreferredStockIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rgls_ClinicalMember" abstract="true" name="ClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_ClassA2ConvertiblePreferredStockAsConvertedMember" abstract="true" name="ClassA2ConvertiblePreferredStockAsConvertedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_GainLossOnLoanForgiveness" abstract="false" name="GainLossOnLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_A2019PlanMember" abstract="true" name="A2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_NonrefundableLeaseCostForAssignment" abstract="false" name="NonrefundableLeaseCostForAssignment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_TwentyTwelvePlanMember" abstract="true" name="TwentyTwelvePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_NumberOfClosings" abstract="false" name="NumberOfClosings" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rgls_SaleOfStockValueOfSharesAvailable" abstract="false" name="SaleOfStockValueOfSharesAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rgls_StrategicAlliancesandCollaborationsMember" abstract="true" name="StrategicAlliancesandCollaborationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_CampusPointLeaseMember" abstract="true" name="CampusPointLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_NumberofMonthlyPayments" abstract="false" name="NumberofMonthlyPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rgls_ClassAThreeConvertiblePreferredStockMember" abstract="true" name="ClassAThreeConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_DebtFinancingAgreementMember" abstract="true" name="DebtFinancingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_DeferredCreditOperatingLeaseLiability" abstract="false" name="DeferredCreditOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rgls_DebtFinancingAgreementTrancheAMember" abstract="true" name="DebtFinancingAgreementTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_EnrollmentMilestoneMember" abstract="true" name="EnrollmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_AccruedExpensePolicyTextBlock" abstract="false" name="AccruedExpensePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rgls_NumberOfOperatingLeaseContracts" abstract="false" name="NumberOfOperatingLeaseContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rgls_StrategicAlliancesDomain" abstract="true" name="StrategicAlliancesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rgls_PrepaidExpensesPolicyTextBlock" abstract="false" name="PrepaidExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rgls_DevelopmentMilestonesMember" abstract="true" name="DevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>rgls-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b020128b-c098-4c8f-bf82-e0af5aef1570,g:5e73ec3e-18f1-4a85-a5f0-f7e7f348b77f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7401e29a-7c34-4bf3-b603-a4dfbc83a246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f81db2da-f0a6-4c46-b67b-194b7fee2ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7401e29a-7c34-4bf3-b603-a4dfbc83a246" xlink:to="loc_us-gaap_LiabilitiesCurrent_f81db2da-f0a6-4c46-b67b-194b7fee2ca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f91f15b0-ae96-4808-8d48-56852181d1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7401e29a-7c34-4bf3-b603-a4dfbc83a246" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f91f15b0-ae96-4808-8d48-56852181d1ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b53a97c9-3c21-493d-ae1f-21b92f1f199a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1e411758-a3de-44f3-adb4-2e88b034d4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b53a97c9-3c21-493d-ae1f-21b92f1f199a" xlink:to="loc_us-gaap_CommonStockValue_1e411758-a3de-44f3-adb4-2e88b034d4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_779106b4-6728-4343-822d-41ebec4a6cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b53a97c9-3c21-493d-ae1f-21b92f1f199a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_779106b4-6728-4343-822d-41ebec4a6cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56ad6d6e-48a8-4d80-99c6-71f051962939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b53a97c9-3c21-493d-ae1f-21b92f1f199a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56ad6d6e-48a8-4d80-99c6-71f051962939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_59b8b04b-c1a7-4cbf-b726-7bfb8925ff56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b53a97c9-3c21-493d-ae1f-21b92f1f199a" xlink:to="loc_us-gaap_PreferredStockValue_59b8b04b-c1a7-4cbf-b726-7bfb8925ff56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f8276f38-5bdd-4869-95f1-387be075504a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d250ea85-d66a-49e9-b00e-70748478c9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8276f38-5bdd-4869-95f1-387be075504a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d250ea85-d66a-49e9-b00e-70748478c9e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1f18f209-5a83-4ec4-86f7-269059e36927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8276f38-5bdd-4869-95f1-387be075504a" xlink:to="loc_us-gaap_AssetsCurrent_1f18f209-5a83-4ec4-86f7-269059e36927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9fa6d744-e101-4802-8b5e-eae40b8519b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8276f38-5bdd-4869-95f1-387be075504a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9fa6d744-e101-4802-8b5e-eae40b8519b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_65d39b19-0279-4be3-b348-f11446ff92fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8276f38-5bdd-4869-95f1-387be075504a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_65d39b19-0279-4be3-b348-f11446ff92fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5c35ad77-ba70-47fd-9edd-4e10d5b76345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8276f38-5bdd-4869-95f1-387be075504a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5c35ad77-ba70-47fd-9edd-4e10d5b76345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b7c7e04-a4b3-4cd5-a745-e9fd9d200b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_16301280-f408-444d-8a15-8a05252a83e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b7c7e04-a4b3-4cd5-a745-e9fd9d200b5d" xlink:to="loc_us-gaap_StockholdersEquity_16301280-f408-444d-8a15-8a05252a83e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_58bf1ece-c8c0-4a4b-92d4-8d76e2e44119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b7c7e04-a4b3-4cd5-a745-e9fd9d200b5d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_58bf1ece-c8c0-4a4b-92d4-8d76e2e44119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f6e2fadf-966a-49b6-abb8-0e9b0689d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b7c7e04-a4b3-4cd5-a745-e9fd9d200b5d" xlink:to="loc_us-gaap_Liabilities_f6e2fadf-966a-49b6-abb8-0e9b0689d48b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9a0e3f1e-e11c-4617-841c-17a9d1052d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_eaab3a12-c4da-418a-9260-1d5ecc00d1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a0e3f1e-e11c-4617-841c-17a9d1052d68" xlink:to="loc_us-gaap_RestrictedCash_eaab3a12-c4da-418a-9260-1d5ecc00d1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_cc71c4de-a4c6-4a81-8b94-fc661608955b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a0e3f1e-e11c-4617-841c-17a9d1052d68" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_cc71c4de-a4c6-4a81-8b94-fc661608955b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b91ebdf1-de9b-4123-b74b-4005dadd35a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a0e3f1e-e11c-4617-841c-17a9d1052d68" xlink:to="loc_us-gaap_OtherAssetsCurrent_b91ebdf1-de9b-4123-b74b-4005dadd35a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4750c6b8-2dfb-4ec0-ae45-057dbca9e463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a0e3f1e-e11c-4617-841c-17a9d1052d68" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4750c6b8-2dfb-4ec0-ae45-057dbca9e463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30c242b5-8975-45e0-ba3a-29897aabab75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a0e3f1e-e11c-4617-841c-17a9d1052d68" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30c242b5-8975-45e0-ba3a-29897aabab75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_53957be3-e9c3-4dfa-bf67-3d8409df0393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_162df37b-8fdb-425a-bfd7-e2d18c0f5804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53957be3-e9c3-4dfa-bf67-3d8409df0393" xlink:to="loc_us-gaap_AccountsPayableCurrent_162df37b-8fdb-425a-bfd7-e2d18c0f5804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ec0f30f2-6367-4ef3-be65-ad57b2745115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53957be3-e9c3-4dfa-bf67-3d8409df0393" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ec0f30f2-6367-4ef3-be65-ad57b2745115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20062a51-cdbb-482e-a630-fc9c9077beb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53957be3-e9c3-4dfa-bf67-3d8409df0393" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20062a51-cdbb-482e-a630-fc9c9077beb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_4c66d07f-d917-49d5-82cf-75a27bae08b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53957be3-e9c3-4dfa-bf67-3d8409df0393" xlink:to="loc_us-gaap_DebtCurrent_4c66d07f-d917-49d5-82cf-75a27bae08b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_438e409b-662b-4cc8-9278-55c220de7a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53957be3-e9c3-4dfa-bf67-3d8409df0393" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_438e409b-662b-4cc8-9278-55c220de7a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AccruedResearchAndDevelopmentCurrent_42f9693b-2363-40b4-a362-f2aa403e76ff" xlink:href="rgls-20210930.xsd#rgls_AccruedResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53957be3-e9c3-4dfa-bf67-3d8409df0393" xlink:to="loc_rgls_AccruedResearchAndDevelopmentCurrent_42f9693b-2363-40b4-a362-f2aa403e76ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e695f03-7ad2-4821-b6da-1e59a696442e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4c19a25-732a-45dc-a263-d000a1e00713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0e695f03-7ad2-4821-b6da-1e59a696442e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4c19a25-732a-45dc-a263-d000a1e00713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_67cfb376-f897-4c12-9f0e-15d48c7264f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0e695f03-7ad2-4821-b6da-1e59a696442e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_67cfb376-f897-4c12-9f0e-15d48c7264f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a7122b9b-0ce1-4712-a2c4-cf1094ed8a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65c0e3fb-474e-4d46-9ee4-450ef008b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a7122b9b-0ce1-4712-a2c4-cf1094ed8a4c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65c0e3fb-474e-4d46-9ee4-450ef008b4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8a6cdb24-e338-43fa-ad54-761a80bb2c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a7122b9b-0ce1-4712-a2c4-cf1094ed8a4c" xlink:to="loc_us-gaap_OperatingExpenses_8a6cdb24-e338-43fa-ad54-761a80bb2c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fed781e2-96d3-4ea5-b206-4478ac1c24ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_02226f66-0a9e-4fb6-b27e-a6638d7b945c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fed781e2-96d3-4ea5-b206-4478ac1c24ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_02226f66-0a9e-4fb6-b27e-a6638d7b945c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_32f41016-c605-4f16-b2c3-ab73afc100fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fed781e2-96d3-4ea5-b206-4478ac1c24ce" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_32f41016-c605-4f16-b2c3-ab73afc100fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e0d8390-b4c2-4327-8d3b-cf4b03363ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_98fefded-bcbc-450b-b841-b19c2d8e6be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e0d8390-b4c2-4327-8d3b-cf4b03363ab5" xlink:to="loc_us-gaap_InterestAndOtherIncome_98fefded-bcbc-450b-b841-b19c2d8e6be8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_07b064bc-e3f4-47a8-9dc5-680d10410439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e0d8390-b4c2-4327-8d3b-cf4b03363ab5" xlink:to="loc_us-gaap_InterestExpense_07b064bc-e3f4-47a8-9dc5-680d10410439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8c652256-d1c4-4af2-9f92-76d6bec33fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e0d8390-b4c2-4327-8d3b-cf4b03363ab5" xlink:to="loc_us-gaap_OperatingIncomeLoss_8c652256-d1c4-4af2-9f92-76d6bec33fe2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f749fa2-6dae-44b0-9a06-dc04746add1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4ef0ee11-229a-4784-a0ec-004049051a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f749fa2-6dae-44b0-9a06-dc04746add1b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4ef0ee11-229a-4784-a0ec-004049051a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9fad16f-5028-4181-81af-400b050ff1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f749fa2-6dae-44b0-9a06-dc04746add1b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9fad16f-5028-4181-81af-400b050ff1e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b50aafff-725d-4dbd-a2f6-1282295767ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b50aafff-725d-4dbd-a2f6-1282295767ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bc349a88-6d26-4043-947f-92db8a064666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bc349a88-6d26-4043-947f-92db8a064666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8731d8d8-696c-4635-bf0d-faa69f6c8f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8731d8d8-696c-4635-bf0d-faa69f6c8f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss_53b873c6-6fac-4432-8960-faf7aac61a0b" xlink:href="rgls-20210930.xsd#rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss_53b873c6-6fac-4432-8960-faf7aac61a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_809def14-6951-4650-9bcc-cc4ac7578f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_809def14-6951-4650-9bcc-cc4ac7578f23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93867c6c-1139-451a-bae6-988b512f79ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_NetIncomeLoss_93867c6c-1139-451a-bae6-988b512f79ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_c106002d-9a5d-4f93-963a-1bbc5cd06ad7" xlink:href="rgls-20210930.xsd#rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_c106002d-9a5d-4f93-963a-1bbc5cd06ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ab4df671-efb2-4558-81b9-55b1ad8af8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ab4df671-efb2-4558-81b9-55b1ad8af8eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_611884ad-d5d8-47d2-bd30-40b21a0feb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_ShareBasedCompensation_611884ad-d5d8-47d2-bd30-40b21a0feb7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b257393a-ac3a-4984-8dfc-86ec59c784b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b257393a-ac3a-4984-8dfc-86ec59c784b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c8334de1-5955-4bf3-bc1d-5983ed34aa61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c8334de1-5955-4bf3-bc1d-5983ed34aa61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e8dae834-2432-4749-b23a-11a19c64a42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e8dae834-2432-4749-b23a-11a19c64a42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_120bfe85-cd0c-45e4-93c1-20554f35dc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_120bfe85-cd0c-45e4-93c1-20554f35dc51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0c42ab39-64a3-41e0-b7ef-9542e2a4a95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0c42ab39-64a3-41e0-b7ef-9542e2a4a95a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_GainLossOnLoanForgiveness_5b1cca90-8651-42c3-b9fb-7e437a47b424" xlink:href="rgls-20210930.xsd#rgls_GainLossOnLoanForgiveness"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7c868e1-fb81-4d0c-b8c5-b6aef552f6ec" xlink:to="loc_rgls_GainLossOnLoanForgiveness_5b1cca90-8651-42c3-b9fb-7e437a47b424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0978738d-aebf-4d84-9d00-5b0291443922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6fa8c9fc-4218-4058-8b51-5978365a691d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0978738d-aebf-4d84-9d00-5b0291443922" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6fa8c9fc-4218-4058-8b51-5978365a691d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f51b843f-841d-47e2-9084-2ac16d14ae1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0978738d-aebf-4d84-9d00-5b0291443922" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f51b843f-841d-47e2-9084-2ac16d14ae1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PaymentsonFinanceLeases_47c0b3c5-e6f6-4845-9e19-92ecc498d015" xlink:href="rgls-20210930.xsd#rgls_PaymentsonFinanceLeases"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0978738d-aebf-4d84-9d00-5b0291443922" xlink:to="loc_rgls_PaymentsonFinanceLeases_47c0b3c5-e6f6-4845-9e19-92ecc498d015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ProceedsFromFederalProgram_70efdf50-fbf9-4be8-8a79-9952615ec270" xlink:href="rgls-20210930.xsd#rgls_ProceedsFromFederalProgram"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0978738d-aebf-4d84-9d00-5b0291443922" xlink:to="loc_rgls_ProceedsFromFederalProgram_70efdf50-fbf9-4be8-8a79-9952615ec270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_0d73e75d-91a6-4d90-a5c6-c98a46a72106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0978738d-aebf-4d84-9d00-5b0291443922" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_0d73e75d-91a6-4d90-a5c6-c98a46a72106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_514fbe9d-5c67-4fdd-868c-10ab73b64de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48021a42-25af-421a-ad77-9bff6f8183c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_514fbe9d-5c67-4fdd-868c-10ab73b64de9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48021a42-25af-421a-ad77-9bff6f8183c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e7ce0e0b-46c0-4db7-a348-21c6d339e917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_514fbe9d-5c67-4fdd-868c-10ab73b64de9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e7ce0e0b-46c0-4db7-a348-21c6d339e917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff67c60e-da12-4592-87ab-3c6d20199fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_514fbe9d-5c67-4fdd-868c-10ab73b64de9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff67c60e-da12-4592-87ab-3c6d20199fb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_feb5c809-d74e-4913-9782-b22513737de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_36d3d2a1-9176-4a79-bd2f-f778b8619651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_feb5c809-d74e-4913-9782-b22513737de2" xlink:to="loc_us-gaap_RestrictedCash_36d3d2a1-9176-4a79-bd2f-f778b8619651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5872de54-9675-4ae7-b9b3-986eba96ee83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_feb5c809-d74e-4913-9782-b22513737de2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5872de54-9675-4ae7-b9b3-986eba96ee83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#DebtFuturePrincipalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e0b4390e-8404-44bb-92d3-879b83d9bc56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c2236c7c-c97e-4879-b6c3-a99c9fdd2bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e0b4390e-8404-44bb-92d3-879b83d9bc56" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c2236c7c-c97e-4879-b6c3-a99c9fdd2bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8efd2c8d-c0fb-4266-bcfb-3e901c896397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e0b4390e-8404-44bb-92d3-879b83d9bc56" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8efd2c8d-c0fb-4266-bcfb-3e901c896397" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityCommonStockReservedforFutureIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e2a7d54c-786c-40d0-abb4-1d8d1adb580e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02266255-5087-4f71-95ed-edd4a3dd1571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e2a7d54c-786c-40d0-abb4-1d8d1adb580e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02266255-5087-4f71-95ed-edd4a3dd1571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d30e70d4-09e1-4c0d-a43c-68b72ebc933f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e2a7d54c-786c-40d0-abb4-1d8d1adb580e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d30e70d4-09e1-4c0d-a43c-68b72ebc933f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c64b9908-976d-4f42-a601-fab65a27362d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e2a7d54c-786c-40d0-abb4-1d8d1adb580e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c64b9908-976d-4f42-a601-fab65a27362d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8cdeeba-0d21-4f9f-a155-d7bb02730260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e2a7d54c-786c-40d0-abb4-1d8d1adb580e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8cdeeba-0d21-4f9f-a155-d7bb02730260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_d65e9322-9d08-476a-95bd-7c2324895d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e2a7d54c-786c-40d0-abb4-1d8d1adb580e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_d65e9322-9d08-476a-95bd-7c2324895d9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#LeasesOperatingandFinanceMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c9f94bbe-dbc9-4a1c-9ef4-96bebacaad4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8a7b086-acc2-4f87-b3bf-2bf96fddd30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_c9f94bbe-dbc9-4a1c-9ef4-96bebacaad4f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8a7b086-acc2-4f87-b3bf-2bf96fddd30d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5e5f9ad3-a5c0-4ac8-8e1f-45b9d308c603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_c9f94bbe-dbc9-4a1c-9ef4-96bebacaad4f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5e5f9ad3-a5c0-4ac8-8e1f-45b9d308c603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8339fdcb-a8df-4345-aa34-289e941c7023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8983742d-f830-4f27-b3a3-5af99b087033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8339fdcb-a8df-4345-aa34-289e941c7023" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8983742d-f830-4f27-b3a3-5af99b087033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b93f9b21-bd0b-49a6-b1a0-b16b42e21304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8339fdcb-a8df-4345-aa34-289e941c7023" xlink:to="loc_us-gaap_OperatingLeaseLiability_b93f9b21-bd0b-49a6-b1a0-b16b42e21304" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1" xlink:type="simple" xlink:href="rgls-20210930.xsd#LeasesOperatingandFinanceMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04db0e49-e539-4e21-ae33-6887addb550e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_294f3160-fd13-417a-ade3-25d816745822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04db0e49-e539-4e21-ae33-6887addb550e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_294f3160-fd13-417a-ade3-25d816745822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_ca3a75f0-27a0-471b-9431-5cce250676e8" xlink:href="rgls-20210930.xsd#rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04db0e49-e539-4e21-ae33-6887addb550e" xlink:to="loc_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_ca3a75f0-27a0-471b-9431-5cce250676e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e1185ccb-4332-47a3-83bd-90d557748fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04db0e49-e539-4e21-ae33-6887addb550e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e1185ccb-4332-47a3-83bd-90d557748fb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_80e5d4b3-66a2-4cc5-a97f-34c5d4ba01c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04db0e49-e539-4e21-ae33-6887addb550e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_80e5d4b3-66a2-4cc5-a97f-34c5d4ba01c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8d6f5e07-4ae8-4e0a-b493-5d7bd16ca1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04db0e49-e539-4e21-ae33-6887addb550e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8d6f5e07-4ae8-4e0a-b493-5d7bd16ca1b6" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>rgls-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b020128b-c098-4c8f-bf82-e0af5aef1570,g:5e73ec3e-18f1-4a85-a5f0-f7e7f348b77f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended" id="i48e02cf5ee1a4fe1b0df4830ae49c628_CONDENSEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f20d1c57-ddc5-49bf-bab2-7554182cce56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f20d1c57-ddc5-49bf-bab2-7554182cce56" xlink:to="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5cbef876-65f2-4649-a5bb-f26a97dcfa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5cbef876-65f2-4649-a5bb-f26a97dcfa8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_2c423230-10a0-45bc-b9a3-fee539b4c0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_RestrictedCash_2c423230-10a0-45bc-b9a3-fee539b4c0b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_64b2a360-8662-463e-b0aa-223f46122efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_64b2a360-8662-463e-b0aa-223f46122efa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_55d11b14-0352-44de-9342-a3c57559a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_55d11b14-0352-44de-9342-a3c57559a0d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_64daf40f-d8d4-4281-ad99-b40a9c446a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_OtherAssetsCurrent_64daf40f-d8d4-4281-ad99-b40a9c446a03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_32f8b61c-9b52-467e-b6cf-1b9b1391c414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_AssetsCurrent_32f8b61c-9b52-467e-b6cf-1b9b1391c414" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fa4fd435-66f8-46ba-a76d-5b72965eaf23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fa4fd435-66f8-46ba-a76d-5b72965eaf23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7ab25dd9-e9a7-4fe4-9421-69d9a4781e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7ab25dd9-e9a7-4fe4-9421-69d9a4781e9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_31c1501c-02c1-4681-ab7d-bc8ecac7cd37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_31c1501c-02c1-4681-ab7d-bc8ecac7cd37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2090e100-fa05-400f-88ea-d7d697053b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2090e100-fa05-400f-88ea-d7d697053b1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4daf7b89-21d2-4214-b18e-f174771c56b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_Assets_4daf7b89-21d2-4214-b18e-f174771c56b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f20d1c57-ddc5-49bf-bab2-7554182cce56" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0c793a87-d788-4b8f-955b-11fb0279cde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_AccountsPayableCurrent_0c793a87-d788-4b8f-955b-11fb0279cde8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_841198d8-53ad-4df8-b229-9c57b30f432a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_841198d8-53ad-4df8-b229-9c57b30f432a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AccruedResearchAndDevelopmentCurrent_6a623c04-3aa8-4ce4-8758-fd8fbba73966" xlink:href="rgls-20210930.xsd#rgls_AccruedResearchAndDevelopmentCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_rgls_AccruedResearchAndDevelopmentCurrent_6a623c04-3aa8-4ce4-8758-fd8fbba73966" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8b474b30-14c5-449b-8db8-8223da69cd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8b474b30-14c5-449b-8db8-8223da69cd8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_089f7c95-82ae-4bbf-a261-3ac89c938e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_DebtCurrent_089f7c95-82ae-4bbf-a261-3ac89c938e4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f0e21469-9d44-4b6b-9ef0-82211ba9a9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f0e21469-9d44-4b6b-9ef0-82211ba9a9bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_52feb90f-d413-4ec0-a401-1aeb3bea16e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_LiabilitiesCurrent_52feb90f-d413-4ec0-a401-1aeb3bea16e7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e9b1dae1-ad82-405c-8946-f8be89c2f66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e9b1dae1-ad82-405c-8946-f8be89c2f66b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5b41b0a8-286a-4948-975a-61241850a602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_Liabilities_5b41b0a8-286a-4948-975a-61241850a602" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bd80ed02-c24c-4664-9205-51d457d9e945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bd80ed02-c24c-4664-9205-51d457d9e945" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2b9e2eaa-44cc-4e07-9f7a-73bbc63f7aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_PreferredStockValue_2b9e2eaa-44cc-4e07-9f7a-73bbc63f7aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4a53d9c4-0d37-4cf2-9550-48d8efb15125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_CommonStockValue_4a53d9c4-0d37-4cf2-9550-48d8efb15125" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6f3e0c7-3176-4674-a83d-c317caf66357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6f3e0c7-3176-4674-a83d-c317caf66357" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea4e7a78-f39a-4d0e-82cc-3ed2e41a0b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea4e7a78-f39a-4d0e-82cc-3ed2e41a0b14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2fe323a-8f47-4d91-9fd9-c145ae0dc8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_StockholdersEquity_d2fe323a-8f47-4d91-9fd9-c145ae0dc8bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9819ad8-d4e0-4953-b55f-800453773c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9819ad8-d4e0-4953-b55f-800453773c2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0fa232a6-853d-4cb6-aa45-e4c73febf2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f20d1c57-ddc5-49bf-bab2-7554182cce56" xlink:to="loc_us-gaap_StatementTable_0fa232a6-853d-4cb6-aa45-e4c73febf2c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9e6fad0c-fe06-4680-85ec-875d60b20f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0fa232a6-853d-4cb6-aa45-e4c73febf2c2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9e6fad0c-fe06-4680-85ec-875d60b20f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e6fad0c-fe06-4680-85ec-875d60b20f60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e6fad0c-fe06-4680-85ec-875d60b20f60" xlink:to="loc_us-gaap_ClassOfStockDomain_9e6fad0c-fe06-4680-85ec-875d60b20f60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e6fad0c-fe06-4680-85ec-875d60b20f60" xlink:to="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_20b2529c-a8fd-4e51-84e7-7e86a92cb603" xlink:href="rgls-20210930.xsd#rgls_ClassA1ConvertiblePreferredStockAsConvertedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:to="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_20b2529c-a8fd-4e51-84e7-7e86a92cb603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_bc6375c1-be79-4ef6-a8f1-1df94fa93bf3" xlink:href="rgls-20210930.xsd#rgls_ClassA2ConvertiblePreferredStockAsConvertedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:to="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_bc6375c1-be79-4ef6-a8f1-1df94fa93bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA3ConvertiblePreferredStockMember_39066631-77f3-408e-97cb-e105afe48cb6" xlink:href="rgls-20210930.xsd#rgls_ClassA3ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:to="loc_rgls_ClassA3ConvertiblePreferredStockMember_39066631-77f3-408e-97cb-e105afe48cb6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended" id="i052bf56c60744775b217de47458dbee2_CONDENSEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d38e9c9-80a3-48b9-8f6f-ef90f4319495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d38e9c9-80a3-48b9-8f6f-ef90f4319495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b0f8ee43-2455-4072-8b7a-0b000192852f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b0f8ee43-2455-4072-8b7a-0b000192852f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f74db51a-c4c2-4b79-b2b2-f5ef4793b19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f74db51a-c4c2-4b79-b2b2-f5ef4793b19e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_685ac6c2-ba08-47a5-b5d5-3e2dd2b11348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_685ac6c2-ba08-47a5-b5d5-3e2dd2b11348" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d486a380-716a-4f66-8bd7-f0d7e9b06656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d486a380-716a-4f66-8bd7-f0d7e9b06656" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_52ba5d26-452d-4d4f-8dd6-13494d9b8953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_52ba5d26-452d-4d4f-8dd6-13494d9b8953" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d2fca25f-d2ab-4c6e-8ff9-18cd2438d473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_CommonStockSharesIssued_d2fca25f-d2ab-4c6e-8ff9-18cd2438d473" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4018473b-32f5-4026-b68e-8659045e3458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4018473b-32f5-4026-b68e-8659045e3458" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7f625e0a-2de3-4bf8-84b2-d48c03437632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_StatementTable_7f625e0a-2de3-4bf8-84b2-d48c03437632" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cf61581e-75c0-42fa-b39a-6b5ab6cb7150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7f625e0a-2de3-4bf8-84b2-d48c03437632" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cf61581e-75c0-42fa-b39a-6b5ab6cb7150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cf61581e-75c0-42fa-b39a-6b5ab6cb7150_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cf61581e-75c0-42fa-b39a-6b5ab6cb7150" xlink:to="loc_us-gaap_ClassOfStockDomain_cf61581e-75c0-42fa-b39a-6b5ab6cb7150_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cf61581e-75c0-42fa-b39a-6b5ab6cb7150" xlink:to="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_cf3c052b-f0b4-4316-a655-a5f515e1120d" xlink:href="rgls-20210930.xsd#rgls_ClassA1ConvertiblePreferredStockAsConvertedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:to="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_cf3c052b-f0b4-4316-a655-a5f515e1120d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_30ce0e51-9ade-4963-96e9-c6c284adeb95" xlink:href="rgls-20210930.xsd#rgls_ClassA2ConvertiblePreferredStockAsConvertedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:to="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_30ce0e51-9ade-4963-96e9-c6c284adeb95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA3ConvertiblePreferredStockMember_aff15aa7-f52f-4826-ac34-ba271e28468f" xlink:href="rgls-20210930.xsd#rgls_ClassA3ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:to="loc_rgls_ClassA3ConvertiblePreferredStockMember_aff15aa7-f52f-4826-ac34-ba271e28468f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i6794d79e7df846a4a5130e5a839261c1_CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8c4bfbc8-ba38-443f-9673-05b2f7860c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8c4bfbc8-ba38-443f-9673-05b2f7860c17" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1ca68a13-b2a8-4802-9365-d1487871c297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_SharesOutstanding_1ca68a13-b2a8-4802-9365-d1487871c297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04a0b474-f1be-4e68-a9fe-d8114003c947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockholdersEquity_04a0b474-f1be-4e68-a9fe-d8114003c947" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dd3abbe8-9ae0-43d7-8bf6-67bcb8dda2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dd3abbe8-9ae0-43d7-8bf6-67bcb8dda2f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da00b73f-ee19-41d1-9a93-c67c86112ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da00b73f-ee19-41d1-9a93-c67c86112ba5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f4a0db56-cfe8-42ea-b541-5ce8e3546901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f4a0db56-cfe8-42ea-b541-5ce8e3546901" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants_23b55ed7-a662-4688-a35e-4b8e8c558269" xlink:href="rgls-20210930.xsd#rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants_23b55ed7-a662-4688-a35e-4b8e8c558269" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants_641366a0-231e-4ba2-be40-d972bccbac95" xlink:href="rgls-20210930.xsd#rgls_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants_641366a0-231e-4ba2-be40-d972bccbac95" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ab7188fd-9cab-4d74-bf9e-2035967fab3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ab7188fd-9cab-4d74-bf9e-2035967fab3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_186a0eb3-05b5-4021-8415-a65b45dda066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_186a0eb3-05b5-4021-8415-a65b45dda066" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1afa2b0-192d-4611-ac1c-311add8e7257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1afa2b0-192d-4611-ac1c-311add8e7257" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c5e002de-2913-41a1-831d-58a6c6e4432c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c5e002de-2913-41a1-831d-58a6c6e4432c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a4cc0e88-af71-49a7-a28e-e17fafd7a564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a4cc0e88-af71-49a7-a28e-e17fafd7a564" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_32ba9516-c179-48ec-8a36-4ae21a9d2502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_32ba9516-c179-48ec-8a36-4ae21a9d2502" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a412050-049b-45fd-af52-71f9d99f774a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a412050-049b-45fd-af52-71f9d99f774a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e3daf44-7b24-46f9-9b74-2182cc4ef0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_NetIncomeLoss_6e3daf44-7b24-46f9-9b74-2182cc4ef0e3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7db8bd50-d464-4f76-8e2e-e42594613f65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_83193bac-872d-499d-99cc-b50176561c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9e91c2ab-853d-401a-988f-efda201e7f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8c4bfbc8-ba38-443f-9673-05b2f7860c17" xlink:to="loc_us-gaap_StatementTable_9e91c2ab-853d-401a-988f-efda201e7f84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76001287-793c-468c-8177-780e78bbe4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9e91c2ab-853d-401a-988f-efda201e7f84" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76001287-793c-468c-8177-780e78bbe4d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_76001287-793c-468c-8177-780e78bbe4d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76001287-793c-468c-8177-780e78bbe4d5" xlink:to="loc_us-gaap_ClassOfStockDomain_76001287-793c-468c-8177-780e78bbe4d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ae8a274-e4b3-4e00-9b01-0e860f8a731e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76001287-793c-468c-8177-780e78bbe4d5" xlink:to="loc_us-gaap_ClassOfStockDomain_4ae8a274-e4b3-4e00-9b01-0e860f8a731e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_0393b79a-219c-4680-8a1f-4cfe93815693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4ae8a274-e4b3-4e00-9b01-0e860f8a731e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_0393b79a-219c-4680-8a1f-4cfe93815693" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e4c884f8-dcf8-4e46-a2a9-f63054e7eaab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9e91c2ab-853d-401a-988f-efda201e7f84" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e4c884f8-dcf8-4e46-a2a9-f63054e7eaab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e4c884f8-dcf8-4e46-a2a9-f63054e7eaab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e4c884f8-dcf8-4e46-a2a9-f63054e7eaab" xlink:to="loc_us-gaap_EquityComponentDomain_e4c884f8-dcf8-4e46-a2a9-f63054e7eaab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e4c884f8-dcf8-4e46-a2a9-f63054e7eaab" xlink:to="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_dec28e5c-716b-4e60-98f3-56eab18adff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:to="loc_us-gaap_PreferredStockMember_dec28e5c-716b-4e60-98f3-56eab18adff5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_11497388-5003-4ec7-929b-1c0b7797060c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:to="loc_us-gaap_CommonStockMember_11497388-5003-4ec7-929b-1c0b7797060c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0b6a28e9-1d7b-4f0b-9f95-4f8ad2777d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0b6a28e9-1d7b-4f0b-9f95-4f8ad2777d08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9cf5f390-d4f3-42ee-ae2b-f267bf1fc84d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:to="loc_us-gaap_RetainedEarningsMember_9cf5f390-d4f3-42ee-ae2b-f267bf1fc84d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i2cca5e8c86c541e28a00a66056dfaccd_FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_86f3a5f1-8388-4239-a524-7b0d49d20443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_49a6a5d3-e5f0-4935-9e93-08f78d24aa67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_86f3a5f1-8388-4239-a524-7b0d49d20443" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_49a6a5d3-e5f0-4935-9e93-08f78d24aa67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cff980df-c296-4893-8da9-462cee6b4708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_86f3a5f1-8388-4239-a524-7b0d49d20443" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cff980df-c296-4893-8da9-462cee6b4708" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d564769a-b71e-4453-bb9d-44fdfabcafd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cff980df-c296-4893-8da9-462cee6b4708" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d564769a-b71e-4453-bb9d-44fdfabcafd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d564769a-b71e-4453-bb9d-44fdfabcafd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d564769a-b71e-4453-bb9d-44fdfabcafd3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d564769a-b71e-4453-bb9d-44fdfabcafd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d9e57f8a-01f2-4160-80bb-fa66c67a915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d564769a-b71e-4453-bb9d-44fdfabcafd3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d9e57f8a-01f2-4160-80bb-fa66c67a915b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_04f2b5f9-6cb0-4509-81f3-c199057823b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d9e57f8a-01f2-4160-80bb-fa66c67a915b" xlink:to="loc_us-gaap_CashEquivalentsMember_04f2b5f9-6cb0-4509-81f3-c199057823b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5d30387-57ff-4dc5-94ff-bcac400942d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cff980df-c296-4893-8da9-462cee6b4708" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5d30387-57ff-4dc5-94ff-bcac400942d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5d30387-57ff-4dc5-94ff-bcac400942d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5d30387-57ff-4dc5-94ff-bcac400942d1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5d30387-57ff-4dc5-94ff-bcac400942d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5d30387-57ff-4dc5-94ff-bcac400942d1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c0ff4f48-c0b7-414d-b9dd-7622495008b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c0ff4f48-c0b7-414d-b9dd-7622495008b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5a56bcea-2ee8-4bd2-93d1-1c76f9250794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5a56bcea-2ee8-4bd2-93d1-1c76f9250794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1d693153-d855-423f-a1b5-924c981998dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1d693153-d855-423f-a1b5-924c981998dc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/DebtNarrativeDetails" xlink:type="extended" id="i5a0068193b0c4085b42c11e6a695a09b_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_3f27ba14-a08b-4186-ad8f-26d659a7b26a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_3f27ba14-a08b-4186-ad8f-26d659a7b26a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c0c5a2f-a3b1-4f0d-8ee8-feed0d443ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c0c5a2f-a3b1-4f0d-8ee8-feed0d443ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e0323285-238c-439e-825a-0ed6881afddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e0323285-238c-439e-825a-0ed6881afddd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberofMonthlyPayments_1dc3b60b-c8bc-4119-aa40-af869dd923ad" xlink:href="rgls-20210930.xsd#rgls_NumberofMonthlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_NumberofMonthlyPayments_1dc3b60b-c8bc-4119-aa40-af869dd923ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfAmendments_3d643af7-564f-403b-bdbc-9e3a617345a0" xlink:href="rgls-20210930.xsd#rgls_NumberOfAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_NumberOfAmendments_3d643af7-564f-403b-bdbc-9e3a617345a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7ea7e819-25fa-4f3c-9ecc-be2c3e43f247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7ea7e819-25fa-4f3c-9ecc-be2c3e43f247" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ForgivenessAmountThreshold_7308085b-355c-40a2-80bc-2a15d787d0c7" xlink:href="rgls-20210930.xsd#rgls_ForgivenessAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_ForgivenessAmountThreshold_7308085b-355c-40a2-80bc-2a15d787d0c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_InterestOnlyPaymentExtension_53f810e7-dcdd-4342-b5e9-c141adbf6474" xlink:href="rgls-20210930.xsd#rgls_InterestOnlyPaymentExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_InterestOnlyPaymentExtension_53f810e7-dcdd-4342-b5e9-c141adbf6474" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PrepaymentRequirement_59197775-6e19-42d6-ae77-cbb849f076d9" xlink:href="rgls-20210930.xsd#rgls_PrepaymentRequirement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_PrepaymentRequirement_59197775-6e19-42d6-ae77-cbb849f076d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e75fee43-c1d7-4596-bbba-404837b95bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e75fee43-c1d7-4596-bbba-404837b95bae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_bdf256c5-73e0-463c-a0c5-2c77243e3362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_RepaymentsOfDebt_bdf256c5-73e0-463c-a0c5-2c77243e3362" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PaymentFee_5a604411-a515-4a14-aa34-8830a9be8716" xlink:href="rgls-20210930.xsd#rgls_PaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_PaymentFee_5a604411-a515-4a14-aa34-8830a9be8716" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfPrepaymentsToLender_3d9510a8-e921-4744-8cfb-a9c7bf05dbce" xlink:href="rgls-20210930.xsd#rgls_NumberOfPrepaymentsToLender"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_NumberOfPrepaymentsToLender_3d9510a8-e921-4744-8cfb-a9c7bf05dbce" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AdditionalExtensionForInterestOnlyPayments_250f1c56-ae59-4966-91cb-432ca9952871" xlink:href="rgls-20210930.xsd#rgls_AdditionalExtensionForInterestOnlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_AdditionalExtensionForInterestOnlyPayments_250f1c56-ae59-4966-91cb-432ca9952871" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_50167fcb-e529-4275-8d9c-0cf641fcfd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_LongTermDebt_50167fcb-e529-4275-8d9c-0cf641fcfd98" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_5c3f5388-6928-47da-8ecb-50d5a25b0e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_5c3f5388-6928-47da-8ecb-50d5a25b0e44" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_7c8a4933-4b09-40d3-8e56-1bfd289719e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_7c8a4933-4b09-40d3-8e56-1bfd289719e2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c48c9028-fc3e-4193-b4ce-36cf84446c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c48c9028-fc3e-4193-b4ce-36cf84446c9c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_fcdf78be-a161-4f61-9482-5e538976cf26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_fcdf78be-a161-4f61-9482-5e538976cf26" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8b916e10-c9d7-4241-9075-13b16d2db826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_us-gaap_DebtInstrumentAxis_8b916e10-c9d7-4241-9075-13b16d2db826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b916e10-c9d7-4241-9075-13b16d2db826_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8b916e10-c9d7-4241-9075-13b16d2db826" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b916e10-c9d7-4241-9075-13b16d2db826_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8b916e10-c9d7-4241-9075-13b16d2db826" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DebtFinancingAgreementMember_954161dc-0589-4a20-ad56-0fbbc2970172" xlink:href="rgls-20210930.xsd#rgls_DebtFinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:to="loc_rgls_DebtFinancingAgreementMember_954161dc-0589-4a20-ad56-0fbbc2970172" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PPPLoanMember_83eada29-4764-4cb7-8c71-d28aefe83b28" xlink:href="rgls-20210930.xsd#rgls_PPPLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:to="loc_rgls_PPPLoanMember_83eada29-4764-4cb7-8c71-d28aefe83b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_TenthAmendmentMember_3a59611e-2d3f-41d3-96b4-263b2bbe4ff2" xlink:href="rgls-20210930.xsd#rgls_TenthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:to="loc_rgls_TenthAmendmentMember_3a59611e-2d3f-41d3-96b4-263b2bbe4ff2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_TermLoanMember_fa8c7c35-9659-448a-9a82-f271e4128e17" xlink:href="rgls-20210930.xsd#rgls_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:to="loc_rgls_TermLoanMember_fa8c7c35-9659-448a-9a82-f271e4128e17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a984d7d7-fa93-4ae4-af89-341b02896460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_us-gaap_VariableRateAxis_a984d7d7-fa93-4ae4-af89-341b02896460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a984d7d7-fa93-4ae4-af89-341b02896460_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_a984d7d7-fa93-4ae4-af89-341b02896460" xlink:to="loc_us-gaap_VariableRateDomain_a984d7d7-fa93-4ae4-af89-341b02896460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_21dba8be-7028-415d-90ca-50b49a7b6ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_a984d7d7-fa93-4ae4-af89-341b02896460" xlink:to="loc_us-gaap_VariableRateDomain_21dba8be-7028-415d-90ca-50b49a7b6ef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7c61ab5c-b468-4552-b9a2-0ce84381fcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_21dba8be-7028-415d-90ca-50b49a7b6ef9" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7c61ab5c-b468-4552-b9a2-0ce84381fcd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesAxis_07f121b0-c05d-485a-97bd-f82bc3a80907" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_rgls_StrategicAlliancesAxis_07f121b0-c05d-485a-97bd-f82bc3a80907" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesDomain_07f121b0-c05d-485a-97bd-f82bc3a80907_default" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rgls_StrategicAlliancesAxis_07f121b0-c05d-485a-97bd-f82bc3a80907" xlink:to="loc_rgls_StrategicAlliancesDomain_07f121b0-c05d-485a-97bd-f82bc3a80907_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesDomain_64bf1b76-790c-40d4-bcb5-e1263e31cf18" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rgls_StrategicAlliancesAxis_07f121b0-c05d-485a-97bd-f82bc3a80907" xlink:to="loc_rgls_StrategicAlliancesDomain_64bf1b76-790c-40d4-bcb5-e1263e31cf18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesandCollaborationsMember_3a415e40-90bf-4228-b1c9-84bb270dc716" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesandCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rgls_StrategicAlliancesDomain_64bf1b76-790c-40d4-bcb5-e1263e31cf18" xlink:to="loc_rgls_StrategicAlliancesandCollaborationsMember_3a415e40-90bf-4228-b1c9-84bb270dc716" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f99ed930-7d84-46b7-a7ad-195f2fa74615" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_srt_CounterpartyNameAxis_f99ed930-7d84-46b7-a7ad-195f2fa74615" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f99ed930-7d84-46b7-a7ad-195f2fa74615_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f99ed930-7d84-46b7-a7ad-195f2fa74615" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f99ed930-7d84-46b7-a7ad-195f2fa74615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46a9965a-e785-4343-99fe-22b09614469b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f99ed930-7d84-46b7-a7ad-195f2fa74615" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46a9965a-e785-4343-99fe-22b09614469b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SanofiMember_f55f0dee-6bf3-4ad1-9e8f-cf3c91d42be0" xlink:href="rgls-20210930.xsd#rgls_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46a9965a-e785-4343-99fe-22b09614469b" xlink:to="loc_rgls_SanofiMember_f55f0dee-6bf3-4ad1-9e8f-cf3c91d42be0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9bf0a159-38b3-4a55-a6d6-6cec3566fdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9bf0a159-38b3-4a55-a6d6-6cec3566fdc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9bf0a159-38b3-4a55-a6d6-6cec3566fdc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9bf0a159-38b3-4a55-a6d6-6cec3566fdc0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9bf0a159-38b3-4a55-a6d6-6cec3566fdc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b22d2883-e9b5-471a-bcf6-27f6b12e697c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9bf0a159-38b3-4a55-a6d6-6cec3566fdc0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b22d2883-e9b5-471a-bcf6-27f6b12e697c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_a21ac4b0-368c-41cc-be63-b7662d5f4535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b22d2883-e9b5-471a-bcf6-27f6b12e697c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_a21ac4b0-368c-41cc-be63-b7662d5f4535" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#DebtFuturePrincipalPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails" xlink:type="extended" id="i35299d406ca843949eed618bc4bc80e4_DebtFuturePrincipalPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_634d60ca-831c-4d1c-acf0-6173bd669a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_634d60ca-831c-4d1c-acf0-6173bd669a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d63b6f59-81e0-4ed6-b69c-28b7f6b8df7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d63b6f59-81e0-4ed6-b69c-28b7f6b8df7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_df51f5f8-c2c9-4bbb-a4d4-c947511f6472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:to="loc_us-gaap_LongTermDebt_df51f5f8-c2c9-4bbb-a4d4-c947511f6472" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e46f202-c655-4e0b-83ca-22eb280d4f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:to="loc_us-gaap_DebtInstrumentTable_8e46f202-c655-4e0b-83ca-22eb280d4f1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7e3b3733-cdd7-419e-9bc7-437688b99ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e46f202-c655-4e0b-83ca-22eb280d4f1a" xlink:to="loc_us-gaap_DebtInstrumentAxis_7e3b3733-cdd7-419e-9bc7-437688b99ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e3b3733-cdd7-419e-9bc7-437688b99ddc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7e3b3733-cdd7-419e-9bc7-437688b99ddc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e3b3733-cdd7-419e-9bc7-437688b99ddc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d075ff7-2f3a-43d9-b570-86f69039665e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7e3b3733-cdd7-419e-9bc7-437688b99ddc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d075ff7-2f3a-43d9-b570-86f69039665e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DebtFinancingAgreementTrancheAMember_a5151ea1-bec5-4a9c-a4a6-306e88bd52e2" xlink:href="rgls-20210930.xsd#rgls_DebtFinancingAgreementTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d075ff7-2f3a-43d9-b570-86f69039665e" xlink:to="loc_rgls_DebtFinancingAgreementTrancheAMember_a5151ea1-bec5-4a9c-a4a6-306e88bd52e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i189dd16fcd454efc9460094969a4a43f_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_74f0f4df-0966-419a-85a2-db69af91a281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_74f0f4df-0966-419a-85a2-db69af91a281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CommonStockVotingRightsVotes_5033f5ca-1084-41d4-b433-7435656f5566" xlink:href="rgls-20210930.xsd#rgls_CommonStockVotingRightsVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_CommonStockVotingRightsVotes_5033f5ca-1084-41d4-b433-7435656f5566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_261d95d9-f3bb-4bfc-9317-7e2932e99115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_261d95d9-f3bb-4bfc-9317-7e2932e99115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease_3c5d526a-8b70-43d9-aafc-69eff58ae0ba" xlink:href="rgls-20210930.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease_3c5d526a-8b70-43d9-aafc-69eff58ae0ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease_862dedde-156f-48af-af94-f4d053a71796" xlink:href="rgls-20210930.xsd#rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease_862dedde-156f-48af-af94-f4d053a71796" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24015f5c-db48-406b-bd53-369ccd932bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24015f5c-db48-406b-bd53-369ccd932bd0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_621445ec-5b96-4ecc-804a-843a59b764ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_621445ec-5b96-4ecc-804a-843a59b764ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfClosings_106db547-46d8-42c2-be1f-bf375afab7af" xlink:href="rgls-20210930.xsd#rgls_NumberOfClosings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_NumberOfClosings_106db547-46d8-42c2-be1f-bf375afab7af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51c40f6f-08e8-4adc-97c4-de234e55c94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51c40f6f-08e8-4adc-97c4-de234e55c94a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e1061ee7-4c5a-4c17-8b43-a79f78d66557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e1061ee7-4c5a-4c17-8b43-a79f78d66557" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85540f7e-8404-407c-a38d-10e8c7d1f5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85540f7e-8404-407c-a38d-10e8c7d1f5c3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NonvotingConvertiblePreferredStockIssued_72d758d6-6f86-4dfa-a5c5-5f1b071ebe32" xlink:href="rgls-20210930.xsd#rgls_NonvotingConvertiblePreferredStockIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_NonvotingConvertiblePreferredStockIssued_72d758d6-6f86-4dfa-a5c5-5f1b071ebe32" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_84b90b2e-e635-4339-940a-6cbfa7dede15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_84b90b2e-e635-4339-940a-6cbfa7dede15" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_f6d97ede-863d-48ad-a547-f1fa83632c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_f6d97ede-863d-48ad-a547-f1fa83632c1b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b3c65122-b4a1-4a5b-97b5-1d7a0b5fa2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b3c65122-b4a1-4a5b-97b5-1d7a0b5fa2f8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3fe71e4d-9b6f-44e1-a21b-197d7e481d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3fe71e4d-9b6f-44e1-a21b-197d7e481d68" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_71ffb35e-edcb-495a-84f2-8991bf83f834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_71ffb35e-edcb-495a-84f2-8991bf83f834" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ca915396-4438-438b-bf61-3b3d6114d580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ca915396-4438-438b-bf61-3b3d6114d580" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b14e1aee-bddb-401d-ab27-a7252bb4aac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_us-gaap_PlanNameAxis_b14e1aee-bddb-401d-ab27-a7252bb4aac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b14e1aee-bddb-401d-ab27-a7252bb4aac2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b14e1aee-bddb-401d-ab27-a7252bb4aac2" xlink:to="loc_us-gaap_PlanNameDomain_b14e1aee-bddb-401d-ab27-a7252bb4aac2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a8e779af-9064-4e7f-b4a7-41751a4dc820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b14e1aee-bddb-401d-ab27-a7252bb4aac2" xlink:to="loc_us-gaap_PlanNameDomain_a8e779af-9064-4e7f-b4a7-41751a4dc820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_A2019PlanMember_5905550b-c926-4f78-9b8e-592efcd041b7" xlink:href="rgls-20210930.xsd#rgls_A2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a8e779af-9064-4e7f-b4a7-41751a4dc820" xlink:to="loc_rgls_A2019PlanMember_5905550b-c926-4f78-9b8e-592efcd041b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ffae77cb-77e0-48ae-84b0-06882d3b26e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_srt_TitleOfIndividualAxis_ffae77cb-77e0-48ae-84b0-06882d3b26e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ffae77cb-77e0-48ae-84b0-06882d3b26e2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ffae77cb-77e0-48ae-84b0-06882d3b26e2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ffae77cb-77e0-48ae-84b0-06882d3b26e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2240dd1a-3274-4619-b1e5-a557dbdaa9e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ffae77cb-77e0-48ae-84b0-06882d3b26e2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2240dd1a-3274-4619-b1e5-a557dbdaa9e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CertainDirectorsandExecutiveOfficersMember_7b506fae-02cd-42df-b03a-7fb740519382" xlink:href="rgls-20210930.xsd#rgls_CertainDirectorsandExecutiveOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2240dd1a-3274-4619-b1e5-a557dbdaa9e4" xlink:to="loc_rgls_CertainDirectorsandExecutiveOfficersMember_7b506fae-02cd-42df-b03a-7fb740519382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_08ed4c8b-e52c-41eb-836a-697b69e1cfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_08ed4c8b-e52c-41eb-836a-697b69e1cfb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08ed4c8b-e52c-41eb-836a-697b69e1cfb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_08ed4c8b-e52c-41eb-836a-697b69e1cfb7" xlink:to="loc_us-gaap_EquityComponentDomain_08ed4c8b-e52c-41eb-836a-697b69e1cfb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56c371dc-dd92-4cd2-9215-d331f85efc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_08ed4c8b-e52c-41eb-836a-697b69e1cfb7" xlink:to="loc_us-gaap_EquityComponentDomain_56c371dc-dd92-4cd2-9215-d331f85efc1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2de81063-01fa-4d54-8b59-2d62a640a711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56c371dc-dd92-4cd2-9215-d331f85efc1e" xlink:to="loc_us-gaap_WarrantMember_2de81063-01fa-4d54-8b59-2d62a640a711" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a94b3ea3-90d8-49fe-8401-35f65c010b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a94b3ea3-90d8-49fe-8401-35f65c010b0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a94b3ea3-90d8-49fe-8401-35f65c010b0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a94b3ea3-90d8-49fe-8401-35f65c010b0a" xlink:to="loc_us-gaap_ClassOfStockDomain_a94b3ea3-90d8-49fe-8401-35f65c010b0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a94b3ea3-90d8-49fe-8401-35f65c010b0a" xlink:to="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember_c589a840-8007-4f2f-b7be-dfa4daf021f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:to="loc_us-gaap_PreferredClassAMember_c589a840-8007-4f2f-b7be-dfa4daf021f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_409946c0-d555-42ce-acd9-887288957ad7" xlink:href="rgls-20210930.xsd#rgls_ClassA2ConvertiblePreferredStockAsConvertedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:to="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_409946c0-d555-42ce-acd9-887288957ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassAThreeConvertiblePreferredStockMember_c7ac0115-3b67-44e5-8d58-ec1db07818e8" xlink:href="rgls-20210930.xsd#rgls_ClassAThreeConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:to="loc_rgls_ClassAThreeConvertiblePreferredStockMember_c7ac0115-3b67-44e5-8d58-ec1db07818e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6e0b9cc4-4139-494f-b138-f8af8c4138db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6e0b9cc4-4139-494f-b138-f8af8c4138db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e0b9cc4-4139-494f-b138-f8af8c4138db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6e0b9cc4-4139-494f-b138-f8af8c4138db" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e0b9cc4-4139-494f-b138-f8af8c4138db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d2a85ca-e2d9-4a41-87c3-6db0c89da37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6e0b9cc4-4139-494f-b138-f8af8c4138db" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d2a85ca-e2d9-4a41-87c3-6db0c89da37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b7538c2b-1ec0-48f0-8964-c1c05ac36d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d2a85ca-e2d9-4a41-87c3-6db0c89da37a" xlink:to="loc_us-gaap_PrivatePlacementMember_b7538c2b-1ec0-48f0-8964-c1c05ac36d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_MilestoneClosingMember_c6976271-f7e6-44e1-b07b-448d62d76507" xlink:href="rgls-20210930.xsd#rgls_MilestoneClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d2a85ca-e2d9-4a41-87c3-6db0c89da37a" xlink:to="loc_rgls_MilestoneClosingMember_c6976271-f7e6-44e1-b07b-448d62d76507" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityShareActivityDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails" xlink:type="extended" id="i8b8744e8cb6e47d4979c3670becd29ad_StockholdersEquityShareActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_67efe92c-51e4-4c3a-8299-ba186fe9805b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:href="rgls-20210930.xsd#rgls_ActivityOfSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_67efe92c-51e4-4c3a-8299-ba186fe9805b" xlink:to="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9b6904d3-3591-49a9-9b50-1e4b5cc2dae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9b6904d3-3591-49a9-9b50-1e4b5cc2dae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6c403015-03a0-4875-9d10-aba382960c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6c403015-03a0-4875-9d10-aba382960c2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dd40ff23-b098-48f5-9b89-bca980a04417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dd40ff23-b098-48f5-9b89-bca980a04417" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_25ebfdf9-a183-48cb-8c78-3a9c61804c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_25ebfdf9-a183-48cb-8c78-3a9c61804c19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d3214b1e-fa87-4790-9212-faafa00458f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8789ea9a-2d2c-4394-8620-24fad7912a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9be37387-2b2c-4a5b-8ffc-c0f4d94deb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4393aa6e-8897-4f35-80b6-bf76ca0d6e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_67efe92c-51e4-4c3a-8299-ba186fe9805b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4393aa6e-8897-4f35-80b6-bf76ca0d6e01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_89eb8d6c-fee0-4915-a6fc-8eeaa7ebc9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4393aa6e-8897-4f35-80b6-bf76ca0d6e01" xlink:to="loc_us-gaap_StatementClassOfStockAxis_89eb8d6c-fee0-4915-a6fc-8eeaa7ebc9b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_89eb8d6c-fee0-4915-a6fc-8eeaa7ebc9b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_89eb8d6c-fee0-4915-a6fc-8eeaa7ebc9b7" xlink:to="loc_us-gaap_ClassOfStockDomain_89eb8d6c-fee0-4915-a6fc-8eeaa7ebc9b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_89eb8d6c-fee0-4915-a6fc-8eeaa7ebc9b7" xlink:to="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassAOneConvertiblePreferredStockMember_fdf311ec-8b7b-4423-be4b-a527599eaada" xlink:href="rgls-20210930.xsd#rgls_ClassAOneConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_rgls_ClassAOneConvertiblePreferredStockMember_fdf311ec-8b7b-4423-be4b-a527599eaada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassATwoConvertiblePreferredStockMember_f88433df-785d-48dc-b7b8-5539767d8b6d" xlink:href="rgls-20210930.xsd#rgls_ClassATwoConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_rgls_ClassATwoConvertiblePreferredStockMember_f88433df-785d-48dc-b7b8-5539767d8b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassAThreeConvertiblePreferredStockMember_97fdaeb6-34e5-4391-92ed-dd6708e0d404" xlink:href="rgls-20210930.xsd#rgls_ClassAThreeConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_rgls_ClassAThreeConvertiblePreferredStockMember_97fdaeb6-34e5-4391-92ed-dd6708e0d404" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_34c31cb2-be59-4739-bc19-a69bf4b0cd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_us-gaap_WarrantMember_34c31cb2-be59-4739-bc19-a69bf4b0cd8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d60b4ecb-0c3b-4c76-bb0c-912efd940517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_us-gaap_CommonStockMember_d60b4ecb-0c3b-4c76-bb0c-912efd940517" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_09279b48-e1a0-4530-8192-621c1662e5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4393aa6e-8897-4f35-80b6-bf76ca0d6e01" xlink:to="loc_us-gaap_PlanNameAxis_09279b48-e1a0-4530-8192-621c1662e5a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_09279b48-e1a0-4530-8192-621c1662e5a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_09279b48-e1a0-4530-8192-621c1662e5a9" xlink:to="loc_us-gaap_PlanNameDomain_09279b48-e1a0-4530-8192-621c1662e5a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_48ca79b3-300c-4a1d-b303-d92a0312b895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_09279b48-e1a0-4530-8192-621c1662e5a9" xlink:to="loc_us-gaap_PlanNameDomain_48ca79b3-300c-4a1d-b303-d92a0312b895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_A2019SPAAnd2020SPAMember_dd928a96-b299-4f6f-bfce-24081ff6b74d" xlink:href="rgls-20210930.xsd#rgls_A2019SPAAnd2020SPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_48ca79b3-300c-4a1d-b303-d92a0312b895" xlink:to="loc_rgls_A2019SPAAnd2020SPAMember_dd928a96-b299-4f6f-bfce-24081ff6b74d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityATMOfferingDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails" xlink:type="extended" id="i39053922922d48058f355d7258e71621_StockholdersEquityATMOfferingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CommissionFeeRate_5d4493b8-3a42-4175-b4ce-61e9a4b4aabe" xlink:href="rgls-20210930.xsd#rgls_CommissionFeeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_rgls_CommissionFeeRate_5d4493b8-3a42-4175-b4ce-61e9a4b4aabe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b9a35bfc-9b2e-4925-b890-4e9b9451351c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b9a35bfc-9b2e-4925-b890-4e9b9451351c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3259d434-d411-4c98-a807-29409d307485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3259d434-d411-4c98-a807-29409d307485" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_e3f4829e-907d-4a9e-a50b-57023e03eea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_us-gaap_PaymentsForCommissions_e3f4829e-907d-4a9e-a50b-57023e03eea7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SaleOfStockValueOfSharesAvailable_9184cfe7-14a2-4dc5-a2ac-e7d4fe8a66b8" xlink:href="rgls-20210930.xsd#rgls_SaleOfStockValueOfSharesAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_rgls_SaleOfStockValueOfSharesAvailable_9184cfe7-14a2-4dc5-a2ac-e7d4fe8a66b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7f4e6aff-7386-444f-bc40-ce8dbb817a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7f4e6aff-7386-444f-bc40-ce8dbb817a18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_09b71903-0116-4e6a-8c54-38d764d697df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7f4e6aff-7386-444f-bc40-ce8dbb817a18" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_09b71903-0116-4e6a-8c54-38d764d697df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_09b71903-0116-4e6a-8c54-38d764d697df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_09b71903-0116-4e6a-8c54-38d764d697df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_09b71903-0116-4e6a-8c54-38d764d697df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338e0b0b-b5a8-44bf-bb33-d6d86b21a715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_09b71903-0116-4e6a-8c54-38d764d697df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338e0b0b-b5a8-44bf-bb33-d6d86b21a715" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AtTheMomentMember_1ee4f587-f103-4e10-88f8-038e5eb8c0fc" xlink:href="rgls-20210930.xsd#rgls_AtTheMomentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338e0b0b-b5a8-44bf-bb33-d6d86b21a715" xlink:to="loc_rgls_AtTheMomentMember_1ee4f587-f103-4e10-88f8-038e5eb8c0fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails" xlink:type="extended" id="ib68b0ce0709a491da6185a5f374f5a45_StockholdersEquityCommonStockReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_85b2541d-63dd-495e-a93e-fe8011f15bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_85b2541d-63dd-495e-a93e-fe8011f15bbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e7a29d20-38bd-440f-a787-1858ae6159a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e7a29d20-38bd-440f-a787-1858ae6159a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8d10f75-eacb-4698-ae80-5eeefb6f3a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8d10f75-eacb-4698-ae80-5eeefb6f3a5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1a6ab685-095a-4aba-a586-9389aa991850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1a6ab685-095a-4aba-a586-9389aa991850" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_72603288-709c-48e3-a601-4abff0a6cdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_72603288-709c-48e3-a601-4abff0a6cdfa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7d115298-6740-4dd5-b5c9-bc65c540f24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7d115298-6740-4dd5-b5c9-bc65c540f24f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7391f618-388f-407f-9f7e-560351890b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7391f618-388f-407f-9f7e-560351890b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7391f618-388f-407f-9f7e-560351890b5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7391f618-388f-407f-9f7e-560351890b5e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7391f618-388f-407f-9f7e-560351890b5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7391f618-388f-407f-9f7e-560351890b5e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_InitialClosingWarrantsMember_3fafa5d8-4c29-4783-a8e8-f2b8baf76639" xlink:href="rgls-20210930.xsd#rgls_InitialClosingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:to="loc_rgls_InitialClosingWarrantsMember_3fafa5d8-4c29-4783-a8e8-f2b8baf76639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_MilestoneClosingWarrantsMember_7f1bffb2-16fe-468a-b063-aed704ae8b9c" xlink:href="rgls-20210930.xsd#rgls_MilestoneClosingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:to="loc_rgls_MilestoneClosingWarrantsMember_7f1bffb2-16fe-468a-b063-aed704ae8b9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_A2020PIPEWarrantsMember_0beb03fe-5b58-4254-a0fd-d9c4c46a33ac" xlink:href="rgls-20210930.xsd#rgls_A2020PIPEWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:to="loc_rgls_A2020PIPEWarrantsMember_0beb03fe-5b58-4254-a0fd-d9c4c46a33ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51dd845e-0210-487d-85b6-c1a00052ac2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51dd845e-0210-487d-85b6-c1a00052ac2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51dd845e-0210-487d-85b6-c1a00052ac2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51dd845e-0210-487d-85b6-c1a00052ac2b" xlink:to="loc_us-gaap_EquityComponentDomain_51dd845e-0210-487d-85b6-c1a00052ac2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51dd845e-0210-487d-85b6-c1a00052ac2b" xlink:to="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_eb1e65c4-1a7a-47f5-884c-aedaf6d4f29b" xlink:href="rgls-20210930.xsd#rgls_ClassA1ConvertiblePreferredStockAsConvertedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:to="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_eb1e65c4-1a7a-47f5-884c-aedaf6d4f29b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_a27026bf-7b7d-4366-bee1-83ad6a20f522" xlink:href="rgls-20210930.xsd#rgls_ClassA2ConvertiblePreferredStockAsConvertedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:to="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_a27026bf-7b7d-4366-bee1-83ad6a20f522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA3ConvertiblePreferredStockMember_78d19a65-f95f-4665-8111-f83b583ce7a4" xlink:href="rgls-20210930.xsd#rgls_ClassA3ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:to="loc_rgls_ClassA3ConvertiblePreferredStockMember_78d19a65-f95f-4665-8111-f83b583ce7a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bf8a82c4-0875-43df-99b4-e1182ecb6355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:to="loc_us-gaap_AwardTypeAxis_bf8a82c4-0875-43df-99b4-e1182ecb6355" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf8a82c4-0875-43df-99b4-e1182ecb6355_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bf8a82c4-0875-43df-99b4-e1182ecb6355" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf8a82c4-0875-43df-99b4-e1182ecb6355_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_900ce5a2-35db-4a42-8077-09c7bddf5ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bf8a82c4-0875-43df-99b4-e1182ecb6355" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_900ce5a2-35db-4a42-8077-09c7bddf5ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f56069e8-53c1-4bf3-8eb0-05269cf837e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_900ce5a2-35db-4a42-8077-09c7bddf5ddf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f56069e8-53c1-4bf3-8eb0-05269cf837e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_71a144fc-3bd9-40b3-aa6a-0bbf5183800d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_71a144fc-3bd9-40b3-aa6a-0bbf5183800d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_71a144fc-3bd9-40b3-aa6a-0bbf5183800d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_71a144fc-3bd9-40b3-aa6a-0bbf5183800d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_71a144fc-3bd9-40b3-aa6a-0bbf5183800d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b52cf074-009d-4940-af11-16b6c08f14d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_71a144fc-3bd9-40b3-aa6a-0bbf5183800d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b52cf074-009d-4940-af11-16b6c08f14d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_TwentyTwelvePlanMember_9aa8ea39-730e-4e12-b286-e3a7410d5f18" xlink:href="rgls-20210930.xsd#rgls_TwentyTwelvePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b52cf074-009d-4940-af11-16b6c08f14d9" xlink:to="loc_rgls_TwentyTwelvePlanMember_9aa8ea39-730e-4e12-b286-e3a7410d5f18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b87989fd-c416-43bc-870d-4244217f9bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b52cf074-009d-4940-af11-16b6c08f14d9" xlink:to="loc_us-gaap_EmployeeStockMember_b87989fd-c416-43bc-870d-4244217f9bf7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityStockOptionandRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails" xlink:type="extended" id="id730a61ea0ad466f981575e7ca6e945f_StockholdersEquityStockOptionandRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76639cc1-ff3a-479e-a8f6-4be40c0e23f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76639cc1-ff3a-479e-a8f6-4be40c0e23f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ff724079-3a8d-42ff-89ec-61cc57516f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ff724079-3a8d-42ff-89ec-61cc57516f9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ea38ab45-2561-40db-990b-8d802fb20a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ea38ab45-2561-40db-990b-8d802fb20a8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_07f87773-bb4a-4e66-8dfa-3ab0b32dad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_07f87773-bb4a-4e66-8dfa-3ab0b32dad3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bd78ba7a-c5ef-4f7f-b4ce-effa9630f18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ac5a6c77-c0e2-4890-a2dc-d9778a92c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ac5a6c77-c0e2-4890-a2dc-d9778a92c28e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb22295d-2ed1-4193-b54f-bffd48624429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb22295d-2ed1-4193-b54f-bffd48624429" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f5e5ed14-d7b5-4c0e-b1b5-7fe9785a760a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f5e5ed14-d7b5-4c0e-b1b5-7fe9785a760a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c4909b64-f14e-4e7e-9e69-0e6fd4f1ab83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c4909b64-f14e-4e7e-9e69-0e6fd4f1ab83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9424a57-166e-4c36-93a1-5230c695f1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3e094fda-4519-44ea-a708-17bdd4b56a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3e094fda-4519-44ea-a708-17bdd4b56a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_065b657e-9a83-4132-8d24-27a2357e446f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_065b657e-9a83-4132-8d24-27a2357e446f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ab371ac-aa31-4f4c-8981-cbbb0144152a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ab371ac-aa31-4f4c-8981-cbbb0144152a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b962a23-89e3-4c26-988d-88af9d1dc7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b962a23-89e3-4c26-988d-88af9d1dc7e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_074a1e06-de94-4748-8bca-40b365f7fa39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d6cecea-0742-4223-9522-5289d141b6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d6cecea-0742-4223-9522-5289d141b6e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd74b649-92e6-41af-bc5f-47bb96cc2337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd74b649-92e6-41af-bc5f-47bb96cc2337" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9a59dd77-8182-46c2-8186-e5731d87cb07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9a59dd77-8182-46c2-8186-e5731d87cb07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e23faa20-c017-4103-93cd-65310210c7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e23faa20-c017-4103-93cd-65310210c7e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_112bd301-7a10-4a2c-8a00-e1b7497df666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fab6b8d-93d1-4243-b9c8-631a241c7e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fab6b8d-93d1-4243-b9c8-631a241c7e81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1f482de3-cb0a-4c43-837c-7f65c35aabcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fab6b8d-93d1-4243-b9c8-631a241c7e81" xlink:to="loc_us-gaap_AwardTypeAxis_1f482de3-cb0a-4c43-837c-7f65c35aabcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f482de3-cb0a-4c43-837c-7f65c35aabcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1f482de3-cb0a-4c43-837c-7f65c35aabcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f482de3-cb0a-4c43-837c-7f65c35aabcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a77f33b-2042-4f72-894d-07786512726e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1f482de3-cb0a-4c43-837c-7f65c35aabcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a77f33b-2042-4f72-894d-07786512726e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aeacf6e3-877d-4219-861b-9b07512ae2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a77f33b-2042-4f72-894d-07786512726e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aeacf6e3-877d-4219-861b-9b07512ae2eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ac445d57-53b5-407f-9fdb-a9bf2310572f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a77f33b-2042-4f72-894d-07786512726e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ac445d57-53b5-407f-9fdb-a9bf2310572f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails" xlink:type="extended" id="ib7632668641c4336861b8ff8fd9d6c24_StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_4300651e-4f14-46c5-ba44-d513f8a6764d" xlink:href="rgls-20210930.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_4300651e-4f14-46c5-ba44-d513f8a6764d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7a493c04-dc66-4065-a6f4-bdca9d029564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7a493c04-dc66-4065-a6f4-bdca9d029564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6452f312-c2b5-42ed-9eb9-6bee37aabb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6452f312-c2b5-42ed-9eb9-6bee37aabb2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b46ffe79-9b54-4842-b321-5bf4b66f6e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b46ffe79-9b54-4842-b321-5bf4b66f6e6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ccc005e4-1532-4b6f-981a-10111e31bb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ccc005e4-1532-4b6f-981a-10111e31bb66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_145f1493-62ab-4fcf-ab01-70c3271ffa1d" xlink:href="rgls-20210930.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_4300651e-4f14-46c5-ba44-d513f8a6764d" xlink:to="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_145f1493-62ab-4fcf-ab01-70c3271ffa1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5167a77-9b0b-4c42-824e-f3db5d36e46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_145f1493-62ab-4fcf-ab01-70c3271ffa1d" xlink:to="loc_us-gaap_AwardTypeAxis_e5167a77-9b0b-4c42-824e-f3db5d36e46f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5167a77-9b0b-4c42-824e-f3db5d36e46f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e5167a77-9b0b-4c42-824e-f3db5d36e46f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5167a77-9b0b-4c42-824e-f3db5d36e46f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e5167a77-9b0b-4c42-824e-f3db5d36e46f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6c558ccc-7769-4f78-b776-05496f4e9b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6c558ccc-7769-4f78-b776-05496f4e9b89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_11d06bf0-b2f7-4fee-b200-512a2c44bf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:to="loc_us-gaap_PerformanceSharesMember_11d06bf0-b2f7-4fee-b200-512a2c44bf7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b36cb2d1-9bbe-4f66-96ad-3d0c93e1c58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:to="loc_us-gaap_EmployeeStockMember_b36cb2d1-9bbe-4f66-96ad-3d0c93e1c58e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityStockBasedCompensationExpenseAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="extended" id="if49ec68f2dd64ad0a12026b47dee289c_StockholdersEquityStockBasedCompensationExpenseAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_77923a4c-a4bf-4cf5-bf45-7a77f5672a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_50ed064e-988c-4876-a655-b9d73db29752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_77923a4c-a4bf-4cf5-bf45-7a77f5672a51" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_50ed064e-988c-4876-a655-b9d73db29752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e6adb84c-d361-44d6-a1ea-c309dc8f1abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_77923a4c-a4bf-4cf5-bf45-7a77f5672a51" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e6adb84c-d361-44d6-a1ea-c309dc8f1abc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a67f2cf1-ad8d-41ed-a9bf-612467442b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e6adb84c-d361-44d6-a1ea-c309dc8f1abc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a67f2cf1-ad8d-41ed-a9bf-612467442b56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a67f2cf1-ad8d-41ed-a9bf-612467442b56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a67f2cf1-ad8d-41ed-a9bf-612467442b56" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a67f2cf1-ad8d-41ed-a9bf-612467442b56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42f68032-7d21-4a80-b5b4-d2ffb639dd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a67f2cf1-ad8d-41ed-a9bf-612467442b56" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42f68032-7d21-4a80-b5b4-d2ffb639dd43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c4258063-e2c2-4508-b926-c69413ba2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42f68032-7d21-4a80-b5b4-d2ffb639dd43" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c4258063-e2c2-4508-b926-c69413ba2c07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f4a8cd5b-0f00-4bce-91a2-314432162345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42f68032-7d21-4a80-b5b4-d2ffb639dd43" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f4a8cd5b-0f00-4bce-91a2-314432162345" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CollaborationsDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#CollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/CollaborationsDetails" xlink:type="extended" id="i839d1fd0886a44fc866bd95c1954a9df_CollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3785ca86-c839-4855-8ada-974c3a867794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3785ca86-c839-4855-8ada-974c3a867794" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CollaborativeAreasGranted_623ee8ef-9533-4cf0-b219-fe9882a6c60a" xlink:href="rgls-20210930.xsd#rgls_CollaborativeAreasGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_CollaborativeAreasGranted_623ee8ef-9533-4cf0-b219-fe9882a6c60a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DeferredRevenueCreditableAgainstFutureMilestones_280e58d6-de78-4d7a-b62b-6005d6ffed3a" xlink:href="rgls-20210930.xsd#rgls_DeferredRevenueCreditableAgainstFutureMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_DeferredRevenueCreditableAgainstFutureMilestones_280e58d6-de78-4d7a-b62b-6005d6ffed3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_7dc2fd08-5954-4ecf-8ef4-249c8e50f20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_us-gaap_ProceedsFromCollaborators_7dc2fd08-5954-4ecf-8ef4-249c8e50f20a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable_fb789f77-58a6-4fc8-8e52-cc9641af80fd" xlink:href="rgls-20210930.xsd#rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable_fb789f77-58a6-4fc8-8e52-cc9641af80fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RoyaltyPercentageBasedOnNetSales_a31306bb-1912-401f-a2be-79f9b09a0c09" xlink:href="rgls-20210930.xsd#rgls_RoyaltyPercentageBasedOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_RoyaltyPercentageBasedOnNetSales_a31306bb-1912-401f-a2be-79f9b09a0c09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AgreementPeriod_f6740c0e-3b1b-4fa6-9ca6-3c0b1f3072c0" xlink:href="rgls-20210930.xsd#rgls_AgreementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_AgreementPeriod_f6740c0e-3b1b-4fa6-9ca6-3c0b1f3072c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_77a91574-79f2-4076-a1a8-33868c1e7b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_77a91574-79f2-4076-a1a8-33868c1e7b6c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_EnrollmentMilestone_8f97e2b3-df6b-4c0b-89a9-3f18f6f2f327" xlink:href="rgls-20210930.xsd#rgls_EnrollmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_EnrollmentMilestone_8f97e2b3-df6b-4c0b-89a9-3f18f6f2f327" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_e3c13c3e-4227-4acc-b3f8-7c7b639a0ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_e3c13c3e-4227-4acc-b3f8-7c7b639a0ccf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DevelopmentMilestoneNotAchievable_3d5ef107-2270-4ee8-92a7-6144a9f59325" xlink:href="rgls-20210930.xsd#rgls_DevelopmentMilestoneNotAchievable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_DevelopmentMilestoneNotAchievable_3d5ef107-2270-4ee8-92a7-6144a9f59325" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesAxis_b73228b0-0094-4582-ad0d-39fc78628d56" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_rgls_StrategicAlliancesAxis_b73228b0-0094-4582-ad0d-39fc78628d56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesDomain_b73228b0-0094-4582-ad0d-39fc78628d56_default" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rgls_StrategicAlliancesAxis_b73228b0-0094-4582-ad0d-39fc78628d56" xlink:to="loc_rgls_StrategicAlliancesDomain_b73228b0-0094-4582-ad0d-39fc78628d56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesDomain_fd62c498-66f0-4221-85de-b0df4fdc9efc" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rgls_StrategicAlliancesAxis_b73228b0-0094-4582-ad0d-39fc78628d56" xlink:to="loc_rgls_StrategicAlliancesDomain_fd62c498-66f0-4221-85de-b0df4fdc9efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesandCollaborationsMember_41b83425-fa2e-411a-9c4a-0e575a60d4a4" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesandCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rgls_StrategicAlliancesDomain_fd62c498-66f0-4221-85de-b0df4fdc9efc" xlink:to="loc_rgls_StrategicAlliancesandCollaborationsMember_41b83425-fa2e-411a-9c4a-0e575a60d4a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SanofiMember_23f2d0b0-8968-49d7-b7d1-f7a042f0d7e4" xlink:href="rgls-20210930.xsd#rgls_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rgls_StrategicAlliancesDomain_fd62c498-66f0-4221-85de-b0df4fdc9efc" xlink:to="loc_rgls_SanofiMember_23f2d0b0-8968-49d7-b7d1-f7a042f0d7e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ff66315e-b9c6-4cad-8cd9-e917531bea9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ff66315e-b9c6-4cad-8cd9-e917531bea9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ff66315e-b9c6-4cad-8cd9-e917531bea9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ff66315e-b9c6-4cad-8cd9-e917531bea9a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ff66315e-b9c6-4cad-8cd9-e917531bea9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ff66315e-b9c6-4cad-8cd9-e917531bea9a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ProofofConceptTrialMember_6f1f4fd5-9cf7-46ec-a916-1067c64843b5" xlink:href="rgls-20210930.xsd#rgls_ProofofConceptTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_ProofofConceptTrialMember_6f1f4fd5-9cf7-46ec-a916-1067c64843b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClinicalMember_41895dda-03e5-4fe0-b790-407d5ef8acf7" xlink:href="rgls-20210930.xsd#rgls_ClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_ClinicalMember_41895dda-03e5-4fe0-b790-407d5ef8acf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RegulatoryAndCommercializationMilestonesMember_f0c0335d-1dd5-4786-b508-cb136e097e99" xlink:href="rgls-20210930.xsd#rgls_RegulatoryAndCommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_RegulatoryAndCommercializationMilestonesMember_f0c0335d-1dd5-4786-b508-cb136e097e99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DevelopmentMilestonesMember_7aaae0af-f9b3-4ecd-a6e2-b28fdddc819a" xlink:href="rgls-20210930.xsd#rgls_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_DevelopmentMilestonesMember_7aaae0af-f9b3-4ecd-a6e2-b28fdddc819a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_EnrollmentMilestoneMember_9586277c-b715-4858-9736-5eb52ef136f3" xlink:href="rgls-20210930.xsd#rgls_EnrollmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_EnrollmentMilestoneMember_9586277c-b715-4858-9736-5eb52ef136f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_MaterialsSoldMember_cda827ef-6c68-4567-aa51-49b5726e18d9" xlink:href="rgls-20210930.xsd#rgls_MaterialsSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_MaterialsSoldMember_cda827ef-6c68-4567-aa51-49b5726e18d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AchievementOfEnrollmentMilestoneMember_3ba5b3fb-11cc-4eb4-b194-a643f258f359" xlink:href="rgls-20210930.xsd#rgls_AchievementOfEnrollmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_AchievementOfEnrollmentMilestoneMember_3ba5b3fb-11cc-4eb4-b194-a643f258f359" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_aa2d9168-281a-415e-97c1-408ef3bcd33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_aa2d9168-281a-415e-97c1-408ef3bcd33c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_aa2d9168-281a-415e-97c1-408ef3bcd33c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_aa2d9168-281a-415e-97c1-408ef3bcd33c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_aa2d9168-281a-415e-97c1-408ef3bcd33c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7fb18a2c-2484-4754-9251-6f6a3f3c7de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_aa2d9168-281a-415e-97c1-408ef3bcd33c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7fb18a2c-2484-4754-9251-6f6a3f3c7de6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DevelopmentCommercializationAndLicenseAgreementMember_b8026a9e-69fe-427f-9c7c-4a08a1989b0b" xlink:href="rgls-20210930.xsd#rgls_DevelopmentCommercializationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7fb18a2c-2484-4754-9251-6f6a3f3c7de6" xlink:to="loc_rgls_DevelopmentCommercializationAndLicenseAgreementMember_b8026a9e-69fe-427f-9c7c-4a08a1989b0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_01f30134-036b-4fe2-b53f-d391f702fbdc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_srt_RangeAxis_01f30134-036b-4fe2-b53f-d391f702fbdc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01f30134-036b-4fe2-b53f-d391f702fbdc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_01f30134-036b-4fe2-b53f-d391f702fbdc" xlink:to="loc_srt_RangeMember_01f30134-036b-4fe2-b53f-d391f702fbdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6738616-f2fa-47b9-9e97-9c1ad1eef0d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_01f30134-036b-4fe2-b53f-d391f702fbdc" xlink:to="loc_srt_RangeMember_b6738616-f2fa-47b9-9e97-9c1ad1eef0d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9711e3bb-7f24-42ce-8042-42d7f4dc551a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b6738616-f2fa-47b9-9e97-9c1ad1eef0d1" xlink:to="loc_srt_MinimumMember_9711e3bb-7f24-42ce-8042-42d7f4dc551a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bc426d9e-48ed-484b-afe1-63f898eec37f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b6738616-f2fa-47b9-9e97-9c1ad1eef0d1" xlink:to="loc_srt_MaximumMember_bc426d9e-48ed-484b-afe1-63f898eec37f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_898505bd-dc1b-4dbe-b0c0-7eb60f9db939" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_srt_StatementGeographicalAxis_898505bd-dc1b-4dbe-b0c0-7eb60f9db939" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_898505bd-dc1b-4dbe-b0c0-7eb60f9db939_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_898505bd-dc1b-4dbe-b0c0-7eb60f9db939" xlink:to="loc_srt_SegmentGeographicalDomain_898505bd-dc1b-4dbe-b0c0-7eb60f9db939_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bdeacb05-a070-42f5-99ad-ce6cb16e86ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_898505bd-dc1b-4dbe-b0c0-7eb60f9db939" xlink:to="loc_srt_SegmentGeographicalDomain_bdeacb05-a070-42f5-99ad-ce6cb16e86ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_38c0b6fa-7cd9-4d04-b478-4bb24d1b9159" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_bdeacb05-a070-42f5-99ad-ce6cb16e86ab" xlink:to="loc_country_US_38c0b6fa-7cd9-4d04-b478-4bb24d1b9159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_05298e19-f696-487f-ba08-12d8cc6c256c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_bdeacb05-a070-42f5-99ad-ce6cb16e86ab" xlink:to="loc_us-gaap_NonUsMember_05298e19-f696-487f-ba08-12d8cc6c256c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regulusrx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ic0fabfecc70c4f1ba9c6166cc7393c1a_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_01630a08-a000-442e-8192-e0b6e2c3d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_NetRentableArea_01630a08-a000-442e-8192-e0b6e2c3d4b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4c8a9a7c-00fd-427f-8b1b-1abc467ab9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4c8a9a7c-00fd-427f-8b1b-1abc467ab9ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3d29998d-86c3-47c2-be3d-b55c78cda966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3d29998d-86c3-47c2-be3d-b55c78cda966" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9d568698-d6cf-4495-9489-c0eb1d4cdc07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9d568698-d6cf-4495-9489-c0eb1d4cdc07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_InitialDirectCostLiability_a04d3f41-324c-4a02-8365-5bd7b49358bd" xlink:href="rgls-20210930.xsd#rgls_InitialDirectCostLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_InitialDirectCostLiability_a04d3f41-324c-4a02-8365-5bd7b49358bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba4ba60c-d178-4471-b2f3-96642b497e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba4ba60c-d178-4471-b2f3-96642b497e08" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DeferredCreditOperatingLeaseLiability_44db15c5-4d3a-4272-a5ae-ed238ec3ae85" xlink:href="rgls-20210930.xsd#rgls_DeferredCreditOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_DeferredCreditOperatingLeaseLiability_44db15c5-4d3a-4272-a5ae-ed238ec3ae85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RentedArea_b90dc053-f63f-4010-99aa-909fe634fe81" xlink:href="rgls-20210930.xsd#rgls_RentedArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_RentedArea_b90dc053-f63f-4010-99aa-909fe634fe81" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_90c75e20-cca0-4def-9416-903d73e80f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_90c75e20-cca0-4def-9416-903d73e80f06" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NonrefundableLeaseCostForAssignment_e0434035-ce9a-4feb-9b66-ca226da93336" xlink:href="rgls-20210930.xsd#rgls_NonrefundableLeaseCostForAssignment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_NonrefundableLeaseCostForAssignment_e0434035-ce9a-4feb-9b66-ca226da93336" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfOperatingLeaseContracts_4dfaa78d-d238-48db-9414-f94ddd79b71f" xlink:href="rgls-20210930.xsd#rgls_NumberOfOperatingLeaseContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_NumberOfOperatingLeaseContracts_4dfaa78d-d238-48db-9414-f94ddd79b71f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsLeasingAccumulatedAmortization_98fb3448-02b7-4c14-9712-8d9c542dd139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsLeasingAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_DeferredCostsLeasingAccumulatedAmortization_98fb3448-02b7-4c14-9712-8d9c542dd139" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_76550de2-4738-4e2b-97e1-bbe0b8996cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_76550de2-4738-4e2b-97e1-bbe0b8996cd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_694fca39-2bdd-40da-bc48-a951bde9aae9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_76550de2-4738-4e2b-97e1-bbe0b8996cd0" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_694fca39-2bdd-40da-bc48-a951bde9aae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_694fca39-2bdd-40da-bc48-a951bde9aae9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_694fca39-2bdd-40da-bc48-a951bde9aae9" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_694fca39-2bdd-40da-bc48-a951bde9aae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7693ba9c-6554-4170-9baf-25727973b6ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_694fca39-2bdd-40da-bc48-a951bde9aae9" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7693ba9c-6554-4170-9baf-25727973b6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PriorPremisesMember_7928efc7-0d28-4127-b596-ecb82272003b" xlink:href="rgls-20210930.xsd#rgls_PriorPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7693ba9c-6554-4170-9baf-25727973b6ea" xlink:to="loc_rgls_PriorPremisesMember_7928efc7-0d28-4127-b596-ecb82272003b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CampusPointLeaseMember_37398c46-0ead-40dc-9740-9bb753d376b1" xlink:href="rgls-20210930.xsd#rgls_CampusPointLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7693ba9c-6554-4170-9baf-25727973b6ea" xlink:to="loc_rgls_CampusPointLeaseMember_37398c46-0ead-40dc-9740-9bb753d376b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RevenueUnderCollaborationsMember_c0794582-0b74-4264-bf5a-deaa88855eda" xlink:href="rgls-20210930.xsd#rgls_RevenueUnderCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="loc_rgls_RevenueUnderCollaborationsMember_c0794582-0b74-4264-bf5a-deaa88855eda" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>rgls-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b020128b-c098-4c8f-bf82-e0af5aef1570,g:5e73ec3e-18f1-4a85-a5f0-f7e7f348b77f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_1ae5f51c-4acc-43e7-a548-f03459a287e3_terseLabel_en-US" xlink:label="lab_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Research and Development Expenses</link:label>
    <link:label id="lab_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:href="rgls-20210930.xsd#rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:to="lab_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f01ae18e-e767-4cb0-a3c2-d6938bcf5e7c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ClinicalMember_7dec8a36-9dcd-4189-adf5-225ef632f7a9_terseLabel_en-US" xlink:label="lab_rgls_ClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical</link:label>
    <link:label id="lab_rgls_ClinicalMember_label_en-US" xlink:label="lab_rgls_ClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical [Member]</link:label>
    <link:label id="lab_rgls_ClinicalMember_documentation_en-US" xlink:label="lab_rgls_ClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClinicalMember" xlink:href="rgls-20210930.xsd#rgls_ClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ClinicalMember" xlink:to="lab_rgls_ClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c339f83-ff4f-4bb1-860d-ded8138c241e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (options) or Vested (RSUs) (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_757fe85e-0984-4ad5-a745-598511143772_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_730c16a4-75ff-4452-abca-5bef2497cb54_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_157174ae-488c-4278-a8e3-839ebc8a1f6e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7b635d10-40eb-459a-bfca-1e63b7e75e54_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_bb3236f6-de02-4722-8326-7aa513141a98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_23e15734-3dbb-4940-b493-7dc66d2a4ab8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_495a7b23-1623-469b-9a87-f452e2526fb9_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7b342222-ebea-4cb7-8d64-410d05a46459_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_101800f9-2460-42a9-8cd5-5302b70f4869_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e321a50e-3ced-4aad-8347-817c2f3fb2e0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bd0733fb-90ac-487d-b57c-2cf0b0e266c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8da1bbe4-1610-4aab-820b-bbdfc512b78d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_213d83ce-53b2-4dc0-bb3e-5c82df0adb7d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3edaeb3d-1be0-41f0-8052-6d4064268a1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_eedfe887-3e94-4c79-ae0c-308d9db9a73a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited/expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_83c6ea1c-2ea3-4d25-bde4-64a0f4232b62_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a3747acc-34c6-47ef-9db6-db71fbe9337e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_TenthAmendmentMember_fa1bef8d-800c-4f5d-949a-a63b05fd103d_terseLabel_en-US" xlink:label="lab_rgls_TenthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenth Amendment</link:label>
    <link:label id="lab_rgls_TenthAmendmentMember_label_en-US" xlink:label="lab_rgls_TenthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenth Amendment [Member]</link:label>
    <link:label id="lab_rgls_TenthAmendmentMember_documentation_en-US" xlink:label="lab_rgls_TenthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenth Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_TenthAmendmentMember" xlink:href="rgls-20210930.xsd#rgls_TenthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_TenthAmendmentMember" xlink:to="lab_rgls_TenthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_998efa30-04d7-4b63-aa68-43323cb0a76c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_DeferredRevenueCreditableAgainstFutureMilestones_af8f0108-027a-4dbb-b41b-4ef8acb8bd65_terseLabel_en-US" xlink:label="lab_rgls_DeferredRevenueCreditableAgainstFutureMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue creditable against future milestones</link:label>
    <link:label id="lab_rgls_DeferredRevenueCreditableAgainstFutureMilestones_label_en-US" xlink:label="lab_rgls_DeferredRevenueCreditableAgainstFutureMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Creditable Against Future Milestones</link:label>
    <link:label id="lab_rgls_DeferredRevenueCreditableAgainstFutureMilestones_documentation_en-US" xlink:label="lab_rgls_DeferredRevenueCreditableAgainstFutureMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Creditable Against Future Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DeferredRevenueCreditableAgainstFutureMilestones" xlink:href="rgls-20210930.xsd#rgls_DeferredRevenueCreditableAgainstFutureMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_DeferredRevenueCreditableAgainstFutureMilestones" xlink:to="lab_rgls_DeferredRevenueCreditableAgainstFutureMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93a89ed6-d438-4e3a-8ce3-751730eca50b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_c3894b84-eef6-41ff-be14-05831fea0217_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowing under term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b5ff87db-bf82-4426-b0b9-98084bf9feda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c5c6cab-3c6d-4232-a4d1-3760eb2802c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cbd3cc76-ce2a-4b6c-aa75-8ce3364b2ff5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_29f065d3-38cd-480d-a76d-b75252b72ec3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_677fa90b-5cdb-4a1d-89c9-88e507c0f3ee_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ActivityOfSharesRollForward_fe1ddc77-ab13-4ace-bad2-df18d46f4276_terseLabel_en-US" xlink:label="lab_rgls_ActivityOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Shares [Roll Forward]</link:label>
    <link:label id="lab_rgls_ActivityOfSharesRollForward_label_en-US" xlink:label="lab_rgls_ActivityOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Shares [Roll Forward]</link:label>
    <link:label id="lab_rgls_ActivityOfSharesRollForward_documentation_en-US" xlink:label="lab_rgls_ActivityOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ActivityOfSharesRollForward" xlink:href="rgls-20210930.xsd#rgls_ActivityOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ActivityOfSharesRollForward" xlink:to="lab_rgls_ActivityOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_554be314-d0d5-41ba-b59a-184e46746017_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a1284c0e-3f65-46c1-9a06-e09fda73c35f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_01f68497-bbee-4b68-93a4-ffdf69dc7a38_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_c6ccb2c1-307f-43ec-b9af-97b7f9d0fcc6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b673cf8a-b654-4a41-803f-0f22572cb939_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable_3624dd77-db9e-4658-980c-9af9d9a038a0_terseLabel_en-US" xlink:label="lab_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential revenue through milestone payments</link:label>
    <link:label id="lab_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable_label_en-US" xlink:label="lab_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Receivable</link:label>
    <link:label id="lab_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable_documentation_en-US" xlink:label="lab_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" xlink:href="rgls-20210930.xsd#rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" xlink:to="lab_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53fb5975-cb83-4b54-b62f-08193d5164da_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities not included in calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_58bbe2b7-c605-44cd-918e-535d40b4f786_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment non-creditable portion recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_561ea2c0-f907-4306-b0a6-8e22d7c444dd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_6e8e76ca-5d75-4342-a4b4-6c6c7c6e84d5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_AtTheMomentMember_787b0fa0-7e1a-408a-8a34-9dd1d073d9d5_terseLabel_en-US" xlink:label="lab_rgls_AtTheMomentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Moment</link:label>
    <link:label id="lab_rgls_AtTheMomentMember_label_en-US" xlink:label="lab_rgls_AtTheMomentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Moment [Member]</link:label>
    <link:label id="lab_rgls_AtTheMomentMember_documentation_en-US" xlink:label="lab_rgls_AtTheMomentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Moment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AtTheMomentMember" xlink:href="rgls-20210930.xsd#rgls_AtTheMomentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_AtTheMomentMember" xlink:to="lab_rgls_AtTheMomentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2156f643-dd5f-4309-b45a-842b33949984_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_a52bf021-d830-45a6-afc7-2e33736421d0_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRevenueExtensibleList_d30a32cc-2392-4c11-8778-0a6320afab19_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_TypeOfRevenueExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRevenueExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRevenueExtensibleList" xlink:to="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99eb18b0-bf5b-4659-9185-fe59b247b88a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0062ff55-79be-429c-a144-8b5a48962a66_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_RoyaltyPercentageBasedOnNetSales_7a558d70-e3a1-410e-afe3-7f8723e5e337_terseLabel_en-US" xlink:label="lab_rgls_RoyaltyPercentageBasedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties based on percentage of net sales</link:label>
    <link:label id="lab_rgls_RoyaltyPercentageBasedOnNetSales_label_en-US" xlink:label="lab_rgls_RoyaltyPercentageBasedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage Based On Net Sales</link:label>
    <link:label id="lab_rgls_RoyaltyPercentageBasedOnNetSales_documentation_en-US" xlink:label="lab_rgls_RoyaltyPercentageBasedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage Based On Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RoyaltyPercentageBasedOnNetSales" xlink:href="rgls-20210930.xsd#rgls_RoyaltyPercentageBasedOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_RoyaltyPercentageBasedOnNetSales" xlink:to="lab_rgls_RoyaltyPercentageBasedOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_608fb3e5-097c-409f-8a34-239efac5a219_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_cf4d2576-738b-4c8b-8acb-4dfce54337d8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ClassA3ConvertiblePreferredStockMember_7ebf6279-ccd6-4033-989e-32cf1d853bb3_terseLabel_en-US" xlink:label="lab_rgls_ClassA3ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-3 Convertible Preferred Stock</link:label>
    <link:label id="lab_rgls_ClassA3ConvertiblePreferredStockMember_ca4c96a7-53cc-44f4-8d79-a3561b820d14_verboseLabel_en-US" xlink:label="lab_rgls_ClassA3ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-3 convertible preferred stock outstanding (as-converted)</link:label>
    <link:label id="lab_rgls_ClassA3ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_rgls_ClassA3ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-3 Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_rgls_ClassA3ConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_rgls_ClassA3ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-3 Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA3ConvertiblePreferredStockMember" xlink:href="rgls-20210930.xsd#rgls_ClassA3ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ClassA3ConvertiblePreferredStockMember" xlink:to="lab_rgls_ClassA3ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_CertainDirectorsandExecutiveOfficersMember_9b390fc3-f6fd-4d7b-96fd-9070a05f15e7_terseLabel_en-US" xlink:label="lab_rgls_CertainDirectorsandExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Directors and Executive Officers</link:label>
    <link:label id="lab_rgls_CertainDirectorsandExecutiveOfficersMember_label_en-US" xlink:label="lab_rgls_CertainDirectorsandExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Directors and Executive Officers [Member]</link:label>
    <link:label id="lab_rgls_CertainDirectorsandExecutiveOfficersMember_documentation_en-US" xlink:label="lab_rgls_CertainDirectorsandExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Directors and Executive Officers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CertainDirectorsandExecutiveOfficersMember" xlink:href="rgls-20210930.xsd#rgls_CertainDirectorsandExecutiveOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_CertainDirectorsandExecutiveOfficersMember" xlink:to="lab_rgls_CertainDirectorsandExecutiveOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e25a0d7a-9ba6-4922-80af-fe3d49a39494_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_e9f57771-5197-4bab-af9b-c9aaef461bf9_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents (money market funds)</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_84cbcba4-b5fa-443d-a488-63052e0ba5cc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of right to purchase common shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_246c6765-e11a-4250-8c12-c2e8de5ff864_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_InitialDirectCostLiability_63235d28-2740-4efb-a64f-fbd4677e8975_terseLabel_en-US" xlink:label="lab_rgls_InitialDirectCostLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial direct cost liability</link:label>
    <link:label id="lab_rgls_InitialDirectCostLiability_label_en-US" xlink:label="lab_rgls_InitialDirectCostLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Direct Cost Liability</link:label>
    <link:label id="lab_rgls_InitialDirectCostLiability_documentation_en-US" xlink:label="lab_rgls_InitialDirectCostLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Direct Cost Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_InitialDirectCostLiability" xlink:href="rgls-20210930.xsd#rgls_InitialDirectCostLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_InitialDirectCostLiability" xlink:to="lab_rgls_InitialDirectCostLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29df142e-68a4-425c-9893-f69dd71f0432_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_551aeb0a-417b-4d62-af7a-74f1e74bd15e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning outstanding number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3690f602-bd22-42ca-9c5e-72f5cd1bc89d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending outstanding number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ee088aee-21d6-424e-affb-8d44610cc27a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c1251aa1-dfe8-4b6f-a44c-1d57b534e194_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d1c44eef-da2d-4a67-b7cc-16b693444443_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_0b9a2d24-b0fd-4fd6-8767-c1758fffaf66_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_87990c14-5f76-4d18-888a-0f1d64a34d8f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversions of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_384d6361-4d5d-46b5-bb43-77f2e08e2cb7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial upfront option payment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_StrategicAlliancesandCollaborationsMember_99003ff5-fc9b-4ed3-b39c-1a172f4a73aa_terseLabel_en-US" xlink:label="lab_rgls_StrategicAlliancesandCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborations</link:label>
    <link:label id="lab_rgls_StrategicAlliancesandCollaborationsMember_label_en-US" xlink:label="lab_rgls_StrategicAlliancesandCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances and Collaborations [Member]</link:label>
    <link:label id="lab_rgls_StrategicAlliancesandCollaborationsMember_documentation_en-US" xlink:label="lab_rgls_StrategicAlliancesandCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances and Collaborations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesandCollaborationsMember" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesandCollaborationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_StrategicAlliancesandCollaborationsMember" xlink:to="lab_rgls_StrategicAlliancesandCollaborationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_NumberOfPrepaymentsToLender_17f770ed-e022-4d21-b007-80c2ead040e9_terseLabel_en-US" xlink:label="lab_rgls_NumberOfPrepaymentsToLender" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of prepayments to lender</link:label>
    <link:label id="lab_rgls_NumberOfPrepaymentsToLender_label_en-US" xlink:label="lab_rgls_NumberOfPrepaymentsToLender" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Prepayments To Lender</link:label>
    <link:label id="lab_rgls_NumberOfPrepaymentsToLender_documentation_en-US" xlink:label="lab_rgls_NumberOfPrepaymentsToLender" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Prepayments To Lender</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfPrepaymentsToLender" xlink:href="rgls-20210930.xsd#rgls_NumberOfPrepaymentsToLender"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_NumberOfPrepaymentsToLender" xlink:to="lab_rgls_NumberOfPrepaymentsToLender" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8bf434a2-f379-477d-9cf6-6b1e4d6ac818_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4f5cf0ac-5e91-436e-b840-a2d2291865a5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e9c50518-ce01-4601-95ac-75dbd3fc802b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_36432a0f-ac7b-4158-a1b2-829e506608b9_terseLabel_en-US" xlink:label="lab_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Shares Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:href="rgls-20210930.xsd#rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:to="lab_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_699c348d-7c65-4e24-a540-f56dbd19f5bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_A2019PlanMember_8dcfd5bb-7216-4787-8460-62e581900d60_terseLabel_en-US" xlink:label="lab_rgls_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_rgls_A2019PlanMember_label_en-US" xlink:label="lab_rgls_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan [Member]</link:label>
    <link:label id="lab_rgls_A2019PlanMember_documentation_en-US" xlink:label="lab_rgls_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_A2019PlanMember" xlink:href="rgls-20210930.xsd#rgls_A2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_A2019PlanMember" xlink:to="lab_rgls_A2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_656ef610-86c9-4f5c-af1b-e9d431ab4495_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5bd94c7e-11ba-497d-8a38-ff9c4be4609f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_342ece07-349c-4e6d-b2e8-ca5e5d27325d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ad23f841-59df-43ad-831d-9b3744009b70_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants_5f4ba538-53cc-4157-830d-4775fe7914b9_terseLabel_en-US" xlink:label="lab_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants_label_en-US" xlink:label="lab_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Exercise of Warrants</link:label>
    <link:label id="lab_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants_documentation_en-US" xlink:label="lab_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Exercise of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:href="rgls-20210930.xsd#rgls_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="lab_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_7912c597-bd58-496d-84b6-be5b7e0850ec_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid materials, net</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_07bf16e3-8e6b-40a8-843d-9a2eff928b7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_CollaborativeAreasGranted_d47fa1ba-015b-4616-80f6-981acbed6910_terseLabel_en-US" xlink:label="lab_rgls_CollaborativeAreasGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of collaborative areas granted</link:label>
    <link:label id="lab_rgls_CollaborativeAreasGranted_label_en-US" xlink:label="lab_rgls_CollaborativeAreasGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Areas Granted</link:label>
    <link:label id="lab_rgls_CollaborativeAreasGranted_documentation_en-US" xlink:label="lab_rgls_CollaborativeAreasGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Areas Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CollaborativeAreasGranted" xlink:href="rgls-20210930.xsd#rgls_CollaborativeAreasGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_CollaborativeAreasGranted" xlink:to="lab_rgls_CollaborativeAreasGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f7575e56-e065-4da8-932d-940edbbe8948_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_94b07814-e65f-4bed-89f1-bde8a73f5ed6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract and other receivables</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_PrepaymentRequirement_ea103576-df94-4b64-bd70-b084a6273e7c_terseLabel_en-US" xlink:label="lab_rgls_PrepaymentRequirement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment requirement</link:label>
    <link:label id="lab_rgls_PrepaymentRequirement_label_en-US" xlink:label="lab_rgls_PrepaymentRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Requirement</link:label>
    <link:label id="lab_rgls_PrepaymentRequirement_documentation_en-US" xlink:label="lab_rgls_PrepaymentRequirement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Requirement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PrepaymentRequirement" xlink:href="rgls-20210930.xsd#rgls_PrepaymentRequirement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_PrepaymentRequirement" xlink:to="lab_rgls_PrepaymentRequirement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_e8fb9a5b-aec9-44f7-a40f-fcbb4d9985d3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_10523b40-a80d-4980-abd4-4d776a77c663_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c0461b7b-4c6c-4e47-90b8-ee238e76c50d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_39347a59-f101-44c0-8688-4aee9e68161b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_32e42d21-837c-4250-9317-0422fa2117aa_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_CampusPointLeaseMember_baee0f36-1ea5-47a9-b4c3-f3431df283d4_terseLabel_en-US" xlink:label="lab_rgls_CampusPointLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Campus Point Lease</link:label>
    <link:label id="lab_rgls_CampusPointLeaseMember_label_en-US" xlink:label="lab_rgls_CampusPointLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Campus Point Lease [Member]</link:label>
    <link:label id="lab_rgls_CampusPointLeaseMember_documentation_en-US" xlink:label="lab_rgls_CampusPointLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Campus Point Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CampusPointLeaseMember" xlink:href="rgls-20210930.xsd#rgls_CampusPointLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_CampusPointLeaseMember" xlink:to="lab_rgls_CampusPointLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5d638518-b89e-4a6d-8107-4b56a616334e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f4ab0489-64c1-434c-8549-82dd56288f4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_95c752bc-05da-4065-aa4e-bf9be67ce805_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cd653f9e-1665-482b-89b6-07bf90a6c603_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_A2020PIPEWarrantsMember_27881611-79b6-47c6-9beb-9774e103a883_terseLabel_en-US" xlink:label="lab_rgls_A2020PIPEWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 PIPE warrants</link:label>
    <link:label id="lab_rgls_A2020PIPEWarrantsMember_label_en-US" xlink:label="lab_rgls_A2020PIPEWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 PIPE Warrants [Member]</link:label>
    <link:label id="lab_rgls_A2020PIPEWarrantsMember_documentation_en-US" xlink:label="lab_rgls_A2020PIPEWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 PIPE Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_A2020PIPEWarrantsMember" xlink:href="rgls-20210930.xsd#rgls_A2020PIPEWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_A2020PIPEWarrantsMember" xlink:to="lab_rgls_A2020PIPEWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d328a5e-125f-477f-abe2-83c15bad56ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_StrategicAlliancesDomain_bd872133-5752-4af0-9939-48907a194bf2_terseLabel_en-US" xlink:label="lab_rgls_StrategicAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Domain]</link:label>
    <link:label id="lab_rgls_StrategicAlliancesDomain_label_en-US" xlink:label="lab_rgls_StrategicAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Domain]</link:label>
    <link:label id="lab_rgls_StrategicAlliancesDomain_documentation_en-US" xlink:label="lab_rgls_StrategicAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesDomain" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_StrategicAlliancesDomain" xlink:to="lab_rgls_StrategicAlliancesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ClassAThreeConvertiblePreferredStockMember_8e0ecf12-0619-4ae5-bb70-6082d91d78c8_terseLabel_en-US" xlink:label="lab_rgls_ClassAThreeConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-3 Convertible Preferred Stock</link:label>
    <link:label id="lab_rgls_ClassAThreeConvertiblePreferredStockMember_label_en-US" xlink:label="lab_rgls_ClassAThreeConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Three Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_rgls_ClassAThreeConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_rgls_ClassAThreeConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Three Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassAThreeConvertiblePreferredStockMember" xlink:href="rgls-20210930.xsd#rgls_ClassAThreeConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ClassAThreeConvertiblePreferredStockMember" xlink:to="lab_rgls_ClassAThreeConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_08ba2fff-7065-4424-a739-35db0ff8581a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4a1eb085-1351-4c0e-b12e-73ae1eaa759d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts and other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_82ff6ccf-b436-4b8a-94fb-4c07f76b6d6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (options) or Vested (RSUs) (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_287fcab8-b4f6-4535-b125-08bf8b662bc7_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_ae724517-1f35-40f2-878e-faa0fb9cdf19_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_a2ebe16d-dd22-4eff-8de6-83dc49ddbf9a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3f4bdf43-dd34-45df-a450-3624ed94110d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_801403a8-e349-4a4d-a127-8a08690612de_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_MaterialsSoldMember_5f607bd8-ca04-4608-8ba2-c4b07e9a5398_terseLabel_en-US" xlink:label="lab_rgls_MaterialsSoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materials Sold</link:label>
    <link:label id="lab_rgls_MaterialsSoldMember_label_en-US" xlink:label="lab_rgls_MaterialsSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materials Sold [Member]</link:label>
    <link:label id="lab_rgls_MaterialsSoldMember_documentation_en-US" xlink:label="lab_rgls_MaterialsSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materials Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_MaterialsSoldMember" xlink:href="rgls-20210930.xsd#rgls_MaterialsSoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_MaterialsSoldMember" xlink:to="lab_rgls_MaterialsSoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_6aaa5300-9301-4733-8a36-9b63a47cc362_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3e709d74-08a5-4136-a7c2-1aa1e8ebf15c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4dce1157-c35d-4fff-b75c-ffbf2175332d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_d722b757-972d-441c-94f4-f086c3f72345_terseLabel_en-US" xlink:label="lab_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_label_en-US" xlink:label="lab_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Three</link:label>
    <link:label id="lab_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_documentation_en-US" xlink:label="lab_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:href="rgls-20210930.xsd#rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:to="lab_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_f11f6964-8660-402d-b6ef-0f9525cad734_terseLabel_en-US" xlink:label="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Table]</link:label>
    <link:label id="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_label_en-US" xlink:label="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Table]</link:label>
    <link:label id="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_documentation_en-US" xlink:label="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:href="rgls-20210930.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:to="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c9ca9599-0758-4288-a5fd-cb6bbdfb6090_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_74ed2633-02d8-4cef-a478-3a17d7878eb3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_73e80d7d-c6a8-4aa9-bff7-8985c3392d1e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_932658c6-4a5f-4706-932b-4edb6799bcc3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6914e05a-2d0e-450a-9ebc-f0fdb4331432_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_d414b25a-640a-4aca-9621-73868e9fd4dd_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net rentable area</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_abd8a67e-f90b-4acc-9c0a-5aafbfe2ab89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited/expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_3673c673-cc1b-478f-9f26-f81e478a4b2f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6bbf5a3f-cbb0-41bf-b947-6b10f9f096e3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_fe306283-aded-4a51-b7d0-d8c810a13f4f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0156d824-93f0-425b-8485-63c1cd9a9d34_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_PaycheckProtectionProgramLoanForgiveness_0da5b2cf-b296-4d4e-befe-96f754b787a7_terseLabel_en-US" xlink:label="lab_rgls_PaycheckProtectionProgramLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program loan forgiveness</link:label>
    <link:label id="lab_rgls_PaycheckProtectionProgramLoanForgiveness_label_en-US" xlink:label="lab_rgls_PaycheckProtectionProgramLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program Loan Forgiveness</link:label>
    <link:label id="lab_rgls_PaycheckProtectionProgramLoanForgiveness_documentation_en-US" xlink:label="lab_rgls_PaycheckProtectionProgramLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program Loan Forgiveness</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PaycheckProtectionProgramLoanForgiveness" xlink:href="rgls-20210930.xsd#rgls_PaycheckProtectionProgramLoanForgiveness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_PaycheckProtectionProgramLoanForgiveness" xlink:to="lab_rgls_PaycheckProtectionProgramLoanForgiveness" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_CommissionFeeRate_2fd19700-abfe-48a9-ae77-97b46d437130_terseLabel_en-US" xlink:label="lab_rgls_CommissionFeeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fee rate</link:label>
    <link:label id="lab_rgls_CommissionFeeRate_label_en-US" xlink:label="lab_rgls_CommissionFeeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Fee Rate</link:label>
    <link:label id="lab_rgls_CommissionFeeRate_documentation_en-US" xlink:label="lab_rgls_CommissionFeeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Fee Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CommissionFeeRate" xlink:href="rgls-20210930.xsd#rgls_CommissionFeeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_CommissionFeeRate" xlink:to="lab_rgls_CommissionFeeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ef2de334-7da1-4187-8f83-8161fc8fc104_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3742d797-9095-4188-830a-133ce6e3c712_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock through ATM</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_1ae0d58b-9ce4-4cb8-9a6b-03973f9f6657_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_ff501b07-bf2b-4ea0-972b-c0913ed16815_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_697982bf-2e35-4bab-a63b-1685f8864206_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_708ecb51-90ec-4ad1-800b-8b9c83cc3fb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9a72daa3-e080-418d-b198-0b4e117cc873_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f742a0d-f852-48c4-8b12-d84c11a87512_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock through ATM (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0d994e1b-5ba7-4466-afdf-e1662867b03d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of obligations under leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e13ff768-72ff-440b-8a7d-584b68de9aaf_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000,000 shares and 200,000,000 authorized at September 30, 2021 and December 31, 2020, respectively; 87,047,832 and 67,432,712 shares issued and outstanding at September 30, 2021 (unaudited) and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_98474cb4-8ea6-436a-aa73-7efcf318dba3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_695c50ce-411e-4067-8c85-bfc9ce93a83e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b909ce57-e7f4-4115-bddf-34405579bf6d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_4207c771-1505-4636-9adc-03832b0c4507_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b2b386d8-927c-4cb7-9670-a3a8702ca49b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a49a0275-6c9c-4dc7-a882-872317474ad6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_338d4a7f-84aa-4cc0-b6ea-2716e0f04e15_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining liability to be paid</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3576c2d8-edf2-4c96-8465-78041dce43dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_DebtFinancingAgreementTrancheAMember_72e8b1ed-7daf-4caf-946c-16af4f1c3d02_terseLabel_en-US" xlink:label="lab_rgls_DebtFinancingAgreementTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing Agreement Tranche A</link:label>
    <link:label id="lab_rgls_DebtFinancingAgreementTrancheAMember_label_en-US" xlink:label="lab_rgls_DebtFinancingAgreementTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing Agreement Tranche A [Member]</link:label>
    <link:label id="lab_rgls_DebtFinancingAgreementTrancheAMember_documentation_en-US" xlink:label="lab_rgls_DebtFinancingAgreementTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing Agreement Tranche A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DebtFinancingAgreementTrancheAMember" xlink:href="rgls-20210930.xsd#rgls_DebtFinancingAgreementTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_DebtFinancingAgreementTrancheAMember" xlink:to="lab_rgls_DebtFinancingAgreementTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c32883a1-7336-40ce-b335-cb7933657658_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_93ada546-822f-4790-bb79-ced4fe81b9bb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b55e6d74-b9cc-4237-affd-c839fc21ab91_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_PriorPremisesMember_38760ab3-43b2-4d2b-8cfb-4a151472f623_terseLabel_en-US" xlink:label="lab_rgls_PriorPremisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Premises</link:label>
    <link:label id="lab_rgls_PriorPremisesMember_label_en-US" xlink:label="lab_rgls_PriorPremisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Premises [Member]</link:label>
    <link:label id="lab_rgls_PriorPremisesMember_documentation_en-US" xlink:label="lab_rgls_PriorPremisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Premises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PriorPremisesMember" xlink:href="rgls-20210930.xsd#rgls_PriorPremisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_PriorPremisesMember" xlink:to="lab_rgls_PriorPremisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_c4d45e59-da35-4dd8-b4a7-03f2e01b9ba9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_37f2f785-370a-4b84-875a-cef615430cb2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_fc01813d-db57-47db-a95c-2146411e6544_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_9163da73-67c1-41b0-ae8c-5419b65e8831_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_224a69eb-ec2d-45a8-aff2-5982db90e39f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_f1b2c141-e24b-4712-8c54-8df9e370c977_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_249bb1e3-61dc-4fe6-9f0d-79096b8163a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amount representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7f414803-79bc-4bfd-98d1-da7df8c8c2bb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4e9e3123-2e36-4c2e-a5ac-cf30e4fc7cc1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_NumberofMonthlyPayments_2ab42bbe-c251-4088-979a-9e85603ddcda_terseLabel_en-US" xlink:label="lab_rgls_NumberofMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly payments</link:label>
    <link:label id="lab_rgls_NumberofMonthlyPayments_label_en-US" xlink:label="lab_rgls_NumberofMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Monthly Payments</link:label>
    <link:label id="lab_rgls_NumberofMonthlyPayments_documentation_en-US" xlink:label="lab_rgls_NumberofMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Monthly Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberofMonthlyPayments" xlink:href="rgls-20210930.xsd#rgls_NumberofMonthlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_NumberofMonthlyPayments" xlink:to="lab_rgls_NumberofMonthlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_PaymentFee_25fc6a9c-9b34-4be9-90ed-c8d439d815e2_terseLabel_en-US" xlink:label="lab_rgls_PaymentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment fee</link:label>
    <link:label id="lab_rgls_PaymentFee_label_en-US" xlink:label="lab_rgls_PaymentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Fee</link:label>
    <link:label id="lab_rgls_PaymentFee_documentation_en-US" xlink:label="lab_rgls_PaymentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PaymentFee" xlink:href="rgls-20210930.xsd#rgls_PaymentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_PaymentFee" xlink:to="lab_rgls_PaymentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ed306343-9c26-4016-893b-05176e4e328f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_933d35f4-a413-4090-999d-e9f20a032196_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c60fe916-e00c-4804-b02f-c5c93aacc0b3_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues (less than in 2020)</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_56c51fc3-b552-4f4f-b36a-afefc4840bb0_terseLabel_en-US" xlink:label="lab_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-1 Convertible Preferred Stock</link:label>
    <link:label id="lab_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_cdd55037-3396-4c56-97e9-6121cb31997a_verboseLabel_en-US" xlink:label="lab_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-1 convertible preferred stock outstanding (as-converted)</link:label>
    <link:label id="lab_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_label_en-US" xlink:label="lab_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-1 Convertible Preferred Stock (As-Converted) [Member]</link:label>
    <link:label id="lab_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_documentation_en-US" xlink:label="lab_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-1 Convertible Preferred Stock (As-Converted) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember" xlink:href="rgls-20210930.xsd#rgls_ClassA1ConvertiblePreferredStockAsConvertedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember" xlink:to="lab_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_AccruedResearchAndDevelopmentCurrent_3d28e7a0-126d-480a-bb2a-f7f858b91614_terseLabel_en-US" xlink:label="lab_rgls_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_rgls_AccruedResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_rgls_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development, Current</link:label>
    <link:label id="lab_rgls_AccruedResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_rgls_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AccruedResearchAndDevelopmentCurrent" xlink:href="rgls-20210930.xsd#rgls_AccruedResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_rgls_AccruedResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e7cf2fcc-58a8-4c8e-a5a4-114488a5cf35_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0f62fc19-d735-4571-8cc7-7dafb9dab3ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid materials</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_886dea41-3985-4ff1-989d-a999349370fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f96f989f-ce07-4ed2-804b-44e78c0375dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ClassATwoConvertiblePreferredStockMember_15fdb96c-5125-4efd-aaf3-42b950c3cf38_terseLabel_en-US" xlink:label="lab_rgls_ClassATwoConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-2 Convertible Preferred Stock</link:label>
    <link:label id="lab_rgls_ClassATwoConvertiblePreferredStockMember_label_en-US" xlink:label="lab_rgls_ClassATwoConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Two Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_rgls_ClassATwoConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_rgls_ClassATwoConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Two Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassATwoConvertiblePreferredStockMember" xlink:href="rgls-20210930.xsd#rgls_ClassATwoConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ClassATwoConvertiblePreferredStockMember" xlink:to="lab_rgls_ClassATwoConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_677f2452-c551-4acd-8beb-9dfe9863281f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4af31483-07f8-4caf-98eb-fe335913ab66_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4620a6e6-172f-418b-a7af-b8a53319961f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_0429786a-9371-4275-b796-1322afaa25b7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_937be52f-94ea-40d4-b853-8fa99f4ff351_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ae609d27-29f0-408a-95ef-a3654194a3fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_8094ec36-edce-4aee-888b-7dd1a0046dfe_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7fd5d7fa-188d-4f18-b469-a81167f44fcc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12a13fae-dc0c-4caa-ad11-86542b1a2b3f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_da5714fd-94e4-45a2-87e2-55db50f43982_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5c5ca51b-d4cd-4d45-a79a-5ed76581abed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32ce0204-e4fb-4bf2-adc3-a51e01949c24_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_DebtFinancingAgreementMember_f5715771-dd31-4cfd-bd67-7d1c17673135_terseLabel_en-US" xlink:label="lab_rgls_DebtFinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing Agreement</link:label>
    <link:label id="lab_rgls_DebtFinancingAgreementMember_label_en-US" xlink:label="lab_rgls_DebtFinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing Agreement [Member]</link:label>
    <link:label id="lab_rgls_DebtFinancingAgreementMember_documentation_en-US" xlink:label="lab_rgls_DebtFinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DebtFinancingAgreementMember" xlink:href="rgls-20210930.xsd#rgls_DebtFinancingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_DebtFinancingAgreementMember" xlink:to="lab_rgls_DebtFinancingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c64f9e9e-e855-4b1f-992d-ffa96bd019d4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants callable (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e09e16c0-7227-4cb6-9609-de8c04956a11_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e4cf7a36-f95a-4031-8a6e-f93b09bda84e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_2e57d755-11c0-4902-b47b-96c2d20c38bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_263bdbc0-9a3e-4e97-ba44-312c1be6fc53_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d96183c1-4ae9-4c75-b6ed-2d89328471fe_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5a4eb2a0-5df0-4bea-80fa-95b24c97292a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss_f1ea7910-e994-47ff-9da4-295d6e8bbcd0_terseLabel_en-US" xlink:label="lab_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss_label_en-US" xlink:label="lab_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right of Use and Lease Liabilities, Net, Gain (Loss)</link:label>
    <link:label id="lab_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss_documentation_en-US" xlink:label="lab_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right of Use and Lease Liabilities, Net, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" xlink:href="rgls-20210930.xsd#rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" xlink:to="lab_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease_d4f06e75-f2bf-42bb-844e-174fd3824a8d_terseLabel_en-US" xlink:label="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of years for increase of authorized shares</link:label>
    <link:label id="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease_label_en-US" xlink:label="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Period for Yearly Increase</link:label>
    <link:label id="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease_documentation_en-US" xlink:label="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Period for Yearly Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease" xlink:href="rgls-20210930.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease" xlink:to="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ProofofConceptTrialMember_39a51deb-f55c-4281-9f34-d3883732934e_terseLabel_en-US" xlink:label="lab_rgls_ProofofConceptTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proof-of-Concept Trial</link:label>
    <link:label id="lab_rgls_ProofofConceptTrialMember_label_en-US" xlink:label="lab_rgls_ProofofConceptTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proofof Concept Trial [Member]</link:label>
    <link:label id="lab_rgls_ProofofConceptTrialMember_documentation_en-US" xlink:label="lab_rgls_ProofofConceptTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proof-of-Concept Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ProofofConceptTrialMember" xlink:href="rgls-20210930.xsd#rgls_ProofofConceptTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ProofofConceptTrialMember" xlink:to="lab_rgls_ProofofConceptTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_611294b6-cdf0-4063-928e-4cea711d7017_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fffb3936-6f52-4fc4-996d-473284b28dc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f7cddce4-7ae0-4ace-8368-a0151185daa1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e446da68-dc64-4b13-bf82-dd9aae8183d1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b3a558c7-c2a1-453e-b090-e33cbcf92cbd_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_85a10142-6117-44d0-9d68-39da155cc612_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e35e2f18-fbf0-49d0-ba2f-b2743eff282d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9934624d-7b2a-4f98-9e8d-f9362791d187_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a03b1c68-19d2-4a20-be77-1591fe3af60d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_b05ba756-5af4-455c-9e82-570de03843da_terseLabel_en-US" xlink:label="lab_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-2 Convertible Preferred Stock</link:label>
    <link:label id="lab_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_7215fdb4-229f-4865-9013-8e992230276b_verboseLabel_en-US" xlink:label="lab_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-2 convertible preferred stock outstanding (as-converted)</link:label>
    <link:label id="lab_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_label_en-US" xlink:label="lab_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-2 Convertible Preferred Stock (As-Converted) [Member]</link:label>
    <link:label id="lab_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_documentation_en-US" xlink:label="lab_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-2 Convertible Preferred Stock (As-Converted) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember" xlink:href="rgls-20210930.xsd#rgls_ClassA2ConvertiblePreferredStockAsConvertedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember" xlink:to="lab_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_725a7799-97dd-4db2-af7e-ebe33887ae30_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_DeferredCreditOperatingLeaseLiability_834bff2e-5d84-4aa0-b4d0-7ecaa1e35049_terseLabel_en-US" xlink:label="lab_rgls_DeferredCreditOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred credit, operating lease liabilities</link:label>
    <link:label id="lab_rgls_DeferredCreditOperatingLeaseLiability_label_en-US" xlink:label="lab_rgls_DeferredCreditOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credit, Operating Lease Liability</link:label>
    <link:label id="lab_rgls_DeferredCreditOperatingLeaseLiability_documentation_en-US" xlink:label="lab_rgls_DeferredCreditOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credit, Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DeferredCreditOperatingLeaseLiability" xlink:href="rgls-20210930.xsd#rgls_DeferredCreditOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_DeferredCreditOperatingLeaseLiability" xlink:to="lab_rgls_DeferredCreditOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a168b99b-8577-4dd4-b2f6-3aef102f34f6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6f1b375f-5d2e-4793-966e-0f993240b37c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a9b1afff-b9f1-417c-85f7-7a171031bcf6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_197a7431-38c4-4c87-969e-ed2fb2374188_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d425c4f1-774d-4250-b2c0-efedb1f97f39_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_74355448-2997-4915-80ef-59bbccb41056_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_38f83c0b-d3c6-4a02-9924-0998b27dfcc1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument effective rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_AgreementPeriod_e28518b0-6743-4852-ade6-61f31ac4c029_terseLabel_en-US" xlink:label="lab_rgls_AgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement period</link:label>
    <link:label id="lab_rgls_AgreementPeriod_label_en-US" xlink:label="lab_rgls_AgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Period</link:label>
    <link:label id="lab_rgls_AgreementPeriod_documentation_en-US" xlink:label="lab_rgls_AgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AgreementPeriod" xlink:href="rgls-20210930.xsd#rgls_AgreementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_AgreementPeriod" xlink:to="lab_rgls_AgreementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e70d827d-3901-4d66-a6d8-cc4caef4ae00_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3b583877-06f7-43b0-ac0d-3377d69988cc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_320f14e3-9687-45e2-81ee-03406412f6ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_50c95242-a316-4da8-8956-ce0ebec40f46_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_313276c0-8486-4913-b233-b40bc16f00bf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7bd45e43-b758-4a3f-b3a5-e1de10af196a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b2b9e488-8acf-48f7-be19-b383a574276e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_PrepaidExpensesPolicyTextBlock_b214492f-3bc5-4421-8538-95701ba5b1ea_terseLabel_en-US" xlink:label="lab_rgls_PrepaidExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Materials</link:label>
    <link:label id="lab_rgls_PrepaidExpensesPolicyTextBlock_label_en-US" xlink:label="lab_rgls_PrepaidExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses [Policy Text Block]</link:label>
    <link:label id="lab_rgls_PrepaidExpensesPolicyTextBlock_documentation_en-US" xlink:label="lab_rgls_PrepaidExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PrepaidExpensesPolicyTextBlock" xlink:href="rgls-20210930.xsd#rgls_PrepaidExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_PrepaidExpensesPolicyTextBlock" xlink:to="lab_rgls_PrepaidExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_368dccb2-b35b-4019-8f0b-ec96437e66b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredClassAMember_af75f709-400d-421d-995e-280ad7821a19_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Class A</link:label>
    <link:label id="lab_us-gaap_PreferredClassAMember_label_en-US" xlink:label="lab_us-gaap_PreferredClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredClassAMember" xlink:to="lab_us-gaap_PreferredClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3a101af3-45d9-4db7-a8ea-0ae1297e575a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d838c056-f527-4aad-bd39-263d97d2f558_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d331bbc9-2ab8-472c-9bbf-7d7cf71541c3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_aa2c03b5-584c-4e7c-b6b4-16c4bb9830f0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsLeasingAccumulatedAmortization_75fff3cb-ed94-4c57-aaa0-da5eb743caaf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsLeasingAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred cost of liability</link:label>
    <link:label id="lab_us-gaap_DeferredCostsLeasingAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_DeferredCostsLeasingAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Leasing, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsLeasingAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsLeasingAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsLeasingAccumulatedAmortization" xlink:to="lab_us-gaap_DeferredCostsLeasingAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3f857683-46f4-4d17-b7bb-538efb45765a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_DevelopmentCommercializationAndLicenseAgreementMember_5f1ce55a-b6ef-4a3d-8e3e-5c92145054f3_terseLabel_en-US" xlink:label="lab_rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Commercialization And License Agreement</link:label>
    <link:label id="lab_rgls_DevelopmentCommercializationAndLicenseAgreementMember_label_en-US" xlink:label="lab_rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Commercialization And License Agreement [Member]</link:label>
    <link:label id="lab_rgls_DevelopmentCommercializationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Commercialization And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:href="rgls-20210930.xsd#rgls_DevelopmentCommercializationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:to="lab_rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0b440375-ce18-4b6c-8fd3-8a8363eb5fc2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a26838f6-b91a-41a7-8fc3-023e6d3107f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_49b6c2a3-c4cf-4ebd-af40-66674f3cf132_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_8fa86dba-e22b-4709-b9d1-a15b448017a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_69dfe385-ea90-45e7-bd01-2f43953cdd8e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4095d2e5-1397-45e7-9863-2bda84e58559_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6687be0-ecb3-479f-a1ac-8d7c884f338f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1c78ecd9-ee64-48a1-b0a3-d3c17a240042_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be5b767a-0011-4b03-b40c-78b13edad41d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ed5b11de-687c-44c5-aad3-eb88d2a4b9c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_732e3892-e805-4df2-9e1b-1296f19617ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_664ecea0-18c6-45b8-bf15-2066d3c88ab2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_be4d285c-9be6-4e0c-97e4-001083f8f497_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2107346a-db91-4dea-83c9-e7096c7dea74_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_MilestoneClosingMember_f94c3bf8-b81c-4d2a-9eb5-ece9234099b7_terseLabel_en-US" xlink:label="lab_rgls_MilestoneClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Closing</link:label>
    <link:label id="lab_rgls_MilestoneClosingMember_label_en-US" xlink:label="lab_rgls_MilestoneClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Closing [Member]</link:label>
    <link:label id="lab_rgls_MilestoneClosingMember_documentation_en-US" xlink:label="lab_rgls_MilestoneClosingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_MilestoneClosingMember" xlink:href="rgls-20210930.xsd#rgls_MilestoneClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_MilestoneClosingMember" xlink:to="lab_rgls_MilestoneClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_21ddd034-b39b-4348-acf1-d2f430410888_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_13b41193-87ba-42d2-8db4-8916e736d990_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_965785e1-a46f-42a4-903e-a0ae24fdf818_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_db0777c5-9792-4d4b-9376-a52c6c698ebb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_AdditionalExtensionForInterestOnlyPayments_b9190d0e-890c-4731-94ac-85460c3539e5_terseLabel_en-US" xlink:label="lab_rgls_AdditionalExtensionForInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional extension for interest only payments</link:label>
    <link:label id="lab_rgls_AdditionalExtensionForInterestOnlyPayments_label_en-US" xlink:label="lab_rgls_AdditionalExtensionForInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Extension for Interest Only Payments</link:label>
    <link:label id="lab_rgls_AdditionalExtensionForInterestOnlyPayments_documentation_en-US" xlink:label="lab_rgls_AdditionalExtensionForInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Extension for Interest Only Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AdditionalExtensionForInterestOnlyPayments" xlink:href="rgls-20210930.xsd#rgls_AdditionalExtensionForInterestOnlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_AdditionalExtensionForInterestOnlyPayments" xlink:to="lab_rgls_AdditionalExtensionForInterestOnlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1605a124-d4dd-46ad-915c-a3c6d1da981e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f0f2b99b-274e-4cdf-8c8b-4a5bfbb3271e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_244f4751-9b9b-4024-bf7f-763a4967171f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_48774125-6814-4628-94ad-fdff1e1aaee0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_da1b6a65-60ac-420a-96ab-9c57a40168d8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_519da0ad-e970-488d-9b0b-08e8726581e2_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent payments due 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d765bf77-8e9a-4e4d-beb1-32b843cb06c6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_InterestOnlyPaymentExtension_59562118-b01b-4fe2-9a0a-d34b22a8e6ed_terseLabel_en-US" xlink:label="lab_rgls_InterestOnlyPaymentExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-only payment extension</link:label>
    <link:label id="lab_rgls_InterestOnlyPaymentExtension_label_en-US" xlink:label="lab_rgls_InterestOnlyPaymentExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Only Payment Extension</link:label>
    <link:label id="lab_rgls_InterestOnlyPaymentExtension_documentation_en-US" xlink:label="lab_rgls_InterestOnlyPaymentExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Only Payment Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_InterestOnlyPaymentExtension" xlink:href="rgls-20210930.xsd#rgls_InterestOnlyPaymentExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_InterestOnlyPaymentExtension" xlink:to="lab_rgls_InterestOnlyPaymentExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d2e2d56b-8694-4723-b193-16244f4677ae_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_d042f787-1887-4c19-a139-c44bc68fe972_terseLabel_en-US" xlink:label="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]</link:label>
    <link:label id="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_label_en-US" xlink:label="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]</link:label>
    <link:label id="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_documentation_en-US" xlink:label="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:href="rgls-20210930.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:to="lab_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_490fb18a-7c89-4355-b230-1db23b874013_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_022de1f5-09d7-4439-b27a-069faab58d08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fa314719-cd92-4f29-a187-c8c04644b54d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_AccruedExpensePolicyTextBlock_6dfd04ba-4805-458a-953d-5e81778b046c_terseLabel_en-US" xlink:label="lab_rgls_AccruedExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial and Preclinical Study Accruals</link:label>
    <link:label id="lab_rgls_AccruedExpensePolicyTextBlock_label_en-US" xlink:label="lab_rgls_AccruedExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expense [Policy Text Block]</link:label>
    <link:label id="lab_rgls_AccruedExpensePolicyTextBlock_documentation_en-US" xlink:label="lab_rgls_AccruedExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expense [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AccruedExpensePolicyTextBlock" xlink:href="rgls-20210930.xsd#rgls_AccruedExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_AccruedExpensePolicyTextBlock" xlink:to="lab_rgls_AccruedExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86723334-4558-49f4-b3b5-a248d519a03e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_97e3b98a-c468-4c9c-92b3-4d1601cc0349_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5febf99e-69fb-4b00-9994-84609a543603_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_72cc6e0c-16d1-4be7-ab7d-0ae36006ec8e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e89b9ac8-e59b-42ec-9e5d-ba9c409b3f2d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_45e4e179-76ac-4c18-ac16-1a649b3c9136_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_RentedArea_ba763b2e-b5be-4df1-8e0d-952696d6c16e_terseLabel_en-US" xlink:label="lab_rgls_RentedArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rented area</link:label>
    <link:label id="lab_rgls_RentedArea_label_en-US" xlink:label="lab_rgls_RentedArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rented Area</link:label>
    <link:label id="lab_rgls_RentedArea_documentation_en-US" xlink:label="lab_rgls_RentedArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rented Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RentedArea" xlink:href="rgls-20210930.xsd#rgls_RentedArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_RentedArea" xlink:to="lab_rgls_RentedArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_b715972c-24de-474a-9855-b7b3f6c0c6e0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_NumberOfOperatingLeaseContracts_3089c1aa-28be-4c02-a906-43ee349ace56_terseLabel_en-US" xlink:label="lab_rgls_NumberOfOperatingLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating lease contracts</link:label>
    <link:label id="lab_rgls_NumberOfOperatingLeaseContracts_label_en-US" xlink:label="lab_rgls_NumberOfOperatingLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Lease Contracts</link:label>
    <link:label id="lab_rgls_NumberOfOperatingLeaseContracts_documentation_en-US" xlink:label="lab_rgls_NumberOfOperatingLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Lease Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfOperatingLeaseContracts" xlink:href="rgls-20210930.xsd#rgls_NumberOfOperatingLeaseContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_NumberOfOperatingLeaseContracts" xlink:to="lab_rgls_NumberOfOperatingLeaseContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_873e81c1-a66d-4baa-8646-e12b4b64b947_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d43553d5-5fae-44d7-9e32-fc25710f7660_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_9e5aa92d-b227-4eec-9497-cc2516a775ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6ec6eed1-e22b-46cb-96f0-2adeca6e7259_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_dd4668d6-01c5-4239-a072-08b889288942_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_FinancingfromSaleProceedsDebtAgreementRevenues_931af8e9-2d73-4aed-8d6c-17e6d4650f2f_terseLabel_en-US" xlink:label="lab_rgls_FinancingfromSaleProceedsDebtAgreementRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing from sale proceeds, debt, and agreement revenues</link:label>
    <link:label id="lab_rgls_FinancingfromSaleProceedsDebtAgreementRevenues_label_en-US" xlink:label="lab_rgls_FinancingfromSaleProceedsDebtAgreementRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing from Sale Proceeds, Debt, Agreement Revenues</link:label>
    <link:label id="lab_rgls_FinancingfromSaleProceedsDebtAgreementRevenues_documentation_en-US" xlink:label="lab_rgls_FinancingfromSaleProceedsDebtAgreementRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing from Sale Proceeds, Debt, Agreement Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_FinancingfromSaleProceedsDebtAgreementRevenues" xlink:href="rgls-20210930.xsd#rgls_FinancingfromSaleProceedsDebtAgreementRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_FinancingfromSaleProceedsDebtAgreementRevenues" xlink:to="lab_rgls_FinancingfromSaleProceedsDebtAgreementRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_15c590ac-afd5-4667-84ca-49c01e828a82_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e2d41fb1-74d3-4bee-8a3e-62d1d1bf533c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_a46ea970-0c5f-47dc-8591-2347210a2f48_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d9d1a131-b3d6-42b8-9611-3e81ffc5270f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_83e5e2a2-2e24-415b-901a-fc66c2d83966_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_885964d3-2a56-4f11-8a92-2d461f35bbe7_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_1ee8ddae-723f-430a-9dd0-9054ca6cd874_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1d333564-4007-49b5-a283-472ec3bebd07_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_TermLoanMember_24dc892a-be36-4915-93b8-8acfe1ef93ce_terseLabel_en-US" xlink:label="lab_rgls_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_rgls_TermLoanMember_label_en-US" xlink:label="lab_rgls_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_rgls_TermLoanMember_documentation_en-US" xlink:label="lab_rgls_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_TermLoanMember" xlink:href="rgls-20210930.xsd#rgls_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_TermLoanMember" xlink:to="lab_rgls_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_febc6151-80b8-4d02-b8ac-636317250e94_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01d14c1c-f56e-4e7e-af0c-6a4812057079_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_TwentyTwelvePlanMember_ee213286-5195-43d9-bfce-9ca47b7636c0_terseLabel_en-US" xlink:label="lab_rgls_TwentyTwelvePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for future grant under 2019 Equity Incentive Plan</link:label>
    <link:label id="lab_rgls_TwentyTwelvePlanMember_label_en-US" xlink:label="lab_rgls_TwentyTwelvePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twelve Plan [Member]</link:label>
    <link:label id="lab_rgls_TwentyTwelvePlanMember_documentation_en-US" xlink:label="lab_rgls_TwentyTwelvePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twelve Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_TwentyTwelvePlanMember" xlink:href="rgls-20210930.xsd#rgls_TwentyTwelvePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_TwentyTwelvePlanMember" xlink:to="lab_rgls_TwentyTwelvePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d35e79e1-2b3a-403f-bc68-1981b3c18246_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_NonvotingConvertiblePreferredStockIssued_4da6038d-91ce-40d2-bfc6-68a9f22e69fd_terseLabel_en-US" xlink:label="lab_rgls_NonvotingConvertiblePreferredStockIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvoting convertible preferred stock issued (in shares)</link:label>
    <link:label id="lab_rgls_NonvotingConvertiblePreferredStockIssued_label_en-US" xlink:label="lab_rgls_NonvotingConvertiblePreferredStockIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvoting Convertible Preferred Stock Issued</link:label>
    <link:label id="lab_rgls_NonvotingConvertiblePreferredStockIssued_documentation_en-US" xlink:label="lab_rgls_NonvotingConvertiblePreferredStockIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvoting Convertible Preferred Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NonvotingConvertiblePreferredStockIssued" xlink:href="rgls-20210930.xsd#rgls_NonvotingConvertiblePreferredStockIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_NonvotingConvertiblePreferredStockIssued" xlink:to="lab_rgls_NonvotingConvertiblePreferredStockIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_bea74dec-4e86-4b87-8295-dca0e8b5fe19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_619283ee-74d7-4d0f-8d39-97a76b6e6447_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8e4aae29-1192-4830-a251-cd6615435c3a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_91c2ec5d-cd89-4310-bfd7-e28a0fc9c3aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_PPPLoanMember_6e60e77c-ca5a-4fce-a5cb-687caff1ae17_terseLabel_en-US" xlink:label="lab_rgls_PPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan</link:label>
    <link:label id="lab_rgls_PPPLoanMember_label_en-US" xlink:label="lab_rgls_PPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan [Member]</link:label>
    <link:label id="lab_rgls_PPPLoanMember_documentation_en-US" xlink:label="lab_rgls_PPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PPPLoanMember" xlink:href="rgls-20210930.xsd#rgls_PPPLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_PPPLoanMember" xlink:to="lab_rgls_PPPLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_150f6dd8-3283-49f4-8dab-7ea71860489e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares used to compute basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4561c7f4-c6a4-4194-8a4c-655e8a94a585_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_ceb6c4e3-7e9d-4ad0-8735-9f473ab6b8d2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_4257211b-7433-440e-8b09-0eeb32b16e71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_6bb79c00-fd47-4f5a-9651-ec295daa6f69_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of the United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ba869878-0301-4b64-9280-dd4c6df3144a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ClassAOneConvertiblePreferredStockMember_51b8dc9c-fcff-42e9-9764-da129d10dc4a_terseLabel_en-US" xlink:label="lab_rgls_ClassAOneConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A-1 Convertible Preferred Stock</link:label>
    <link:label id="lab_rgls_ClassAOneConvertiblePreferredStockMember_label_en-US" xlink:label="lab_rgls_ClassAOneConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A One Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_rgls_ClassAOneConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_rgls_ClassAOneConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A One Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassAOneConvertiblePreferredStockMember" xlink:href="rgls-20210930.xsd#rgls_ClassAOneConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ClassAOneConvertiblePreferredStockMember" xlink:to="lab_rgls_ClassAOneConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ae72800-b2f4-45f7-8baf-6b55e5294937_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ae2a0d38-48ef-46fc-9e8e-e12ccc3cd397_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversions of convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e830fd1b-64c5-4692-9905-ebe1b1e7c70d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversions/Exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1ef44940-0d07-4727-8012-6d0631067893_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_CommonStockVotingRightsVotes_cbddb9ab-8b5c-49db-82d5-cf20f958dbc8_terseLabel_en-US" xlink:label="lab_rgls_CommonStockVotingRightsVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock voting rights votes</link:label>
    <link:label id="lab_rgls_CommonStockVotingRightsVotes_label_en-US" xlink:label="lab_rgls_CommonStockVotingRightsVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Voting Rights Votes</link:label>
    <link:label id="lab_rgls_CommonStockVotingRightsVotes_documentation_en-US" xlink:label="lab_rgls_CommonStockVotingRightsVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Voting Rights Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CommonStockVotingRightsVotes" xlink:href="rgls-20210930.xsd#rgls_CommonStockVotingRightsVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_CommonStockVotingRightsVotes" xlink:to="lab_rgls_CommonStockVotingRightsVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7ba4436f-8f66-49af-a3de-370508f94392_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_53580bf5-59d7-42b6-aac7-c15799b7ae07_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7c21fb22-e996-4201-853d-95747050d184_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_ca1df0a6-217a-42c1-8fda-79cba7c559a4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_11ede5ef-3118-442e-980d-88caa3e508eb_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c89ca764-2327-49de-abf2-fb3892d937ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c13ed9fb-89f6-44ca-8ee9-bdfdba8bbd60_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_df3288bc-b178-4fba-a2a6-7f424da99e6f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_2aab2aae-c6a2-483b-a2cd-f95f2ff0d356_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_RegulatoryAndCommercializationMilestonesMember_f7af09fd-8222-4516-8e16-667d85224c81_terseLabel_en-US" xlink:label="lab_rgls_RegulatoryAndCommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Commercialization Milestones</link:label>
    <link:label id="lab_rgls_RegulatoryAndCommercializationMilestonesMember_label_en-US" xlink:label="lab_rgls_RegulatoryAndCommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Commercialization Milestones [Member]</link:label>
    <link:label id="lab_rgls_RegulatoryAndCommercializationMilestonesMember_documentation_en-US" xlink:label="lab_rgls_RegulatoryAndCommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Commercialization Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RegulatoryAndCommercializationMilestonesMember" xlink:href="rgls-20210930.xsd#rgls_RegulatoryAndCommercializationMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_RegulatoryAndCommercializationMilestonesMember" xlink:to="lab_rgls_RegulatoryAndCommercializationMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_1f29589b-750d-4e37-a17d-3a8018cb8bf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangibles</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cecaa862-dd67-4936-8fd3-6e18e0f7d270_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ef5b8701-2c81-4248-b382-b12c28091dfb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_NonrefundableLeaseCostForAssignment_c5f0078e-0193-4f11-a9e2-2b5542194deb_terseLabel_en-US" xlink:label="lab_rgls_NonrefundableLeaseCostForAssignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable lease cost for assignment</link:label>
    <link:label id="lab_rgls_NonrefundableLeaseCostForAssignment_label_en-US" xlink:label="lab_rgls_NonrefundableLeaseCostForAssignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Lease Cost for Assignment</link:label>
    <link:label id="lab_rgls_NonrefundableLeaseCostForAssignment_documentation_en-US" xlink:label="lab_rgls_NonrefundableLeaseCostForAssignment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Lease Cost for Assignment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NonrefundableLeaseCostForAssignment" xlink:href="rgls-20210930.xsd#rgls_NonrefundableLeaseCostForAssignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_NonrefundableLeaseCostForAssignment" xlink:to="lab_rgls_NonrefundableLeaseCostForAssignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6785d740-1773-435f-8d13-aef97a79d51b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8193b4cd-8918-4470-bffc-1bfb674ff5dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_SaleOfStockValueOfSharesAvailable_0ae624b0-d27c-42c3-84f3-85bb49637ece_terseLabel_en-US" xlink:label="lab_rgls_SaleOfStockValueOfSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount eligible to be drawn down under the ATM</link:label>
    <link:label id="lab_rgls_SaleOfStockValueOfSharesAvailable_label_en-US" xlink:label="lab_rgls_SaleOfStockValueOfSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value of Shares Available</link:label>
    <link:label id="lab_rgls_SaleOfStockValueOfSharesAvailable_documentation_en-US" xlink:label="lab_rgls_SaleOfStockValueOfSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value of Shares Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SaleOfStockValueOfSharesAvailable" xlink:href="rgls-20210930.xsd#rgls_SaleOfStockValueOfSharesAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_SaleOfStockValueOfSharesAvailable" xlink:to="lab_rgls_SaleOfStockValueOfSharesAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_NumberOfAmendments_281158cb-264a-4fa5-ab0d-d6a8cc6f74c8_terseLabel_en-US" xlink:label="lab_rgls_NumberOfAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of times agreement was amended</link:label>
    <link:label id="lab_rgls_NumberOfAmendments_label_en-US" xlink:label="lab_rgls_NumberOfAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Amendments</link:label>
    <link:label id="lab_rgls_NumberOfAmendments_documentation_en-US" xlink:label="lab_rgls_NumberOfAmendments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Amendments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfAmendments" xlink:href="rgls-20210930.xsd#rgls_NumberOfAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_NumberOfAmendments" xlink:to="lab_rgls_NumberOfAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0d57292a-3496-4977-be51-1d72749011cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_265a3e5b-200a-44d4-91ae-28eec8f33106_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b5b8e6e5-fdd9-44bb-a48f-9df67388b8e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_86624c9b-aa1b-4f4a-92b9-014b088af6fb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a8a8222d-f39b-4c58-a070-6fffe4f85d1b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_8786ff18-039f-489b-bd9f-67e7fc78d6f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_MilestoneClosingWarrantsMember_90a9caa3-ed2a-4cca-a950-c493c157f265_terseLabel_en-US" xlink:label="lab_rgls_MilestoneClosingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 PIPE Milestone Closing warrants</link:label>
    <link:label id="lab_rgls_MilestoneClosingWarrantsMember_label_en-US" xlink:label="lab_rgls_MilestoneClosingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Closing Warrants [Member]</link:label>
    <link:label id="lab_rgls_MilestoneClosingWarrantsMember_documentation_en-US" xlink:label="lab_rgls_MilestoneClosingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Closing Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_MilestoneClosingWarrantsMember" xlink:href="rgls-20210930.xsd#rgls_MilestoneClosingWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_MilestoneClosingWarrantsMember" xlink:to="lab_rgls_MilestoneClosingWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_35423628-2d8d-4126-a8a4-f8f61e1ae91c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_602d2694-0758-46ad-aee0-b5c5b8a26a5b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1a645847-45bc-4f21-93f8-6c3db228ff8e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_AchievementOfEnrollmentMilestoneMember_21609875-4e90-416b-8bf1-c70144cd62c6_terseLabel_en-US" xlink:label="lab_rgls_AchievementOfEnrollmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Enrollment Milestone</link:label>
    <link:label id="lab_rgls_AchievementOfEnrollmentMilestoneMember_label_en-US" xlink:label="lab_rgls_AchievementOfEnrollmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Enrollment Milestone [Member]</link:label>
    <link:label id="lab_rgls_AchievementOfEnrollmentMilestoneMember_documentation_en-US" xlink:label="lab_rgls_AchievementOfEnrollmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Enrollment Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AchievementOfEnrollmentMilestoneMember" xlink:href="rgls-20210930.xsd#rgls_AchievementOfEnrollmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_AchievementOfEnrollmentMilestoneMember" xlink:to="lab_rgls_AchievementOfEnrollmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_162f6c88-03be-4c2c-9d23-e8cd129ca3ce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5fd4a04-9568-42ec-aaaf-af7dd204c3f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_047ee6f8-bee4-4d42-8bb5-4fb115bebf37_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_02b90eba-251d-4125-bdbb-a09e56aef3a1_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5723eb77-0038-4ace-9211-1d513b7b5b07_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_9366d84e-d826-4504-bf43-77ecc49d1063_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_379cc09b-2afc-4839-b10c-54a792268e87_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_SanofiMember_5eb6e7b7-394d-4158-a244-ad874879108e_terseLabel_en-US" xlink:label="lab_rgls_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_rgls_SanofiMember_label_en-US" xlink:label="lab_rgls_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_rgls_SanofiMember_documentation_en-US" xlink:label="lab_rgls_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SanofiMember" xlink:href="rgls-20210930.xsd#rgls_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_SanofiMember" xlink:to="lab_rgls_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_A2019SPAAnd2020SPAMember_e227837b-b0cd-4212-8ac7-eb65715e3d53_terseLabel_en-US" xlink:label="lab_rgls_A2019SPAAnd2020SPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 SPA and 2020 SPA</link:label>
    <link:label id="lab_rgls_A2019SPAAnd2020SPAMember_label_en-US" xlink:label="lab_rgls_A2019SPAAnd2020SPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 SPA and 2020 SPA [Member]</link:label>
    <link:label id="lab_rgls_A2019SPAAnd2020SPAMember_documentation_en-US" xlink:label="lab_rgls_A2019SPAAnd2020SPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 SPA and 2020 SPA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_A2019SPAAnd2020SPAMember" xlink:href="rgls-20210930.xsd#rgls_A2019SPAAnd2020SPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_A2019SPAAnd2020SPAMember" xlink:to="lab_rgls_A2019SPAAnd2020SPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_632d0de2-e7ff-415e-ba4f-f36036db6afb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ProceedsFromFederalProgram_41110979-156f-4591-afe6-1681e690e0be_terseLabel_en-US" xlink:label="lab_rgls_ProceedsFromFederalProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowing under Paycheck Protection Program</link:label>
    <link:label id="lab_rgls_ProceedsFromFederalProgram_label_en-US" xlink:label="lab_rgls_ProceedsFromFederalProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Federal Program</link:label>
    <link:label id="lab_rgls_ProceedsFromFederalProgram_documentation_en-US" xlink:label="lab_rgls_ProceedsFromFederalProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Federal Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ProceedsFromFederalProgram" xlink:href="rgls-20210930.xsd#rgls_ProceedsFromFederalProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ProceedsFromFederalProgram" xlink:to="lab_rgls_ProceedsFromFederalProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6fd718ff-5d04-4228-8dba-f6c294ddb69d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_50fa2429-4f6d-45e6-a07c-446e2b42c1d4_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_f112fa00-92e0-429f-9297-ebdb76ece7d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of term loan, less debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_623dcbe4-e5a5-487f-b993-5df973ce23b1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_PaymentsonFinanceLeases_555eb8d4-63ee-4ab3-88c3-43d25f0f8900_negatedLabel_en-US" xlink:label="lab_rgls_PaymentsonFinanceLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on financing leases</link:label>
    <link:label id="lab_rgls_PaymentsonFinanceLeases_label_en-US" xlink:label="lab_rgls_PaymentsonFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on Finance Leases</link:label>
    <link:label id="lab_rgls_PaymentsonFinanceLeases_documentation_en-US" xlink:label="lab_rgls_PaymentsonFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PaymentsonFinanceLeases" xlink:href="rgls-20210930.xsd#rgls_PaymentsonFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_PaymentsonFinanceLeases" xlink:to="lab_rgls_PaymentsonFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_NumberOfClosings_62c80fd2-9eab-43a3-b087-7c211386f9cd_terseLabel_en-US" xlink:label="lab_rgls_NumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of closings</link:label>
    <link:label id="lab_rgls_NumberOfClosings_label_en-US" xlink:label="lab_rgls_NumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Closings</link:label>
    <link:label id="lab_rgls_NumberOfClosings_documentation_en-US" xlink:label="lab_rgls_NumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Closings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfClosings" xlink:href="rgls-20210930.xsd#rgls_NumberOfClosings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_NumberOfClosings" xlink:to="lab_rgls_NumberOfClosings" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ActivityOfSharesTableTextBlock_6499f8f0-695c-49bc-ad1e-1ed7a0f309d8_terseLabel_en-US" xlink:label="lab_rgls_ActivityOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Shares</link:label>
    <link:label id="lab_rgls_ActivityOfSharesTableTextBlock_label_en-US" xlink:label="lab_rgls_ActivityOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Shares [Table Text Block]</link:label>
    <link:label id="lab_rgls_ActivityOfSharesTableTextBlock_documentation_en-US" xlink:label="lab_rgls_ActivityOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ActivityOfSharesTableTextBlock" xlink:href="rgls-20210930.xsd#rgls_ActivityOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ActivityOfSharesTableTextBlock" xlink:to="lab_rgls_ActivityOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5f71be5f-e476-4be9-b7c8-de61608999ec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbceeb66-7a2e-4537-8892-2fe6ccd38cac_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf4399c1-62b8-4863-8652-bb3b1982e9a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55ac7840-7142-4c49-81a4-9a72ef845d16_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_7456aecf-ac1c-4a19-ac0b-0aa9f659606f_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b66eabc6-e531-439e-a8d2-2dad8aa57473_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_78534b02-378f-4406-8c21-8d8d225d43d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_110b22aa-54a8-4fec-b275-03eb0e2410e0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_EnrollmentMilestoneMember_c44cecca-cdab-479e-8adf-2479c3627d25_terseLabel_en-US" xlink:label="lab_rgls_EnrollmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enrollment Milestone</link:label>
    <link:label id="lab_rgls_EnrollmentMilestoneMember_label_en-US" xlink:label="lab_rgls_EnrollmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enrollment Milestone [Member]</link:label>
    <link:label id="lab_rgls_EnrollmentMilestoneMember_documentation_en-US" xlink:label="lab_rgls_EnrollmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enrollment Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_EnrollmentMilestoneMember" xlink:href="rgls-20210930.xsd#rgls_EnrollmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_EnrollmentMilestoneMember" xlink:to="lab_rgls_EnrollmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2522a6f3-15fe-4fb1-94f4-cb344c5c0715_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_eaf4cb7b-e2bb-4206-8393-f1225e17ef9f_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_9cfef688-cc99-4de9-83d4-9ce41bf89c9e_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_eeed0743-aa52-4cda-9250-7267ebdf978b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_9f3283d2-c79e-4959-b86e-7ac76bd43697_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6d202122-6c11-415c-bf90-3b4b8ec30480_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7339c79c-b95d-4632-94d4-9fea692f1308_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6fce8efd-4d32-4945-afde-f9d6a7693259_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8dc8a4fb-31a0-4456-b352-aefa883899e9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (options) or Vested (RSUs) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_00b1364b-1ebb-4d72-beda-49e966358e28_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares used to compute diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease_15a96e8c-8e3b-46e3-9c36-ac6f5992a983_terseLabel_en-US" xlink:label="lab_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized yearly increase</link:label>
    <link:label id="lab_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease_label_en-US" xlink:label="lab_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Yearly Increase</link:label>
    <link:label id="lab_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease_documentation_en-US" xlink:label="lab_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Yearly Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease" xlink:href="rgls-20210930.xsd#rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease" xlink:to="lab_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9b9c9ac0-141c-497b-b884-08de7530e10a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9aaca4ad-e51a-42e3-9753-72d0f2a63b8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_fcd2ddee-8e80-435b-a7ea-e8568a851ecd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_978bedc1-18da-48ba-9a32-dd0785051053_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_ForgivenessAmountThreshold_78a688b4-34d2-498e-9c18-9a198913d89a_terseLabel_en-US" xlink:label="lab_rgls_ForgivenessAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness threshold amount</link:label>
    <link:label id="lab_rgls_ForgivenessAmountThreshold_label_en-US" xlink:label="lab_rgls_ForgivenessAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Amount Threshold</link:label>
    <link:label id="lab_rgls_ForgivenessAmountThreshold_documentation_en-US" xlink:label="lab_rgls_ForgivenessAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ForgivenessAmountThreshold" xlink:href="rgls-20210930.xsd#rgls_ForgivenessAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_ForgivenessAmountThreshold" xlink:to="lab_rgls_ForgivenessAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0fdeda3a-db36-49d6-8d0b-533a16808852_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2a3f897e-569f-40f5-bb8c-1cd30b277cac_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0f9ffd79-1b16-4016-8f32-d6b7faae6438_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_93ee08f9-6e04-4670-8ccf-83983a857d9e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d2a76d8c-bbbb-408f-ab1e-2ad7fbef001a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_87aaed00-bc05-4e84-a7c6-cd6738f561dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4f08e714-5e0f-42d3-9dcc-53d179c2604a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c84a0a17-e414-446e-984f-fa151ac17bcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (options) or Vested (RSUs)(in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_d33e0a1b-2feb-41d4-bac9-4e5ea9fc3005_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6440abb6-f29d-4dd0-942c-48088331f8c5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_78b86781-ddec-411e-821d-4a169f1f923b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_8779e5c7-621f-4f29-b022-69c2e79f5ffc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_1c61b8db-69c3-482a-afb6-e4898d5021b8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan shares</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_d5fd4d44-4fe9-47d9-81af-01083041c94d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_eaa892ac-4cd8-4577-83df-39cafcba34e1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_StrategicAlliancesAxis_036b33c1-c3d0-4c08-9877-5f475bc935c0_terseLabel_en-US" xlink:label="lab_rgls_StrategicAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Axis]</link:label>
    <link:label id="lab_rgls_StrategicAlliancesAxis_label_en-US" xlink:label="lab_rgls_StrategicAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Axis]</link:label>
    <link:label id="lab_rgls_StrategicAlliancesAxis_documentation_en-US" xlink:label="lab_rgls_StrategicAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesAxis" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_StrategicAlliancesAxis" xlink:to="lab_rgls_StrategicAlliancesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_DevelopmentMilestonesMember_b23d22f6-3167-4318-8a76-f9ff2888a36b_terseLabel_en-US" xlink:label="lab_rgls_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_rgls_DevelopmentMilestonesMember_label_en-US" xlink:label="lab_rgls_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_rgls_DevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_rgls_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DevelopmentMilestonesMember" xlink:href="rgls-20210930.xsd#rgls_DevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_DevelopmentMilestonesMember" xlink:to="lab_rgls_DevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_319b9b3e-7447-4757-9019-9ecbd75614b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_068ac25f-1fb4-420f-8fe3-bd0d4ec2672e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f1f8e74b-462e-4064-a8f5-1f2aa8c06dd8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_df26d55c-eeea-4547-9375-dce900311e6b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3dbe7ca-05e4-476d-b990-2e736a7a6008_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_DevelopmentMilestoneNotAchievable_f0e36d23-2c7a-4e12-bbe4-7ed66177ad92_terseLabel_en-US" xlink:label="lab_rgls_DevelopmentMilestoneNotAchievable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone not achievable</link:label>
    <link:label id="lab_rgls_DevelopmentMilestoneNotAchievable_label_en-US" xlink:label="lab_rgls_DevelopmentMilestoneNotAchievable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Not Achievable</link:label>
    <link:label id="lab_rgls_DevelopmentMilestoneNotAchievable_documentation_en-US" xlink:label="lab_rgls_DevelopmentMilestoneNotAchievable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Not Achievable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DevelopmentMilestoneNotAchievable" xlink:href="rgls-20210930.xsd#rgls_DevelopmentMilestoneNotAchievable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_DevelopmentMilestoneNotAchievable" xlink:to="lab_rgls_DevelopmentMilestoneNotAchievable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_892dbeac-533e-4dc7-b451-da7bed6a33f5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_GainLossOnLoanForgiveness_aab505d8-9c07-4582-9276-8f9fdd12796b_negatedTerseLabel_en-US" xlink:label="lab_rgls_GainLossOnLoanForgiveness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on PPP Loan forgiveness</link:label>
    <link:label id="lab_rgls_GainLossOnLoanForgiveness_label_en-US" xlink:label="lab_rgls_GainLossOnLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Loan Forgiveness</link:label>
    <link:label id="lab_rgls_GainLossOnLoanForgiveness_documentation_en-US" xlink:label="lab_rgls_GainLossOnLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Loan Forgiveness</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_GainLossOnLoanForgiveness" xlink:href="rgls-20210930.xsd#rgls_GainLossOnLoanForgiveness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_GainLossOnLoanForgiveness" xlink:to="lab_rgls_GainLossOnLoanForgiveness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f7b330a6-185f-4ca5-bf63-b6b364d1b13b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1b02773e-04f2-4fe4-85c2-9f2af8088462_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_50397860-8044-4099-9de6-cfeb8ce48531_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_9f9a5433-b0be-48dd-9a95-43e538ec7efd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants_777eb139-9177-4211-8a7b-e136cecea6c3_terseLabel_en-US" xlink:label="lab_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants</link:label>
    <link:label id="lab_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="rgls-20210930.xsd#rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9cbaade3-5140-4897-bee4-e62bce58d5d2_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f4cc1e6f-2d9e-4e5b-8c98-6a03c1176074_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_EnrollmentMilestone_52e882b6-b9cf-4f41-a72a-77059afa3641_terseLabel_en-US" xlink:label="lab_rgls_EnrollmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enrollment Milestone</link:label>
    <link:label id="lab_rgls_EnrollmentMilestone_label_en-US" xlink:label="lab_rgls_EnrollmentMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enrollment Milestone</link:label>
    <link:label id="lab_rgls_EnrollmentMilestone_documentation_en-US" xlink:label="lab_rgls_EnrollmentMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enrollment Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_EnrollmentMilestone" xlink:href="rgls-20210930.xsd#rgls_EnrollmentMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_EnrollmentMilestone" xlink:to="lab_rgls_EnrollmentMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_InitialClosingWarrantsMember_4f22b134-8f78-4919-ac9d-4ebe1a389e67_terseLabel_en-US" xlink:label="lab_rgls_InitialClosingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 PIPE Initial Closing warrants</link:label>
    <link:label id="lab_rgls_InitialClosingWarrantsMember_label_en-US" xlink:label="lab_rgls_InitialClosingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Closing Warrants [Member]</link:label>
    <link:label id="lab_rgls_InitialClosingWarrantsMember_documentation_en-US" xlink:label="lab_rgls_InitialClosingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Closing Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_InitialClosingWarrantsMember" xlink:href="rgls-20210930.xsd#rgls_InitialClosingWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_InitialClosingWarrantsMember" xlink:to="lab_rgls_InitialClosingWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb7961fb-8e31-456e-acdf-05d90d9a3fe2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_32aec05a-8ad3-4479-9306-4b177814f34e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rgls_RevenueUnderCollaborationsMember_label_en-US" xlink:label="lab_rgls_RevenueUnderCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Under Collaborations [Member]</link:label>
    <link:label id="lab_rgls_RevenueUnderCollaborationsMember_documentation_en-US" xlink:label="lab_rgls_RevenueUnderCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Under Collaborations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RevenueUnderCollaborationsMember" xlink:href="rgls-20210930.xsd#rgls_RevenueUnderCollaborationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rgls_RevenueUnderCollaborationsMember" xlink:to="lab_rgls_RevenueUnderCollaborationsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>rgls-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b020128b-c098-4c8f-bf82-e0af5aef1570,g:5e73ec3e-18f1-4a85-a5f0-f7e7f348b77f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regulusrx.com/role/Cover" xlink:type="simple" xlink:href="rgls-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_75fd794e-6e20-4ec3-8c7a-4fd8450ad107" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_DocumentType_75fd794e-6e20-4ec3-8c7a-4fd8450ad107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_80018da9-b24b-49a1-ae5a-98f37964b3cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_DocumentQuarterlyReport_80018da9-b24b-49a1-ae5a-98f37964b3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c0590a6b-d81d-4be9-ba59-9abe130b5c76" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_DocumentPeriodEndDate_c0590a6b-d81d-4be9-ba59-9abe130b5c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_09e6b377-4fd6-41b5-80b8-7213ef197992" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_DocumentTransitionReport_09e6b377-4fd6-41b5-80b8-7213ef197992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_50f44d2b-6edf-4544-bd81-88aae87da8e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityFileNumber_50f44d2b-6edf-4544-bd81-88aae87da8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e296d7f5-e010-44aa-84a4-7ad52cfc1ee8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e296d7f5-e010-44aa-84a4-7ad52cfc1ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_728bcf7e-e128-4120-94b4-267c67fad278" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityTaxIdentificationNumber_728bcf7e-e128-4120-94b4-267c67fad278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8b0ee606-cff3-4992-af9e-a29da18477ee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityAddressAddressLine1_8b0ee606-cff3-4992-af9e-a29da18477ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3f4b1120-fbf5-4aab-af3f-d9844cb0edbc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityAddressCityOrTown_3f4b1120-fbf5-4aab-af3f-d9844cb0edbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_59dffec4-63ea-45bf-be08-eae8b5e55002" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityAddressStateOrProvince_59dffec4-63ea-45bf-be08-eae8b5e55002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bd9bb40c-b267-4c3b-8875-c5a2bc55f67f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityAddressPostalZipCode_bd9bb40c-b267-4c3b-8875-c5a2bc55f67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b9fbdcaf-4ab9-4d3f-8238-446492623b36" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_CityAreaCode_b9fbdcaf-4ab9-4d3f-8238-446492623b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_848e0a2c-88c5-404b-945e-5d824ce6bec0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_LocalPhoneNumber_848e0a2c-88c5-404b-945e-5d824ce6bec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3f1e9681-f736-4fd2-ac67-5e2bf832c873" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_Security12bTitle_3f1e9681-f736-4fd2-ac67-5e2bf832c873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2559531d-d9f3-4744-a131-47b45fb01a56" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_TradingSymbol_2559531d-d9f3-4744-a131-47b45fb01a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_104ef668-528c-4789-a52c-958b09ef8604" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_SecurityExchangeName_104ef668-528c-4789-a52c-958b09ef8604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6da9adbc-3299-4421-b8d2-4394cfdf8c5e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityCurrentReportingStatus_6da9adbc-3299-4421-b8d2-4394cfdf8c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0c91778c-4256-4565-9310-be8314c396a9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityInteractiveDataCurrent_0c91778c-4256-4565-9310-be8314c396a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_be87ac9c-f864-4312-8af7-15482513eac9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityFilerCategory_be87ac9c-f864-4312-8af7-15482513eac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_609a5c35-c938-40d5-b6f9-6206b4843fb4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntitySmallBusiness_609a5c35-c938-40d5-b6f9-6206b4843fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bd0881e1-8b95-43ea-a666-267f8a3f1744" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityEmergingGrowthCompany_bd0881e1-8b95-43ea-a666-267f8a3f1744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_941e1d5a-bcfe-4f03-9ae4-d19ed14ffb6c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityShellCompany_941e1d5a-bcfe-4f03-9ae4-d19ed14ffb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_12f7cd74-300e-4406-9288-f34c3caa75cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_12f7cd74-300e-4406-9288-f34c3caa75cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f07af455-9e79-4ea8-8665-b11f1d6867ee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_AmendmentFlag_f07af455-9e79-4ea8-8665-b11f1d6867ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_80afae2f-b917-4c27-b908-d947de160f1d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_DocumentFiscalYearFocus_80afae2f-b917-4c27-b908-d947de160f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f5bdf39d-4ac9-4e63-8e26-8187010cce95" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f5bdf39d-4ac9-4e63-8e26-8187010cce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e713fd94-f1c7-40b3-bc26-8914ad8c6583" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityRegistrantName_e713fd94-f1c7-40b3-bc26-8914ad8c6583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_71094a4d-0abe-48d6-8537-616ddb3bc3b9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_EntityCentralIndexKey_71094a4d-0abe-48d6-8537-616ddb3bc3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6b01fed6-8739-48b3-aa52-4c6d116210e8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f6aea54-a3a0-43b9-aaa2-fe5c7c2ce10e" xlink:to="loc_dei_CurrentFiscalYearEndDate_6b01fed6-8739-48b3-aa52-4c6d116210e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_de30b618-5c30-4a1b-97e8-7f9240fdd22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0fa232a6-853d-4cb6-aa45-e4c73febf2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_de30b618-5c30-4a1b-97e8-7f9240fdd22d" xlink:to="loc_us-gaap_StatementTable_0fa232a6-853d-4cb6-aa45-e4c73febf2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9e6fad0c-fe06-4680-85ec-875d60b20f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0fa232a6-853d-4cb6-aa45-e4c73febf2c2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9e6fad0c-fe06-4680-85ec-875d60b20f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e6fad0c-fe06-4680-85ec-875d60b20f60" xlink:to="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_20b2529c-a8fd-4e51-84e7-7e86a92cb603" xlink:href="rgls-20210930.xsd#rgls_ClassA1ConvertiblePreferredStockAsConvertedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:to="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_20b2529c-a8fd-4e51-84e7-7e86a92cb603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_bc6375c1-be79-4ef6-a8f1-1df94fa93bf3" xlink:href="rgls-20210930.xsd#rgls_ClassA2ConvertiblePreferredStockAsConvertedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:to="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_bc6375c1-be79-4ef6-a8f1-1df94fa93bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA3ConvertiblePreferredStockMember_39066631-77f3-408e-97cb-e105afe48cb6" xlink:href="rgls-20210930.xsd#rgls_ClassA3ConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7c6c150e-a177-4ae7-bc61-beac403f25bf" xlink:to="loc_rgls_ClassA3ConvertiblePreferredStockMember_39066631-77f3-408e-97cb-e105afe48cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f20d1c57-ddc5-49bf-bab2-7554182cce56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0fa232a6-853d-4cb6-aa45-e4c73febf2c2" xlink:to="loc_us-gaap_StatementLineItems_f20d1c57-ddc5-49bf-bab2-7554182cce56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f20d1c57-ddc5-49bf-bab2-7554182cce56" xlink:to="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5cbef876-65f2-4649-a5bb-f26a97dcfa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5cbef876-65f2-4649-a5bb-f26a97dcfa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_2c423230-10a0-45bc-b9a3-fee539b4c0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_RestrictedCash_2c423230-10a0-45bc-b9a3-fee539b4c0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_64b2a360-8662-463e-b0aa-223f46122efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_64b2a360-8662-463e-b0aa-223f46122efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_55d11b14-0352-44de-9342-a3c57559a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_55d11b14-0352-44de-9342-a3c57559a0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_64daf40f-d8d4-4281-ad99-b40a9c446a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_OtherAssetsCurrent_64daf40f-d8d4-4281-ad99-b40a9c446a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_32f8b61c-9b52-467e-b6cf-1b9b1391c414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61a69903-fa91-4648-b5ee-f43a9fb48c17" xlink:to="loc_us-gaap_AssetsCurrent_32f8b61c-9b52-467e-b6cf-1b9b1391c414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fa4fd435-66f8-46ba-a76d-5b72965eaf23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fa4fd435-66f8-46ba-a76d-5b72965eaf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7ab25dd9-e9a7-4fe4-9421-69d9a4781e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7ab25dd9-e9a7-4fe4-9421-69d9a4781e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_31c1501c-02c1-4681-ab7d-bc8ecac7cd37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_31c1501c-02c1-4681-ab7d-bc8ecac7cd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2090e100-fa05-400f-88ea-d7d697053b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2090e100-fa05-400f-88ea-d7d697053b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4daf7b89-21d2-4214-b18e-f174771c56b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0e9817a-1ece-4adb-9142-4e46dd589dca" xlink:to="loc_us-gaap_Assets_4daf7b89-21d2-4214-b18e-f174771c56b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f20d1c57-ddc5-49bf-bab2-7554182cce56" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0c793a87-d788-4b8f-955b-11fb0279cde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_AccountsPayableCurrent_0c793a87-d788-4b8f-955b-11fb0279cde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_841198d8-53ad-4df8-b229-9c57b30f432a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_841198d8-53ad-4df8-b229-9c57b30f432a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AccruedResearchAndDevelopmentCurrent_6a623c04-3aa8-4ce4-8758-fd8fbba73966" xlink:href="rgls-20210930.xsd#rgls_AccruedResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_rgls_AccruedResearchAndDevelopmentCurrent_6a623c04-3aa8-4ce4-8758-fd8fbba73966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8b474b30-14c5-449b-8db8-8223da69cd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8b474b30-14c5-449b-8db8-8223da69cd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_089f7c95-82ae-4bbf-a261-3ac89c938e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_DebtCurrent_089f7c95-82ae-4bbf-a261-3ac89c938e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f0e21469-9d44-4b6b-9ef0-82211ba9a9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f0e21469-9d44-4b6b-9ef0-82211ba9a9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_52feb90f-d413-4ec0-a401-1aeb3bea16e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_LiabilitiesCurrent_52feb90f-d413-4ec0-a401-1aeb3bea16e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e9b1dae1-ad82-405c-8946-f8be89c2f66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_52db5e7d-3ab0-477c-9659-326c6869d71f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e9b1dae1-ad82-405c-8946-f8be89c2f66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5b41b0a8-286a-4948-975a-61241850a602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_Liabilities_5b41b0a8-286a-4948-975a-61241850a602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bd80ed02-c24c-4664-9205-51d457d9e945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bd80ed02-c24c-4664-9205-51d457d9e945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2b9e2eaa-44cc-4e07-9f7a-73bbc63f7aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_PreferredStockValue_2b9e2eaa-44cc-4e07-9f7a-73bbc63f7aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4a53d9c4-0d37-4cf2-9550-48d8efb15125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_CommonStockValue_4a53d9c4-0d37-4cf2-9550-48d8efb15125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6f3e0c7-3176-4674-a83d-c317caf66357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6f3e0c7-3176-4674-a83d-c317caf66357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea4e7a78-f39a-4d0e-82cc-3ed2e41a0b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea4e7a78-f39a-4d0e-82cc-3ed2e41a0b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2fe323a-8f47-4d91-9fd9-c145ae0dc8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dfef9dc-3fe5-40af-9c39-96925358bc53" xlink:to="loc_us-gaap_StockholdersEquity_d2fe323a-8f47-4d91-9fd9-c145ae0dc8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9819ad8-d4e0-4953-b55f-800453773c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d4e7c9-66ae-4156-ad04-d528d04feb3b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9819ad8-d4e0-4953-b55f-800453773c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c66a1d32-37f7-4650-9467-cb8df640e9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7f625e0a-2de3-4bf8-84b2-d48c03437632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c66a1d32-37f7-4650-9467-cb8df640e9c2" xlink:to="loc_us-gaap_StatementTable_7f625e0a-2de3-4bf8-84b2-d48c03437632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cf61581e-75c0-42fa-b39a-6b5ab6cb7150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7f625e0a-2de3-4bf8-84b2-d48c03437632" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cf61581e-75c0-42fa-b39a-6b5ab6cb7150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cf61581e-75c0-42fa-b39a-6b5ab6cb7150" xlink:to="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_cf3c052b-f0b4-4316-a655-a5f515e1120d" xlink:href="rgls-20210930.xsd#rgls_ClassA1ConvertiblePreferredStockAsConvertedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:to="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_cf3c052b-f0b4-4316-a655-a5f515e1120d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_30ce0e51-9ade-4963-96e9-c6c284adeb95" xlink:href="rgls-20210930.xsd#rgls_ClassA2ConvertiblePreferredStockAsConvertedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:to="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_30ce0e51-9ade-4963-96e9-c6c284adeb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA3ConvertiblePreferredStockMember_aff15aa7-f52f-4826-ac34-ba271e28468f" xlink:href="rgls-20210930.xsd#rgls_ClassA3ConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1d69bb19-2c84-48bf-b582-7a57fc96cba3" xlink:to="loc_rgls_ClassA3ConvertiblePreferredStockMember_aff15aa7-f52f-4826-ac34-ba271e28468f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7f625e0a-2de3-4bf8-84b2-d48c03437632" xlink:to="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d38e9c9-80a3-48b9-8f6f-ef90f4319495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d38e9c9-80a3-48b9-8f6f-ef90f4319495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b0f8ee43-2455-4072-8b7a-0b000192852f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b0f8ee43-2455-4072-8b7a-0b000192852f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f74db51a-c4c2-4b79-b2b2-f5ef4793b19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f74db51a-c4c2-4b79-b2b2-f5ef4793b19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_685ac6c2-ba08-47a5-b5d5-3e2dd2b11348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_685ac6c2-ba08-47a5-b5d5-3e2dd2b11348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d486a380-716a-4f66-8bd7-f0d7e9b06656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d486a380-716a-4f66-8bd7-f0d7e9b06656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_52ba5d26-452d-4d4f-8dd6-13494d9b8953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_52ba5d26-452d-4d4f-8dd6-13494d9b8953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d2fca25f-d2ab-4c6e-8ff9-18cd2438d473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_CommonStockSharesIssued_d2fca25f-d2ab-4c6e-8ff9-18cd2438d473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4018473b-32f5-4026-b68e-8659045e3458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6136deb8-9f5d-4880-9874-1b26400f465c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4018473b-32f5-4026-b68e-8659045e3458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3e93a132-1c19-4ecc-ace6-130333275617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_RevenuesAbstract_3e93a132-1c19-4ecc-ace6-130333275617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f399c084-9cbb-473b-9641-8c4083132b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3e93a132-1c19-4ecc-ace6-130333275617" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f399c084-9cbb-473b-9641-8c4083132b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f762dadc-c1dd-4f81-b66c-a2c90b22e9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f762dadc-c1dd-4f81-b66c-a2c90b22e9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_507bb0c2-39b1-4da7-ab49-861beb314a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f762dadc-c1dd-4f81-b66c-a2c90b22e9e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_507bb0c2-39b1-4da7-ab49-861beb314a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b95bf70b-1e9e-446c-8e81-a2514c25863c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f762dadc-c1dd-4f81-b66c-a2c90b22e9e6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b95bf70b-1e9e-446c-8e81-a2514c25863c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1278dcd6-6a52-4741-b677-60bf1cfd8378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f762dadc-c1dd-4f81-b66c-a2c90b22e9e6" xlink:to="loc_us-gaap_OperatingExpenses_1278dcd6-6a52-4741-b677-60bf1cfd8378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_30e95612-8858-45bb-9478-52299226d924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_OperatingIncomeLoss_30e95612-8858-45bb-9478-52299226d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_139f51ac-0c03-43b9-8f31-1a380acf759f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_139f51ac-0c03-43b9-8f31-1a380acf759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_20b7b0fe-dea6-456a-84b0-b47ec69b84b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_139f51ac-0c03-43b9-8f31-1a380acf759f" xlink:to="loc_us-gaap_InterestAndOtherIncome_20b7b0fe-dea6-456a-84b0-b47ec69b84b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f0e6aa47-78a8-472c-a3ab-f4e59473871e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_139f51ac-0c03-43b9-8f31-1a380acf759f" xlink:to="loc_us-gaap_InterestExpense_f0e6aa47-78a8-472c-a3ab-f4e59473871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d20adcf8-32b9-43c0-9165-1847aedaf794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d20adcf8-32b9-43c0-9165-1847aedaf794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9c2c97d0-6b00-4478-bf86-34ec4beb44d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9c2c97d0-6b00-4478-bf86-34ec4beb44d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c5630a4a-dd01-48a0-9ee6-7f4a91749a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_NetIncomeLoss_c5630a4a-dd01-48a0-9ee6-7f4a91749a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_14a71fd9-f8d5-441c-806b-4bd8e1339b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_EarningsPerShareBasic_14a71fd9-f8d5-441c-806b-4bd8e1339b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a7580204-df8f-4c64-b915-c5db666f7233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a7580204-df8f-4c64-b915-c5db666f7233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e1a73d62-872d-4d5f-a732-88afc9bc27a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e1a73d62-872d-4d5f-a732-88afc9bc27a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63115313-1465-4ce7-bd1b-9232f23867f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63115313-1465-4ce7-bd1b-9232f23867f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRevenueExtensibleList_c16c3924-3090-46a9-bd91-3eb577a2726e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c1b91f-9610-423e-92df-1e91f7052bcb" xlink:to="loc_us-gaap_TypeOfRevenueExtensibleList_c16c3924-3090-46a9-bd91-3eb577a2726e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5eb68764-da45-4444-8f9d-56437393009b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9e91c2ab-853d-401a-988f-efda201e7f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5eb68764-da45-4444-8f9d-56437393009b" xlink:to="loc_us-gaap_StatementTable_9e91c2ab-853d-401a-988f-efda201e7f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76001287-793c-468c-8177-780e78bbe4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9e91c2ab-853d-401a-988f-efda201e7f84" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76001287-793c-468c-8177-780e78bbe4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ae8a274-e4b3-4e00-9b01-0e860f8a731e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76001287-793c-468c-8177-780e78bbe4d5" xlink:to="loc_us-gaap_ClassOfStockDomain_4ae8a274-e4b3-4e00-9b01-0e860f8a731e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_0393b79a-219c-4680-8a1f-4cfe93815693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4ae8a274-e4b3-4e00-9b01-0e860f8a731e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_0393b79a-219c-4680-8a1f-4cfe93815693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e4c884f8-dcf8-4e46-a2a9-f63054e7eaab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9e91c2ab-853d-401a-988f-efda201e7f84" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e4c884f8-dcf8-4e46-a2a9-f63054e7eaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e4c884f8-dcf8-4e46-a2a9-f63054e7eaab" xlink:to="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_dec28e5c-716b-4e60-98f3-56eab18adff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:to="loc_us-gaap_PreferredStockMember_dec28e5c-716b-4e60-98f3-56eab18adff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_11497388-5003-4ec7-929b-1c0b7797060c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:to="loc_us-gaap_CommonStockMember_11497388-5003-4ec7-929b-1c0b7797060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0b6a28e9-1d7b-4f0b-9f95-4f8ad2777d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0b6a28e9-1d7b-4f0b-9f95-4f8ad2777d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9cf5f390-d4f3-42ee-ae2b-f267bf1fc84d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d23bca99-44df-49d9-afd3-ad76975021cc" xlink:to="loc_us-gaap_RetainedEarningsMember_9cf5f390-d4f3-42ee-ae2b-f267bf1fc84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8c4bfbc8-ba38-443f-9673-05b2f7860c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9e91c2ab-853d-401a-988f-efda201e7f84" xlink:to="loc_us-gaap_StatementLineItems_8c4bfbc8-ba38-443f-9673-05b2f7860c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8c4bfbc8-ba38-443f-9673-05b2f7860c17" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1ca68a13-b2a8-4802-9365-d1487871c297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_SharesOutstanding_1ca68a13-b2a8-4802-9365-d1487871c297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04a0b474-f1be-4e68-a9fe-d8114003c947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockholdersEquity_04a0b474-f1be-4e68-a9fe-d8114003c947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dd3abbe8-9ae0-43d7-8bf6-67bcb8dda2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dd3abbe8-9ae0-43d7-8bf6-67bcb8dda2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da00b73f-ee19-41d1-9a93-c67c86112ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da00b73f-ee19-41d1-9a93-c67c86112ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f4a0db56-cfe8-42ea-b541-5ce8e3546901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f4a0db56-cfe8-42ea-b541-5ce8e3546901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants_23b55ed7-a662-4688-a35e-4b8e8c558269" xlink:href="rgls-20210930.xsd#rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants_23b55ed7-a662-4688-a35e-4b8e8c558269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants_641366a0-231e-4ba2-be40-d972bccbac95" xlink:href="rgls-20210930.xsd#rgls_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants_641366a0-231e-4ba2-be40-d972bccbac95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ab7188fd-9cab-4d74-bf9e-2035967fab3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ab7188fd-9cab-4d74-bf9e-2035967fab3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_186a0eb3-05b5-4021-8415-a65b45dda066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_186a0eb3-05b5-4021-8415-a65b45dda066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1afa2b0-192d-4611-ac1c-311add8e7257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1afa2b0-192d-4611-ac1c-311add8e7257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c5e002de-2913-41a1-831d-58a6c6e4432c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c5e002de-2913-41a1-831d-58a6c6e4432c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a4cc0e88-af71-49a7-a28e-e17fafd7a564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a4cc0e88-af71-49a7-a28e-e17fafd7a564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_32ba9516-c179-48ec-8a36-4ae21a9d2502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_32ba9516-c179-48ec-8a36-4ae21a9d2502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a412050-049b-45fd-af52-71f9d99f774a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a412050-049b-45fd-af52-71f9d99f774a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e3daf44-7b24-46f9-9b74-2182cc4ef0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_NetIncomeLoss_6e3daf44-7b24-46f9-9b74-2182cc4ef0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7db8bd50-d464-4f76-8e2e-e42594613f65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_SharesOutstanding_7db8bd50-d464-4f76-8e2e-e42594613f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_83193bac-872d-499d-99cc-b50176561c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5889d586-b9d3-458f-9e25-6c8faf977346" xlink:to="loc_us-gaap_StockholdersEquity_83193bac-872d-499d-99cc-b50176561c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="rgls-20210930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4415cdf4-25d1-4482-b8c3-25ad63de6427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_362799b6-0202-4ee4-8554-5ae6965a13f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4415cdf4-25d1-4482-b8c3-25ad63de6427" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_362799b6-0202-4ee4-8554-5ae6965a13f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a15ed96-d79b-4a49-a003-eee5f8f86750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_362799b6-0202-4ee4-8554-5ae6965a13f5" xlink:to="loc_us-gaap_NetIncomeLoss_9a15ed96-d79b-4a49-a003-eee5f8f86750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b697197-30fd-42dd-b5af-cc858531feb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_362799b6-0202-4ee4-8554-5ae6965a13f5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b697197-30fd-42dd-b5af-cc858531feb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a19f8343-a8a0-447a-862b-a88fa4fc5d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b697197-30fd-42dd-b5af-cc858531feb7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a19f8343-a8a0-447a-862b-a88fa4fc5d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d6999413-4f1e-4eaf-b9c8-f4def3dac9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b697197-30fd-42dd-b5af-cc858531feb7" xlink:to="loc_us-gaap_ShareBasedCompensation_d6999413-4f1e-4eaf-b9c8-f4def3dac9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_GainLossOnLoanForgiveness_14684a04-a49a-45bb-a724-f45361a6da59" xlink:href="rgls-20210930.xsd#rgls_GainLossOnLoanForgiveness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b697197-30fd-42dd-b5af-cc858531feb7" xlink:to="loc_rgls_GainLossOnLoanForgiveness_14684a04-a49a-45bb-a724-f45361a6da59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_76ff84d0-e98a-4c41-a761-54ed540b44a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b697197-30fd-42dd-b5af-cc858531feb7" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_76ff84d0-e98a-4c41-a761-54ed540b44a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b697197-30fd-42dd-b5af-cc858531feb7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9d911a54-75f8-4ee6-9865-7dd5a51283a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9d911a54-75f8-4ee6-9865-7dd5a51283a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_24521585-0766-4959-9efc-c33e993f3db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_24521585-0766-4959-9efc-c33e993f3db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1bb8594c-7a45-4431-96a6-af67cc0546c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1bb8594c-7a45-4431-96a6-af67cc0546c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f869a530-fbf5-46ff-9bd6-1a3867e94637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f869a530-fbf5-46ff-9bd6-1a3867e94637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cdd634ce-cd10-432e-ace9-bb9af8c020c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cdd634ce-cd10-432e-ace9-bb9af8c020c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_342a98ec-1e5c-44c4-8364-5110f044c9c0" xlink:href="rgls-20210930.xsd#rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_342a98ec-1e5c-44c4-8364-5110f044c9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c1cc703c-d7ce-4deb-8957-1bb06177357a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c1cc703c-d7ce-4deb-8957-1bb06177357a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss_2d765aa4-66b1-48f4-be72-52a87abc275b" xlink:href="rgls-20210930.xsd#rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss_2d765aa4-66b1-48f4-be72-52a87abc275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e78c8ea3-c51e-49e4-a2af-f19c03712fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e78c8ea3-c51e-49e4-a2af-f19c03712fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c4c8d332-fc2a-438a-857f-e96ca789c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eba02b01-2c36-4e59-935d-7cca06a0ebe5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c4c8d332-fc2a-438a-857f-e96ca789c0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08ae4d6c-9fb5-4399-82f2-65ff0c38d7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_362799b6-0202-4ee4-8554-5ae6965a13f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08ae4d6c-9fb5-4399-82f2-65ff0c38d7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d99121d0-c51b-4bab-95b7-098ab399c42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4415cdf4-25d1-4482-b8c3-25ad63de6427" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d99121d0-c51b-4bab-95b7-098ab399c42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a854ce17-e6aa-4688-bbbc-ba39aae78ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d99121d0-c51b-4bab-95b7-098ab399c42d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a854ce17-e6aa-4688-bbbc-ba39aae78ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8d95ad7d-cc20-43fb-bbde-33dbe6a51a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d99121d0-c51b-4bab-95b7-098ab399c42d" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8d95ad7d-cc20-43fb-bbde-33dbe6a51a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5f97a73-49af-418b-938b-b1c5e2f68eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d99121d0-c51b-4bab-95b7-098ab399c42d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5f97a73-49af-418b-938b-b1c5e2f68eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2e81cd11-a52a-4fee-85d1-1f4a0fcc795d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4415cdf4-25d1-4482-b8c3-25ad63de6427" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2e81cd11-a52a-4fee-85d1-1f4a0fcc795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ProceedsFromFederalProgram_bb8c8e14-b64d-4800-89d3-e87d6e46b68e" xlink:href="rgls-20210930.xsd#rgls_ProceedsFromFederalProgram"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2e81cd11-a52a-4fee-85d1-1f4a0fcc795d" xlink:to="loc_rgls_ProceedsFromFederalProgram_bb8c8e14-b64d-4800-89d3-e87d6e46b68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2b98cf85-dcce-4130-8de0-f80865e59b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2e81cd11-a52a-4fee-85d1-1f4a0fcc795d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2b98cf85-dcce-4130-8de0-f80865e59b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e7a9db52-1b49-46f4-b75a-53f046850070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2e81cd11-a52a-4fee-85d1-1f4a0fcc795d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e7a9db52-1b49-46f4-b75a-53f046850070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_36c6a4cc-6bd5-4513-8774-dcd58a225504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2e81cd11-a52a-4fee-85d1-1f4a0fcc795d" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_36c6a4cc-6bd5-4513-8774-dcd58a225504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PaymentsonFinanceLeases_2658c015-0616-4f86-a2ad-787ca375e9e3" xlink:href="rgls-20210930.xsd#rgls_PaymentsonFinanceLeases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2e81cd11-a52a-4fee-85d1-1f4a0fcc795d" xlink:to="loc_rgls_PaymentsonFinanceLeases_2658c015-0616-4f86-a2ad-787ca375e9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_adc36027-f69d-4665-80ba-8f32ae4990b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2e81cd11-a52a-4fee-85d1-1f4a0fcc795d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_adc36027-f69d-4665-80ba-8f32ae4990b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff7489f1-32ad-4442-aaaa-e00487aed6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4415cdf4-25d1-4482-b8c3-25ad63de6427" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff7489f1-32ad-4442-aaaa-e00487aed6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9dfa9c10-0f72-465b-8a45-b44911213d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4415cdf4-25d1-4482-b8c3-25ad63de6427" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9dfa9c10-0f72-465b-8a45-b44911213d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d0f6550-db6d-40ff-98c7-d90a1d27f267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4415cdf4-25d1-4482-b8c3-25ad63de6427" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d0f6550-db6d-40ff-98c7-d90a1d27f267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_974f3e2d-8145-408b-ae6d-ba5d93905f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4415cdf4-25d1-4482-b8c3-25ad63de6427" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_974f3e2d-8145-408b-ae6d-ba5d93905f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_568bfbb6-d45c-4701-9eca-e0b45ebb433e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_974f3e2d-8145-408b-ae6d-ba5d93905f30" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_568bfbb6-d45c-4701-9eca-e0b45ebb433e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_537403f4-9ff0-41de-bb2c-f070526da961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_974f3e2d-8145-408b-ae6d-ba5d93905f30" xlink:to="loc_us-gaap_RestrictedCash_537403f4-9ff0-41de-bb2c-f070526da961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f42ad83-5458-4eb3-ae89-1ed790e22e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_974f3e2d-8145-408b-ae6d-ba5d93905f30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f42ad83-5458-4eb3-ae89-1ed790e22e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_8b6809b0-91d3-47ec-b049-7e72eff14742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4415cdf4-25d1-4482-b8c3-25ad63de6427" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_8b6809b0-91d3-47ec-b049-7e72eff14742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PaycheckProtectionProgramLoanForgiveness_56994ae7-de3b-4170-9f6e-be1c5141571e" xlink:href="rgls-20210930.xsd#rgls_PaycheckProtectionProgramLoanForgiveness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8b6809b0-91d3-47ec-b049-7e72eff14742" xlink:to="loc_rgls_PaycheckProtectionProgramLoanForgiveness_56994ae7-de3b-4170-9f6e-be1c5141571e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_69c62c4c-ce65-445b-b260-1afdfabd0363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8b6809b0-91d3-47ec-b049-7e72eff14742" xlink:to="loc_us-gaap_InterestPaidNet_69c62c4c-ce65-445b-b260-1afdfabd0363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_f68fff23-73c0-4cf6-85b8-8e7d83b520dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8b6809b0-91d3-47ec-b049-7e72eff14742" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_f68fff23-73c0-4cf6-85b8-8e7d83b520dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="rgls-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7aa2828c-73ba-4a55-8f92-b85cf8a12235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2bb743e0-09bd-44d5-964c-134db457b66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7aa2828c-73ba-4a55-8f92-b85cf8a12235" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2bb743e0-09bd-44d5-964c-134db457b66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="rgls-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ef9df925-1170-4668-adf3-ae3192350e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dac84907-663d-4b66-8471-3913f30dfcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef9df925-1170-4668-adf3-ae3192350e1e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dac84907-663d-4b66-8471-3913f30dfcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_eb94c8f4-5f03-4c8a-98e1-4c54d1a06bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef9df925-1170-4668-adf3-ae3192350e1e" xlink:to="loc_us-gaap_UseOfEstimates_eb94c8f4-5f03-4c8a-98e1-4c54d1a06bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2d9e6cd9-824e-4c5b-95b6-dd719c9a4404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef9df925-1170-4668-adf3-ae3192350e1e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2d9e6cd9-824e-4c5b-95b6-dd719c9a4404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a44acf54-d2ac-4c40-9022-999d8331edf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef9df925-1170-4668-adf3-ae3192350e1e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a44acf54-d2ac-4c40-9022-999d8331edf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AccruedExpensePolicyTextBlock_1e8d171f-6295-43c9-897f-b168079fceda" xlink:href="rgls-20210930.xsd#rgls_AccruedExpensePolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef9df925-1170-4668-adf3-ae3192350e1e" xlink:to="loc_rgls_AccruedExpensePolicyTextBlock_1e8d171f-6295-43c9-897f-b168079fceda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PrepaidExpensesPolicyTextBlock_4daeedf6-1d23-4081-bda7-5a52c5b981c1" xlink:href="rgls-20210930.xsd#rgls_PrepaidExpensesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef9df925-1170-4668-adf3-ae3192350e1e" xlink:to="loc_rgls_PrepaidExpensesPolicyTextBlock_4daeedf6-1d23-4081-bda7-5a52c5b981c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_51895a0c-6bc4-42dd-a79f-f7f196a19932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef9df925-1170-4668-adf3-ae3192350e1e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_51895a0c-6bc4-42dd-a79f-f7f196a19932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a3915a43-452f-4c08-b8e5-740bfdbf2bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef9df925-1170-4668-adf3-ae3192350e1e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a3915a43-452f-4c08-b8e5-740bfdbf2bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a7c239de-9349-4d04-a242-97bc3d5c9761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_FinancingfromSaleProceedsDebtAgreementRevenues_0606d057-dcfb-481c-a776-242f5c9a467b" xlink:href="rgls-20210930.xsd#rgls_FinancingfromSaleProceedsDebtAgreementRevenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a7c239de-9349-4d04-a242-97bc3d5c9761" xlink:to="loc_rgls_FinancingfromSaleProceedsDebtAgreementRevenues_0606d057-dcfb-481c-a776-242f5c9a467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e38674d-75af-47c1-b148-69db75b88b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a7c239de-9349-4d04-a242-97bc3d5c9761" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e38674d-75af-47c1-b148-69db75b88b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/NetLossPerShare" xlink:type="simple" xlink:href="rgls-20210930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5cf97741-b49a-4eb2-a098-f62fe4e7b6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_afaf027a-e694-4f93-99c7-26222f71dfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5cf97741-b49a-4eb2-a098-f62fe4e7b6c5" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_afaf027a-e694-4f93-99c7-26222f71dfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_06f9d446-fe3b-4e4a-b483-45e2dd6ccccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_383da9fd-db91-46cc-96f0-19e755218a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_06f9d446-fe3b-4e4a-b483-45e2dd6ccccf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_383da9fd-db91-46cc-96f0-19e755218a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/Investments" xlink:type="simple" xlink:href="rgls-20210930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ba3b6d97-a389-40e0-882b-9010b0e20f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c600739e-cd53-462d-ab27-116b6fb3091f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ba3b6d97-a389-40e0-882b-9010b0e20f83" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c600739e-cd53-462d-ab27-116b6fb3091f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="rgls-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2c4f7ca6-ce36-4304-bc02-d57b6c5f0f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_9b4fc1dc-b0c2-47e7-a786-87a51e64a603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2c4f7ca6-ce36-4304-bc02-d57b6c5f0f39" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_9b4fc1dc-b0c2-47e7-a786-87a51e64a603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="rgls-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_113c32a9-b2a8-4541-9583-417b1db3bc07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54df4b62-a104-4a6e-82b4-e898812904ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_113c32a9-b2a8-4541-9583-417b1db3bc07" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54df4b62-a104-4a6e-82b4-e898812904ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9635d2ae-99d1-4010-97da-9c8009f6bf72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cff980df-c296-4893-8da9-462cee6b4708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9635d2ae-99d1-4010-97da-9c8009f6bf72" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cff980df-c296-4893-8da9-462cee6b4708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d564769a-b71e-4453-bb9d-44fdfabcafd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cff980df-c296-4893-8da9-462cee6b4708" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d564769a-b71e-4453-bb9d-44fdfabcafd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d9e57f8a-01f2-4160-80bb-fa66c67a915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d564769a-b71e-4453-bb9d-44fdfabcafd3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d9e57f8a-01f2-4160-80bb-fa66c67a915b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_04f2b5f9-6cb0-4509-81f3-c199057823b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d9e57f8a-01f2-4160-80bb-fa66c67a915b" xlink:to="loc_us-gaap_CashEquivalentsMember_04f2b5f9-6cb0-4509-81f3-c199057823b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5d30387-57ff-4dc5-94ff-bcac400942d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cff980df-c296-4893-8da9-462cee6b4708" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5d30387-57ff-4dc5-94ff-bcac400942d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5d30387-57ff-4dc5-94ff-bcac400942d1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c0ff4f48-c0b7-414d-b9dd-7622495008b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c0ff4f48-c0b7-414d-b9dd-7622495008b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5a56bcea-2ee8-4bd2-93d1-1c76f9250794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5a56bcea-2ee8-4bd2-93d1-1c76f9250794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1d693153-d855-423f-a1b5-924c981998dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c4c9161-1808-4d43-954c-c43f9af2d552" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1d693153-d855-423f-a1b5-924c981998dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_86f3a5f1-8388-4239-a524-7b0d49d20443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cff980df-c296-4893-8da9-462cee6b4708" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_86f3a5f1-8388-4239-a524-7b0d49d20443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_49a6a5d3-e5f0-4935-9e93-08f78d24aa67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_86f3a5f1-8388-4239-a524-7b0d49d20443" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_49a6a5d3-e5f0-4935-9e93-08f78d24aa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/Debt" xlink:type="simple" xlink:href="rgls-20210930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7bb34d15-fc6e-494a-be14-456abb2fa159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_8ec1a129-059b-43fb-9531-ea58770e5878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7bb34d15-fc6e-494a-be14-456abb2fa159" xlink:to="loc_us-gaap_LongTermDebtTextBlock_8ec1a129-059b-43fb-9531-ea58770e5878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/DebtTables" xlink:type="simple" xlink:href="rgls-20210930.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6b8a96e6-985d-44a8-a082-b23af53fa354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f532de1d-4573-4271-9493-7c5bab48d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6b8a96e6-985d-44a8-a082-b23af53fa354" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f532de1d-4573-4271-9493-7c5bab48d36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0031abaf-3458-499c-8e6b-2c6c30394e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0031abaf-3458-499c-8e6b-2c6c30394e1a" xlink:to="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8b916e10-c9d7-4241-9075-13b16d2db826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_us-gaap_DebtInstrumentAxis_8b916e10-c9d7-4241-9075-13b16d2db826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8b916e10-c9d7-4241-9075-13b16d2db826" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DebtFinancingAgreementMember_954161dc-0589-4a20-ad56-0fbbc2970172" xlink:href="rgls-20210930.xsd#rgls_DebtFinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:to="loc_rgls_DebtFinancingAgreementMember_954161dc-0589-4a20-ad56-0fbbc2970172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PPPLoanMember_83eada29-4764-4cb7-8c71-d28aefe83b28" xlink:href="rgls-20210930.xsd#rgls_PPPLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:to="loc_rgls_PPPLoanMember_83eada29-4764-4cb7-8c71-d28aefe83b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_TenthAmendmentMember_3a59611e-2d3f-41d3-96b4-263b2bbe4ff2" xlink:href="rgls-20210930.xsd#rgls_TenthAmendmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:to="loc_rgls_TenthAmendmentMember_3a59611e-2d3f-41d3-96b4-263b2bbe4ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_TermLoanMember_fa8c7c35-9659-448a-9a82-f271e4128e17" xlink:href="rgls-20210930.xsd#rgls_TermLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31e501c6-ee15-4326-ac2d-16359d676291" xlink:to="loc_rgls_TermLoanMember_fa8c7c35-9659-448a-9a82-f271e4128e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a984d7d7-fa93-4ae4-af89-341b02896460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_us-gaap_VariableRateAxis_a984d7d7-fa93-4ae4-af89-341b02896460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_21dba8be-7028-415d-90ca-50b49a7b6ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_a984d7d7-fa93-4ae4-af89-341b02896460" xlink:to="loc_us-gaap_VariableRateDomain_21dba8be-7028-415d-90ca-50b49a7b6ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7c61ab5c-b468-4552-b9a2-0ce84381fcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_21dba8be-7028-415d-90ca-50b49a7b6ef9" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7c61ab5c-b468-4552-b9a2-0ce84381fcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesAxis_07f121b0-c05d-485a-97bd-f82bc3a80907" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_rgls_StrategicAlliancesAxis_07f121b0-c05d-485a-97bd-f82bc3a80907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesDomain_64bf1b76-790c-40d4-bcb5-e1263e31cf18" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_StrategicAlliancesAxis_07f121b0-c05d-485a-97bd-f82bc3a80907" xlink:to="loc_rgls_StrategicAlliancesDomain_64bf1b76-790c-40d4-bcb5-e1263e31cf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesandCollaborationsMember_3a415e40-90bf-4228-b1c9-84bb270dc716" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesandCollaborationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_StrategicAlliancesDomain_64bf1b76-790c-40d4-bcb5-e1263e31cf18" xlink:to="loc_rgls_StrategicAlliancesandCollaborationsMember_3a415e40-90bf-4228-b1c9-84bb270dc716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f99ed930-7d84-46b7-a7ad-195f2fa74615" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_srt_CounterpartyNameAxis_f99ed930-7d84-46b7-a7ad-195f2fa74615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46a9965a-e785-4343-99fe-22b09614469b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f99ed930-7d84-46b7-a7ad-195f2fa74615" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46a9965a-e785-4343-99fe-22b09614469b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SanofiMember_f55f0dee-6bf3-4ad1-9e8f-cf3c91d42be0" xlink:href="rgls-20210930.xsd#rgls_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46a9965a-e785-4343-99fe-22b09614469b" xlink:to="loc_rgls_SanofiMember_f55f0dee-6bf3-4ad1-9e8f-cf3c91d42be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9bf0a159-38b3-4a55-a6d6-6cec3566fdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9bf0a159-38b3-4a55-a6d6-6cec3566fdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b22d2883-e9b5-471a-bcf6-27f6b12e697c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9bf0a159-38b3-4a55-a6d6-6cec3566fdc0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b22d2883-e9b5-471a-bcf6-27f6b12e697c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_a21ac4b0-368c-41cc-be63-b7662d5f4535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b22d2883-e9b5-471a-bcf6-27f6b12e697c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_a21ac4b0-368c-41cc-be63-b7662d5f4535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c4d733d-d512-43a7-b143-eeda5d20b9ae" xlink:to="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_3f27ba14-a08b-4186-ad8f-26d659a7b26a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_3f27ba14-a08b-4186-ad8f-26d659a7b26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c0c5a2f-a3b1-4f0d-8ee8-feed0d443ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c0c5a2f-a3b1-4f0d-8ee8-feed0d443ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e0323285-238c-439e-825a-0ed6881afddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e0323285-238c-439e-825a-0ed6881afddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberofMonthlyPayments_1dc3b60b-c8bc-4119-aa40-af869dd923ad" xlink:href="rgls-20210930.xsd#rgls_NumberofMonthlyPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_NumberofMonthlyPayments_1dc3b60b-c8bc-4119-aa40-af869dd923ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfAmendments_3d643af7-564f-403b-bdbc-9e3a617345a0" xlink:href="rgls-20210930.xsd#rgls_NumberOfAmendments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_NumberOfAmendments_3d643af7-564f-403b-bdbc-9e3a617345a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7ea7e819-25fa-4f3c-9ecc-be2c3e43f247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7ea7e819-25fa-4f3c-9ecc-be2c3e43f247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ForgivenessAmountThreshold_7308085b-355c-40a2-80bc-2a15d787d0c7" xlink:href="rgls-20210930.xsd#rgls_ForgivenessAmountThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_ForgivenessAmountThreshold_7308085b-355c-40a2-80bc-2a15d787d0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_InterestOnlyPaymentExtension_53f810e7-dcdd-4342-b5e9-c141adbf6474" xlink:href="rgls-20210930.xsd#rgls_InterestOnlyPaymentExtension"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_InterestOnlyPaymentExtension_53f810e7-dcdd-4342-b5e9-c141adbf6474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PrepaymentRequirement_59197775-6e19-42d6-ae77-cbb849f076d9" xlink:href="rgls-20210930.xsd#rgls_PrepaymentRequirement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_PrepaymentRequirement_59197775-6e19-42d6-ae77-cbb849f076d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e75fee43-c1d7-4596-bbba-404837b95bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e75fee43-c1d7-4596-bbba-404837b95bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_bdf256c5-73e0-463c-a0c5-2c77243e3362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_RepaymentsOfDebt_bdf256c5-73e0-463c-a0c5-2c77243e3362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PaymentFee_5a604411-a515-4a14-aa34-8830a9be8716" xlink:href="rgls-20210930.xsd#rgls_PaymentFee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_PaymentFee_5a604411-a515-4a14-aa34-8830a9be8716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfPrepaymentsToLender_3d9510a8-e921-4744-8cfb-a9c7bf05dbce" xlink:href="rgls-20210930.xsd#rgls_NumberOfPrepaymentsToLender"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_NumberOfPrepaymentsToLender_3d9510a8-e921-4744-8cfb-a9c7bf05dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AdditionalExtensionForInterestOnlyPayments_250f1c56-ae59-4966-91cb-432ca9952871" xlink:href="rgls-20210930.xsd#rgls_AdditionalExtensionForInterestOnlyPayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_rgls_AdditionalExtensionForInterestOnlyPayments_250f1c56-ae59-4966-91cb-432ca9952871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_50167fcb-e529-4275-8d9c-0cf641fcfd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_LongTermDebt_50167fcb-e529-4275-8d9c-0cf641fcfd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_5c3f5388-6928-47da-8ecb-50d5a25b0e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_5c3f5388-6928-47da-8ecb-50d5a25b0e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_7c8a4933-4b09-40d3-8e56-1bfd289719e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_7c8a4933-4b09-40d3-8e56-1bfd289719e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c48c9028-fc3e-4193-b4ce-36cf84446c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c48c9028-fc3e-4193-b4ce-36cf84446c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_fcdf78be-a161-4f61-9482-5e538976cf26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85009a50-730b-4939-a900-93c5de3ebeba" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_fcdf78be-a161-4f61-9482-5e538976cf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#DebtFuturePrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b8389897-4fd2-4d16-8c61-80080c4938ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e46f202-c655-4e0b-83ca-22eb280d4f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8389897-4fd2-4d16-8c61-80080c4938ac" xlink:to="loc_us-gaap_DebtInstrumentTable_8e46f202-c655-4e0b-83ca-22eb280d4f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7e3b3733-cdd7-419e-9bc7-437688b99ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e46f202-c655-4e0b-83ca-22eb280d4f1a" xlink:to="loc_us-gaap_DebtInstrumentAxis_7e3b3733-cdd7-419e-9bc7-437688b99ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d075ff7-2f3a-43d9-b570-86f69039665e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7e3b3733-cdd7-419e-9bc7-437688b99ddc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d075ff7-2f3a-43d9-b570-86f69039665e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DebtFinancingAgreementTrancheAMember_a5151ea1-bec5-4a9c-a4a6-306e88bd52e2" xlink:href="rgls-20210930.xsd#rgls_DebtFinancingAgreementTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d075ff7-2f3a-43d9-b570-86f69039665e" xlink:to="loc_rgls_DebtFinancingAgreementTrancheAMember_a5151ea1-bec5-4a9c-a4a6-306e88bd52e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e46f202-c655-4e0b-83ca-22eb280d4f1a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_634d60ca-831c-4d1c-acf0-6173bd669a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_634d60ca-831c-4d1c-acf0-6173bd669a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d63b6f59-81e0-4ed6-b69c-28b7f6b8df7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d63b6f59-81e0-4ed6-b69c-28b7f6b8df7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_df51f5f8-c2c9-4bbb-a4d4-c947511f6472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e213983-d7a2-44dc-a7d1-108cf43f7fed" xlink:to="loc_us-gaap_LongTermDebt_df51f5f8-c2c9-4bbb-a4d4-c947511f6472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad49e799-26a8-413d-a470-3a04de6663e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_14042b82-607f-4e7f-ae73-62506b5b560a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad49e799-26a8-413d-a470-3a04de6663e0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_14042b82-607f-4e7f-ae73-62506b5b560a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf40a2cd-d326-4641-b7b1-2c201c07a9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ActivityOfSharesTableTextBlock_14c0ebba-b025-4467-97d2-f9f9adf880f4" xlink:href="rgls-20210930.xsd#rgls_ActivityOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf40a2cd-d326-4641-b7b1-2c201c07a9ab" xlink:to="loc_rgls_ActivityOfSharesTableTextBlock_14c0ebba-b025-4467-97d2-f9f9adf880f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_ff266c37-d202-4f2f-9190-3167bcedd4f7" xlink:href="rgls-20210930.xsd#rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf40a2cd-d326-4641-b7b1-2c201c07a9ab" xlink:to="loc_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_ff266c37-d202-4f2f-9190-3167bcedd4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5a6817cf-aa3b-45cb-b50d-2f014825351d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf40a2cd-d326-4641-b7b1-2c201c07a9ab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5a6817cf-aa3b-45cb-b50d-2f014825351d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_95be3f6b-4ee5-4a32-984e-3c7b5eea9b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf40a2cd-d326-4641-b7b1-2c201c07a9ab" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_95be3f6b-4ee5-4a32-984e-3c7b5eea9b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_55f357ab-d6cf-41ac-b4f1-d6f85c00119e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf40a2cd-d326-4641-b7b1-2c201c07a9ab" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_55f357ab-d6cf-41ac-b4f1-d6f85c00119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_007d7a74-6141-4311-b9cb-c49a17ec751f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_007d7a74-6141-4311-b9cb-c49a17ec751f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b14e1aee-bddb-401d-ab27-a7252bb4aac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_us-gaap_PlanNameAxis_b14e1aee-bddb-401d-ab27-a7252bb4aac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a8e779af-9064-4e7f-b4a7-41751a4dc820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b14e1aee-bddb-401d-ab27-a7252bb4aac2" xlink:to="loc_us-gaap_PlanNameDomain_a8e779af-9064-4e7f-b4a7-41751a4dc820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_A2019PlanMember_5905550b-c926-4f78-9b8e-592efcd041b7" xlink:href="rgls-20210930.xsd#rgls_A2019PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a8e779af-9064-4e7f-b4a7-41751a4dc820" xlink:to="loc_rgls_A2019PlanMember_5905550b-c926-4f78-9b8e-592efcd041b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ffae77cb-77e0-48ae-84b0-06882d3b26e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_srt_TitleOfIndividualAxis_ffae77cb-77e0-48ae-84b0-06882d3b26e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2240dd1a-3274-4619-b1e5-a557dbdaa9e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ffae77cb-77e0-48ae-84b0-06882d3b26e2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2240dd1a-3274-4619-b1e5-a557dbdaa9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CertainDirectorsandExecutiveOfficersMember_7b506fae-02cd-42df-b03a-7fb740519382" xlink:href="rgls-20210930.xsd#rgls_CertainDirectorsandExecutiveOfficersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2240dd1a-3274-4619-b1e5-a557dbdaa9e4" xlink:to="loc_rgls_CertainDirectorsandExecutiveOfficersMember_7b506fae-02cd-42df-b03a-7fb740519382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_08ed4c8b-e52c-41eb-836a-697b69e1cfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_08ed4c8b-e52c-41eb-836a-697b69e1cfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56c371dc-dd92-4cd2-9215-d331f85efc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_08ed4c8b-e52c-41eb-836a-697b69e1cfb7" xlink:to="loc_us-gaap_EquityComponentDomain_56c371dc-dd92-4cd2-9215-d331f85efc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2de81063-01fa-4d54-8b59-2d62a640a711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56c371dc-dd92-4cd2-9215-d331f85efc1e" xlink:to="loc_us-gaap_WarrantMember_2de81063-01fa-4d54-8b59-2d62a640a711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a94b3ea3-90d8-49fe-8401-35f65c010b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a94b3ea3-90d8-49fe-8401-35f65c010b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a94b3ea3-90d8-49fe-8401-35f65c010b0a" xlink:to="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember_c589a840-8007-4f2f-b7be-dfa4daf021f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:to="loc_us-gaap_PreferredClassAMember_c589a840-8007-4f2f-b7be-dfa4daf021f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_409946c0-d555-42ce-acd9-887288957ad7" xlink:href="rgls-20210930.xsd#rgls_ClassA2ConvertiblePreferredStockAsConvertedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:to="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_409946c0-d555-42ce-acd9-887288957ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassAThreeConvertiblePreferredStockMember_c7ac0115-3b67-44e5-8d58-ec1db07818e8" xlink:href="rgls-20210930.xsd#rgls_ClassAThreeConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8a85a355-926e-4331-b640-155e1756faff" xlink:to="loc_rgls_ClassAThreeConvertiblePreferredStockMember_c7ac0115-3b67-44e5-8d58-ec1db07818e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6e0b9cc4-4139-494f-b138-f8af8c4138db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6e0b9cc4-4139-494f-b138-f8af8c4138db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d2a85ca-e2d9-4a41-87c3-6db0c89da37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6e0b9cc4-4139-494f-b138-f8af8c4138db" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d2a85ca-e2d9-4a41-87c3-6db0c89da37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b7538c2b-1ec0-48f0-8964-c1c05ac36d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d2a85ca-e2d9-4a41-87c3-6db0c89da37a" xlink:to="loc_us-gaap_PrivatePlacementMember_b7538c2b-1ec0-48f0-8964-c1c05ac36d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_MilestoneClosingMember_c6976271-f7e6-44e1-b07b-448d62d76507" xlink:href="rgls-20210930.xsd#rgls_MilestoneClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d2a85ca-e2d9-4a41-87c3-6db0c89da37a" xlink:to="loc_rgls_MilestoneClosingMember_c6976271-f7e6-44e1-b07b-448d62d76507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_54f844f6-939d-450b-a914-9efd6488dbd1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_74f0f4df-0966-419a-85a2-db69af91a281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_74f0f4df-0966-419a-85a2-db69af91a281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CommonStockVotingRightsVotes_5033f5ca-1084-41d4-b433-7435656f5566" xlink:href="rgls-20210930.xsd#rgls_CommonStockVotingRightsVotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_CommonStockVotingRightsVotes_5033f5ca-1084-41d4-b433-7435656f5566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_261d95d9-f3bb-4bfc-9317-7e2932e99115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_261d95d9-f3bb-4bfc-9317-7e2932e99115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease_3c5d526a-8b70-43d9-aafc-69eff58ae0ba" xlink:href="rgls-20210930.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease_3c5d526a-8b70-43d9-aafc-69eff58ae0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease_862dedde-156f-48af-af94-f4d053a71796" xlink:href="rgls-20210930.xsd#rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease_862dedde-156f-48af-af94-f4d053a71796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24015f5c-db48-406b-bd53-369ccd932bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24015f5c-db48-406b-bd53-369ccd932bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_621445ec-5b96-4ecc-804a-843a59b764ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_621445ec-5b96-4ecc-804a-843a59b764ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfClosings_106db547-46d8-42c2-be1f-bf375afab7af" xlink:href="rgls-20210930.xsd#rgls_NumberOfClosings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_NumberOfClosings_106db547-46d8-42c2-be1f-bf375afab7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51c40f6f-08e8-4adc-97c4-de234e55c94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51c40f6f-08e8-4adc-97c4-de234e55c94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e1061ee7-4c5a-4c17-8b43-a79f78d66557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e1061ee7-4c5a-4c17-8b43-a79f78d66557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85540f7e-8404-407c-a38d-10e8c7d1f5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85540f7e-8404-407c-a38d-10e8c7d1f5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NonvotingConvertiblePreferredStockIssued_72d758d6-6f86-4dfa-a5c5-5f1b071ebe32" xlink:href="rgls-20210930.xsd#rgls_NonvotingConvertiblePreferredStockIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_rgls_NonvotingConvertiblePreferredStockIssued_72d758d6-6f86-4dfa-a5c5-5f1b071ebe32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_84b90b2e-e635-4339-940a-6cbfa7dede15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_84b90b2e-e635-4339-940a-6cbfa7dede15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_f6d97ede-863d-48ad-a547-f1fa83632c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_f6d97ede-863d-48ad-a547-f1fa83632c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b3c65122-b4a1-4a5b-97b5-1d7a0b5fa2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b3c65122-b4a1-4a5b-97b5-1d7a0b5fa2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3fe71e4d-9b6f-44e1-a21b-197d7e481d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3fe71e4d-9b6f-44e1-a21b-197d7e481d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_71ffb35e-edcb-495a-84f2-8991bf83f834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_71ffb35e-edcb-495a-84f2-8991bf83f834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ca915396-4438-438b-bf61-3b3d6114d580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_252fd6d8-24fb-4595-808f-13f1c9db128f" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ca915396-4438-438b-bf61-3b3d6114d580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityShareActivityDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_63f77e4f-0fb1-4d52-b052-786fb03df56d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4393aa6e-8897-4f35-80b6-bf76ca0d6e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_63f77e4f-0fb1-4d52-b052-786fb03df56d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4393aa6e-8897-4f35-80b6-bf76ca0d6e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_89eb8d6c-fee0-4915-a6fc-8eeaa7ebc9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4393aa6e-8897-4f35-80b6-bf76ca0d6e01" xlink:to="loc_us-gaap_StatementClassOfStockAxis_89eb8d6c-fee0-4915-a6fc-8eeaa7ebc9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_89eb8d6c-fee0-4915-a6fc-8eeaa7ebc9b7" xlink:to="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassAOneConvertiblePreferredStockMember_fdf311ec-8b7b-4423-be4b-a527599eaada" xlink:href="rgls-20210930.xsd#rgls_ClassAOneConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_rgls_ClassAOneConvertiblePreferredStockMember_fdf311ec-8b7b-4423-be4b-a527599eaada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassATwoConvertiblePreferredStockMember_f88433df-785d-48dc-b7b8-5539767d8b6d" xlink:href="rgls-20210930.xsd#rgls_ClassATwoConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_rgls_ClassATwoConvertiblePreferredStockMember_f88433df-785d-48dc-b7b8-5539767d8b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassAThreeConvertiblePreferredStockMember_97fdaeb6-34e5-4391-92ed-dd6708e0d404" xlink:href="rgls-20210930.xsd#rgls_ClassAThreeConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_rgls_ClassAThreeConvertiblePreferredStockMember_97fdaeb6-34e5-4391-92ed-dd6708e0d404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_34c31cb2-be59-4739-bc19-a69bf4b0cd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_us-gaap_WarrantMember_34c31cb2-be59-4739-bc19-a69bf4b0cd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d60b4ecb-0c3b-4c76-bb0c-912efd940517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_04d793f9-cfc0-41bc-94d2-cb70c8af564d" xlink:to="loc_us-gaap_CommonStockMember_d60b4ecb-0c3b-4c76-bb0c-912efd940517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_09279b48-e1a0-4530-8192-621c1662e5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4393aa6e-8897-4f35-80b6-bf76ca0d6e01" xlink:to="loc_us-gaap_PlanNameAxis_09279b48-e1a0-4530-8192-621c1662e5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_48ca79b3-300c-4a1d-b303-d92a0312b895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_09279b48-e1a0-4530-8192-621c1662e5a9" xlink:to="loc_us-gaap_PlanNameDomain_48ca79b3-300c-4a1d-b303-d92a0312b895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_A2019SPAAnd2020SPAMember_dd928a96-b299-4f6f-bfce-24081ff6b74d" xlink:href="rgls-20210930.xsd#rgls_A2019SPAAnd2020SPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_48ca79b3-300c-4a1d-b303-d92a0312b895" xlink:to="loc_rgls_A2019SPAAnd2020SPAMember_dd928a96-b299-4f6f-bfce-24081ff6b74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_67efe92c-51e4-4c3a-8299-ba186fe9805b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4393aa6e-8897-4f35-80b6-bf76ca0d6e01" xlink:to="loc_us-gaap_ClassOfStockLineItems_67efe92c-51e4-4c3a-8299-ba186fe9805b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:href="rgls-20210930.xsd#rgls_ActivityOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_67efe92c-51e4-4c3a-8299-ba186fe9805b" xlink:to="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9b6904d3-3591-49a9-9b50-1e4b5cc2dae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9b6904d3-3591-49a9-9b50-1e4b5cc2dae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6c403015-03a0-4875-9d10-aba382960c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6c403015-03a0-4875-9d10-aba382960c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dd40ff23-b098-48f5-9b89-bca980a04417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dd40ff23-b098-48f5-9b89-bca980a04417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_25ebfdf9-a183-48cb-8c78-3a9c61804c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_25ebfdf9-a183-48cb-8c78-3a9c61804c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d3214b1e-fa87-4790-9212-faafa00458f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d3214b1e-fa87-4790-9212-faafa00458f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8789ea9a-2d2c-4394-8620-24fad7912a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8789ea9a-2d2c-4394-8620-24fad7912a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9be37387-2b2c-4a5b-8ffc-c0f4d94deb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ActivityOfSharesRollForward_c56e8aee-09b8-4781-9823-63abb8e8eae6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9be37387-2b2c-4a5b-8ffc-c0f4d94deb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityATMOfferingDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c48708c1-acae-47ed-bf93-504c342efee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7f4e6aff-7386-444f-bc40-ce8dbb817a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c48708c1-acae-47ed-bf93-504c342efee3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7f4e6aff-7386-444f-bc40-ce8dbb817a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_09b71903-0116-4e6a-8c54-38d764d697df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7f4e6aff-7386-444f-bc40-ce8dbb817a18" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_09b71903-0116-4e6a-8c54-38d764d697df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338e0b0b-b5a8-44bf-bb33-d6d86b21a715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_09b71903-0116-4e6a-8c54-38d764d697df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338e0b0b-b5a8-44bf-bb33-d6d86b21a715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AtTheMomentMember_1ee4f587-f103-4e10-88f8-038e5eb8c0fc" xlink:href="rgls-20210930.xsd#rgls_AtTheMomentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_338e0b0b-b5a8-44bf-bb33-d6d86b21a715" xlink:to="loc_rgls_AtTheMomentMember_1ee4f587-f103-4e10-88f8-038e5eb8c0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7f4e6aff-7386-444f-bc40-ce8dbb817a18" xlink:to="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CommissionFeeRate_5d4493b8-3a42-4175-b4ce-61e9a4b4aabe" xlink:href="rgls-20210930.xsd#rgls_CommissionFeeRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_rgls_CommissionFeeRate_5d4493b8-3a42-4175-b4ce-61e9a4b4aabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b9a35bfc-9b2e-4925-b890-4e9b9451351c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b9a35bfc-9b2e-4925-b890-4e9b9451351c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3259d434-d411-4c98-a807-29409d307485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3259d434-d411-4c98-a807-29409d307485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_e3f4829e-907d-4a9e-a50b-57023e03eea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_us-gaap_PaymentsForCommissions_e3f4829e-907d-4a9e-a50b-57023e03eea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SaleOfStockValueOfSharesAvailable_9184cfe7-14a2-4dc5-a2ac-e7d4fe8a66b8" xlink:href="rgls-20210930.xsd#rgls_SaleOfStockValueOfSharesAvailable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_25c22b3f-5b9a-4b90-9b4a-429cd8961eb8" xlink:to="loc_rgls_SaleOfStockValueOfSharesAvailable_9184cfe7-14a2-4dc5-a2ac-e7d4fe8a66b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a47f6b47-29be-42b2-89a7-aef2cf0d3682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a47f6b47-29be-42b2-89a7-aef2cf0d3682" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7391f618-388f-407f-9f7e-560351890b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7391f618-388f-407f-9f7e-560351890b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7391f618-388f-407f-9f7e-560351890b5e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_InitialClosingWarrantsMember_3fafa5d8-4c29-4783-a8e8-f2b8baf76639" xlink:href="rgls-20210930.xsd#rgls_InitialClosingWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:to="loc_rgls_InitialClosingWarrantsMember_3fafa5d8-4c29-4783-a8e8-f2b8baf76639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_MilestoneClosingWarrantsMember_7f1bffb2-16fe-468a-b063-aed704ae8b9c" xlink:href="rgls-20210930.xsd#rgls_MilestoneClosingWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:to="loc_rgls_MilestoneClosingWarrantsMember_7f1bffb2-16fe-468a-b063-aed704ae8b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_A2020PIPEWarrantsMember_0beb03fe-5b58-4254-a0fd-d9c4c46a33ac" xlink:href="rgls-20210930.xsd#rgls_A2020PIPEWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8c30578c-dd2c-4095-9268-d6ff5338e09d" xlink:to="loc_rgls_A2020PIPEWarrantsMember_0beb03fe-5b58-4254-a0fd-d9c4c46a33ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51dd845e-0210-487d-85b6-c1a00052ac2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51dd845e-0210-487d-85b6-c1a00052ac2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51dd845e-0210-487d-85b6-c1a00052ac2b" xlink:to="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_eb1e65c4-1a7a-47f5-884c-aedaf6d4f29b" xlink:href="rgls-20210930.xsd#rgls_ClassA1ConvertiblePreferredStockAsConvertedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:to="loc_rgls_ClassA1ConvertiblePreferredStockAsConvertedMember_eb1e65c4-1a7a-47f5-884c-aedaf6d4f29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_a27026bf-7b7d-4366-bee1-83ad6a20f522" xlink:href="rgls-20210930.xsd#rgls_ClassA2ConvertiblePreferredStockAsConvertedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:to="loc_rgls_ClassA2ConvertiblePreferredStockAsConvertedMember_a27026bf-7b7d-4366-bee1-83ad6a20f522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClassA3ConvertiblePreferredStockMember_78d19a65-f95f-4665-8111-f83b583ce7a4" xlink:href="rgls-20210930.xsd#rgls_ClassA3ConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d4eca18-21b6-4d46-b8c4-452914a7cb00" xlink:to="loc_rgls_ClassA3ConvertiblePreferredStockMember_78d19a65-f95f-4665-8111-f83b583ce7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bf8a82c4-0875-43df-99b4-e1182ecb6355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:to="loc_us-gaap_AwardTypeAxis_bf8a82c4-0875-43df-99b4-e1182ecb6355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_900ce5a2-35db-4a42-8077-09c7bddf5ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bf8a82c4-0875-43df-99b4-e1182ecb6355" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_900ce5a2-35db-4a42-8077-09c7bddf5ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f56069e8-53c1-4bf3-8eb0-05269cf837e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_900ce5a2-35db-4a42-8077-09c7bddf5ddf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f56069e8-53c1-4bf3-8eb0-05269cf837e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_71a144fc-3bd9-40b3-aa6a-0bbf5183800d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_71a144fc-3bd9-40b3-aa6a-0bbf5183800d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b52cf074-009d-4940-af11-16b6c08f14d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_71a144fc-3bd9-40b3-aa6a-0bbf5183800d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b52cf074-009d-4940-af11-16b6c08f14d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_TwentyTwelvePlanMember_9aa8ea39-730e-4e12-b286-e3a7410d5f18" xlink:href="rgls-20210930.xsd#rgls_TwentyTwelvePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b52cf074-009d-4940-af11-16b6c08f14d9" xlink:to="loc_rgls_TwentyTwelvePlanMember_9aa8ea39-730e-4e12-b286-e3a7410d5f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b87989fd-c416-43bc-870d-4244217f9bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b52cf074-009d-4940-af11-16b6c08f14d9" xlink:to="loc_us-gaap_EmployeeStockMember_b87989fd-c416-43bc-870d-4244217f9bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9c6f6f7-a3a3-45d0-ad17-393229c7ba3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_85b2541d-63dd-495e-a93e-fe8011f15bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_85b2541d-63dd-495e-a93e-fe8011f15bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e7a29d20-38bd-440f-a787-1858ae6159a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e7a29d20-38bd-440f-a787-1858ae6159a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8d10f75-eacb-4698-ae80-5eeefb6f3a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8d10f75-eacb-4698-ae80-5eeefb6f3a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1a6ab685-095a-4aba-a586-9389aa991850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1a6ab685-095a-4aba-a586-9389aa991850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_72603288-709c-48e3-a601-4abff0a6cdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_72603288-709c-48e3-a601-4abff0a6cdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7d115298-6740-4dd5-b5c9-bc65c540f24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0817958b-beb0-4023-b4dc-745abe9455d0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7d115298-6740-4dd5-b5c9-bc65c540f24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityStockOptionandRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66f7675a-b438-43e0-b8e5-9128e1659bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fab6b8d-93d1-4243-b9c8-631a241c7e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66f7675a-b438-43e0-b8e5-9128e1659bf1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fab6b8d-93d1-4243-b9c8-631a241c7e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1f482de3-cb0a-4c43-837c-7f65c35aabcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fab6b8d-93d1-4243-b9c8-631a241c7e81" xlink:to="loc_us-gaap_AwardTypeAxis_1f482de3-cb0a-4c43-837c-7f65c35aabcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a77f33b-2042-4f72-894d-07786512726e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1f482de3-cb0a-4c43-837c-7f65c35aabcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a77f33b-2042-4f72-894d-07786512726e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aeacf6e3-877d-4219-861b-9b07512ae2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a77f33b-2042-4f72-894d-07786512726e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aeacf6e3-877d-4219-861b-9b07512ae2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ac445d57-53b5-407f-9fdb-a9bf2310572f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a77f33b-2042-4f72-894d-07786512726e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ac445d57-53b5-407f-9fdb-a9bf2310572f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fab6b8d-93d1-4243-b9c8-631a241c7e81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76639cc1-ff3a-479e-a8f6-4be40c0e23f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76639cc1-ff3a-479e-a8f6-4be40c0e23f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ff724079-3a8d-42ff-89ec-61cc57516f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ff724079-3a8d-42ff-89ec-61cc57516f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ea38ab45-2561-40db-990b-8d802fb20a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ea38ab45-2561-40db-990b-8d802fb20a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_07f87773-bb4a-4e66-8dfa-3ab0b32dad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_07f87773-bb4a-4e66-8dfa-3ab0b32dad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bd78ba7a-c5ef-4f7f-b4ce-effa9630f18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c1fe71ff-e30f-4f7a-a9cf-792e203e0e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bd78ba7a-c5ef-4f7f-b4ce-effa9630f18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ac5a6c77-c0e2-4890-a2dc-d9778a92c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ac5a6c77-c0e2-4890-a2dc-d9778a92c28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb22295d-2ed1-4193-b54f-bffd48624429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb22295d-2ed1-4193-b54f-bffd48624429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f5e5ed14-d7b5-4c0e-b1b5-7fe9785a760a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f5e5ed14-d7b5-4c0e-b1b5-7fe9785a760a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c4909b64-f14e-4e7e-9e69-0e6fd4f1ab83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c4909b64-f14e-4e7e-9e69-0e6fd4f1ab83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9424a57-166e-4c36-93a1-5230c695f1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384fb243-6b5e-40ac-bc5f-1e04d9ccb093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9424a57-166e-4c36-93a1-5230c695f1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3e094fda-4519-44ea-a708-17bdd4b56a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3e094fda-4519-44ea-a708-17bdd4b56a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_065b657e-9a83-4132-8d24-27a2357e446f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_065b657e-9a83-4132-8d24-27a2357e446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ab371ac-aa31-4f4c-8981-cbbb0144152a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ab371ac-aa31-4f4c-8981-cbbb0144152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b962a23-89e3-4c26-988d-88af9d1dc7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b962a23-89e3-4c26-988d-88af9d1dc7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_074a1e06-de94-4748-8bca-40b365f7fa39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_516a7f19-89f0-4baa-90a8-b261889a41bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_074a1e06-de94-4748-8bca-40b365f7fa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d38c44-f108-4e13-bd7f-b0de808a0ac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d6cecea-0742-4223-9522-5289d141b6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d6cecea-0742-4223-9522-5289d141b6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd74b649-92e6-41af-bc5f-47bb96cc2337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd74b649-92e6-41af-bc5f-47bb96cc2337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9a59dd77-8182-46c2-8186-e5731d87cb07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9a59dd77-8182-46c2-8186-e5731d87cb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e23faa20-c017-4103-93cd-65310210c7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e23faa20-c017-4103-93cd-65310210c7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_112bd301-7a10-4a2c-8a00-e1b7497df666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e795cdd-240a-4277-bf0c-3182eeaaefd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_112bd301-7a10-4a2c-8a00-e1b7497df666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_685ab295-811a-44f5-b37f-5c782a1b598d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_145f1493-62ab-4fcf-ab01-70c3271ffa1d" xlink:href="rgls-20210930.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_685ab295-811a-44f5-b37f-5c782a1b598d" xlink:to="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_145f1493-62ab-4fcf-ab01-70c3271ffa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5167a77-9b0b-4c42-824e-f3db5d36e46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_145f1493-62ab-4fcf-ab01-70c3271ffa1d" xlink:to="loc_us-gaap_AwardTypeAxis_e5167a77-9b0b-4c42-824e-f3db5d36e46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e5167a77-9b0b-4c42-824e-f3db5d36e46f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6c558ccc-7769-4f78-b776-05496f4e9b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6c558ccc-7769-4f78-b776-05496f4e9b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_11d06bf0-b2f7-4fee-b200-512a2c44bf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:to="loc_us-gaap_PerformanceSharesMember_11d06bf0-b2f7-4fee-b200-512a2c44bf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b36cb2d1-9bbe-4f66-96ad-3d0c93e1c58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54f703eb-b18f-4038-8d97-23fe59af18ce" xlink:to="loc_us-gaap_EmployeeStockMember_b36cb2d1-9bbe-4f66-96ad-3d0c93e1c58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_4300651e-4f14-46c5-ba44-d513f8a6764d" xlink:href="rgls-20210930.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_145f1493-62ab-4fcf-ab01-70c3271ffa1d" xlink:to="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_4300651e-4f14-46c5-ba44-d513f8a6764d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_4300651e-4f14-46c5-ba44-d513f8a6764d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7a493c04-dc66-4065-a6f4-bdca9d029564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7a493c04-dc66-4065-a6f4-bdca9d029564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6452f312-c2b5-42ed-9eb9-6bee37aabb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6452f312-c2b5-42ed-9eb9-6bee37aabb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b46ffe79-9b54-4842-b321-5bf4b66f6e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b46ffe79-9b54-4842-b321-5bf4b66f6e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ccc005e4-1532-4b6f-981a-10111e31bb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2fb5c24f-ece6-4d09-8aee-d4588760a20d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ccc005e4-1532-4b6f-981a-10111e31bb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#StockholdersEquityStockBasedCompensationExpenseAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69fb2c01-b121-4748-bbee-b33157712d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e6adb84c-d361-44d6-a1ea-c309dc8f1abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69fb2c01-b121-4748-bbee-b33157712d62" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e6adb84c-d361-44d6-a1ea-c309dc8f1abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a67f2cf1-ad8d-41ed-a9bf-612467442b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e6adb84c-d361-44d6-a1ea-c309dc8f1abc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a67f2cf1-ad8d-41ed-a9bf-612467442b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42f68032-7d21-4a80-b5b4-d2ffb639dd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a67f2cf1-ad8d-41ed-a9bf-612467442b56" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42f68032-7d21-4a80-b5b4-d2ffb639dd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c4258063-e2c2-4508-b926-c69413ba2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42f68032-7d21-4a80-b5b4-d2ffb639dd43" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c4258063-e2c2-4508-b926-c69413ba2c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f4a8cd5b-0f00-4bce-91a2-314432162345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42f68032-7d21-4a80-b5b4-d2ffb639dd43" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f4a8cd5b-0f00-4bce-91a2-314432162345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_77923a4c-a4bf-4cf5-bf45-7a77f5672a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e6adb84c-d361-44d6-a1ea-c309dc8f1abc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_77923a4c-a4bf-4cf5-bf45-7a77f5672a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_50ed064e-988c-4876-a655-b9d73db29752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_77923a4c-a4bf-4cf5-bf45-7a77f5672a51" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_50ed064e-988c-4876-a655-b9d73db29752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/Collaborations" xlink:type="simple" xlink:href="rgls-20210930.xsd#Collaborations"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/Collaborations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_79a802f7-73b0-4f22-8be4-2634db5395d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e31edd25-8da8-4234-bc7e-8eb2ffa234a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_79a802f7-73b0-4f22-8be4-2634db5395d0" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e31edd25-8da8-4234-bc7e-8eb2ffa234a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/CollaborationsDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#CollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/CollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c714937b-b770-4954-97d2-93387180b6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c714937b-b770-4954-97d2-93387180b6bb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesAxis_b73228b0-0094-4582-ad0d-39fc78628d56" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_rgls_StrategicAlliancesAxis_b73228b0-0094-4582-ad0d-39fc78628d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesDomain_fd62c498-66f0-4221-85de-b0df4fdc9efc" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_StrategicAlliancesAxis_b73228b0-0094-4582-ad0d-39fc78628d56" xlink:to="loc_rgls_StrategicAlliancesDomain_fd62c498-66f0-4221-85de-b0df4fdc9efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_StrategicAlliancesandCollaborationsMember_41b83425-fa2e-411a-9c4a-0e575a60d4a4" xlink:href="rgls-20210930.xsd#rgls_StrategicAlliancesandCollaborationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_StrategicAlliancesDomain_fd62c498-66f0-4221-85de-b0df4fdc9efc" xlink:to="loc_rgls_StrategicAlliancesandCollaborationsMember_41b83425-fa2e-411a-9c4a-0e575a60d4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_SanofiMember_23f2d0b0-8968-49d7-b7d1-f7a042f0d7e4" xlink:href="rgls-20210930.xsd#rgls_SanofiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rgls_StrategicAlliancesDomain_fd62c498-66f0-4221-85de-b0df4fdc9efc" xlink:to="loc_rgls_SanofiMember_23f2d0b0-8968-49d7-b7d1-f7a042f0d7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ff66315e-b9c6-4cad-8cd9-e917531bea9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ff66315e-b9c6-4cad-8cd9-e917531bea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ff66315e-b9c6-4cad-8cd9-e917531bea9a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ProofofConceptTrialMember_6f1f4fd5-9cf7-46ec-a916-1067c64843b5" xlink:href="rgls-20210930.xsd#rgls_ProofofConceptTrialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_ProofofConceptTrialMember_6f1f4fd5-9cf7-46ec-a916-1067c64843b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_ClinicalMember_41895dda-03e5-4fe0-b790-407d5ef8acf7" xlink:href="rgls-20210930.xsd#rgls_ClinicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_ClinicalMember_41895dda-03e5-4fe0-b790-407d5ef8acf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RegulatoryAndCommercializationMilestonesMember_f0c0335d-1dd5-4786-b508-cb136e097e99" xlink:href="rgls-20210930.xsd#rgls_RegulatoryAndCommercializationMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_RegulatoryAndCommercializationMilestonesMember_f0c0335d-1dd5-4786-b508-cb136e097e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DevelopmentMilestonesMember_7aaae0af-f9b3-4ecd-a6e2-b28fdddc819a" xlink:href="rgls-20210930.xsd#rgls_DevelopmentMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_DevelopmentMilestonesMember_7aaae0af-f9b3-4ecd-a6e2-b28fdddc819a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_EnrollmentMilestoneMember_9586277c-b715-4858-9736-5eb52ef136f3" xlink:href="rgls-20210930.xsd#rgls_EnrollmentMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_EnrollmentMilestoneMember_9586277c-b715-4858-9736-5eb52ef136f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_MaterialsSoldMember_cda827ef-6c68-4567-aa51-49b5726e18d9" xlink:href="rgls-20210930.xsd#rgls_MaterialsSoldMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_MaterialsSoldMember_cda827ef-6c68-4567-aa51-49b5726e18d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AchievementOfEnrollmentMilestoneMember_3ba5b3fb-11cc-4eb4-b194-a643f258f359" xlink:href="rgls-20210930.xsd#rgls_AchievementOfEnrollmentMilestoneMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd485a56-65b2-4501-89af-55dd5088e09f" xlink:to="loc_rgls_AchievementOfEnrollmentMilestoneMember_3ba5b3fb-11cc-4eb4-b194-a643f258f359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_aa2d9168-281a-415e-97c1-408ef3bcd33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_aa2d9168-281a-415e-97c1-408ef3bcd33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7fb18a2c-2484-4754-9251-6f6a3f3c7de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_aa2d9168-281a-415e-97c1-408ef3bcd33c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7fb18a2c-2484-4754-9251-6f6a3f3c7de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DevelopmentCommercializationAndLicenseAgreementMember_b8026a9e-69fe-427f-9c7c-4a08a1989b0b" xlink:href="rgls-20210930.xsd#rgls_DevelopmentCommercializationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7fb18a2c-2484-4754-9251-6f6a3f3c7de6" xlink:to="loc_rgls_DevelopmentCommercializationAndLicenseAgreementMember_b8026a9e-69fe-427f-9c7c-4a08a1989b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_01f30134-036b-4fe2-b53f-d391f702fbdc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_srt_RangeAxis_01f30134-036b-4fe2-b53f-d391f702fbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6738616-f2fa-47b9-9e97-9c1ad1eef0d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_01f30134-036b-4fe2-b53f-d391f702fbdc" xlink:to="loc_srt_RangeMember_b6738616-f2fa-47b9-9e97-9c1ad1eef0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9711e3bb-7f24-42ce-8042-42d7f4dc551a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b6738616-f2fa-47b9-9e97-9c1ad1eef0d1" xlink:to="loc_srt_MinimumMember_9711e3bb-7f24-42ce-8042-42d7f4dc551a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bc426d9e-48ed-484b-afe1-63f898eec37f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b6738616-f2fa-47b9-9e97-9c1ad1eef0d1" xlink:to="loc_srt_MaximumMember_bc426d9e-48ed-484b-afe1-63f898eec37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_898505bd-dc1b-4dbe-b0c0-7eb60f9db939" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_srt_StatementGeographicalAxis_898505bd-dc1b-4dbe-b0c0-7eb60f9db939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bdeacb05-a070-42f5-99ad-ce6cb16e86ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_898505bd-dc1b-4dbe-b0c0-7eb60f9db939" xlink:to="loc_srt_SegmentGeographicalDomain_bdeacb05-a070-42f5-99ad-ce6cb16e86ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_38c0b6fa-7cd9-4d04-b478-4bb24d1b9159" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_bdeacb05-a070-42f5-99ad-ce6cb16e86ab" xlink:to="loc_country_US_38c0b6fa-7cd9-4d04-b478-4bb24d1b9159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_05298e19-f696-487f-ba08-12d8cc6c256c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_bdeacb05-a070-42f5-99ad-ce6cb16e86ab" xlink:to="loc_us-gaap_NonUsMember_05298e19-f696-487f-ba08-12d8cc6c256c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54de0eb6-21aa-48a7-8904-a9df4ad886a9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3785ca86-c839-4855-8ada-974c3a867794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3785ca86-c839-4855-8ada-974c3a867794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CollaborativeAreasGranted_623ee8ef-9533-4cf0-b219-fe9882a6c60a" xlink:href="rgls-20210930.xsd#rgls_CollaborativeAreasGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_CollaborativeAreasGranted_623ee8ef-9533-4cf0-b219-fe9882a6c60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DeferredRevenueCreditableAgainstFutureMilestones_280e58d6-de78-4d7a-b62b-6005d6ffed3a" xlink:href="rgls-20210930.xsd#rgls_DeferredRevenueCreditableAgainstFutureMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_DeferredRevenueCreditableAgainstFutureMilestones_280e58d6-de78-4d7a-b62b-6005d6ffed3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_7dc2fd08-5954-4ecf-8ef4-249c8e50f20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_us-gaap_ProceedsFromCollaborators_7dc2fd08-5954-4ecf-8ef4-249c8e50f20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable_fb789f77-58a6-4fc8-8e52-cc9641af80fd" xlink:href="rgls-20210930.xsd#rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable_fb789f77-58a6-4fc8-8e52-cc9641af80fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RoyaltyPercentageBasedOnNetSales_a31306bb-1912-401f-a2be-79f9b09a0c09" xlink:href="rgls-20210930.xsd#rgls_RoyaltyPercentageBasedOnNetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_RoyaltyPercentageBasedOnNetSales_a31306bb-1912-401f-a2be-79f9b09a0c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_AgreementPeriod_f6740c0e-3b1b-4fa6-9ca6-3c0b1f3072c0" xlink:href="rgls-20210930.xsd#rgls_AgreementPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_AgreementPeriod_f6740c0e-3b1b-4fa6-9ca6-3c0b1f3072c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_77a91574-79f2-4076-a1a8-33868c1e7b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_77a91574-79f2-4076-a1a8-33868c1e7b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_EnrollmentMilestone_8f97e2b3-df6b-4c0b-89a9-3f18f6f2f327" xlink:href="rgls-20210930.xsd#rgls_EnrollmentMilestone"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_EnrollmentMilestone_8f97e2b3-df6b-4c0b-89a9-3f18f6f2f327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_e3c13c3e-4227-4acc-b3f8-7c7b639a0ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_e3c13c3e-4227-4acc-b3f8-7c7b639a0ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DevelopmentMilestoneNotAchievable_3d5ef107-2270-4ee8-92a7-6144a9f59325" xlink:href="rgls-20210930.xsd#rgls_DevelopmentMilestoneNotAchievable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7d3bb9b-8610-45e8-a8f7-3dd92deff546" xlink:to="loc_rgls_DevelopmentMilestoneNotAchievable_3d5ef107-2270-4ee8-92a7-6144a9f59325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/Leases" xlink:type="simple" xlink:href="rgls-20210930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b03f7493-d5a6-4d5e-9257-b95c604e8b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_48791d36-a7ab-4f3c-8da9-95ab37c0d939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b03f7493-d5a6-4d5e-9257-b95c604e8b0c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_48791d36-a7ab-4f3c-8da9-95ab37c0d939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/LeasesTables" xlink:type="simple" xlink:href="rgls-20210930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f81dffb1-9a44-4e3b-9c00-508803688916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_da52bf90-2d93-4309-a5bd-f97be43eb571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f81dffb1-9a44-4e3b-9c00-508803688916" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_da52bf90-2d93-4309-a5bd-f97be43eb571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9a945a04-6504-4f22-a275-c65ac0d1828a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_76550de2-4738-4e2b-97e1-bbe0b8996cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9a945a04-6504-4f22-a275-c65ac0d1828a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_76550de2-4738-4e2b-97e1-bbe0b8996cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_694fca39-2bdd-40da-bc48-a951bde9aae9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_76550de2-4738-4e2b-97e1-bbe0b8996cd0" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_694fca39-2bdd-40da-bc48-a951bde9aae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7693ba9c-6554-4170-9baf-25727973b6ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_694fca39-2bdd-40da-bc48-a951bde9aae9" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7693ba9c-6554-4170-9baf-25727973b6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_PriorPremisesMember_7928efc7-0d28-4127-b596-ecb82272003b" xlink:href="rgls-20210930.xsd#rgls_PriorPremisesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7693ba9c-6554-4170-9baf-25727973b6ea" xlink:to="loc_rgls_PriorPremisesMember_7928efc7-0d28-4127-b596-ecb82272003b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_CampusPointLeaseMember_37398c46-0ead-40dc-9740-9bb753d376b1" xlink:href="rgls-20210930.xsd#rgls_CampusPointLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7693ba9c-6554-4170-9baf-25727973b6ea" xlink:to="loc_rgls_CampusPointLeaseMember_37398c46-0ead-40dc-9740-9bb753d376b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_76550de2-4738-4e2b-97e1-bbe0b8996cd0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_01630a08-a000-442e-8192-e0b6e2c3d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_NetRentableArea_01630a08-a000-442e-8192-e0b6e2c3d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4c8a9a7c-00fd-427f-8b1b-1abc467ab9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4c8a9a7c-00fd-427f-8b1b-1abc467ab9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3d29998d-86c3-47c2-be3d-b55c78cda966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3d29998d-86c3-47c2-be3d-b55c78cda966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9d568698-d6cf-4495-9489-c0eb1d4cdc07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9d568698-d6cf-4495-9489-c0eb1d4cdc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_InitialDirectCostLiability_a04d3f41-324c-4a02-8365-5bd7b49358bd" xlink:href="rgls-20210930.xsd#rgls_InitialDirectCostLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_InitialDirectCostLiability_a04d3f41-324c-4a02-8365-5bd7b49358bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba4ba60c-d178-4471-b2f3-96642b497e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba4ba60c-d178-4471-b2f3-96642b497e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_DeferredCreditOperatingLeaseLiability_44db15c5-4d3a-4272-a5ae-ed238ec3ae85" xlink:href="rgls-20210930.xsd#rgls_DeferredCreditOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_DeferredCreditOperatingLeaseLiability_44db15c5-4d3a-4272-a5ae-ed238ec3ae85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_RentedArea_b90dc053-f63f-4010-99aa-909fe634fe81" xlink:href="rgls-20210930.xsd#rgls_RentedArea"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_RentedArea_b90dc053-f63f-4010-99aa-909fe634fe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_90c75e20-cca0-4def-9416-903d73e80f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_90c75e20-cca0-4def-9416-903d73e80f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NonrefundableLeaseCostForAssignment_e0434035-ce9a-4feb-9b66-ca226da93336" xlink:href="rgls-20210930.xsd#rgls_NonrefundableLeaseCostForAssignment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_NonrefundableLeaseCostForAssignment_e0434035-ce9a-4feb-9b66-ca226da93336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_NumberOfOperatingLeaseContracts_4dfaa78d-d238-48db-9414-f94ddd79b71f" xlink:href="rgls-20210930.xsd#rgls_NumberOfOperatingLeaseContracts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_rgls_NumberOfOperatingLeaseContracts_4dfaa78d-d238-48db-9414-f94ddd79b71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsLeasingAccumulatedAmortization_98fb3448-02b7-4c14-9712-8d9c542dd139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsLeasingAccumulatedAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_013ab8d4-8576-4389-8e8a-287e93929be6" xlink:to="loc_us-gaap_DeferredCostsLeasingAccumulatedAmortization_98fb3448-02b7-4c14-9712-8d9c542dd139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails" xlink:type="simple" xlink:href="rgls-20210930.xsd#LeasesOperatingandFinanceMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b509f545-2b48-4e46-8221-8bce206fb48e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b509f545-2b48-4e46-8221-8bce206fb48e" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f4500905-e12b-484d-94ba-995dcf637ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f4500905-e12b-484d-94ba-995dcf637ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8950418c-6923-4241-85c9-77d9eca8d700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8950418c-6923-4241-85c9-77d9eca8d700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d784da5-4bc6-47f2-997b-c4cfdd388f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d784da5-4bc6-47f2-997b-c4cfdd388f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66236d11-4711-4c02-8257-992ec63db4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66236d11-4711-4c02-8257-992ec63db4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_f81571dd-1071-4f58-b75f-5c7ad185b97a" xlink:href="rgls-20210930.xsd#rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_f81571dd-1071-4f58-b75f-5c7ad185b97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_93115d91-bedc-4dac-b0aa-66b5b9bf11ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_93115d91-bedc-4dac-b0aa-66b5b9bf11ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bfd1b21f-abc6-4537-9e7c-a8acf654a664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bfd1b21f-abc6-4537-9e7c-a8acf654a664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5dbb5531-22a2-4b32-aa4c-6a3aef18a107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_us-gaap_OperatingLeaseLiability_5dbb5531-22a2-4b32-aa4c-6a3aef18a107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3a2b21d6-68f4-44fa-a7f8-699421077916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3a2b21d6-68f4-44fa-a7f8-699421077916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9c28d8f-b161-4522-bf08-b744de89b45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d7f78a18-3997-4fb2-a45a-530c61e1de72" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9c28d8f-b161-4522-bf08-b744de89b45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1" xlink:type="simple" xlink:href="rgls-20210930.xsd#LeasesOperatingandFinanceMaturitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>rgls-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rgls="http://www.regulusrx.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rgls-20210930.xsd" xlink:type="simple"/>
    <context id="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8111d7345b08453e894915175538e2d9_I20211105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2021-11-05</instant>
        </period>
    </context>
    <context id="i1ffdb10c152a4544a6ac91e853bf0328_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5c50d853f72c4c36960bcf1c2165224d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec5a7ece68f34af9a1c0b10216bcff29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA1ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA1ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0e7272b1621e4746803c762bf1a81ca5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec8b178ce8274601b70fd58c2f287d14_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6f0c73a09494482383aa980fa7b3693f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic60d06be298b4e55a466408378417d03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i868ed48256c846129326496101c3afa4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i01168e5978e14e958219e06962200018_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c3f16817aff4123aca2966839b53fda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iddc56a36fc5e488986a42a9c474e76c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72366e3fa5d44f0e9f12dbd590832293_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id753b733b8084902acfdb79365d408e4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i70db96b959cb44848f3b413e51827d92_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i051ea96b453f429caa68e3801ce5bc29_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if883ca285d9e4b31bc6d7edfdd22e3b6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if6ee41175879423c93045b232c54bfe7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iea678063a4e5490b8f065fd950d4952d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i266c364e78cb46aeab7659ca36e88cbf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7a3a053cc647497aacd5d5b56004d10f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8cfad87cc9de4cc090746542475df981_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idb4b3672299546139d7e04d964128b42_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5525c2dcee4a4d748f8cfbc31dfc8db3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9d36a105ae449beb839ab6a815bcf59_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i020405b1a3e24f1281f97a16daf92291_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i32e9077c24de4469bfd47b1d8acb39a3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7fdcfbfd5e98440c85fbaf81e72f285d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4935d8a23a6f420385a4f517fac836e2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id1ca9e82037e4fc2adef24baea0d6e30_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i69c825f130c2462d822bff3231997bf0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c707f52c3ad423d9929a3b102a980e8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie3d073fce4e748a79a7a58c6ebd79572_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c592b3c93f247f4bdddc3f28cf0bcc4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1329e87d85994ed5aec3fc36abc2f3f6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1eb8b8d131534c03ad4f1dc07b5cd25c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3092be79f8214d54a1f70f92a5d08c86_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i00b19f57325c448582fbbc67739c326b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb8e219bee614949b739b6c590453b4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if3320ae2f75043c2bb5c26a7ec8241e0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46dcde68ee6949fabac04d61528c3adb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i88172ee03d6b45da9f2508fc8c899e50_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0839129300ae490a88abf37136846111_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i57e728fa3cb540d5917b1e146d5c075e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iec31e70363d949bc869ebd9d662e556f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6fdfa6760cde47c78598ec14f20df863_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i41608b92ab1e405c9505107aa8fd4a10_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ica4813bf265846af86e7cc13ba14b04c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id6f736255edb4fd394dcac61f435857f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i937a88a09ffe475e93aa3271b6d32b6e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i106931b626c24de2b02765bb0b3ff2e3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if57f750264234676ba54c29635f86b6e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0273fa1e721f4669bb524150f471d493_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icd72b68db08a4f389c46d913ec8ff603_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i797de9f7b8c94355addeba1011495bd6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if302f494d5d1498abe569565dbdf97a7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d1408d312334eb79d917b31476e9f45_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iddcc9b19c42a47b09baa002a71fba35e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3d830f02b3e14451ad9e64b964c38013_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i90d7713a719f4a73b660cf6b5827d495_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6725b24da6f44eb8a2bdef563ccfd0e1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6943c5db1485450bb348ad14827a1cd3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i865538f5e6944ffbab25f061268e630e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ccc29ee690e4861959d540c320ce357_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d268293b00748cb90f4f7273393b95f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia9f6d4248d2b4dc986c29c6a7ad68bf0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icac0a725c51e4495a0c3d3346febea7b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id5d5b6ce568c40dc86b3246c0c3574fc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2b2751e06f46463a94612500556b66a8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2e558bd57cca45c5b203fdaf82f601e8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7c3dd88f2ee24d50940e2d23ae23e499_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8e6bf61ba9c4435e80870c56d0a0f96b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a47324fa24547688554544bf8a88ebb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i63e7c32d4abb4857a652dbaf35a42b0b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3b42f9a435294e1c9a483222e912c132_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i09deb282dd9b4bf58f7a624fb80f547f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2fdd8f019e3c491b8732a68d899250a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ce7ee44d1194a78aa295bd978dc3ae7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86b176df93ed4f47b0455d5746bf050e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6383c5f184bf4004ba7ac38c997e14c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i523ebcbfef6d4b6aa814dd3ff356bd8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f7695f94fcc4a2b92b921a5c6aa94bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ecd930760914ed780a9b7337dc50c31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f4532b2830348528c01118566cacbce_D20160622-20160622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-22</startDate>
            <endDate>2016-06-22</endDate>
        </period>
    </context>
    <context id="ica365f62a18542a3bd628586ba2316d7_I20160617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-17</instant>
        </period>
    </context>
    <context id="i56addd06803544669ea6adfb1f85223b_D20160617-20160617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-17</startDate>
            <endDate>2016-06-17</endDate>
        </period>
    </context>
    <context id="i03875b50705141378eeb6a7f3db6d93c_D20171001-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="ic806cb07df3044b1b53e64130fffba72_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="i892f5ef11b7f487eb34d5314ea17e4fd_D20200825-20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TenthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-25</startDate>
            <endDate>2020-08-25</endDate>
        </period>
    </context>
    <context id="iefd75439e0974679b47a6cff8366c288_I20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TenthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-25</instant>
        </period>
    </context>
    <context id="i380cfb226da64264aa858aa432603785_D20200930-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rgls:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-30</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b747865a07948508c75f1aa6b053b63_D20201008-20201008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rgls:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-08</startDate>
            <endDate>2020-10-08</endDate>
        </period>
    </context>
    <context id="id16ee745789f48d18517ec4b1a9769cf_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rgls:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i8c8cb641775b42569a9458112a507826_D20200930-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-30</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i46549a65d985413b8403edb46967d1b0_D20201008-20201008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-08</startDate>
            <endDate>2020-10-08</endDate>
        </period>
    </context>
    <context id="ic64856709b654f068e893bde533341f9_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ic7d6534d80e9479592a4aa31ef10377f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2905a20cdd80471abc18cd4877622e4b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i923277ec32bd4699a80593ceda7d7e81_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2de3b934180e4445a01ae3a427e91b3f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:DebtFinancingAgreementTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifd548549c7b7438bb6836f7b080e3d0f_I20200423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rgls:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-23</instant>
        </period>
    </context>
    <context id="ie53dd4b291ee4100afcd9f063f293242_D20200122-20200122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-22</startDate>
            <endDate>2020-01-22</endDate>
        </period>
    </context>
    <context id="ie740123647534dc7b2a846af038991a4_D20200122-20200122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <startDate>2020-01-22</startDate>
            <endDate>2020-01-22</endDate>
        </period>
    </context>
    <context id="i9a1f2d1ed7234256bace1246be18d4ee_I20200122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-22</instant>
        </period>
    </context>
    <context id="ie68f8c41edfb46ee9870928b23961edc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3322efb25d9a4f5f9fb3224308d86541_I20190503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
        </entity>
        <period>
            <instant>2019-05-03</instant>
        </period>
    </context>
    <context id="i674455781c874bdbbef4fcb1f436968d_D20190507-20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="i0f2c4232052049e3a363d782b40cb6bc_I20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="i50625ecf1d0a45eeb2ecec6aac3745e9_I20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="i81b3e274349048899a6baf2136cbce5c_D20190507-20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="icd6803fc0e58407c98e7e6efe7b48823_I20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="i21a6fc5988124fb9a3c0daca71b52647_D20190507-20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="iead2605b5d6e40c59a34f098e26f325d_D20191224-20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2019-12-24</endDate>
        </period>
    </context>
    <context id="i360a9fad1f764e37b7a0392838193495_I20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-24</instant>
        </period>
    </context>
    <context id="i6e3c72e4f312454cb6e94e3624438bd4_D20191224-20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2019-12-24</endDate>
        </period>
    </context>
    <context id="i9e9d49856529484a9241d0f6562c00ce_D20191224-20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2019-12-24</endDate>
        </period>
    </context>
    <context id="ief922b305f3046a1a28f76ddcd1e5862_D20191224-20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2019-12-24</endDate>
        </period>
    </context>
    <context id="i7662e8163acd4dc8adc61570e5adde5d_I20191224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:MilestoneClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-24</instant>
        </period>
    </context>
    <context id="if073e6ccc7cc48ab99b972e5ac765b10_D20201204-20201204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-04</startDate>
            <endDate>2020-12-04</endDate>
        </period>
    </context>
    <context id="ie514dfd04114480cb2e11b8bf5bb0435_I20201204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-04</instant>
        </period>
    </context>
    <context id="i919f61d52aec4ec9804c967d05a0ac34_I20201204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-04</instant>
        </period>
    </context>
    <context id="i6a2c7b41e9fc4304b5170c4d5ee66271_I20201204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-04</instant>
        </period>
    </context>
    <context id="i77c7496e13cb499b9175da4b6316b202_D20201204-20201204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-04</startDate>
            <endDate>2020-12-04</endDate>
        </period>
    </context>
    <context id="i1ba02a52203c4223911077232c49cee7_I20201204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-04</instant>
        </period>
    </context>
    <context id="ic598bb91fd7e4fed8d09bafbe5180ce0_D20201204-20201204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rgls:CertainDirectorsandExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-04</startDate>
            <endDate>2020-12-04</endDate>
        </period>
    </context>
    <context id="ib0a0858e919543a98b9c64121d1e1830_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbea8938a1694e83b04dda860ed7dd2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia79e9b8c233642bbb9cebdf5dfb40760_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45d5562fcca646dd99b09cd41afa34ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i752592ed38104bc78a16c74ec4d542fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia03dfcdae3b1407bb022fb54e0a8156b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i383282b176b840d4a8c19a6ac7b18315_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6af434f9895c4a8abcdc67b6e14c6efe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic0bbfe3a36da493c9161915cc9d72948_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia36e6a371c8a44609f70ce29521cf931_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5dd6bbd169a646cdac5d2d64ecd91d4a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i62444203267d47c385eec5d087d4d8da_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i39b26e0a123149da8e318c905c14d733_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c861e934bbb434fb65de130aef4d7f0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i26455c9e63ec418298d96a228a52ea5c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i74040130c2df49589afc08ad9a809499_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i254490f02c4c4c589f3f3c5081713988_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i95228771e65f4d69be9591692885d592_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9c2c3a10cf064f479a81fd8b17777c0f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4f4afbe5d8c34f8998934e3231e70d99_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3dc0c2d79507405e933216b019d4edde_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if247eeb7c16c4eb39296da50e9a88a87_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id0325f8a593a4d04848243185ea3662f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic7022c7df72d41e099622cfcf6c5ac69_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie294014d4c6e4e89b676a5f599db291f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7e29c7e6e8d7461aa5503106164f57ee_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id175542746b14dbe92632e7c763d73a4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4e4836ff49d45a0813f0bf3e816e560_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7fc483577ed845e8bf93c991053ea7c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f8532096be04b6d9015d6367f7d8fdc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic55ea03d6757422cb1b7c98ef85d4d29_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i436d75c6db184475b193def39aa233c2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i24d7ff325bb64f3ba97014fba8f446f6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie1f198ef1d3d40c590316253a4a859b3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib871a39aa1ac437eaa31e7324e95ec4f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1e829145a1ef44a3801129514bd80961_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i968ebf92b9924a3f927dd3367b7ee9b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica7c16fbdde44fcab2f8edcb368cb2ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6455474e083246cbbfdf27a81a04fd9c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23dd736c354b4baca7d8a7e5ad03a16f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i20b9351df4284c69984f500e694a6369_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3352e5aab04142a5979bb162e53c6330_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2451dacc95664a628df7a419490f93d5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i74a57decb14440bf86a20216c8b58def_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i688d71ec835347f28d95349cfa461c90_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i86de16f9b2f842129ce65f588a7a7aa9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i230bbacb14564b7287002929b04072b6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iaf1162c4370f4f1495d1b38cb8c36886_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3dc114989d2e49059136125c88e9d784_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ida746cb1127f4a02913c9868d13207b9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i17a1ebeb40054eee85bbb7562a88622b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0bc530cdf0a042f3b6cfcb98f0abe16d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iec999a5bafc747db893bef4a0ad2b58a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idf571b5851d240cc8cda05c8c168c970_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1b2924209bd04bb7a40a2a56f99caa9f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie2af4520400a4c80a524537bc2037d39_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1b1959cfd8084de1ad61cf35bcfd27a2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7c97aedbf36c4a329ed8b131afa706da_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6923a101d07842c3b5768ebb561bc42e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iac6b75c985414d3a94e6080ae2260895_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8fa784103a1544b79cc572714fbd6000_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i070064518ba64c48988cb9ebab49b967_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id7db41969a844eb099ad7cacafdc6a43_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb123cc427924d9d83494db5ea171543_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3593e979f61242e4974999e7d07215d2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i786a3068e05841b28df2e45b562e51ee_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i99418e2e85d14e5491bd379d2557e64f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i952837312fd74bb6ad3761bd0f543858_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rgls:ClassAThreeConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1c184c7909e14f73a331173806592ad9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id5de04397b02498d82ebeda41dd65f11_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rgls:A2019SPAAnd2020SPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i76e2ff0b853b425197ddbce613a8c517_I20181212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-12</instant>
        </period>
    </context>
    <context id="i89cc80809f64492f8d626470ab85255a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b63a4e5d7f548ab874621e4d0e59f70_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0f0579c541c24aefa982bf42729d197c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3c72dba56f1642e4bb4ba0d460f36bff_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7c836c16b926435386de34b3cc16d880_I20210810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="i6122f172c1574c4da14a5e4fd4d6e9da_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AtTheMomentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6e0fa5dcfa6f41d78143b478d0a01b56_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rgls:ClassA1ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8a0c87ad7a8d436fa4ccaa34c29d3a34_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rgls:ClassA2ConvertiblePreferredStockAsConvertedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia8b79769fd334fd287d6b5137a7b5c74_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rgls:ClassA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic8041ada6a3e4d52bcb9c494a7798bca_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rgls:InitialClosingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3341a1d23c5c4c2cace6220943a0f34f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rgls:MilestoneClosingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3dd5d41a28e04fa0b27f308560cc92c1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rgls:A2020PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2c2342f58c454d05b39c846426605b48_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifdae785f59024129a26a080f3e9b9224_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:TwentyTwelvePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i00f4406481484bada9b1cf86ce076050_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i951d796d9ed84f84b26dc055c3e072b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i644ae87d631747999899d8f3a2d4e933_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib11f92ae4880433b90d114da1ab87247_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i70017d07079c4189905253f72a203dfa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic504631e11784f66848db26f50687d26_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6794a82e447847f0b259ae873682904e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd5e74c99c434af4873f28aa394abae8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e4dc078f58b49e3b773f4556b8a3b41_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58b8f3c6cf464d83b2c2ae2abd93eef6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65465aaa0a2b4eff99ceadebe06d4c4b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f2e97743f414d1694ca8d0fce5260f4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id179c53c4d4246068ac3e3d9d3e878bf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia4c9397744df49d28775440c5244e2ab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i817be33db9a14559bd6acb439e8aab8f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id91c48b0026b42dc91f4d51602dab771_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i207c6ee7766e4b7b8321acdabc61f642_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib574d1151949442b9717daf3b9f1afcd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i91edac16aa02482ab13c5c6191291f75_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:StrategicAlliancesandCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00c63c04aad146a4a4b300df5bf7b017_D20120701-20120731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-07-01</startDate>
            <endDate>2012-07-31</endDate>
        </period>
    </context>
    <context id="i3bcfd2d3e6b4477b9224c2ddab8e9c58_D20140201-20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-02-01</startDate>
            <endDate>2014-02-28</endDate>
        </period>
    </context>
    <context id="i9f4e945ac07d4765bd2b5ffc2566e5ae_D20130601-20130630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-06-01</startDate>
            <endDate>2013-06-30</endDate>
        </period>
    </context>
    <context id="i41a9a1a9f277465e8d50fdad1c657692_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ProofofConceptTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1929ac258c9c450cae6fef04bef7a0e8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba95955f98f043a68a1e97b6a00b2b51_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ClinicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i153b7153a94d40aebf670759f33de31f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:RegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i54a4f0ed7dc74ea5888ebe893d2216a7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibfab0a14bbcd45099cc675f73f91da2d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26e5dcd2596c41159528a70c01a1e7c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3fabccc96bc64e1d9de7b84c7b313a57_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0f3e037391ac473094c869e8548228db_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ifa94d177b51946f9b13662dc829b3dc7_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="if665882f71ff45d8bb6f588594d45f74_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="ibe78a5b02aa8476385726b454cc854b6_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:EnrollmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i353569e61e144d2db9c5ffc37b740344_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i29b7fba7009e439bbd4b1263221e7cf2_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i2e7415adf3f848789ba227aa56299001_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i1806af5ab5b1428dbecc44603e625189_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:MaterialsSoldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i5d5dfcdeeecf40d4bbfce822eba097da_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:AchievementOfEnrollmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i539bb433e4534e329bc2c02884235317_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ifa5bd7d664de45838a638a9e07b56636_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i38edd55d27744d19aae8f3e58923a1d8_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ia8ceffe851924b93b694c2c233f516a4_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i4a88aa30ce5f40f6915bd8be98ea9592_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i03c5d4dd537e4ff08c58974c361af177_I20190619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:PriorPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-19</instant>
        </period>
    </context>
    <context id="i25175afe9d9d4c0f895fef5eab8d5af5_I20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:PriorPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-01</instant>
        </period>
    </context>
    <context id="i158c1d7853cc43d08c48916341fcc559_I20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:CampusPointLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="i695ef34b99df4efc8fc1b1d5d72d82f2_D20210211-20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:CampusPointLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="i9f5be9f84b7d49a28e6d8c05f8aaaa70_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rgls:CampusPointLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="payment">
        <measure>rgls:payment</measure>
    </unit>
    <unit id="amendment">
        <measure>rgls:amendment</measure>
    </unit>
    <unit id="prepayment">
        <measure>rgls:prepayment</measure>
    </unit>
    <unit id="vote">
        <measure>rgls:vote</measure>
    </unit>
    <unit id="closing">
        <measure>rgls:closing</measure>
    </unit>
    <unit id="target">
        <measure>rgls:target</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="contract">
        <measure>rgls:contract</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl8xLTEtMS0xLTYxMDM_d31c86ce-273a-4803-8aca-5c23a9ecd0f0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl8yLTEtMS0xLTYxMDM_8940b273-28a2-4dac-92a7-e5aff592b199">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl8zLTEtMS0xLTYxMDM_80f620cf-c933-4d94-94a3-a2394d258026">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl80LTEtMS0xLTYxMDM_30e5274d-11be-497d-b18f-deabbd48dd2b">REGULUS THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl81LTEtMS0xLTYxMDM_56355a57-4d0b-44f1-9d12-8aa4eed7df00">0001505512</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180L2ZyYWc6N2FjYmZiOTA3ODlkNDY4Nzg0ZDQ2YzRlNDA3ODQxNGUvdGFibGU6YzI5YTZiZjg2YTFjNDZlYjkyZWFjMDIwODBmZWY4ZjIvdGFibGVyYW5nZTpjMjlhNmJmODZhMWM0NmViOTJlYWMwMjA4MGZlZjhmMl82LTEtMS0xLTYxMDM_136ddd96-3995-4f25-a8b2-047ef2573111">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_565d7559-28ba-4345-9a0b-75933eaa77e7">http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_59cfb3be-2728-482e-ae52-18bdd71ebc3f">http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_7ca68d24-3d91-478b-b761-58d0319ff7a8">http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0wLTEtMS02MTAz_90ce62b6-7870-4d8c-9f4c-aed84ce70c1e">http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember</us-gaap:TypeOfRevenueExtensibleList>
    <dei:DocumentType
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6ZmNhMDg5ODYwMTllNDU2MGFkNThmNDlmNTUwNjFkYjYvdGFibGVyYW5nZTpmY2EwODk4NjAxOWU0NTYwYWQ1OGY0OWY1NTA2MWRiNl8wLTItMS0xLTYxMDM_a0ee81bd-bfdb-403a-aad8-b65092e09918">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NmJkMjU5ZmQ2ZmI1NDFjNTk4OTAzMTc4MjczNGIzYmUvdGFibGVyYW5nZTo2YmQyNTlmZDZmYjU0MWM1OTg5MDMxNzgyNzM0YjNiZV8wLTAtMS0xLTYxMDM_336bf064-d9c3-4d10-817a-7cb662f52689">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xMjU_5a30e98d-a5a3-4ff6-82c4-29d192864013">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6ZTNiYmRlYWQyNTdkNGUzMmE0OGNkY2FjMDljZTYwYTAvdGFibGVyYW5nZTplM2JiZGVhZDI1N2Q0ZTMyYTQ4Y2RjYWMwOWNlNjBhMF8wLTAtMS0xLTYxMDM_080defea-8a50-4057-87b3-6cb2739d9e2a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc0_303baa3f-d620-4a7c-b882-6d080919f23c">001-35670</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl8wLTAtMS0xLTYxMDM_1031ccba-af0a-4b0b-836d-9314b31dd743">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl8wLTItMS0xLTYxMDM_ef8340f3-665c-43b8-95a9-4b7424e05c55">26-4738379</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl8zLTAtMS0xLTYxMDM_2f8a134a-2a05-4b09-8577-aea272dd6587">4224 Campus Point Court, Suite 210</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl8zLTItMS0xLTYxMDM_b850c983-9a80-41a8-b8f3-233c1df663c7">92121</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl80LTAtMS0xLTYxMDM_5fbade03-a80a-4484-8c7b-c95f4e5d2dda">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NDA1ODA4MTk4M2EwNDU1Mzk3ZWUxYzAzMThmZWNiZDIvdGFibGVyYW5nZTo0MDU4MDgxOTgzYTA0NTUzOTdlZTFjMDMxOGZlY2JkMl81LTAtMS0xLTYxMDM_bdd676b3-b4b2-4f9d-9f25-4f7b0c6afd3d">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc1_50f44ecb-d0f8-4cc8-8e4a-73534e13b356">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc2_cd8c4110-fbe4-4660-8fee-cd4bec3c115c">202-6300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NTBkN2M4ZDg1YmY1NDM2YWE3MTcxNTYxMmQyNmVhNjgvdGFibGVyYW5nZTo1MGQ3YzhkODViZjU0MzZhYTcxNzE1NjEyZDI2ZWE2OF8xLTAtMS0xLTYxMDM_90df24c1-df4a-4f93-8af6-a3b5acbf88b4">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NTBkN2M4ZDg1YmY1NDM2YWE3MTcxNTYxMmQyNmVhNjgvdGFibGVyYW5nZTo1MGQ3YzhkODViZjU0MzZhYTcxNzE1NjEyZDI2ZWE2OF8xLTItMS0xLTYxMDM_3f4a11ab-cd51-4aee-9e74-f80e3fc5a49d">RGLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6NTBkN2M4ZDg1YmY1NDM2YWE3MTcxNTYxMmQyNmVhNjgvdGFibGVyYW5nZTo1MGQ3YzhkODViZjU0MzZhYTcxNzE1NjEyZDI2ZWE2OF8xLTQtMS0xLTYxMDM_5c2b25d3-a78f-4be5-8fd9-9b7b28236b51">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc3_9ec55fb2-7546-443c-b584-f7dcacb32ced">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTc4_705aadb4-59b4-4382-9440-551860a56ad1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6M2Q2ZjhiZWUxZTIwNDRhOWFkNDhmZjVlOGYxYTVjZjIvdGFibGVyYW5nZTozZDZmOGJlZTFlMjA0NGE5YWQ0OGZmNWU4ZjFhNWNmMl8xLTAtMS0xLTYxMDM_2fde46eb-57df-4075-904e-5ad190b3e375">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6M2Q2ZjhiZWUxZTIwNDRhOWFkNDhmZjVlOGYxYTVjZjIvdGFibGVyYW5nZTozZDZmOGJlZTFlMjA0NGE5YWQ0OGZmNWU4ZjFhNWNmMl8xLTYtMS0xLTYxMDM_0c23cc09-9235-4a4a-a92e-33549451c259">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGFibGU6M2Q2ZjhiZWUxZTIwNDRhOWFkNDhmZjVlOGYxYTVjZjIvdGFibGVyYW5nZTozZDZmOGJlZTFlMjA0NGE5YWQ0OGZmNWU4ZjFhNWNmMl8yLTYtMS0xLTYxMDM_7349673c-485d-495d-8d7d-b909d572639d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xODgy_8250a955-7464-4081-99b7-1bb46ce7798b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8111d7345b08453e894915175538e2d9_I20211105"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xL2ZyYWc6MTk5ZjkzZmIyYmRkNGY3ODk0ODNhN2E0MDhkNTMxNTMvdGV4dHJlZ2lvbjoxOTlmOTNmYjJiZGQ0Zjc4OTQ4M2E3YTQwOGQ1MzE1M18xOTE0_a316034f-a30b-4dfb-acc8-3f86a532f8a5"
      unitRef="shares">87047832</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNC0xLTEtMS02MTAz_844fd44b-abf6-4651-86b5-b5f3f7b8a66a"
      unitRef="usd">35848000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNC0zLTEtMS02MTAz_f0369073-affe-41e9-8267-4019e2d24313"
      unitRef="usd">31087000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNi0xLTEtMS02MTAz_ec9fd2b2-ae90-4f7d-903f-7924f0460043"
      unitRef="usd">62000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNi0zLTEtMS02MTAz_52900be6-3553-4700-89e2-1406947e1eef"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNy0xLTEtMS02MTAz_1db43bc1-aa1d-4ea3-9368-0dc5ec797627"
      unitRef="usd">0</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNy0zLTEtMS02MTAz_6fd1c589-7380-4177-a5be-268a231888ba"
      unitRef="usd">503000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfOC0xLTEtMS02MTAz_51169c70-d893-4fd8-8df4-88ae22fd168a"
      unitRef="usd">3010000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfOC0zLTEtMS02MTAz_9c0eeb07-1034-4ab8-be6e-3d2a1dca7787"
      unitRef="usd">3314000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfOS0xLTEtMS02MTAz_2fc8c1b7-954c-4816-adc5-942c1df34d48"
      unitRef="usd">1066000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfOS0zLTEtMS02MTAz_3ba58bad-f878-4a35-94a3-ba2cc148e692"
      unitRef="usd">1826000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTAtMS0xLTEtNjEwMw_b9cd008f-d28b-4190-8a23-bac0a6011f43"
      unitRef="usd">39986000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTAtMy0xLTEtNjEwMw_2732b7da-9e9d-4222-8de7-bbfc3112c302"
      unitRef="usd">36730000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTEtMS0xLTEtNjEwMw_3bf55de3-0915-4e86-8088-52e0e1076846"
      unitRef="usd">277000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTEtMy0xLTEtNjEwMw_95b4c357-7505-4e59-ad84-84f027ce073d"
      unitRef="usd">472000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTItMS0xLTEtNjEwMw_05aeaf9f-8366-44f3-ac53-0712a0be9b12"
      unitRef="usd">89000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTItMy0xLTEtNjEwMw_e8f618e8-5a27-4dfb-91ae-7823c4fc608e"
      unitRef="usd">125000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTMtMS0xLTEtNjEwMw_b58440a4-8782-499e-8c48-e4fbeaf0898e"
      unitRef="usd">2690000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTMtMy0xLTEtNjEwMw_43ea867b-98e9-490e-82e4-2d284924f730"
      unitRef="usd">253000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTQtMS0xLTEtNjEwMw_75fd47fe-489e-4119-8361-87c40033dd23"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTQtMy0xLTEtNjEwMw_72bd9e3d-5894-41ca-b359-ba8062993c7c"
      unitRef="usd">24000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTUtMS0xLTEtNjEwMw_a429bdec-4b57-4e1c-87b5-9c681b7a584e"
      unitRef="usd">43042000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTUtMy0xLTEtNjEwMw_84c2cd50-4097-413a-8300-34a7bd15a6e4"
      unitRef="usd">37604000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTgtMS0xLTEtNjEwMw_a885b34e-2755-488d-95e2-d259e65f3361"
      unitRef="usd">586000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTgtMy0xLTEtNjEwMw_9b8870ed-6fbf-4c16-935e-9e5bd9037212"
      unitRef="usd">535000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTktMS0xLTEtNjEwMw_acc190b5-da60-4790-9bfe-169c13e1d72d"
      unitRef="usd">775000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMTktMy0xLTEtNjEwMw_71b90a55-b137-4d53-b9b9-17e26ce450de"
      unitRef="usd">581000</us-gaap:AccruedLiabilitiesCurrent>
    <rgls:AccruedResearchAndDevelopmentCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjAtMS0xLTEtNjEwMw_0c4a3c6e-9251-4e87-953c-3da5b3187843"
      unitRef="usd">2347000</rgls:AccruedResearchAndDevelopmentCurrent>
    <rgls:AccruedResearchAndDevelopmentCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjAtMy0xLTEtNjEwMw_70c1b0b0-27fb-4ce9-8537-dc1799dfb138"
      unitRef="usd">1097000</rgls:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjEtMS0xLTEtNjEwMw_16e7d35c-d2d8-4686-8272-948d2f583339"
      unitRef="usd">1427000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjEtMy0xLTEtNjEwMw_e863ec26-0174-44ba-b192-52411cb47c3f"
      unitRef="usd">1743000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjItMS0xLTEtNjEwMw_7bc5e95e-bb1d-4946-8c74-1f0156d19410"
      unitRef="usd">4668000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjItMy0xLTEtNjEwMw_81e20453-b41f-4149-b59b-c258e445af9e"
      unitRef="usd">4652000</us-gaap:DebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjUtMS0xLTEtNjEwMw_78341102-c52e-4ddc-aaa9-68ce3ebfcb5d"
      unitRef="usd">1657000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjUtMy0xLTEtNjEwMw_f5b24770-6c38-48c7-92fb-d3e4ee521fb8"
      unitRef="usd">2970000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjYtMS0xLTEtNjEwMw_e706ea8d-3b83-4063-8395-be2d04575607"
      unitRef="usd">11460000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMjYtMy0xLTEtNjEwMw_844ee5c8-537e-4c95-818c-0e25a9288174"
      unitRef="usd">11578000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzAtMS0xLTEtNjEwMw_e681f4a7-b86d-4f49-ace5-c7ff3e655a84"
      unitRef="usd">2570000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzAtMy0xLTEtNjEwMw_6e6c554a-dc30-446e-a564-964fddd9aeb1"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzItMS0xLTEtNjEwMw_226c549d-befd-4225-aec8-cf66afe139d2"
      unitRef="usd">14030000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzItMy0xLTEtNjEwMw_edb16882-239a-4bf1-ac49-2abcc228da06"
      unitRef="usd">11578000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzMtMS0xLTEtNjEwMw_4923c1bb-7057-4a6f-a90a-de3ef50ee081"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzMtMy0xLTEtNjEwMw_0ba4382c-0e4e-4e9e-87a0-a04196a23753"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzQz_13ebbc0b-2f20-41ce-8907-b85fc874b0cd"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzQz_4b6ff5cd-194c-4be6-a93e-d8947bafaf12"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_046d87c0-be1b-49f4-a7dc-93929e917244"
      unitRef="shares">256700</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_53b663ad-94a5-4278-8e9a-4b8a4a02ddeb"
      unitRef="shares">256700</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_75a74915-ecdf-475d-b9f2-6c870404f813"
      unitRef="shares">256700</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_a32d9995-f714-4c51-9c28-db0bc474268c"
      unitRef="shares">256700</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_c027a46b-951e-415f-ba0d-089765503e6f"
      unitRef="shares">256700</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjk1ZTMxY2EwZjAyZjRkMWY5YzFiN2UwN2Q0OTYyN2Y0XzU3_f8e6116e-b629-4ec7-8fe7-93d63cd221b6"
      unitRef="shares">256700</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ib69d43c380ba4ddebfd21ea6ce174b7c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMS0xLTEtNjEwMw_33955a6a-9643-4308-a0ab-a23a3daf2434"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iec5a7ece68f34af9a1c0b10216bcff29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzUtMy0xLTEtNjEwMw_433a9699-0a38-4f50-9b63-36028e5e1c81"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzQz_8eadd80f-cab9-424b-bfb5-c8dc6dbc52a3"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iec8b178ce8274601b70fd58c2f287d14_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzQz_eba3f7d3-a2e2-48f5-b8a4-8c21c7192fb4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzU3_928f4314-12a6-4c49-8958-346b112234cf"
      unitRef="shares">1330832</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iec8b178ce8274601b70fd58c2f287d14_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzU3_dfe47a93-b316-4896-a37d-fad235acc366"
      unitRef="shares">1330832</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzU3_f5063e13-e5b1-49e3-99d0-9ccca111cc53"
      unitRef="shares">1330832</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzY0_1d3c41bb-ccc2-4bdc-a60f-68da7d87921e"
      unitRef="shares">1416453</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzY0_3a8e8aa2-ccb7-4ecd-92e3-6a3a44ee2c19"
      unitRef="shares">1416453</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmI1ODBhNzFhNDJhYzQ3M2ZhMWU2MjE2YmRjOGQ0NzhhXzY0_795f0864-baf3-40c3-86d7-39635282aa8a"
      unitRef="shares">1416453</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="iec8b178ce8274601b70fd58c2f287d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMS0xLTEtNjEwMw_09aaef99-89ca-40cd-bdb1-5f44ad68cfb0"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0e7272b1621e4746803c762bf1a81ca5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzYtMy0xLTEtNjEwMw_56682c0b-2c63-4116-8615-aec2a3e5257f"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzQz_41bbe767-94f8-432b-a41a-642f557e2b22"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic60d06be298b4e55a466408378417d03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzQz_e981ec38-ab73-4465-8fd3-73e169d3de80"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_5b9631a6-6d77-4296-802f-c157f039c622"
      unitRef="shares">258707</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic60d06be298b4e55a466408378417d03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_89b4a14a-ab23-4b1f-8c2e-4cc915634c3b"
      unitRef="shares">258707</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_bdf48984-e605-4385-8661-8dd2af2ece17"
      unitRef="shares">258707</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic60d06be298b4e55a466408378417d03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_c8156336-82f3-4b77-989b-21a1f5157d59"
      unitRef="shares">258707</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic60d06be298b4e55a466408378417d03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_f4292218-a880-4a0c-b0f4-adec6a13d7ca"
      unitRef="shares">258707</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMC0xLTEtNjEwMy90ZXh0cmVnaW9uOjczYTVkNmFmMThhNTRlMGE4ZmE0MGFlMjJkZTAxY2Y0XzU3_f85bd27c-7fc8-4bc5-b1d7-0ed581855f77"
      unitRef="shares">258707</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="i6f0c73a09494482383aa980fa7b3693f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMS0xLTEtNjEwMw_ded0372e-3f64-4a4a-8da6-3c2f2e1a76f4"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ic60d06be298b4e55a466408378417d03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzctMy0xLTEtNjEwMw_9d4fcf3b-eb32-47ee-b408-40058ee6403c"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzE4_0998ab02-d030-48de-b753-5be3fe939c08"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzE4_5b3256dc-7860-46c7-b210-35203c65d09d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzMy_b951a404-f150-46ee-b193-24d368b54beb"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzQ2_97d30e61-6000-4953-959b-977c5bfefd6c"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzExNA_0d0d2474-71f0-47e2-b292-f9218b9df631"
      unitRef="shares">87047832</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzExNA_c2fb4856-4018-40e9-89f8-673aafa1eae3"
      unitRef="shares">87047832</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzEyMQ_db4fd1fb-5e8b-4959-b2e7-0cb307ede5ec"
      unitRef="shares">67432712</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMC0xLTEtNjEwMy90ZXh0cmVnaW9uOmM5NTRmYTY3NjEyMzRjNDVhZGU5NjA1OTgxNDY2NTYzXzEyMQ_eb7d3271-98e7-4eb7-b3da-28eb4d342905"
      unitRef="shares">67432712</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMS0xLTEtNjEwMw_62b3eeee-f5b1-4baf-b022-7aaed1b0eb8e"
      unitRef="usd">87000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzgtMy0xLTEtNjEwMw_a76acad1-7667-409b-bbf7-a3baa9358659"
      unitRef="usd">67000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzktMS0xLTEtNjEwMw_e376153c-9794-4151-b737-d9cd41dd77df"
      unitRef="usd">476643000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfMzktMy0xLTEtNjEwMw_7ebe81ce-8afc-4898-9036-488b1a6076a4"
      unitRef="usd">453002000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDEtMS0xLTEtNjEwMw_8d105ebc-2a84-454e-91ce-16aad7b5e768"
      unitRef="usd">-447720000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDEtMy0xLTEtNjEwMw_de75f1d4-1ed4-4691-92e8-75a1f29c856b"
      unitRef="usd">-427045000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDItMS0xLTEtNjEwMw_88dd299c-011c-4ecd-8f38-3237f12dbc68"
      unitRef="usd">29012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDItMy0xLTEtNjEwMw_9f27063c-50f3-4c51-9fa6-266d5cc82f17"
      unitRef="usd">26026000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDMtMS0xLTEtNjEwMw_df304bb7-cd32-46b9-94f6-276022f96685"
      unitRef="usd">43042000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18xOS9mcmFnOjdlNjY1MDFmYTNlYjRlYjE4Y2FhMDVjNjY0NTZjNTE3L3RhYmxlOjNjNGM5OTRhODExODQ3ZmNiMjg2YTNhOTQxYjU2MTNmL3RhYmxlcmFuZ2U6M2M0Yzk5NGE4MTE4NDdmY2IyODZhM2E5NDFiNTYxM2ZfNDMtMy0xLTEtNjEwMw_50c959dc-6861-4df2-9f6d-699e5abe257e"
      unitRef="usd">37604000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0xLTEtMS02MTAz_5e0981da-e334-4094-8210-59edb1e5763b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC0zLTEtMS02MTAz_4fb5e8c3-84e0-4f27-9fd5-dc00f4364020"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC01LTEtMS02MTAz_2822f4cb-f798-433e-9f01-cdd135c064cf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNC03LTEtMS02MTAz_1888301c-e9c2-4867-b09c-af1b0b22d673"
      unitRef="usd">5006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNS0xLTEtMS02MTAz_67478895-7752-487c-8f7f-aad796fbf8e4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNS0zLTEtMS02MTAz_3d8ac9c0-44aa-4767-8ca6-937aab505904"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNS01LTEtMS02MTAz_1868ab70-775b-4272-845e-f8e2716751ec"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNS03LTEtMS02MTAz_d0a7c41d-0214-4efa-a247-689bed8741f2"
      unitRef="usd">5006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNy0xLTEtMS02MTAz_6dd8d99e-3372-4a6a-8bf7-86078f3d6358"
      unitRef="usd">5915000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNy0zLTEtMS02MTAz_066b32ed-c848-4a53-8257-11f30727e145"
      unitRef="usd">4036000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNy01LTEtMS02MTAz_c3a1c60d-1cc9-4029-9ec3-8b453d1b5160"
      unitRef="usd">13385000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfNy03LTEtMS02MTAz_669be64a-c539-40fc-83ef-60732efbdfe5"
      unitRef="usd">11396000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOC0xLTEtMS02MTAz_2e764590-3c0b-4d07-8a4f-a93b7fe4b874"
      unitRef="usd">2504000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOC0zLTEtMS02MTAz_b23013a2-3b06-43e4-ad9b-eca1b246c104"
      unitRef="usd">2059000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOC01LTEtMS02MTAz_47e3ce90-88b0-4abf-bd2f-bfbc9c624424"
      unitRef="usd">7471000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOC03LTEtMS02MTAz_31deeca3-34ad-4a37-bdfb-60a12f0a2866"
      unitRef="usd">6736000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOS0xLTEtMS02MTAz_fc73d992-3b0a-4dae-878d-8414fc49c003"
      unitRef="usd">8419000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOS0zLTEtMS02MTAz_965ba984-3730-433b-8bdf-5cfd551985be"
      unitRef="usd">6095000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOS01LTEtMS02MTAz_0d46ad32-9025-4341-9995-dbc6b97e9372"
      unitRef="usd">20856000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfOS03LTEtMS02MTAz_74b3554d-2060-45a9-a077-9a52e22d8ca7"
      unitRef="usd">18132000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTAtMS0xLTEtNjEwMw_a4a07e65-dcae-48e4-8bb9-997e7d2f830e"
      unitRef="usd">-8419000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTAtMy0xLTEtNjEwMw_305c06f5-201a-4255-bdc2-76de2dafecea"
      unitRef="usd">-1095000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTAtNS0xLTEtNjEwMw_fcbc66dd-3042-41da-8da1-5e4ce7222009"
      unitRef="usd">-20856000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTAtNy0xLTEtNjEwMw_7620c854-a0bf-42d4-92d0-7d84425c027f"
      unitRef="usd">-13126000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTItMS0xLTEtNjEwMw_3cc2d1f8-f40b-48dc-b1a9-1a5468ed4c2a"
      unitRef="usd">1000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTItMy0xLTEtNjEwMw_cf10c740-ce12-4017-bf26-e630ad71bbf1"
      unitRef="usd">38000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTItNS0xLTEtNjEwMw_b60a5e3d-841a-4aa4-abbe-4af6977fe709"
      unitRef="usd">823000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTItNy0xLTEtNjEwMw_550410ba-abfd-4376-ac29-c5f0abcb28e4"
      unitRef="usd">127000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpense
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTMtMS0xLTEtNjEwMw_977b551b-8bea-47f7-953f-ceaffa85ea14"
      unitRef="usd">210000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTMtMy0xLTEtNjEwMw_5a16cc64-308e-4245-90ba-70fac2bb2395"
      unitRef="usd">466000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTMtNS0xLTEtNjEwMw_8f2f82d2-aba2-4664-9612-3cdb95a65579"
      unitRef="usd">641000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTMtNy0xLTEtNjEwMw_b9d04fd7-b658-484e-b750-54b37c4092be"
      unitRef="usd">1416000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTUtMS0xLTEtNjEwMw_4d213056-1970-41fe-93dd-d620be08939e"
      unitRef="usd">-8628000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTUtMy0xLTEtNjEwMw_a17aab4f-f93d-4b9b-a547-5f24fbd270b2"
      unitRef="usd">-1523000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTUtNS0xLTEtNjEwMw_64894ab0-c60e-412b-af30-8182b0990ba1"
      unitRef="usd">-20674000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTUtNy0xLTEtNjEwMw_207bc442-7ff9-4fb0-9d72-968475e95865"
      unitRef="usd">-14415000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTYtMS0xLTEtNjEwMw_4322e17d-9c84-4749-9c00-5fdbe6420a23"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTYtMy0xLTEtNjEwMw_56f82adb-1bb6-4e09-b51f-815119f5cb3c"
      unitRef="usd">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTYtNS0xLTEtNjEwMw_317869bd-4bd1-4d96-987b-f30f1de163b8"
      unitRef="usd">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTYtNy0xLTEtNjEwMw_87a8408c-5745-437b-9a01-3a5f11f08527"
      unitRef="usd">-7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTctMS0xLTEtNjEwMw_55af8e09-2d3a-428d-84f8-8ba4ee657fa1"
      unitRef="usd">-8628000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTctMy0xLTEtNjEwMw_6be744ee-f2fb-4bca-bf7b-ebb0d1c2875d"
      unitRef="usd">-1524000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTctNS0xLTEtNjEwMw_8a92fd52-c528-409e-b7fa-b617bd612476"
      unitRef="usd">-20675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMTctNy0xLTEtNjEwMw_76880a23-a1ff-412b-aca2-01ef9885c851"
      unitRef="usd">-14408000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtMS0xLTEtNjEwMw_6b7ed4f8-bd95-415a-b62f-1ca9d995a2b9"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtMS0xLTEtNjEwMw_f2eaed93-08f4-4b98-b1ac-6e2841437cff"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtMy0xLTEtNjEwMw_698b1cc2-74fe-4d56-9444-a7ac366c77b1"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtMy0xLTEtNjEwMw_ec79aa01-f36b-458d-ac60-d6ea97b73d87"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtNS0xLTEtNjEwMw_0b420a0f-cb22-41a1-b07f-f189a5e80d29"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtNS0xLTEtNjEwMw_935ff82e-eaa3-4dfd-a0b5-733e1c52c56c"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtNy0xLTEtNjEwMw_0c61de94-accc-4433-9afe-69a5c7c4a454"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjEtNy0xLTEtNjEwMw_638a014f-1539-48d4-8ce0-b3c65c4f430f"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItMS0xLTEtNjEwMw_2ce63866-2ca9-4fb8-9ac5-d3d72be1f819"
      unitRef="shares">87042437</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItMS0xLTEtNjEwMw_fbb8e4a7-2734-4730-aa60-d90d0f37ecd0"
      unitRef="shares">87042437</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItMy0xLTEtNjEwMw_f2b1087e-efe3-45c4-a226-e813272d3aa8"
      unitRef="shares">38137281</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItMy0xLTEtNjEwMw_fd246c27-92fe-4e7c-b1d3-80b4bc688c13"
      unitRef="shares">38137281</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItNS0xLTEtNjEwMw_d1448ed7-5e07-4d2c-b8c2-92949d64e93b"
      unitRef="shares">78560760</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItNS0xLTEtNjEwMw_e429cb10-751b-490a-a9ce-1f3079dad128"
      unitRef="shares">78560760</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItNy0xLTEtNjEwMw_05a89572-7a46-47d8-a91a-b7e118e2b3e7"
      unitRef="shares">30695137</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yMi9mcmFnOmI3NDYwYjAzMmJhZjQxZGE5Mzk1Y2ExNDA1OGRhMTZhL3RhYmxlOjA4NTE4YWJjOTg3NzRmNmY5YjRiNzYxOGRlN2ZmOWIwL3RhYmxlcmFuZ2U6MDg1MThhYmM5ODc3NGY2ZjliNGI3NjE4ZGU3ZmY5YjBfMjItNy0xLTEtNjEwMw_d99f9e42-4f15-44a2-9eb2-4e1f6612b42c"
      unitRef="shares">30695137</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i01168e5978e14e958219e06962200018_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtMS0xLTEtNjEwMw_1659305c-af51-455e-923b-3562b8b9d1f5"
      unitRef="shares">1931860</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i01168e5978e14e958219e06962200018_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtMy0xLTEtNjEwMw_25d6fe5e-86eb-49c9-a036-43cd4c3ed176"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i5c3f16817aff4123aca2966839b53fda_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtNS0xLTEtNjEwMw_16286674-d184-464e-ac1f-96ccf9d37ba1"
      unitRef="shares">67432712</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5c3f16817aff4123aca2966839b53fda_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtNy0xLTEtNjEwMw_8cca0a76-1c76-4715-8fed-71a650f4873e"
      unitRef="usd">67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iddc56a36fc5e488986a42a9c474e76c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtOS0xLTEtNjEwMw_7accb952-f756-4fc3-aab9-13d57eedf4e7"
      unitRef="usd">453002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72366e3fa5d44f0e9f12dbd590832293_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtMTMtMS0xLTYxMDM_51a9f9df-c2b5-40d4-be5d-fb4e2082f63f"
      unitRef="usd">-427045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDQtMTUtMS0xLTYxMDM_c59157a6-f50c-4301-8aef-6fde859770c1"
      unitRef="usd">26026000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDYtNS0xLTEtNjEwMw_c3591dfa-2d62-482d-86f6-2299bf7f4ccf"
      unitRef="shares">16902</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDctNS0xLTEtNjEwMw_56fa5659-3e31-4c13-8600-219ec2ec749a"
      unitRef="shares">26770</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDctOS0xLTEtNjEwMw_e3a6551d-31f3-4c2d-a8b3-dc78a2638ed5"
      unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDctMTUtMS0xLTYxMDM_c48bd710-a30d-420f-a792-a3fe1c0f08e5"
      unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <rgls:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDgtNS0xLTEtNjEwMw_cbe093de-f40c-4d88-b4e3-0ce4d4756e0e"
      unitRef="shares">2418681</rgls:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <rgls:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDgtNy0xLTEtNjEwMw_e59ecaee-6715-41c6-a574-5cdf10e446bd"
      unitRef="usd">3000</rgls:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <rgls:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDgtOS0xLTEtNjEwMw_5479e610-c837-4e88-89d7-5e95b505d9d6"
      unitRef="usd">663000</rgls:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <rgls:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDgtMTUtMS0xLTYxMDM_40581095-e97f-49e3-bfec-c90d4d284db0"
      unitRef="usd">666000</rgls:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDktNS0xLTEtNjEwMw_f5fd469f-d37c-46c7-8ee6-109477397148"
      unitRef="shares">4009585</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDktNy0xLTEtNjEwMw_431b1789-c19e-4887-9889-9490889abffb"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDktOS0xLTEtNjEwMw_7d0d8451-0f6b-4388-82f5-12a99e871179"
      unitRef="usd">5709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNDktMTUtMS0xLTYxMDM_9c211d31-b860-49c8-bbbd-71377aed5d11"
      unitRef="usd">5713000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTAtNS0xLTEtNjEwMw_60850dcf-656b-4b95-a836-6a8a742809a3"
      unitRef="shares">4122</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTAtOS0xLTEtNjEwMw_5de3c655-7851-4ee5-9777-e4b1522a60e6"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTAtMTUtMS0xLTYxMDM_3c74956b-5abf-4e31-9b07-8c435d1a4e16"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i70db96b959cb44848f3b413e51827d92_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtMS0xLTEtNjEwMw_9f11bf20-37ca-449d-a898-57d7d8d1ebb2"
      unitRef="shares">-78036</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtNS0xLTEtNjEwMw_8dfacee3-2a55-4908-811d-1f5c33f4316e"
      unitRef="shares">780360</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i2b2bba8bb1e5422caccf5a70fdf6d1d5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtNy0xLTEtNjEwMw_62a7d5b4-567d-4a53-bcde-32ef21f4d9fd"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtOS0xLTEtNjEwMw_0e2ea32b-278e-47a3-90ad-741ddee3bee5"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTEtMTUtMS0xLTYxMDM_a400509c-5574-4b31-a399-6a270d123439"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i24e9d9fe7f3340e48e4a22fd9c65bec9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTItOS0xLTEtNjEwMw_92db44b6-4700-462f-9fa1-b9ab90b3e6fb"
      unitRef="usd">691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTItMTUtMS0xLTYxMDM_a40ba516-098b-4589-98af-3255901ae0b0"
      unitRef="usd">691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i051ea96b453f429caa68e3801ce5bc29_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTgtMTMtMS0xLTYxMDM_fb939133-eb09-4687-a343-c931c43ef3ab"
      unitRef="usd">-6013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id753b733b8084902acfdb79365d408e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTgtMTUtMS0xLTYxMDM_0ebbfa46-8ac3-4fd2-8e36-6e60cd0c1118"
      unitRef="usd">-6013000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="if883ca285d9e4b31bc6d7edfdd22e3b6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktMS0xLTEtNjEwMw_aac89ea6-f901-4e05-bc7d-2adb0e85e4a5"
      unitRef="shares">1853824</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if883ca285d9e4b31bc6d7edfdd22e3b6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktMy0xLTEtNjEwMw_134c2998-4d3c-45b0-95ff-a25dadf9383c"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if6ee41175879423c93045b232c54bfe7_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktNS0xLTEtNjEwMw_8f86f476-0d1e-4f0c-b504-4f5c5e91e7ce"
      unitRef="shares">74689132</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if6ee41175879423c93045b232c54bfe7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktNy0xLTEtNjEwMw_35e205c1-b420-45a0-b8ca-c8471e9a39f9"
      unitRef="usd">75000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea678063a4e5490b8f065fd950d4952d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktOS0xLTEtNjEwMw_80d42f4f-9b93-4626-9c64-71c8dc0b3b32"
      unitRef="usd">460092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i266c364e78cb46aeab7659ca36e88cbf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktMTMtMS0xLTYxMDM_011b9794-375f-4e0c-88ac-c839053fc290"
      unitRef="usd">-433058000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a3a053cc647497aacd5d5b56004d10f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNTktMTUtMS0xLTYxMDM_d975a4eb-289e-4a89-96e9-343821b12d3f"
      unitRef="usd">27111000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjAtNS0xLTEtNjEwMw_748b71e3-c517-4e39-8460-63d4966459f9"
      unitRef="shares">16849</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjEtNS0xLTEtNjEwMw_768e4f7a-011c-4f59-b014-6fb3be6ee95f"
      unitRef="shares">958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjEtMTUtMS0xLTYxMDM_f32e2636-b3f5-4eec-b9b0-f857eb72f19a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <rgls:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjItNS0xLTEtNjEwMw_f1585a5d-ee34-43b1-8cb8-d45220d8303d"
      unitRef="shares">250000</rgls:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <rgls:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="idb4b3672299546139d7e04d964128b42_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjItOS0xLTEtNjEwMw_a813343b-da36-4749-a130-d0a90ea47e8e"
      unitRef="usd">166000</rgls:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <rgls:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjItMTUtMS0xLTYxMDM_a8705e91-6cbe-445e-b99a-099f887c7967"
      unitRef="usd">166000</rgls:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjMtNS0xLTEtNjEwMw_34da03c6-2919-4001-8c17-7f6b1810b845"
      unitRef="shares">12007546</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjMtNy0xLTEtNjEwMw_19bb4261-da53-441d-96a8-ebf21028cea6"
      unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idb4b3672299546139d7e04d964128b42_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjMtOS0xLTEtNjEwMw_47e8bc81-202b-4ebb-b3c0-31daf645b208"
      unitRef="usd">14819000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjMtMTUtMS0xLTYxMDM_7ab7653e-ceac-4c5a-aebd-802d921aba91"
      unitRef="usd">14831000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i5525c2dcee4a4d748f8cfbc31dfc8db3_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjUtMS0xLTEtNjEwMw_4612f375-9bbb-49b3-b239-bbc777927efa"
      unitRef="shares">-7585</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i5c6bbfc58bcb4b4f9f6bda4b6b1e8279_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjUtNS0xLTEtNjEwMw_d19b6369-c40f-4f70-acfb-46396ede66c8"
      unitRef="shares">75850</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjUtMTUtMS0xLTYxMDM_0bd6c0f8-cfd9-41a3-a1c5-feb863e15f77"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idb4b3672299546139d7e04d964128b42_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjYtOS0xLTEtNjEwMw_fc49d0f8-5c0e-4a41-8baa-1c54144af738"
      unitRef="usd">754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjYtMTUtMS0xLTYxMDM_a468fd2c-ea94-4877-98e0-12781b904a98"
      unitRef="usd">754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ia9d36a105ae449beb839ab6a815bcf59_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjctMTMtMS0xLTYxMDM_a2553734-8bd1-494e-b7ad-28dc5f06bee8"
      unitRef="usd">-6034000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8cfad87cc9de4cc090746542475df981_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjctMTUtMS0xLTYxMDM_6c241c7d-978e-48b9-99f7-43c723d703f8"
      unitRef="usd">-6034000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i020405b1a3e24f1281f97a16daf92291_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtMS0xLTEtNjEwMw_cd19176a-da4b-4319-ac76-369ad7cbe2a8"
      unitRef="shares">1846239</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i020405b1a3e24f1281f97a16daf92291_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtMy0xLTEtNjEwMw_5048faa0-937d-4de7-bef4-ecd7a9e65b8f"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i32e9077c24de4469bfd47b1d8acb39a3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtNS0xLTEtNjEwMw_b181ddc2-70fd-4bb0-bc77-380f48ed031b"
      unitRef="shares">87040335</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i32e9077c24de4469bfd47b1d8acb39a3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtNy0xLTEtNjEwMw_37aef6b3-4715-4430-8fed-b10dffd14561"
      unitRef="usd">87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fdcfbfd5e98440c85fbaf81e72f285d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtOS0xLTEtNjEwMw_2774be93-43ac-4d60-b216-aa88ea57cea3"
      unitRef="usd">475831000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4935d8a23a6f420385a4f517fac836e2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtMTMtMS0xLTYxMDM_8b6d6ff2-2174-4cef-a373-bb40b4adfffb"
      unitRef="usd">-439092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1ca9e82037e4fc2adef24baea0d6e30_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNjgtMTUtMS0xLTYxMDM_d3540efb-14dd-4b36-a99b-3b7733a9d1f3"
      unitRef="usd">36828000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i69c825f130c2462d822bff3231997bf0_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzMtNS0xLTEtNjc3Nw_859662d6-2bfc-47cb-9920-a777edd2885a"
      unitRef="shares">7497</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8c707f52c3ad423d9929a3b102a980e8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzMtOS0xLTEtNjc3Nw_5737e134-3e86-42e9-acd6-7252d4d119b5"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzMtMTUtMS0xLTY3Nzc_db9b0c94-ac2b-4f8a-ad3c-902528cc3d16"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8c707f52c3ad423d9929a3b102a980e8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtOS0xLTEtNjc3OQ_e976f7e6-a742-45f8-994f-25664a24980e"
      unitRef="usd">807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtMTUtMS0xLTY3Nzk_07ef892c-b583-4067-b149-adadd9c18a78"
      unitRef="usd">807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ie3d073fce4e748a79a7a58c6ebd79572_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMTMtMS0xLTY3Nzk_bde71601-3af0-4feb-a4d0-3f6d6b75a977"
      unitRef="usd">-8628000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMTUtMS0xLTY3Nzk_f1a1ab34-3b52-4b69-99e6-e8c46ef2a1d7"
      unitRef="usd">-8628000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4c592b3c93f247f4bdddc3f28cf0bcc4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMS0xLTEtNjc3OQ_70e828bd-7ada-4d86-96ac-9e5ba51a65ac"
      unitRef="shares">1846239</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4c592b3c93f247f4bdddc3f28cf0bcc4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMy0xLTEtNjc3OQ_bd212719-bc6a-4c8a-b290-ff2b9560d976"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i1329e87d85994ed5aec3fc36abc2f3f6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctNS0xLTEtNjc3OQ_4ab03ddf-f5d1-4852-8783-e0abc5f0b8fe"
      unitRef="shares">87047832</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1329e87d85994ed5aec3fc36abc2f3f6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctNy0xLTEtNjc3OQ_0224085e-6b0c-45f0-93c1-df636a5b95c5"
      unitRef="usd">87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1eb8b8d131534c03ad4f1dc07b5cd25c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctOS0xLTEtNjc3OQ_945b28d8-de71-464d-9510-e85056cf6e55"
      unitRef="usd">476643000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3092be79f8214d54a1f70f92a5d08c86_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMTMtMS0xLTY3Nzk_82e2eac0-06dc-4c9d-93f9-8c7708aa134e"
      unitRef="usd">-447720000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMTUtMS0xLTY3Nzk_7b58f1bf-7f9a-46a9-9f47-6facfb9394e5"
      unitRef="usd">29012000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i00b19f57325c448582fbbc67739c326b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtMS0xLTEtNjEwMw_8c1cf5b6-2985-47d5-8cc3-a91ba3ae0d78"
      unitRef="shares">3704288</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i00b19f57325c448582fbbc67739c326b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtMy0xLTEtNjEwMw_8beea695-4a3c-4f9b-8c1d-c84eb0a56f01"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="idb8e219bee614949b739b6c590453b4e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtNS0xLTEtNjEwMw_63301f51-0674-4bce-83f0-31a6e7fd0cd4"
      unitRef="shares">21018663</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idb8e219bee614949b739b6c590453b4e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtNy0xLTEtNjEwMw_2d1ba0f7-0b85-4044-97b4-701790ee857c"
      unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3320ae2f75043c2bb5c26a7ec8241e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtOS0xLTEtNjEwMw_559ed2d9-6b51-4fa1-8a58-111cc64802ac"
      unitRef="usd">431305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46dcde68ee6949fabac04d61528c3adb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtMTMtMS0xLTYxMDM_f98129c2-ada4-48ed-9405-571e03ffe31a"
      unitRef="usd">-411315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i88172ee03d6b45da9f2508fc8c899e50_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzAtMTUtMS0xLTYxMDM_548bb742-e4c6-41fa-88bb-897e04b85325"
      unitRef="usd">20015000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzItNS0xLTEtNjEwMw_5fbeafd2-825e-4a87-a299-f8f17d8f12f5"
      unitRef="shares">21166</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzQtNS0xLTEtNjEwMw_d119fef4-21f1-4711-81af-315c20ce1a81"
      unitRef="shares">468</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzQtMTUtMS0xLTYxMDM_8428b4a2-142c-4529-bcd7-aa8755bcf841"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtNS0xLTEtNjEwMw_47f88a82-9ee2-4f3c-bd22-b8959c6f99f1"
      unitRef="shares">1666</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i57e728fa3cb540d5917b1e146d5c075e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtOS0xLTEtNjEwMw_8073806e-5382-48d2-972a-bacd0a0c18a5"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzUtMTUtMS0xLTYxMDM_45df6831-c65a-46cd-b81e-320b1ccd81e4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iec31e70363d949bc869ebd9d662e556f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMS0xLTEtNjEwMw_adf3d10f-5236-4674-b178-de81862828fa"
      unitRef="shares">-656682</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iec31e70363d949bc869ebd9d662e556f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMy0xLTEtNjEwMw_80186c5d-7e05-44d9-9c4d-7e59d51abd7a"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtNS0xLTEtNjEwMw_36f37a70-dbbe-4080-91ba-bbee6ce5885c"
      unitRef="shares">6566820</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtNy0xLTEtNjEwMw_f796119a-33a6-4825-950c-8bc436582523"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i57e728fa3cb540d5917b1e146d5c075e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtOS0xLTEtNjEwMw_e12546d5-ca70-4709-85bd-9e3453a9e458"
      unitRef="usd">-6000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzYtMTUtMS0xLTYxMDM_e6024b3b-70aa-4d88-8242-0e5ea12ff44b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i57e728fa3cb540d5917b1e146d5c075e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctOS0xLTEtNjEwMw_49f3e77c-e41c-4556-9ad7-c79edfbe37de"
      unitRef="usd">823000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzctMTUtMS0xLTYxMDM_04617552-337e-4c07-9f2b-fa54c9c38ae2"
      unitRef="usd">823000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i6fdfa6760cde47c78598ec14f20df863_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzgtMTMtMS0xLTYxMDM_f429f4f7-de17-4bd6-b506-d2220310da83"
      unitRef="usd">-5937000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0839129300ae490a88abf37136846111_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzgtMTUtMS0xLTYxMDM_308837c4-62d8-4754-9579-8cab6df3c0c8"
      unitRef="usd">-5937000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i41608b92ab1e405c9505107aa8fd4a10_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktMS0xLTEtNjEwMw_67bb3d32-0d43-4726-9dc8-1c83bf56e572"
      unitRef="shares">3047606</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i41608b92ab1e405c9505107aa8fd4a10_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktMy0xLTEtNjEwMw_1eea81a5-8b72-427f-aa01-afc1c1091966"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ica4813bf265846af86e7cc13ba14b04c_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktNS0xLTEtNjEwMw_d79553fa-8e1d-4e40-82ef-0a6d0834a239"
      unitRef="shares">27608783</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ica4813bf265846af86e7cc13ba14b04c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktNy0xLTEtNjEwMw_02e20b17-a214-4587-819f-d8956e10f2df"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6f736255edb4fd394dcac61f435857f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktOS0xLTEtNjEwMw_c53c3b6b-0669-4984-b8b9-5971dd3d27e1"
      unitRef="usd">432123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i937a88a09ffe475e93aa3271b6d32b6e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktMTMtMS0xLTYxMDM_e6a95ee6-b2a7-4a5e-87f1-3dee79608534"
      unitRef="usd">-417252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i106931b626c24de2b02765bb0b3ff2e3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfNzktMTUtMS0xLTYxMDM_fe95b13a-5633-419b-9c82-5ba58363b1c6"
      unitRef="usd">14902000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if57f750264234676ba54c29635f86b6e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODAtOS0xLTEtNjEwMw_2d00f672-4481-4eff-9489-711bbc2e5016"
      unitRef="usd">629000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0273fa1e721f4669bb524150f471d493_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODAtMTUtMS0xLTYxMDM_053a93b9-5e2f-496f-bcb6-4518ebb24070"
      unitRef="usd">629000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="icd72b68db08a4f389c46d913ec8ff603_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODEtNS0xLTEtNjEwMw_216aaa05-988d-4726-b60e-770351fadb89"
      unitRef="shares">17703</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i797de9f7b8c94355addeba1011495bd6_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItMS0xLTEtNjEwMw_39336956-f9a4-4973-99a8-7f6ca73b4faf"
      unitRef="shares">-829643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i797de9f7b8c94355addeba1011495bd6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItMy0xLTEtNjEwMw_29427da7-d433-4a71-bb75-ee6e8d577050"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="icd72b68db08a4f389c46d913ec8ff603_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItNS0xLTEtNjEwMw_f7b4060c-b1b9-4331-b3af-f9963204fe1b"
      unitRef="shares">8296430</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="icd72b68db08a4f389c46d913ec8ff603_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItNy0xLTEtNjEwMw_2d0bbb4c-3fc6-4c39-9dea-48e37e138dc7"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if57f750264234676ba54c29635f86b6e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItOS0xLTEtNjEwMw_cce0ffe1-205b-48dc-95bc-08028520e35c"
      unitRef="usd">-7000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0273fa1e721f4669bb524150f471d493_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODItMTUtMS0xLTYxMDM_36fcd041-b81f-4916-9a3c-2c627c495c1b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="if302f494d5d1498abe569565dbdf97a7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODMtMTMtMS0xLTYxMDM_63f28ae6-68cb-4bd6-94da-51d30b4db8db"
      unitRef="usd">-6947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0273fa1e721f4669bb524150f471d493_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODMtMTUtMS0xLTYxMDM_6fdd7a6f-3870-45b8-b903-c124bb57fdca"
      unitRef="usd">-6947000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i1d1408d312334eb79d917b31476e9f45_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtMS0xLTEtNjEwMw_e4ba5f23-56d0-421b-b6c3-ec1195ced2a1"
      unitRef="shares">2217963</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1d1408d312334eb79d917b31476e9f45_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtMy0xLTEtNjEwMw_c5b08cc5-7578-46e7-96aa-66e901e9793d"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="iddcc9b19c42a47b09baa002a71fba35e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtNS0xLTEtNjEwMw_7bea14dc-384b-4bd4-bdc4-d55cf70c57ad"
      unitRef="shares">35922916</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iddcc9b19c42a47b09baa002a71fba35e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtNy0xLTEtNjEwMw_854302d0-c535-40af-8761-856a838e6882"
      unitRef="usd">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d830f02b3e14451ad9e64b964c38013_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtOS0xLTEtNjEwMw_6b9d4832-36a0-4e78-ad0d-2b59b759167a"
      unitRef="usd">432745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90d7713a719f4a73b660cf6b5827d495_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtMTMtMS0xLTYxMDM_2eadcfbe-9416-4763-a318-60762b23bb15"
      unitRef="usd">-424199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6725b24da6f44eb8a2bdef563ccfd0e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfODQtMTUtMS0xLTYxMDM_b6305a1f-0057-4b5d-a2b9-eb5db9633252"
      unitRef="usd">8584000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6943c5db1485450bb348ad14827a1cd3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAxLTktMS0xLTY3ODE_67f83c0e-cb74-4b2b-b688-ba1c6854a067"
      unitRef="usd">692000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAxLTE1LTEtMS02Nzgx_be9a93e3-7b7e-48f0-88e1-8b6d440b1e57"
      unitRef="usd">692000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAyLTUtMS0xLTY3ODE_dc7d1e10-cbdd-43a8-a530-948be9c4d48b"
      unitRef="shares">19368</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAzLTUtMS0xLTY3ODM_223090ad-474a-4ef6-bbaf-071d5f4e2653"
      unitRef="shares">3332</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6943c5db1485450bb348ad14827a1cd3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAzLTktMS0xLTY3ODM_39900ef0-b7f6-4c2a-9229-6c54a26c5a64"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTAzLTE1LTEtMS02Nzgz_fead3ab9-b552-4091-871c-020874c41db8"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i865538f5e6944ffbab25f061268e630e_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTEtMS0xLTY3ODU_f1e39344-dcc9-4233-8c63-35cebf841e43"
      unitRef="shares">-321748</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i865538f5e6944ffbab25f061268e630e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTMtMS0xLTY3ODU_1549a643-35d7-47e1-9169-26f9ee355129"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTUtMS0xLTY3ODU_6d8cc970-b7ed-4466-a0da-024cb7b6ca5d"
      unitRef="shares">3217480</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i1f1c5c68ffc94d1eba0fdf3925292acb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTctMS0xLTY3ODU_bb1790b0-1b2f-4b29-9793-83d63b88bc38"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6943c5db1485450bb348ad14827a1cd3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTktMS0xLTY3ODU_056bcd16-f8c4-4d09-b857-335e80ac87fc"
      unitRef="usd">-3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA0LTE1LTEtMS02Nzg1_ad21ffe7-46e7-47b5-9bb8-6ecaca8feecb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="i5ccc29ee690e4861959d540c320ce357_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA1LTEzLTEtMS02Nzg3_d01c470a-0c03-4dc8-b0d2-4abfc85da25a"
      unitRef="usd">-1524000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA1LTE1LTEtMS02Nzg3_b2bf5f31-3b62-48fa-a69c-66712c9b94f5"
      unitRef="usd">-1524000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4d268293b00748cb90f4f7273393b95f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTEtMS0xLTY3ODk_3cdbd3f6-9483-4c02-a324-5747648fd7b7"
      unitRef="shares">1896215</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4d268293b00748cb90f4f7273393b95f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTMtMS0xLTY3ODk_52a83e8d-c3ed-45a2-b883-2353fd6c03fb"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ia9f6d4248d2b4dc986c29c6a7ad68bf0_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTUtMS0xLTY3ODk_982f8f78-0187-4220-99ed-56c8a47d6dc5"
      unitRef="shares">39163096</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia9f6d4248d2b4dc986c29c6a7ad68bf0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTctMS0xLTY3ODk_a5bead61-14df-4fa2-ad32-0c8bed8fde16"
      unitRef="usd">39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icac0a725c51e4495a0c3d3346febea7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTktMS0xLTY3ODk_170e9b73-d6fa-40ec-9f94-b0a9a652da4b"
      unitRef="usd">433436000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5d5b6ce568c40dc86b3246c0c3574fc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTEzLTEtMS02Nzg5_2d302ab0-8fc3-4af6-951f-cd4fdcc0fca7"
      unitRef="usd">-425723000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b2751e06f46463a94612500556b66a8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yNS9mcmFnOjFhNzNmN2NjY2M4MDRlY2RhYzgwOTU4ZmUyMzFmODhmL3RhYmxlOjQyOGIxMzA0YmU0NzRhYzZhNzg0NzNkOTA4Yzg4NzdlL3RhYmxlcmFuZ2U6NDI4YjEzMDRiZTQ3NGFjNmE3ODQ3M2Q5MDhjODg3N2VfMTA2LTE1LTEtMS02Nzg5_af7d91b9-3b3e-4737-b1cd-002959bb6360"
      unitRef="usd">7754000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNC0xLTEtMS02MTAz_ed4db5cd-a21a-4b5e-837d-db7cbfaeb247"
      unitRef="usd">-20675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNC0zLTEtMS02MTAz_25d275e7-a39f-466c-b0e5-95cc003dae30"
      unitRef="usd">-14408000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNi0xLTEtMS02MTAz_dd337a14-7b0f-4c01-a784-0dc3342ea671"
      unitRef="usd">418000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNi0zLTEtMS02MTAz_f407b566-fffe-41c1-88b8-5899b554f6ca"
      unitRef="usd">362000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNy0xLTEtMS02MTAz_58ea0307-46e1-46ce-a025-5baecd486512"
      unitRef="usd">2252000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNy0zLTEtMS02MTAz_033d400d-b70a-4c4d-830d-124fc6b04f45"
      unitRef="usd">2144000</us-gaap:ShareBasedCompensation>
    <rgls:GainLossOnLoanForgiveness
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTAtMS0xLTEtNjEwMw_106ce340-cd10-48e1-b97a-6bc3afd6e6cd"
      unitRef="usd">662000</rgls:GainLossOnLoanForgiveness>
    <rgls:GainLossOnLoanForgiveness
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTAtMy0xLTEtNjEwMw_737db966-9243-4b6b-8e69-6d718d4287b0"
      unitRef="usd">0</rgls:GainLossOnLoanForgiveness>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTEtMS0xLTEtNjEwMw_58e21f8e-d64e-4e8b-b393-dbad4f021306"
      unitRef="usd">39000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTEtMy0xLTEtNjEwMw_c8825d49-e1e7-4529-a84d-224d03853f14"
      unitRef="usd">148000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTMtMS0xLTEtNjEwMw_2ec80fd1-fc8e-47ad-8393-a73dffcf14a3"
      unitRef="usd">-503000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTMtMy0xLTEtNjEwMw_eff29475-b0a2-4008-8d3f-782a27c75825"
      unitRef="usd">2859000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTQtMS0xLTEtNjEwMw_3f341ce3-3da7-44fc-bf05-f31b8c7bfe0d"
      unitRef="usd">-304000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTQtMy0xLTEtNjEwMw_b0eb9d1c-3f0a-4274-8259-f243fbc209d9"
      unitRef="usd">-536000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTUtMS0xLTEtNjEwMw_0114b12e-866d-46a9-80bb-662857352be2"
      unitRef="usd">-784000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTUtMy0xLTEtNjEwMw_29072e7d-bd1a-431d-8382-3fadb6a0c550"
      unitRef="usd">-145000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTctMS0xLTEtNjEwMw_6cb7c5f9-744b-458e-9bd7-6f67dbaa0d8e"
      unitRef="usd">51000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTctMy0xLTEtNjEwMw_17bb56c9-bec3-4144-b9fc-ae6eccbc3406"
      unitRef="usd">-219000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTgtMS0xLTEtNjEwMw_5c69d468-d311-4f8e-a057-0099c82a9588"
      unitRef="usd">193000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTgtMy0xLTEtNjEwMw_89b3054c-a7e0-4f5c-b2bd-b69b67e280f6"
      unitRef="usd">-208000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <rgls:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTktMS0xLTEtNjEwMw_6d887bf7-6031-40d5-bb38-4e765aac0ddd"
      unitRef="usd">1250000</rgls:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <rgls:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMTktMy0xLTEtNjEwMw_d339e775-bfda-49b5-9dd7-d07ca1770d57"
      unitRef="usd">380000</rgls:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjAtMS0xLTEtNjEwMw_f1868818-0457-4b9e-8e7b-21e75bb115c1"
      unitRef="usd">-316000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjAtMy0xLTEtNjEwMw_928f2510-b0ff-4e2e-bddf-575391a79043"
      unitRef="usd">-416000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <rgls:OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjItMS0xLTEtNjEwMw_ec835309-6451-4e34-9c40-7c1380730685"
      unitRef="usd">291000</rgls:OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss>
    <rgls:OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjItMy0xLTEtNjEwMw_662ce760-129c-4ee6-a9b4-7d61c9a2a5cc"
      unitRef="usd">-112000</rgls:OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjMtMS0xLTEtNjEwMw_301835bf-bee9-4351-a0f6-62b4c7937736"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjMtMy0xLTEtNjEwMw_2430ee67-1235-4957-8a12-1d2125a62d32"
      unitRef="usd">-6000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjUtMS0xLTEtNjEwMw_56558b62-3f11-4ef6-88b8-926b0a39f5b8"
      unitRef="usd">-729000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjUtMy0xLTEtNjEwMw_7feed7fa-2477-49ea-a0f2-8cabba827a39"
      unitRef="usd">-1212000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjYtMS0xLTEtNjEwMw_833dc7a0-e7a3-447a-ba08-91522d7c9246"
      unitRef="usd">-16297000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMjYtMy0xLTEtNjEwMw_3c3b6602-b081-43f8-bd7e-7bcbd9ec5326"
      unitRef="usd">-15725000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzAtMS0xLTEtNjEwMw_8c9a24fc-cf2b-428a-bbed-7a42da1bff74"
      unitRef="usd">210000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzAtMy0xLTEtNjEwMw_393bf966-c3f7-4f6f-a990-3b3d7b08924d"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzItMS0xLTEtNjEwMw_93234ac2-c233-4db9-afc8-275be73a4478"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzItMy0xLTEtNjEwMw_319be98f-20f9-4ffd-b74b-a71d12023665"
      unitRef="usd">11000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzMtMS0xLTEtNjEwMw_116da160-9dbd-4173-a2fc-8ae5cd140399"
      unitRef="usd">-210000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzMtMy0xLTEtNjEwMw_1b8f784b-cb02-4687-95e6-e44cf78d9a0e"
      unitRef="usd">-11000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <rgls:ProceedsFromFederalProgram
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzYtMS0xLTEtNjEwMw_af7c21de-0a9e-4341-b9c1-4baf1664390d"
      unitRef="usd">0</rgls:ProceedsFromFederalProgram>
    <rgls:ProceedsFromFederalProgram
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzYtMy0xLTEtNjEwMw_a1050fd2-0661-4b96-9299-7b3080319ba3"
      unitRef="usd">662000</rgls:ProceedsFromFederalProgram>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzgtMS0xLTEtNjEwMw_4a8bbb98-d09f-4827-b4bd-dbc14c91c9d4"
      unitRef="usd">21384000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzgtMy0xLTEtNjEwMw_64981942-339b-4e6a-9e0e-4f8f78b60afe"
      unitRef="usd">3000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzktMS0xLTEtNjEwMw_9fb1c702-b632-45d2-a721-06859575d9f8"
      unitRef="usd">27000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfMzktMy0xLTEtNjEwMw_e0e79b90-2a39-49ef-b2ac-1cc4b46aa78f"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDAtMS0xLTEtNjEwMw_07a83af1-9ba5-4ebe-a7cd-d1f80ac2b465"
      unitRef="usd">0</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDAtMy0xLTEtNjEwMw_3f30e50c-050d-4d69-a4c5-348c2fe7795f"
      unitRef="usd">1000000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <rgls:PaymentsonFinanceLeases
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDMtMS0xLTEtNjEwMw_1f75e73e-f821-4e7a-9f92-aa34f643be28"
      unitRef="usd">81000</rgls:PaymentsonFinanceLeases>
    <rgls:PaymentsonFinanceLeases
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDMtMy0xLTEtNjEwMw_d87317e2-6a14-4868-9419-0ac9fb778836"
      unitRef="usd">207000</rgls:PaymentsonFinanceLeases>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDQtMS0xLTEtNjEwMw_b494c15c-2990-40be-a226-8e412b2229cd"
      unitRef="usd">21330000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDQtMy0xLTEtNjEwMw_2070c2cf-6532-4e91-aaf3-ee5c7c79f7d5"
      unitRef="usd">-542000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDUtMS0xLTEtNjEwMw_8e3ce6f4-ad2e-4d4d-b3e2-05cdaf841b2a"
      unitRef="usd">4823000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDUtMy0xLTEtNjEwMw_bdc28a46-960e-414c-a45d-18f37c9f4aec"
      unitRef="usd">-16278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDYtMS0xLTEtNjEwMw_7324ec56-5a46-4fd3-af94-82bcfcff06e9"
      unitRef="usd">31087000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i88172ee03d6b45da9f2508fc8c899e50_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDYtMy0xLTEtNjEwMw_27f01717-03c9-4d46-b3af-ff2deaf3bf24"
      unitRef="usd">34121000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDctMS0xLTEtNjEwMw_09224614-15ca-42f4-abd2-7258691670e1"
      unitRef="usd">35910000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2b2751e06f46463a94612500556b66a8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDctMy0xLTEtNjEwMw_b0d0825b-ed35-40c2-8bc0-f3c1c5db8b18"
      unitRef="usd">17843000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDktMS0xLTEtNjEwMw_825717fa-5fa3-4a7e-aac5-8e319f0ae1b6"
      unitRef="usd">35848000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2b2751e06f46463a94612500556b66a8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNDktMy0xLTEtNjEwMw_e6c0f428-aaec-4db8-af28-e1bc4a829ee4"
      unitRef="usd">17843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTAtMS0xLTEtNjEwMw_8c44756b-1699-4053-913d-f6a4b66749a1"
      unitRef="usd">62000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i2b2751e06f46463a94612500556b66a8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTAtMy0xLTEtNjEwMw_7e7fa16d-9a31-4328-aeb8-8972ba2a1242"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTEtMS0xLTEtNjEwMw_a733c5a5-d860-4198-a2bb-0f86d3725340"
      unitRef="usd">35910000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2b2751e06f46463a94612500556b66a8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTEtMy0xLTEtNjEwMw_21b12417-0da5-4fd5-a8f5-2d478a4045dd"
      unitRef="usd">17843000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <rgls:PaycheckProtectionProgramLoanForgiveness
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTQtMS0xLTEtNjEwMw_408cdf83-4358-4cb8-8e60-a05c38a8a9cd"
      unitRef="usd">662000</rgls:PaycheckProtectionProgramLoanForgiveness>
    <rgls:PaycheckProtectionProgramLoanForgiveness
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTQtMy0xLTEtNjEwMw_2af432d0-fab1-49fa-83d1-824e000bd30c"
      unitRef="usd">0</rgls:PaycheckProtectionProgramLoanForgiveness>
    <us-gaap:InterestPaidNet
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTUtMS0xLTEtNjEwMw_ba251137-a58d-4928-a8d8-417b4e7fd8e6"
      unitRef="usd">329000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTUtMy0xLTEtNjEwMw_0109369d-ede5-4cb9-80fb-f1f666d7365b"
      unitRef="usd">1066000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTYtMS0xLTEtNjEwMw_3a7cf638-919d-4252-b92f-1299d95f4deb"
      unitRef="usd">-1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18yOC9mcmFnOjEwOGZhMjg1YjBiMzRkOTdiYzI5Mzc5NTIzNWVhZDlmL3RhYmxlOjliMzc2MTI2MTc2NjQyN2RhZmMyYWFkODE2YjIyZWY3L3RhYmxlcmFuZ2U6OWIzNzYxMjYxNzY2NDI3ZGFmYzJhYWQ4MTZiMjJlZjdfNTYtMy0xLTEtNjEwMw_6c799c6e-7478-450a-b34d-1a6da28c0671"
      unitRef="usd">-1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwMzA_250ce6bb-7a50-4ca3-87d0-2fef1aac80e0">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#x2019;s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, from which the balance sheet information herein was derived.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a&#160;going&#160;concern.&#160;Through the date of the issuance of these financial statements, we have principally been financed through proceeds received from the sale of our common stock and other equity securities, debt financings, up-front payments and milestones received from collaboration agreements, totaling $505.6 million.&#160;As of&#160;September&#160;30, 2021, we had approximately $35.8&#160;million of cash and cash equivalents. Based on our operating plans, we believe our cash and cash equivalents may not be sufficient to fund our operations for the period one year following the issuance of these financial statements. As a result, there is substantial doubt about our ability to continue as a going concern. All amo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unts due under the Term Loan (see note 5) have been classified as a current liability as of September 30, 2021 and December 31, 2020, due to the considerations discussed above and the assessment that the material adverse change clause under the Term Loan is not within our control. In the first quarter of 2021, we received a waiver from the Lender (as defined below) with respect to noncompliance with a covenant under the Loan Agreement (as defined below). We are in compliance with all Loan Agreement covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity, or cease operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Additionally, the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under license and collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which could affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i)&#160;the fair value of the award is determined on the grant date, (ii)&#160;we assess the probability of the individual milestones under the award being achieved and (iii)&#160;the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical Trial and Preclinical Study Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites and CROs and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepaid Materials&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our preclinical and clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process.&#160;We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which an impairment is identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Subsequently, in November 2018, the FASB issued&#160;ASU&#160;2018-19,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Codification Improvements to Topic 326, Financial Instruments-Credit Losses&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;ASU 2016-13&#160;requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d reasonable and supportable forecasts.&#160;ASU 2016-13&#160;also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December&#160;15, 2022, with early adoption permitted. We are assessing the impact this standard will have on our financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Reference Rate Reform (Topic 848), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;which provides guidance around reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation in response to concerns about structural risks of interbank offered rates and the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments in the ASU provide option expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform and apply only if such contracts, hedging relationships and other transactions that reference LIBOR or another reference rate are expected to be discontinued because of reference rate reform. The guidance does not apply to contract modifications made, and hedging relationships entered into or evaluated, after December 31, 2022. We are assessing the impact this standard will have on our financial statements and disclosures. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#x2019;s annual fiscal year. The adoption of this standard on January 1, 2021 did not impact our financial statements or disclosures.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNDc_800cee70-73cf-42b4-9ba9-72a168effe1c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#x2019;s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, from which the balance sheet information herein was derived.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <rgls:FinancingfromSaleProceedsDebtAgreementRevenues
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTcyOA_4097b252-ae73-466d-83a2-f684ad1ce0c2"
      unitRef="usd">505600000</rgls:FinancingfromSaleProceedsDebtAgreementRevenues>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTc3NA_3b3c9bd4-4b8b-429f-bd70-1f0bd43ab622"
      unitRef="usd">35800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:UseOfEstimates
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNDU_5066d37c-028e-4614-b26c-4ce92b4744f5">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Additionally, the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwMzI_bafb1f2d-4e49-4458-9e2d-fa3a3bfcbec5">&lt;div style="margin-top:6pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under license and collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which could affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwMzM_2e7faf4e-49c2-41b4-93c9-43343b315c35">Stock-Based Compensation&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i)&#160;the fair value of the award is determined on the grant date, (ii)&#160;we assess the probability of the individual milestones under the award being achieved and (iii)&#160;the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <rgls:AccruedExpensePolicyTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNjY_58ca4c1d-956c-40b5-8e65-7683fd0653f6">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical Trial and Preclinical Study Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites and CROs and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.&lt;/span&gt;&lt;/div&gt;</rgls:AccruedExpensePolicyTextBlock>
    <rgls:PrepaidExpensesPolicyTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNDE_2da8207a-f6d1-4643-a028-325631346eb8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepaid Materials&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our preclinical and clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process.&#160;We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which an impairment is identified.&lt;/span&gt;&lt;/div&gt;</rgls:PrepaidExpensesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNC9mcmFnOjc0N2UzZmViZmY1YTRhNmY5MmNkNGRkZTU3ZTdlODA3L3RleHRyZWdpb246NzQ3ZTNmZWJmZjVhNGE2ZjkyY2Q0ZGRlNTdlN2U4MDdfMTYwNTE_ea6b5713-690f-477b-bb08-86c7eb3912b4">&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Subsequently, in November 2018, the FASB issued&#160;ASU&#160;2018-19,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Codification Improvements to Topic 326, Financial Instruments-Credit Losses&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;ASU 2016-13&#160;requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d reasonable and supportable forecasts.&#160;ASU 2016-13&#160;also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December&#160;15, 2022, with early adoption permitted. We are assessing the impact this standard will have on our financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Reference Rate Reform (Topic 848), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;which provides guidance around reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation in response to concerns about structural risks of interbank offered rates and the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments in the ASU provide option expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform and apply only if such contracts, hedging relationships and other transactions that reference LIBOR or another reference rate are expected to be discontinued because of reference rate reform. The guidance does not apply to contract modifications made, and hedging relationships entered into or evaluated, after December 31, 2022. We are assessing the impact this standard will have on our financial statements and disclosures. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#x2019;s annual fiscal year. The adoption of this standard on January 1, 2021 did not impact our financial statements or disclosures.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfMTE2NA_3d94d3c7-01e1-4685-b839-710ce6d2d3aa">Net Loss Per ShareBasic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method or if-converted method. Dilutive common stock equivalents are comprised of stock options, restricted stock units and convertible preferred stock outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.Potentially dilutive securities not included in the calculation of diluted net loss per common share, because to do so would be anti-dilutive, were (in common stock equivalent shares) 28,635,276 for the three months and nine months ended September 30, 2021, consisting of convertible preferred stock, stock options and restricted stock units, and 25,813,032 for the three and nine months ended September 30, 2020, consisting of convertible preferred stock, stock options and restricted stock units.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfODc4_4545037f-d5f4-42cc-8070-e00a6f749987"
      unitRef="shares">28635276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfODc4_fd399e00-9f67-485e-a67e-924b55fbcc85"
      unitRef="shares">28635276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfMTAyNw_0c775e68-4b15-406e-bf03-dd1dd6bedbf7"
      unitRef="shares">25813032</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N18zNy9mcmFnOjc4OWJmMDBjM2Q0YjQ4MzQ5Y2MwOTk1MDNjYzQwMDMzL3RleHRyZWdpb246Nzg5YmYwMGMzZDRiNDgzNDljYzA5OTUwM2NjNDAwMzNfMTAyNw_86e61d16-9bab-402a-8729-8f8c08e0ee81"
      unitRef="shares">25813032</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180MC9mcmFnOmM4ZmI1ZDYwYjQyYjQ5YTQ5OWE3NDJhZjBhMmQzY2RiL3RleHRyZWdpb246YzhmYjVkNjBiNDJiNDlhNDk5YTc0MmFmMGEyZDNjZGJfNDQ3_0e80aac6-5854-4add-b5d3-8613d1b1c1f1">InvestmentsHistorically, we have invested our excess cash primarily in debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. We generally hold our investments to maturity and do not sell our investments before we have recovered our amortized cost basis. As of September&#160;30, 2021 and December&#160;31, 2020, our cash balance was comprised entirely of cash and cash equivalents (money market funds).</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RleHRyZWdpb246NGYxMTkyY2E1Mzk4NGY4ODhjODA4MGQyMjYzODgyZmFfMjY4Mg_3044fb1d-ead2-4fa1-9677-ef494338041a">Fair Value Measurements&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i)&#160;independent, (ii)&#160;knowledgeable, (iii)&#160;able to transact, and (iv)&#160;willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management&#x2019;s own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Assets Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We obtain pricing information from quoted market prices or quotes from brokers/dealers. We have historically determined the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RleHRyZWdpb246NGYxMTkyY2E1Mzk4NGY4ODhjODA4MGQyMjYzODgyZmFfMjY4OQ_9cc30120-ca36-4d33-9fb7-385951ba372a">Fair Value Measurements&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i)&#160;independent, (ii)&#160;knowledgeable, (iii)&#160;able to transact, and (iv)&#160;willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management&#x2019;s own assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RleHRyZWdpb246NGYxMTkyY2E1Mzk4NGY4ODhjODA4MGQyMjYzODgyZmFfMjY4NQ_30e9fd45-33f8-4477-8e3b-bd8adad12d3b">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e558bd57cca45c5b203fdaf82f601e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfMy0xLTEtMS02MTAz_a24c473b-2325-48d6-b009-8f4c8ea5c82d"
      unitRef="usd">33904000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c3dd88f2ee24d50940e2d23ae23e499_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfMy0zLTEtMS02MTAz_91e465ac-5c31-46a4-a44a-243230de35fa"
      unitRef="usd">33904000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8e6bf61ba9c4435e80870c56d0a0f96b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfMy01LTEtMS02MTAz_f1d8832c-652d-4462-9ee0-321ec2f9bcd8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3a47324fa24547688554544bf8a88ebb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfMy03LTEtMS02MTAz_304709f8-68d8-4589-8b66-38e4dbf28164"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfOS0xLTEtMS02MTAz_600d62c2-6d3e-48e2-918b-077ae118571c"
      unitRef="usd">33904000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i63e7c32d4abb4857a652dbaf35a42b0b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfOS0zLTEtMS02MTAz_4257727e-0313-44ab-bc38-6aab36894a59"
      unitRef="usd">33904000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3b42f9a435294e1c9a483222e912c132_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfOS01LTEtMS02MTAz_93f475a8-8c95-4ef0-8bad-11b39ade817b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i09deb282dd9b4bf58f7a624fb80f547f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOjNiYzg5ODQ3OGE2ZDQ1YmFhNTYxMDcwNWQxZjczZmI5L3RhYmxlcmFuZ2U6M2JjODk4NDc4YTZkNDViYWE1NjEwNzA1ZDFmNzNmYjlfOS03LTEtMS02MTAz_a3b5f424-79fe-43d3-980a-96437cb41e7d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2fdd8f019e3c491b8732a68d899250a0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfMy0xLTEtMS02MTAz_47445caa-48f0-44cd-bb99-2711c8d5e4e2"
      unitRef="usd">26901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ce7ee44d1194a78aa295bd978dc3ae7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfMy0zLTEtMS02MTAz_aaddfa74-a4d1-4aa3-b55b-1b144e29fad8"
      unitRef="usd">26901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i86b176df93ed4f47b0455d5746bf050e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfMy01LTEtMS02MTAz_a0862e58-65b3-4947-aa4f-5230ac892294"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6383c5f184bf4004ba7ac38c997e14c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfMy03LTEtMS02MTAz_c66753f5-b05f-4d01-8ebb-1e598be0c495"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c50d853f72c4c36960bcf1c2165224d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfOS0xLTEtMS02MTAz_dd086341-c675-4124-98ac-c05606fd4a6b"
      unitRef="usd">26901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i523ebcbfef6d4b6aa814dd3ff356bd8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfOS0zLTEtMS02MTAz_84adc3f5-a85f-4529-8283-863152f9e6dc"
      unitRef="usd">26901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5f7695f94fcc4a2b92b921a5c6aa94bc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfOS01LTEtMS02MTAz_1dec5b7a-3190-41d1-93ee-0f71b14a5cc9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6ecd930760914ed780a9b7337dc50c31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180My9mcmFnOjRmMTE5MmNhNTM5ODRmODg4YzgwODBkMjI2Mzg4MmZhL3RhYmxlOmQ2MWU0NGYzYWZiNzQ3NDY5Yjk1ZDQ2ZmEzNTM5ZWU2L3RhYmxlcmFuZ2U6ZDYxZTQ0ZjNhZmI3NDc0NjliOTVkNDZmYTM1MzllZTZfOS03LTEtMS02MTAz_30a8db9c-bf93-4103-bdce-a0b1f73546d5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LongTermDebtTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNjkxMQ_b2171780-6515-496f-be54-805884cf4fbe">Debt&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term Loan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 17, 2016, we entered into a loan and security agreement ("Loan Agreement") with Oxford Finance, LLC, (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lender&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), pursuant to which we received $20.0 million in proceeds, net of debt issuance costs, on June 22, 2016 (the "Term Loan"). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding Term Loan will mature on May 1, 2022 (the &#x201c;Maturity Date&#x201d;) and bears interest at a floating per annum rate equal to (i) 8.51% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wall Street Journal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) 0.44%. Under the original Loan Agreement, we were required to make interest-only payments through June 1, 2018, followed by 24 equal monthly payments of principal and unpaid accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Agreement was amended eight times between October 2017 through May 2019. On May 1, 2020 we entered into a ninth amendment to the Term Loan with the Lender (the &#x201c;Ninth Amendment&#x201d;). Pursuant to the terms of the Ninth Amendment, (i) the approximately $0.7&#160;million of loan proceeds (the "PPP Loan") we received under the Paycheck Protection Program ("PPP") was included as permitted indebtedness under the terms of the Term Loan, (ii) we agreed to apply for forgiveness of the maximum amount of PPP Loan permissible in accordance with the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and use best efforts to cause not less than $0.5&#160;million of the PPP Loan to be forgiven by the PPP Loan lender on or before September 30, 2020 and (iii) we agreed not to amend any material provision in any document relating to the PPP Loan nor make any prepayment of the PPP Loan unless such prepayment is necessary or advisable due to change in the applicable law or guidance issued by the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Small Business Administration (&#x201c;SBA&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ugust 25, 2020 we entered into a tenth amendment to the Term Loan with the Lender (the "Tenth Amendment").  Pursuant to the terms of the Tenth Amendment, we are eligible for up to an additional seven months of interest only payments in the event we paid down $10.0&#160;million in loan principal before April 30, 2021 (the "Principal Paydown Event"). In the event the Principal Paydown Event did not occur by April 30, 2021, we would make principal and accrued interest payments, in arrears, commencing May 1, 2021, in accordance with the terms of the Eighth Amendment. If the Principal Paydown Event occurred after April 30, 2021 but on or before July 31, 2021, we would recommence an extended interest only payment period through December 31, 2021. In the event we received the additional interest only period, principal and accrued interest payments would recommence on January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We received $1.0&#160;million, $4.0&#160;million and $5.0&#160;million in proceeds from Sanofi (see Note 7) on September 30, 2020, October 8, 2020 and November 30, 2020, respectively. Under the terms of the Tenth Amendment, we prepaid $1.0&#160;million, $4.0&#160;million and $5.0&#160;million of outstanding principal to the Lender on September 30, 2020, October 8, 2020 and November 30, 2020, respectively, for a total of $10.0&#160;million. We also paid the applicable 5.5% final payment fees related to the three prepayments to the Lender. As the Principal Paydown Event occurred by April 30, 2021, we received an additional seven &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;months of interest only payment extension and are not obligated to make principal payments on the Term Loan until January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the proceeds from the Term Loan solely for working capital and to fund our general business requirements.  Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, other than our intellectual property, for which the Lender currently has a positive lien, and certain assets under finance lease obligations. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement. The Loan Agreement includes customary events of default, including instances of a material adverse change in our operations, that may require prepayment of the outstanding Term Loan. During the first quarter of 2021, we received a waiver from the Lender with respect to noncompliance with a covenant under the Loan Agreement. We are in compliance with all Loan Agreement covenants as of the date of the filing of this Form 10-Q.&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, $4.7 million was outstanding under the Term Loan. An additional $1.3 million is also payable at the conclusion of the Term Loan (presented in other current liabilities on our balance sheet at September 30, 2021). We had less than $0.1 million of debt issuance costs outstanding as of September 30, 2021, which are being accreted to interest expense over the life of the Term Loan using an effective interest rate of 8.98%. The exit fees are being accrued over the life of the Term Loan through interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 23, 2020, we received the proceeds from the PPP Loan in the amount of approximately $0.7&#160;million from Silicon Valley Bank, as lender, pursuant to the PPP of the CARES Act. The PPP Loan was set to mature on April 23, 2022 and bore interest at a rate of 1.0% per annum. The PPP Loan was evidenced by a promissory note dated April 23, 2020, which contained customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The PPP Loan was prepayable by us at any time prior to maturity with no prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the CARES Act and PPP Flexibility Act, loan forgiveness is available for the sum of documented payroll costs, covered mortgage interest, covered rent payments and covered utilities during the 24 week period beginning on the date of loan disbursement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; For purposes of the PPP, payroll costs exclude compensation of an individual employee in excess of $100,000, annualized, prorated for the covered period. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines during the covered period as compared to specified reference periods, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%, unless certain safe harbors are satisfied. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal and includes accrued interest.&lt;/span&gt;&lt;/div&gt;We have used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments, and we sought forgiveness in accordance with the program. We received full forgiveness of our PPP Loan in the second quarter of 2021. We accounted for the full forgiveness of our PPP Loan by recording a gain in interest and other income for the nine months ended September 30, 2021.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="i8f4532b2830348528c01118566cacbce_D20160622-20160622"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMTgw_77b2b6a2-3b4b-4a38-b751-85ab8e86f7a2"
      unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ica365f62a18542a3bd628586ba2316d7_I20160617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzk3_f2d0661a-9ec5-4ca3-a8dc-cc3888e17198"
      unitRef="number">0.0851</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i56addd06803544669ea6adfb1f85223b_D20160617-20160617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNjE1_a59cc6ab-35e7-4df2-8baa-dbf20a755292"
      unitRef="number">0.0044</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <rgls:NumberofMonthlyPayments
      contextRef="ica365f62a18542a3bd628586ba2316d7_I20160617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNzM2_888ce3d1-cd3f-42ef-a3d9-ca9900b1ff77"
      unitRef="payment">24</rgls:NumberofMonthlyPayments>
    <rgls:NumberOfAmendments
      contextRef="i03875b50705141378eeb6a7f3db6d93c_D20171001-20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfODM2_06fe2256-3530-4c40-b289-b1053c1f1204"
      unitRef="amendment">8</rgls:NumberOfAmendments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic806cb07df3044b1b53e64130fffba72_I20200501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMTA1OQ_b2adb290-a2d4-4d5a-a91c-aee2ab5927ba"
      unitRef="usd">700000</us-gaap:DebtInstrumentFaceAmount>
    <rgls:ForgivenessAmountThreshold
      contextRef="ic806cb07df3044b1b53e64130fffba72_I20200501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMTQ0OQ_86e3db31-c42b-45a3-9627-b35731847656"
      unitRef="usd">500000</rgls:ForgivenessAmountThreshold>
    <rgls:InterestOnlyPaymentExtension
      contextRef="i892f5ef11b7f487eb34d5314ea17e4fd_D20200825-20200825"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjAyOQ_942823b2-7108-4d59-8ebb-666986c5585f">P7M</rgls:InterestOnlyPaymentExtension>
    <rgls:PrepaymentRequirement
      contextRef="iefd75439e0974679b47a6cff8366c288_I20200825"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjA4NA_f062bc37-1f1f-4fa1-bd77-22fcbb971f73"
      unitRef="usd">10000000</rgls:PrepaymentRequirement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i380cfb226da64264aa858aa432603785_D20200930-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjcxMg_c58b5919-f0f6-48c5-b879-69a6b0e7c661"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b747865a07948508c75f1aa6b053b63_D20201008-20201008"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjcxNg_7570894e-b04f-45a0-a4d5-da7c378670c2"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id16ee745789f48d18517ec4b1a9769cf_D20201130-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjcyMw_4219a6ef-b0bb-4c6e-aae8-3c4a4dc699c0"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RepaymentsOfDebt
      contextRef="i8c8cb641775b42569a9458112a507826_D20200930-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjg5MA_5c832357-4787-4f21-84f5-583b483d56c8"
      unitRef="usd">1000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i46549a65d985413b8403edb46967d1b0_D20201008-20201008"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjg5NA_ea46e260-3b12-4daa-bc63-a3e3f82dc262"
      unitRef="usd">4000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ic64856709b654f068e893bde533341f9_D20201130-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMjkwMQ_efe2a8e7-78f1-4554-bc1c-dd39a933974d"
      unitRef="usd">5000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ic7d6534d80e9479592a4aa31ef10377f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzAzNA_7cddae61-6b6d-4a58-951a-29c35e84102f"
      unitRef="usd">10000000</us-gaap:RepaymentsOfDebt>
    <rgls:PaymentFee
      contextRef="i2905a20cdd80471abc18cd4877622e4b_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzA2Ng_c2292099-4b48-469b-bdc0-2c6a3c3b7e87"
      unitRef="number">0.055</rgls:PaymentFee>
    <rgls:NumberOfPrepaymentsToLender
      contextRef="i2905a20cdd80471abc18cd4877622e4b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzEwMw_1566d8a7-bf20-4546-91a6-3b0a5020c142"
      unitRef="prepayment">3</rgls:NumberOfPrepaymentsToLender>
    <rgls:AdditionalExtensionForInterestOnlyPayments
      contextRef="ic7d6534d80e9479592a4aa31ef10377f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfMzIxOA_bf9209ac-a3b4-4c3e-970e-ef2466f86cb5">P7M</rgls:AdditionalExtensionForInterestOnlyPayments>
    <us-gaap:LongTermDebt
      contextRef="i923277ec32bd4699a80593ceda7d7e81_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNDM2Ng_b65bbebf-2af3-4b48-9ca4-9311bca2b3cd"
      unitRef="usd">4700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i923277ec32bd4699a80593ceda7d7e81_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNDQyMA_415c5da7-a2d2-4266-87f0-d5b97b8be36f"
      unitRef="usd">1300000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i923277ec32bd4699a80593ceda7d7e81_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNDU3MQ_797478db-2a38-4648-844d-67ec5faf1a8c"
      unitRef="usd">100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i923277ec32bd4699a80593ceda7d7e81_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNDc0Mg_d1a6ec82-c89a-4780-818b-4c4d6982e081"
      unitRef="number">0.0898</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNjkxMA_ce68e097-cad2-4131-a21a-f597f01cf57f">&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i2de3b934180e4445a01ae3a427e91b3f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RhYmxlOjVjNDgxYmI3ZTYxNzQ3OThiZDYwZGM5Y2FhNzNjOGQ4L3RhYmxlcmFuZ2U6NWM0ODFiYjdlNjE3NDc5OGJkNjBkYzljYWE3M2M4ZDhfMS0xLTEtMS02MTAz_410bea09-b791-47c1-8043-e5f43137d75b"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i2de3b934180e4445a01ae3a427e91b3f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RhYmxlOjVjNDgxYmI3ZTYxNzQ3OThiZDYwZGM5Y2FhNzNjOGQ4L3RhYmxlcmFuZ2U6NWM0ODFiYjdlNjE3NDc5OGJkNjBkYzljYWE3M2M4ZDhfMi0xLTEtMS02MTAz_76380507-7166-4a1e-a836-a110e88e546c"
      unitRef="usd">4681000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt
      contextRef="i2de3b934180e4445a01ae3a427e91b3f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RhYmxlOjVjNDgxYmI3ZTYxNzQ3OThiZDYwZGM5Y2FhNzNjOGQ4L3RhYmxlcmFuZ2U6NWM0ODFiYjdlNjE3NDc5OGJkNjBkYzljYWE3M2M4ZDhfMy0xLTEtMS02MTAz_ba77679f-7731-43c7-9d30-e1468e625f48"
      unitRef="usd">4681000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifd548549c7b7438bb6836f7b080e3d0f_I20200423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180Ni9mcmFnOjM1NjhlN2JmZjI2ZjQ2M2I4YmM4YTRhZDc2ZGIwZTIwL3RleHRyZWdpb246MzU2OGU3YmZmMjZmNDYzYjhiYzhhNGFkNzZkYjBlMjBfNTA4OQ_b0d6a8f5-c2a3-44f2-b7f7-59c2f67fc02c"
      unitRef="usd">700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNTQ_8856501c-99b7-4663-9f18-66b4d5e52f4f">Stockholders&#x2019; Equity&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, there were 87,047,832 shares of common stock outstanding. Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by our Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2019, the Company's board of directors approved, and on August 1, 2019 the Company's stockholders approved, the Company's 2019 Equity Incentive Plan (the "2019 Plan"). The 2019 Plan is intended as the successor to and continuation of the Company's 2012 Equity Incentive Plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares authorized for issuance under the 2019 Plan may be increased by (a) the shares subject to outstanding stock awards granted under the Company&#x2019;s 2009 Equity Incentive Plan (the &#x201c;2009 Plan&#x201d;) and the Company&#x2019;s 2012 Equity Incentive Plan (together the with 2009 Plan, the &#x201c;Prior Plans&#x201d;) that on or after the effective date of the 2019 Plan (i) expire or terminate for any reason prior to exercise or settlement; (ii) are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise return to the Company, or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award. No further grants will be made under the Prior Plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s. In addition, on January 22, 2020, an additional 4,166,860 shares of common stock became available for issuance under the 2019 Plan pu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rsuant to the Milestone Closing (defined below) of the May 2019 SPA (defined below). Further, on January&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each year, for a period of not more than ten years, beginning on January&#160;1, 2021 and continuing through January&#160;1, 2029, the number of shares authorized for issuance under the 2019 Plan will increase by 5.0% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares as may be determined by our Board of Directors. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, 853,111 shares of common stock were available for new equity award grants under the 2019 Plan and 10,172,886 shares of common stock are reserved for issuance pursuant to equity awards outstanding as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Private Placements of Common Stock, Non-Voting Preferred Stock and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 3, 2019, we entered into a securities purchase agreement (the "May 2019 SPA") with certain institutional and other accredited investors, including certain directors, executive officers and employees of the Company (the &#x201c;Purchasers&#x201d;), pursuant to which we agreed to sell and issue shares of our common stock, shares of our newly designated non-voting convertible preferred stock, and warrants to purchase common stock, in up to two closings, in a private placement transaction (the &#x201c;Private Placement&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At an initial closing under the May 2019 SPA that occurred on May 7, 2019 (the &#x201c;Initial Closing&#x201d;), we sold and issued to the Purchasers (i) 9,730,534 shares of common stock and accompanying warrants to purchase up to an aggregate of 9,730,534 shares of common stock at a combined purchase price of $1.205 per share, and (ii) 415,898 shares of non-voting Class A-1 convertible preferred stock, in lieu of shares of common stock, at a price of $10.80 per share, and accompanying warrants to purchase an aggregate of 4,158,980 shares of common stock at a price of $0.125 for each share of common stock underlying such warrants. Total gross proceeds from the Initial Closing were approximately $16.7 million, which does not include any proceeds that may be received upon exercise of the warrants. Each share of non-voting Class A-1 convertible preferred stock is convertible into 10 shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of five years following the date of issuance and have an exercise price of $1.08 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise "cashless" basis. An aggregate of 526,083 shares of common stock and warrants to purchase up to 526,083 shares of common stock were purchased for $0.6 million by certain directors and executive officers of the Company under the Initial Closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the May 2019 SPA, in the event our Board of Directors unanimously resolved to recommence our Phase 1 multiple ascending dose clinical trial of our RGLS4326 product candidate for the treatment of ADPKD (the &#x201c;Phase 1 Trial&#x201d;) based on correspondence from the U.S. Food and Drug Administration&#x2019;s Division of Cardiovascular and Renal Products, and thereafter but on or before December 31, 2019, we made a public announcement of our plan to recommence the Phase 1 Trial (the &#x201c;Public Announcement&#x201d;), we would sell and the Purchasers would purchase, at a second closing under the May 2019 SPA (&#x201c;Milestone Closing&#x201d;), shares of our non-voting convertible preferred stock and accompanying warrants to purchase shares of Common Stock (collectively, "Milestone Securities"). On December&#160;15, 2019, the Company's Board of Directors unanimously resolved to recommence the Phase 1 Trial based on correspondence from the U.S. Food&#160;&amp;amp; Drug Administration&#x2019;s Division of Cardiovascular and Renal Products and on December&#160;16, 2019, we made the related Public Announcement, triggering the Milestone Closing, which occurred on December&#160;24, 2019. At the Milestone Closing, we sold and issued to the Purchasers 3,288,390 shares of&#160;non-voting&#160;Class&#160;A-2&#160;convertible preferred stock and accompanying warrants to purchase an aggregate of 32,883,900 shares of common stock for an aggregate purchase price of approximately $26.0 million. Net proceeds to the Company from the Milestone Closing were approximately $24.6 million. Each share of&#160;non-voting&#160;Class&#160;A-2&#160;convertible preferred stock is convertible into 10 shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants will be exercisable for a period of five years following the date of issuance and have an exercise price of $0.666 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise &#x201c;cashless&#x201d; basis. An aggregate of 121,581 shares of Class A-2 convertible preferred stock and warrants to purchase up to 1,215,810 shares of common stock were purchased for approximately $1.0 million by certain directors and executive officers of the Company under the Milestone Closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluated the non-voting Class A-1 convertible preferred stock and common stock warrants sold in the Initial Closing and the Class A-2 convertible preferred stock and common stock warrants sold in the Milestone Closing under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and determined permanent equity treatment was appropriate for these freestanding financial instruments. The Initial Closing and Milestone Closing did not include any embedded features that required bifurcation. The non-voting Class A-2 convertible preferred stock and warrants issuable under the Milestone Closing were not subject to accounting recognition until the Milestone Closing occurred, as the terms of the Milestone Closing did not provide a right or an obligation on either the Company nor the Purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 1, 2020, we entered into a Securities Purchase Agreement (the "December 2020 SPA") with certain institutional and other accredited investors, including certain directors, executive officers and employees of the Company (the &#x201c;2020 Purchasers&#x201d;), pursuant to which we agreed to sell and issue shares of our common stock, shares of newly designated non-voting convertible preferred stock and warrants to purchase common stock (the &#x201c;2020 PIPE&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing under the December 2020 SPA that occurred on December 4, 2020 (the &#x201c;2020 Closing&#x201d;), we sold and issued to the 2020 Purchasers (i) 24,341,607 shares of common stock and accompanying warrants to purchase up to an aggregate of 18,256,204 shares of common stock at a combined purchase price of $0.7464 per share, and (ii) 272,970 shares of non-voting Class A-3 convertible preferred stock, in lieu of shares of common stock, at a price of $6.22 per share, and accompanying warrants to purchase an aggregate of 2,047,276 shares of common stock at a price of  $0.125 for each share of common stock underlying such warrants. Total gross proceeds from the 2020 Closing were approximately $19.4&#160;million, which does not include any proceeds that may be received upon exercise of the warrants. Each share of non-voting Class A-3 convertible preferred stock is convertible into 10 shares of common stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of five years following the date of issuance and have an exercise price of $0.7464 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise "cashless" basis. An aggregate of 833,208 shares of common stock and warrants to purchase up to 624,906 shares of common stock were purchased for $0.6&#160;million by certain directors and executive officers of the Company at the 2020 Closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluated the non-voting Class A-3 convertible preferred stock and common stock warrants sold in the 2020 PIPE under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and determined permanent equity treatment was appropriate for these freestanding financial instruments and there were no embedded features that required bifurcation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes preferred stock conversions and warrant exercises (and the related impact on common stoc&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;k) under the 2019 SPA and 2020 SPA for the three and nine months ended September 30, 2021 and 2020 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class A-1 Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class A-2 Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class A-3 Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September&#160;30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On December 12, 2018, we entered into a Common Stock Sales Agreement (the &#x201c;Stock Sales Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC (&#x201c;HCW&#x201d;), pursuant to which we may sell and issue shares of our common stock from time to time through HCW, as our sales agent (the &#x201c;ATM Offering&#x201d;). We have no obligation to sell any shares of common stock in the ATM Offering, and may at any time suspend offers under the Stock Sales Agreement or terminate the Stock Sales Agreement. Subject to the terms and conditions of the Stock Sales Agreement, HCW will use its commercially reasonable efforts to sell shares of our common stock from time to time based upon our instructions (including any price, time or size limits or other parameters or conditions that we may impose, subject to certain restrictions). We pay HCW a commission of 3.0% of the gross sales price of any shares sold under the Stock Sales Agreement. No shares were sold under the ATM Offering during the three months ended September 30, 2021. A total of 16,017,131 shares were sold and settled for proceeds of $20.5&#160;million (net of $0.8&#160;million in offering costs) under the ATM Offering during the nine months ended September 30, 2021. No shares were sold under the ATM Offering during the three and nine months ended September 30, 2020. On August 10, 2021, we increased the amount of common stock available for sale in ATM Offerings under the Stock Sales Agreement to $50.0&#160;million. At September 30, 2021, approximately $50.0&#160;million remained available for sale in the ATM Offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares of common stock were reserved for future issuance as of September&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A-1 convertible preferred stock outstanding (as-converted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A-2 convertible preferred stock outstanding (as-converted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A-3 convertible preferred stock outstanding (as-converted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 PIPE Initial Closing warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 PIPE Milestone Closing warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 PIPE warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock available for future grant under 2019 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock option and RSU (together Stock Awards) activity under all equity incentive plans for the nine months ended September&#160;30, 2021 (shares in thousands):&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Awards outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised (options) or Vested (RSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Awards outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan, 2015 Inducement Plan, 2019 Equity Incentive Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNzY_e70e8261-41f1-4b04-874c-f407bf8f5d25"
      unitRef="shares">87047832</us-gaap:CommonStockSharesOutstanding>
    <rgls:CommonStockVotingRightsVotes
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTU3_d7766a34-90ad-4f1c-8a76-aaab1479cff1"
      unitRef="vote">1</rgls:CommonStockVotingRightsVotes>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ie53dd4b291ee4100afcd9f063f293242_D20200122-20200122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTQ5NQ_f02b0368-c0b1-426d-b424-5bc043e7cca4"
      unitRef="shares">4166860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <rgls:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease
      contextRef="ie740123647534dc7b2a846af038991a4_D20200122-20200122"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTcyNg_272d9693-f04e-4c9a-96b9-e04392b5ec38">P10Y</rgls:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease>
    <rgls:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease
      contextRef="i9a1f2d1ed7234256bace1246be18d4ee_I20200122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTg4MQ_e702c0ec-718b-4f48-b2d4-4255dc842255"
      unitRef="number">0.050</rgls:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie68f8c41edfb46ee9870928b23961edc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjA5Mg_6f90976f-bd12-489e-bae5-e35f3fb2fd53"
      unitRef="shares">853111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie68f8c41edfb46ee9870928b23961edc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjE4NQ_d49032d0-86dd-4aef-9717-2732c8722d01"
      unitRef="shares">10172886</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <rgls:NumberOfClosings
      contextRef="i3322efb25d9a4f5f9fb3224308d86541_I20190503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjgwOA_44464227-ec10-4900-9239-b5402b2b8b4b"
      unitRef="closing">2</rgls:NumberOfClosings>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i674455781c874bdbbef4fcb1f436968d_D20190507-20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzAyNg_6c082dca-b893-49ac-b734-e552bbd2e208"
      unitRef="shares">9730534</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzExMg_233cc08b-97f8-493d-af46-58f255242aa2"
      unitRef="shares">9730534</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzE3MA_884b277d-44f3-44aa-a6db-d2af40a2c571"
      unitRef="usdPerShare">1.205</us-gaap:SaleOfStockPricePerShare>
    <rgls:NonvotingConvertiblePreferredStockIssued
      contextRef="i0f2c4232052049e3a363d782b40cb6bc_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzE5Mw_dfe5a96c-6ff1-49db-867f-d920cea71adb"
      unitRef="shares">415898</rgls:NonvotingConvertiblePreferredStockIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0f2c4232052049e3a363d782b40cb6bc_I20190507"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzMwNQ_448975f8-400c-48e8-8370-5d6df38bc5d9"
      unitRef="usdPerShare">10.80</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i0f2c4232052049e3a363d782b40cb6bc_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzM3Mw_c40ccd12-b5c3-4cbf-8f19-fc2cb1aaabfc"
      unitRef="shares">4158980</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i50625ecf1d0a45eeb2ecec6aac3745e9_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzQxMw_5ef626a1-17b6-408a-a972-63cc1c35fac1"
      unitRef="usdPerShare">0.125</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i674455781c874bdbbef4fcb1f436968d_D20190507-20190507"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzUzOA_e3006c20-8a78-41f1-b7a1-0f36fafa9ed4"
      unitRef="usd">16700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzcxMw_8b7f3a67-1715-4ff5-8ae6-3fd6e00a2979"
      unitRef="shares">10</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzg0OQ_292c385e-4dac-4981-8bb4-49e518e3fd47">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i05cc6e4dd5674e3e84af93d7cc9d57b2_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMzkxMw_a5d07ef9-fb0c-442b-8246-73645adc4533"
      unitRef="usdPerShare">1.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i81b3e274349048899a6baf2136cbce5c_D20190507-20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNDEwOA_2ae85153-cb3d-480d-9d81-9e43ce715ce9"
      unitRef="shares">526083</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="icd6803fc0e58407c98e7e6efe7b48823_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNDE2NQ_e31fd439-173f-4638-8ceb-7dd8fd22d256"
      unitRef="shares">526083</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
      contextRef="i21a6fc5988124fb9a3c0daca71b52647_D20190507-20190507"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNDIxMA_2c04822e-5441-4655-b226-ba4c05a4a3a5"
      unitRef="usd">600000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iead2605b5d6e40c59a34f098e26f325d_D20191224-20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTQ5Ng_61a07309-2bee-4a2c-9545-c5e6a7569a43"
      unitRef="shares">3288390</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i360a9fad1f764e37b7a0392838193495_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTYxMg_72db59e5-ccda-48cb-b5ad-9f5a0d1f794d"
      unitRef="shares">32883900</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iead2605b5d6e40c59a34f098e26f325d_D20191224-20191224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTY4Nw_7242cb38-9378-4c8a-ab3b-9d02554355ec"
      unitRef="usd">26000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6e3c72e4f312454cb6e94e3624438bd4_D20191224-20191224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTc2NQ_3b70ec6f-bb65-47ea-ba8e-7b96519b5b90"
      unitRef="usd">24600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i9e9d49856529484a9241d0f6562c00ce_D20191224-20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTg1Mg_f8f32fec-32c8-41bc-bf38-6a4042c39a00"
      unitRef="number">10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i360a9fad1f764e37b7a0392838193495_I20191224"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNTk5Mg_b4809165-73a0-48c5-97aa-d757211521e6">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i360a9fad1f764e37b7a0392838193495_I20191224"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNjA1Ng_568134f1-e36c-410c-ae80-855ab81723d4"
      unitRef="usdPerShare">0.666</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ief922b305f3046a1a28f76ddcd1e5862_D20191224-20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNjI1MQ_2aa056ac-469f-4e47-b62f-569eb593801f"
      unitRef="shares">121581</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7662e8163acd4dc8adc61570e5adde5d_I20191224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNjMzMw_dd5bf243-60e1-48ba-ae79-52e8b156295e"
      unitRef="shares">1215810</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ief922b305f3046a1a28f76ddcd1e5862_D20191224-20191224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNjM5Mg_ac21899f-fd60-4687-a62e-65a9e4eed08e"
      unitRef="usd">1000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if073e6ccc7cc48ab99b972e5ac765b10_D20201204-20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfNzkxNw_05418956-48b4-4c0c-91ea-3ca108c007d8"
      unitRef="shares">24341607</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie514dfd04114480cb2e11b8bf5bb0435_I20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODAwMw_4ce3f4f2-02ec-4c58-bd28-d54882ef7a28"
      unitRef="shares">18256204</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ie514dfd04114480cb2e11b8bf5bb0435_I20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODA2MQ_3c4344e3-3c4e-4939-bc9f-b4d74a740331"
      unitRef="usdPerShare">0.7464</us-gaap:SaleOfStockPricePerShare>
    <rgls:NonvotingConvertiblePreferredStockIssued
      contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODA4NA_2787941e-b273-411f-a7f0-e5494dee8f92"
      unitRef="shares">272970</rgls:NonvotingConvertiblePreferredStockIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODE5Ng_1607d588-fe4f-4657-9269-985dfba9b3f5"
      unitRef="usdPerShare">6.22</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODI2NA_3e899e68-2735-457d-9f40-4216736a9d4a"
      unitRef="shares">2047276</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i6a2c7b41e9fc4304b5170c4d5ee66271_I20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODMwNQ_94abde67-0224-4f89-85d4-d99ed99a2272"
      unitRef="usdPerShare">0.125</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="if073e6ccc7cc48ab99b972e5ac765b10_D20201204-20201204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODQyNw_d27358aa-0407-47c8-9d57-35e62210d6be"
      unitRef="usd">19400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="ie514dfd04114480cb2e11b8bf5bb0435_I20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODYwMg_0a1725de-5855-4443-b11a-f24fa8f8007a"
      unitRef="shares">10</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODczOA_f8c2360f-1c6b-4937-bac0-f08536fbd4bc">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i919f61d52aec4ec9804c967d05a0ac34_I20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODgwMg_8e41323d-31b8-4416-8679-b0bb9786425f"
      unitRef="usdPerShare">0.7464</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i77c7496e13cb499b9175da4b6316b202_D20201204-20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfODk5Nw_571fba30-51cd-4a01-8eff-496a3cae6310"
      unitRef="shares">833208</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i1ba02a52203c4223911077232c49cee7_I20201204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfOTA1NA_033cbc3c-cf61-4b37-8875-9dcb19c020da"
      unitRef="shares">624906</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
      contextRef="ic598bb91fd7e4fed8d09bafbe5180ce0_D20201204-20201204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfOTA5OQ_20740177-a272-4226-87e6-0323388259d1"
      unitRef="usd">600000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <rgls:ActivityOfSharesTableTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNjc_84826c54-1101-49c2-9dc7-4fbf870e773b">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes preferred stock conversions and warrant exercises (and the related impact on common stoc&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;k) under the 2019 SPA and 2020 SPA for the three and nine months ended September 30, 2021 and 2020 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class A-1 Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class A-2 Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class A-3 Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversions/Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September&#160;30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rgls:ActivityOfSharesTableTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib0a0858e919543a98b9c64121d1e1830_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS0xLTEtMS02MTAz_7c0ee33b-5bd7-40b9-8e0e-082ebd7e1f19"
      unitRef="shares">257000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idbea8938a1694e83b04dda860ed7dd2d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS0zLTEtMS02MTAz_b772b120-064e-4f86-a6a8-18f1446779eb"
      unitRef="shares">1416000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia79e9b8c233642bbb9cebdf5dfb40760_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS01LTEtMS02MTAz_51b7041b-ddd1-4a65-8153-b1c1b324720c"
      unitRef="shares">259000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i45d5562fcca646dd99b09cd41afa34ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS03LTEtMS02MTAz_b525e801-fed5-478d-8cf5-a28cca07bc77"
      unitRef="shares">66038000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i752592ed38104bc78a16c74ec4d542fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMS05LTEtMS02MTAz_1161cee6-0eab-4a74-b3df-a790bdcdfbb2"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia03dfcdae3b1407bb022fb54e0a8156b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS0xLTEtMS02MTAz_1387c637-3957-4035-867a-69d353a887f2"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i383282b176b840d4a8c19a6ac7b18315_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS0zLTEtMS02MTAz_44b8c279-d07f-4eca-8270-de43fc986008"
      unitRef="shares">-78000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i6af434f9895c4a8abcdc67b6e14c6efe_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS01LTEtMS02MTAz_c705b212-6dcf-4ed7-84e9-e9eeb62d86ce"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ic0bbfe3a36da493c9161915cc9d72948_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS03LTEtMS02MTAz_eea01386-7c47-4387-bc87-70f39902b943"
      unitRef="shares">-3920000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia36e6a371c8a44609f70ce29521cf931_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNS05LTEtMS02MTAz_c4a62b85-e610-4d2a-af04-dc32f0de8bdf"
      unitRef="shares">3199000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5dd6bbd169a646cdac5d2d64ecd91d4a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi0xLTEtMS02MTAz_2ec6a882-0c4c-44e6-830c-25570cecd5d0"
      unitRef="shares">257000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i62444203267d47c385eec5d087d4d8da_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi0zLTEtMS02MTAz_9ff1c85d-237d-4c25-979e-30738fbc6576"
      unitRef="shares">1338000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i39b26e0a123149da8e318c905c14d733_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi01LTEtMS02MTAz_8a137ba9-5eea-43f4-90a5-0fbf622ac8ea"
      unitRef="shares">259000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8c861e934bbb434fb65de130aef4d7f0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi03LTEtMS02MTAz_05491f08-aa92-436c-8eb6-4a17c77024d8"
      unitRef="shares">62118000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i26455c9e63ec418298d96a228a52ea5c_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNi05LTEtMS02MTAz_a296dd12-5a01-4626-9571-33f9184b5349"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i74040130c2df49589afc08ad9a809499_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy0xLTEtMS02MTAz_65af5b89-ee58-4cca-a98a-8f7e83f1ec7f"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i254490f02c4c4c589f3f3c5081713988_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy0zLTEtMS02MTAz_dfff1149-4b9e-41a8-af87-d327227ecbcd"
      unitRef="shares">-7000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i95228771e65f4d69be9591692885d592_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy01LTEtMS02MTAz_d69ddea4-dd38-4d49-9ccd-c5f2ca314ca8"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i9c2c3a10cf064f479a81fd8b17777c0f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy03LTEtMS02MTAz_9d0f50c0-edc0-4d7b-9622-9016b751a60b"
      unitRef="shares">-250000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i4f4afbe5d8c34f8998934e3231e70d99_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfNy05LTEtMS02MTAz_b145b5bd-969e-4374-a179-6155e39e3478"
      unitRef="shares">326000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3dc0c2d79507405e933216b019d4edde_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC0xLTEtMS02MTAz_5163f8db-5490-4c1e-84e4-b5864f660559"
      unitRef="shares">257000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if247eeb7c16c4eb39296da50e9a88a87_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC0zLTEtMS02MTAz_b307e0fe-dcb5-487a-a457-df5d866ed1c2"
      unitRef="shares">1331000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id0325f8a593a4d04848243185ea3662f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC01LTEtMS02MTAz_5a55169a-14e0-4e1e-b06b-4ee595e92e6e"
      unitRef="shares">259000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic7022c7df72d41e099622cfcf6c5ac69_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC03LTEtMS02MTAz_c502a444-0b04-4dea-aeaf-2bdb9f5c5820"
      unitRef="shares">61868000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie294014d4c6e4e89b676a5f599db291f_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOC05LTEtMS02MTAz_7f770aa1-271b-42be-998c-43e6eb4d102f"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i7e29c7e6e8d7461aa5503106164f57ee_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS0xLTEtMS03MDI4_e4dc04c7-6667-4a10-a931-f0fa21df55da"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="id175542746b14dbe92632e7c763d73a4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS0zLTEtMS03MDI4_62c73e11-cbfd-4fe0-92a8-25048e774e81"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ic4e4836ff49d45a0813f0bf3e816e560_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS01LTEtMS03MDI4_1acdff92-2ea0-403b-b838-ac13dea95a2a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i7fc483577ed845e8bf93c991053ea7c9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS03LTEtMS03MDI4_7caead83-89a1-4fc4-bc0d-f6e934fc4153"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i8f8532096be04b6d9015d6367f7d8fdc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfOS05LTEtMS03MDI4_7bab3502-fe38-45f9-8f6c-52bd09362629"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic55ea03d6757422cb1b7c98ef85d4d29_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtMS0xLTEtNzAyOA_936b6b8d-7a05-47f1-8375-ec86156e2a6f"
      unitRef="shares">257000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i436d75c6db184475b193def39aa233c2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtMy0xLTEtNzAyOA_218c2bea-fe2e-4054-8116-c21cc0696e5c"
      unitRef="shares">1331000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i24d7ff325bb64f3ba97014fba8f446f6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtNS0xLTEtNzAyOA_24a5cf31-865f-4ca4-b491-0f90cd5a947b"
      unitRef="shares">259000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie1f198ef1d3d40c590316253a4a859b3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtNy0xLTEtNzAyOA_f2d97dd8-4701-4b7c-8022-e37c36147da7"
      unitRef="shares">61868000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib871a39aa1ac437eaa31e7324e95ec4f_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtOS0xLTEtNzAyOA_0a629ba4-5dd3-406d-b8b4-e2d5cba936ea"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1e829145a1ef44a3801129514bd80961_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtMS0xLTEtNjEwMw_6c320d1c-344c-4dbe-b2b7-1d2f203d7897"
      unitRef="shares">416000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i968ebf92b9924a3f927dd3367b7ee9b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtMy0xLTEtNjEwMw_f9d4d964-be2f-4732-add4-185d6a42144e"
      unitRef="shares">3288000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ica7c16fbdde44fcab2f8edcb368cb2ec_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtNS0xLTEtNjEwMw_7694428e-715d-4e8e-b32b-5614c8fa846a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i6455474e083246cbbfdf27a81a04fd9c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtNy0xLTEtNjEwMw_bb7db8ad-27ca-4ce8-9731-af8f942e937e"
      unitRef="shares">46774000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i23dd736c354b4baca7d8a7e5ad03a16f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTAtOS0xLTEtNjEwMw_2cbf65a3-1765-4528-82c9-fb74a78fd98c"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i20b9351df4284c69984f500e694a6369_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtMS0xLTEtNjEwMw_a345c910-b246-418b-b6ef-5760592674b1"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i3352e5aab04142a5979bb162e53c6330_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtMy0xLTEtNjEwMw_b34ea499-4868-4123-8535-a3a485630005"
      unitRef="shares">-656000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2451dacc95664a628df7a419490f93d5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtNS0xLTEtNjEwMw_d7d5be39-268b-461e-ae42-84852f4cd604"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i74a57decb14440bf86a20216c8b58def_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtNy0xLTEtNjEwMw_c1ee3a4f-c93a-4da5-a5f3-7ed9d37eb75b"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i688d71ec835347f28d95349cfa461c90_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTMtOS0xLTEtNjEwMw_957f7324-eac5-4d70-bb13-05746e348525"
      unitRef="shares">6567000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i86de16f9b2f842129ce65f588a7a7aa9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtMS0xLTEtNjEwMw_aac84331-bd1d-470b-a0be-7c1d5a42871f"
      unitRef="shares">416000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i230bbacb14564b7287002929b04072b6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtMy0xLTEtNjEwMw_c5a8a11d-4fb3-47c3-9834-8ddfb18f30dc"
      unitRef="shares">2632000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaf1162c4370f4f1495d1b38cb8c36886_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtNS0xLTEtNjEwMw_3da56389-9714-4445-8c4d-bb41f2df6791"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3dc114989d2e49059136125c88e9d784_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtNy0xLTEtNjEwMw_c9dc4af8-bb6c-4119-8a29-e54f6b9b1e3a"
      unitRef="shares">46774000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ida746cb1127f4a02913c9868d13207b9_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTQtOS0xLTEtNjEwMw_00dcaa2c-26ad-4d93-9430-27633a119111"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i17a1ebeb40054eee85bbb7562a88622b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtMS0xLTEtNjEwMw_03a847a1-51f5-4fe6-9422-6392b4b686c0"
      unitRef="shares">-159000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i0bc530cdf0a042f3b6cfcb98f0abe16d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtMy0xLTEtNjEwMw_41dcc9cb-51d5-466f-b313-aa9d040cb6b0"
      unitRef="shares">-671000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iec999a5bafc747db893bef4a0ad2b58a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtNS0xLTEtNjEwMw_2e26fe55-c015-4642-a4a0-7432d87f9883"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="idf571b5851d240cc8cda05c8c168c970_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtNy0xLTEtNjEwMw_ce09ab51-ff76-40f8-a690-01167a9c5570"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1b2924209bd04bb7a40a2a56f99caa9f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTUtOS0xLTEtNjEwMw_127bb13d-b039-43f9-8b06-8d5568f02487"
      unitRef="shares">8296000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie2af4520400a4c80a524537bc2037d39_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtMS0xLTEtNjEwMw_3cd31de6-9cf2-4659-a394-50bddff41694"
      unitRef="shares">257000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1b1959cfd8084de1ad61cf35bcfd27a2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtMy0xLTEtNjEwMw_56b180fa-a862-4bed-9ae5-cd44edb387e2"
      unitRef="shares">1961000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7c97aedbf36c4a329ed8b131afa706da_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtNS0xLTEtNjEwMw_befdbb12-d736-4d05-8332-13be0ea9ba24"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i6923a101d07842c3b5768ebb561bc42e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtNy0xLTEtNjEwMw_e3390658-f1d0-4060-88a5-8b2f7d3190da"
      unitRef="shares">46774000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac6b75c985414d3a94e6080ae2260895_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTYtOS0xLTEtNjEwMw_e15e769f-a7b5-48a2-9b89-45b95d866f7c"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i8fa784103a1544b79cc572714fbd6000_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktMS0xLTEtNzAzMQ_8dedfc6d-7fdb-49c3-81a1-15d5cb2f53ee"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i070064518ba64c48988cb9ebab49b967_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktMy0xLTEtNzAzMQ_0d3985ed-8833-4056-a137-61463b681e84"
      unitRef="shares">-322000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="id7db41969a844eb099ad7cacafdc6a43_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktNS0xLTEtNzAzMQ_2bb28dbb-dd54-4201-bb87-5e76f7b1cd0d"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ifb123cc427924d9d83494db5ea171543_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktNy0xLTEtNzAzMQ_d52175a0-f652-469b-84bb-22a246847f7d"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i3593e979f61242e4974999e7d07215d2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMTktOS0xLTEtNzAzMQ_7eb31570-efc2-484b-b66d-0a58a803338a"
      unitRef="shares">3217000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i786a3068e05841b28df2e45b562e51ee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtMS0xLTEtNzAzMQ_2a89bee6-4a58-43f0-97ab-95aeaecc2089"
      unitRef="shares">257000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i99418e2e85d14e5491bd379d2557e64f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtMy0xLTEtNzAzMQ_da65353e-4716-475b-9e20-610bac222f57"
      unitRef="shares">1639000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i952837312fd74bb6ad3761bd0f543858_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtNS0xLTEtNzAzMQ_16d99668-6b26-49d3-9794-758b0eab6912"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1c184c7909e14f73a331173806592ad9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtNy0xLTEtNzAzMQ_37e25d1d-c92e-4a79-a29e-b7ed571f718f"
      unitRef="shares">46774000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id5de04397b02498d82ebeda41dd65f11_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjk1NTVkMDY3YTYxZDQ2NTU5MzNhY2M2ZDQzZDNiYzcxL3RhYmxlcmFuZ2U6OTU1NWQwNjdhNjFkNDY1NTkzM2FjYzZkNDNkM2JjNzFfMjAtOS0xLTEtNzAzMQ_a10b1e35-2a4a-4479-abd6-89ef0e87a2d8"
      unitRef="shares"
      xsi:nil="true"/>
    <rgls:CommissionFeeRate
      contextRef="i76e2ff0b853b425197ddbce613a8c517_I20181212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTA2MTg_be25db5b-ac4a-4d29-9ece-115c8ce5dc90"
      unitRef="number">0.030</rgls:CommissionFeeRate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i89cc80809f64492f8d626470ab85255a_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjc0ODc3OTA4MzIyMA_fe17811c-154f-4c31-bb1b-2480f66374f7"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i4b63a4e5d7f548ab874621e4d0e59f70_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTA4NjY_d060c737-f938-4f7d-904d-582d2a69bf98"
      unitRef="shares">16017131</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i4b63a4e5d7f548ab874621e4d0e59f70_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTA5MTQ_5a23e24b-21df-4919-816c-4212e5ac9d1c"
      unitRef="usd">20500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsForCommissions
      contextRef="i4b63a4e5d7f548ab874621e4d0e59f70_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTA5MjU_3220afca-f774-4a8f-b90f-24b62a553098"
      unitRef="usd">800000</us-gaap:PaymentsForCommissions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i0f0579c541c24aefa982bf42729d197c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTEwMTM_1891194e-458a-4d63-9162-83a380c77ded"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3c72dba56f1642e4bb4ba0d460f36bff_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTEwMTM_e0397060-b4a6-490e-b9be-d37268b2bf70"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <rgls:SaleOfStockValueOfSharesAvailable
      contextRef="i7c836c16b926435386de34b3cc16d880_I20210810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTEzMjQ_1922ef70-112b-4b97-beff-0791b7ba73e1"
      unitRef="usd">50000000</rgls:SaleOfStockValueOfSharesAvailable>
    <rgls:SaleOfStockValueOfSharesAvailable
      contextRef="i6122f172c1574c4da14a5e4fd4d6e9da_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMjc0ODc3OTA4MzIyMg_82b436b7-8340-4630-8976-34fa9245e508"
      unitRef="usd">50000000</rgls:SaleOfStockValueOfSharesAvailable>
    <rgls:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNzM_a58dd564-cc84-445c-962a-5742901214ff">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares of common stock were reserved for future issuance as of September&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A-1 convertible preferred stock outstanding (as-converted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A-2 convertible preferred stock outstanding (as-converted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A-3 convertible preferred stock outstanding (as-converted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 PIPE Initial Closing warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 PIPE Milestone Closing warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 PIPE warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock available for future grant under 2019 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rgls:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6e0fa5dcfa6f41d78143b478d0a01b56_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMC0xLTEtMS02MTAz_fe8806d8-1f6e-486a-a70d-80503d008f65"
      unitRef="shares">2567000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8a0c87ad7a8d436fa4ccaa34c29d3a34_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMS0xLTEtMS02MTAz_6f4fdee2-aefb-4a6f-a6cd-edb7b080817a"
      unitRef="shares">13308000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia8b79769fd334fd287d6b5137a7b5c74_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMi0xLTEtMS02MTAz_3c0679fa-89ab-4160-9331-5d69ea709c13"
      unitRef="shares">2587000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic8041ada6a3e4d52bcb9c494a7798bca_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMy0xLTEtMS02MTAz_9b6dfe54-4d24-4824-89d2-fb490a271dd0"
      unitRef="shares">12778000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3341a1d23c5c4c2cace6220943a0f34f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfNC0xLTEtMS02MTAz_6a5d4ed4-fc5a-4bd6-b3af-a491895aca6e"
      unitRef="shares">30595000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3dd5d41a28e04fa0b27f308560cc92c1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfNS0xLTEtMS02MTAz_37510c07-0903-4cba-a027-8738d019c150"
      unitRef="shares">18495000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfNi0xLTEtMS02MTAz_89944826-8b13-4f71-bb0a-b987f5444724"
      unitRef="shares">9727000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i2c2342f58c454d05b39c846426605b48_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfNy0xLTEtMS02MTAz_25bf7002-483b-47a2-b082-5ba6e824cc68"
      unitRef="shares">446000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ifdae785f59024129a26a080f3e9b9224_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfOC0xLTEtMS02MTAz_87e9f2bb-d182-45ea-811e-fa17c394467f"
      unitRef="shares">853000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i00f4406481484bada9b1cf86ce076050_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMTEtMS0xLTEtNjEwMw_c788c80e-b461-446b-9cf8-49137fedd654"
      unitRef="shares">260000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjEyYjQxMWJjOGY1ODRjNDk4Y2EzZmZmMmVkYzA3YzMyL3RhYmxlcmFuZ2U6MTJiNDExYmM4ZjU4NGM0OThjYTNmZmYyZWRjMDdjMzJfMTItMS0xLTEtNjEwMw_d74e71a2-2708-473c-8241-fa07cdc7278c"
      unitRef="shares">91616000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNTc_a9c700ff-5058-4146-8e58-e6f610af11a2">&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock option and RSU (together Stock Awards) activity under all equity incentive plans for the nine months ended September&#160;30, 2021 (shares in thousands):&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Awards outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised (options) or Vested (RSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Awards outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i951d796d9ed84f84b26dc055c3e072b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMS0xLTEtMS02MTAz_d97cd4de-c459-4852-aa22-72cd076567ac"
      unitRef="shares">6813000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i951d796d9ed84f84b26dc055c3e072b5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMS0zLTEtMS02MTAz_2191d2c3-64f0-413b-8e00-7272da434f4b"
      unitRef="usdPerShare">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i644ae87d631747999899d8f3a2d4e933_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMS01LTEtMS02MTAz_1e502e6b-4948-43d5-be7b-169525698bf1"
      unitRef="shares">34000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i644ae87d631747999899d8f3a2d4e933_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMS03LTEtMS02MTAz_bc0f28ee-2e67-403e-ba40-99daec94d23f"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMi0xLTEtMS02MTAz_19dd0372-2c87-4104-be7b-931340736c6c"
      unitRef="shares">3143000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMi0zLTEtMS02MTAz_e551bd87-dc9f-49bc-bfa1-47e8e297c40f"
      unitRef="usdPerShare">1.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMi01LTEtMS02MTAz_e61b30e1-e55e-4d0f-9fd5-7e8eab143b1b"
      unitRef="shares">446000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMi03LTEtMS02MTAz_0cb8727c-4b3d-4701-9389-32be5b1e6fa8"
      unitRef="usdPerShare">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMy0xLTEtMS02MTAz_7fd79264-7e2f-4d45-87dd-e180727225fb"
      unitRef="shares">28000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMy0zLTEtMS02MTAz_899a96bf-f898-4104-b221-42167597983d"
      unitRef="usdPerShare">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMy01LTEtMS02MTAz_7d229427-226c-4769-b03a-7f650ac1cf92"
      unitRef="shares">34000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfMy03LTEtMS02MTAz_eae324b2-a6a8-4b82-be6a-6c28e6d1d742"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNC0xLTEtMS02MTAz_80440033-d47a-4140-822a-123970a3ab3d"
      unitRef="shares">201000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNC0zLTEtMS02MTAz_5138296e-1e44-4f12-857c-330d769a4e1b"
      unitRef="usdPerShare">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNC01LTEtMS02MTAz_38cb478a-353c-43a4-8519-d8c76889580f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i6bd987c2ff6e4b4d800356fb14a9ce38_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNC03LTEtMS02MTAz_77be09df-b523-41a8-a0da-58c1919e3e96"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib11f92ae4880433b90d114da1ab87247_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNS0xLTEtMS02MTAz_ed60c82f-aa6a-4395-881f-d04e6a2e38fd"
      unitRef="shares">9727000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib11f92ae4880433b90d114da1ab87247_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNS0zLTEtMS02MTAz_217a5b1f-6ece-4a16-9b92-186c083eac52"
      unitRef="usdPerShare">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2c2342f58c454d05b39c846426605b48_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNS01LTEtMS02MTAz_18cd3a57-529b-4900-9e1e-4e2b30aae770"
      unitRef="shares">446000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2c2342f58c454d05b39c846426605b48_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjkwNjE0YjdmOTQxMjQ4Y2NhZGUxYzQ5ODRjYzczOGU4L3RhYmxlcmFuZ2U6OTA2MTRiN2Y5NDEyNDhjY2FkZTFjNDk4NGNjNzM4ZThfNS03LTEtMS02MTAz_2e2fd8a0-a91b-4c4f-87c8-411aa876fb3f"
      unitRef="usdPerShare">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNTk_7fc0c1cf-fa65-477a-88c4-02acfc0a9bf1">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan, 2015 Inducement Plan, 2019 Equity Incentive Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i70017d07079c4189905253f72a203dfa_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMy0xLTEtMS02MTAz_57ee9282-d30c-4a37-a78c-bafe9aace1b3"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic504631e11784f66848db26f50687d26_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMy0zLTEtMS02MTAz_66ea33d9-1862-4395-b1d0-b2a0668cea77"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMy01LTEtMS02MTAz_3a4b8325-0c7b-4344-954c-c5406285c75f"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMy03LTEtMS02MTAz_f6353944-73d3-4c26-b042-4c31a50fe95c"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i70017d07079c4189905253f72a203dfa_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNC0xLTEtMS02MTAz_50c43a11-1137-4787-9998-6b6bb1704eb1"
      unitRef="number">0.960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic504631e11784f66848db26f50687d26_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNC0zLTEtMS02MTAz_fe6ca959-a228-48da-b286-4aaa47fa7653"
      unitRef="number">0.953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNC01LTEtMS02MTAz_97657759-7ac3-4ced-8e45-04372d029a16"
      unitRef="number">0.958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNC03LTEtMS02MTAz_d89d2d4a-c90b-4c4b-aceb-81654f0c1941"
      unitRef="number">0.954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i70017d07079c4189905253f72a203dfa_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNS0xLTEtMS02MTAz_5ddbfcf4-76ee-46e7-8bdf-753efe00e5bb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic504631e11784f66848db26f50687d26_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNS0zLTEtMS02MTAz_fd3699f0-89aa-45be-8666-2f85120edd6c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNS01LTEtMS02MTAz_dd7b9f32-a5ab-4598-b9b3-ae1ca4fe7c4b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNS03LTEtMS02MTAz_5cd76485-0c16-4cc7-ae8c-c3aac5b9f3ab"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i70017d07079c4189905253f72a203dfa_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNi0xLTEtMS02MTAz_e3429c41-9d17-4422-adaf-01f3c2ab018d">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic504631e11784f66848db26f50687d26_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNi0zLTEtMS02MTAz_cfd0fba9-4db8-49aa-b921-30ed4246fc96">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i689d25cead1341d6b5bb295befe38df3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNi01LTEtMS02MTAz_ffc32455-c009-4064-935d-961b92454d34">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia31b4203409c4ed48d93c755e6b7e4f3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfNi03LTEtMS02MTAz_ae7ea73d-fc3e-4125-aeec-cf607661df6a">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOC0xLTEtMS02MTAz_ab19d7fb-b82c-4bf9-8036-f2183009d487"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6794a82e447847f0b259ae873682904e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOC0zLTEtMS02MTAz_467524dd-0979-4979-9215-0fd6d0a28e39"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOC01LTEtMS02MTAz_01eb436b-2d26-403e-97c2-a779ccd01e1b"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOC03LTEtMS02MTAz_f1234f0d-0cab-4ec0-9852-6d21f6c917a2"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOS0xLTEtMS02MTAz_af7ef04b-7347-4672-a67d-2b27cb0c3b7f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6794a82e447847f0b259ae873682904e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOS0zLTEtMS02MTAz_dfd7a4da-b6f3-414e-8a0c-c576d4bf41a8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOS01LTEtMS02MTAz_d47d05bf-1d55-4c64-a5d0-1be0d53cf0c2"
      unitRef="number">0.957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfOS03LTEtMS02MTAz_92fc891c-9b98-4c29-96a1-56eb6a3f73e9"
      unitRef="number">0.954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTAtMS0xLTEtNjEwMw_7ade320c-57a7-4a00-82ff-7a0ea0e7d770"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6794a82e447847f0b259ae873682904e_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTAtMy0xLTEtNjEwMw_bd287384-0e57-4b22-ae43-936856c18569"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTAtNS0xLTEtNjEwMw_c6908f46-9252-4752-bdca-84f8179b432b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTAtNy0xLTEtNjEwMw_649c3ab0-d77a-438e-b2ba-a4bb4dbaafa9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icb2adc73dabe4527bf0567859e913cbd_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTEtMS0xLTEtNjEwMw_ce9e5049-1228-43c1-a6f5-01b0999ac5dd">P0M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6794a82e447847f0b259ae873682904e_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTEtMy0xLTEtNjEwMw_de001074-4064-4832-8503-631638aae37d">P0M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ieb1043cdb9ee4918a3ec0383591580ad_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTEtNS0xLTEtNjEwMw_175bd7e4-24a9-4910-b9a8-bd100b989b87">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icd94f4d307354b779be9ca288442e0a2_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTEtNy0xLTEtNjEwMw_833f65ee-bba6-4fbb-a513-6eca5ca9188b">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTMtMS0xLTEtNjEwMw_d057f558-f092-4179-ba76-d95e58132182"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTMtMy0xLTEtNjEwMw_cd44560e-4d63-4066-8476-4b1becba4d6f"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTMtNS0xLTEtNjEwMw_4cecff88-880b-471a-afa2-d7cc6558ae83"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTMtNy0xLTEtNjEwMw_7163b286-bd26-4d99-bb9b-613453ee145f"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTQtMS0xLTEtNjEwMw_7750c938-3abf-4e03-b479-700ca0c51787"
      unitRef="number">1.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTQtMy0xLTEtNjEwMw_d1a44f61-bfc3-47be-91b3-6a46a9bc7624"
      unitRef="number">0.949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTQtNS0xLTEtNjEwMw_a667423d-32e1-433a-8159-3596affc4ed9"
      unitRef="number">1.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTQtNy0xLTEtNjEwMw_d0fd8e89-13f1-4561-ac3a-c25fd2c73436"
      unitRef="number">0.982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTUtMS0xLTEtNjEwMw_c6bfe0ed-3ce0-48fa-9761-f57eded9c512"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTUtMy0xLTEtNjEwMw_89f5fe1f-dbd5-48d5-adf3-adf3d99c5967"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTUtNS0xLTEtNjEwMw_29adf1a6-6479-46b1-a67d-c2cbc9c85080"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTUtNy0xLTEtNjEwMw_83310da3-c3c0-479e-85b4-19aa3379447a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i15455a16e1cc4b388bc341c5e452a21a_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTYtMS0xLTEtNjEwMw_821651f5-b060-4c73-b083-cdfb150adda4">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9536c804a15d4f9789ce307493ed34cd_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTYtMy0xLTEtNjEwMw_e61fc404-2fc8-48cc-8243-5afc29dd5b04">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia51369ffaf10496fa3b8d6c0d53f1f77_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTYtNS0xLTEtNjEwMw_83e41215-c870-4413-bf8a-449259ee736e">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ifcbf24e6f04e49159dffb46a0de71ca2_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOjM5NTUzZjhjOWYyZDRiMDg4Yzg5ZjZmZWI4MWVjOTNkL3RhYmxlcmFuZ2U6Mzk1NTNmOGM5ZjJkNGIwODhjODlmNmZlYjgxZWM5M2RfMTYtNy0xLTEtNjEwMw_48bbfd39-0422-42f3-91c9-60625c3b5fb1">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RleHRyZWdpb246NjBhZDhkZWI4NDVhNDVhNDkzZDcyNTc1YjcyYWJmNzNfMTIxNjQ_6a6df8fa-eab0-4fcd-9c75-dd50841b6d00">&lt;div style="margin-top:13pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd5e74c99c434af4873f28aa394abae8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfMi0xLTEtMS02MTAz_f555b0d7-d4bf-4f02-915c-76955bf36b46"
      unitRef="usd">277000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e4dc078f58b49e3b773f4556b8a3b41_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfMi0zLTEtMS02MTAz_045f3b94-5a4c-470c-88b7-d3129654fe92"
      unitRef="usd">255000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i58b8f3c6cf464d83b2c2ae2abd93eef6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfMi01LTEtMS02MTAz_ffb50154-5583-4928-b66b-1c82fd58ee8e"
      unitRef="usd">687000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65465aaa0a2b4eff99ceadebe06d4c4b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfMi03LTEtMS02MTAz_413d3a50-58f8-49df-a41a-4d4b42007211"
      unitRef="usd">571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f2e97743f414d1694ca8d0fce5260f4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNC0xLTEtMS02MTAz_dc1de5d9-e3d3-4cae-9588-083292e1a214"
      unitRef="usd">530000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id179c53c4d4246068ac3e3d9d3e878bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNC0zLTEtMS02MTAz_6c5f8ffe-5d86-4687-900e-ab1946c64670"
      unitRef="usd">437000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4c9397744df49d28775440c5244e2ab_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNC01LTEtMS02MTAz_def3c9d6-6093-4ecf-800e-78885de3acb1"
      unitRef="usd">1565000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i817be33db9a14559bd6acb439e8aab8f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNC03LTEtMS02MTAz_2b64a11d-8ae1-4882-87e6-4a7d8449ba30"
      unitRef="usd">1573000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i868ed48256c846129326496101c3afa4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNi0xLTEtMS02MTAz_e2ec0734-5ba9-4ceb-8f37-997f356868b1"
      unitRef="usd">807000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic56cf83fca0c4816901fa48d871dc2ee_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNi0zLTEtMS02MTAz_5cc8324a-7417-49be-a226-7a84c3693216"
      unitRef="usd">692000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNi01LTEtMS02MTAz_72c74275-78c8-4090-80f9-6317bf8f761b"
      unitRef="usd">2252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic92abe9ea2d04f87a56c76facb7ebd5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N180OS9mcmFnOjYwYWQ4ZGViODQ1YTQ1YTQ5M2Q3MjU3NWI3MmFiZjczL3RhYmxlOmQwZWFiOWY5YmY0MzRjYjNiMzA4MzM3OTM3ZWFhMTJiL3RhYmxlcmFuZ2U6ZDBlYWI5ZjliZjQzNGNiM2IzMDgzMzc5MzdlYWExMmJfNi03LTEtMS02MTAz_4bd87544-be58-4b11-b4bd-3486e089efbf"
      unitRef="usd">2144000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNzE4MQ_cc6c697e-ab25-4221-8fda-9ffd87a00c19">Collaborations&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from our strategic collaborations was zero for the three and nine months ended September 30, 2021, compared to $5.0&#160;million for the three and nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sanofi&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;micro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RNA alliance targets to be developed under such agreement. The following elements were delivered as part of the strategic collaboration with Sanofi: (1)&#160;a license for up to four &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;micro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RNA targets; and (2)&#160;a research license under our technology collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which Sanofi was granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;micro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport syndrome. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2014, we and Sanofi entered into a second amended and restated collaboration and license agreement (the &#x201c;2014 Sanofi Amendment&#x201d;) to discover, develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;micro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RNA therapeutics to focus on specific orphan disease and oncology targets. Under the terms of the 2014 Sanofi Amendment, Sanofi had opt-in rights to our clinical fibrosis program targeting miR-21 for the treatment of Alport syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical program targeting miR-221/222 for hepatocellular carcinoma (&#x201c;HCC&#x201d;). We were responsible for developing each of these programs to proof-of-concept, at which time Sanofi had an exclusive option on each program. If Sanofi chooses to exercise its option on any of these programs, Sanofi would reimburse us for a significant portion of our preclinical and clinical development costs and would also pay us an option exercise fee for any such program, provided that $1.25&#160;million of the $2.5&#160;million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;be creditable against such option exercise fee. We are eligible to receive royalties on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;micro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products relating to our preclinical program targeting miR-221/222. As indicated below, we entered into an additional amendment with Sanofi in November 2018, under which Sanofi's opt-in rights to our miR-21 programs under the 2014 Sanofi Amendment were relinquished. Sanofi's opt-in rights with regard to our miR-221/222 preclinical program under the 2014 Sanofi Amendment remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are eligible to receive milestone payments related to the development and commercialization of miR-221/222 for HCC of up to $38.8 million for proof-of-concept option exercise fees (net of $1.25 million creditable, as noted above), $25.0 million for clinical milestones and up to $130.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales of any products from the miR-221/222 program which, in the case of sales in the United States, will be in the middle of the 10% to 20% range, and, in the case of sales outside of the United States, will range from the low end to the middle of the 10% to 20% range, depending upon the volume of sales. If we exercise our option to co-promote a miR-221/222 product, we will continue to be eligible to receive royalties on net sales of each product in the United States at the same rate, unless we elect to share a portion of Sanofi&#x2019;s profits from sales of such product in the United States in lieu of royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, we entered into an amendment to the 2014 Sanofi Amendment with Sanofi to modify the parties&#x2019; rights and obligations with respect to our miR-21 programs, including our RG-012 program (the &#x201c;2018 Sanofi Amendment&#x201d;). Under the terms of the 2018 Sanofi Amendment, we have granted Sanofi a worldwide, royalty-free, fee-bearing, exclusive license, with the right to grant sublicenses, under our know-how and patents to develop and commercialize miR-21 compounds and products for all indications, including Alport Syndrome. Sanofi will control and will assume all responsibilities and obligations for developing and commercializing each of our miR-21 programs, including our obligations regarding the administration and expense of clinical trials and all other costs, including in-license royalties and other in-license payments, related to our miR-21 programs. Under the terms of the 2018 Sanofi Amendment, we have assigned to Sanofi certain agreements, product-specific patents and all materials directed to miR-21 or to any miR-21 compound or product and are required to provide reasonable technical assistance to Sanofi for a period of 24 months after the date of the 2018 Sanofi Amendment. Under the terms of the 2018 Sanofi Amendment, we were eligible to receive approximately $6.8 million in upfront payments for the license and for miR-21 program-related materials (collectively, the &#x201c;Upfront Amendment Payments&#x201d;). We were also eligible to receive up to $40.0 million in development milestone payments, including a $10.0&#160;million payment for an interim enrollment milestone (the "Enrollment Milestone"). In addition, Sanofi has agreed to reimburse us for certain out-of-pocket transition activities and assume our upstream license royalty obligations. In 2019, we completed the performance obligations under the 2018 Sanofi Amendment and recognized revenue for the $6.8&#160;million in Upfront Amendment Payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we entered into an amendment to the 2018 Sanofi Amendment (the "2020 Sanofi Amendment"). Under the terms of the 2020 Sanofi Amendment, we agreed to transfer to Sanofi additional RG-012 development program materials (the &#x201c;Materials&#x201d;) in exchange for a payment from Sanofi of $1.0&#160;million (the &#x201c;Transfer Payment&#x201d;). In addition, in lieu of the $10.0&#160;million Enrollment Milestone under the 2018 Sanofi Amendment, Sanofi agreed to pay us a $4.0&#160;million milestone upon the completion of the transfer and verification of the Materials, and $5.0&#160;million upon achievement of the Enrollment Milestone. Additionally, we are eligible to receive $25.0&#160;million upon achievement of an additional development milestone related to Sanofi's development of the miR-21 compounds. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we received $1.0&#160;million in exchange for the transfer of the Materials to Sanofi, and received an additional $4.0&#160;million in October 2020 as a result of Sanofi's completion and verification of the Materials in September 2020. As the performance obligations associated with both of these payments had been satisfied under Topic 606 as of September 30, 2020, both amounts were recognized as revenue in the third quarter of 2020. In November 2020, we received $5.0&#160;million upon achievement of the Enrollment Milestone. As the performance obligations associated with this payment had been satisfied under Topic 606 as of December 31, 2020, this amount was recognized as revenue in the fourth quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e $25.0 million in development milestone payments (variable consideration) is fully constrained and therefore, does not meet the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; criteria for revenue recognition.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id91c48b0026b42dc91f4d51602dab771_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfODA_1832be8a-01ea-4718-bb69-ea3e3c40e3de"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i207c6ee7766e4b7b8321acdabc61f642_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfODA_cf87dce1-367c-4844-986d-d3adcb737960"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib574d1151949442b9717daf3b9f1afcd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMTU0_1e5bca90-b038-4655-b8c2-5a60f19862dc"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91edac16aa02482ab13c5c6191291f75_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjc0ODc3OTA3ODY1MQ_25382cf1-df35-413d-ab52-e294ae8bc0d0"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <rgls:CollaborativeAreasGranted
      contextRef="i00c63c04aad146a4a4b300df5bf7b017_D20120701-20120731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTUz_3bbea230-4ba8-4c12-bf07-f365d12f3db1"
      unitRef="target">4</rgls:CollaborativeAreasGranted>
    <rgls:DeferredRevenueCreditableAgainstFutureMilestones
      contextRef="i3bcfd2d3e6b4477b9224c2ddab8e9c58_D20140201-20140228"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjAzNw_7ab8332a-f4d8-4327-b097-693677d5fea9"
      unitRef="usd">1250000</rgls:DeferredRevenueCreditableAgainstFutureMilestones>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i9f4e945ac07d4765bd2b5ffc2566e5ae_D20130601-20130630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjA0Nw_2972c3ad-5f5a-4d4b-80e4-643bc11ef658"
      unitRef="usd">2500000</us-gaap:ProceedsFromCollaborators>
    <rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
      contextRef="i41a9a1a9f277465e8d50fdad1c657692_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjg1Mg_fb4c087a-d1e3-4554-9cc9-6e1cb20373f7"
      unitRef="usd">38800000</rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable>
    <rgls:DeferredRevenueCreditableAgainstFutureMilestones
      contextRef="i1929ac258c9c450cae6fef04bef7a0e8_D20210101-20210930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjkwNQ_82ecb6b8-5077-4c23-b103-75d8707a812d"
      unitRef="usd">1250000</rgls:DeferredRevenueCreditableAgainstFutureMilestones>
    <rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
      contextRef="iba95955f98f043a68a1e97b6a00b2b51_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjkzNw_1f76afae-655e-46d3-9df6-a5583b655b32"
      unitRef="usd">25000000</rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable>
    <rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
      contextRef="i153b7153a94d40aebf670759f33de31f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMjk3NA_def3f23a-54ea-4911-a7ed-2a4fab42c084"
      unitRef="usd">130000000</rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable>
    <rgls:RoyaltyPercentageBasedOnNetSales
      contextRef="i54a4f0ed7dc74ea5888ebe893d2216a7_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMzIyOA_612b5cb3-19b1-4183-bf49-092060e4253b"
      unitRef="number">0.10</rgls:RoyaltyPercentageBasedOnNetSales>
    <rgls:RoyaltyPercentageBasedOnNetSales
      contextRef="ibfab0a14bbcd45099cc675f73f91da2d_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMzIzNA_e3d4babb-66bb-4b5b-b69c-b0e76a193c34"
      unitRef="number">0.20</rgls:RoyaltyPercentageBasedOnNetSales>
    <rgls:RoyaltyPercentageBasedOnNetSales
      contextRef="i26e5dcd2596c41159528a70c01a1e7c8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMzM0OQ_c79fa114-61b1-4a18-af92-2a50f07b94fe"
      unitRef="number">0.10</rgls:RoyaltyPercentageBasedOnNetSales>
    <rgls:RoyaltyPercentageBasedOnNetSales
      contextRef="i3fabccc96bc64e1d9de7b84c7b313a57_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfMzM1NQ_be2a1ba2-00e0-4551-9f5a-37ef0c4a1fdf"
      unitRef="number">0.20</rgls:RoyaltyPercentageBasedOnNetSales>
    <rgls:AgreementPeriod
      contextRef="i0f3e037391ac473094c869e8548228db_D20181101-20181130"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNDg2MA_336dfbf2-4876-429c-ab64-1f569d2471f5">P24M</rgls:AgreementPeriod>
    <rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
      contextRef="ifa94d177b51946f9b13662dc829b3dc7_I20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNDk5Ng_457c4699-3a2f-4a40-9620-044edb57765b"
      unitRef="usd">6800000</rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable>
    <rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
      contextRef="if665882f71ff45d8bb6f588594d45f74_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTE2NQ_caa25f3e-5535-4fab-b0d2-0d3bcdb49943"
      unitRef="usd">40000000</rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable>
    <rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
      contextRef="ibe78a5b02aa8476385726b454cc854b6_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTIxNQ_c1162a4f-efba-4810-925a-f3b011503b9d"
      unitRef="usd">10000000</rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i353569e61e144d2db9c5ffc37b740344_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTU1Mw_f2b306fd-ae31-4d78-95b0-68c12f9e750d"
      unitRef="usd">6800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i29b7fba7009e439bbd4b1263221e7cf2_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTg3OA_fc1f0464-b0fa-41a6-a16a-093427181516"
      unitRef="usd">1000000</us-gaap:ProceedsFromCollaborators>
    <rgls:EnrollmentMilestone
      contextRef="i2e7415adf3f848789ba227aa56299001_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNTkzNQ_7bc65534-7822-4067-b8ec-83c32640c9f0"
      unitRef="usd">10000000</rgls:EnrollmentMilestone>
    <rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
      contextRef="i1806af5ab5b1428dbecc44603e625189_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjAxOA_c9485a65-7a9b-4a4d-be4c-b04c1d636228"
      unitRef="usd">4000000</rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable>
    <rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
      contextRef="i5d5dfcdeeecf40d4bbfce822eba097da_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjEwNg_9cad7950-53bf-416d-9aa7-ea4de6b39cae"
      unitRef="usd">5000000</rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable>
    <rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable
      contextRef="i539bb433e4534e329bc2c02884235317_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjE5Ng_aa34c20f-ba44-40b5-bb72-8d5b3db673b5"
      unitRef="usd">25000000</rgls:RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ifa5bd7d664de45838a638a9e07b56636_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjM0Mw_299423d9-072b-47e0-92a1-f8c71d4185a9"
      unitRef="usd">1000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i38edd55d27744d19aae8f3e58923a1d8_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjQzMA_15a1a590-c382-4697-bdfb-afc942c112cd"
      unitRef="usd">4000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ia8ceffe851924b93b694c2c233f516a4_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNjc2OA_9b4adb63-9040-41ce-83d6-5c956351b312"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerAssetNet>
    <rgls:DevelopmentMilestoneNotAchievable
      contextRef="i4a88aa30ce5f40f6915bd8be98ea9592_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181NS9mcmFnOjJiNTk0NGRiNThlMTQ1OGE5ODU3NTdmOTUyZmI0OTUxL3RleHRyZWdpb246MmI1OTQ0ZGI1OGUxNDU4YTk4NTc1N2Y5NTJmYjQ5NTFfNzAzMQ_ed81afc7-8afa-40a1-ac11-bec029cccb37"
      unitRef="usd">25000000</rgls:DevelopmentMilestoneNotAchievable>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNjI0OQ_3e8a47a5-9a7f-490b-aa1e-e22d9067a20d">LeasesAt the inception of a contractual arrangement, we determine whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. For operating leases with an initial term greater than 12 months, we recognize operating lease right of use assets ("ROU assets") and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease ROU assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when we are reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For &lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our operating leases, we generally cannot determine the interest rate implicit in the lease, in which case we use our incremental borrowing rate as the discount rate for the lease. We estimate our incremental borrowing rate for our operating leases based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with a lease term of 12 months or less at inception are not recorded on the unaudited condensed balance sheet. Instead, we recognize lease expense for these leases on a straight-line basis over the lease term. Our lease agreements do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Certain leases require us to pay taxes, insurance, utilities, and maintenance costs for the building, which do not represent lease components. We elected to not separate lease and non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;19, 2019, we entered into a lease agreement (the &#x201c;Prior Lease&#x201d;) with&#160;ARE SD Region No.44 LLC ("Landlord") for the lease of approximately 8,727 square feet of rentable area of the building located at 10628 Science Center Drive, Suite 225, San Diego, California 92121 (the &#x201c;Prior Premises&#x201d;). The commencement date of the Prior Lease was July&#160;1, 2019 (the &#x201c;Prior Commencement Date&#x201d;). We used the Prior Premises as our principal executive offices and as a laboratory for research and development and other related uses. The term of the Prior Lease (the &#x201c;Prior Initial Term&#x201d;) was two years, six months, ending December&#160;31, 2021. The base rent payments due for the Prior Premises were $0.4 million in 2020 and $0.4 million in 2021, net of certain rent abatement terms. We were also responsible for the payment of additional rent to cover our share of the annual operating expenses of the building, the annual tax expenses of the building and the annual utilities cost of the building.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2019, we recorded a $0.8 million lease liability for the Prior Lease, which was calculated as the present value of future lease payments to be made under the Prior Lease. A $0.6 million ROU asset was also recorded on July 1, 2019, which represents the difference between the lease liability and the remaining $0.2 million deferred credit for the reduction of the lease liability under the operating lease agreement with Landlord dated February 25, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2021, we entered into a lease agreement (the "Campus Point Lease") with ARE-SD Region No. 61, LLC (as successor in interest to ARE-SD Region No. 58, LLC) ("Campus Point Landlord"), for the lease of approximately 13,438 square feet of rentable area located at 4224 Campus Point Court, Suite 210, San Diego, California, 92121 (the "Campus Point Premises"). The commencement date of the Campus Point Lease was April 15, 2021. However, for accounting purposes the lease commencement date was February 11, 2021. We are using the Campus Point Premises as our new principal executive offices and as a laboratory for research and development, manufacturing and other related uses. The term of the Campus Point Lease (&#x201c;Campus Point Initial Term&#x201d;) is 60 months, ending April 30, 2026. The aggregate base rent due over the initial term of the Campus Point Lease is approximately $3.8&#160;million. We are also responsible for the payment of additional amounts to cover our share of the annual operating expenses of the building, the annual tax expenses of the building and the utilities costs for the building.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2021, concurrently with entry into the Campus Point Lease, we entered into an Assignment and Assumption of Lease (the &#x201c;Assignment Agreement&#x201d;) with Turning Point Therapeutics, Inc. (&#x201c;Assignee&#x201d;) and a Consent to Assignment (the "Consent") with Landlord. Pursuant to the Assignment Agreement, we assigned all rights, title, and interest under the Prior Lease to Assignee and delivered the Prior Premises to Assignee&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on April 22, 202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1. Pursuant to the Assignment Agreement, Assignee paid us $60,000 in non-refundable assignment consideration. Additionally, the Consent stipulates that we were not required to pay a fee pursuant to the Prior Lease in connection with the assignment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The execution of the Campus Point Lease, Consent, and Assignment Agreement resulted in a modification which was not accounted for as a separate contract. Rather, we accounted for the three contracts with Campus Point Landlord in combination, as they were entered into at the same time and negotiated as a package to achieve the same commercial objective. We accounted for a $0.2&#160;million reduction in the lease liability for the Prior Lease as a deferred credit that is amortized as a reduction to rent expense over the term of the Campus Point Lease. A lease liability of less than $0.1&#160;million and ROU asset of less than $0.1&#160;million remained with respect to the Prior Lease and was fully amortized as of April 30, 2021. On February 11, 2021, we recorded a $3.2&#160;million lease liability for the Campus Point Lease, which was calculated as the present value of future lease payments to be made under the Campus Point Lease. A $3.0&#160;million ROU asset was also recorded on February 11, 2021, which represents the difference between the lease liability and the $0.2&#160;million deferred credit for the reduction of the lease liability under the Prior Lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our future lease payments under operating leases at September 30, 2021 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of obligations under leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:NetRentableArea
      contextRef="i03c5d4dd537e4ff08c58974c361af177_I20190619"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjA0Ng_1b4475b5-e373-434a-b874-24e71d00c615"
      unitRef="sqft">8727</us-gaap:NetRentableArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i03c5d4dd537e4ff08c58974c361af177_I20190619"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjQ4MQ_eecfb8f4-b1ca-48c7-8f31-82f878e70662">P2Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i03c5d4dd537e4ff08c58974c361af177_I20190619"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjU2Ng_45efdfaa-3518-495b-a7f8-f2990f740a94"
      unitRef="usd">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i03c5d4dd537e4ff08c58974c361af177_I20190619"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjU4MQ_17c449ea-7b1a-4675-9c20-fb7bb735c9b0"
      unitRef="usd">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <rgls:InitialDirectCostLiability
      contextRef="i25175afe9d9d4c0f895fef5eab8d5af5_I20190701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMjg3Nw_ff36eb46-b872-4978-8575-bdb71e9e62bd"
      unitRef="usd">800000</rgls:InitialDirectCostLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i25175afe9d9d4c0f895fef5eab8d5af5_I20190701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMzAyMA_d9099204-a594-4b56-b160-123b653bd6f9"
      unitRef="usd">600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <rgls:DeferredCreditOperatingLeaseLiability
      contextRef="i25175afe9d9d4c0f895fef5eab8d5af5_I20190701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMzE0Ng_0ed24db5-adb2-4934-bf9a-84faa4601de3"
      unitRef="usd">200000</rgls:DeferredCreditOperatingLeaseLiability>
    <rgls:RentedArea
      contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfMzUxMA_2d647ce2-64ab-4065-8d0b-0e937f637170"
      unitRef="sqft">13438</rgls:RentedArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNDAzNQ_f41796f0-3276-4e35-ac50-7cb857ae24b8">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNDE1NQ_604dfea8-197e-4f0d-ad1a-5051f2852bcc"
      unitRef="usd">3800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <rgls:NonrefundableLeaseCostForAssignment
      contextRef="i695ef34b99df4efc8fc1b1d5d72d82f2_D20210211-20210211"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNDg3NQ_0eb5d136-0a6e-42f6-9055-c59b3667494f"
      unitRef="usd">60000</rgls:NonrefundableLeaseCostForAssignment>
    <rgls:NumberOfOperatingLeaseContracts
      contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTI0NQ_5e991dac-c9c6-4213-8519-621469666a21"
      unitRef="contract">3</rgls:NumberOfOperatingLeaseContracts>
    <us-gaap:DeferredCostsLeasingAccumulatedAmortization
      contextRef="i9f5be9f84b7d49a28e6d8c05f8aaaa70_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTQzMw_d44f5733-7581-4a0b-bf26-f3a3f0e97f64"
      unitRef="usd">200000</us-gaap:DeferredCostsLeasingAccumulatedAmortization>
    <rgls:InitialDirectCostLiability
      contextRef="i9f5be9f84b7d49a28e6d8c05f8aaaa70_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTYzMQ_2a31d9c1-086d-4b22-8d3a-3c1c2ef173ca"
      unitRef="usd">100000</rgls:InitialDirectCostLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9f5be9f84b7d49a28e6d8c05f8aaaa70_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTY2MQ_e3bf64f4-b2c1-417f-83ce-862af4a2ff9f"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <rgls:InitialDirectCostLiability
      contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTc4Nw_b422f106-ae8d-45c3-8fd6-c45f3633b548"
      unitRef="usd">3200000</rgls:InitialDirectCostLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNTk0NA_282c745e-5d83-43db-8e3a-bd95a0720139"
      unitRef="usd">3000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <rgls:DeferredCreditOperatingLeaseLiability
      contextRef="i158c1d7853cc43d08c48916341fcc559_I20210211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNjA2NQ_acbbba8f-a047-4a75-80e2-e90cd2b6fbfc"
      unitRef="usd">200000</rgls:DeferredCreditOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RleHRyZWdpb246YjY0ODgyODA2NGYwNGFiNWJiNzEzZmQ0YjMyYmFhNGRfNjI1NA_ea31f4dc-5565-4ba9-b680-8eb3f43011a9">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our future lease payments under operating leases at September 30, 2021 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of obligations under leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMS0xLTEtMS02MTAz_7574649f-d2bb-49b7-b35e-5448200bb51b"
      unitRef="usd">185000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMi0xLTEtMS02MTAz_548686a8-a674-4fb1-aac9-fc38b48e307a"
      unitRef="usd">754000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfNy0xLTEtMS02MTAz_04a6b193-e175-4593-a94a-a32f53585a07"
      unitRef="usd">776000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfOC0xLTEtMS02MTAz_ade42d09-53a0-4cf6-94c5-dcfadafbae2b"
      unitRef="usd">800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <rgls:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfOS0xLTEtMS02MTAz_66f7ecba-7699-4461-a863-64d7eb328586"
      unitRef="usd">1101000</rgls:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTAtMS0xLTEtNjEwMw_2743e306-1df0-4ed4-99b4-a07d52f776c0"
      unitRef="usd">3616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTEtMS0xLTEtNjEwMw_8efb1ff3-9fdf-4439-9d3f-c304f11f55b6"
      unitRef="usd">471000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTItMS0xLTEtNjEwMw_bd40e21a-a63c-4dc9-9913-b02acef4e0f1"
      unitRef="usd">3145000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTMtMS0xLTEtNjEwMw_2ce13fb9-84db-446a-be16-1bc94c76e986"
      unitRef="usd">575000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1ffdb10c152a4544a6ac91e853bf0328_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZDNhMjUyODZmOTQ5NjFhZjMyYjcwOTQ3ZGNjNTk3L3NlYzoxYmQzYTI1Mjg2Zjk0OTYxYWYzMmI3MDk0N2RjYzU5N181OC9mcmFnOmI2NDg4MjgwNjRmMDRhYjViYjcxM2ZkNGIzMmJhYTRkL3RhYmxlOmM3NTJiOTAzMmI0NDRhNTlhZDVjNTBkNjBkZjk1YWE1L3RhYmxlcmFuZ2U6Yzc1MmI5MDMyYjQ0NGE1OWFkNWM1MGQ2MGRmOTVhYTVfMTQtMS0xLTEtNjEwMw_1b02ef54-7a85-4f6b-8575-21fdeb664891"
      unitRef="usd">2570000</us-gaap:OperatingLeaseLiabilityNoncurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959541045176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-4738379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4224 Campus Point Court, Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">202-6300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RGLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,047,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">REGULUS THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001505512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540720216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,848<span></span>
</td>
<td class="nump">$ 31,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Contract and other receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid materials, net</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">3,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">39,986<span></span>
</td>
<td class="nump">36,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">2,690<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,042<span></span>
</td>
<td class="nump">37,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">2,347<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of term loan, less debt issuance costs</a></td>
<td class="nump">4,668<span></span>
</td>
<td class="nump">4,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="nump">2,970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,460<span></span>
</td>
<td class="nump">11,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, less current portion</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,030<span></span>
</td>
<td class="nump">11,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares and 200,000,000 authorized at September 30, 2021 and December 31, 2020, respectively; 87,047,832 and 67,432,712 shares issued and outstanding at September 30, 2021 (unaudited) and December&#160;31, 2020, respectively</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">476,643<span></span>
</td>
<td class="nump">453,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(447,720)<span></span>
</td>
<td class="num">(427,045)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">29,012<span></span>
</td>
<td class="nump">26,026<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">43,042<span></span>
</td>
<td class="nump">37,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA1ConvertiblePreferredStockAsConvertedMember', window );">Class A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember', window );">Class A-2 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA3ConvertiblePreferredStockMember', window );">Class A-3 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA1ConvertiblePreferredStockAsConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassA1ConvertiblePreferredStockAsConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959631791048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,330,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,330,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">87,047,832<span></span>
</td>
<td class="nump">67,432,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">87,047,832<span></span>
</td>
<td class="nump">67,432,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA1ConvertiblePreferredStockAsConvertedMember', window );">Class A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">256,700<span></span>
</td>
<td class="nump">256,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">256,700<span></span>
</td>
<td class="nump">256,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">256,700<span></span>
</td>
<td class="nump">256,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember', window );">Class A-2 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,416,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,416,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,330,832<span></span>
</td>
<td class="nump">1,416,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA3ConvertiblePreferredStockMember', window );">Class A-3 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">258,707<span></span>
</td>
<td class="nump">258,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">258,707<span></span>
</td>
<td class="nump">258,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">258,707<span></span>
</td>
<td class="nump">258,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA1ConvertiblePreferredStockAsConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassA1ConvertiblePreferredStockAsConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540560760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,915<span></span>
</td>
<td class="nump">4,036<span></span>
</td>
<td class="nump">13,385<span></span>
</td>
<td class="nump">11,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,504<span></span>
</td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">7,471<span></span>
</td>
<td class="nump">6,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,419<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">20,856<span></span>
</td>
<td class="nump">18,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,419)<span></span>
</td>
<td class="num">(1,095)<span></span>
</td>
<td class="num">(20,856)<span></span>
</td>
<td class="num">(13,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest and other expense</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(641)<span></span>
</td>
<td class="num">(1,416)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(8,628)<span></span>
</td>
<td class="num">(1,523)<span></span>
</td>
<td class="num">(20,674)<span></span>
</td>
<td class="num">(14,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (8,628)<span></span>
</td>
<td class="num">$ (1,524)<span></span>
</td>
<td class="num">$ (20,675)<span></span>
</td>
<td class="num">$ (14,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in usd per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in usd per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used to compute basic net loss per share (in shares)</a></td>
<td class="nump">87,042,437<span></span>
</td>
<td class="nump">38,137,281<span></span>
</td>
<td class="nump">78,560,760<span></span>
</td>
<td class="nump">30,695,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used to compute diluted net loss per share (in shares)</a></td>
<td class="nump">87,042,437<span></span>
</td>
<td class="nump">38,137,281<span></span>
</td>
<td class="nump">78,560,760<span></span>
</td>
<td class="nump">30,695,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible List]</a></td>
<td class="text">Revenue Under Collaborations [Member]<span></span>
</td>
<td class="text">Revenue Under Collaborations [Member]<span></span>
</td>
<td class="text">Revenue Under Collaborations [Member]<span></span>
</td>
<td class="text">Revenue Under Collaborations [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959539405416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Convertible preferred stock </div>
<div>Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,018,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,704,288<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 20,015<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 431,305<span></span>
</td>
<td class="num">$ (411,315)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,566,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(656,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,608,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,047,606<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">14,902<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">432,123<span></span>
</td>
<td class="num">(417,252)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,018,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,704,288<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">20,015<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">431,305<span></span>
</td>
<td class="num">(411,315)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,163,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,896,215<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">7,754<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">433,436<span></span>
</td>
<td class="num">(425,723)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,608,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,047,606<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">14,902<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">432,123<span></span>
</td>
<td class="num">(417,252)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,296,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(829,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,922,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,217,963<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">8,584<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">432,745<span></span>
</td>
<td class="num">(424,199)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,217,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(321,748)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,163,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,896,215<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">7,754<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">433,436<span></span>
</td>
<td class="num">(425,723)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,432,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,931,860<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">26,026<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">453,002<span></span>
</td>
<td class="num">(427,045)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,418,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock through ATM (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,009,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock through ATM</a></td>
<td class="nump">5,713<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">5,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,689,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853,824<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">27,111<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">460,092<span></span>
</td>
<td class="num">(433,058)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,432,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,931,860<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">26,026<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">453,002<span></span>
</td>
<td class="num">(427,045)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,047,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,846,239<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">29,012<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">476,643<span></span>
</td>
<td class="num">(447,720)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,689,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853,824<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">27,111<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">460,092<span></span>
</td>
<td class="num">(433,058)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock through ATM (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,007,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock through ATM</a></td>
<td class="nump">14,831<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">14,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,585)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,040,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,846,239<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">36,828<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">475,831<span></span>
</td>
<td class="num">(439,092)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,047,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,846,239<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 29,012<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 476,643<span></span>
</td>
<td class="num">$ (447,720)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540595048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,675)<span></span>
</td>
<td class="num">$ (14,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_GainLossOnLoanForgiveness', window );">Gain on PPP Loan forgiveness</a></td>
<td class="num">(662)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Contracts and other receivables</a></td>
<td class="nump">503<span></span>
</td>
<td class="num">(2,859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid materials</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">51<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">193<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(316)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="nump">291<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(729)<span></span>
</td>
<td class="num">(1,212)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,297)<span></span>
</td>
<td class="num">(15,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(210)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ProceedsFromFederalProgram', window );">Proceeds from borrowing under Paycheck Protection Program</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">21,384<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Principal payments on term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_PaymentsonFinanceLeases', window );">Payments on financing leases</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">21,330<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">4,823<span></span>
</td>
<td class="num">(16,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">31,087<span></span>
</td>
<td class="nump">34,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">35,910<span></span>
</td>
<td class="nump">17,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">35,848<span></span>
</td>
<td class="nump">17,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">35,910<span></span>
</td>
<td class="nump">17,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_PaycheckProtectionProgramLoanForgiveness', window );">Paycheck Protection Program loan forgiveness</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="num">(329)<span></span>
</td>
<td class="num">(1,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_GainLossOnLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_GainLossOnLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Research and Development Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Right of Use and Lease Liabilities, Net, Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_PaycheckProtectionProgramLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paycheck Protection Program Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_PaycheckProtectionProgramLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_PaymentsonFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments on Finance Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_PaymentsonFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ProceedsFromFederalProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Federal Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_ProceedsFromFederalProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959538520072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, from which the balance sheet information herein was derived.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a&#160;going&#160;concern.&#160;Through the date of the issuance of these financial statements, we have principally been financed through proceeds received from the sale of our common stock and other equity securities, debt financings, up-front payments and milestones received from collaboration agreements, totaling $505.6 million.&#160;As of&#160;September&#160;30, 2021, we had approximately $35.8&#160;million of cash and cash equivalents. Based on our operating plans, we believe our cash and cash equivalents may not be sufficient to fund our operations for the period one year following the issuance of these financial statements. As a result, there is substantial doubt about our ability to continue as a going concern. All amo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unts due under the Term Loan (see note 5) have been classified as a current liability as of September 30, 2021 and December 31, 2020, due to the considerations discussed above and the assessment that the material adverse change clause under the Term Loan is not within our control. In the first quarter of 2021, we received a waiver from the Lender (as defined below) with respect to noncompliance with a covenant under the Loan Agreement (as defined below). We are in compliance with all Loan Agreement covenants.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity, or cease operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Additionally, the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under license and collaboration agreements. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which could affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i)&#160;the fair value of the award is determined on the grant date, (ii)&#160;we assess the probability of the individual milestones under the award being achieved and (iii)&#160;the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites and CROs and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Materials</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our preclinical and clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process.&#160;We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which an impairment is identified.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequently, in November 2018, the FASB issued&#160;ASU&#160;2018-19,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;ASU 2016-13&#160;requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d reasonable and supportable forecasts.&#160;ASU 2016-13&#160;also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December&#160;15, 2022, with early adoption permitted. We are assessing the impact this standard will have on our financial statements and disclosures.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reference Rate Reform (Topic 848), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which provides guidance around reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation in response to concerns about structural risks of interbank offered rates and the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments in the ASU provide option expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform and apply only if such contracts, hedging relationships and other transactions that reference LIBOR or another reference rate are expected to be discontinued because of reference rate reform. The guidance does not apply to contract modifications made, and hedging relationships entered into or evaluated, after December 31, 2022. We are assessing the impact this standard will have on our financial statements and disclosures. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. The adoption of this standard on January 1, 2021 did not impact our financial statements or disclosures.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959537068600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method or if-converted method. Dilutive common stock equivalents are comprised of stock options, restricted stock units and convertible preferred stock outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.Potentially dilutive securities not included in the calculation of diluted net loss per common share, because to do so would be anti-dilutive, were (in common stock equivalent shares) 28,635,276 for the three months and nine months ended September 30, 2021, consisting of convertible preferred stock, stock options and restricted stock units, and 25,813,032 for the three and nine months ended September 30, 2020, consisting of convertible preferred stock, stock options and restricted stock units.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959539040712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">InvestmentsHistorically, we have invested our excess cash primarily in debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. We generally hold our investments to maturity and do not sell our investments before we have recovered our amortized cost basis. As of September&#160;30, 2021 and December&#160;31, 2020, our cash balance was comprised entirely of cash and cash equivalents (money market funds).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959537044248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i)&#160;independent, (ii)&#160;knowledgeable, (iii)&#160;able to transact, and (iv)&#160;willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management&#8217;s own assumptions.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets Measured at Fair Value</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value as of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value as of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>We obtain pricing information from quoted market prices or quotes from brokers/dealers. We have historically determined the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959539040712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2016, we entered into a loan and security agreement ("Loan Agreement") with Oxford Finance, LLC, (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lender</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), pursuant to which we received $20.0 million in proceeds, net of debt issuance costs, on June 22, 2016 (the "Term Loan"). </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding Term Loan will mature on May 1, 2022 (the &#8220;Maturity Date&#8221;) and bears interest at a floating per annum rate equal to (i) 8.51% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) 0.44%. Under the original Loan Agreement, we were required to make interest-only payments through June 1, 2018, followed by 24 equal monthly payments of principal and unpaid accrued interest.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement was amended eight times between October 2017 through May 2019. On May 1, 2020 we entered into a ninth amendment to the Term Loan with the Lender (the &#8220;Ninth Amendment&#8221;). Pursuant to the terms of the Ninth Amendment, (i) the approximately $0.7&#160;million of loan proceeds (the "PPP Loan") we received under the Paycheck Protection Program ("PPP") was included as permitted indebtedness under the terms of the Term Loan, (ii) we agreed to apply for forgiveness of the maximum amount of PPP Loan permissible in accordance with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and use best efforts to cause not less than $0.5&#160;million of the PPP Loan to be forgiven by the PPP Loan lender on or before September 30, 2020 and (iii) we agreed not to amend any material provision in any document relating to the PPP Loan nor make any prepayment of the PPP Loan unless such prepayment is necessary or advisable due to change in the applicable law or guidance issued by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Small Business Administration (&#8220;SBA&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ugust 25, 2020 we entered into a tenth amendment to the Term Loan with the Lender (the "Tenth Amendment").  Pursuant to the terms of the Tenth Amendment, we are eligible for up to an additional seven months of interest only payments in the event we paid down $10.0&#160;million in loan principal before April 30, 2021 (the "Principal Paydown Event"). In the event the Principal Paydown Event did not occur by April 30, 2021, we would make principal and accrued interest payments, in arrears, commencing May 1, 2021, in accordance with the terms of the Eighth Amendment. If the Principal Paydown Event occurred after April 30, 2021 but on or before July 31, 2021, we would recommence an extended interest only payment period through December 31, 2021. In the event we received the additional interest only period, principal and accrued interest payments would recommence on January 1, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We received $1.0&#160;million, $4.0&#160;million and $5.0&#160;million in proceeds from Sanofi (see Note 7) on September 30, 2020, October 8, 2020 and November 30, 2020, respectively. Under the terms of the Tenth Amendment, we prepaid $1.0&#160;million, $4.0&#160;million and $5.0&#160;million of outstanding principal to the Lender on September 30, 2020, October 8, 2020 and November 30, 2020, respectively, for a total of $10.0&#160;million. We also paid the applicable 5.5% final payment fees related to the three prepayments to the Lender. As the Principal Paydown Event occurred by April 30, 2021, we received an additional seven </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">months of interest only payment extension and are not obligated to make principal payments on the Term Loan until January 1, 2022.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the proceeds from the Term Loan solely for working capital and to fund our general business requirements.  Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, other than our intellectual property, for which the Lender currently has a positive lien, and certain assets under finance lease obligations. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement. The Loan Agreement includes customary events of default, including instances of a material adverse change in our operations, that may require prepayment of the outstanding Term Loan. During the first quarter of 2021, we received a waiver from the Lender with respect to noncompliance with a covenant under the Loan Agreement. We are in compliance with all Loan Agreement covenants as of the date of the filing of this Form 10-Q.&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, $4.7 million was outstanding under the Term Loan. An additional $1.3 million is also payable at the conclusion of the Term Loan (presented in other current liabilities on our balance sheet at September 30, 2021). We had less than $0.1 million of debt issuance costs outstanding as of September 30, 2021, which are being accreted to interest expense over the life of the Term Loan using an effective interest rate of 8.98%. The exit fees are being accrued over the life of the Term Loan through interest expense.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:4pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, we received the proceeds from the PPP Loan in the amount of approximately $0.7&#160;million from Silicon Valley Bank, as lender, pursuant to the PPP of the CARES Act. The PPP Loan was set to mature on April 23, 2022 and bore interest at a rate of 1.0% per annum. The PPP Loan was evidenced by a promissory note dated April 23, 2020, which contained customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The PPP Loan was prepayable by us at any time prior to maturity with no prepayment penalties.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the CARES Act and PPP Flexibility Act, loan forgiveness is available for the sum of documented payroll costs, covered mortgage interest, covered rent payments and covered utilities during the 24 week period beginning on the date of loan disbursement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> For purposes of the PPP, payroll costs exclude compensation of an individual employee in excess of $100,000, annualized, prorated for the covered period. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines during the covered period as compared to specified reference periods, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%, unless certain safe harbors are satisfied. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal and includes accrued interest.</span></div>We have used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments, and we sought forgiveness in accordance with the program. We received full forgiveness of our PPP Loan in the second quarter of 2021. We accounted for the full forgiveness of our PPP Loan by recording a gain in interest and other income for the nine months ended September 30, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959537093144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, there were 87,047,832 shares of common stock outstanding. Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by our Board of Directors. </span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Equity Incentive Plan</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2019, the Company's board of directors approved, and on August 1, 2019 the Company's stockholders approved, the Company's 2019 Equity Incentive Plan (the "2019 Plan"). The 2019 Plan is intended as the successor to and continuation of the Company's 2012 Equity Incentive Plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares authorized for issuance under the 2019 Plan may be increased by (a) the shares subject to outstanding stock awards granted under the Company&#8217;s 2009 Equity Incentive Plan (the &#8220;2009 Plan&#8221;) and the Company&#8217;s 2012 Equity Incentive Plan (together the with 2009 Plan, the &#8220;Prior Plans&#8221;) that on or after the effective date of the 2019 Plan (i) expire or terminate for any reason prior to exercise or settlement; (ii) are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise return to the Company, or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award. No further grants will be made under the Prior Plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. In addition, on January 22, 2020, an additional 4,166,860 shares of common stock became available for issuance under the 2019 Plan pu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rsuant to the Milestone Closing (defined below) of the May 2019 SPA (defined below). Further, on January&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year, for a period of not more than ten years, beginning on January&#160;1, 2021 and continuing through January&#160;1, 2029, the number of shares authorized for issuance under the 2019 Plan will increase by 5.0% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares as may be determined by our Board of Directors. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, 853,111 shares of common stock were available for new equity award grants under the 2019 Plan and 10,172,886 shares of common stock are reserved for issuance pursuant to equity awards outstanding as of September 30, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Private Placements of Common Stock, Non-Voting Preferred Stock and Warrants</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2019, we entered into a securities purchase agreement (the "May 2019 SPA") with certain institutional and other accredited investors, including certain directors, executive officers and employees of the Company (the &#8220;Purchasers&#8221;), pursuant to which we agreed to sell and issue shares of our common stock, shares of our newly designated non-voting convertible preferred stock, and warrants to purchase common stock, in up to two closings, in a private placement transaction (the &#8220;Private Placement&#8221;).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At an initial closing under the May 2019 SPA that occurred on May 7, 2019 (the &#8220;Initial Closing&#8221;), we sold and issued to the Purchasers (i) 9,730,534 shares of common stock and accompanying warrants to purchase up to an aggregate of 9,730,534 shares of common stock at a combined purchase price of $1.205 per share, and (ii) 415,898 shares of non-voting Class A-1 convertible preferred stock, in lieu of shares of common stock, at a price of $10.80 per share, and accompanying warrants to purchase an aggregate of 4,158,980 shares of common stock at a price of $0.125 for each share of common stock underlying such warrants. Total gross proceeds from the Initial Closing were approximately $16.7 million, which does not include any proceeds that may be received upon exercise of the warrants. Each share of non-voting Class A-1 convertible preferred stock is convertible into 10 shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of five years following the date of issuance and have an exercise price of $1.08 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise "cashless" basis. An aggregate of 526,083 shares of common stock and warrants to purchase up to 526,083 shares of common stock were purchased for $0.6 million by certain directors and executive officers of the Company under the Initial Closing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the May 2019 SPA, in the event our Board of Directors unanimously resolved to recommence our Phase 1 multiple ascending dose clinical trial of our RGLS4326 product candidate for the treatment of ADPKD (the &#8220;Phase 1 Trial&#8221;) based on correspondence from the U.S. Food and Drug Administration&#8217;s Division of Cardiovascular and Renal Products, and thereafter but on or before December 31, 2019, we made a public announcement of our plan to recommence the Phase 1 Trial (the &#8220;Public Announcement&#8221;), we would sell and the Purchasers would purchase, at a second closing under the May 2019 SPA (&#8220;Milestone Closing&#8221;), shares of our non-voting convertible preferred stock and accompanying warrants to purchase shares of Common Stock (collectively, "Milestone Securities"). On December&#160;15, 2019, the Company's Board of Directors unanimously resolved to recommence the Phase 1 Trial based on correspondence from the U.S. Food&#160;&amp; Drug Administration&#8217;s Division of Cardiovascular and Renal Products and on December&#160;16, 2019, we made the related Public Announcement, triggering the Milestone Closing, which occurred on December&#160;24, 2019. At the Milestone Closing, we sold and issued to the Purchasers 3,288,390 shares of&#160;non-voting&#160;Class&#160;A-2&#160;convertible preferred stock and accompanying warrants to purchase an aggregate of 32,883,900 shares of common stock for an aggregate purchase price of approximately $26.0 million. Net proceeds to the Company from the Milestone Closing were approximately $24.6 million. Each share of&#160;non-voting&#160;Class&#160;A-2&#160;convertible preferred stock is convertible into 10 shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants will be exercisable for a period of five years following the date of issuance and have an exercise price of $0.666 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise &#8220;cashless&#8221; basis. An aggregate of 121,581 shares of Class A-2 convertible preferred stock and warrants to purchase up to 1,215,810 shares of common stock were purchased for approximately $1.0 million by certain directors and executive officers of the Company under the Milestone Closing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated the non-voting Class A-1 convertible preferred stock and common stock warrants sold in the Initial Closing and the Class A-2 convertible preferred stock and common stock warrants sold in the Milestone Closing under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and determined permanent equity treatment was appropriate for these freestanding financial instruments. The Initial Closing and Milestone Closing did not include any embedded features that required bifurcation. The non-voting Class A-2 convertible preferred stock and warrants issuable under the Milestone Closing were not subject to accounting recognition until the Milestone Closing occurred, as the terms of the Milestone Closing did not provide a right or an obligation on either the Company nor the Purchasers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2020, we entered into a Securities Purchase Agreement (the "December 2020 SPA") with certain institutional and other accredited investors, including certain directors, executive officers and employees of the Company (the &#8220;2020 Purchasers&#8221;), pursuant to which we agreed to sell and issue shares of our common stock, shares of newly designated non-voting convertible preferred stock and warrants to purchase common stock (the &#8220;2020 PIPE&#8221;).  </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing under the December 2020 SPA that occurred on December 4, 2020 (the &#8220;2020 Closing&#8221;), we sold and issued to the 2020 Purchasers (i) 24,341,607 shares of common stock and accompanying warrants to purchase up to an aggregate of 18,256,204 shares of common stock at a combined purchase price of $0.7464 per share, and (ii) 272,970 shares of non-voting Class A-3 convertible preferred stock, in lieu of shares of common stock, at a price of $6.22 per share, and accompanying warrants to purchase an aggregate of 2,047,276 shares of common stock at a price of  $0.125 for each share of common stock underlying such warrants. Total gross proceeds from the 2020 Closing were approximately $19.4&#160;million, which does not include any proceeds that may be received upon exercise of the warrants. Each share of non-voting Class A-3 convertible preferred stock is convertible into 10 shares of common stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of five years following the date of issuance and have an exercise price of $0.7464 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise "cashless" basis. An aggregate of 833,208 shares of common stock and warrants to purchase up to 624,906 shares of common stock were purchased for $0.6&#160;million by certain directors and executive officers of the Company at the 2020 Closing.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated the non-voting Class A-3 convertible preferred stock and common stock warrants sold in the 2020 PIPE under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and determined permanent equity treatment was appropriate for these freestanding financial instruments and there were no embedded features that required bifurcation. </span></div><div style="text-indent:31.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes preferred stock conversions and warrant exercises (and the related impact on common stoc</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k) under the 2019 SPA and 2020 SPA for the three and nine months ended September 30, 2021 and 2020 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A-1 Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A-2 Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A-3 Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(671)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,296&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September&#160;30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ATM Offering</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 12, 2018, we entered into a Common Stock Sales Agreement (the &#8220;Stock Sales Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;), pursuant to which we may sell and issue shares of our common stock from time to time through HCW, as our sales agent (the &#8220;ATM Offering&#8221;). We have no obligation to sell any shares of common stock in the ATM Offering, and may at any time suspend offers under the Stock Sales Agreement or terminate the Stock Sales Agreement. Subject to the terms and conditions of the Stock Sales Agreement, HCW will use its commercially reasonable efforts to sell shares of our common stock from time to time based upon our instructions (including any price, time or size limits or other parameters or conditions that we may impose, subject to certain restrictions). We pay HCW a commission of 3.0% of the gross sales price of any shares sold under the Stock Sales Agreement. No shares were sold under the ATM Offering during the three months ended September 30, 2021. A total of 16,017,131 shares were sold and settled for proceeds of $20.5&#160;million (net of $0.8&#160;million in offering costs) under the ATM Offering during the nine months ended September 30, 2021. No shares were sold under the ATM Offering during the three and nine months ended September 30, 2020. On August 10, 2021, we increased the amount of common stock available for sale in ATM Offerings under the Stock Sales Agreement to $50.0&#160;million. At September 30, 2021, approximately $50.0&#160;million remained available for sale in the ATM Offering.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares Reserved for Future Issuance</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares of common stock were reserved for future issuance as of September&#160;30, 2021 (in thousands):</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-1 convertible preferred stock outstanding (as-converted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-2 convertible preferred stock outstanding (as-converted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-3 convertible preferred stock outstanding (as-converted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 PIPE Initial Closing warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 PIPE Milestone Closing warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 PIPE warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for future grant under 2019 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,616&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock option and RSU (together Stock Awards) activity under all equity incentive plans for the nine months ended September&#160;30, 2021 (shares in thousands):</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.926%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Awards outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised (options) or Vested (RSUs)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Awards outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,727&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan, 2015 Inducement Plan, 2019 Equity Incentive Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dividend yield </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr></table></div><div style="margin-top:13pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540808136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text">Collaborations<div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from our strategic collaborations was zero for the three and nine months ended September 30, 2021, compared to $5.0&#160;million for the three and nine months ended September 30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sanofi</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA alliance targets to be developed under such agreement. The following elements were delivered as part of the strategic collaboration with Sanofi: (1)&#160;a license for up to four </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA targets; and (2)&#160;a research license under our technology collaboration.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which Sanofi was granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport syndrome. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, we and Sanofi entered into a second amended and restated collaboration and license agreement (the &#8220;2014 Sanofi Amendment&#8221;) to discover, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutics to focus on specific orphan disease and oncology targets. Under the terms of the 2014 Sanofi Amendment, Sanofi had opt-in rights to our clinical fibrosis program targeting miR-21 for the treatment of Alport syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical program targeting miR-221/222 for hepatocellular carcinoma (&#8220;HCC&#8221;). We were responsible for developing each of these programs to proof-of-concept, at which time Sanofi had an exclusive option on each program. If Sanofi chooses to exercise its option on any of these programs, Sanofi would reimburse us for a significant portion of our preclinical and clinical development costs and would also pay us an option exercise fee for any such program, provided that $1.25&#160;million of the $2.5&#160;million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be creditable against such option exercise fee. We are eligible to receive royalties on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products relating to our preclinical program targeting miR-221/222. As indicated below, we entered into an additional amendment with Sanofi in November 2018, under which Sanofi's opt-in rights to our miR-21 programs under the 2014 Sanofi Amendment were relinquished. Sanofi's opt-in rights with regard to our miR-221/222 preclinical program under the 2014 Sanofi Amendment remained unchanged.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are eligible to receive milestone payments related to the development and commercialization of miR-221/222 for HCC of up to $38.8 million for proof-of-concept option exercise fees (net of $1.25 million creditable, as noted above), $25.0 million for clinical milestones and up to $130.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales of any products from the miR-221/222 program which, in the case of sales in the United States, will be in the middle of the 10% to 20% range, and, in the case of sales outside of the United States, will range from the low end to the middle of the 10% to 20% range, depending upon the volume of sales. If we exercise our option to co-promote a miR-221/222 product, we will continue to be eligible to receive royalties on net sales of each product in the United States at the same rate, unless we elect to share a portion of Sanofi&#8217;s profits from sales of such product in the United States in lieu of royalties.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we entered into an amendment to the 2014 Sanofi Amendment with Sanofi to modify the parties&#8217; rights and obligations with respect to our miR-21 programs, including our RG-012 program (the &#8220;2018 Sanofi Amendment&#8221;). Under the terms of the 2018 Sanofi Amendment, we have granted Sanofi a worldwide, royalty-free, fee-bearing, exclusive license, with the right to grant sublicenses, under our know-how and patents to develop and commercialize miR-21 compounds and products for all indications, including Alport Syndrome. Sanofi will control and will assume all responsibilities and obligations for developing and commercializing each of our miR-21 programs, including our obligations regarding the administration and expense of clinical trials and all other costs, including in-license royalties and other in-license payments, related to our miR-21 programs. Under the terms of the 2018 Sanofi Amendment, we have assigned to Sanofi certain agreements, product-specific patents and all materials directed to miR-21 or to any miR-21 compound or product and are required to provide reasonable technical assistance to Sanofi for a period of 24 months after the date of the 2018 Sanofi Amendment. Under the terms of the 2018 Sanofi Amendment, we were eligible to receive approximately $6.8 million in upfront payments for the license and for miR-21 program-related materials (collectively, the &#8220;Upfront Amendment Payments&#8221;). We were also eligible to receive up to $40.0 million in development milestone payments, including a $10.0&#160;million payment for an interim enrollment milestone (the "Enrollment Milestone"). In addition, Sanofi has agreed to reimburse us for certain out-of-pocket transition activities and assume our upstream license royalty obligations. In 2019, we completed the performance obligations under the 2018 Sanofi Amendment and recognized revenue for the $6.8&#160;million in Upfront Amendment Payments. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an amendment to the 2018 Sanofi Amendment (the "2020 Sanofi Amendment"). Under the terms of the 2020 Sanofi Amendment, we agreed to transfer to Sanofi additional RG-012 development program materials (the &#8220;Materials&#8221;) in exchange for a payment from Sanofi of $1.0&#160;million (the &#8220;Transfer Payment&#8221;). In addition, in lieu of the $10.0&#160;million Enrollment Milestone under the 2018 Sanofi Amendment, Sanofi agreed to pay us a $4.0&#160;million milestone upon the completion of the transfer and verification of the Materials, and $5.0&#160;million upon achievement of the Enrollment Milestone. Additionally, we are eligible to receive $25.0&#160;million upon achievement of an additional development milestone related to Sanofi's development of the miR-21 compounds. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we received $1.0&#160;million in exchange for the transfer of the Materials to Sanofi, and received an additional $4.0&#160;million in October 2020 as a result of Sanofi's completion and verification of the Materials in September 2020. As the performance obligations associated with both of these payments had been satisfied under Topic 606 as of September 30, 2020, both amounts were recognized as revenue in the third quarter of 2020. In November 2020, we received $5.0&#160;million upon achievement of the Enrollment Milestone. As the performance obligations associated with this payment had been satisfied under Topic 606 as of December 31, 2020, this amount was recognized as revenue in the fourth quarter of 2020.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e $25.0 million in development milestone payments (variable consideration) is fully constrained and therefore, does not meet the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> criteria for revenue recognition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959538547800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesAt the inception of a contractual arrangement, we determine whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. For operating leases with an initial term greater than 12 months, we recognize operating lease right of use assets ("ROU assets") and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease ROU assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when we are reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For <div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our operating leases, we generally cannot determine the interest rate implicit in the lease, in which case we use our incremental borrowing rate as the discount rate for the lease. We estimate our incremental borrowing rate for our operating leases based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with a lease term of 12 months or less at inception are not recorded on the unaudited condensed balance sheet. Instead, we recognize lease expense for these leases on a straight-line basis over the lease term. Our lease agreements do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Certain leases require us to pay taxes, insurance, utilities, and maintenance costs for the building, which do not represent lease components. We elected to not separate lease and non-lease components.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;19, 2019, we entered into a lease agreement (the &#8220;Prior Lease&#8221;) with&#160;ARE SD Region No.44 LLC ("Landlord") for the lease of approximately 8,727 square feet of rentable area of the building located at 10628 Science Center Drive, Suite 225, San Diego, California 92121 (the &#8220;Prior Premises&#8221;). The commencement date of the Prior Lease was July&#160;1, 2019 (the &#8220;Prior Commencement Date&#8221;). We used the Prior Premises as our principal executive offices and as a laboratory for research and development and other related uses. The term of the Prior Lease (the &#8220;Prior Initial Term&#8221;) was two years, six months, ending December&#160;31, 2021. The base rent payments due for the Prior Premises were $0.4 million in 2020 and $0.4 million in 2021, net of certain rent abatement terms. We were also responsible for the payment of additional rent to cover our share of the annual operating expenses of the building, the annual tax expenses of the building and the annual utilities cost of the building.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2019, we recorded a $0.8 million lease liability for the Prior Lease, which was calculated as the present value of future lease payments to be made under the Prior Lease. A $0.6 million ROU asset was also recorded on July 1, 2019, which represents the difference between the lease liability and the remaining $0.2 million deferred credit for the reduction of the lease liability under the operating lease agreement with Landlord dated February 25, 2019. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2021, we entered into a lease agreement (the "Campus Point Lease") with ARE-SD Region No. 61, LLC (as successor in interest to ARE-SD Region No. 58, LLC) ("Campus Point Landlord"), for the lease of approximately 13,438 square feet of rentable area located at 4224 Campus Point Court, Suite 210, San Diego, California, 92121 (the "Campus Point Premises"). The commencement date of the Campus Point Lease was April 15, 2021. However, for accounting purposes the lease commencement date was February 11, 2021. We are using the Campus Point Premises as our new principal executive offices and as a laboratory for research and development, manufacturing and other related uses. The term of the Campus Point Lease (&#8220;Campus Point Initial Term&#8221;) is 60 months, ending April 30, 2026. The aggregate base rent due over the initial term of the Campus Point Lease is approximately $3.8&#160;million. We are also responsible for the payment of additional amounts to cover our share of the annual operating expenses of the building, the annual tax expenses of the building and the utilities costs for the building.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2021, concurrently with entry into the Campus Point Lease, we entered into an Assignment and Assumption of Lease (the &#8220;Assignment Agreement&#8221;) with Turning Point Therapeutics, Inc. (&#8220;Assignee&#8221;) and a Consent to Assignment (the "Consent") with Landlord. Pursuant to the Assignment Agreement, we assigned all rights, title, and interest under the Prior Lease to Assignee and delivered the Prior Premises to Assignee</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on April 22, 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. Pursuant to the Assignment Agreement, Assignee paid us $60,000 in non-refundable assignment consideration. Additionally, the Consent stipulates that we were not required to pay a fee pursuant to the Prior Lease in connection with the assignment.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The execution of the Campus Point Lease, Consent, and Assignment Agreement resulted in a modification which was not accounted for as a separate contract. Rather, we accounted for the three contracts with Campus Point Landlord in combination, as they were entered into at the same time and negotiated as a package to achieve the same commercial objective. We accounted for a $0.2&#160;million reduction in the lease liability for the Prior Lease as a deferred credit that is amortized as a reduction to rent expense over the term of the Campus Point Lease. A lease liability of less than $0.1&#160;million and ROU asset of less than $0.1&#160;million remained with respect to the Prior Lease and was fully amortized as of April 30, 2021. On February 11, 2021, we recorded a $3.2&#160;million lease liability for the Campus Point Lease, which was calculated as the present value of future lease payments to be made under the Campus Point Lease. A $3.0&#160;million ROU asset was also recorded on February 11, 2021, which represents the difference between the lease liability and the $0.2&#160;million deferred credit for the reduction of the lease liability under the Prior Lease.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future lease payments under operating leases at September 30, 2021 are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligations under leases</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959536940856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, from which the balance sheet information herein was derived.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Additionally, the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under license and collaboration agreements. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which could affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i)&#160;the fair value of the award is determined on the grant date, (ii)&#160;we assess the probability of the individual milestones under the award being achieved and (iii)&#160;the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_AccruedExpensePolicyTextBlock', window );">Clinical Trial and Preclinical Study Accruals</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites and CROs and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_PrepaidExpensesPolicyTextBlock', window );">Prepaid Materials</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Materials</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our preclinical and clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process.&#160;We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which an impairment is identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequently, in November 2018, the FASB issued&#160;ASU&#160;2018-19,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;ASU 2016-13&#160;requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d reasonable and supportable forecasts.&#160;ASU 2016-13&#160;also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December&#160;15, 2022, with early adoption permitted. We are assessing the impact this standard will have on our financial statements and disclosures.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reference Rate Reform (Topic 848), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which provides guidance around reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation in response to concerns about structural risks of interbank offered rates and the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments in the ASU provide option expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform and apply only if such contracts, hedging relationships and other transactions that reference LIBOR or another reference rate are expected to be discontinued because of reference rate reform. The guidance does not apply to contract modifications made, and hedging relationships entered into or evaluated, after December 31, 2022. We are assessing the impact this standard will have on our financial statements and disclosures. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. The adoption of this standard on January 1, 2021 did not impact our financial statements or disclosures.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i)&#160;independent, (ii)&#160;knowledgeable, (iii)&#160;able to transact, and (iv)&#160;willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management&#8217;s own assumptions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_AccruedExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expense [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_AccruedExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_PrepaidExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_PrepaidExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959537000616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value as of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value as of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959536735112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Debt Maturities</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959542925336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ActivityOfSharesTableTextBlock', window );">Activity of Shares</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes preferred stock conversions and warrant exercises (and the related impact on common stoc</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k) under the 2019 SPA and 2020 SPA for the three and nine months ended September 30, 2021 and 2020 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A-1 Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A-2 Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A-3 Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(671)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,296&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversions/Exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September&#160;30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock', window );">Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares of common stock were reserved for future issuance as of September&#160;30, 2021 (in thousands):</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-1 convertible preferred stock outstanding (as-converted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-2 convertible preferred stock outstanding (as-converted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A-3 convertible preferred stock outstanding (as-converted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 PIPE Initial Closing warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 PIPE Milestone Closing warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 PIPE warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for future grant under 2019 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,616&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="margin-top:7pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock option and RSU (together Stock Awards) activity under all equity incentive plans for the nine months ended September&#160;30, 2021 (shares in thousands):</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.926%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Awards outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised (options) or Vested (RSUs)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Awards outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,727&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan, 2015 Inducement Plan, 2019 Equity Incentive Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dividend yield </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:13pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands):</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ActivityOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Activity of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_ActivityOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Shares Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959536990872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future lease payments under operating leases at September 30, 2021 are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligations under leases</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959537013224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_FinancingfromSaleProceedsDebtAgreementRevenues', window );">Financing from sale proceeds, debt, and agreement revenues</a></td>
<td class="nump">$ 505,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,848<span></span>
</td>
<td class="nump">$ 31,087<span></span>
</td>
<td class="nump">$ 17,843<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_FinancingfromSaleProceedsDebtAgreementRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing from Sale Proceeds, Debt, Agreement Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_FinancingfromSaleProceedsDebtAgreementRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959543051096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">28,635,276<span></span>
</td>
<td class="nump">25,813,032<span></span>
</td>
<td class="nump">28,635,276<span></span>
</td>
<td class="nump">25,813,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959539217288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value on a recurring basis</a></td>
<td class="nump">$ 33,904<span></span>
</td>
<td class="nump">$ 26,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value on a recurring basis</a></td>
<td class="nump">33,904<span></span>
</td>
<td class="nump">26,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents (money market funds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value on a recurring basis</a></td>
<td class="nump">33,904<span></span>
</td>
<td class="nump">26,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents (money market funds) | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value on a recurring basis</a></td>
<td class="nump">33,904<span></span>
</td>
<td class="nump">26,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents (money market funds) | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents (money market funds) | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value on a recurring basis</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959538752376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">20 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 08, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 17, 2016 </div>
<div>payment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>prepayment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>prepayment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>amendment</div>
</th>
<th class="th">
<div>May 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NumberOfAmendments', window );">Number of times agreement was amended | amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_StrategicAlliancesandCollaborationsMember', window );">Revenue under collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_StrategicAlliancesandCollaborationsMember', window );">Revenue under collaborations | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementMember', window );">Debt Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from borrowing under term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NumberofMonthlyPayments', window );">Number of monthly payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument effective rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementMember', window );">Debt Financing Agreement | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rgls_PPPLoanMember', window );">PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ForgivenessAmountThreshold', window );">Forgiveness threshold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rgls_PPPLoanMember', window );">PPP Loan | Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rgls_TenthAmendmentMember', window );">Tenth Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_InterestOnlyPaymentExtension', window );">Interest-only payment extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_PrepaymentRequirement', window );">Prepayment requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rgls_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_PaymentFee', window );">Payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NumberOfPrepaymentsToLender', window );">Number of prepayments to lender | prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_AdditionalExtensionForInterestOnlyPayments', window );">Additional extension for interest only payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_AdditionalExtensionForInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Extension for Interest Only Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_AdditionalExtensionForInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ForgivenessAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_ForgivenessAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_InterestOnlyPaymentExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Only Payment Extension</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_InterestOnlyPaymentExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NumberOfAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Amendments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_NumberOfAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NumberOfPrepaymentsToLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Prepayments To Lender</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_NumberOfPrepaymentsToLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NumberofMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Monthly Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_NumberofMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_PaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_PaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_PrepaymentRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment Requirement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_PrepaymentRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_StrategicAlliancesAxis=rgls_StrategicAlliancesandCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_StrategicAlliancesAxis=rgls_StrategicAlliancesandCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rgls_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rgls_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rgls_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rgls_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rgls_TenthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rgls_TenthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rgls_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rgls_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959541156968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Future Principal Payments) (Details) - Debt Financing Agreement Tranche A<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">4,681<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 4,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rgls_DebtFinancingAgreementTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540264280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 04, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 22, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 24, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 07, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 03, 2019 </div>
<div>closing</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,047,832<span></span>
</td>
<td class="nump">67,432,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_CommonStockVotingRightsVotes', window );">Common stock voting rights votes | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease', window );">Number of years for increase of authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NumberOfClosings', window );">Number of closings | closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share sold (in shares)</a></td>
<td class="nump">24,341,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,730,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants callable (in shares)</a></td>
<td class="nump">18,256,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,730,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.7464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received | $</a></td>
<td class="nump">$ 19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rgls_MilestoneClosingMember', window );">Milestone Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants callable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,158,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NonvotingConvertiblePreferredStockIssued', window );">Nonvoting convertible preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember', window );">Class A-2 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember', window );">Class A-2 Convertible Preferred Stock | Milestone Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,288,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants callable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,883,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassAThreeConvertiblePreferredStockMember', window );">Class A-3 Convertible Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants callable (in shares)</a></td>
<td class="nump">2,047,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NonvotingConvertiblePreferredStockIssued', window );">Nonvoting convertible preferred stock issued (in shares)</a></td>
<td class="nump">272,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.7464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Preferred Class A | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Class A-3 Convertible Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rgls_CertainDirectorsandExecutiveOfficersMember', window );">Certain Directors and Executive Officers | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share sold (in shares)</a></td>
<td class="nump">833,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rgls_CertainDirectorsandExecutiveOfficersMember', window );">Certain Directors and Executive Officers | Preferred Class A | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants callable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of right to purchase common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rgls_CertainDirectorsandExecutiveOfficersMember', window );">Certain Directors and Executive Officers | Class A-2 Convertible Preferred Stock | Milestone Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants callable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,215,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rgls_CertainDirectorsandExecutiveOfficersMember', window );">Certain Directors and Executive Officers | Class A-3 Convertible Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants callable (in shares)</a></td>
<td class="nump">624,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of right to purchase common shares | $</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rgls_A2019PlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,166,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease', window );">Number of additional shares authorized yearly increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,172,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_CommonStockVotingRightsVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Voting Rights Votes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_CommonStockVotingRightsVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NonvotingConvertiblePreferredStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonvoting Convertible Preferred Stock Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_NonvotingConvertiblePreferredStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NumberOfClosings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Closings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_NumberOfClosings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Period for Yearly Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Yearly Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rgls_MilestoneClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rgls_MilestoneClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassAThreeConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassAThreeConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rgls_CertainDirectorsandExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rgls_CertainDirectorsandExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rgls_A2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rgls_A2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540150536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Share Activity) (Details) - shares<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ActivityOfSharesRollForward', window );"><strong>Activity of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,432,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">87,047,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassAOneConvertiblePreferredStockMember', window );">Class A-1 Convertible Preferred Stock | 2019 SPA and 2020 SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ActivityOfSharesRollForward', window );"><strong>Activity of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">416,000<span></span>
</td>
<td class="nump">416,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions/Exercises (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(159,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">416,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassATwoConvertiblePreferredStockMember', window );">Class A-2 Convertible Preferred Stock | 2019 SPA and 2020 SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ActivityOfSharesRollForward', window );"><strong>Activity of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,331,000<span></span>
</td>
<td class="nump">1,338,000<span></span>
</td>
<td class="nump">1,416,000<span></span>
</td>
<td class="nump">1,961,000<span></span>
</td>
<td class="nump">2,632,000<span></span>
</td>
<td class="nump">3,288,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions/Exercises (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="num">(78,000)<span></span>
</td>
<td class="num">(322,000)<span></span>
</td>
<td class="num">(671,000)<span></span>
</td>
<td class="num">(656,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,331,000<span></span>
</td>
<td class="nump">1,331,000<span></span>
</td>
<td class="nump">1,338,000<span></span>
</td>
<td class="nump">1,639,000<span></span>
</td>
<td class="nump">1,961,000<span></span>
</td>
<td class="nump">2,632,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rgls_ClassAThreeConvertiblePreferredStockMember', window );">Class A-3 Convertible Preferred Stock | 2019 SPA and 2020 SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ActivityOfSharesRollForward', window );"><strong>Activity of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">259,000<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions/Exercises (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">259,000<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrants | 2019 SPA and 2020 SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ActivityOfSharesRollForward', window );"><strong>Activity of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">61,868,000<span></span>
</td>
<td class="nump">62,118,000<span></span>
</td>
<td class="nump">66,038,000<span></span>
</td>
<td class="nump">46,774,000<span></span>
</td>
<td class="nump">46,774,000<span></span>
</td>
<td class="nump">46,774,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions/Exercises (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="num">(3,920,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">61,868,000<span></span>
</td>
<td class="nump">61,868,000<span></span>
</td>
<td class="nump">62,118,000<span></span>
</td>
<td class="nump">46,774,000<span></span>
</td>
<td class="nump">46,774,000<span></span>
</td>
<td class="nump">46,774,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | 2019 SPA and 2020 SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ActivityOfSharesRollForward', window );"><strong>Activity of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions/Exercises (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">326,000<span></span>
</td>
<td class="nump">3,199,000<span></span>
</td>
<td class="nump">3,217,000<span></span>
</td>
<td class="nump">8,296,000<span></span>
</td>
<td class="nump">6,567,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ActivityOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Activity of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_ActivityOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassAOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassAOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rgls_A2019SPAAnd2020SPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rgls_A2019SPAAnd2020SPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassATwoConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassATwoConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rgls_ClassAThreeConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rgls_ClassAThreeConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959541397048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (ATM Offering) (Details) - At The Moment - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 10, 2021</div></th>
<th class="th"><div>Dec. 12, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_CommissionFeeRate', window );">Commission fee rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share sold (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,017,131<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Payments for commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_SaleOfStockValueOfSharesAvailable', window );">Amount eligible to be drawn down under the ATM</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_CommissionFeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission Fee Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_CommissionFeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_SaleOfStockValueOfSharesAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Value of Shares Available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_SaleOfStockValueOfSharesAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rgls_AtTheMomentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rgls_AtTheMomentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540361912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Common Stock Reserved for Future Issuance) (Details)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock options outstanding (in shares)</a></td>
<td class="nump">9,727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">91,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rgls_TwentyTwelvePlanMember', window );">Common stock available for future grant under 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for future grant (in shares)</a></td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for future grant (in shares)</a></td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">RSUs outstanding (in shares)</a></td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rgls_ClassA1ConvertiblePreferredStockAsConvertedMember', window );">Class A-1 convertible preferred stock outstanding (as-converted)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">2,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember', window );">Class A-2 convertible preferred stock outstanding (as-converted)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">13,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rgls_ClassA3ConvertiblePreferredStockMember', window );">Class A-3 convertible preferred stock outstanding (as-converted)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rgls_InitialClosingWarrantsMember', window );">2019 PIPE Initial Closing warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">12,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rgls_MilestoneClosingWarrantsMember', window );">2019 PIPE Milestone Closing warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">30,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rgls_A2020PIPEWarrantsMember', window );">2020 PIPE warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">18,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rgls_TwentyTwelvePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rgls_TwentyTwelvePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rgls_ClassA1ConvertiblePreferredStockAsConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rgls_ClassA1ConvertiblePreferredStockAsConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rgls_ClassA2ConvertiblePreferredStockAsConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rgls_ClassA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rgls_ClassA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rgls_InitialClosingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rgls_InitialClosingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rgls_MilestoneClosingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rgls_MilestoneClosingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rgls_A2020PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rgls_A2020PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540375400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Stock Option and RSU Activity) (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending outstanding number (in shares)</a></td>
<td class="nump">9,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning outstanding number (in shares)</a></td>
<td class="nump">6,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (options) or Vested (RSUs) (in shares)</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled/forfeited/expired (in shares)</a></td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending outstanding number (in shares)</a></td>
<td class="nump">9,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">1.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (options) or Vested (RSUs) (in usd per share) | $ / shares</a></td>
<td class="nump">0.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled/forfeited/expired (in usd per share) | $ / shares</a></td>
<td class="nump">1.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Exercised (options) or Vested (RSUs) (in shares)</a></td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled/forfeited/expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (options) or Vested (RSUs)(in usd per share) | $ / shares</a></td>
<td class="nump">1.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled/forfeited/expired (in usd per share) | $ / shares</a></td>
<td class="nump">1.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540374232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">95.30%<span></span>
</td>
<td class="nump">95.80%<span></span>
</td>
<td class="nump">95.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">95.70%<span></span>
</td>
<td class="nump">95.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">0 months<span></span>
</td>
<td class="text">0 months<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">103.10%<span></span>
</td>
<td class="nump">94.90%<span></span>
</td>
<td class="nump">104.40%<span></span>
</td>
<td class="nump">98.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959629729976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 807<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
<td class="nump">$ 2,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
<td class="nump">$ 1,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959539681336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations (Details)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2012 </div>
<div>target</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues (less than in 2020)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_StrategicAlliancesandCollaborationsMember', window );">Revenue under collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues (less than in 2020)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_CollaborativeAreasGranted', window );">Number of collaborative areas granted | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Initial upfront option payment</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable', window );">Potential revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_AgreementPeriod', window );">Agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Upfront payment non-creditable portion recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_EnrollmentMilestone', window );">Enrollment Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract with customer, asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DevelopmentMilestoneNotAchievable', window );">Development milestone not achievable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Minimum | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RoyaltyPercentageBasedOnNetSales', window );">Royalties based on percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Minimum | Outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RoyaltyPercentageBasedOnNetSales', window );">Royalties based on percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Maximum | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RoyaltyPercentageBasedOnNetSales', window );">Royalties based on percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Maximum | Outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RoyaltyPercentageBasedOnNetSales', window );">Royalties based on percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Development Commercialization And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DeferredRevenueCreditableAgainstFutureMilestones', window );">Deferred revenue creditable against future milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Initial upfront option payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Proof-of-Concept Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable', window );">Potential revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable', window );">Potential revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Regulatory and Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable', window );">Potential revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable', window );">Potential revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Enrollment Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable', window );">Potential revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Materials Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable', window );">Potential revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember', window );">Sanofi | Achievement of Enrollment Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable', window );">Potential revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_AgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_AgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_CollaborativeAreasGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Areas Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_CollaborativeAreasGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DeferredRevenueCreditableAgainstFutureMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Creditable Against Future Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_DeferredRevenueCreditableAgainstFutureMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DevelopmentMilestoneNotAchievable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Not Achievable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_DevelopmentMilestoneNotAchievable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_EnrollmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enrollment Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_EnrollmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Milestone Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_RoyaltyPercentageBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage Based On Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_RoyaltyPercentageBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_StrategicAlliancesAxis=rgls_StrategicAlliancesandCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_StrategicAlliancesAxis=rgls_StrategicAlliancesandCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_StrategicAlliancesAxis=rgls_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_StrategicAlliancesAxis=rgls_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rgls_DevelopmentCommercializationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rgls_DevelopmentCommercializationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rgls_ProofofConceptTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rgls_ProofofConceptTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rgls_ClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rgls_ClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rgls_RegulatoryAndCommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rgls_RegulatoryAndCommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rgls_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rgls_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rgls_EnrollmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rgls_EnrollmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rgls_MaterialsSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rgls_MaterialsSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rgls_AchievementOfEnrollmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rgls_AchievementOfEnrollmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959540346584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Feb. 11, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>contract</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 19, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining liability to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Base rent payments due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating lease payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rgls_PriorPremisesMember', window );">Prior Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining liability to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Base rent payments due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_InitialDirectCostLiability', window );">Initial direct cost liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DeferredCreditOperatingLeaseLiability', window );">Deferred credit, operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rgls_CampusPointLeaseMember', window );">Campus Point Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_InitialDirectCostLiability', window );">Initial direct cost liability</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DeferredCreditOperatingLeaseLiability', window );">Deferred credit, operating lease liabilities</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RentedArea', window );">Rented area | ft&#178;</a></td>
<td class="nump">13,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating lease payments due</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NonrefundableLeaseCostForAssignment', window );">Nonrefundable lease cost for assignment</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NumberOfOperatingLeaseContracts', window );">Number of operating lease contracts | contract</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsLeasingAccumulatedAmortization', window );">Deferred cost of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DeferredCreditOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Credit, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_DeferredCreditOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_InitialDirectCostLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Direct Cost Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_InitialDirectCostLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NonrefundableLeaseCostForAssignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Lease Cost for Assignment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_NonrefundableLeaseCostForAssignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NumberOfOperatingLeaseContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Operating Lease Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_NumberOfOperatingLeaseContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_RentedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rented Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_RentedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsLeasingAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the accumulated amortization, as of the reporting date, which represents the periodic charge to earnings of initial direct costs which have been deferred and are being allocated over the lease term in proportion to the recognition of rental income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919138-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123394419&amp;loc=d3e40588-112709<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123394697&amp;loc=d3e40879-112712<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsLeasingAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rgls_PriorPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rgls_PriorPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rgls_CampusPointLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rgls_CampusPointLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959541751576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Operating and Finance Maturities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining 2021</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree', window );">Thereafter</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of obligations under leases</a></td>
<td class="nump">3,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(575)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">$ 2,570<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, After Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rgls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#<(K5\2AORU_)SX/<@7>JJ6%(WDR24"!?"V#'V<D98IL69QS\JM]#OI,4FA
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M/>CM>YW".E0X==O9'I-@F,@<5@C.1[8JJ(<"\E-AISSEA5%(S:;?*=).^"C
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MV_1G#<F2=-_\Q*3:A:>G <$^X1J@QA>,R=>&WHH7GU[&_P!02P,$%     @
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MTQZ98&&^W"#U=:D<N%?)?:M2M83LJYB<8U4CXF@.FB ;6Z[FH DBEN5K5 &
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M*:W].%@MU<O[I"BK=5,?*F\K\W1</CIZL%JD9;'KBY#K,<#U$.?PA/&MS?P
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M3I-8/?"5@/K\-LO*QS?5#ZEL?\OG]/]02P,$%     @ ^8YJ4ULL2@DN!P
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MK2=+$1C'B"V,2JJ!!X0IKL=\,]8U02 QOC.%@W<@+C[0P@ED#X@@#! ;6L[
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MMM$P57 C?2*%TDX;<+I19);V)@;4@9GGQ6\"SIS0]F8D8^]-$)<(_!P2>,-
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M?.B$0O@VRQQ9KH[OKS@<]0Y'P>'H_]+YS^ KR2]O92Z4VA[ !J$4:P09#+
MTUC IQR=@URX$FHKN:6DVK()UR0'+34'U00N,$M82BUT+H4*%Y(:WQ*<C]S8
MVEC1[>[C10PKLT:K/?+0U7QL+#OD_F0X.A"Z "JQ-?W"8\ U=AO# P);H/5Z
MH32JE2B? P(R7+;D'V(;2 H#VA!P?ZH_;#/DU\$^;(NYU]3%+2IC2?[D76X<
M^9:4+H99")/KA[#*T+Y],SA)/^XJ*3B\Q'S_:A"NV,!SAB1F0G&.V*W@K)J*
M<^K8"0N2%CDJI@]FGBLL\$<CUUQ!7O&[RFC<<H3VD0?ILM&%>Q__K9Z2O5:M
MT*["0/+^&DUMU_:G_<R;M:W^;-X.S!MA5_R:H'#)T#0^/8[ MD.HW9"I0^-G
MAGB,A&7)<QNM-^#[I3&TVW@'_3_!]!=02P,$%     @ ^8YJ4X,# Q._!0
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ML4!BAA+HH:0A2*G(29>76]8IR.=.90!H!66>V\8$95;"!VD*Z0HOT$J&"-6
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M\20FQP)87UITMO:##?2/[,M_ %!+ P04    " #YCFI3AVZS?(0+  !P'@
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M]!2CQ.28- <W*96)-601!7Y(*I^E(O7\@] VCE99-U3K&W<5O0+L@',L-8V
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M[/M'DS!'I2_>M/P:'A#UIN:/6R5A-CV ^VMC?/I"&^3?9;S\'U!+ P04
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M/2Z [_%5^/@+;I#^?LSK_P%02P,$%     @ ^8YJ4S@_,X7( @  TP8  !D
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M6-!?![4SH/-<*;O9N #=?VSV%U!+ P04    " #YCFI3"KHW550"  #N!
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MI), =#LWVH55M?=JIBPYWX<EC5K4[@*=%TK9P\(EZ(?WZB]02P,$%     @
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M[^I&*Q!M2VLGBM?VDF^XTBW##@O]%T!A O1^QKG:3TR"_K\2_0-02P,$%
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MC[R^1^:PX'EB'N3F U0)=:V_2":Z^"6;RC;P2)1K(],*C!&D(BO_^8^J$"T
M[;P 8!6 '0H(*T!8)%I&5J1UPPT?#Y7<$&6MT9L=%+4IT)B-R"R-4Z/PJD"<
M&=]RH<@7GN1 /@'7N0+DR&ARUKKP08#B*HJ?"-XVY)W6@ 8\FY,[P6<B$4:
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M+692(K6 K6G!0Q^.(SPI/^GE</MS3(4AAE$].Z.N<P5]<J\6L!N=)4+H.-]
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M\/IIR_J#+#?5LWOWI93ENGJ[8E3E"]U _;XL2_GR03\.N'OF]>H_4$L#!!0
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M/HB"7P ,8/@C\ W-^M>!'S5)BS1^U('_5Y6O,?OIAW 4_$8W@.H\N8 '#?!
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MF2A>2"LN)%_EK^L\<BEYE']<,CIG(AL WR\X9$]=9 \H7PL\_@]02P,$%
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M5>_!G?=1N'Y/A>W_ $>_ 5!+ P04    " #ZCFI3EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( /J.:E,XY+7:80,
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MH01!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M
M(:M (:M (:M (:M (6N*0M84A:PI"EE3%+*F_TG6#ZV7?_T/L%V36JKFX,^Z
M'ZVS+U!+ 0(4 Q0    ( /F.:E,'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ^8YJ4[&F8"#O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ ^8YJ4YE<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #YCFI3*8*E,48%  !Q%0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ ^8YJ4__'2)]6!@  N!H  !@              ("!B@T  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( /F.:E,V[F5]D@,  (81
M   8              " @184  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #YCFI3,^I-,U$%   Q%@  &               @('>%P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ^8YJ4W(6R@CJ
M"@  UT<  !@              ("!91T  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( /F.:E-;+$H)+@<  #X>   8              "
M@84H  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #YCFI3
M+<X^63P7  ";0P  &               @('I+P  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ ^8YJ4_&UH_M[ P  X @  !@
M     ("!6T<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M /F.:E/S5/_-X0(  !4&   8              " @0Q+  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #YCFI3@P,#$[\%  !P#P  &0
M            @($C3@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( /F.:E.';K-\A L  ' >   9              " @1E4  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ^8YJ4Y][&F$*$@
M3$   !D              ("!U%\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #YCFI3'#,#&5L+  "C(0  &0              @($5
M<@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( /F.:E-D
M+DG1P0H  )P>   9              " @:=]  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ ^8YJ4P1++P($%P  2T8  !D
M     ("!GX@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /F.:E,-)];)G (  &,&   9              "
M@;ZO  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ ^8YJ
M4Z5 -T:% @  V@8  !D              ("!D;(  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #YCFI3%MDCGX$#   .$0  &0
M        @(%-M0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( /J.:E,3:$(4_P4   <=   9              " @06Y  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ^HYJ4_$ZL=XB @  S 0
M !D              ("!.[\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #ZCFI3Z2.5I<X'  #_*@  &0              @(&4P0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( /J.:E-TERY#
M704   DA   9              " @9G)  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ ^HYJ4T5_4H4V P  Z@D  !D
M ("!+<\  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #Z
MCFI3#N9PJ \$   X$P  &0              @(&:T@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( /J.:E.GG_^E+@0  '02   9
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M970S,RYX;6Q02P$"% ,4    " #ZCFI3Y(0W3 P#  #C"   &0
M    @('5[@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M /J.:E-A*" ?,0,  ! 4   -              "  1CR  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ ^HYJ4Y>*NQS     $P(   L              ( !
M=/4  %]R96QS+RYR96QS4$L! A0#%     @ ^HYJ4SCDM=IA P  XQ8   \
M             ( !7?8  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /J.
M:E.,WU^M;@$  -T4   :              "  >OY  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( /J.:E,&5T)WCP$  ' 5   3
M          "  9'[  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     J "H
*70L  %']      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>279</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110105 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/Collaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/FairValueMeasurements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/Debt</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/StockholdersEquity</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2326304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/Leases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/NetLossPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/DebtTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Debt (Future Principal Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails</Role>
      <ShortName>Debt (Future Principal Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/DebtTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/StockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Stockholders' Equity (Share Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails</Role>
      <ShortName>Stockholders' Equity (Share Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/StockholdersEquityTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Stockholders' Equity (ATM Offering) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails</Role>
      <ShortName>Stockholders' Equity (ATM Offering) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/StockholdersEquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Stockholders' Equity (Common Stock Reserved for Future Issuance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity (Common Stock Reserved for Future Issuance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/StockholdersEquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Stockholders' Equity (Stock Option and RSU Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails</Role>
      <ShortName>Stockholders' Equity (Stock Option and RSU Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/StockholdersEquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/StockholdersEquityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails</Role>
      <ShortName>Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/StockholdersEquityTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/CollaborationsDetails</Role>
      <ShortName>Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/Collaborations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rgls-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Leases (Operating and Finance Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails</Role>
      <ShortName>Leases (Operating and Finance Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regulusrx.com/role/LeasesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="rgls-20210930.htm">rgls-20210930.htm</File>
    <File>ex-311x20210930.htm</File>
    <File>ex-312x20210930.htm</File>
    <File>ex-321x20210930.htm</File>
    <File>rgls-20210930.xsd</File>
    <File>rgls-20210930_cal.xml</File>
    <File>rgls-20210930_def.xml</File>
    <File>rgls-20210930_lab.xml</File>
    <File>rgls-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rgls-20210930.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "contextCount": 279,
   "dts": {
    "calculationLink": {
     "local": [
      "rgls-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rgls-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rgls-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rgls-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rgls-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rgls-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 390,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 4,
    "http://xbrl.sec.gov/dei/2021": 6,
    "total": 10
   },
   "keyCustom": 42,
   "keyStandard": 262,
   "memberCustom": 32,
   "memberStandard": 24,
   "nsprefix": "rgls",
   "nsuri": "http://www.regulusrx.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.regulusrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Fair Value Measurements",
     "role": "http://www.regulusrx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110105 - Disclosure - Debt",
     "role": "http://www.regulusrx.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114106 - Disclosure - Stockholders' Equity",
     "role": "http://www.regulusrx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Collaborations",
     "role": "http://www.regulusrx.com/role/Collaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Leases",
     "role": "http://www.regulusrx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.regulusrx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Debt (Tables)",
     "role": "http://www.regulusrx.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rgls:ActivityOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.regulusrx.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rgls:ActivityOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326304 - Disclosure - Leases (Tables)",
     "role": "http://www.regulusrx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED BALANCE SHEETS",
     "role": "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "rgls:FinancingfromSaleProceedsDebtAgreementRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "rgls:FinancingfromSaleProceedsDebtAgreementRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i868ed48256c846129326496101c3afa4_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Net Loss Per Share (Details)",
     "role": "http://www.regulusrx.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i868ed48256c846129326496101c3afa4_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details)",
     "role": "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i03875b50705141378eeb6a7f3db6d93c_D20171001-20190531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rgls:NumberOfAmendments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "amendment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Debt (Narrative) (Details)",
     "role": "http://www.regulusrx.com/role/DebtNarrativeDetails",
     "shortName": "Debt (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i03875b50705141378eeb6a7f3db6d93c_D20171001-20190531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rgls:NumberOfAmendments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "amendment",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i2de3b934180e4445a01ae3a427e91b3f_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Debt (Future Principal Payments) (Details)",
     "role": "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails",
     "shortName": "Debt (Future Principal Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i2de3b934180e4445a01ae3a427e91b3f_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "role": "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "rgls:CommonStockVotingRightsVotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i5c50d853f72c4c36960bcf1c2165224d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Stockholders' Equity (Share Activity) (Details)",
     "role": "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails",
     "shortName": "Stockholders' Equity (Share Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rgls:ActivityOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib0a0858e919543a98b9c64121d1e1830_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i76e2ff0b853b425197ddbce613a8c517_I20181212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rgls:CommissionFeeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Stockholders' Equity (ATM Offering) (Details)",
     "role": "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails",
     "shortName": "Stockholders' Equity (ATM Offering) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i76e2ff0b853b425197ddbce613a8c517_I20181212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rgls:CommissionFeeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rgls:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Stockholders' Equity (Common Stock Reserved for Future Issuance) (Details)",
     "role": "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
     "shortName": "Stockholders' Equity (Common Stock Reserved for Future Issuance) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rgls:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ifdae785f59024129a26a080f3e9b9224_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rgls:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Stockholders' Equity (Stock Option and RSU Activity) (Details)",
     "role": "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails",
     "shortName": "Stockholders' Equity (Stock Option and RSU Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i951d796d9ed84f84b26dc055c3e072b5_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i70017d07079c4189905253f72a203dfa_D20210701-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Details)",
     "role": "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails",
     "shortName": "Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i70017d07079c4189905253f72a203dfa_D20210701-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i868ed48256c846129326496101c3afa4_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Details)",
     "role": "http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails",
     "shortName": "Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i868ed48256c846129326496101c3afa4_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i868ed48256c846129326496101c3afa4_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Collaborations (Details)",
     "role": "http://www.regulusrx.com/role/CollaborationsDetails",
     "shortName": "Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i00c63c04aad146a4a4b300df5bf7b017_D20120701-20120731",
      "decimals": "INF",
      "lang": "en-US",
      "name": "rgls:CollaborativeAreasGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "target",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.regulusrx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i03c5d4dd537e4ff08c58974c361af177_I20190619",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Leases (Operating and Finance Maturities) (Details)",
     "role": "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails",
     "shortName": "Leases (Operating and Finance Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i1ffdb10c152a4544a6ac91e853bf0328_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i868ed48256c846129326496101c3afa4_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "i868ed48256c846129326496101c3afa4_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "idb8e219bee614949b739b6c590453b4e_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ied8118cc1de544ca88b4fb69510806fb_D20200101-20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "role": "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Net Loss Per Share",
     "role": "http://www.regulusrx.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Investments",
     "role": "http://www.regulusrx.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rgls-20210930.htm",
      "contextRef": "ib3b1bf0e990e4d20917e21e6573cc4a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regulusrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rgls_A2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Plan [Member]",
        "label": "2019 Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "A2019PlanMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_A2019SPAAnd2020SPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 SPA and 2020 SPA",
        "label": "2019 SPA and 2020 SPA [Member]",
        "terseLabel": "2019 SPA and 2020 SPA"
       }
      }
     },
     "localname": "A2019SPAAnd2020SPAMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_A2020PIPEWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 PIPE Warrants",
        "label": "2020 PIPE Warrants [Member]",
        "terseLabel": "2020 PIPE warrants"
       }
      }
     },
     "localname": "A2020PIPEWarrantsMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_AccruedExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expense [Policy Text Block]",
        "label": "Accrued Expense [Policy Text Block]",
        "terseLabel": "Clinical Trial and Preclinical Study Accruals"
       }
      }
     },
     "localname": "AccruedExpensePolicyTextBlock",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rgls_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development, Current",
        "label": "Accrued Research and Development, Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_AchievementOfEnrollmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Enrollment Milestone",
        "label": "Achievement of Enrollment Milestone [Member]",
        "terseLabel": "Achievement of Enrollment Milestone"
       }
      }
     },
     "localname": "AchievementOfEnrollmentMilestoneMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ActivityOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Activity of Shares",
        "label": "Activity of Shares [Roll Forward]",
        "terseLabel": "Activity of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ActivityOfSharesRollForward",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rgls_ActivityOfSharesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Activity of Shares",
        "label": "Activity of Shares [Table Text Block]",
        "terseLabel": "Activity of Shares"
       }
      }
     },
     "localname": "ActivityOfSharesTableTextBlock",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rgls_AdditionalExtensionForInterestOnlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Extension for Interest Only Payments",
        "label": "Additional Extension for Interest Only Payments",
        "terseLabel": "Additional extension for interest only payments"
       }
      }
     },
     "localname": "AdditionalExtensionForInterestOnlyPayments",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rgls_AgreementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Period",
        "label": "Agreement Period",
        "terseLabel": "Agreement period"
       }
      }
     },
     "localname": "AgreementPeriod",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rgls_AtTheMomentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Moment [Member]",
        "label": "At The Moment [Member]",
        "terseLabel": "At The Moment"
       }
      }
     },
     "localname": "AtTheMomentMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_CampusPointLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Campus Point Lease",
        "label": "Campus Point Lease [Member]",
        "terseLabel": "Campus Point Lease"
       }
      }
     },
     "localname": "CampusPointLeaseMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_CertainDirectorsandExecutiveOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Directors and Executive Officers [Member]",
        "label": "Certain Directors and Executive Officers [Member]",
        "terseLabel": "Certain Directors and Executive Officers"
       }
      }
     },
     "localname": "CertainDirectorsandExecutiveOfficersMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ClassA1ConvertiblePreferredStockAsConvertedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A-1 Convertible Preferred Stock (As-Converted) [Member]",
        "label": "Class A-1 Convertible Preferred Stock (As-Converted) [Member]",
        "terseLabel": "Class A-1 Convertible Preferred Stock",
        "verboseLabel": "Class A-1 convertible preferred stock outstanding (as-converted)"
       }
      }
     },
     "localname": "ClassA1ConvertiblePreferredStockAsConvertedMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ClassA2ConvertiblePreferredStockAsConvertedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A-2 Convertible Preferred Stock (As-Converted) [Member]",
        "label": "Class A-2 Convertible Preferred Stock (As-Converted) [Member]",
        "terseLabel": "Class A-2 Convertible Preferred Stock",
        "verboseLabel": "Class A-2 convertible preferred stock outstanding (as-converted)"
       }
      }
     },
     "localname": "ClassA2ConvertiblePreferredStockAsConvertedMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ClassA3ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A-3 Convertible Preferred Stock",
        "label": "Class A-3 Convertible Preferred Stock [Member]",
        "terseLabel": "Class A-3 Convertible Preferred Stock",
        "verboseLabel": "Class A-3 convertible preferred stock outstanding (as-converted)"
       }
      }
     },
     "localname": "ClassA3ConvertiblePreferredStockMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ClassAOneConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A One Convertible Preferred Stock [Member]",
        "label": "Class A One Convertible Preferred Stock [Member]",
        "terseLabel": "Class A-1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "ClassAOneConvertiblePreferredStockMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ClassAThreeConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Three Convertible Preferred Stock",
        "label": "Class A Three Convertible Preferred Stock [Member]",
        "terseLabel": "Class A-3 Convertible Preferred Stock"
       }
      }
     },
     "localname": "ClassAThreeConvertiblePreferredStockMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ClassATwoConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Two Convertible Preferred Stock [Member]",
        "label": "Class A Two Convertible Preferred Stock [Member]",
        "terseLabel": "Class A-2 Convertible Preferred Stock"
       }
      }
     },
     "localname": "ClassATwoConvertiblePreferredStockMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical",
        "label": "Clinical [Member]",
        "terseLabel": "Clinical"
       }
      }
     },
     "localname": "ClinicalMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_CollaborativeAreasGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Areas Granted",
        "label": "Collaborative Areas Granted",
        "terseLabel": "Number of collaborative areas granted"
       }
      }
     },
     "localname": "CollaborativeAreasGranted",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rgls_CommissionFeeRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission Fee Rate",
        "label": "Commission Fee Rate",
        "terseLabel": "Commission fee rate"
       }
      }
     },
     "localname": "CommissionFeeRate",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rgls_CommonStockVotingRightsVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Voting Rights Votes",
        "label": "Common Stock Voting Rights Votes",
        "terseLabel": "Common stock voting rights votes"
       }
      }
     },
     "localname": "CommonStockVotingRightsVotes",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rgls_DebtFinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Financing Agreement",
        "label": "Debt Financing Agreement [Member]",
        "terseLabel": "Debt Financing Agreement"
       }
      }
     },
     "localname": "DebtFinancingAgreementMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_DebtFinancingAgreementTrancheAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Financing Agreement Tranche A [Member]",
        "label": "Debt Financing Agreement Tranche A [Member]",
        "terseLabel": "Debt Financing Agreement Tranche A"
       }
      }
     },
     "localname": "DebtFinancingAgreementTrancheAMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_DeferredCreditOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Credit, Operating Lease Liability",
        "label": "Deferred Credit, Operating Lease Liability",
        "terseLabel": "Deferred credit, operating lease liabilities"
       }
      }
     },
     "localname": "DeferredCreditOperatingLeaseLiability",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_DeferredRevenueCreditableAgainstFutureMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue Creditable Against Future Milestones",
        "label": "Deferred Revenue Creditable Against Future Milestones",
        "terseLabel": "Deferred revenue creditable against future milestones"
       }
      }
     },
     "localname": "DeferredRevenueCreditableAgainstFutureMilestones",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_DevelopmentCommercializationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Commercialization And License Agreement",
        "label": "Development Commercialization And License Agreement [Member]",
        "terseLabel": "Development Commercialization And License Agreement"
       }
      }
     },
     "localname": "DevelopmentCommercializationAndLicenseAgreementMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_DevelopmentMilestoneNotAchievable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestone Not Achievable",
        "label": "Development Milestone Not Achievable",
        "terseLabel": "Development milestone not achievable"
       }
      }
     },
     "localname": "DevelopmentMilestoneNotAchievable",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestones [Member]",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_EnrollmentMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enrollment Milestone",
        "label": "Enrollment Milestone",
        "terseLabel": "Enrollment Milestone"
       }
      }
     },
     "localname": "EnrollmentMilestone",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_EnrollmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enrollment Milestone",
        "label": "Enrollment Milestone [Member]",
        "terseLabel": "Enrollment Milestone"
       }
      }
     },
     "localname": "EnrollmentMilestoneMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_FinancingfromSaleProceedsDebtAgreementRevenues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing from Sale Proceeds, Debt, Agreement Revenues",
        "label": "Financing from Sale Proceeds, Debt, Agreement Revenues",
        "terseLabel": "Financing from sale proceeds, debt, and agreement revenues"
       }
      }
     },
     "localname": "FinancingfromSaleProceedsDebtAgreementRevenues",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_ForgivenessAmountThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness Amount Threshold",
        "label": "Forgiveness Amount Threshold",
        "terseLabel": "Forgiveness threshold amount"
       }
      }
     },
     "localname": "ForgivenessAmountThreshold",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_GainLossOnLoanForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Loan Forgiveness",
        "label": "Gain (Loss) on Loan Forgiveness",
        "negatedTerseLabel": "Gain on PPP Loan forgiveness"
       }
      }
     },
     "localname": "GainLossOnLoanForgiveness",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Accrued Research and Development Expenses",
        "label": "Increase (Decrease) in Accrued Research and Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_InitialClosingWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Closing Warrants [Member]",
        "label": "Initial Closing Warrants [Member]",
        "terseLabel": "2019 PIPE Initial Closing warrants"
       }
      }
     },
     "localname": "InitialClosingWarrantsMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_InitialDirectCostLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Direct Cost Liability",
        "label": "Initial Direct Cost Liability",
        "terseLabel": "Initial direct cost liability"
       }
      }
     },
     "localname": "InitialDirectCostLiability",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_InterestOnlyPaymentExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Only Payment Extension",
        "label": "Interest Only Payment Extension",
        "terseLabel": "Interest-only payment extension"
       }
      }
     },
     "localname": "InterestOnlyPaymentExtension",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rgls_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Three",
        "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Three",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_MaterialsSoldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Materials Sold",
        "label": "Materials Sold [Member]",
        "terseLabel": "Materials Sold"
       }
      }
     },
     "localname": "MaterialsSoldMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_MilestoneClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Closing [Member]",
        "label": "Milestone Closing [Member]",
        "terseLabel": "Milestone Closing"
       }
      }
     },
     "localname": "MilestoneClosingMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_MilestoneClosingWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Closing Warrants [Member]",
        "label": "Milestone Closing Warrants [Member]",
        "terseLabel": "2019 PIPE Milestone Closing warrants"
       }
      }
     },
     "localname": "MilestoneClosingWarrantsMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_NonrefundableLeaseCostForAssignment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Lease Cost for Assignment",
        "label": "Nonrefundable Lease Cost for Assignment",
        "terseLabel": "Nonrefundable lease cost for assignment"
       }
      }
     },
     "localname": "NonrefundableLeaseCostForAssignment",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_NonvotingConvertiblePreferredStockIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonvoting Convertible Preferred Stock Issued",
        "label": "Nonvoting Convertible Preferred Stock Issued",
        "terseLabel": "Nonvoting convertible preferred stock issued (in shares)"
       }
      }
     },
     "localname": "NonvotingConvertiblePreferredStockIssued",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rgls_NumberOfAmendments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Amendments",
        "label": "Number Of Amendments",
        "terseLabel": "Number of times agreement was amended"
       }
      }
     },
     "localname": "NumberOfAmendments",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rgls_NumberOfClosings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Closings",
        "label": "Number of Closings",
        "terseLabel": "Number of closings"
       }
      }
     },
     "localname": "NumberOfClosings",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rgls_NumberOfOperatingLeaseContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Operating Lease Contracts",
        "label": "Number of Operating Lease Contracts",
        "terseLabel": "Number of operating lease contracts"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseContracts",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "rgls_NumberOfPrepaymentsToLender": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Prepayments To Lender",
        "label": "Number Of Prepayments To Lender",
        "terseLabel": "Number of prepayments to lender"
       }
      }
     },
     "localname": "NumberOfPrepaymentsToLender",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rgls_NumberofMonthlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Monthly Payments",
        "label": "Number of Monthly Payments",
        "terseLabel": "Number of monthly payments"
       }
      }
     },
     "localname": "NumberofMonthlyPayments",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rgls_OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Right of Use and Lease Liabilities, Net, Gain (Loss)",
        "label": "Operating Lease Right of Use and Lease Liabilities, Net, Gain (Loss)",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_PPPLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PPP Loan",
        "label": "PPP Loan [Member]",
        "terseLabel": "PPP Loan"
       }
      }
     },
     "localname": "PPPLoanMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_PaycheckProtectionProgramLoanForgiveness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program Loan Forgiveness",
        "label": "Paycheck Protection Program Loan Forgiveness",
        "terseLabel": "Paycheck Protection Program loan forgiveness"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanForgiveness",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_PaymentFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Fee",
        "label": "Payment Fee",
        "terseLabel": "Payment fee"
       }
      }
     },
     "localname": "PaymentFee",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rgls_PaymentsonFinanceLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments on Finance Leases",
        "label": "Payments on Finance Leases",
        "negatedLabel": "Payments on financing leases"
       }
      }
     },
     "localname": "PaymentsonFinanceLeases",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_PrepaidExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses [Policy Text Block]",
        "label": "Prepaid Expenses [Policy Text Block]",
        "terseLabel": "Prepaid Materials"
       }
      }
     },
     "localname": "PrepaidExpensesPolicyTextBlock",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rgls_PrepaymentRequirement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Requirement",
        "label": "Prepayment Requirement",
        "terseLabel": "Prepayment requirement"
       }
      }
     },
     "localname": "PrepaymentRequirement",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_PriorPremisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior Premises",
        "label": "Prior Premises [Member]",
        "terseLabel": "Prior Premises"
       }
      }
     },
     "localname": "PriorPremisesMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ProceedsFromFederalProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Federal Program",
        "label": "Proceeds From Federal Program",
        "terseLabel": "Proceeds from borrowing under Paycheck Protection Program"
       }
      }
     },
     "localname": "ProceedsFromFederalProgram",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_ProofofConceptTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proof-of-Concept Trial",
        "label": "Proofof Concept Trial [Member]",
        "terseLabel": "Proof-of-Concept Trial"
       }
      }
     },
     "localname": "ProofofConceptTrialMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_RegulatoryAndCommercializationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory and Commercialization Milestones [Member]",
        "label": "Regulatory and Commercialization Milestones [Member]",
        "terseLabel": "Regulatory and Commercialization Milestones"
       }
      }
     },
     "localname": "RegulatoryAndCommercializationMilestonesMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_RentedArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rented Area",
        "label": "Rented Area",
        "terseLabel": "Rented area"
       }
      }
     },
     "localname": "RentedArea",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "rgls_RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Milestone Receivable",
        "label": "Revenue Recognition, Milestone Method, Potential Milestone Receivable",
        "terseLabel": "Potential revenue through milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialMilestoneReceivable",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_RoyaltyPercentageBasedOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage Based On Net Sales",
        "label": "Royalty Percentage Based On Net Sales",
        "terseLabel": "Royalties based on percentage of net sales"
       }
      }
     },
     "localname": "RoyaltyPercentageBasedOnNetSales",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rgls_SaleOfStockValueOfSharesAvailable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Value of Shares Available",
        "label": "Sale of Stock, Value of Shares Available",
        "terseLabel": "Amount eligible to be drawn down under the ATM"
       }
      }
     },
     "localname": "SaleOfStockValueOfSharesAvailable",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Shares Reserved For Future Issuance",
        "label": "Schedule Of Shares Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]",
        "label": "Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]",
        "terseLabel": "Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Table]",
        "label": "Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Table]",
        "terseLabel": "Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Table]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Period for Yearly Increase",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Period for Yearly Increase",
        "terseLabel": "Number of years for increase of authorized shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rgls_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Yearly Increase",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Yearly Increase",
        "terseLabel": "Number of additional shares authorized yearly increase"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedYearlyIncrease",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rgls_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Exercise of Warrants",
        "label": "Stock Issued During Period, Shares, Exercise of Warrants",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "rgls_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Exercise of Warrants",
        "label": "Stock Issued During Period, Value, Exercise of Warrants",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rgls_StrategicAlliancesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Alliances [Axis]",
        "label": "Strategic Alliances [Axis]",
        "terseLabel": "Strategic Alliances [Axis]"
       }
      }
     },
     "localname": "StrategicAlliancesAxis",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rgls_StrategicAlliancesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Alliances [Domain]",
        "label": "Strategic Alliances [Domain]",
        "terseLabel": "Strategic Alliances [Domain]"
       }
      }
     },
     "localname": "StrategicAlliancesDomain",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_StrategicAlliancesandCollaborationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Alliances and Collaborations [Member]",
        "label": "Strategic Alliances and Collaborations [Member]",
        "terseLabel": "Revenue under collaborations"
       }
      }
     },
     "localname": "StrategicAlliancesandCollaborationsMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_TenthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenth Amendment",
        "label": "Tenth Amendment [Member]",
        "terseLabel": "Tenth Amendment"
       }
      }
     },
     "localname": "TenthAmendmentMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rgls_TwentyTwelvePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twelve Plan [Member]",
        "label": "Twenty Twelve Plan [Member]",
        "terseLabel": "Common stock available for future grant under 2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwentyTwelvePlanMember",
     "nsuri": "http://www.regulusrx.com/20210930",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r43",
      "r77",
      "r78",
      "r168",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r167",
      "r195",
      "r247",
      "r248",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r385",
      "r387",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r167",
      "r195",
      "r247",
      "r248",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r385",
      "r387",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r167",
      "r195",
      "r238",
      "r247",
      "r248",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r385",
      "r387",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r167",
      "r195",
      "r238",
      "r247",
      "r248",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r385",
      "r387",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r42",
      "r43",
      "r77",
      "r78",
      "r168",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r233",
      "r236",
      "r386",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r233",
      "r236",
      "r386",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r139",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Contract and other receivables"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26",
      "r343"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r279",
      "r280",
      "r281",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r249",
      "r251",
      "r285",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r251",
      "r276",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities not included in calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r75",
      "r124",
      "r127",
      "r133",
      "r142",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r299",
      "r301",
      "r317",
      "r341",
      "r343",
      "r360",
      "r374"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r40",
      "r75",
      "r142",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r299",
      "r301",
      "r317",
      "r341",
      "r343"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r252",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r24",
      "r68"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r60",
      "r68",
      "r70"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r60",
      "r318"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents (money market funds)"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r72",
      "r75",
      "r95",
      "r96",
      "r97",
      "r99",
      "r101",
      "r109",
      "r110",
      "r111",
      "r142",
      "r153",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r193",
      "r194",
      "r198",
      "r202",
      "r317",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r220",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants callable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding (in shares)",
        "periodStartLabel": "Warrants outstanding (in shares)",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r295",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/Collaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r151",
      "r364",
      "r380"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total common shares reserved for future issuance (in shares)",
        "totalLabel": "Total common shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Common stock, shares outstanding (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r343"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 400,000,000 shares and 200,000,000 authorized at September 30, 2021 and December 31, 2020, respectively; 87,047,832 and 67,432,712 shares issued and outstanding at September 30, 2021 (unaudited) and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r222",
      "r223",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract with customer, asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Upfront payment non-creditable portion recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r193",
      "r194",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r16",
      "r17",
      "r205",
      "r211",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of term loan, less debt issuance costs"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r74",
      "r79",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r185",
      "r186",
      "r187",
      "r188",
      "r329",
      "r361",
      "r362",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate, percentage"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r182",
      "r362",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r164",
      "r185",
      "r186",
      "r327",
      "r329",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "PPP loan"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Debt fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r31",
      "r184",
      "r327",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument effective rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r31",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate, percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33",
      "r74",
      "r79",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r185",
      "r186",
      "r187",
      "r188",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r33",
      "r74",
      "r79",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r185",
      "r186",
      "r187",
      "r188",
      "r211",
      "r215",
      "r216",
      "r217",
      "r326",
      "r327",
      "r329",
      "r330",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsLeasingAccumulatedAmortization": {
     "auth_ref": [
      "r331",
      "r332",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, the accumulated amortization, as of the reporting date, which represents the periodic charge to earnings of initial direct costs which have been deferred and are being allocated over the lease term in proportion to the recognition of rental income.",
        "label": "Deferred Costs, Leasing, Accumulated Amortization",
        "terseLabel": "Deferred cost of liability"
       }
      }
     },
     "localname": "DeferredCostsLeasingAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r25",
      "r171",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r122"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r52",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r93",
      "r95",
      "r99",
      "r100",
      "r101",
      "r105",
      "r106",
      "r307",
      "r308",
      "r367",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r52",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r95",
      "r99",
      "r100",
      "r101",
      "r105",
      "r106",
      "r307",
      "r308",
      "r367",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "Employee stock purchase plan shares"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails",
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r48",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r108",
      "r143",
      "r210",
      "r218",
      "r279",
      "r280",
      "r281",
      "r291",
      "r292",
      "r306",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r388",
      "r389",
      "r390",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r309",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r309",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r173",
      "r185",
      "r186",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r310",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r173",
      "r239",
      "r240",
      "r245",
      "r246",
      "r310",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r173",
      "r185",
      "r186",
      "r239",
      "r240",
      "r245",
      "r246",
      "r310",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r173",
      "r185",
      "r186",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r310",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r173",
      "r185",
      "r186",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r50",
      "r124",
      "r126",
      "r129",
      "r132",
      "r134",
      "r357",
      "r365",
      "r369",
      "r383"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r76",
      "r91",
      "r92",
      "r123",
      "r290",
      "r293",
      "r294",
      "r384"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Contracts and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r65",
      "r354"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid materials"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r49",
      "r121",
      "r325",
      "r328",
      "r368"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest and other expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r59",
      "r62",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r358",
      "r370",
      "r393",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Operating lease payments due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails",
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022",
        "verboseLabel": "Base rent payments due 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails",
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remaining 2021",
        "verboseLabel": "Remaining liability to be paid"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails",
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r75",
      "r128",
      "r142",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r300",
      "r301",
      "r302",
      "r317",
      "r341",
      "r342"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r75",
      "r142",
      "r317",
      "r343",
      "r363",
      "r378"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r75",
      "r142",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r300",
      "r301",
      "r302",
      "r317",
      "r341",
      "r342",
      "r343"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r172",
      "r183",
      "r185",
      "r186",
      "r362",
      "r375"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term Debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r79",
      "r152",
      "r176"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r44",
      "r45",
      "r48",
      "r51",
      "r67",
      "r75",
      "r83",
      "r85",
      "r86",
      "r87",
      "r88",
      "r91",
      "r92",
      "r98",
      "r124",
      "r126",
      "r129",
      "r132",
      "r134",
      "r142",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r308",
      "r317",
      "r366",
      "r381"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Net rentable area"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside of the United States"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r124",
      "r126",
      "r129",
      "r132",
      "r134"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of obligations under leases"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease obligations",
        "verboseLabel": "Lease liability, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/LeasesOperatingandFinanceMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset",
        "verboseLabel": "ROU asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r39",
      "r343"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r29",
      "r343"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Payments for commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisition of intangibles"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r252",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Preferred Class A [Member]",
        "terseLabel": "Preferred Class A"
       }
      }
     },
     "localname": "PreferredClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r343"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r144",
      "r145"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid materials, net"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Initial upfront option payment"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-term Debt",
        "verboseLabel": "Proceeds from borrowing under term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.",
        "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants",
        "terseLabel": "Proceeds from issuance of right to purchase common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r278"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r148",
      "r343",
      "r371",
      "r379"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-term Debt",
        "negatedTerseLabel": "Principal payments on term loan"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r287",
      "r355",
      "r407"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r70",
      "r359",
      "r376"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "RSUs outstanding"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r218",
      "r282",
      "r343",
      "r377",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r143",
      "r279",
      "r280",
      "r281",
      "r291",
      "r292",
      "r306",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r119",
      "r120",
      "r125",
      "r130",
      "r131",
      "r135",
      "r136",
      "r138",
      "r232",
      "r233",
      "r356"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues (less than in 2020)",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.regulusrx.com/role/CollaborationsDetails",
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Share sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock price (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r251",
      "r275",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r251",
      "r275",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Debt Maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r252",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r255",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r35",
      "r72",
      "r109",
      "r110",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r202",
      "r208",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled/forfeited/expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled/forfeited/expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in usd per share)",
        "periodStartLabel": "Beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Exercised (options) or Vested (RSUs) (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (options) or Vested (RSUs)(in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r256",
      "r258"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Canceled/forfeited/expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled/forfeited/expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r257",
      "r277"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending outstanding number (in shares)",
        "periodStartLabel": "Beginning outstanding number (in shares)",
        "terseLabel": "Common stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in usd per share)",
        "periodStartLabel": "Beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r250",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (options) or Vested (RSUs) (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r252",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r270",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityAssumptionsUsedtoEstimateFairValueofStockOptionsandPerformanceStockandEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r72",
      "r75",
      "r95",
      "r96",
      "r97",
      "r99",
      "r101",
      "r109",
      "r110",
      "r111",
      "r142",
      "r153",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r193",
      "r194",
      "r198",
      "r202",
      "r210",
      "r317",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r46",
      "r47",
      "r48",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r108",
      "r143",
      "r210",
      "r218",
      "r279",
      "r280",
      "r281",
      "r291",
      "r292",
      "r306",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r388",
      "r389",
      "r390",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r108",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r175",
      "r210",
      "r211",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversions of convertible preferred stock (in shares)",
        "verboseLabel": "Conversions/Exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r210",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r210",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock through ATM (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r210",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r210",
      "r218",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (options) or Vested (RSUs) (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.regulusrx.com/role/StockholdersEquityStockOptionandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r210",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversions of convertible preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r210",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r210",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock through ATM"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r210",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r21",
      "r22",
      "r75",
      "r140",
      "r142",
      "r317",
      "r343"
     ],
     "calculation": {
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r209",
      "r218",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityATMOfferingDetails",
      "http://www.regulusrx.com/role/StockholdersEquityCommonStockReservedforFutureIssuanceDetails",
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regulusrx.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares used to compute diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r93",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares used to compute basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regulusrx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123394419&loc=d3e40588-112709"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123394697&loc=d3e40879-112712"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919138-209958"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r409": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r410": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r411": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r412": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r413": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r414": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r415": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001628280-21-022902-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-022902-xbrl.zip
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M7BAMB<K).Z4S$G9:_R0J(1,^*V5IR#3EFA:\M"(V9)S' 7CD^"E[I!N0-]2
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M:^2]9=5,&0O/\2P.:YD8%JJ.@7Z9E)K;TH3IZJ*$,\=CSH"*8Y9P,KGFLCK
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M7BAMB<K)A=(9"3NM?Q.5D F?E;(T9)IR30M>6A$;,L[C #QR_)(]T@W(!VK
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M%37P+PSF?.-G0BOB=(UM9S6%1L">I=V<\L0OBZJK_YV3^\75V6]02P,$%
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M,$1,.&IY9)#0_-.$VI#*8)-!_T!'JG#YP?P9C,1MU2PG,TF1LXBZ2GD&*+)
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MF9%<H+G/#!UJ.QAKN^6?4CBW@/"A4_')!*?B*YYLGKR+CD%*XYQ@@#6?0-$
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MJ/C\:5LYCML_C7'PLNNK&.[V>-ONX#3V-BYZ/;SPR]*ZLE4.RCBQR8_S'CN
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MRF5>3B'\3ZT'OGKK/!/AH!SDNVUW0OFN#!>V=4-P;\1>3E&W6?:B'W1[>8+
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M2<%&I?/FTH0!9<8R:8E&8Y:W*&!L&=3!5R*D@_=XO2O\L_4NYA&:)0&&D 1
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M3'*)_.C" SR?44@!4EAK,<!T$%/.(A]MB"X2&0 #F"7RL@L/\'S6PB46C5*
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MX_!1\F#XL.A$]+#5/J84M:"&@3/<Y57G>:\:G@25%D9;!ZQN;\2/FL%)=0N
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M'Z-KBJB)*W;!UY@6$[]L];1Z18;FOCCZ-,MQ<08/DG-5^LV+?N/@-/;L>;S
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M8J@2";\<)3BH-G\JPE 6[4=+M9OL!9\,VF,W[$H&[<3I/DK72EKZN9^W=DO
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MH]"6<VE.DS?5\U6][3??A=(*HTE$N8#3/.!T/D,FL+>,6H?!&.R!!4-!4Z$
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MC=+31/D" :8BAQP:AR1N["3.%9;8(^S]W2_GM,34UT01W]$/FJC(*&: B1'
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M8.<T,$0TZ)#S-RWCU&/+D\EN;&+:I*HLT&MLT(\=&RL&O32#GHZ"":%M$,R
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M? H&*,K%(R-/<L(&&.$<;!(A2.$#\28&%TQB-->&,PH,/',86$(HH\# T\!
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MGWM=<I"4!NPXR50F+WW7]+<L2U]9^LK2M_@6=L&\!\>\:;J/G, ^Z.3H.>>
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M,7K,N, 9R0J"%01[S@@FHW<QP18/6C&&G.+1FJAPD"02Q?W-"#9O684";XO
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MOA&D/)A#2H:U)%[&/4Q25"'3&!@9,1,31H+C48L+9@.)4 \,(8N M2$!2ZO
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MY?71<E[RC911RG(/!!51FV=0 T.H TASI[&TD OT(-#RH44PE &7 9<!W\B
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MOA?"46:T<<%2[F 0D!H:1!L(=5-;.J_349C./D_^O/KW,6_4PWW[0<*X4;V
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MS6WFPCH"HY85=A=\4#/NJ]F@"SWLI[#'9D,U\=%A9D@/0Z)^U=@\[M_1DR3
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ML-%<;,AH<A:UPUK4F(S:;-LXL$DZP*I0EV2?&4X^MK4P:N:<E4.J:G_U'[.
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MY0!=M5&;>6LM.S;/S/?-KF/\[M\ZWC0\[Z"ZMX/KNBIML2[R>I$@4=>$7](
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MZVH]<^DIO^2LHOEQ_%J)0,[W@!OF4D55LD?5_:BI\#";:SAS:LQG,M6]O7+
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M%N5U!_/B6)U65<V68I]N8QYY%K\=Y2+U3.>YK+Z7+TR-]S5O;K]W&@:*W^+
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M7(O4: LD%Y+/UO'V.[!#M%$B"Q2,/>(Z:J29PD@$&1+3SH-)6,84ZA7I 0M
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M-@/H[B#IW9(ST7K-X1"0"R3D4C&'+'81*4^"L)QJ1=)MIN4^KA*QEL7/SS#
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MO* ?@Q5/*8?QCW$OSHVS:E,8KVE#49NXH !IV'*OL164"Z:<IYBIP";AEQ5
MUV8QW!U8?5STFC(?& G95^H3!1M(&&29X4A@%T)*G$C#VW%6+8NO5FJ($4 W
M06/-0R0V2.(3$PY>HLK2LUF\36&\/_Z?-VV$=+#X9)'5$OC?@?UI;!3(!\YC
M<$RK2/,X*R/;<58M BR57'JC+)!)8M)SRZB)08/J2VRR"LM@+X< ;0KCCV+^
M!0>HBRF J4)1[G6'>, ":<8H(LQ%'*UQEMY>]73+_C\=^TM#F268!*PTIYXY
MH7*#<B<D<9[3>"L*0)O">-L@,*\!1,8,ED*C!.>81_5@I+4%)' T@:%&# YM
M"N/]I#!:+YT2WFC!"0_,&AXE!E,Z4@K_&C'+7VT*X]URS8*3+Q(1E30)6>4$
MXMI29)PVB MG1-!2)N7;%,8VA?%.JH-!N]:<Y$[$@G.GC/="497GR 8)"VV"
M"6H23+A@U&0;=7P0$/-E=M+\]ZUW>SK$D+P,2(&6CKCQ#&EB"2(BS]"C2; 8
MVZCCTP**JV8V*M .N"#:6<D]UT9K[TQTUG'CC%270(HVL_%!0,/)'#3@P$ I
M!-368*_G(?026<(4DH1+YJ0F48/ASNARV7&;V?B3(<(5$Y94<)P8::SF/#IL
MC W*6V]3\-)RUJH.CQ,?MN=5!^H<U<$Y%(+@B%,X3N>T0MEF2<H1'W!H58<6
M*,X&BN0(9=YSJ@SEP03-N.'!B6B) JNC!8K'"A3SBD00E"AA,4I2Y/"_<4AS
MP U*+>52<Y54"Q0M4)S7QD 8%HTR21+*<R<#Q8TQ406L*%BJ](I T68V/B2T
MV)E7*U1TC B%44P>T *0 CDI \)6:*LQ8TS;,KJ4W%8+QC:S\=8R&]_'H]'L
M>/3;2V^L]W3I@)YP8%1I:1F6.F*A.<FZ> )H%$[DV1(D3@*C*["PS7^X,SS[
MO+GH8:56&Q>C1!P +&=J8V24=<@(&VWTGF)M[B#Y\4;\\E"BHBT\W&",N^%$
M1QJU"(1'P0UQ@2D3J! J2I[.AH<V<?+^L&/!<K)2,,$BXHH @"@!L!$I1I)@
M8 A*:1(J)TY*MMQPHD6/%CUN@!Z":J88H2DHL-6E!>R0@" X"<ZTT)=#CS;I
M\D<!QX)OELA@C)0:24<!.$Q@H'08CI30#D?KI"'TCI(N6^AXXM!!/-'<*X--
M)#PI9ADC1#&-I3#4!G,KBD>;L'G; #*O>3 5J<@-Y[VAH'Y899"E)B*G8A"*
M)$5TNIN$S9\"/RZ?SGGMQ[U>OTH1(N;,*(<I-SIH&ET,EI,0I$B$S/+F#9(]
M6]Z[$N\M>$ M:/<D,H&HY19QGGG/!8FTB0E'K2P-^KIIGP]O;O93OK(<UK]'
M%M@>_@V=K]-3W1X?@JSV]>^9A3N]L:V/&2Z;W',&Y#Z/AZ-..IE+SZ5T0Q2,
MJ('8#?[]? K*Y<MF;M4(?$XW%'SFMZ/^L)._[M=![,+W?HV_'7?"Z&"B$,Q\
ML $P?/H1ZP"NQJ.S/S*S; _KC(,?K]?0O*8\,V5V.V;_/AA,5G-D]T'N#:+]
M@FR"Q?YJN\?V9+CV[[EG.NSTT,(>GOOXESVB^N\%(JAA55DG9,348Q&Y(=*"
M4-;,)$Z8=CEOLVH^$\/FJ%3+PR>"5I0KPHGEQLLDI8PT&:>E,_.K/+2#?7BF
M)BJR<$)GQE)^0,RA'-WF[E:UD\"$!'ES)DU?EQ?._-P]//X2Y1(*C[_3JUY&
M7R(M%:$YR$+T>G4<J\).,52=WJA?V:H6TU61T]5[$,K#:G-_$.,A7%<]&QW$
M*MN %/^V\HKR'OGME^JX,SJH_KOQ8J/Z8#N]XZ)05?_''A[]!M^PL5[]^>>+
MZEESI_^^^##YW'IU-!X,QZ"@5[":XX../\AK/+0GU3!VNQ6H"U4GQUFK6EFI
M^JGJCP= MF75P[*F-.@?5B/8O'R/^M\#V/I]6-"+#^N5'9:/#,O*@5,7GFN6
M3B;+@J>(U8']&JM>O^H[P*&:J>#^S;).9A8TMY@.7 4WG[WK>GF,_$QV5#Y:
MUC@<#X\BO-[/5PU!*P-MKGQT]5'TX<TX  RQHWCV91O5^['[''W9SGQ5_LRP
M?#]P>BCH6]9\YAW6\Z;!<<)3CH>QZHR&Y?ERK83M=D\J0+EAOY?E404Z:G\
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M);EQ)YGEP TJ":Z!R!27E$0><!0F-9TAR60R[<7D=E%>5$MSET(POOWYXU[
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MQ0.>I@DXC?7TGV#D]N><$X%>3@S+PQ/=0XLM"#]CH!\J#PP0Q2C0(0;7?:Y
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MD=JB?&2BA"0IQ_1DFO9ECGF/DSA<_N!]E!/T>8W'C5N^U;/963\:Y@/^[%X
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MO^F570 /D@]:BWP \E&OR4\U+:RPC>%OF#GU>Y/@\7*6X'&S8\[%K?6 WF0
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MD.0%."(QDAAJJB?6MI)J76D@S[N+L&(MR_9X+#7ZO]+8L)32UYQ(?:G4(TI
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M-.^4G?I=FH&JSQI$8M>R A*Q@(W<T\&+R"9&3/8IG5)"A1T$28OI\*>CV,/
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M?# &ZE UDC>+.0(T$,-UP_(AI8)R/-T<ZV<3B_,9A$='L"(#7=R0]&+RP"M
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MKWAZZ5@O4+69C%&_1>NKV/X ]]*Q'+'RY@&(E?[L/O?NO'X C]VW<G"_AQ3
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MF:!FI!%7%?Z3*2_(N6#&'C')\,MRW9/WRJ^ML.-:#$Z*CD72P_'.&+YY!V^
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M' 2_P"H4%,%:ZA7"?D:T9\48I 5&65%3##G/MU$Y-U3K\(S:*;J*X%7S2LG
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M^IB:]?KN[* CTVJ^O((K4Z\+A<R=/-C:J2Z'=J,'+"X %I=E<%N1)<TJR(Q
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M$JPI*U,RX D>BQS%GDWZ;09".B%69JD5\:37/+'?T"=#TUFP@&01E@>BM&E
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M_?W_;^]+F]O&LBS_"L(SW6U70+(6;TI/=X125E:Z*KVT97?.S)<)B !%E$&
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MLS#9,+82W)D$?C[%FC 76HR09C+JRO]<YSD+I=S!6NR;+H  <MS. M]T4"#
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M7E!SMUNP!56'5L=L"/]V/^+5" Y/L8(10NM_@.F7B33SXRII6LE<F&1ST$@
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MC<#;$UZ#8]>]X"X'RK/V9I+",G=SJG@ADJ-Y;J!5O2UA^>M,<K<7^*[*N@W
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M% & 8)NQQ!<=WQ@6"]*=@2N!O!TYU]DQ>PYUC#IKE]I%MLF\HG6350ZK4HP
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MB43.!4<DG^2M*,)9VK?&0\/.EY3C>3^:,$+[TQ7&X(M"(J=/1IU=?.,PDC^
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M"B+E)"*.@:K[?-&JVE7P880!+HIDDGU^8B%(:H*!HBZH[*>O2]QO>9R_5"J
M8>%BT16*Z9801\_G!="43&;9Y*,$SH.NDN#\"<(K2R&%D! %QP8?X[8,*,VZ
M@,PN*.*8<X[0EFO]NA:!/>*#D:<$A=OD5S4TII;$:EBV'CE&Y#GH113%R)<;
MZL] P'%);2M )6"HK*SMV$[Q=4UQ!GY3Z6%])L3M&V\ R ,3 $%:[71MI^J[
M3)583)DK2CQ81X[I]IJ* /3 6PT4C5S:8GX@:=%C9&_KTY$Q9ES'@8M;V83O
M-K=)>HE'K0LL>^RA%#:6%6U9831$GD;NV(#9'&GMJ&HBC #^_X81Q(AA);>1
MN% )N(,->TEXU/)>WYB^Z,8F%XI@?[[__8J.^N\]]$'*@AE<34:::QKT.@=[
M6IU4R_57*OXY2^2#V-\@+"5OT-<&Q2>!;*A^VX:^B #,RHOD@LLQW%&<0+]'
MX@)HX@6:^CS.I)J?ZX9"$&!2$L8Q(U)3LQ,H$&8^97R).A-$Q!A/<VG2V_8Z
MT/Z!I:P5-X+Z+DIA8*TL[*TF<*_S?2G',][-Q9TH&D%9=!IVI'-F%:@^"\I2
MH8' 0(XZ7[3J)L4/F(V,Z;HHL=D2R6V#G-SP+/5G0D8#1I4RX:J4A*\!^8 V
MIJ<UCXK%FTIZR6V^ ?&668W+ &>U6V._OIR;(D___5Z^?YX>)@>/#YX]F1X]
M.GJRGTP/#\Z?[AT]>II.)H^/GOZ__;V]>QO0Y06'PN-'_0,3?G-#V:B7[T]?
M\;;=C3Z\?G?ZUY=G[T_?G;Z(SHY_.SV+WOP2G?[GAY?O_P_0;'YX]_+]2T K
MO'X1?3@[A3^^???FY/3TQ=F=2M7L/07@=[6.;N:'1/8\78WL^9(M<7COUN*!
M[O(&/=R-7IS^<OSAM_=GT8>W;UZ['?GZY9MW9F/>J4U(W1?CFW#3E?;DSV)\
M'^U&KUZ^/G5&]Y=39VM?O#P[^>W-V8=W7SFG-]I0 _4R%;[Z Y-[M,'DWOC$
M/=Z-WKS_]?1=]/+U+V_>O3I^__+-ZSO5!(7"$=NS<' 6/OLF9^'^P>T_"]T0
M379 A=!%(#\UW=RMTN7S/VY$OR.&<?4FC9[L1J?_^]>7/[]\O]J2?F[-7>.;
M''Q!XF.D--8BKD!W&XCE[2"#[:+)?I)_/ <9#1=5_927>&G\DDPP;U%87<@/
M-DD*'@H<%?HS+[RC)[N'CP# ][_:VOW_5&[,RW(7E^7#-AW^[=GNH\='*_^Z
MM[N_\F_KKGJX>[BW^J]?>]5GCW:/'JW^JKWL0QP'&@LWVC ]_W[O\-[J=3.9
M9"XPE\WTT\'B4[0?LJG#_NK/!$W"#81),$BGGS ?@X;D-?*YZ#KDX?F:-]^#
M][[WQZXQ,GJT?6_5^+W(FDF=(]=6,'"\=GIG+#>?;SHB;(?^T*A>]S6N89/<
MPFD^W-W_%OOB+EB$T=3U=WSG=;1.T^FUO3@]7YI-.!/]$[;!P*?<,R6CSE1&
MMO/YC3]@-*NSJ3,R;;OXZ>'#JZNK7?>8NQ?5Y</C>C(#PNZ'67J1U _3I$T>
M[C_>>_QX_^"A>]S])P?/#IZY_^SM/SO<?_PP^[1SZ'P2]_.3P[W=6>OFX]B@
MU]X)>NTD1*^]#-!K7!QXAZ1A2#)WW\/;*-&,0!/L"FBKB(^@R.TQJ8'Y[VIO
MSW]VB+$JENZ/ 'N&Y/POT,"WO[?SG]']7X"(Y76U&[F7VCE\_.3IWH.829"4
M0P64A+S>YB'V.3YYX *CI.]#;RWXG]""']QBSV9K$6^+1=P_<A;P\?ZS@Z.]
MHZ/]AZDSA$\?/TFS3X?[9!![M@_MHVAR?P-CN?M-K"7S./9MY;.=OW^1J=1>
M.+25S\9LY5H,Y]:0_AD-Z>'6D&X-Z8:&],#]]V#OV;.'Z?Z3HZ=/GOZ@AO1O
M79E%^T^(I'KK<OXHEO+1UE)N+>6F+N?1_J/#_:>'SN5\=G3T^/%J2_DB U8Q
M-7MOU:PU<?2.R-S!;O[F^\B)YY:5&D#$5L5"WFK/!U&W_P&;^6_?S%J^2I81
M<L_N'WVIK7RTM95WU%8^WMK*K:W<V%8>'KBXW-G*9X^=6WGPC6TE);_18-(_
M0=6&?WD]MO,S_B;=VYE1^L=],)OT3V=0^1&-6:7?C-O64)SBX,G6S/Y89O;)
MULQNS>RFP?O>X?[>DT?[#]/#HT=/UB1!_YA'>GA='JGJ3G^A7[K"+56RKD?$
MU;4UFC^*T7RZ-9I;H_GU1O/@,PE/-ERW,,P_N,XP?VM/?U1[^FQK3[?V].OM
MZ>$-V-.#;V)/#[?V=&M/O[T]/=K:TZT]W31W^N2)^[^#IP]39UF/]IZ9J'ZT
MZO[SDH3*K@75^2W+Z\^V@,X?R>H]VD+R;X.5OM87?Z<6)6?)3V]9QJ6,;MP\
M_XG/C\\W"V";C#>^-[%DXNVRN&V(:83>;U?%C[@JUL _$4>\714_XJI8 W5#
MS.1V5?R8JV(EJ ?18=M5\2.NBM48!,2R;!?%=E'8&BO6ZK>+8KLH;*$("XXW
MNR@PI[I=%[<LX8V5DYM=&+O;3/6?/U.]I1[8FJN-\ZON_Q[M'1Q"?O71P2?H
MN]\[D@0K5L< E4!2:P0^Z.$<OJI,]V@,ZG4-Y"NOJTO"*!RMIA38VL _HPW<
ML@9L;> ?2! ^.EAC =]V[K*@7O@[JE[^(:-W*]I8MV;NKIJY;<O_ULQ]?<;B
M#EJY/XHZW9JZNVGJ#O>W *RM;;[MMAE!2ON?@';)1]$^8#;,42>S/)LZHYE-
M.E ]B-Z0D&*TZ&H0S\6N@G>=]-WO'R8[^X_N)P] IVK_<2H_T+7.0*<];W/W
MGJ>?6(CKF/2ZG.5_M+60\*(/D:G^/VY6D&)4'>'6J%0<]1:)^=];IS?Q'UNY
M@C^=7,'M=#NVV?0?\Q@_V/P8_R4ODQ)5++?'^#;0^8,6YV!W_R]_V88Z6QMY
M^VWDP1\*=0"CLHG]W'\6?=@]VSW9#96A]P\?[\6@8I^DU0(R4O8[P2>/]IZH
MC4WJ\Z3,FITWGXIL*>;U8&_O8&M>?PCSNK^WO_OR]=G6OOYYW_E___SNM^AE
MV;0)I*9?5),.:!IV@]??[NH_W:X^._GU1UGA/^RN?I]\JLIJOG3>1)N5#3@9
M9Y-9-D^VV_Q'V>8GQ[_]*$M^N\W]-C])BDE74%SQ6UY^/(?*]';3_R";_L7I
M+S_*!MAN>K_I7V33O,RW>_Z'W/._'?_\HZS_[9[W>_ZWY#PKMMO]A]ON;]^=
M_BA+?[O=_79_6V>-6Y!;Q_Y'W/5W%KU^$\/U?I:Y=[N$XEARD473NII_70/=
M+&FB\RPKHZG[5=)"Z2POHY<(D(I@G_[(NVX $UR-1;L)%-K1[K/'AU^#0CN0
M+WY3O-@1X,6>?@N\F(Q066$-?,VDCGWRBPUF;QULN/_;:G%#F_\K$2%W[36=
MC7.G_\2B")HHJ3-GK]SS1].N+O-FY@Q64Q69,V]M%263235WC^I^F.5-]$\U
M?369OLV1!&6*MRJK5FZ''2C.2L)%%E63(2]Q^-5G&Z*W"*E C,?AO=QSG6?1
MZMZ:O(2W=._G'@>>:M!S'4=7L\S]JB;.TO/,/7$&"#/$Y^*'4VC6=I_(JFGL
M+GV1U&F1-?@Z<.6+K,SJI# / =Y8X=ZA@Z/&G0Y--YGQ XR<#D-L=9[^^[U\
M_SP]3 X>'SQ[,CUZ=/1D/YD>'IP_W7,6(YU,'A\]_7_[^X_OC2"R5P&B5QCA
MSWWM^A;QTU$<]=G+O[X^?O_AW>G9RD=ET^\VFON.;$C!0#]"O/0-@<#?FNT"
M*Z?._MGE=0;.>+/Q4J<O*B< .!QIY[;D).D:M[QQH_+VI-4/4@GN#V[1 =/N
M>39+BBGL K@0(H_X [#*LPXV!%XOZ=I95;NW2W='CN9O.WP'&PU?+ZA;,^_L
M/WU?]^'I[N/]1U_C/CQZO'MP\.0:4.Q[1YNY#U_RMX/=)X^>??-G=4/P^& S
M(/]GW)&[%'5\)DMQ="=?RIV=7=$UD7,WZF21=>[!&A< 348#GS^OM_7">04_
M>8Z4_3ULJ=VDS?(N3?;/RY_^9&^T<>;P+KW4P^9A]#?G8R]FT=O=Z-?D(BF_
MZ6[<(%WP%1^]"R.[>:*9_ _T2A<MQ%AY&LGSW:4WWJZCK=G9\*6@_I!#W&7:
M$0:M"ML%M%U JU[J_MLZ+R?Y(BF&Z^;!;4BD?\>/;CWF/\62WGK,=^*EP&,^
MJ?,&L+%-DB9?<DIM#Z,?SRO>KI6M^;#+8;SU=KLR?OB585S:P?(8<6F_%#*Q
M02GO>W(RW1;ZI2=[J^F7'IY7Z=+]9];.B__X_U!+ P04    " #ZCFI3MH7.
M_0H/   ,D   $0   ')G;',M,C R,3 Y,S N>'-D[5U;D]JX$G[/K]#A97>K
M#@$&)G.I3+8<!A+JS  'R&;W:4O8,JAB+%:69X;]]:<EVV &+&28B_<P5:D$
MVWU1ZVNU6BW9^?CKP\Q#=X0'E/E7I=K[:@D1WV8.]2=7I6^C=OF\].NG=^\^
M_JM<_OWSX 9=,SN<$5^@)B=8$ ?=4S%%WQT2_$ N9S/TG?$?] Z7RY\44Y/-
M%YQ.I@*=5$]JCY_RRW'UI%H[.1^7[>K%>;EAG[OEL7M^4B95[)YBXM9.SZK_
MGER>DK,ZL>ND7#MW:^4&/C\MXU.W6G;/R)E;;YR/S\Y<)?0AN SL*9EA!(;Y
MP>5#<%6:"C&_K%3N[^_?W]??,SZIG%2KM<KOMS=#15J*:3WJ_UBC?AAS+Z&O
M5^3C,0Y(0LXGWKIP3B:A%P;\X;W-9A5I;_6B7DW(I3"J$4_]0&#?7HIW!"^+
MQ9P$VWG@<44^EGJJY6JM?%)+:W+$DBVMYK02/2PA+ 2GXU"0-N.S:^+BT .6
MT/\KQ!YU*7' $3PBH5XC2#T6F$^(Z.(9">;8)B9=\>D=0A(B.ILS+I"_P>OB
M8*S:&G"AV*1E=; L O6&V5@H3Y7T06+<!E>%>"*05^65C/</@5.JF+<@#,H3
MC.=[M"+-&;4DOI._-2F?K5U<7%0>I!-N;\=6IU+T9?FS7#O)IS;+.\UUPU4Y
MX7N*-JP&8+XV)'P'MF'KB,ORB%V<ZCHP;,;V$6S8"0F#M/XTC\* V.\G[*YB
ML] 7?*'<><<0V,:27"CGWT>_0V@>W0FY_+%%)_9])A2_O!/?F\^I[[+H!MR2
M#G.9>,V N$E<W9@@M@Q-]<\EYC9GWHYQ7)ES-B=<4!*D)Q<E8,J)>U624TPY
MB9Y_>GC\'EJ2D&PH6'=]^;@"+,2[65F2\$KONRH% (!'HKXILN%S3O(:#BP!
MS%T*Z'^\_3;V\MH/+';H_7^8[Q WK_G 0GVZA_62>P3/$76N2DT&F7$)R7O?
M!AU-@J-T1M2)N$3@JB6?JI!UPA]47F719:2X/E8>TSZ2$@;$Z?F?U._'KATS
MQR0:QD<^8<RWWIE;V>*;2>_I^K37O6YUAZWKS]:-U6VVAE];K='0O).WLVMZ
MO:9Z_02Z>@A]1I)N3^2@6!"*)!T]$GW,P:0I$10:>2 LZ[+T&,FQ:X@1^GE-
M\"_'B-EP9(U:MZWN:-AK]_JM@37J]+I#JWO=[-WV!ZVO0-3YK773&^XQM'+(
MUF-:KU8;F9BNM*!>&ZWT(%"$UC0AJ>K806Y^M;I?6L-.=SCJ-?_SM7=SW1H,
M6__]UAG]<=UJ=YJ=T6% &\C7@]V Y84AV+$NU.FBM+:?4*0/_1QK//J1W;2&
M7]LWO>\'#N*5&#V$I]7J!U,(0212,H\(H\\XH %S^RDCL.\,P]D,\P5SAW3B
M4Q>F)%]8MEKU4G_29QZU(=,U1O @)1I\(9FNU:+LDP:VQX*0$[A0ZA!S45HA
M HTH5BF?I92BE5:4J'US 2-T7M05C%P"EE@GS^,2D*/%OXXIB!\"V#41F'HO
MXQR)+IUO-*KUQG/Y1JS_F%RC2\0-"X(^X<,IK%Z,87[,IX_PC9I:Z:Y!!A*0
M%(% !E)"CK?;\PZR#';]N#EMF(!PE*.@X]^10,C<TAR#-(_>^S_45 UAK>-3
MW$?4SVU,^6_8"\DMP;(C\O7X=FY]WY_5U%I_K>^E'*0$H;2D8\=AA,=>CBQ0
M)T.'2;UZ7M^<P#,P03]'$H\I&&WMV.7-KY1PS.WIPF7<"@(B LAR;B@>4X_*
MK8N8R<%BR<+\ ;%#SB'947E2WMGFQ1JDG[\N&IMA---M4@^6#4300A0U4:6&
MJ48FW ["(BT4DLAE4Z,D\Y>CG""OR5@8^XLBUH9E6/"KJMP:EI+MR+HT9\A-
ML6@C;*U6WTSU)/,QAE-I=Q=S#LVXRYUH;V76AJD:1*J-C"/J^Z6@XXTA[5!
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M47Q#H?H4**_/QYN%1_U@0<72M@N@%UG1ES"&/)P-M(DY"*-)MJZT#C!.7*9
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M^2$ZXI)X"I%0*JET5#$O&M5KWP?M@6Y4\TQY"UK=J.RNJJ]ZI?[78=VYJ<T
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M9JWTB22%T8 TB9.0!"V]41R]M@S!M$G%W8YG%>JX[XLZ%113L4_YM(,XG"/
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M5!?TM)S./N'D]9@<4)R<US</9!$V!JX@T 9)VZ8S$+(K($PVV@<;A6DS[HX
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M'&G[23* $]Y##-P9^AO'=*-\_E5PMHL>7HKKLKS4N_'9V<OQI-8V'"1MT-4
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M9P\T>>#@>3\LV40!#=CQ#J=(#_QT,LK/\0N>C3]7C$L#<WEDD)30CAD)*)(
MI9DC"U,82,8K+F,0J5'5M [@=N\G]*C.N^ESO>JB@<G_=QSA))P1PI-\3J*N
M04:SX1>\";+0N%/6$5AAM:1[(@^%!T'J54H*;H14N@EA.L$[)LKTKX\=95X^
M&Y\1O<;++HQ;'.2M?E ?IW,=(-XZ<G.D+%XR<\X$I4IRQL3L=>)>J^!S&:Q^
MY'93\MHSO^#UPV8BQ9LQ,6_U7W^@3].0YD"^N7W)9AFCCS7;FYBBT4%PQ8+,
MV0N29-&JC5/2YRBVWQ._X.@"7](\?D9^80VC_.=P]NG9Q71&TWCRXL]T=E%[
M39Y,ISB=1_?\.9#6Z10<+<1$ E!.:W A!_!6)4F_)W^Z36[2(\#N?@'<&T?O
M;K%M5=OCECN/1[LE. R+VK^8![1H(SHLX+6L[4CF]X#<0T'OG @FW6E.OB;.
M=.TKOD.:]"CS'FWU.:KG6' RP;QD\#/Z.)S58XZ3CR3:Z>SE1:TW^=OP#(G*
M(YP.A&.H7:YM7*P#E6V :$0$PYC.-2TARVX$V?3-WRMOFFJH03+5V\DX(>;I
M8C&\%-%X,AW8G$0U8T#[FK:"J0"Q7H%0/CG4K(C;:TM?02#K('V'G.I733UF
M%\W)OB3Y\O1U'M=T2>Q%V//;,9G&LV$XN_H]?1>'7^8GLR5:YXNUH%TP-1+:
M$7(M("5O:GEZQTJW)(FM8'R'I-JQ[OK.W'DW_AK.9E_?XB01P/!Q<35P.GJ#
ML_>!H Z"Y)*9&(%[+D Q7B"(B&!]\9'YP!+SW8CUP)N^6^[TJ8&[]-!;T>/D
MXP3G@UZV["O&*GH?@HR\)EP07WVB/V1BD1?)K/A68O=>-MQZ\/>J_&WD>U?7
M9EL#9I4']WH8XB)=_<8B]]]DO5L;/-=652I69M9H"1X<2.F,2QQM;)3:O1G.
M[Y!<.U#H7?K9K9::%R.2\%D5P]4>.7#%6Q110BZFYBHP$H(/'F3AKI@BBA2V
MTW*SXN'?(2MZD?-=O;L6RTX]+YK1'CA F;A,$FOC- LJI 11%@<VV7J63]M?
M:I,[>1^J[Y \O2OK+I'\EN<Y5S=\5\Q^,YZ=I$]#7!C:,FLLG%D@<#1LI&%[
M$2P8KE3P17LI=*?EY,%7?8?\:*"#%2=^/898]B"Q15245AD91@."AP#*T6B<
M9PKJ!94*N=Y=->I/VOM8=A5<N7>V'@@=]AU6N4C1KU?<^'&83L[.AC4I:CJ/
MT(E6"N$B \9JUW+M!(3,,DA?DG5&N'P[G')=W8V5S]]_9.1^-#[N5_)]WXK<
MA;0,JN@":G489&=:[".BL3<]W*_7+82X,PV7;$12WH$QA54+CH/3&6O_I*)*
M3AY+.D#-K@E"W*UB-Y%=>X6&4;X9&+,,6U(\.JF$AA($V>B<!_!)!6"HK0Z&
M9174(S6\YI6[+EG<BW[NUW@?PNT[JN%]&(W+< E$R"(R(W8[;QPHGRU$FSD4
M&Y@2A66+';5\[:E/7Y&/%5&#&.&:F'Q:KMD4\U6I%&,DUUB[A!E0*61P*7M
MSZV6/&+P;2Z)5\+YSNVS_E35(-#@KC#"ZO%?AJMV@-LTA65#P/M):NE!U;>S
M3G>@IP;+TZ:P<U9.!VW Z#@/H>?U^+B UCEKYAPRWZB\W2'0ZH$DF/VS:A/U
M]&V;OIV,QV5,2SEMX9\)7 V!6);K*;QNV)J,I%ILQ6"B]9@;X,S89)13,G8[
MC%W[BMT?PC;5S+AWL?8>6TN_':8K*(H[3P,A"UBBKN5T&!E9GM5[Q7H([ (A
M[!90>^.Y1ZS6+038]\1]5],WZA>^GE1_Y_R<+#ABV?"_PXWPIJN=BR4FI<[
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M]IJ9O/QU_2/2VO$?__;_ U!+ P04    " #ZCFI38-;\H<BU  !)KP< %0
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MV562_K1D#ZIZ9.T-1A-K3C3*_4<K-"A;J0%;2B"W<@/5"OYO/VUA&&A^%I-
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MP#2[D1/4@MZ 6E18:&B$!;>=X'D;5TZ@!#6VND<<U?AR4O[0&'.[J1\O?S!
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M985E(RS8D?8&M/*&8Q=G:(+RR^511V489Q ..<;]QGXLT[ARC8VVJD^[UEG
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MJ=ZLU$,U$YD0/#'&$(J(AA@I 7G.-,P))SJ7D19^W1LOC#>UC[X1]P;4 M^
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MRO)(9U$"N4P2\P4+!G.1*D@2G0H9<T%SV4[RJZ7\;J9X+>MP$_RJF=%IS^[
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MJ_3U';T";ON(24[JB$>2PW9,VF PH5)A?2=N&B7$O*7_/DJ+]9V4\;HFG1/
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MZJLJQ;Q2[_6FY5>J,6>IV5JG2 @;JD$,04;29@ZD6I$\QCZA&EYC3XT.=QN
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MD(^QS(X,M]M"&A+$L?;2K;"&CT$M[D#=:5RA"9N9>6G0<=,S'2$XRM%TO6^
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MOVOGB=7=^?EB-Q[O,J;-Y[(G813SBEHPGI%OK/G;,? %MF"@3N^SA1>5-CW
M1_5C_>5/-7M6?U_,U]]6DPI2R7+CZBN*<X (D8#RG(.<*(*+NB)0%9-GM>2+
MV D#CDWQ&<7[!J4;S+:3LB9)R'[R@,Q^X&GD[$]Z1^*ZXAIC0!1E "DD 5?<
MC*V"$U0*GM>B3I',X9:^&6+>,UU0#-0%;K/6$, FGKK\,@[<9?]+L67V:1YQ
MJKH5Q!?)17!BS"AS$UR"+#17P<7R B*HSAS+;T_M)Q6MZ@)" G@..4!:%8":
M^0K($O&B8$352CK'3/75-#:*V]@*]H.A=@%3'H$[O?CVTUM4U!+SU]F8FUU<
M3BS /&*;8@$W4#13*(!^T4LNH/3&*_46,%R$DDL[#F*2G%X(\_X_JY69C,6W
M^[E\HY[5;/'8;.GL%I@VMM[&T7]9F)6(7BR_FY5F(X"]^F)J[ [ 9*$*6=4<
MD)HB@'!1 FXO6\*Z.6RL,69>$0]1K!H;+6\:E;&YS/::=;B<W[3,.DQ=VYJX
MP+9U=YEM7^#A99R^=O-J!^_!Q%/$D)WG[?U&!3NJ*QS'LD']XJA@'CO)<0L/
M\)B#-_BW-V7O5ZNG[ZVZ]=_5^MM"VFM9'Z9S]7ZMOJ\F,D>%Q@0#2,P?2$ *
M&"PI$ AQ41.M*':2E1W$VK%-$4UC,L=#Q.SL(>*>CL9>V^^RMO59<Q7S#PM
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M'G1P'C;G> 0>_39PDC?]L2>JPU"MF$UAGXM* X2E *2B$!0EPL;18H5&7JD
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MO8Y(Y$FUI\*!9]3K33^=3AW>"9M+/ZMG-7]2JWN^:I8"DX(Q;OZOK%A=DQ.
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MMA^*_JW:"^\.N$_;;_WA)NV59P,X\..3C<;YI#OE>NO-"))K60"J&#>4QTK
M<X(!%@6$):DU%4X[LV=+'YLKT]IGUR*BL]!C%)] YT!PMP"2F-EV6+R.@(4'
ME=V"R4 <YH&-'W==:GLO:9V\-!Q;7;+W@*8N/A2DG[J>/D_7/S_I=D.FR:#Z
M1?U8OS(V_?ND1I1JHG-0TTH 1+D 3$(%H)*8Y;K,J20>NJE]=8V-NS;6VJ^R
MM==+S+,75@<FBP=68EX[Q:G+ )U9:[/&7#\=U%[HO/1/8T$XF.ZI\R?G*W/J
M@L05>=/>(H:4-75IRY&<J=,K$37[FQV72F/(5:6!0K@&B"L*.!8$2%7#.B>4
M4N641>AJ36.CSHM"\%X[6=<!=CPXBP%;ZKVM4,3B:..[;G;%T;\?;O?+N=%.
M.O8W[(=MRV6K;_;_-A;SF<WL8O.S6JV74[%6TO["7N8_^(>])R>2"Z5X70/,
M"@5056) ""U H54MA"R)8,)?@?0FFWS&T'"ZHM;(YFJ1L#^HG;D96V=\*SIJ
MQEMKDR<AW=2)0J.24@%!77 "$*E+0.JJ )R7'%)2*,H*7^70@;LPO1YH;P<J
MFXKJ);JNJIC !.4 0U0 )! %!#($*,.%T@15$M:3]6+-9B/KMIU-Z;KLBZVC
MZ:^[,[UFNFRY;4GS^R$[SM%1&*H[4CL331\T0VC/P+ML9WNV'5_'_[;W0D2?
M(P:P<?V2FRP:UG>) =Z)?Q.E4#\?2-CCQ>7/R>^_33"R^J-" R:@ (A!:G[*
M.<@9H[JN:)W7VF5EM"MR;$N@W^?3=1/@QM:N&T=[^/3S55BK$Y/.[Q_??WG[
M)OOMR_V7M[_=3AVG;>P)&NX>;H=_]Y==\/!>48,,W%/3-Z/OS&\"KV>;@?A)
M-W%TF\W@_7BZ]_,O9MFR8LT-H8E9,"C&10U454)@G$\%&)%FU2"9)(Q5&&$O
M_3^?RL<V+!M#L]5B)L-#?+W =_,\4D&:>,Q;LYN]RC:,=W>*<QC0:X#>LS_B
MC=P U.)>E_4Q8-B[K '0G%PT#2DC]$[#5A[U@2T_+9MI4S9731_4LJEU@DE5
M(IX7H,1$ X3R&A!ANH5(0V9%)5'I=A3E4>?8V*N3]%U9F[-'ULDPW)[3U %]
MQQ547$Q3KY,.%)*-P7;7M36YTQ$P1K=<%O,2@C-$D2\=7*]WX$L&SD"<7BIP
M?S50_+3)YMP%-&_$)"80YKPH&+/BI@0@K03@!:Y 7BJ>JP+!7.5>6J?G:AD=
MZ707"]JT[__=4\CT+(YN9'(S.JD/OAO[MO<(DHB.]&(05X?T;$W#RH[V-?9$
M9;3WX8!(F,LI5P5"0@G!@) V9 ^;!11A4H/"_"C*NL"RJ)R#8/XR^8)O3!!\
M4T[@OT(:X%AY?Z.D^OTK9?=-F,[WM@R^8TC:ZY>G-U5JWCT'ZS5[G*[9K%WY
M?58KM7Q6\MUB^>YI_;14[[O;A).B,HY1K4L *ZV:+(B (HV X*5ASTKD&#IQ
M9+ %8Z//[CBL6[&U^R'+SOA,FX6&;LS?W<>\X<JY;V<III'@F -5<#.A%78I
M7=(2:&@6T@IBI:GV.L=,VEG#G5V.LK.\5][QNV#0=7AG_F8/\?-^-[1-R#9M
M2+(J]X,OU1K=T8J76K'[@=2S?O<L*&PZ:Z_Q;)>?5&BE:T* $)0")!4U]"<1
MH$(AR#6A@GJEEC\L?FP346N=R^K4!3LW-@I')#'5N(/A32'GVQR5'XZJ&'3P
MGV_>\<B^\%1PHD3CV2[9[/U<JA__M_HY44K)'*,2,%;9 "S) "VJ'."BQHI;
M/0#B) -]L8:Q#=ZW72Z_ULJL,3,S=GKG/SP"LG\81X$G^?+;$YF0M(;G6W]+
M)L.C$H=.7GB^06?R%5YX,'#^7<SE8O[>B@MP-O_W3UJKI9*?V5I]>/_JT^=N
MNX/JLC#S< &$W6%#M** DUH!S 2NN41E3;TRB3G5.K8!WQJ=;:W..K,S:W?V
M2V.YYY+##7W'B3TVIJGG>Q<X$V1,]L(IKH_@5/.PKH,/&"<>A=?+_H[&;TH\
M+0WCO?TAOED%;2M\,JEM,@U8%* 6$-IT$P)P37-0<L2)$F6.B--!WZ4*QL8Z
M&QNSC9&-OHZ[DW$6Q.L^QJW0)"8/3U2\'(R^I@?Y%V<+',R]Z&O.OG?1^UR8
M<_%9/:OYD[+"RJ\7\V;=\<_I^MOKI]5Z\5TM'Q:SJ?BYNS^,RY(:!\,,:%I)
M@.JR !39Q;]6K*:%AF7N%4;D5_W8!GYG??99B<77^;0W/B\&^FY>1CI,$S/&
M!LY&O7]C>O:GL3W;&)_]T9KO=#O>V^\(0RZJ ^)IPJ">2!@\QRY)8"F!H=YV
ME[2-N'QCJ'/^M562;C=,FU]VV3O>_E!+,5TI.:FU4$1IPV[2L!NBJ ),2P4T
ME37#-2V+BGH%?'N;,#::V^PC-TI$^T&4C=:PZLRVOUVT+;DA.MR_OX@4A"'-
MS4AB.4"HJ@$OJP(PI1DA):%443<]O,0]-JA:WM:T[)>N4WZU\9G_:#+49+]\
M_NUW\P]#=I/;W)5VL*3V>&_/Z;7-VK5IW\K&_S_TW]7U#_T/1CGN!0!_,X:]
M!A ,T\EE@/"2PN:]HQQ4FQL(;Z:SITUJ\=6GI_5JS>;2F#/)<P[+&G$ E8UI
MD+@ 7$EFIC]%Z[JLB"J\_'K/^L<VXYUD<.RB&I[LD%TO["SX:!J2R;8]V5RM
ML]EBM=I=(@CG5M^N<R/6A!V2F%5/DA:>7)3:L_LNZUH4CRP#D8O*E+XV#$J3
M@0 =<V1H,0'!RDUAO"<)(/^Y>V0_"6!KU$+?2]FL]C>A%_=/ZV^+Y?1?2OXO
MQ9:SG^_G8FG/<B>P8K161 "B2L.KM2J!#7H&3-2ZHK1@E+AG/1_,[+'1\6[$
MLVT+-I3,MFW(?C:-, Y3VPJ/*.+A/HA^MAYO-X_?==Y])+OV;V:('0)9"T'V
M?LP?B4?H^B@_EH%"X<?WT?C%VP_>=[WQ^\-9,]Q]@,$1/KA?,'SM_@>XW16P
M-LV>+?7M7-IDQ1/*J:!,Y  B*S)#,0><$ 1R(A6NRES!G+D>XEZJ9&Q^QN8N
M8I?;T5J:&5.;!.GNQ[D7(;U^I!L#J,0S=1!&7H>[UT (.N"]6.A@A[S7FK5_
MT'OUV<#3$/%-R:=&E^)L&O3]G:B-ZN^1@#1E3##$)% 59  5=D%CZ #@0N:Z
M8'7)B9/V5#R3QD8BC<7=1FZV,=ES>_WV?G+<;A\4_0'7$%LW;S?9;C;7[[:=
MXJ.T[K_''@W:N'ONMYLU[!Y\-!A/]N3CE1R>:O/]?+5>-FLE4_]T]=NC\>?D
MI_D_V')JJ[*!>G"BA2RD5 H017* RHH#AA4#BE0U8:2"RBWIC6_%8V/6QM)L
MU9AJ\S4]=\9F2V/MG=U[%W;1^=715_/N!S=.38%N8N:T)F<[F^^R%NG?MDAO
M#&\"?^.F_/2!*GH^4*?*!T\6Z@/)N4RB7N_?$%?S;3$S;ZRLMNGZY\?%6KTQ
M_NILL7I:[CN,F' E!020V/-$PAF@K"R E#DF55[!O/+33W2M>6SLM6_X?\U:
MTP.B+IQ ]PBVB UE:B?O#(J9-3O;V6W\NB0>G2]<\8,EG&H?/D;"!Y2SH1%>
M!00<^+TSS9L^J[E:K>Z_6QG9+Z9O5K;6"2:L)H0C4")IP_V( E1 8D@*4D)A
M*0EUVN>Z4L_8V&C/TFR],3)CC=$>9R(]P#J<=,6!*S'C["/56IEMS8R#E,=Q
M3QS$!CJ?"4+.[PCE.AZ]9QX]KP]W2'&]#0>G"@Z/A_ITQC&TG\4G;27KW\T6
M?^Z4"W(ME60E Y*7M:%)60,B<PZJLF2P)CDA5>'GQEVN;&Q<N;6U2;%I\SPT
MY@:+0O0"[>JZQ8$ON;<6C%R >W8=DL@>64^% SMAUYM^ZG<YO!-&)!\7\\6C
M6IK99?[U_5PLOJNW/^RVFMI^Y 4K-:%8@:JF&J!<5X!S(@ 4LLQY@;%-Q>7!
M)E=K'!NE?%I_4TL;J61,S7Y1K;&_>LK#7L?9C4RBHI>84?9MS=YW^'7F_IJ$
M5YS1B4HNUVL=E&&<03BF&?<7_;AFM5Q//BLV>[NR/'8_E_?"^+1/,WNUYHUZ
M7"HQ;;S;-VHEEM-F%_^3?EA:6]8_F_27N:9:2TP!Y-!X-+GY@VB[,55SK!E3
M-2J=0MYOMF1LW&1O%=OY>F.C5]K1V_NEG[,&13LUEWD"[4Q=T4#JHS13R1Z=
MF;\=4]GM5@Q"<=' VE!?O )O2JG<;*Q]F,[5>^/GK2:T5"HGFH):Y0B@&N>
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MJZ+7]L/$$OV/!G#>&_6L9HM'^PW\?3I39B$_5ZMNY<V+4A:%KHU[6&. 2D@
M8;@&5C^A((0P0XS.Q-=3T=C8;\_4;&>KQ\CN ]6!_B)!E9@#SZ-T?6_##RX/
M-HP$VT"4& J?'R\Z8-)+CGWO#\>0#JTXH$F7YV-(MUL=CV[WHH244UXJ@!$R
M7(DK#&@.*:!*<(FK&B+NE3S\4D7CX\HC!?%&VR1L4^@BN&Y;0S$@2\Z906C=
MJ*]^"D5"/?6]REY0/_VTR?UZZ6>>]]\_^DV)IZ59E\*"?YFN9VJ2UX2)HM(
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M[/Q;H9+$?]X+8?-566VHY6)N?A3M1/"PF$W%S_;/70Y+0@OCIS,K;U<J@*3
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M4I7.E[</2A[;0&R,\\Y.?PI8__"["8;D1]R."'C%VYYM;5"P[6%)@T7:GFW
M?ICM^0?"EG$/!ABU7"JYK^)#-645*LU"*^<*("(EH(Q6 )6J*HD26&DOG91S
ME8QM.&YM;/5 _-9&9U%T6\S<BDWB,7H$2P(UI#X HKKT9RL:U ?O:^JQT]S[
M;)!>PMG,+XWCO=KDZ_BD_\FL6[Y>33#&BL/2S+X08X *".U]8@X4+&NAA&*U
M*#V$%+PJ'QLW7,Y>]6A^5)W]]K=_=BW(;':35E3-47XXJ),<-LT30I_<0[^<
MKJHUWVK][K#?-"$AWEYR#\EP'TP'(C+^OBH100!>D8_P*W-(78F@UAX)3H25
M$;!GHMCL[<I&D%N)?6$^QZ>9/8E\HQZ72DR;#]/>TORD'Y8VL^GZ9W<YF K.
MF%0EJ"#*C6=),>!*(:#J@@M5$5E)]RV60"/&-KLTUXK-^-E8Z7DA^Z;^<-B[
M&0#EQ!.)/\!^NSPW(G3[IE"H </M(=T(T<&6TZUEA2V4[^7_^[1:-Z$G7Q:?
ME6WT=*8^JO7[N7$)E3UB_;(XEVI[FYQVEVI[=\")A("JUJ"05-DL11P000FH
M65X*"'&=8^2ST$YAY-CH<J^-V7J1+3>MS.9JG<U,"^V_VI^%36;_U.:OW\^O
M?3U]_7 ?@-L>P4MW:V)^/NK1;0,ST\*L;>(F+L3\VK8SVS34'GS^\GO;Q[_N
M)?;>M3?)J6;*#HFZYY'$T$'W3%)"?;SGDK2N@#V;MW.#U.P@V'M2%8J0@M>
M4V'3 2 (&"X8P#BO*-.LK)'3^<BE"L9&]SL3=W<,/%;XYR!TV#6Y$9C$A)D
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MB4F =]P,,S$-'#8W30)H3[+:I*@C,$'H8O[5)AJU<JF[.\%EP93(*P8(DR5
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M(0.XHD@;9\_I\LX>$E<Z(,O)-8IXWZ1EW$>21B ZDN4=! @><DLFP3ON0W9
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M7=\-^2#+Y7>RE;9#+K1QL<1H(*M:KF4)6!Y3-8^BTABCDHVFJNY$WKA/52/
MYA;@#BO##H!YE643+:UBD@ZV+X6!XADA1I&@,,NT,#EXPYL@\"H=X[Y(C0^U
M(Z32 ::.M+6+(N?02=!*U_8X41+?G >.V7J&0J!L$SUK;W@V>[4:'[&/)_,.
MX@(?3K]^G6V,HS [-XY>S\MB^64K\4MMSASSD8'G=6"(Q021*0\6K<!2N+*J
MT2"_W0@<MU*TF8790CRC9RF%[^DSIG^\6R[6F.HVSA)EKG<9U<9[%9"\.Y21
M[@I+VRN&+@SD27/BJN4[YBSMN.+(LRU:R'K1FO$=7-*OY_19I)#KB+ZWN)X8
MGXQ(*D%"4YLSZ0A1& 8\E%Q"S$R:-C/JKA$R<F500S@-P?DNGD*WG3\_AC]P
M=;Z'8EPI14BP,I&%FHH!IZ,#AY:N]:@%RVVR>6_2,G)F[J, Z"C^#Z9\AIXC
M]DM835>+\N[2YX5Y_G#ZY4M8?E^4#]-/\VF9IEJ$M&WP52?O+F;35!^TKVQN
MMREC1ZTWS RRX;8\T(2RF\M<0-:&()QPB3 6 ZB@-;CBJUVF4W&!"R';M$J^
MFZ:CFYLO/X7YV:")YXOYBCX^A[,A%)=E<E+.$@/"[,)J7;V8KM)LL3I=XD=B
M_B^S;9YHM$HB SK;]8$S:_"&5#N7*D>E;32FS9O?T#L9>5+),"B\T?!\3''_
M4ZK=L=1O1VIX+'6,Q6<"O@9>70UEC(.02PV<2.[I$#"\[NAUKXXW8C@IUQ;X
MOOWSQZG+(3GEF05C))TZ.F3@E"4Z/9=%LEQ2;A.DWHV^;E7G/HBYKCH;B*8#
M)_BW%9Z4EZOUE*QS7$TP>I5J6S!=&!GER07P#CE]I57F@9F82Q-@7:5CY.%,
M;0!T!*L[ ,I[_(;S4ZPE&;?U\;I^#$3V:%*NG6@4UCUM*H<-Y&RY3SXHU:RF
M81\Z1Y[;U 9H#475 1!OGU2VK1 B*_;U/!'GI]^P]NK8FB;?)[2'D(I6D$5(
M=7H/ \^$ .]]=E)RS(V:KAQ [,@CFMI LK70QGZ<.&M&?-9V^/H)X^@RM[R
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M4 Y@= =0>;.8Y\5\,WTYAOD_3@I1@;GNY\WK7T[>G^E)FPP/42>(RM0";2V
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MQ1C)SL@*DE=6<UYS?MN\WNS]6OSHZ2E# 6HO'A^.C\4ZS!I&-#^L%^D?M8"
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M\-H>S@ZLKF_N/">H4Q5 I2S "ZXA2\F+TV1S\C;O#K>2,W)88#AQ+X;F?0<
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MI"K1BXY!@LYL"H""5+ *BH.S28*ALY2<ST':1M[?@[3UDH=R% BN0VM8B72
ML7?+Z3=R8=[-0MKX,6=:.EHM71(1.*;ZD%7(A/1&0>*)Z9"DR:)1)M.M](R,
MI8&E?L-T/UH$8]M9OTYGI+P7<WP^6ZRF\T_G=[WQU@C+H5@T]:XG>X+92%^Y
M;$2V1K/=#/3;/W_D;(0VJ!B*GQWHEEMU\)N+9BA""[K,LP.A2JW6\F0),E>
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M_)N[7'W[D!:AB/EB,WOQ_>Q=6OWND+2)XY03Y3U02QD(0C,XYA-HFZTGUI%
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MXT*VC"Y?/#[O?__K_P%02P$"% ,4    " #ZCFI36^\ZO>L'  #C)0  $P
M            @ $     97@M,S$Q>#(P,C$P.3,P+FAT;5!+ 0(4 Q0    (
M /J.:E,=#;4=V <  ,PE   3              "  1P(  !E>"TS,3)X,C R
M,3 Y,S N:'1M4$L! A0#%     @ ^HYJ4]:A F(#!@  9"4  !,
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H<RTR,#(Q,#DS,%]P<F4N>&UL4$L%!@     )  D 30(   $G!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
